<SEC-DOCUMENT>0001558370-22-001539.txt : 20220222
<SEC-HEADER>0001558370-22-001539.hdr.sgml : 20220222
<ACCEPTANCE-DATETIME>20220222121258
ACCESSION NUMBER:		0001558370-22-001539
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220222
DATE AS OF CHANGE:		20220222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVRx, Inc.
		CENTRAL INDEX KEY:			0001235912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40545
		FILM NUMBER:		22656682

	BUSINESS ADDRESS:	
		STREET 1:		9201 WEST BROADWAY AVENUE
		STREET 2:		SUITE 650
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55445
		BUSINESS PHONE:		7634162850

	MAIL ADDRESS:	
		STREET 1:		9201 WEST BROADWAY AVENUE
		STREET 2:		SUITE 650
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55445

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVRX INC
		DATE OF NAME CHANGE:	20030527
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tmb-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 2/22/2022 1:07:44 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: f428c294-065d-4ba1-90cc-fc9ad11d6ddb -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:cvrx="http://www.cvrx.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" xs:nil="true" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_0htmWiR1l0-oVHAWAyf0UQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" xs:nil="true" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_SkOF68hLmkeEGP9aOGLNCA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityCentralIndexKey" id="Tc_c0jPe0diSkSfNdsCtMjVQQ_2_1">0001235912</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:DocumentFiscalYearFocus" id="Tc_7RP57kWlCk6ddKyIPE4a4A_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:DocumentFiscalPeriodFocus" id="Tc_wXUsJX2ik0WeER6vF0Ufkg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:AmendmentFlag" id="Narr_Ae5QhOk9ck-_TG9LL4v7nQ">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_5pg87fbRIkKIPG2d7UU4QA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_byZi4mWJc0C6vryvKDO1NA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" id="Hidden_CHwWvOCpqkalJ4DpOnMy7w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" id="Hidden_eK-8jgn7QEO0ypzWDE_TsQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" id="Hidden_ViAT-p-9bUmfp12LJKjAFg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" id="Hidden_hwtDLgJumE2RaB-hUrfXrQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_OiXATJAeOEWMUr6BK9NIwg">20399337</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_dLnUJPKZnUehAo0SsgSNng" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" id="Hidden_hGmV6LR9xUyVdc_b1EBWDQ">24700000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2019_To_1_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_814Td6NHJU2LA3ME4089rw" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" id="Hidden_M0BZTFHNU0ipFi78VUubmw">24700000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_6_22_2021_To_6_22_2021_os5QyOYe3E-ZHagmcHHjZA" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_33FQYq2nDUGydCuOJK10Rw">0.025</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_F_D18IC5BEuK0j9gsJLwVA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_0XkIKc5vtkaAz_u2UX8LPw">223541754</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_hW0XHasF1EqKmki-9OASVQ">360412</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_GlL9e5dCzU2TRSGzqgA9yQ">2454686</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_WIbgbBDQSUeSK852Ql0xGg">2963069</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_I2CPLNNNTEqPHzyLFDHo3A">4308394</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_HR3YeE_xcUa647uDv07mmA">8631967</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_v3NMNR0jRkSXP-mwxlXtBw">10135320</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_jPTbjUbrSkaozDE6EHAXtA">29548318</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_39tfPm6F3kCPPgcE17HUrQ">165500000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_-Y-YqAH9UEGLKbzC_205Pw">223541754</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_P2E57QTxoUSi8yLB5BySbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_YiZ4tVb_lEOCzdR1fmlZww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_gSHtkKETBkOZK6zcbuEF5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesf2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriese2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesd2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesc2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesb2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesa2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_p0RfPfIa3UWcDTlEg4P0KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_GBAq1vgtgUGuG5-Ar6ag-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RUHOGigFiEuJTBLQGUN3cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_OV8o_orI0kaBRnMMLVzv6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_nw03FdpgikWG68cst93DrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_Ddc3yM7430mMAAMMP8Suag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2021_To_6_22_2021_os5QyOYe3E-ZHagmcHHjZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-22</xbrli:startDate><xbrli:endDate>2021-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NRVdw4MrM0yuymfM2lEBNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SygLLO7d6keB2YcBMuzXRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fZBmRrBVpEW4r7ljKujLsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TXEPtHeAnEu5aSDgEVIuTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8bbj7mTQvkKRbK8e00U2-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_k3U9zkOYDk-3HOWZzCltuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zeiT1HWqrEK40Ol6L2ZKYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S5U_tTlMW0qlftdPLa9DZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bMSZQxnqxEqCmCBMOX938g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e__ks_GGFkytwC3zHBuP5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NZvrdn8yFkWAX4fnEQO45A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6tiymcp8Wk-c2D6KmqY0og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_JGMICHAQEEu3PrOrJyDdFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zsm1WUir-k6VgUpvr7OdPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_sTmU2osx-U-5lEzqPECixw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_Pz24LA4lyUOU54enYn6jCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_rMwLYGHbQE6dNGAJjgqUTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_Fm3g4MulRkuGfrsRDzx3EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_30RcSPGNvEamYzAz2-IrUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_dgYIHQpY50SIFkVijZlZVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_dW1zDaWfyk2oy7oOo2LrKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_kdt0eqlvgUeFDlocBEsHgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_2-T0O75ws02nTypOsGbMvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_NA4nBO9IeUeJcRmeWYh52A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_9YKJ16k5pUK-Co6rlduK-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_DE_U05bs9aJIU6iqEyxRNqWpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_uUcu3GeHRUyZPto-aW7cuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_US_aqbgUY-uCkOAp8sxbW2muQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_DE_4mGJWS3mdUGj2uJ_PoEshg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_pDRh1cot40q_8Y3o2VYqGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qbNP5EMaT0ugnnKkSC2ccQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_f6ItviTz1USvtPXYmohPkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_rfzInbLWC0WZAH9zijqO7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_W8mwFgZUB0-M5Mhl98X9vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_JVTdDeParEGGJ2t4jtbpsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Hw_YMxt6zk2W-1GMsneLZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_Shk5JCIfNUKOH63sKxBD4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_qcikURBbNkqhIs-KAt4sHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_D22BP1wD10eBV-IdknkzyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_8_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Yz5mooOlEEu0wI3NjQvG0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2019_To_5_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_dLnUJPKZnUehAo0SsgSNng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_814Td6NHJU2LA3ME4089rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_12_31_2016_srt_StatementScenarioAxis_cvrx_OperationalMilestoneClosingMember_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_TKhCqTifZ0aCZQX-reWoVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:OperationalMilestoneClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_6RQJgllZt0K-iekb1XdaUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_OKok4WEvikOohFGKGTT-vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GImtIEFIfUmLgGy9Whzecg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_3_2021_To_11_3_2021_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_fNfZEgGsO0yZp9z4dnf9og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2021-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ogL9DuiJFUOrmGs4jXH1PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yHbljhgpY0mbvZF0ftxdIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_z_YBcxDzik24JD_7beeSKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WXCPeSjuN0mwsFbO09y0Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_y3rSgJAX9EGQxWbuV_L1FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xQ4PL8s8EU69GgtfV_9c1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S0-dIu-pxUOkwdi2LzQL7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_C35XEWZJAU6-Xgd6ERjcqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_3_2021_To_11_3_2021_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherExpenseMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_ID5K4-Y0vE-LBHZCpZLEYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2021-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_spHQMK4XMUiiug-F7DvVwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_A_ndJ_mgvE2v6o03-Ks7wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_KNUV7a2UVk-AWL-jkX8qUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_ARf2RRaIzk6UxSql8Of4JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W4X_2dSbnkGc95kko6HZAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_16bB4IFwrUapwzsWJeRraA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_R_I0EY29n0W_Ped5vMxkzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D2BA-9J5XE-PbX6gbNm_aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_RKtvIKc5LkyhjXn68Zj14A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_PH-M6rDzJkyqGZQxfL2QnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_YzRnuQXlH02VKNNMxJ0Jag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_mytN74qZAE-E5cluV0a_Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Pg0bkL4urUCnAduxdRREcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_LU9Pb5rH30abdxp9blQkkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvrx:BiosenseWebsterInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseSeriesGPreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_xrHiwCtXlEGvfX5Nxy-WiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_oDN2lEZu7EKFxKQVBpzLOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_MX0otz1v_E62VZpoRgXl2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvrx:BiosenseWebsterInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseSeriesGPreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvrx:BiosenseWebsterInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseSeriesGPreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BejIF-DRL0aswumRwwIyHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_sIVU4EK2E0GdoOrH6UNCKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_z1FXD3BKKUuyMZ9Pt2aLwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_PlOty7i4fUGsptJeEqXFFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aBap4qmv00-_PB2zQLVyyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_zfsXsnHsBUWf8PinLKwvcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bk4XMJevEEOkeqMW-LrPQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_nTVDTqoC4EGDzTZXxwMKtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_rITtj_g4X0aaNNHUoD6CHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KP_E6votUkOpAaxA54qxHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_IVyA6xFKREe6yCN57Qbv9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Z2T5WpbvEECoGfLG7ZECvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fYLvldHF7ESQu3O88FcTxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember__Rt_uAI5zEe9X0cpvPTtiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HZTSfAFE00aFsq1LVh0T7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_Rj3REBVBCEmO0bZWuNdaXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_14_2022_fw8KXFtSr0qiXvq0PQOA0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_98TiYSuyBEyI_7e_iTGzOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_n8heRn9N5UGTUj53vhPYSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Wr3bFBKF6Uuwn1r7P4sYpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_XAEp1PMrjEePzao7rysu6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_mJX9dbF0-kOVnbsfnZIlqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_48tuazk8rES1QsAP9ElvuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_bFjTgGhLakqfsDzkd9x64A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_bnP6fucus0u5PpGTSQpeQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_yzrdiZL4ykShGVaP8kB8EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_AHM5B_OrqE2hM2md5KwcBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_zXBgdB9Wm0KMsLVbZrH5Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_5vT5q4Y0Gka2WmjvA6i6vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_nBAhCE3xjEOe547YDdUyhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_dGFrNR414EyLMrXxL6FSSQ"><xbrli:measure>cvrx:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_263d32d0_d185_433c_8bbf_34081d462db4"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:DocumentType" id="Narr_rnceL-N0AkCak25DB5-qTQ"><b style="font-size:9pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">(Mark&#160;One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:DocumentAnnualReport" id="Narr_J9uOqC2b70KBk9PrwiKM1w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL&#160;REPORT&#160;PURSUANT&#160;TO&#160;SECTION&#160;13&#160;OR&#160;15(d)&#160;OF&#160;THE&#160;SECURITIES EXCHANGE&#160;ACT OF 1934</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:DocumentPeriodEndDate" id="Narr_sbR2giYieUaGXdK2OkNKVw"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:CurrentFiscalYearEndDate" id="Narr_mjVJNflkAEizYVIpC4yWxw"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2021</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">or</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:DocumentTransitionReport" id="Narr_m0lTdPD4IUubzHDH0pVBIg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE&#160;ACT OF 1934</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityFileNumber" id="Narr_Eg0qEVN1gUiHcb5WmoCRNA"><b style="font-size:8pt;font-weight:bold;">001-40545</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityRegistrantName" id="Narr_qJAUExItTEumVenFrjtv3w"><b style="font-weight:bold;">CVRx,&#160;Inc</b></ix:nonNumeric><b style="font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_819b9bde_8cd4_4de4_9076_e2d9865fa0d4"></a><a id="Tc_-QdzdCWgU0GNJ06hKrmOcQ_2_0"></a><a id="Tc_zXuvQK_YQUiTtOYutZ34fQ_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityIncorporationStateCountryCode" id="Tc_O7LYxyuvmEigNGOkxQ93Ag_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityTaxIdentificationNumber" id="Tc_IDfBNfMXK0-OOaJntp7EHw_1_1"><b style="font-size:8pt;font-weight:bold;">41-1983744</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other&#160;jurisdiction of</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityAddressAddressLine1" id="Narr_LFXUeru2OE6ftqGyPJox2g"><b style="font-size:9pt;font-weight:bold;">9201 West Broadway Avenue</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityAddressAddressLine2" id="Narr_aYHUsx4sD0ChL8vpch9e7Q"><b style="font-size:9pt;font-weight:bold;">Suite&#160;650</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityAddressCityOrTown" id="Narr_ezCo47NrDUmKVSQT53Pn8w"><b style="font-size:9pt;font-weight:bold;">Minneapolis</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityAddressStateOrProvince" id="Narr_kHK1XsndZ0iapAuoofbrBw"><b style="font-size:9pt;font-weight:bold;">MN</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityAddressPostalZipCode" id="Narr_Z_XEBlJPJ0OMR7RAvYlizQ"><b style="font-size:9pt;font-weight:bold;">55445</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices) (Zip Code)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:CityAreaCode" id="Narr_A7N1E_gDC0KnMkZsPaDW8Q"><b style="font-size:9pt;font-weight:bold;">763</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:LocalPhoneNumber" id="Narr_twAzHAs3i06eIEMb89G7gw"><b style="font-size:9pt;font-weight:bold;">416-2840</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_3cc5f012_3bc5_4340_8a8f_6338e861fa29"></a><div style="margin-left:-1.5pt;"><a id="Tc_SG9qAJWqJ0GOouyr5jKKnw_1_0"></a><a id="Tc_JyTwg6onJEKt0pe-UWjdnA_1_2"></a><a id="Tc_3rnAep1NG0iEQQocG3ZytQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:31.72%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:31.87%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:23.35pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:31.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:31.87%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Name of each exchange</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">on which registered</p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:31.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:Security12bTitle" id="Tc_95cD_i0Mq0yQGQnA-2RjmQ_2_0"><b style="font-size:9pt;font-weight:bold;">Common stock,</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">par value $0.01 per share</b></p></td><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:TradingSymbol" id="Tc_68n6rB2Rm0u-lBYR1kCJQw_2_2"><b style="font-size:9pt;font-weight:bold;">CVRX</b></ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:SecurityExchangeName" id="Tc_NvPfn1NRFkqT2FdSYJzh-A_2_4"><b style="font-size:9pt;font-weight:bold;">The Nasdaq Global Select Market</b></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_yP0-SsDDxU2GaeTZ4cSHiA"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityVoluntaryFilers" id="Narr_x6sfvGnOUEK9IQ7s34vIAw"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityCurrentReportingStatus" id="Narr_y1gH9d7IpEeUAQg5qX5X2Q"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityInteractiveDataCurrent" id="Narr_dFM91SVZW0Cn6nsNWs2qwQ"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_23356ced_cb12_41e3_af93_822ee7640bf8"></a><a id="Tc_Gov5rp_kakGADQG7kSHjlw_1_0"></a><a id="Tc_N9zrXH9n0kG6YHbkNOj7Kw_1_1"></a><a id="Tc_znzWFWEOSE-Zjk_cWZxl5A_1_2"></a><a id="Tc_6jjwm7DDg02bDZNTBRXhpQ_1_3"></a><a id="Tc_I9LxSWhEjkGJP8DZOwn57Q_3_1"></a><a id="Tc_NJ_cuNy6QUCvr0i00ONhBQ_3_2"></a><a id="Tc_x7fmGwL52UG9mKq4lI14fQ_3_4"></a><a id="Tc_d7PjV3Y9SEWqTLCWPFlBDg_3_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:25.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:3.65pt;"><td style="vertical-align:bottom;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6.3pt;"><td style="vertical-align:middle;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.05pt;"><td style="vertical-align:bottom;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityFilerCategory" id="Tc_EKZH7No1rEmuKdyY2l1MGw_3_0"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span>&#160;&#160;</p></td><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntitySmallBusiness" id="Tc_gvWbonJtM0ido3LN18FU8A_3_3"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Emerging&#160;growth&#160;company</p></td><td style="vertical-align:bottom;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityEmergingGrowthCompany" id="Narr_n0Rx-D-LkkWE2_z6OMdkkg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityExTransitionPeriod" id="Narr_bQm3YWrk70KUTR_XBTSZ0g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:IcfrAuditorAttestationFlag" id="Narr_-NLVwVooMkamF_ADfV59PA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:EntityShellCompany" id="Narr_yZjEbaI4mk-4l79p0bH-lQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Global Select Market on June 30, 2021, the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021_Rj3REBVBCEmO0bZWuNdaXw" decimals="-5" name="dei:EntityPublicFloat" id="Narr_Se9ONxU8pki0Mlck1E6EFA">9.6</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">As of February 14, 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_14_2022_fw8KXFtSr0qiXvq0PQOA0A" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_RtTZxl9gmkC_pmejKwn2tw">20,477,600</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.01 per share outstanding.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 15pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt 0pt 15pt 0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0890569f_7edb_40db_a750_519d306d2eca"></a><a id="TOC"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TABLE OF CONTENTS</p><a id="_f6018d1b_ed6c_4b00_a1fb_9915d2f385cf"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:84.28%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.08%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:84.28%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#CautionaryNoteonForwardLookingStatements"><span style="font-style:normal;font-weight:normal;">Cautionary Note on Forward-Looking Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#SummaryRiskFactors"><span style="font-style:normal;font-weight:normal;">Summary Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTI"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1Business"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1Business"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">45</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1BUnresolvedStaffComments"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1B.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1BUnresolvedStaffComments"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">80</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">2.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">80</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item3LegalProceedings"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">3.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item3LegalProceedings"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">80</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item4MineSafetyDisclosures"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">4.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item4MineSafetyDisclosures"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">80</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTII"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item5MarketforRegistrants"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">5.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item5MarketforRegistrants"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">81</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">81</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">7.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">81</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">7A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">91</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">8.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">93</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9AControlsandProcedures"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9AControlsandProcedures"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9BOtherInformation"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9B.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9BOtherInformation"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9c"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9c"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTIII"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">10.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">112</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item11ExecutiveCompensation"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">11.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item11ExecutiveCompensation"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">112</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">12.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">112</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">13.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">112</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">14.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">112</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTIV"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item15Exhibits"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">15.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item15Exhibits"><span style="font-style:normal;font-weight:normal;">Exhibit and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">113</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">16.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">117</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:84.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">118</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3e940c30_c48e_40f6_9f5f_33da05c776ee"></a><a id="CautionaryNoteonForwardLookingStatements"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cautionary Note&#160;on Forward-Looking Statements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;). All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements, including statements regarding our future results of operations and financial position, business strategy, the impact of the ongoing and global COVID-19 pandemic on our business, financial results and financial position, clinical trial results, prospective products, product approvals, research and development costs, timing and likelihood of success and the plans and objectives of management for future operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In some cases, you can identify forward-looking statements by terms such as &#8216;&#8216;may,&#8217;&#8217; &#8216;&#8216;will,&#8217;&#8217; &#8216;&#8216;should,&#8217;&#8217; &#8216;&#8216;expect,&#8217;&#8217; &#8216;&#8216;plan,&#8217;&#8217; &#8216;&#8216;anticipate,&#8217;&#8217; &#8216;&#8216;could,&#8217;&#8217; &#8216;&#8216;intend,&#8217;&#8217; &#8216;&#8216;target,&#8217;&#8217; &#8216;&#8216;project,&#8217;&#8217; &#8216;&#8216;contemplate,&#8217;&#8217; &#8216;&#8216;believe,&#8217;&#8217; &#8216;&#8216;estimate,&#8217;&#8217; &#8216;&#8216;predict,&#8217;&#8217; &#8216;&#8216;potential&#8217;&#8217; or &#8216;&#8216;continue&#8217;&#8217; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, the important factors discussed in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, which are summarized below. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="SummaryRiskFactors"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Summary Risk Factors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a history of significant losses, which we expect to continue and we may not be able to achieve or sustain profitability;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our principal stockholders, management and directors (four of whom are affiliated with our principal stockholders) own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a limited history operating as a commercial company and are highly dependent on a single product, Barostim and the failure to obtain market acceptance in the U.S. for Barostim would negatively impact our business, liquidity and results of operations;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have limited commercial sales experience marketing and selling Barostim, and if we are unable to establish and maintain sales and marketing capabilities, we will be unable to successfully commercialize Barostim or generate sustained and increasing product revenue;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we must demonstrate to physicians and patients the merits of Barostim;</span></td><td style="width:23.05pt;"></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if third-party payors do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our industry is competitive; if our competitors, many of which are large, well-established companies with substantially greater resources than us and have a long history of competing in the heart failure market, are better able to develop and market products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim, our business will be adversely impacted;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if we fail to receive access to hospitals, our sales may decrease;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we are dependent upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers, making us vulnerable to supply shortages, loss or degradation in performance of the suppliers and price fluctuations, which could harm our business;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including the outbreak of the novel strain of coronavirus disease, COVID-19, could adversely affect our business;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may face product liability claims that could be costly, divert management&#8217;s attention and harm our reputation;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may in the future become involved in lawsuits to protect or enforce our intellectual property, which could be expensive and time consuming, and ultimately unsuccessful, and could result in the diversion of significant resources, thereby hindering our ability to effectively commercialize our existing or future products;</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if we fail to retain our key executives or recruit and hire new employees, our operations and financial results may be adversely affected while we attract other highly qualified personnel; and</span></td><td style="width:23.05pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we will continue to obtain long-term clinical data regarding the safety and efficacy of our products, which could impact future adoption and regulatory approvals.</span></td><td style="width:23.05pt;"></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8deca1de_a4e5_40b4_91ff_3a4e35e7606d"></a><a id="PARTI"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART I</b></p><a id="_10630c51_31e3_4ab7_a6e4_32daa475922f"></a><a id="Item1Business"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 1. Business</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Our proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System (&#8220;ANS&#8221;), which causes heart failure (&#8220;HF&#8221;) and other cardiovascular diseases. Our second-generation product, Barostim, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HF with reduced Ejection Fraction (&#8220;HFrEF&#8221;), or systolic HF. Barostim provides Baroreflex Activation Therapy (&#8220;BAT,&#8221; or &#8220;Barostim Therapy&#8221;) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate the cardiovascular function. We have developed a significant body of published clinical evidence that supports the strong value proposition of Barostim Therapy and its ability to meaningfully improve the quality of life for patients suffering from HFrEF. We estimate that our initial annual market opportunity for HFrEF is $1.4&#160;billion in the U.S. and $1.5 billion in select European Markets (Germany, France, Italy, Spain and the United Kingdom, or &#8220;EU5&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HF is one of the most prevalent and devastating cardiovascular diseases. We estimate that there are approximately 26&#160;million people globally suffering from HF, including approximately 6.2&#160;million people in the U.S. and 8.6&#160;million people in EU5. Every year, 1.3&#160;million and 1.4&#160;million new patients are diagnosed with HF in the U.S. and select EU5, respectively. HF is characterized by the heart&#8217;s inability to effectively circulate blood throughout the body resulting in insufficient levels of oxygen and nourishment to various body parts. This impacts a patient&#8217;s ability to function and leads to a variety of symptoms such as shortness of breath, extreme fatigue, exercise intolerance, swelling and fluid retention that affects the patient&#8217;s quality of life, both physically and emotionally. HF usually develops from an imbalance of the ANS, which is also the primary cause of multiple other cardiovascular diseases, such as hypertension, angina pectoris and arrhythmia. The ANS plays a vital role in the function of the heart and is strongly influenced by baroreceptors located in certain arterial walls.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are currently focused on the treatment of patients with HFrEF, which represents approximately 40% of the patients with HF. In HFrEF, the left ventricle loses its ability to contract properly, resulting in insufficient power to pump and push the necessary quantities of blood into circulation. Approximately 75% of HFrEF patients die within five years of being admitted to the hospital for HFrEF. Patients with HFrEF are typically placed on a treatment progression plan during which they are initially given Guideline Directed Medical Therapy (&#8220;GDMT&#8221;) to help manage symptoms, and then progress to more invasive and costly treatment options involving other implantable devices with the most severe patients often requiring Left Ventricular Assist Devices (&#8220;LVADs&#8221;) or heart transplants. These other implantable devices mostly target different HFrEF patient populations, may require an invasive procedure that places hardware directly inside the heart, and are not designed to address the imbalance of the ANS that causes the disease. We believe there is a significant need and market opportunity for a safe, effective and minimally invasive device-based treatment option for HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We believe Barostim offers meaningful benefits for patients, physicians and payors that will continue to drive adoption of our therapy. The primary benefits include:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Addresses significant unmet medical need.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim addresses a life-threatening disease for patients who failed to receive adequate benefits from existing treatments and who have no alternative treatment options. Based on this, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) granted Barostim a Breakthrough Device designation for HFrEF in June&#160;2015.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Safe and effective treatment.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our BeAT-HF pivotal trial demonstrated compelling safety and effectiveness data regarding the clinical benefits of Barostim for HFrEF. These results showed significant improvement in the following patient-centered outcomes:</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by Minnesota Living with Heart Failure (&#8220;MLWHF&#8221;)):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated a 14-point improvement in quality of life for patients in the device arm relative to patients in the control arm. A 5-point improvement is considered clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6 Minute Hall Walk (&#8220;6MHW&#8221;) distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that patients in the device arm were able to improve the distance they walked in a six-minute period by 60 meters more than patients in the control arm. A 25-meter improvement in walking distance is considered clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by New York Heart Association (&#8220;NYHA&#8221;) classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that 65% of patients in the device arm improved at least one NYHA class as compared to only 31% in the control arm, with 13% of patients improving two NYHA classes in the device arm as compared to only 2% in the control arm.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Widely accepted mechanism of action.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our platform technology is based on a widely accepted mechanism of action and is designed to address the imbalance of the ANS, which causes HFrEF and other cardiovascular diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Strong global clinical evidence.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The benefits of treatment with Barostim were shown to be similarly robust and reproducible across all three of our HF clinical studies, including BAT-in-HF (Phase&#160;I), HOPE4HF (Phase&#160;II) and BeAT-HF (Phase&#160;III pivotal trial), evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. Barostim Therapy&#8217;s trial results have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the Journal of the American College of Cardiology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Minimally invasive implant procedure.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim&#8217;s implantable pulse generator (&#8220;IPG&#8221;) and stimulation lead are implanted during a minimally invasive procedure typically performed in an outpatient setting that lasts approximately one hour and involves two small skin incisions. Our device does not require hardware to be implanted in the heart or vasculature, which is the case with most other device-based treatments indicated for different HFrEF patient populations. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential reduction in total healthcare costs for HFrEF patients.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;A Company-sponsored and co-authored cost-impact analysis, which was published in&#160;</span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">BMC Cardiovascular Disorders</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, a peer-reviewed manuscript, predicted that BAT plus GDMT would become the lower-cost alternative treatment within three&#160;years from implantation, as compared to GDMT alone, resulting in significant cost savings to healthcare systems.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Inherent patient compliance and durability.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim ensures patient compliance, unlike most commercially available drug treatments, as it requires no device interaction by the patient. Our device has a battery that does not require recharging, has an average service life of five&#160;years and is replaced through a short outpatient procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an IPG and a stimulation lead and is programmed by a wireless clinician-controlled programmer that communicates with the IPG. The IPG contains the electronics and battery in a hermetic enclosure and controls and delivers the imperceptible and persistent electrical pulses to the carotid baroreceptors through the stimulation lead attached to the exterior wall of the carotid artery. These electrical pulses delivered to the baroreceptors increase signals to the brain to modulate the cardiovascular function, thereby improving symptoms of HFrEF. Our wireless programmer allows physicians to verify and customize the therapy to the patient&#8217;s needs by adjusting the intensity and frequency of the electrical pulses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have developed a significant clinical data set that demonstrates the safety, effectiveness, patient adherence and durable benefits of Barostim Therapy. Our BeAT-HF pivotal trial, which was a multi-center, prospective, randomized, controlled trial, met the primary safety and effectiveness endpoints and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">demonstrated meaningful improvement in the quality of life, both physically and emotionally, for patients suffering from HFrEF. These results led to FDA Premarket Approval (&#8220;PMA&#8221;) approval of Barostim in August&#160;2019 on an accelerated basis of only four&#160;months from the submission of the clinical trial report. We continue to develop and expand upon our significant body of published clinical evidence that supports the meaningful benefits of Barostim Therapy. We have also established a U.S. patient registry to evaluate and assess real world outcomes from HFrEF patients who have been implanted with Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We primarily sell Barostim to hospitals through a direct sales organization in the U.S. and Germany and through distributors in Austria, Spain, Italy, the Nordic region and other European countries. Our global sales and marketing team engages in sales efforts and promotional activities focused on electrophysiologists (&#8220;EPs&#8221;), HF specialists, general cardiologists and vascular surgeons. We are prioritizing our sales and marketing efforts on high volume EP centers that are strategically located and on building long-standing relationships with key physicians. We support these physicians through all aspects of the patient journey, which includes initial diagnosis, surgical support and patient follow-up. We also highlight our compelling clinical benefits and value proposition to build awareness and adoption among physicians through targeted key opinion leader (&#8220;KOL&#8221;) development, referral network education and direct-to-consumer marketing. We utilize direct communication channels to inform and educate patients about Barostim Therapy and utilize a qualification process to aid in the identification of the appropriate patients for our therapy. In the U.S., Barostim is fully reimbursed by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) across all regions. We offer assistance to patients and providers with reimbursement approvals, if required. We plan to continue actively expanding our direct sales force and commercial organization in the U.S., which is where we expect to focus most of our sales and marketing efforts in the near-term.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The primary focus of our research and development efforts in the near-term will be the continued technological advancement of Barostim, including tools to simplify the implant procedure for physicians. In 2022, we expect to launch an enhanced IPG that will be approximately 10% smaller in size and improve the battery life by approximately 20% to an average of six&#160;years. We are also developing a new implant toolkit called BATwire, which enables an ultrasound-guided implant procedure to implant Barostim and the use of local anesthetics, potentially expanding our annual market opportunity in the U.S. In the future, we plan to explore Barostim&#8217;s potential to expand its indications for use to other cardiovascular diseases, including different forms of HF, hypertension and arrhythmias. Expansions into these or other new indications would require additional FDA approvals and may involve additional clinical trials or modifications to Barostim to treat such indications. If clinical studies for future indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We generated revenue of $13.0&#160;million, a gross margin of 72% and a net loss of $43.1&#160;million for the year ended December&#160;31, 2021, compared to revenue of $6.1&#160;million, a gross margin of 76% and a net loss of $14.1&#160;million for the year ended December&#160;31, 2020. Revenue for 2020 and 2021 was negatively impacted due to the global pandemic associated with COVID-19. Specifically, in March&#160;2020, healthcare facilities and clinics began restricting in-person access to their clinicians, reducing patient consultations and treatments or temporarily closing their facilities. As a result, beginning in the second week of March&#160;2020, substantially all of our then-scheduled procedures were postponed, and numerous other cases could not be scheduled. During May&#160;2020, the widespread shutdown resulted in key physician-society conferences being moved to a virtual setting, which directly impacted the commercial launch in the U.S. By the beginning of the fourth quarter of 2020, implant centers had resumed procedures in the U.S. and Europe. Procedure volumes were negatively impacted by the Delta and Omicron variants of COVID-19 in the third and fourth quarters of 2021. Our accumulated deficit as of December 31, 2021 and 2020 was $394.8 million and $351.7&#160;million, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our success factors</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are focused on transforming the lives of patients suffering from cardiovascular diseases by developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions, which we believe offer a compelling value proposition for large and significantly underpenetrated markets. We believe the continued growth of our company will be driven by the following success factors:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Novel solution offering meaningful clinical benefits to an underserved patient population suffering from HFrEF.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim is the first and only commercially available neuromodulation device indicated to improve symptoms for HFrEF patients who currently have no viable device-based treatment alternatives. Barostim has demonstrated clinically meaningful symptomatic improvement across industry-standard HF patient-centered outcomes. Our therapy works by sending persistent and imperceptible electrical pulses to baroreceptors located in the wall of the carotid artery, which increases signals to the brain to modulate the cardiovascular function, thereby improving symptoms of HFrEF. Barostim&#8217;s IPG and stimulation lead are implanted and sutured subcutaneously during a one-hour, minimally invasive procedure with no hardware implanted in the heart or vasculature. Additionally, once implanted, Barostim has an average service life of five&#160;years and an implantable battery that does not require recharging. Barostim ensures patient compliance, unlike most commercially available drug treatments, as it requires no device interaction by the patient. With these features, we believe the revolutionary Barostim has the potential to transform the treatment paradigm and become the standard of care for many of the 26&#160;million people worldwide with HFrEF, representing an initial annual market opportunity of $2.9&#160;billion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Significant body of clinical evidence targeting a widely accepted mechanism of action.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The benefits of treatment with Barostim were similarly robust and reproducible across our three HFrEF clinical studies, including BAT-in-HF (Phase&#160;I), HOPE4HF (Phase&#160;II) and BeAT-HF (Phase&#160;III pivotal trial), evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. Our HOPE4HF clinical trial results led to CE Mark approval and FDA Breakthrough Device designation for HFrEF, and our BeAT-HF pivotal trial results led to FDA approval on an accelerated basis of only four&#160;months from the submission of the clinical trial report. Our trial results have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the Journal of the American College of Cardiology. The BeAT-HF pivotal trial, which was a multi-center, prospective, randomized, controlled trial, met its primary endpoints and the positive safety and effectiveness data exceeded the pre-specified performance criteria across multiple dimensions, which measure the improvement in the quality of the patients&#8217; daily lives. Importantly, the significant benefits of our therapy were observed despite a four-fold uptake of ARNI in the control arm, as compared to the device arm.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Favorable reimbursement paradigm for both outpatient and inpatient settings.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim is currently indicated for HFrEF patients, 67% of whom are above the age of 65, and therefore are eligible for Medicare or Medicare Advantage. In the U.S.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim is reimbursed for outpatient and inpatient procedures by the CMS, with established coverage policies and Current Procedural Terminology (&#8220;CPT&#8221;) payment codes. Barostim Therapy is eligible for payment across all seven local Medicare administrative contractor (&#8220;MAC&#8221;) regions, representing 38&#160;million covered lives as of July&#160;2020. Of note, CMS awarded Barostim Transitional Pass-Through (&#8220;TPT&#8221;) payment for outpatient procedures that adds the device cost as a pass-through to the calculated procedure cost in the payment code, which took effect in January&#160;2021. In addition, CMS awarded Barostim a New Technology Add-on Payment (&#8220;NTAP&#8221;) for inpatient procedures in the amount of 65% of the device cost that is incremental to reimbursement provided for the implant procedure, which took effect in October&#160;2020. As part of our ongoing reimbursement strategy to broaden payor coverage, we are currently building a dedicated market access team to help patients and providers work with private payors to secure the appropriate prior authorization approvals in advance of initial treatment, which we believe will drive additional positive coverage outcomes for up to approximately 20% of our target-indicated patient population.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Targeted and methodical approach to market development in the U.S.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We have established a systematic approach to market development that centers on active engagement with physicians and patients. Our direct sales organization is focused on prioritizing high volume EP centers that are strategically located and on building long-standing relationships with key physicians. We support these physicians through all aspects of the patient journey, which includes initial patient diagnosis, surgical support and patient follow-up. Due to the lack of commercially available device-based treatments for our target-indicated patient population, our sales force is keenly focused on increasing awareness by educating referral physicians on the compelling clinical results and strong value proposition of Barostim Therapy. We </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">build upon this multi-pronged approach with direct-to-consumer marketing initiatives which help to educate patients and frequently results in patient leads. We believe that our approach to engagement across multiple stakeholders will continue to drive increased awareness of, and demand for, our therapy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Platform technology protected by a comprehensive and broad IP portfolio.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We developed an integrated platform technology, Barostim, which is designed to leverage the power of the brain and nervous system to address the primary cause of HF and other cardiovascular diseases. Barostim is our second-generation HFrEF product, which is FDA approved and CE Marked, providing access to an initial estimated annual market opportunity of $2.9&#160;billion in the U.S. and EU5. While we are currently focused on the treatment of HFrEF patients with limited viable device-based treatment alternatives, we believe our platform technology has the potential to provide benefits to a broader set of patients suffering from cardiovascular diseases. Our platform technology is supported by our comprehensive portfolio of wholly owned intellectual property, which includes patents, know-how and trade secrets, including therapy regimens, IPGs, leads and electrodes, delivery tools and implant methods. As of December&#160;31, 2021, we owned 54 issued U.S. patents and had three pending U.S. patent applications. Outside of the U.S., we owned seven patents in multiple countries and had one pending application.&#160;Our trademark portfolio contains nine trademarks in the U.S. and multiple other countries.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Experienced management team with deep expertise in the HF market and supported by key investors.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our senior management team has over 180&#160;years of combined experience in the medical technology industry. Specifically, our team has extensive operating experience in product development, regulatory approval and commercialization activities as well as established relationships with industry specialists in the academic, clinical and commercial HF markets. Members of our management team have served in leadership positions with well-regarded medical technology companies such as Medtronic, Boston Scientific/Guidant, Abbott/St. Jude and General Electric, as well as flag-ship industry societies, including AdvaMed. Since our founding, we have been supported by leading medical technology investors including Johnson &amp; Johnson Development Corp., New Enterprise Associates, Gilde Healthcare Partners, Vensana Capital, Treo Ventures and Action Potential Venture Capital, among others.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our growth drivers</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our mission is to capitalize upon our first mover advantage to become the global leader in providing clinically proven, innovative and minimally invasive neuromodulation solutions that improve the health of patients with HFrEF and other cardiovascular diseases. Our strategic levers to drive continued growth are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to build a commercialization infrastructure with a specialized direct sales and marketing team in the U.S. </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We have grown our commercial team in the U.S. to include a direct sales force with substantial applicable medical device sales and clinical experience. Similarly, our marketing team has a significant amount of domain expertise and a strong track record of success. Our Account Managers, along with the support from our Clinical Field Specialists, are responsible for establishing, growing and supporting implant centers and referral physicians. We plan to expand our commercial organization in the U.S. by adding a strategic mix of highly qualified Account Managers and Clinical Field Specialists. Our direct sales force will leverage our existing network of EPs to maximize early commercial traction.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Promote awareness among payors, physicians and patients to accelerate adoption of Barostim.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> We believe Barostim has the potential to become the standard of care for our target-indicated patient population, which currently lacks commercially available device-based treatment options. The vast majority of our indicated patients are well-defined under the purview of an EP and may have already been pre-indicated for an implantable cardiac defibrillator (&#8220;ICD&#8221;). As a result, we believe that raising awareness among EPs of Barostim Therapy and its clinical benefits will be an effective strategy to accelerate market adoption. We intend to continue to increase engagement with key stakeholders in the decision-making process, including EPs, HF specialists, general cardiologists, vascular surgeons, referring primary care physicians and patients with HF, as well as hospital administrators and third-party payors. In addition, we plan to continue to educate and train physicians as well as continue to publish additional clinical data in peer reviewed publications, online and at various industry conferences. We also plan to continue promoting </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patient awareness through our direct-to-consumer marketing initiatives, which includes social media advertising, patient webinars and online videos. We believe this market development strategy will further support adoption of Barostim.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand upon our significant body of clinical evidence.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> We will continue to develop and expand upon our growing body of published clinical evidence that endorses the strong value proposition of Barostim Therapy. We also plan to continue enrollment of the U.S. patient registry to evaluate and assess real world patient outcomes, as well as publish additional long-term data to further increase awareness and adoption of Barostim and for inclusion in the medical guidelines.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue innovation of Barostim to enhance our value proposition.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;We are committed to driving continuous innovation and technological advancement of Barostim, specifically around simplifying the implant procedure and use of our therapy. For example, we are currently developing a new implant toolkit called BATwire, which enables an ultrasound-guided procedure to implant Barostim and the use of local anesthetics, potentially expanding our addressable patient population to include those who are deemed clinically unfit for the current procedure. In addition, as a result of this simplified implantation process, we believe more physicians, including EPs, would be confident and comfortable implanting Barostim. In 2022, we also expect to launch an enhanced IPG in the U.S. that will be approximately 10% smaller in size and improve the battery life by approximately 20% to an average of six&#160;years. We believe our product roadmap coupled with a more simplified procedural process would improve clinical outcomes, optimize patient adoption and comfort, increase access of Barostim to a greater number of patients and allow more physicians to perform the procedure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Leverage our platform technology to expand into new indications and strategically pursue new international markets.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;HF is a prevalent, devastating and costly condition that affects over 26&#160;million people worldwide. While we are currently focused on the treatment of HFrEF patients, we believe our technology has the potential to provide benefits to a broader set of patients suffering from other cardiovascular diseases. Through additional investment in clinical research and development, our goal is to explore Barostim&#8217;s potential to expand the indications for use to other areas, while continuing to increase its market adoption and implantation in indicated patients with HFrEF. In addition, we are pursuing a morbidity and mortality indication in HF which would expand our addressable patient population. While our primary commercial focus in the near-term is on the large opportunity within the U.S., we plan to selectively expand our commercial and regulatory efforts in international markets.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our market and industry</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of HF</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HF is one of the most prevalent and devastating cardiovascular diseases. It is estimated that HF currently affects approximately 26&#160;million people globally, including approximately 6.2&#160;million people in the U.S. and approximately 8.6&#160;million people in the EU5. Every year, 1.3&#160;million and 1.4&#160;million new patients are diagnosed with HF in the U.S. and the EU5, respectively. HF is associated with a five-fold increase in sudden cardiac death. Despite currently available pharmaceutical and device-based treatments, projections by the American Heart Association&#8217;s (&#8220;AHA&#8221;) 2020 Heart Disease and Stroke Statistics show that the prevalence of HF is expected to increase approximately 46% from 2012 to 2030 in the U.S. alone due to an aging population and health issues related to diabetes and obesity. There is no known prevention for HF other than the treatment of the common risk factors associated with the disease, such as hypertension, diabetes and obesity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HF is a debilitating, progressive and potentially life-threatening condition where the heart does not pump enough blood throughout the body. Without proper blood circulation, insufficient levels of oxygen and nourishment are delivered to various body parts, impacting a person&#8217;s ability to function and leading to a variety of symptoms that affect quality of life, both physically and emotionally, such as shortness of breath, extreme fatigue, exercise intolerance, swelling and fluid retention. HF usually develops as a result of an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:168.51pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">imbalance of the ANS, which is also the primary cause of multiple other cardiovascular diseases, such as hypertension, angina pectoris and arrhythmia.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The role of the imbalance of ANS in HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The ANS, which is a part of the peripheral nervous system, plays a vital role in the function of the heart. It is a collection of receptors and neurons that acts outside of a person&#8217;s conscious awareness, regulating bodily functions such as bodily fluid production, urination and sexual responses. There are two primary components of the ANS that impact heart functionality: the sympathetic system and the parasympathetic system.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The sympathetic system of the ANS is responsible for preparing the body for action through the &#8220;fight or flight&#8221; response. When the body perceives a threat in the environment, the sympathetic system reacts by increasing the heart rate, widening the airways to allow for easier breathing, releasing stored energy, increasing strength in the muscles and slowing digestion and other bodily processes that are not as critical for taking action. These changes prepare the body to respond appropriately to a threat in its environment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The parasympathetic system of the ANS is responsible for restoring the body to a state of calm through the &#8220;rest and digest&#8221; counter response in order to maintain homeostasis. This is done by decreasing the heart rate, conserving energy, constricting the airways, relaxing the muscles and increasing digestion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k006.jpg" alt="Logo&#10;&#10;Description automatically generated with low confidence" style="display:inline-block;height:168.51pt;width:204.6pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These two systems are strongly influenced by baroreceptors that are located in certain arterial walls. The baroreceptors regulate the baroreflex, which is one of the body&#8217;s homeostatic mechanisms that help to maintain blood pressure at nearly constant levels. Baroreceptors provide beat-by-beat regulation of the body&#8217;s circulatory system by sending electrical signals to the brain.<br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Healthy individuals have balanced sympathetic and parasympathetic activities, promoting the effective function of the heart. However, there are many factors, including a person&#8217;s diet, lifestyle and underlying conditions such as diabetes and obesity that can cause an imbalance of the ANS. This imbalance, or the elevated levels of sympathetic activity and reduced levels of parasympathetic activity, may result in additional stress on the heart, leading to HF and potentially death.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview of HFrEF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">When the heart pumps, oxygen-rich blood travels from the lungs, through the left atrium and into the left ventricle from where it is pumped to the rest of the body. Given that the left ventricle is responsible for the majority of the heart&#8217;s pumping power, it is larger than the other chambers and critical for proper heart functionality. In left-sided or left-ventricular HF, the left side of the heart must work much harder to pump the same of amount of blood it would under healthy conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There are two types of left-sided HF, HFrEF, or systolic heart failure, and HF with preserved Ejection Fraction (&#8220;HFpEF&#8221;), or diastolic heart failure. In HFrEF, the left ventricle loses its ability to contract properly, resulting in insufficient power to pump and push the necessary quantities of blood into circulation. In HFpEF, the left </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:198pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">ventricle loses its ability to relax properly (due to muscle stiffness), leading to the improper filling of blood in the heart during the resting period between heartbeats.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k007.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:197.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:423.6pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are currently focused on the treatment of patients with HFrEF, which represents approximately 40% of the patients with HF. These patients currently have limited commercially available device-based treatment options that improve HFrEF symptoms such as shortness of breath, fatigue, weakness, swelling of the legs and feet, reduced ability to exercise, a persistent cough, an increased need to urinate and sudden weight gain. Approximately 75% of HFrEF patients die within five years of being admitted to the hospital for HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Given HFrEF is a multifactorial and heterogeneous disease, physicians use a variety of indicators in the underlying pathology, severity of symptoms and a patient&#8217;s functional limitations to classify HF patients. Below are some of the common indicators used by cardiologists to diagnose HF:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NYHA classification:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The NYHA classification guidelines are the most common measure of HF severity and allow physicians to classify patients into four groups based on observed symptoms and functional limitations. The least severe functional status is NYHA Class&#160;I (mild) with the most advanced being NYHA Class&#160;IV (critical). The majority of patients are initially identified as NYHA Class&#160;I or II and typically progress into subsequently worse states of the disease despite current treatment options. On average, patients who progress to a NYHA Class&#160;III either worsen to Class&#160;IV or die after 3.3&#160;years. HFrEF patients are typically classified as NYHA Class&#160;II (moderate) or Class&#160;III (severe).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Level of N-terminal prohormone B-type natriuretic peptide (&#8220;NT-proBNP&#8221;):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;NT-proBNP, a non-active prohormone in the heart, is released due to pressure changes inside the heart. NT-proBNP is considered to be at a normal level when it is &lt; 125pg/ml for patients 0&#8211;74&#160;years old and &lt; 450pg/ml for patients 75&#8211;99&#160;years old. Generally, patients with HF have elevated NT-proBNP levels, with those &gt; 1600pg/ml associated with an extremely poor prognosis and low responses to treatments.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Left ventricular ejection fraction (&#8220;LVEF&#8221;):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;LVEF is a widely utilized indicator of systolic heart function, or the heart&#8217;s ability to pump blood throughout the body. It measures the&#160;percentage of blood that is ejected from the left ventricle with each beat. A LVEF &lt; 50% is considered dysfunctional and indicative of HFrEF.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Co-morbidities / clinical fit:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;A patient&#8217;s co-morbidities, such as severe chronic obstructive pulmonary disease (COPD), kidney disease or carotid stenosis, as well as a patient&#8217;s physical and psychological fit contribute to a physician&#8217;s treatment recommendation given the use of general anesthesia in most HF-related device-based treatment options.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">QRS complex:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The QRS complex is a classification of ventricle depolarization, or the heart&#8217;s ability to open once contracted. It measures the way in which electrical signals travel through the heart and considers the mechanics and duration of the ventricle depolarization. A narrow QRS complex, or a QRS &lt; 120 milliseconds, is usually driven by a right bundle branch block, which is a blockage along the pathway that electrical pulses travel through to the right ventricle in order to generate a heartbeat. A wide QRS complex, or a QRS&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8805;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;150 milliseconds, is usually driven by a left bundle branch block, which is a blockage impacting the pathway to the left ventricle.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Existing treatments for HFrEF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients with HFrEF are typically placed on a treatment progression plan during which they are initially given GDMT to help manage symptoms. GDMT usually includes a progression or combination of prescribed drugs such as Diuretics, Beta-blockers, ACE Inhibitors, ARBs, ARNIs, SGLT2 Inhibitors and Sinus Node Inhibitors. After being treated with pharmaceuticals for a short period, if the symptoms persist, patients move to more invasive and costly treatment options involving other implantable devices, with the most severe patients often requiring LVADs or heart transplants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other commercially available implantable devices</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantable Cardiac Defibrillators (ICD)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">ICDs are indicated for patients with NYHA Class&#160;II or III and LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% for both wide and narrow QRS. However, these devices are generally used to prevent sudden cardiac arrest rather than reduce HFrEF symptoms as their electrical shocks focus on restoring a normal heartbeat when a heart beats too quickly or randomly. Given their purpose and mechanism of action, these devices are not a treatment for HFrEF but are used in conjunction with other treatment options that focus on reducing HF symptoms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Cardiac Resynchronization Therapy (&#8220;CRT&#8221;)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CRTs, or biventricular pacing, are indicated for patients with NYHA Class&#160;II or III, LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and wide QRS. These devices are primarily used to reduce symptoms of HFrEF by generating electrical pulses to regulate the pace of a heartbeat. While CRTs can alleviate symptoms for patients with a wide QRS, they are not eligible for patients with a narrow QRS, which represents approximately 59% of patients with NYHA Class&#160;II or III and LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35%. These devices can be combined with an ICD, which are referred to as CRT-D.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Cardiac Contractility Modulation (&#8220;CCM&#8221;)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CCM is eligible for patients with a NYHA Class&#160;III, LVEF 25%&#8211;45%, narrow QRS and normal sinus rhythm. CCM requires an invasive procedure whereby an IPG is implanted under the skin of the upper chest with electrical leads running through the veins and attached inside the heart&#8217;s ventricles, sending electrical pulses to the heart after it contracts. The device is rechargeable and therefore requires patients to recharge the battery on a regular basis.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Left Ventricular Assist Device (LVAD)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">LVAD is an irreversible, invasive surgery generally reserved for critical HFrEF patients with NYHA Class&#160;IV. An LVAD is a mechanical pump that is implanted inside a patient&#8217;s chest and helps pump blood throughout the body. While LVADs do not replace the heart, they do require open chest surgery and often result in the destruction of a portion of the heart. Patients who do not respond to LVADs usually have no other treatment options and become candidates for heart transplants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Despite currently available pharmaceutical and device-based treatments, HF remains underpenetrated and imposes significant direct and indirect costs on the healthcare system through patient care, morbidity, unpaid </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:222pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">care costs, premature mortality and lost productivity. We estimate there are approximately 800,000 HF hospitalizations every year in the U.S., representing approximately $39.5&#160;billion in annual spending.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barostim&#8217;s market opportunity</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We estimate that our initial annual market opportunity for HFrEF is $2.9&#160;billion. This includes a $1.4&#160;billion initial market opportunity based on approximately 55,000 new HFrEF patients in the U.S., and a $1.5&#160;billion initial market opportunity based on approximately 61,000 new HFrEF patients in EU5. The graphic below indicates what we believe would be the stratification of our annual addressable patient population in the U.S. based on our indication for use and excludes patients who are clinically or psychologically unfit or who have severe comorbidities:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k008.jpg" alt="A screenshot of a computer&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:221.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:230.3pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The annual market opportunity for Barostim is based on the following HF classifications:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NYHA Class&#160;III or II (with recent history of III):&#160;</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Barostim provides symptomatic relief for patients with NYHA Class&#160;III or II (with recent history of III), or patients who generally have limits on basic daily activities but are comfortable when resting. We estimate this represents approximately 722,000 of the 1.3&#160;million annual new HF patients in the U.S.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NT-proBNP &lt; 1600pg/ml when stable:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim targets patients who have NT-proBNP &lt; 1600pg/ml, which represents approximately 470,000 of the 722,000 of NYHA Class&#160;III or II (with recent history of III) annual HF patients in the U.S.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Left ventricular ejection fraction (LVEF)&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:-0.2pt;">&#8804;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">&#160;35%:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim targets patients with a LVEF&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8804;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;35%, which we estimate represents approximately 182,000 of the 470,000 annual HF patients with NT-proBNP &lt; 1600pg/ml in the U.S.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Clinically fit:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim is not indicated for HFrEF patients with certain contra-indications, including carotid atherosclerosis and ulcerative plaques, among others. Physicians often exclude patients who are not deemed clinically fit to undergo Barostim procedure. We estimate this represents approximately 94,000 of the 182,000 annual HFrEF patients with LVEF&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8804;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;35% in the U.S.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Not indicated for CRT:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#160;&#160;Barostim targets patients who are not indicated for CRT, particularly patients with QRS &lt; 120ms. We estimate this represents approximately 55,000 of the 94,000 annual HFrEF patients in the U.S. who are clinically fit.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:159.03pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Limitations of other commercially available device-based option for indicated HFrEF patients</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There is only one other commercially available device-based option, Cardiac Contractility Modulation (CCM), that targets a subset of the same HFrEF patient population indicated for Barostim. CCM is offered by a single privately-held medical technology company and while it has the potential to improve a patient&#8217;s quality of life and reduce symptoms of HFrEF, it is not designed to address the imbalance of the ANS. We believe CCM is associated with the following drawbacks that have resulted in a remaining significant unmet need for a safe, effective and minimally invasive device-based treatment option for HFrEF patients:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Limited overlap in target patient population:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;CCM is indicated for a limited population of HF patients with a NYHA Class&#160;III, LVEF 25%&#8211;45%, narrow QRS and normal sinus rhythm. Within this population, a subset of patients indicated for Barostim are also eligible for CCM, namely those with NYHA Class&#160;III and LVEF 25%&#8211;35%. As a result, Barostim is the only FDA approved device indicated to improve symptoms for HFrEF patients with NYHA Class&#160;III and LVEF &lt;25%, as well as with NYHA Class&#160;II (with a recent history of Class&#160;III) and LVEF&#160;&#8804;35%.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k009.jpg" alt="A screenshot of a computer&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:158.68pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:348pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Limited clinical effectiveness in patients with LVEF 25&#8211;35%:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">&#160;Based on published clinical data, CCM demonstrated lower effectiveness in the patients with LVEF 25&#8211;35% as compared to the patients with LVEF 35&#8211;45% across all three evaluated areas: exercise capacity, quality of life and functional status. Patients with LVEF 25&#8211;35% who were implanted with CCM walked only 10 additional meters in six minutes and improved the patients&#8217; quality of life by only nine points as compared to the control arm. Furthermore, only 25% of these patients showed an improvement in functional status.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#8203;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:197.08pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k010.jpg" alt="Table&#10;&#10;Description automatically generated" style="display:inline-block;height:197.08pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:361.2pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Invasive procedure:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;CCM requires an invasive procedure that places hardware directly inside the heart, which increases risks to patients. This approach involves a pacemaker-type device to be placed under the skin of the upper chest with two to three electrical leads running through the veins and attached to the heart&#8217;s ventricle.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Requires patient compliance</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">:&#160;CCM devices require patients to charge the battery inside the IPG as often as once per week, which may result in a lack of patient compliance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our solution</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We developed our Barostim platform technology to transform the treatment of HFrEF and other cardiovascular diseases and become the standard of care for this vulnerable and underpenetrated patient population. We believe Barostim offers meaningful benefits for patients, physicians and payors that will continue to drive adoption of our therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">&#160;</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview of Barostim Therapy</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our integrated platform technology, Barostim, leverages the power of the brain and nervous system to address the primary cause of HFrEF and other cardiovascular diseases. Our product, Barostim, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HFrEF. Barostim Therapy utilizes a widely accepted mechanism of action and works by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to decrease sympathetic activity and increase parasympathetic activity. This integrated response to rebalancing the ANS is well understood to normalize blood pressure, improve remodeling of the heart, increase vasodilation (widening of blood vessels) and improve kidney function. Based on the results of our BeAT-HF pivotal trial, Barostim has demonstrated its ability to meaningfully improve the quality of daily life, both physically and emotionally, for patients suffering from HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barostim</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim consists of two implantable components: an IPG and a stimulation lead. The image below depicts the relative location and size of Barostim under the patient&#8217;s skin:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:201.02pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k011.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:200.57pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:292.8pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantable pulse generator</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The current IPG contains the electronics and battery in a hermetic enclosure, has an average service life of five&#160;years and includes a battery that does not require any recharging. The IPG provides control and delivery of electrical pulses to baroreceptors located in the wall of the carotid artery through the stimulation lead. Nominal dimensions for the current IPG are listed in the figure below:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k012.jpg" alt="A picture containing table&#10;&#10;Description automatically generated" style="display:inline-block;height:126pt;width:234pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Stimulation lead</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The stimulation lead is attached via six suture points to the exterior wall of the carotid artery and is connected to the current IPG. This allows the stimulation lead to carry the electrical pulses from the IPG to the baroreceptors located in the wall of the carotid artery. The stimulation lead terminates with a two-millimeter electrode. There are two lengths of the stimulation lead available to allow for anatomical variations to be used at the physician&#8217;s discretion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:135pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k013.jpg" alt="A picture containing text, device&#10;&#10;Description automatically generated" style="display:inline-block;height:135pt;width:435pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Ancillary surgical accessories</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to the IPG and stimulation lead, we provide physicians with single-use surgical tools, including the port plug, torque wrench, implant tool and implant adaptor, all of which were designed to facilitate the implantation of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Programmer</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Once implanted, Barostim is managed wirelessly by a programmer that communicates with the IPG. The programmer can be used to assist in verifying the desired location of the stimulation electrode during the implant procedure and allows physicians to input their patient&#8217;s therapy parameters and retrieve information on the status of the IPG, including the remaining battery life, without touching the IPG or the patient.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k014.jpg" alt="A picture containing text, electronics, computer, computer&#10;&#10;Description automatically generated" style="display:inline-block;height:131.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:168pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treating patients with Barostim</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Patient selection</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is indicated for the improvement of symptoms of HFrEF&#8201;&#8212;&#8201;quality of life, 6MHW and functional status&#8201;&#8212;&#8201;for patients who remain symptomatic despite treatment with GDMT, are NYHA Class&#160;III or II (who had a recent history of Class&#160;III), have a left ventricular ejection fraction&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35%, a NT-proBNP &lt; 1600 pg/ml and are not indicated for CRT according to the AHA/American College of Cardiology (&#8220;ACC&#8221;)/European Society of Cardiology (&#8220;ESC&#8221;) guidelines.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Once a patient is diagnosed with HFrEF and recommended for an ICD and/or CRT, general cardiologists will usually refer them to EPs. EPs will often conduct a series of diagnostic tests, including an electrocardiogram, ultrasound and various blood tests, from which they will determine the patient&#8217;s eligibility for our therapy. The vast majority of our indicated patients are well-defined under the purview of an EP and may have already been pre-indicated for an ICD, whether or not they chose to undergo the ICD implantation procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantation</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is implanted during a short, minimally invasive procedure that is typically performed on an outpatient basis by a vascular surgeon and possibly an EP. The procedure has two steps. During the first step, a small incision is made on the right side of the neck to expose the carotid sinus. The physician uses the implant tool to hold the lead electrode in contact with the outside wall of the carotid artery while the lead is temporarily connected to the IPG to verify the location of the electrode. After the electrode is sutured in place, the second step begins by making a small incision below the right clavicle where a pocket is created under the skin to hold the IPG. The main body of the stimulation lead is tunneled under the skin, but over the clavicle, from the neck to the pocket. The lead connector is inserted and secured into the IPG header. Lastly, the IPG is placed in the pocket and a few stiches are used to close each incision.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This implantation procedure, which typically lasts one hour, is usually performed under general anesthesia and may require a short hospital stay. While patients may experience mild discomfort and swelling at the incision sites for a few days, this often can be managed with over-the-counter pain medications. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Activation/Titration</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After Barostim is implanted and activated, the patient attends a few follow-up visits with their doctor, during which the device is progressively titrated from a moderate level to a higher amplitude of electrical stimulation. The primary objective of these follow-up visits is for the patient to reach the optimal level of stimulation, which is typically achieved approximately three&#160;months after implantation. The exact level of stimulation varies from patient to patient based on the response to Barostim Therapy. Barostim can be adjusted through a digital wireless programmer, allowing the clinician to monitor and customize the therapy to the patient&#8217;s needs by adjusting the intensity and frequency of the electrical pulses being sent to the carotid artery. After the titration period, it is recommended that the patient attend a clinical visit two times each year to check impedance, battery longevity and adequacy of programming.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Key benefits for patients, physicians and payors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is designed to advance patient care and provide a safe, effective and economically attractive treatment option to an underserved patient population suffering from HFrEF. We believe the following factors offer meaningful benefits for patients, physicians and payors that will continue to drive broad adoption of our therapy:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Addresses significant unmet medical need. </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Barostim addresses a life-threatening disease for patients who failed to receive adequate benefits from existing treatments and who have no alternative treatment options. Based on this, the FDA granted Barostim a Breakthrough Device designation for HFrEF in June&#160;2015.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Safe and effective treatment.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our clinical trial results demonstrated compelling safety and effectiveness data regarding the HFrEF clinical benefits of Barostim. These results showed significant improvement in the following HF patient-centered outcomes:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by MLWHF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated a 14-point improvement in quality of life for patients in the device arm relative to patients in the control arm. A 5-point improvement is considered to be clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6MHW distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that patients in the device arm were able to improve their walking distance in a six-minute period by 60 meters more than that of patients in the control arm. A 25-meter improvement in walking distance is considered to be clinically meaningful.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by NYHA classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that 65% of patients who were in the device arm improved at least one NYHA class as compared to only 31% in the control arm, with 13% of patients improving two NYHA classes in the device arm as compared to only 2% in the control arm.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NT-proBNP (Serum biomarker used as indicator of severity of HF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that patients in the device arm had a 25% improvement in NT-proBNP relative to that of patients in the control arm. A 10% improvement is considered to be clinically meaningful.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The significant benefits of our therapy were observed despite a four-fold uptake of ARNI medication in the control arm, as compared to the device arm.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Widely accepted mechanism of action.&#160;</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our platform technology is based on a widely accepted mechanism of action and is designed to address the imbalance of the ANS, which causes HFrEF and other cardiovascular diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Strong global clinical evidence.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The benefits of treatment with Barostim were shown to be similarly robust and reproducible across all three of our HF clinical studies, including BAT-in-HF (Phase&#160;I), HOPE4HF (Phase&#160;II) and BeAT-HF (Phase&#160;III pivotal trial), evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. The BeAT-HF pivotal trial, which was a multi-center, prospective, randomized, controlled trial, met its primary endpoints and the positive safety and effectiveness data exceeded the pre-specified performance criteria across multiple dimensions, measuring the improvement in the quality of patients&#8217; daily lives. Barostim Therapy&#8217;s trial results have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the Journal of the American College of Cardiology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Minimally invasive implant procedure.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim&#8217;s IPG and stimulation lead are implanted during a minimally invasive implant procedure typically performed in an outpatient setting that lasts approximately one hour and involves two small skin incisions. Our device does not require hardware to be implanted in the heart or vasculature, which is the case with most other device-based treatments indicated for different HFrEF patient populations. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure. In addition, we are currently developing a new implant toolkit called BATwire, which enables an ultrasound-guided procedure to implant Barostim and the use of local anesthetics. As a result of this simplified implantation process, we believe more physicians, including EPs, would be confident and comfortable implanting Barostim, thereby expanding our addressable patient population to include those who are deemed clinically unfit for the current procedure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential reduction in total healthcare costs for HFrEF patients.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;In addition to providing improved physical and health-related benefits and quality of life for patients, we estimate Barostim has the potential to result in cost savings to healthcare systems. A Company-sponsored and co-authored cost-impact analysis, which was published in&#160;</span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">BMC Cardiovascular Disorders</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, a peer-reviewed manuscript, predicted BAT plus GDMT would become the lower-cost alternative treatment within three&#160;years from implantation, as compared to GDMT alone, resulting in significant cost savings to healthcare systems.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Inherent patient compliance and durability.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim ensures patient compliance, unlike most commercially available drug treatments, as it requires no device interaction by the patient. Our device has a battery that does not require recharging, has an average service life of five&#160;years and is replaced through a short outpatient procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical results and studies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness of Barostim in HFrEF is supported by compelling data, which demonstrated similarly robust and reproducible results across our three clinical trials evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. We designed our BeAT-HF (Phase&#160;III) pivotal trial in collaboration with the FDA under the Breakthrough Devices Program, which was </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.02pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">implemented to accelerate the approval of novel therapies targeting unmet needs for debilitating or life-threatening conditions. Our BeAT-HF pivotal trial met the primary safety and effectiveness endpoints and demonstrated meaningful improvement in the quality of life, both physically and emotionally, for patients suffering from HFrEF. These results led to the FDA approval of Barostim in August&#160;2019 on an accelerated basis of only four&#160;months from the submission of the final clinical trial report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is indicated for the improvement of symptoms of HFrEF&#8201;&#8212;&#8201;quality of life, 6MHW and functional status&#8201;&#8212;&#8201;for patients who remain symptomatic despite treatment with GDMT, are NYHA Class&#160;III or Class&#160;II (with a recent history of Class&#160;III), have a LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35%, a NT-proBNP &lt; 1,600 pg/ml and excluding patients indicated for CRT according to AHA/ACC/ESC guidelines.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness of Barostim Therapy have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the publication of the pivotal trial results in the Journal of the American College of Cardiology. The table below summarizes the clinical measurements, results and outcomes from our HF trials, including improvements in HF symptoms, patient-reported quality of life measures and our therapy&#8217;s favorable safety profile.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k015.jpg" alt="Table&#10;&#10;Description automatically generated" style="display:inline-block;height:206.72pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:448.88pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have established a U.S. patient registry to evaluate and assess real world patient outcomes from patients who have been implanted with Barostim. Investment in clinical evidence continues to be one of our core strategies, and we intend to continue to develop and expand upon a significant body of published clinical evidence that supports the safety and effectiveness of Barostim Therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pivotal Phase&#160;III Study: BeAT-HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Overview</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">BeAT-HF is a multi-center, prospective, randomized, controlled trial that began in April&#160;2016 to develop scientific evidence for the safety and effectiveness of BAT with Barostim. Between May&#160;2016 and July&#160;2020, 467 adult patients were randomized at 72 sites within the U.S. and one site in the United Kingdom.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The BeAT-HF study was designed to encompass two stages in an integrated and seamless approach:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(1)&#160;&#160;&#160;A pre-market stage that examined three primary effectiveness endpoints, quality of life, 6MHW and NT-proBNP as well as one safety endpoint that included the major adverse neurological or cardiovascular system or procedure-related event rate (&#8220;MANCE&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:267pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(2)&#160;&#160;&#160;A post-market stage that will examine the effects of BAT on rates of HF hospitalization and cardiovascular mortality and potentially expand the indication for Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients were eligible for the trial if they were NYHA Class&#160;III or Class&#160;II (with a recent history of Class&#160;III); had an LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and NT-proBNP &lt; 1,600 pg/ml; were able to complete a 6MHW distance of 150 to 400 meters; were on stable optimal GDMT for&#160;<span style="letter-spacing:0.2pt;">&#8805;</span>&#160;4 weeks; had at least one carotid artery that was below the level of the mandible with no ulcerative carotid arterial plaques or stenosis&#160;<span style="letter-spacing:0.2pt;">&#8805;</span>&#160;50%; and were an acceptable surgical candidate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients who had AHA/ACC/ESC Class&#160;I indication for a CRT were excluded, and there were no restrictions for atrial fibrillation or atrial flutter.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients who met all eligibility criteria with complete baseline measurements were randomized 1:1 to receive Barostim Therapy plus GDMT (&#8220;BAT+&#8221;) or GDMT alone (&#8220;Control&#8221;). BAT+ was delivered by implanting patients with a Barostim Neo System, while keeping the patient on maximally tolerated GDMT. Control was defined as maximally tolerated GDMT.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the pre-market stage of the BeAT-HF pivotal trial, four patient cohorts were developed in collaboration with the FDA under the Breakthrough Devices Program and shown in the following graphic:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k016.jpg" alt="Graphical user interface, text, application, Teams&#10;&#10;Description automatically generated" style="display:inline-block;height:267pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:439.38pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cohort A (n=271):&#160;In the six-month data available, improvements were seen in two of the three primary effectiveness endpoints, and the safety endpoint MANCE-free rate of 94% exceeded the performance criteria of 85% (p = 0.002). There was no statistically significant reduction in NT-proBNP observed, which contrasted the significant reduction of NT-proBNP seen in the HOPE4HF Phase&#160;II trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cohort B (n=162):&#160;Results from cohort A led to the hypothesis-generating cohort B, which included 162 of the 271 patients in cohort A with an NT-proBNP &lt; 1,600 pg/ml. In the six-month data available, improvements were seen in all three primary effectiveness endpoints and resulted in a MANCE-free rate of 97%. A hypothesis was then formally articulated in a revised statistical analysis plan (&#8220;SAP&#8221;). This SAP was submitted and reviewed with FDA before the cohort C completed its six-month follow-up period.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:423.6pt;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cohort C (n=102):&#160;Results from cohort B led to the hypothesis-confirming cohort C, which consisted of 102 patients with NT-proBNP &lt;1,600 pg/ml. In the six-month data available for cohort C, improvements were seen in all three primary effectiveness endpoints. This confirmed the findings in cohort B.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cohort D (n=264):&#160;Cohort D is a combined cohort, representing the intended use population, and consisted of 264 patients combined from cohorts B and C. Data from cohort D was used to define the indication for use and the labeling of Barostim in the PMA submission.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Trial results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The study consisted of 1,090 enrolled patients across 92 centers, of which 467 met the eligibility criteria and were randomized in the trial. In the pre-market stage, 264 randomized patients who met the intended use criteria were randomized 1:1 with 130 patients in the BAT+ group and 134 patients in the Control group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k017.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:423.6pt;width:420.6pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness data in the BeAT-HF pivotal trial support the HFrEF clinical benefits of Barostim. These results demonstrated that BAT is safe in patients with HFrEF and significantly improves the patient-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">centered symptomatic endpoints of the quality of life score, 6MHW and functional status, as well as the confirmatory nature of the evidence provided by a reduction of NT-proBNP.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by MLWHF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 14-point reduction (improvement) in quality of life for patients in the BAT+ group relative to patients in the Control group (p &lt; 0.001; 95% CI:&#160;-19&#160;to&#160;-9).&#160;MLWHF is a self-administered disease-specific questionnaire for HF, which is comprised of 21 questions rated on six-point Likert scales, representing different degrees of impact of HF on a patient&#8217;s quality of life, and is approved by the FDA as a Medical Device Development Tool. According to the medical community, a five-point reduction (improvement) is considered to be clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6MHW distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 60-meter increase in the distance patients in the BAT+ group were able to walk on a flat, hard surface in a six-minute period relative to that of patients in the Control group (p &lt; 0.001; 95% CI: 40 to 80 meters). According to the medical community, the 6MHW is an index of a patient&#8217;s ability to perform daily activities; an improvement of 25 meters or more is considered to be clinically meaningful to HFrEF patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by NYHA classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT demonstrated that 65% of patients in the BAT+ group improved at least one NYHA class (p &lt; 0.001; 95% CI: 22% to 46%) as compared to only 31% in the Control group, and 13% of patients in the BAT+ group improved two NYHA classes as compared to only 2% in the Control group.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NT-proBNP (serum biomarker used as indicator of severity of HF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 25% greater reduction (improvement) in NT-proBNP for patients in the BAT+ group relative to that of patients in the Control group (p=0.004; 95% CI =&#160;-38%&#160;to&#160;-9%).&#160;According to independent research that took place in a large multicenter pharmaceutical clinical trial, a 10% change in NT-proBNP is associated with a change in the subsequent risk of cardiovascular mortality and HF hospitalization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Safety</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The MANCE-free rate exceeded the performance criteria of 85%, with 121 out of 125 implanted patients being event free, resulting in an event-free rate of 97% (p &lt; 0.001; 95% 1-sided CI: 93% to 100%).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Effectiveness results in context</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">While Barostim is not intended to compete with CRT therapies, it is useful to compare the symptomatic results achieved by CRT devices when they were initially FDA approved. Patients suffering from HFrEF have similar outcomes and symptoms irrespective of whether they are indicated for CRT, and thus provide a good proxy to understand the adoption of these therapies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:297pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20211231x10k018.jpg" alt="Table&#10;&#10;Description automatically generated" style="display:inline-block;height:297pt;width:456pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">The results presented in this table have been derived from publicly available reports of clinical trials run independently of the Company or meta-analyses of such clinical results. The Company has not performed any head-to-head trials comparing any of these other HF therapies with Barostim. As such, the results of these other clinical trials may not be comparable to clinical results for Barostim. The design of these other trials vary in material ways from the design of the clinical trials for Barostim. For further information and to understand these material differences, you should read the relevant reports or meta-analyses.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Ancillary analysis</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the initial six-month follow-up period, there was a disproportionately higher number of medications added in the Control group when compared to BAT+ group. Control patients were more likely to have a new class of drugs added (36 [29%] Control vs 21 [18%] in BAT+; difference of 11%, p=0.049; 95% CI: 1% to 22%) and were more likely to have a new ARNI added (20 [16%] Control vs 5 [4%] BAT+; difference of 12%, p=0.003; 95% CI: 4% to 19%). The significant symptomatic improvement in the BAT+ group demonstrated in the trial was observed despite a disproportionate increase in the number of medications in the Control group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to the results noted above, we observed a reduction in the rate of cardiovascular serious adverse events (non-HF related events) by 51% (events per patient-year; 0.101 BAT+ vs 0.206 Control; nominal p= 0.023; 95% CI: 0.10 to 0.73) and there were no significant differences in blood pressure or heart rate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The BeAT-HF pivotal trial continued enrolling patients in the post-market stage of the trial in order to determine if Barostim demonstrates a statistically significant improvement in morbidity and mortality in patients with HFrEF. Enrollment was completed and patient follow-up continues to collect morbidity and mortality events until the pre-specified number of events has been accumulated. The patient follow-up data is expected to accrue by the end of 2022. If we successfully obtain FDA approval for a morbidity and mortality indication in HFrEF, we believe our addressable patient population would expand significantly and our therapy could be included at a higher class in the HF medical guidelines.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;II Study: HOPE4HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HOPE4HF was a multinational, prospective, randomized, controlled trial that began in May&#160;2012 to demonstrate the safety and performance of BAT with Barostim. A total of 146 patients (72 in the U.S. and 74 in Germany, Italy, France and Canada) at 45 centers were randomized 1:1 with 76 patients in the BAT+ group and 70 patients in the Control group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients were eligible for the study based on symptoms, historical treatment plan and anatomical criteria, including if they were NYHA Class&#160;III, received GDMT for their HF, had a LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and were considered a suitable surgical candidate, among others. Patients were excluded from the study if they had recently experienced NYHA Class&#160;IV, recently received an ICD or CRT, or had known baroreflex failure, among others.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety endpoints were system- and procedure-related complications and system- and procedure-related MANCE within six&#160;months of implantation. The effectiveness endpoints included changes in functional status, quality of life as measured by the MLWHF, exercise capacity as measured by 6MHW distance, cardiac function as measured by echocardiography and serum biomarkers. Additional hypothesis generating observations were made to assess outcome as measured by HF hospitalizations and HF hospitalization days.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The overall MANCE-free rate was 97% (lower 95% CI bound 91%). Patients assigned to BAT+ group, compared with Control group patients, experienced improvements in MLWHF quality of life score (&#8211;17 &#177; 2.8 points BAT+ vs. 2.1 &#177; 3.1 points Control; p &lt; 0.001), 6MHW distance (60 &#177; 14 meters BAT+ vs. 1.5 &#177; 13 meters Control; p=0.004) and NT-pro BNP (-69 pg/ml BAT+ vs. 130 pg/ml Control; p =0.02). BAT+ patients also experienced at least a one-class improvement in NYHA class when compared to the Control group (55% BAT+ vs 24% Control; p=0.002) and showed a trend toward fewer days hospitalized for HF (p=0.08) as compared to the Control group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Positive safety and performance results from the 146-patient combined, randomized, controlled clinical trials were presented in the late breaking clinical trial session of the American College of Cardiology and the European Society of Cardiology HF conference in 2015. The favorable data from this trial were published in the&#160;<i style="font-style:italic;">Journal of the American College of Cardiology&#8201;&#8212;&#8201;Heart Failure</i>&#160;in 2015<i style="font-style:italic;">.</i>&#160;These results led to CE Mark approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Subgroup analysis</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The study had a prespecified subgroup analysis of patients who were treated at baseline with CRT versus patients without CRT. Of the 146 patients who were randomized, 140 were active at baseline: 45 patients had a CRT and 95 patients did not have a CRT. The results of this subgroup analysis showed a MANCE-free rate at six&#160;months of 100% in the CRT group and a 96% rate in the no-CRT group. At six&#160;months, the quality of life as measured by the MLWHF, 6MHW distance, LVEF and NT-pro BNP were significantly improved in the BAT+ group with no-CRT compared to control patients with no-CRT. In the no-CRT BAT+ group, HF hospitalizations were significantly reduced when comparing the periods before and after implant. Patients who received BAT+ showed a symptomatic improvement in the CRT group and the improvements were even more pronounced in the no-CRT group. The results of the substudy were presented in the Late Breaking Clinical Trial session of the Heart Rhythm Society in 2015 and published in the&#160;<i style="font-style:italic;">European Journal of Heart Failure.</i>&#160;The substudy results led to FDA Breakthrough Device designation for HFrEF in June&#160;2015.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;I Study: BAT in HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">BAT in HF was our first-in-human study of Barostim Therapy for the treatment of HF that was published in 2014. This study was a single-center, open-label evaluation, designed to evaluate the safety and performance of Barostim Therapy in patients with NYHA Class&#160;III receiving optimized medical therapy for their HF and had an LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;40%. Patients who had been implanted with a CRT device were excluded from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">this trial until six&#160;months after activation. Eleven patients met the eligibility criteria and received Barostim. After six&#160;months of Barostim Therapy, the mechanism of action was assessed with serial measurement of muscle sympathetic nerve activity (&#8220;MSNA&#8221;) and clinical measures of quality of life and functional capacity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">MSNA was reduced over six&#160;months from 45 &#177; 7.7 to 31 &#177; 8.3 bursts/minute and from 68 &#177; 13 to 45 &#177; 12 bursts/&#8203;100 heartbeats, decreases of 31% and 33%, respectively (p &lt; 0.01). Concomitant improvements occurred in baroreflex sensitivity, ejection fraction, NYHA class and quality of life as measured by the MLWHF and 6MHW distance (p&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;0.05 each). On an observational basis, hospitalization and emergency department visits for worsening HF were reduced.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This study provided the first evidence that chronic stimulation of carotid baroreceptors markedly and persistently reduced the sympathetic activation characterizing HF patients. It also demonstrated that the reduction is accompanied by the improvement of a major modulator of sympathetic activity, the arterial baroreflex and baroreflex activation is accompanied by favorable therapeutic impact on cardiac function and clinical profile, as shown in the improved quality of life, increased exercise tolerance and improved functional status.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other clinical trials</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">BATwire implant toolkit</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the second half of 2020, the FDA approved a two-stage pivotal trial design to assess the safety and effectiveness of the BATwire implant toolkit. This trial is expected to enroll 180 subjects and follow 71 implanted subjects for one year. If the trial data meets the safety and effectiveness endpoints, we will submit an application for a PMA-supplement approval by FDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Hypertension</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have completed two clinical trials in Europe and North America for the treatment of drug-resistant hypertension using our first-generation Barostim Therapy device called Rheos, including a randomized, controlled double-blinded 322-patient trial that completed enrollment in 2009. In 2010, we determined this study was successful in achieving three of the required five safety and effectiveness endpoints (&#8220;<i style="font-style:italic;">Baroreflex Activation Therapy Lowers Blood Pressure in Patients with Resistant Hypertension: Results from the Double-Blind, Randomized, Placebo-Controlled Rheos Pivotal Trial</i>,&#8221; by John D. Bisognano, M.D. et al that was published in 2011 in the Journal of the American College of Cardiology, volume 58, No. 7, 2011). Because of these results, we decided not to pursue PMA approval of the Rheos device, and instead focused our development roadmap on completing our second-generation system, Barostim. In 2014 we submitted a request for a Humanitarian Device Exemption (&#8220;HDE&#8221;) to commercialize Barostim Legacy, our second generation IPG for the subjects that were enrolled in the Rheos Pivotal trial, who are benefitting clinically from Rheos (estimated at the time to be 70&#8211;80% of the subjects enrolled) and whose IPG battery had become depleted. In December&#160;2014, after a favorable review of the long-term clinical data from the Rheos pivotal hypertension trial, the FDA granted the HDE to Barostim Legacy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Since 2011, we have completed one clinical trial in Europe and North America for the treatment of drug-resistant hypertension using Barostim (&#8220;<i style="font-style:italic;">Minimally Invasive System for Baroreflex Activation Therapy Chronically Lowers Blood Pressure with Pacemaker-like Safety Profile: Results from the Barostim Neo Trial</i>,&#8221; by Uta C. Hoppe, M.D. et al, in the Journal of the American Society of Hypertension, volume 5, no.&#160;4, 2012).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In August&#160;2011, we received CE Mark approval for Barostim for the treatment of resistant hypertension. In October&#160;2012, we received FDA approval to conduct a pivotal trial for the treatment of resistant hypertension entitled &#8220;<i style="font-style:italic;">Barostim Hypertension Pivotal Study</i>.&#8221; On April&#160;12, 2013, the study had its first enrollment. However, a redirection of our limited available financial and personnel resources to develop Barostim Therapy in HFrEF led to putting the trial on hold. In December&#160;2019, after review of the clinical data and the competitive </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">landscape, FDA granted a Breakthrough Device designation for Barostim for the treatment of resistant hypertension.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">HFpEF</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In March&#160;2020, after review of early clinical data and the competitive landscape, the FDA granted a Breakthrough Device designation for Barostim for the treatment of HFpEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sales and marketing</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have established a systematic approach to market development which centers on active engagement across three key stakeholders in the HFrEF treatment paradigm&#8212;patients, physicians and hospitals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim has FDA approval to improve symptoms of HFrEF in the U.S. and CE Mark for the treatment of HFrEF and hypertension in Europe. We market our therapy in the U.S. to hospitals and clinics where EPs, HF specialists, general cardiologists and vascular surgeons treat patients with HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We primarily sell Barostim to hospitals through a direct sales organization in the U.S. and Germany, and through distributors in Austria, Spain, Italy, the Nordic region and other European countries. Our global sales and marketing team engages in sales efforts and promotional activities focused on EPs, HF specialists, general cardiologists and vascular surgeons. We are actively expanding our direct sales force and commercial organization in the U.S., which is where we expect to focus most of our sales and marketing efforts in the near-term.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our direct sales representatives, which we refer to as Account Managers, generally have substantial and applicable medical device experience, specifically in the cardiovascular space, and market our products directly to the approximately 2,500 EPs, 800 HF specialists and 20,000 general cardiologists in the U.S. We support these physicians through all aspects of the patient journey, which includes initial diagnosis, surgical support and patient follow-up. Our Account Managers are focused on prioritizing high volume EP centers that are strategically located and on building long-standing relationships with key physicians who have strong connectivity to the HFrEF patient population that may be eligible for our therapy. We also employ Field Clinical Specialists who generally have experience in medical device clinical support. Our Field Clinical Specialists work to ensure that every procedure is done correctly by educating the implanting physicians, including vascular surgeons and EPs, about the technical aspects of Barostim and the implantation procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Similar to our direct sales team, our marketing team has a significant amount of relevant expertise and a strong track record of success in the medical device industry. Our marketing organization is focused on building physician awareness through targeted KOL development, referral network education and direct-to-consumer marketing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In terms of patient education, we utilize direct communication channels to inform patients about Barostim Therapy and to enable them to connect with active sites that offer Barostim. Our primary method of patient outreach is through digital social networks. We use a qualification process to aid in the identification of the appropriate patients for our therapy. The objective of this outreach is to target these patients and make them aware of our education webinars and website, where they can find a wealth of information on HFrEF and the purpose and benefits of Barostim Therapy, based on our approved labeling.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to driving broad awareness and increasing physician and patient education, our marketing team has developed the in-house resources necessary to assist patients and physicians in the process of obtaining prior authorization approval for their procedures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Third-party coverage and reimbursement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Coding and payment in the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the U.S., we sell Barostim primarily to hospitals, where the device is implanted in an outpatient setting. Our customers bill various third-party payors, such as government agencies, administrative contractors, commercial payors and integrated managed care organizations, for the cost required to treat each patient.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Third-party payors generally require physicians and hospitals to identify the service for which they are seeking reimbursement for by using CPT codes, which are created and maintained by the American Medical Association. Implantation of Barostim is described by CPT code 0266T, a Category III code approved in July&#160;2011 and effective as of January&#160;2012. Hospitals are able to use this code to submit for a system implant payment. CPT code 0268T is used to submit for an IPG replacement procedure payment, and CPT codes 0272T and 0273T are used for interrogation and programming of the IPG, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physician reimbursement under Medicare is generally based on a defined fee schedule, the Physician Fee Schedule, through which payment amounts are determined by the relative values of the professional services rendered. Medicare provides reimbursement to hospitals using Barostim under the hospital outpatient prospective system (&#8220;HOPPS&#8221;), which provides bundled amounts generally intended to reimburse a hospital for all facility costs related to procedures performed in its outpatient setting. Under the HOPPS, the national Medicare payment to a hospital for a new patient implant or an IPG replacement is paid using the Level&#160;5 Neurostimulator payment code APC 5465, which has a national average of $30,063 in 2022. Payment codes such as APC 5465 are indexed to adjust for cost of living and thus vary by location. These payments generally cover the hospital&#8217;s costs for the device and the implantation procedure. CMS also granted a TPT payment for the implantation of Barostim in an outpatient setting, which took effect in January&#160;2021. The TPT payment is an incremental payment for new and innovative technologies that meet certain qualifications. It allows hospitals to bill for a pass-through of the device cost, which includes up to $35,000, and can be added to the procedure costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We anticipate inpatient procedures to continue to represent a small&#160;percentage of our sales. For these inpatient procedures, ICD-10-PCS codes 0JH60MZ + 03HL3M are commonly mapped into Diagnosis Related Group (&#8220;DRG&#8221;) 252, which has an established national average Medicare payment of $21,930 in 2022. CMS also granted an NTAP that is added to the DRG for a three-year period starting in October&#160;2020 to cover the implantation of Barostim in an inpatient setting. The NTAP is an incremental inpatient payment for new and innovative technologies that meet certain qualifications. This payment allows hospitals to be reimbursed an additional $22,750 (65% of the total cost of the device), for a total national average Medicare payment of $44,680 in 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The surgeon implanting Barostim is paid an additional physician payment under the Medicare Physician Fee Schedule, which we believe is a reasonable amount for this type of procedure. The physician that manages the device performs multiple device interrogations and is paid using the payment code APC 5721, which has a national average of $140 per visit in 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement rates from commercial payors vary depending on a variety of factors, including, the commercial payor and contract terms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government program and commercial payor coverage in the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">A core pillar of our reimbursement strategy involves continuing to broaden our current coverage. Since approximately 67% of our target treatment population includes Medicare-eligible patients, we have prioritized CMS coverage while simultaneously developing processes to engage commercial payors. As of July 2020, all MACs have retired automatic coverage denial policies, thereby allowing hospitals to be paid for our procedure. In November 2021 CMS repealed its proposed rule entitled &#8220;Medicare Program; Medicare Coverage of Innovative Technology (&#8220;MCIT&#8221;) and Definition of &#8216;Reasonable and Necessary,&#8217;&#8221; which would have created an expedited process for Medicare coverage for breakthrough devices, and created greater </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">clarity around the definition of &#8220;reasonable and necessary&#8221; for coverage determinations.  Although the rule has been repealed, existing mechanisms remain to obtain Medicare coverage for breakthrough devices.  CMS has committed to considering additional process improvements to increase access to innovative devices. We will continue to monitor developments in this space, including decisions made by private payors, if any.       </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">A second pillar of our reimbursement strategy includes leveraging our in-house market access team to assist patients and physicians in obtaining appropriate prior authorization approvals in advance of treatment on a case-by-case basis where positive coverage policies currently do not exist. We believe our market access team is highly effective in working with patients and physicians to obtain prior authorizations for systems similar to Barostim, including handling the appeals process. We believe that we will continue to benefit from this efficient prior authorization process in the near-and-long-term by expanding on our positive coverage policies with commercial payors. We intend to have discussions with commercial payors to establish these positive coverage policies by highlighting our compelling and robust clinical data, the potential economic cost-savings associated with our highly compliant treatment, increased patient demand and support from leading medical societies and KOLs. As our operations continue to grow, we intend to further expand our market access team accordingly.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reimbursement outside of the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outside the U.S., reimbursement levels vary by country and within some countries, by region. We are currently selling Barostim in Germany, where the German Institute of Medical Documentation and Information supports various codes for reimbursement coverage. OPS code 5-059.c6 covers the implantation or replacement of a device stimulating the peripheral nervous system by activating the baroreceptors. This OPS code is combined with G-DRG ICD I50.13 to cover reimbursement of Barostim for the treatment of HFrEF. It can also be combined with G-DRG ICD I10.10 to cover reimbursement of Barostim for the treatment of hypertension. These DRG codes for both indications are combined with ZE code ZE2021-86 to cover the cost of the device. Barostim also is eligible for reimbursement in certain other European countries, where annual healthcare budgets for the hospital generally determine the number of patients to be treated and the prices to be paid for the related devices that may be purchased.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our research and development team has significant experience bringing innovative medical devices to market, including minimally invasive neuromodulation systems.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are committed to ongoing research and development efforts of Barostim with an emphasis on improving clinical outcomes, optimizing patient adoption and comfort, increasing access for a greater number of patients and allowing more physicians to perform the procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The primary focus of our research and development efforts in the near-term will be the continued technological advancement of Barostim, including tools to simplify the implant procedure for physicians. For example, in 2022 we expect to launch an enhanced IPG that will be approximately 10% smaller in size and improve the battery life by approximately 20% to an average of six&#160;years. We are also developing a new implant toolkit called BATwire, which enables an ultrasound-guided procedure to implant Barostim and the use of local anesthetics. This has the potential to expand our annual market opportunity in the U.S. by an estimated $1&#160;billion, or by 39,000 additional patients who are deemed clinically unfit for the current procedure. This simplified procedure would also allow EPs to complete the procedure in an outpatient catheter lab center.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">While we are currently focused on the treatment of patients with HFrEF, we believe our platform technology can provide meaningful benefits to a broader set of patients suffering from cardiovascular diseases with significant unmet needs. If we receive positive mortality and morbidity data from the post-market stage of the BeAT-HF pivotal trial, we plan to request that the FDA limit certain patient exclusions and add the claim &#8220;Treatment for Heart Failure&#8221; to our current indication. We believe this would increase our annual market </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">opportunity in the U.S. by an estimated $2.2&#160;billion, or by 88,000 additional patients. Our longer-term goal is to explore Barostim&#8217;s potential to expand the indications for use to other cardiovascular diseases, including different forms of HF, hypertension and arrhythmias. Expansions into these or other new indications would require additional FDA approvals and may involve additional clinical trials or modifications to Barostim to treat such indications. If clinical studies for future indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For the&#160;years ended December&#160;31, 2021 and 2020, we incurred research and development expenses of $7.5&#160;million and $6.4&#160;million, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our industry is subject to rapid change from the introduction of new products and technologies and other activities of industry participants. We consider our primary competition to be other device-based therapies designed to treat patients with HFrEF and a narrow QRS complex.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There is only one other commercially available device-based option, CCM, that targets a limited subset of the same HFrEF patient population indicated for Barostim. CCM is offered by a single privately-held medical technology company and has the potential to improve a patient&#8217;s quality of life and reduce symptoms of HFrEF. However, CCM is associated with a number of drawbacks, including not being designed to address the imbalance of the ANS; less favorable clinical effectiveness results in patients with LVEF 25&#8211;35% as compared to patients with LVEF 35&#8211;45% related to exercise capacity, quality of life and functional status; implantation through an invasive procedure that includes running electrical leads through the veins and attaching them to the heart&#8217;s ventricle, which may lead to increased risks to the patient; and the requirement that patients regularly charge the battery in their implanted device.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We believe that the primary competitive factors in the HFrEF treatment market are:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product safety, reliability and durability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">quality and volume of clinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adoption by patients, physicians and hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate reimbursement for our device;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product ease of use and patient comfort;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales force expansion, experience and access;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product availability, support and service;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing and supply chain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technological innovation and product enhancements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property portfolio.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Aside from device-based treatments, pharmaceutical therapies are widely used to treat HFrEF and have been in use longer and are better known to physicians and patients than Barostim. However, because Barostim is designed to be used in conjunction with pharmaceutical therapies to alleviate the symptoms of HFrEF, we do not consider existing pharmaceutical therapies to be direct competitors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We also compete with other medical technology companies to recruit and retain qualified sales, training and other personnel.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual property</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We rely on a combination of patent, copyright, trademark and trade secret laws and confidentiality and invention assignment agreements to protect our intellectual property rights. As of December&#160;31, 2021, we owned 54 issued U.S. patents and had three pending U.S. patent applications.&#160;Outside of the U.S., we owned seven patents in multiple countries and had one pending application.&#160;Our trademark portfolio focuses on nine trademarks in the U.S. and multiple other countries. Our patents cover aspects of our integrated platform technology, Barostim, including baroreflex methods, stimulus regimes, mapping methods, electrode designs, disease treatments, closed loop control, burst intervals, connection structures and baroreceptor locations, as well as future product concepts. The term of individual patents depends on the legal term for patents in the countries in which they are granted. In most countries, including the U.S., the patent term is generally 20 years from the earliest claimed filing date of a nonprovisional patent application in the applicable country. There is no active patent litigation involving any of our patents, and we have not received any notices of patent infringement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#8203;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We also rely, in part, upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. We protect our proprietary rights through a variety of methods, including confidentiality and assignment agreements with suppliers, employees, consultants and others who may have access to our proprietary information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our pending patent applications may not result in issued patents, and we cannot assure you that any current or subsequently issued patents will protect our intellectual property rights or provide us with any competitive advantage. While there is no active litigation involving any of our patents or other intellectual property rights and we have not received any notices of patent infringement, we may be required to enforce or defend our intellectual property rights against third parties in the future. See &#8220;Risk Factors&#8212;Risks Related to Intellectual Property&#8221; for additional information regarding these and other risks related to our intellectual property portfolio and their potential effect on us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing and supply</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We manage all aspects of manufacturing operations and product supply of Barostim, which includes final assembly, testing and packaging of our IPG and stimulation lead, at our 23,890 square foot headquarters in Minneapolis, Minnesota. With minimal capital investment, our existing operations are capable of producing 5,000 IPGs and 5,000 stimulation leads per shift per year, and our manufacturing line was designed to be expandable and scalable in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We currently source certain components for Barostim from a limited number of suppliers, including the module, module board, radio-frequency module, magnet switch, battery and application-specific integrated circuits for the IPG and the electrode for the stimulation lead. Our suppliers manufacture the components they produce for us and test our components and devices to meet our specifications. We maintain sufficient levels of inventory to mitigate potential supply disruption and to achieve more favorable volume-based pricing. We continue to seek to broaden and strengthen our supply chain through additional sourcing channels.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We select our suppliers to ensure that Barostim and its components are safe and effective, adhere to all applicable standards and regulations, are high quality and meet our supply needs. We employ a rigorous supplier assessment, qualification and selection process targeted to suppliers that meet the requirements of the FDA and relevant Canadian, European Union (&#8220;EU&#8221;) and Australian regulatory authorities and quality standards supported by internal policies and procedures. Our quality assurance process monitors and maintains supplier performance through qualification and periodic supplier reviews and audits. We received ISO certification for our quality management system and our most recent audits have not identified any major nonconformities. We are registered with the FDA as a medical device manufacturer and licensed by the State of Minnesota to manufacture our device.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><b style="font-weight:bold;">Seasonality</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that any revenue we generate could fluctuate from quarter to quarter as a result of timing and seasonality. We anticipate mild seasonality based on national holiday patterns specific to certain nations. These seasonal variations are difficult to predict accurately and may vary amongst different markets. In addition to the above factors, in the U.S. it is possible that we may experience seasonality based on patients&#8217; annual deductibility limits under their health insurance coverage. In Europe, we may be required to engage in a contract bidding process in order to sell Barostim, which processes are only open at certain periods of time, and we may not be successful in such bidding processes. In addition, it is possible that we may experience variations in demand for our product in the first fiscal quarter of each year in Europe, following publication of new coverage status and changes in hospital budgets pertaining to allocation of funds to purchase products such as Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government regulation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products and our operations are subject to extensive regulation by the FDA and other federal and state authorities in the U.S., as well as comparable authorities in the European Economic Area (&#8220;EEA&#8221;). Our products are subject to regulation as medical devices under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), as implemented and enforced by the FDA. The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, effectiveness, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, device tracking, adverse event reporting, recalls, safety alerts, injunctions, seizures, bans, advertising, promotion, marketing and distribution and import and export of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to U.S. regulations, we are subject to a variety of regulations in the EEA governing clinical trials and the commercial sales and distribution of our products. Whether or not we have or are required to obtain FDA clearance or approval for a product, we will be required to obtain authorization before commencing clinical trials and to obtain marketing authorization or approval of our products under the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials or commercialize our products in those countries. The approval process varies from country to country and the time may be longer or shorter than that required for FDA clearance or approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FDA pre-market clearance and approval requirements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Unless an exemption applies, each medical device commercially distributed in the U.S. requires either FDA clearance of a 510(k) premarket notification, HDE, or PMA approval. Under the FDCA, medical devices are classified into one of three classes&#8212;Class&#160;I, Class&#160;II or Class&#160;III or De Novo&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation (&#8220;QSR&#8221;), facility registration and product listing, reporting of adverse medical events and truthful and non-misleading labeling, advertising, and promotional materials. Class&#160;II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class&#160;I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class&#160;II devices are required to submit to the FDA a premarket notification under Section&#160;510(k) of the FDCA requesting permission to commercially distribute the device. De Novo is a medical device with no prior predicate device or premarket device for comparing substantial equivalence to; however, the FDA believes it is subject to 510(k) premarket notification. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#8220;substantially equivalent&#8221; to either a device that was legally </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">marketed prior to May&#160;28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, or another commercially available device that was cleared through the 510(k) process.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class&#160;III, requiring approval of an HDE or PMA. Some pre-amendment devices are unclassified but are subject to the FDA&#8217;s premarket notification and clearance process in order to be commercially distributed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our currently U.S. marketed Barostim devices are Class&#160;III devices which have received both a PMA and an HDE approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PMA &amp; HDE approval pathway</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Class&#160;III devices require PMA or HDE approval before they can be marketed, although some pre-amendment Class&#160;III devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180&#160;days under the FDCA to complete its review of a PMA, although in practice, the FDA&#8217;s review often takes significantly longer, and at times can take up to several&#160;years. An Advisory Committee or panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#8217;s recommendation. In addition, the FDA will generally conduct a preapproval inspection of the applicant or its third-party manufacturers&#8217; or suppliers&#8217; manufacturing facility or facilities to ensure compliance with the QSR.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s) according to the instructions for use or labeling. The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance or study when deemed necessary to protect the public health or to provide additional safety and effectiveness data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of&#160;years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and typically does not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the HDE constitute valid scientific evidence and that there is reasonable assurance that the device is safe and has probable benefit for its intended use(s) according to the instructions for use or labeling. The HDE approved devices are subject to the same requirement elements and changes as the above PMA devices. An additional limitation for HDE devices is they must be prescribed for a patient population that has a medical condition or disease that afflicts less than 8,000 people per year in the United States and have been designated as a Humanitarian Use Device by FDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trials are almost always required to support a PMA and are sometimes required to support an HDE, 510(k) or De Novo submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;), regulations which govern investigational device labeling, prohibit promotion of the investigational device and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must be approved prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a subject and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30&#160;days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the study must be approved by, and conducted under the oversight of, an institutional review board (&#8220;IRB&#8221;), for each clinical site. The IRB is responsible for the initial and continuing review of the IDE and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of subjects, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators, informed consent for subjects, financial reporting on investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA regulations and must obtain subject informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Post-market regulation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment registration and device listing with the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling and marketing regulations, which require that promotion is truthful, not misleading, fairly balanced and provide adequate directions for use and that all claims are substantiated and also prohibit the promotion of products for unapproved or &#8220;off-label&#8221; uses and impose other restrictions on labeling; FDA guidance on off-label dissemination of information and responding to unsolicited requests for information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Sunshine Act and various state and foreign laws on reporting remunerative relationships with health care customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute (and similar state laws) prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal False Claims Act (and similar state laws) prohibiting, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing, or knowingly and improperly avoiding or decreasing, an obligation to pay or transmit money to the federal government. The government may assert that a claim includes items or services resulting from a violation of the federal Anti-Kickback Statute and thus constitutes a false or fraudulent claim for purposes of the false claims statute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of a supplement for certain modifications to PMA and HDE devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">complying with the federal law and regulations requiring Unique Device Identifiers (UDI) on devices and also requiring the submission of certain information about each device to the FDA&#8217;s Global Unique Device Identification Database (GUDID);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We may be subject to similar foreign laws that may include applicable post-marketing requirements such as safety surveillance. Our manufacturing processes are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file and complaint files. As a manufacturer, our facilities, records and manufacturing processes are subject to periodic scheduled or unscheduled inspections by the FDA. Our failure to maintain compliance with the QSR or other applicable regulatory requirements could result in the shut-down of, or restrictions on, our manufacturing operations and the recall or seizure of our products. The discovery of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls, withdrawals, injunctions, or administrative detention or seizure of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions or partial suspension or total shutdown of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawing 510(k) clearances or PMA approvals that have already been granted; refusal to grant export or import approvals for our products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of medical devices in the EEA</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the EEA, in order to be placed on the market, medical devices require a CE Mark and a corresponding declaration of conformity. For our medical devices, the CE Mark must be issued by an organization accredited by a Member State of the EEA to conduct conformity assessments, a so-called Notified Body. Conformity assessments are conducted to demonstrate that the medical device meets the legal requirements set forth in the regulations and standards to ensure that it meets general safety and performance criteria. Clinical investigations or evidence of the safety and clinical outcomes, among other things, may be required for issuance of a CE Mark. With a CE Mark, the medical devices are generally marketable in the entire EEA. A CE Mark was issued for Barostim for the treatment of hypertension in 2011 and for the treatment of HFrEF in 2014.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Medical devices regulated under the MDD (as defined below) are classified into one of four classes&#8201;&#8212;&#8201;Class&#160;I, Class&#160;IIa, Class&#160;IIb or Class&#160;III&#8201;&#8212;&#8201;based on the extent of the regulatory controls necessary and sufficient to provide reasonable assurance of safety and effectiveness of the device. The Automatic Implantable Medical Device Directive (&#8220;AIMDD&#8221;) applies to implantable electrical active medical devices that are typically considered to be Class&#160;III under MDD and similar controls for the highest risk devices. The classification corresponds to the level of potential hazard inherent in the type of device concerned. Class&#160;I includes devices with the lowest risk to the patient. Class&#160;IIa and Class&#160;IIb devices are higher risk devices and Class&#160;III devices are devices with a significant risk, which are subject to more regulatory oversight to ensure the safety and effectiveness of the device, such as performance standards and post-market surveillance. Barostim is classified and regulated under the AIMDD.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">EU Legislation: medical devices regulation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On April&#160;5, 2017, the European Parliament passed the MDR (as defined below). The regulations entered into force on May&#160;25, 2017 and progressively replaced the MDD after a transition period. The transition period was extended in April&#160;2020, and the regulation became fully effective on May&#160;26, 2021. Until then, different European countries interpreted and implemented the MDD and AIMDD in different ways. The MDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and to ensure a high level of safety and health while supporting innovation. The regulations impose strict demands on medical device manufacturers and the Notified Bodies whom they must involve in the conformity assessment procedure. The new regulations:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require demonstration of clinically meaningful outcomes for the performance of the medical device;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require stricter control of Class&#160;IIb and Class&#160;III medical devices during the clinical investigational phase;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require rigorous post-market oversight by the manufacturer and increased post-market surveillance authority by the Notified Body, including unannounced audits, and product sample checks and testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Provide greater transparency by establishing a central database (EUDAMED) to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Strengthen rules for the assessment of certain high-risk devices, which may have to undergo an additional check by an independent expert panel before they are placed on the market.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The regulatory framework governing medical devices underwent a major change when the Medical Devices Regulation (Regulation (EU) 2017/745&#8201;&#8212;&#8201;&#8220;MDR&#8221;) became effective. The MDR repealed and replaced the EU Medical Devices Directive (Council Directive 93/42/EEC&#8201;&#8212;&#8201;&#8220;MDD&#8221; or Council Directive 90/385/EEC). Unlike directives, which must be implemented into the national laws of the EEA, the regulations are directly applicable, without the need for adoption by EEA member state laws implementing them, in all EEA member states and are intended to eliminate differences in the regulation of medical devices among EEA member states. To avoid market disruption and allow a smooth transition from the MDD/AIMDD to the MDR, several transitional provisions are in place, which include the certificates provided under the MDD/AIMDD remaining valid and devices lawfully placed on the market continuing to be made available on the market or put into service, both under certain prerequisites and until a certain time.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of medical devices under MDR</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CE Marking</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Manufacturers of medical devices must comply with the general safety and performance requirements of the MDR in order to obtain a CE mark for the product and market the product in the EEA. To demonstrate compliance with the general safety and performance requirements, the manufacturer must undergo a conformity assessment procedure which requires the involvement of a Notified Body except for low-risk medical devices of Class&#160;I. The Notified Body typically audits the quality management system of the manufacturer, which must comply with the current version of ISO 13485, which requires manufacturers to follow defined and approved design and development procedures, testing, control, documentation and other quality assurance procedures throughout the entire design and manufacturing process. The Notified Body also reviews the Technical File that includes the Biological Evaluation, Clinical Evaluation and Risk </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Management reports, among other items, submitted for approval of the CE Mark. If the quality management system audit and the technical file review is successful, the Notified Body issues certificates of conformity. These certificates entitle the manufacturer to draw up the EU declaration of conformity and affix the CE Mark to the labeling of its medical devices and place the medical device on the market.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CE marking in UK</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Since January&#160;1, 2021, a medical device with an EEA-issued CE mark will continue to be recognized in the UK (excluding Northern Ireland) until June&#160;30, 2023. Certificates issued by EU-recognized Notified Bodies will continue to be valid for the UK market until June&#160;30, 2023. Since January&#160;1, 2021, all medical devices placed on the UK market need to be registered with the Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;). There are different grace periods depending on the type of medical device to allow time for compliance with the new registration process. Where a medical device is not already registered with the MHRA, a conformity assessment must be conducted by an &#8220;authorised&#8221; body (a so-called UK Approved Body, approved by the MHRA) and a separate dossier application for the UK Conformity Assessed (&#8220;UKCA&#8221;) marking must be submitted. However, the data to support an EEA-issued CE mark will probably be sufficient for a UKCA mark. Manufacturers based outside the UK who wish to place a device on the UK market need to appoint a single UK Responsible Person who will take responsibility for the product in the UK.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical investigation</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For our medical devices, clinical investigations or evidence will be required to demonstrate safety, performance and the expected clinical outcomes. The term &#8220;performance&#8221; describes how the medical device functions. Under the MDR, performance must be linked to expected clinical metrics and outcomes. From a practical standpoint, &#8220;performance&#8221; is analogous to the term &#8220;effectiveness&#8221; when applied to our medical devices. Clinical investigations must be conducted in accord with Good Clinical Practices (ISO 14155) and are subject to audits by the Notified Bodies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-market surveillance</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After a medical device is placed on the market, numerous regulatory requirements apply, which link to the manufacturer&#8217;s continuous review of risk management information. As an integral part of its quality management system, the manufacturer must establish and maintain a systematic procedure to proactively collect and review real-life experience and data gained from their devices placed on the market. Post-market surveillance is comprised of, but not limited to, reports of serious adverse events, device deficiency reports, product complaints from consumers and health care professionals, field safety corrective actions and post-marketing clinical studies/updated clinical evaluation reports. Manufacturers must guarantee that their medical device continues to provide the promised benefit to patients as well as the lack of any unacceptable risks, through a constant and systematic approach to post-market surveillance. Further, manufacturers, medical practitioners and medical institutions are obliged to report any incident involving a medical device, including any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labelling or the instructions for use which might lead to or might have led to the death of a patient or to a serious deterioration in his or her state of health. The reporting also includes any device recalls. Manufacturers have to prepare a periodic safety update report for each device summarizing the results and conclusions of the analyses of the post-market surveillance data gathered.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-compliance</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If we fail to comply with applicable EU regulatory requirements, we may be subject to, among other things, fines, product recalls, seizure of products, operating restrictions and criminal prosecution. Failure to comply with EU regulatory requirements could prevent us from developing, manufacturing and later selling the products in the EU.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal, state and foreign fraud and abuse and physician payment transparency laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state laws restrict our business practices. These laws include, without limitation, foreign, federal and state anti-kickback and false claims laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including stock, stock options and the compensation derived through ownership interests.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Recognizing that the federal Anti-Kickback Statute is broad and may prohibit many innocuous or beneficial arrangements within the healthcare industry, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) issued regulations in July&#160;1991, which HHS has referred to as &#8220;safe harbors.&#8221; These safe harbor regulations set forth certain provisions which, if met in form and substance, will assure medical device manufacturers, healthcare providers and other parties that they will not be prosecuted under the federal Anti-Kickback Statute. Additional safe harbor provisions providing similar protections have been published intermittently since 1991. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Our arrangements with physicians, hospitals and other persons or entities who are in a position to refer may not fully meet the stringent criteria specified in the various safe harbors. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (described below).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $100,000 for each violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines of up to $100,000 and imprisonment of up to 10&#160;years. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid. Liability under the federal Anti-Kickback Statute may also arise because of the intentions or actions of the parties with whom we do business. While we are not aware of any such intentions or actions, we have only limited knowledge regarding the intentions or actions underlying those arrangements. Conduct and business arrangements that do not fully satisfy one of these safe harbor provisions may result in increased scrutiny by government enforcement authorities. The majority of states also have anti-kickback laws that establish similar prohibitions and, in some cases, may apply more broadly to items or services covered by any third-party payor, including commercial insurers and self-pay patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. The federal civil False Claims Act also applies to false </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability under the civil federal civil False Claims Act.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, private parties may initiate &#8220;qui tam&#8221; whistleblower lawsuits against any person or entity under the federal civil False Claims Act in the name of the government and share in the proceeds of the lawsuit. Penalties for federal civil False Claim Act violations include fines for each false claim, plus up to three times the amount of damages sustained by the federal government and, most critically, may provide the basis for exclusion from the federally funded healthcare program. On May&#160;20, 2009, the Fraud Enforcement Recovery Act of 2009 (&#8220;FERA&#8221;), was enacted, which modifies and clarifies certain provisions of the federal civil False Claims Act. In part, FERA amends the federal civil False Claims Act such that penalties may now apply to any person, including an organization that does not contract directly with the government, who knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim paid in part by the federal government. The government may further prosecute conduct constituting a false claim under the federal criminal False Claims Act. The criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious or fraudulent and, unlike the federal civil False Claims Act, requires proof of intent to submit a false claim. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties ranging from $11,181 to $22,363 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Civil Monetary Penalty Act of 1981 imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) also created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Many foreign countries have similar laws relating to healthcare fraud and abuse. Foreign laws and regulations may vary greatly from country to country. For example, the advertising and promotion of our products is subject to EU Directives concerning misleading and comparative advertising and unfair commercial practices, as well as other EEA member state legislation governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals. Also, many U.S. states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, there has been a recent trend of increased foreign, federal and state regulation of payments and transfers of value provided to healthcare professionals or entities. The federal Physician Payments Sunshine Act imposes annual reporting requirements on certain drug, biologics, medical supplies and device manufacturers for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Plan for payments and other transfers of value provided by them, directly or indirectly, to physicians (including physician family members), certain other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. A manufacturer&#8217;s failure to submit timely, accurately and completely the required information for all payments, transfers of value or ownership or investment interests may result in civil monetary penalties of $11,052 per failure up to an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">aggregate of $165,786 per year (or up to an aggregate of $1.105&#160;million per year for &#8220;knowing failures&#8221;). Manufacturers must submit reports by the 90th day of each calendar year. Certain foreign countries and U.S. states also mandate implementation of commercial compliance programs, impose restrictions on device manufacturer marketing practices and require tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data privacy and security laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are also subject to various federal, state and foreign laws that protect the confidentiality of certain patient health information, including patient medical records and restrict the use and disclosure of patient health information by healthcare providers, such as HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), in the U.S.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA established uniform standards governing the conduct of certain electronic healthcare transactions and requires certain entities, called covered entities, to comply with standards that include the privacy and security of protected health information (&#8220;PHI&#8221;). HIPAA also requires business associates, such as independent contractors or agents of covered entities that have access to PHI in connection with providing a service to or on behalf of a covered entity, of covered entities to enter into business associate agreements with the covered entity and to safeguard the covered entity&#8217;s PHI against improper use and disclosure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The HIPAA privacy regulations cover the use and disclosure of PHI by covered entities as well as business associates, which are defined to include subcontractors that create, receive, maintain, or transmit PHI on behalf of a business associate. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, or to request restrictions on the use or disclosure of PHI. The security regulations establish requirements for safeguarding the confidentiality, integrity and availability of PHI that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify any individual whose PHI is breached according to the specifications set forth in the breach notification rule. The HIPAA privacy and security regulations establish a uniform federal &#8220;floor&#8221; and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI as defined under HIPAA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA requires the notification of patients, and other compliance actions, in the event of a breach of unsecured PHI. If notification to patients of a breach is required, such notification must be provided without unreasonable delay and in no event later than 60 calendar days after discovery of the breach. In addition, if the PHI of 500 or more individuals is improperly used or disclosed, we would be required to report the improper use or disclosure to HHS, which would post the violation on its website, and to the media. Failure to comply with the HIPAA privacy and security standards can result in civil monetary penalties up to $55,910 per violation, not to exceed $1.68&#160;million per calendar year for non-compliance of an identical provision and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities, such as us, and their business associates for compliance with the HIPAA privacy and security standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a&#160;percentage of the civil monetary penalty paid by the violator.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the EU, we may be subject to laws relating to our collection, control, processing and other use of personal data (i.e., data relating to an identifiable living individual). We process personal data in relation to our operations. We process data of both our employees and our customers, including health and medical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">information. The data privacy regime in the EU includes the EU Data Protection Directive (95/46/EC) regarding the processing of personal data and the free movement of such data, the E-Privacy Directive 2002/58/EC and national laws implementing each of them. Each EU Member State has transposed the requirements laid down by the Data Protection Directive and E-Privacy Directive into its own national data privacy regime and therefore the laws may differ by jurisdiction, sometimes significantly. We need to ensure compliance with the rules in each jurisdiction where we are established or are otherwise subject to local privacy laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The requirements include that personal data may only be collected for specified, explicit and legitimate purposes based on a legal grounds set out in the local laws and may only be processed in a manner consistent with those purposes. Personal data must also be adequate, relevant, not excessive in relation to the purposes for which it is collected, be secure, not be transferred outside of the EEA unless certain steps are taken to ensure an adequate level of protection and must not be kept for longer than necessary for the purposes of collection. To the extent that we process, control or otherwise use sensitive data relating to living individuals (for example, patients&#8217; health or medical information), more stringent rules apply, limiting the circumstances and the manner in which we are legally permitted to process that data and transfer that data outside of the EEA. In particular, in order to process such data, explicit consent to the processing (including any transfer) is usually required from the data subject (being the person to whom the personal data relates).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The new EU-wide General Data Protection Regulation (&#8220;GDPR&#8221;) became applicable on May&#160;25, 2018, replacing the previous data protection laws issued by each EU Member State based on the Directive 95/46/EC. Unlike the Directive (which needed to be transposed at national level), the GDPR text is directly applicable in each EU member state, resulting in a more uniform application of data privacy laws across the EU. The GDPR imposes onerous accountability obligations, requiring data controllers and processors to maintain a record of their data processing and policies. It requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of information, increases requirements pertaining to pseudonymized (i.e., key-coded) data, introduces mandatory data breach notification requirements and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. Fines for non-compliance with the GDPR are significant&#8212;the greater of EUR 20&#160;million or 4% of global turnover. The GDPR provides that EU Member States may introduce further conditions, including limitations, to the processing of genetic, biometric or health data, which could limit our ability to collect, use and share personal data, or could cause our compliance costs to increase, ultimately having an adverse impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are subject to the supervision of local data protection authorities in those jurisdictions where we are established or otherwise subject to applicable law.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We depend on a number of third parties in relation to our provision of our services, a number of which process personal data on our behalf. With each such provider we enter into contractual arrangements to ensure that they only process personal data according to our instructions, and that they have sufficient technical and organizational security measures in place. Where we transfer personal data outside the EEA, we do so in compliance with the relevant data export requirements. We take our data protection obligations seriously, as any improper disclosure, particularly with regard to our customers&#8217; sensitive personal data, could negatively impact our business and/or our reputation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare reform</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The implementation of the Affordable Care Act in the U.S., for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The Affordable Care Act provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research and implemented payment system reforms, including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally, the Affordable Care Act has expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. There have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect additional challenges and amendments in the future. Moreover, the Biden Administration and the U.S. Congress may take further action regarding the Affordable Care Act. In 2017, the Tax Cuts and Jobs Acts was enacted, which, among other things, removed penalties for not complying with the individual mandate to carry health insurance, effective in 2019.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, including hospitals and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-bribery and corruption laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our U.S. operations are subject to the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;). We are required to comply with the FCPA, which generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments to foreign officials for the purpose of obtaining or retaining business or other benefits. In addition, the FCPA imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of &#8220;off books&#8221; slush funds from which such improper payments can be made. We also are subject to similar anticorruption legislation implemented in Europe under the Organization for Economic Co-operation and Development&#8217;s Convention on Combating Bribery of Foreign Public Officials in International Business Transactions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">&#160;</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Environmental laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our facilities and operations are also subject to complex federal, state, local and foreign environmental and occupational safety laws and regulations, including those relating to discharges of substances in the air, water and land, the handling, storage and disposal of wastes and the clean-up of properties contaminated by pollutants. We do not expect that the ongoing costs of compliance with these environmental requirements will have a material impact on our consolidated earnings, capital expenditures or competitive position.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Human capital management</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December&#160;31, 2021, we had approximately 109 employees worldwide, all of which were employed on a full-time basis. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relationship with our employees to be good.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our mission</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our mission is to advance health for people everywhere, giving each patient a fuller life. In seeking to accomplish our mission, we rely on our values, which are central to our human capital management policies and practices. These values are:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Commitments are Sacred&#8201;&#8212;&#8201;Honor relationships by doing what we say, when we say we&#8217;ll do it.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bold Mindset, Driven Spirit&#8201;&#8212;&#8201;Always push the boundaries, energetically seeking out impactful opportunities and inspiring others.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Pioneer with Purpose&#8230;and a Smile!&#8201;&#8212;&#8201;As individuals, team leaders and industry innovators, it&#8217;s how we pave the way forward that defines us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Collaborate with Enjoyment&#8201;&#8212;&#8201;Achieve goals and celebrate as a team.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Determination overcomes Targets&#8201;&#8212;&#8201;Determine the pathway, overcome obstacles, accelerate and successfully implement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Embrace the Challenge of Change&#8201;&#8212;&#8201;Have an eye for identifying when change is needed, and the flexibility to chart a new course.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Health and safety</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">We are acutely focused on the health and safety of our employees in the workplace. Our health and safety team monitors various metrics in an effort to ensure we are providing a safe environment to work. These results are shared with relevant regulatory agencies as required and presented to our management team.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Available&#160;Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:10pt 0pt 0pt 0pt;">We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form&#160;8-K and amendments to those reports, available free of charge at our website as soon as reasonably practicable after they have been filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Our website address is www.cvrx.com. Information on our website is not part of this Annual Report on Form 10-K. The SEC maintains a website that contains the materials we file with the SEC at www.sec.gov.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_300eca78_9b91_4572_b9f8_3c153f927469"></a><a id="Item1ARiskFactors"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item&#160;1A. Risk Factors</b></p><a id="_Hlk78377047"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our reputation, business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations</i><i style="font-style:italic;">.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_Hlk78377086"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our business</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.11;margin:14pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We have a history of significant losses, which we expect to continue, and we may not be able to achieve or sustain profitability. If we do not achieve and sustain profitability, our financial condition could suffer.</span></p><a id="_Hlk78525051"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have experienced significant net losses since our inception and we expect to continue to incur losses for the foreseeable future. We incurred net losses of $43.1 million and $14.1 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020, our accumulated deficit was $394.8 million and $351.7 million, respectively. We expect to continue to incur significant sales and marketing, research and development, regulatory and other expenses as we grow our U.S. commercial sales force and expand our marketing efforts to increase adoption of Barostim, expand existing relationships with our customers, add new features to Barostim, obtain regulatory clearances or approvals for our planned or future products and conduct clinical trials on our existing and planned or future products. In addition, we expect our general and administrative expenses to continue to increase following our initial public offering (&#8220;IPO&#8221;) due to the additional costs associated with being a public company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Until our IPO, we financed our operations primarily through convertible preferred stock financings and amounts borrowed under our loan and security agreement (&#8220;Horizon loan agreement&#8221;) with Horizon Technology Finance Corporation. We have devoted substantially all of our financial resources to research and development activities as well as general and administrative expenses associated with our operations, including clinical and regulatory initiatives to obtain marketing approval. We will need to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our expected future operating losses, combined with our prior operating losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations.</p><a id="_Hlk78377182"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:14pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We have a limited history operating as a commercial company and are highly dependent on a single product, Barostim. The failure to obtain market acceptance in the U.S. for Barostim would negatively impact our business, liquidity and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Since our inception, we have generated minimal revenue as our activities have consisted primarily of developing Barostim Therapy, conducting our BeAT-HF pre-market and post-market pivotal studies in the U.S. and filing for regulatory approvals. We first commercialized Barostim in the EEA in 2012 and in the U.S. in 2020 and therefore do not have a long history operating as a commercial company. We expect substantially all of our revenue to continue to be derived from sales of Barostim for the foreseeable future, the majority of which will be generated in the U.S. Because of its recent commercial introduction in the U.S., Barostim has limited product and brand recognition. In addition, demand for Barostim may decline or may not increase as quickly as we expect. If we are unable to achieve significant market acceptance in the U.S. for Barostim, our results of operations will be adversely affected. Because we do not yet have other products currently in development, if we are unsuccessful in commercializing Barostim or are unable to market Barostim as a result of a quality problem, failure to maintain regulatory approvals, unexpected or serious complications or other unforeseen negative effects related to Barostim or the other factors discussed in these risk factors, we would lose our main source of revenue, and our business, reputation, liquidity and results of operations will be materially and adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk78377405"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.08;margin:4pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">We</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">have</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">limited</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">commercial</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">sales</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">experience</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">marketing</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">and</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">selling</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">Barostim,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">and</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">if</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">we</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">are</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">unable</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">to establish and maintain sales and marketing capabilities, we will be unable to successfully commercialize Barostim</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">or</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">generate</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">sustained</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">and</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">increasing</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">product</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">revenue.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We currently have a limited sales and marketing organization. As a result, we have limited experience marketing and selling Barostim. In order to generate future revenue growth, we plan to expand the size and geographic scope of our U.S. direct sales and marketing organization. In order to increase our sales and marketing efforts, we will need to retain, grow and develop a substantial number of direct sales personnel. We </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">intend to make a significant investment in recruiting and training sales representatives for our commercialization effort in the U.S. There is significant competition for sales personnel experienced in relevant medical device sales. Once hired, the training process is lengthy because it requires significant education for new sales representatives to achieve the level of clinical competency with our products expected by physicians. Upon completion of the training, our sales representatives typically require lead time in the field to grow their network of accounts and achieve the productivity levels we expect them to reach in any individual territory. Furthermore, the use of our product will often require or benefit from direct support from us. If we are unable to attract, motivate, develop and retain a sufficient number of qualified sales personnel, and if our sales representatives do not achieve the productivity levels we expect them to reach, our revenue will not grow at the rate we expect and our financial performance will suffer. Because the competition for direct medical sales personnel is high, we cannot be certain we will be able to hire and retain additional sales personnel on favorable or commercially reasonable terms, if at all. Failure to hire or retain qualified sales representatives would prevent us from expanding our business and generating revenue. Any of these risks may adversely affect our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We must demonstrate to physicians and patients the merits of Barostim.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physicians play a significant role in determining the course of a patient&#8217;s treatment and, subsequently, the type of product that will be used to treat a patient. As a result, our success depends, in large part, on effectively marketing Barostim to physicians. In order for us to sell Barostim, we must successfully demonstrate to physicians and patients the merits of Barostim Therapy for use in treating patients with HFrEF. Specifically, Barostim provides symptomatic relief for patients with NYHA Class III or II (with recent history of III), have a LVEF &#8804; 35% and a NT-proBNP &lt; 1,600 pg/ml. Acceptance of Barostim depends on educating physicians as to the distinctive characteristics, perceived benefits, safety, ease of use and cost-effectiveness of Barostim and communicating to physicians the proper application of Barostim Therapy for patients who meet Barostim&#8217;s eligibility criteria. If we are not successful in convincing physicians of the merits of Barostim Therapy, they may not use Barostim and we may be unable to increase our sales, sustain our growth or achieve profitability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, physicians typically need to perform several procedures to become comfortable using Barostim. If a physician experiences difficulties during an initial procedure or otherwise, that physician may be less likely to continue to use our product or to recommend it to other physicians. It is critical to the success of our commercialization efforts to educate physicians on the proper use of Barostim, and to provide them with adequate product support during clinical procedures. If we do not provide support to physicians or do not adequately educate physicians on the benefits and proper use of Barostim, physicians may not use or advocate for Barostim. In such circumstances, our results of operations would be materially adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients may not choose or be able to receive Barostim if, among other potential reasons, they are reluctant to receive an implantable device as opposed to an alternative, non-implantable treatment, they are worried about potential adverse effects of Barostim, or they are unable to obtain adequate third-party coverage or reimbursement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If third-party payors do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our success in marketing Barostim depends and will continue to depend in large part on whether U.S. and international government health administrative authorities, private health insurers and other organizations adequately cover and reimburse customers for the cost of our products. In the U.S., we expect to derive nearly all our revenue from sales of Barostim to hospitals that typically bill various third-party payors, including Medicare, Medicaid, private commercial insurance companies, health maintenance organizations and other healthcare-related organizations, to cover all or a portion of the costs and fees associated with procedures using Barostim and bill patients for any applicable deductibles or co-payments. Access to adequate coverage and reimbursement for procedures using Barostim by third-party payors is essential to the acceptance of our products by our customers.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Payors in the U.S. generally require hospitals and physicians to identify the proper CPT codes for the service for which they are seeking reimbursement. Procedures using Barostim are currently mapped to CPT code 0266T for the implantation of the device, which is a Category III CPT code. While customers are currently being reimbursed for our procedure, this may not continue in the future, as payors may determine this Category III CPT code to be investigational. This uncertainty could result in some of our target customers being unwilling to adopt Barostim over more established or lower cost therapeutic alternatives. While we intend to request that our codes be promoted to Category I by the American Medical Association, there can be no assurance that such efforts will be successful.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Medicare reimbursement levels are important to increasing adoption of Barostim because nearly two-thirds of the target patient population for Barostim is over the age of 65. Effective January 2021, CMS awarded Barostim a TPT payment for outpatient procedures that adds the device cost as a pass-through payment to the calculated procedure payment. The calculated procedure payment depends on many factors, including the location of the hospitals and their billing practices, and may not adequately cover hospital costs associated with the procedure. In addition, CMS awarded Barostim an NTAP for inpatient procedures, which took effect in October 2020. The NTAP is for 65% of the device cost and is incremental to the standard payment provided for the implant procedure. Hospitals are responsible for billing for the procedures to receive the additional payment, when such increase in payment is necessary and there can be no assurance that hospitals will accurately perform these billing procedures. The TPT payment and the NTAP are only effective for up to three years. While we intend to request that Barostim be reclassified into a higher Medicare reimbursement level, there can be no assurance that such efforts will be successful. Any future decline in the amount Medicare is willing to reimburse our customers for procedures using Barostim could make it difficult for new customers to adopt Barostim and could create additional pricing pressure for us, which could adversely affect our ability to invest in and grow our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the U.S., no uniform policy of coverage and reimbursement for medical device products and services exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services can differ significantly from payor to payor. In addition, payors continually review new technologies for possible coverage and can, without notice, deny coverage for these new products and procedures. As a result, the coverage determination process is often a time-consuming and costly process for physicians as well as hospitals that often requires us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained. Accordingly, until such time as Barostim gains broader acceptance by third-party payors as a treatment for HFrEF, hospitals and physicians may encounter delays and additional administrative burdens, such as the submission of supporting documentation, in obtaining reimbursement. Such delays and additional burdens may make it less likely for physicians and hospitals to adopt Barostim. Any future decline in the amount third-party payors are willing to reimburse our customers for procedures using Barostim could make it difficult for new customers to adopt Barostim and could create additional pricing pressure for us, which could adversely affect our ability to invest in and grow our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement systems in international markets vary significantly by country and by region within some countries, and reimbursement approvals must be obtained on a country-by-country basis. In many international markets, a product must be approved for reimbursement before it can be approved for sale in that country. Further, many international markets have government-managed healthcare systems that control reimbursement for new devices and procedures. In most markets, there are private insurance systems as well as government-managed systems. If sufficient coverage and reimbursement is not available for our current or future products, in either the U.S. or internationally, the demand for our products and our revenues will be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our industry is highly competitive. If our competitors, many of which are large, well-established companies with substantially greater resources than us and have a long history of competing in the HF market, are better able to develop and market products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim, our business will be adversely impacted.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The medical device industry is highly competitive and subject to technological change. Our success depends, in part, upon our ability to establish a competitive position in the market by securing broad market acceptance of Barostim Therapy and Barostim for the treatment of HFrEF. Any product we develop that achieves regulatory clearance or approval, including Barostim, will have to compete for market acceptance and market share. We believe that the primary competitive factors in the market are demonstrated clinical effectiveness, product safety, reliability and<span style="letter-spacing:-1.7pt;"> </span>durability, ease of use, product support and service, minimal side effects and salesforce experience and relationships. Many of our current and potential competitors that are addressing other HF indications are publicly traded, or are divisions of publicly-traded, established medical device companies that have substantially greater financial, technical, sales and marketing resources than we do, such as Medtronic plc, Boston Scientific Corporation, Abbott Laboratories and LivaNova PLC. We may also face competition from other competitors, such as Impulse Dynamics, which is a private company with a medical device indicated for a subset of our target patient population, or companies with active system development programs that may emerge in the future. Many of the companies developing or marketing competing products enjoy several advantages over us, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">more experienced sales</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">forces;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater name</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recognition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">more</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">programs</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">networks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">earlier regulatory</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">long</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">relationships</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">significant patent portfolios, including issued U.S. and foreign patents and pending patent applications, as well as the resources to enforce patents against us or any of our third-party suppliers and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">integrate</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">and/or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">their</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrated</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">develop</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">enhancements</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">new</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">offerings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">history</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reliability,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">safety</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">durability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ability</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">offer</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">rebates</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">bundle</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">offerings</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">offer</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">discounts</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incentives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">human</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">resources</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">development,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater experience in and resources for conducting research and development, clinical studies, manufacturing, preparing regulatory submissions, obtaining regulatory clearance or approval for products and marketing approved products.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our competitors may develop and patent processes or products earlier than us, obtain patents that may apply to us at any time, obtain regulatory clearance or approvals for competing products more rapidly than us or develop more effective or less expensive products or technologies that render our technology or products obsolete or less competitive. We also face fierce competition in recruiting and retaining qualified sales, scientific and management personnel, establishing clinical trial sites and enrolling patients in clinical studies. If our competitors are more successful than us in these matters, our business may be harmed. In addition, we face a particular challenge overcoming the long-standing practices by some physicians of using the products of our larger, more established competitors. Physicians who have completed many successful implants using the products made by these competitors may be reluctant to try new products from a source with which they are less familiar. If these physicians do not try and subsequently adopt our product, then our revenue growth will slow or decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to receive access to hospitals, our sales may decrease.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the U.S., in order for physicians to use Barostim, we expect that the hospitals where these physicians treat patients will typically require us to enter into purchasing contracts. This process can be lengthy, time-consuming and require extensive negotiations and management time, which could include an approval by a customer&#8217;s value analysis committee. In the EU, from time to time certain institutions require us to engage in a contract bidding process in the event that such institutions are considering making purchase commitments that exceed specified cost thresholds, which vary by jurisdiction. These processes are only open at certain periods of time, and we may not be successful in the bidding process. If we do not receive access to hospitals via these contracting processes or otherwise, or if we are unable to secure contracts or tender successful bids, our sales may decrease and our operating results may be harmed. Furthermore, we may expend significant effort in these time-consuming processes and still may not obtain a purchase contract from such hospitals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are dependent upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers, making us vulnerable to supply shortages, loss or degradation in performance of the suppliers and price fluctuations, which could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We currently source certain components for Barostim from a limited number of suppliers. Our ability to supply Barostim commercially depends, in part, on our ability to obtain a supply of these components that has been manufactured in accordance with regulatory requirements and in sufficient quantities for commercialization and clinical testing. We have not entered into manufacturing, supply or quality agreements with any of our limited suppliers, some of which supply components critical to our products, such as modules, batteries and electrodes. We currently have no plans to enter into any such contracts and we cannot guarantee that our suppliers will be able to meet our demand for their products and services, either because of the nature of our arrangements with those suppliers, our limited experience with those suppliers, or due to our relative importance as a customer to those suppliers. Further, due to our limited operating history and expected future expansion, it may be difficult for us to assess their ability to timely meet our demand in the future based on past performance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our suppliers may encounter problems during manufacturing for a variety of reasons, including, for example, failure to follow specific protocols and procedures, failure to comply with applicable legal and regulatory requirements, equipment malfunction and environmental factors, failure to properly conduct their own business affairs and infringement of third-party intellectual property rights, any of which could delay or impede their ability to meet our requirements. Our reliance on these third-party suppliers also subjects us to other risks that could harm our business, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not a major customer of many of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may threaten or enforce their intellectual property rights against our suppliers, which may cause disruptions or delays in shipment, or may force our suppliers to cease conducting business with us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to obtain an adequate supply of components in a timely manner or on commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our suppliers, especially new suppliers, may make errors in manufacturing that could negatively affect the efficacy or safety of Barostim or cause delays in shipment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have difficulty locating and qualifying alternative suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">switching components or suppliers may require product redesign and possibly submission to the FDA, EEA or other foreign regulatory bodies, which could significantly impede or delay our commercial activities; one or more of our limited source suppliers may be unwilling or unable to supply components of Barostim;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">other customers may use fair or unfair negotiation tactics and/or pressures to impede our use of the supplier;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we do not conduct formal environmental, social or governance due diligence on our supply chain and thus may not be aware if our suppliers pose such risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of a fire, natural disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in a timely manner; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our suppliers may encounter financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Establishing additional or replacement suppliers for the components or processes used in Barostim, if required, could be time-consuming and expensive. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the limited sourced components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to cancel orders. Given our reliance on certain limited source suppliers, we are especially susceptible to supply shortages because we have limited alternate suppliers currently available.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.07;margin:0.05pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><span style="color:#231f20;">Our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">business</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">strategy</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">depends</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">ability</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.6pt;"> </span><span style="color:#231f20;">manufacture</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">current</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">future</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">sufficient quantities</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">timely</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">basis</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">so</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">as</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">meet</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">consumer</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">demand,</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">while</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">adhering</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">quality</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">standards, complying</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">requirements</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">managing</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">manufacturing</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">costs.</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;letter-spacing:-0.15pt;">We</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">subject</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">numerous</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">risks relating</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">manufacturing</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">capabilities,</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">including:</span></p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">quality or reliability defects in product components that we source from third-party suppliers, including manufacturing compliance with federal and state regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to secure product components in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to increase production of products to meet demand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to modify production lines to enable us to efficiently produce future products or implement changes in current products in response to regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">potential damage to or destruction of our manufacturing equipment or manufacturing facility.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0pt 18pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">If demand for Barostim increases, we will have to invest additional resources to purchase components, hire and train employees and enhance our manufacturing processes. If we fail to increase our production capacity efficiently, our sales may not increase in line with our forecasts and our operating margins could fluctuate or decline. In addition, although we expect some of our product candidates in development to share product features and components with Barostim, manufacturing of these product candidates may require the modification of our production lines, the hiring of specialized employees, the identification of new suppliers for specific components, or the development of new manufacturing technologies. It may not be possible for us to manufacture these product candidates at a cost or in quantities sufficient to make these product candidates commercially viable. Any of these factors may affect our ability to manufacture our product and could reduce our gross margin and profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We operate at a facility in one location and any disruption at this facility could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our principal offices and our only manufacturing facility are located in Minneapolis, Minnesota. Substantially all of our operations are conducted at this location, including our manufacturing processes, research, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">development and engineering activities, customer and technical support and management and administrative functions. In addition, substantially all of our inventory of component supplies and finished goods is held at the manufacturing facility. Vandalism, terrorism or a natural or other disaster, such as a fire or flood, could damage or destroy our manufacturing equipment or our inventory of component supplies or finished goods, cause substantial delays in our operations, result in the loss of key information and cause us to incur additional expenses. Our manufacturing facility in Minneapolis, Minnesota is our only manufacturing facility, and if it is damaged or rendered inoperable or inaccessible due to political, social or economic upheaval or due to natural or other disasters, it would be difficult or impossible for us to manufacture our product for a period of time, which may lead to a loss of customers and significant impairment of our financial condition and operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We take precautions to safeguard this facility, including acquiring insurance, employing back-up generators, adopting health and safety protocols and utilizing off-site storage of computer data. Our insurance may not cover our losses in any particular case. In addition, regardless of the level of insurance coverage, damage to our facility may harm our business, financial condition and operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">A pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including the outbreak of the novel strain of coronavirus disease, COVID-19, could adversely affect our business.</span></p><a id="_Hlk94537289"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If a pandemic, epidemic or outbreak of an infectious disease occurs in the U.S. or worldwide, our business may be adversely affected. In December 2019, a novel strain of coronavirus, SARS-CoV-2, was identified in Wuhan, China. Since then, SARS-CoV-2, and the resulting disease, COVID-19, has spread to most countries and all 50 states within the U.S. The COVID-19 pandemic has negatively impacted our business, financial condition and results of operations by decreasing and delaying the number of procedures performed using Barostim and the pandemic may continue to negatively impact our business, financial condition and results of operations. Similar to the general trend in elective and other surgical procedures, the number of procedures performed using Barostim decreased significantly when healthcare organizations in the U.S. prioritized the treatment of patients with COVID-19 or altered their operations to prepare for and respond to the pandemic. We believe the COVID-19 pandemic has also negatively impacted the number of HFrEF diagnoses as hospitals focus on COVID-19 and as patients postpone healthcare visits and treatments. Specifically, a significant number of procedures using our products were postponed or cancelled beginning in March 2020. By the beginning of the fourth quarter of 2020, implant centers had resumed procedures in the U.S. and Europe; however, procedure volumes were again negatively impacted by the Delta and Omicron variants of COVID-19 in the third and fourth quarters of 2021 and continuing into 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Numerous state and local jurisdictions have imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Such orders or restrictions have resulted in reduced operations at our headquarters, slowdowns and delays, travel restrictions and cancellation of events and have restricted the ability of our front-line sales representatives to attend procedures in which our products are used, among other effects, thereby negatively impacting our operations. Other disruptions or potential disruptions include restrictions on the ability of our sales representatives and other personnel to travel and access customers for training and case support; inability of our suppliers to manufacture components and parts and to deliver these to us on a timely basis, or at all; disruptions in our production schedule and ability to manufacture and assemble products; inventory shortages or obsolescence; delays in actions of regulatory bodies; delays in clinical trials and studies; diversion of or limitations on employee resources that would otherwise be focused on the operations of our business, including because of sickness of employees or their families or the desire of employees to avoid contact with groups of people; delays in growing or reductions in our sales organization, including through delays in hiring, lay-offs, furloughs or other losses of sales representatives; restrictions in our ability to ship our products to customers; business adjustments or disruptions of certain third parties, including suppliers, medical institutions and clinical investigators with whom we conduct business; and additional government requirements or other incremental mitigation efforts that may impact our or our suppliers&#8217; capacity to manufacture our products. The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and spread of COVID-19 and its </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">variants and the durability of immunity offered by vaccines developed to prevent infection, as well as other actions to contain COVID-19 and its variants or treat its impact, among others.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">While the potential economic impact brought by and the duration of any pandemic, epidemic or outbreak of an infectious disease, including COVID-19, may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in and may in the future result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of an infectious disease, including COVID-19, could materially affect our business. Such economic recession could have a material adverse effect on our long-term business as hospitals curtail and reduce capital and overall spending. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our international operations subject us to certain operating risks, which could adversely impact our results of operations and financial condition.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales of Barostim outside the U.S. represented a majority of our revenue from sales as recently as the year ended December 31, 2020. In 2012, we began selling Barostim in the EEA directly to hospitals and through distributors. The sale and shipment of Barostim across international borders, as well as the purchase of components from international sources, subjects us to U.S. and foreign governmental trade, import and export and customs regulations and laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Compliance with these regulations and laws is costly and exposes us to penalties for non-compliance. Other laws and regulations that can significantly impact us include various anti-bribery laws, including the FCPA, as well as export controls laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our international operations expose us and our distributors to risks inherent in operating in foreign jurisdictions. These risks include, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in enforcing our intellectual property rights and in defending against third-party threats and intellectual property enforcement actions against us, our distributors, or any of our third-party suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced or varied protection for intellectual property rights in some countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">potential pricing pressure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a shortage of high-quality sales representatives and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive disadvantage to competition with established business and customer relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of additional U.S. and foreign governmental controls or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">economic instability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in duties and tariffs, license obligations and other non-tariff barriers to trade;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of restrictions on the activities of foreign agents, representatives and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">scrutiny of U.S. and foreign tax authorities, which could result in significant fines, penalties and additional taxes being imposed on us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">laws and business practices favoring local companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">longer payment cycles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in maintaining consistency with our internal guidelines;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of costly and lengthy new export licensing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of U.S. or international sanctions against a country, company, person or entity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of new trade restrictions.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">If any of these risks are realized, our sales in non-U.S. jurisdictions may be adversely affected and our results of operations would suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Consolidation in the healthcare industry or group purchasing organizations could lead to demands for price concessions, which may affect our ability to sell Barostim at prices necessary to support our current business strategies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Healthcare costs have risen significantly over the past decade, which has resulted in or led to numerous cost reform initiatives by legislators, regulators and third-party payors. Cost reform has triggered a consolidation trend in the healthcare industry to aggregate purchasing power, which may create more requests for price concessions in the future. Additionally, group purchasing organizations, independent delivery networks and large single accounts may continue to use their market power to consolidate purchasing decisions for hospitals. We expect that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among our future customers, which may exert further downward pressure on the prices of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to properly manage our growth effectively, our business could suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We intend to continue to grow and may experience periods of rapid growth and expansion, which could place a significant additional strain on our limited personnel, information technology systems and other resources. In particular, the hiring of our direct sales force requires significant management, financial and other supporting resources. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To achieve our revenue goals, we must successfully increase manufacturing output to meet expected customer demand. We may experience difficulties with manufacturing yields, quality control, component supply and shortages of qualified personnel, among other problems. Any of these problems could result in delays in product availability and increases in expenses. Any such delay or increased expense could adversely affect our ability to generate our revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Future growth will also impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. In addition, rapid and significant growth will place a strain on our administrative and operational infrastructure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In order to manage our operations and growth we will need to continue to improve our operational and management controls, reporting and information technology systems and financial internal control procedures. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our operating results and may have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 10pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If clinical studies for future indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We will likely need to conduct additional clinical studies in the future to support approval for new indications. For example, we are currently pursuing a morbidity and mortality indication for patients with HFrEF, which, if successful, could significantly expand our addressable patient population. However, we cannot assure you that the morbidity and mortality data will be sufficient to allow us to achieve FDA approval for expansion of this indication. In addition, if the morbidity and mortality data is perceived to be negative, such data may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">impact the adoption of Barostim, notwithstanding our existing clinical data and FDA approval. Clinical testing takes many years, is expensive and carries uncertain outcomes. The initiation and completion of any of these studies, including the post-market stage of our BeAT-HF pivotal trial, may be prevented, delayed, or halted for numerous reasons, including, but not limited to, the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, IRBs, ethics committees, EU competent authorities or other regulatory authorities do not approve a clinical study protocol, force us to modify a previously approved protocol, or place a clinical study on hold;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients do not enroll in, or enroll at a lower rate than we expect, or do not complete a clinical study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients or investigators do not comply with study protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients do not return for post-treatment follow-up at the expected rate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients experience serious or unexpected adverse side effects for a variety of reasons that may or may not be related to our products, such as the advanced stage of co-morbidities that may exist at the time of treatment, causing a clinical study to be put on hold;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sites participating in an ongoing clinical study withdraw, requiring us to engage new sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties or delays associated with establishing additional clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party clinical investigators decline to participate in our clinical studies, do not perform the clinical studies on the anticipated schedule, or perform in a manner inconsistent with the investigator agreement, clinical study protocol, good clinical practices, other FDA, IRB or ethics committee requirements and EEA member state or other foreign regulations governing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party organizations do not perform data collection and analysis in a timely or accurate manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory inspections of our clinical studies or manufacturing facilities require us to undertake corrective action or suspend or terminate our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in federal, state, or foreign governmental statutes, regulations or policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">interim results are inconclusive or unfavorable as to immediate and long-term safety or efficacy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the study design is inadequate to demonstrate safety and efficacy; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the statistical endpoints are not met.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trials can fail at any stage. Our clinical studies, including the post-market stage of our BeAT-HF pivotal trial related to the morbidity and mortality indication for patients with HFrEF, may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical or non-clinical studies in addition to those we have planned. The impacts of the COVID-19 pandemic, which may have afflicted certain participants in the post-market pivotal trial, are unknown, but they may exacerbate certain of the risks described above. In addition, if the FDA determines for any reason, including safety or their risk-benefit analysis, that the results of the post-market stage of our BeAT-HF pivotal trial or any other future trial are negative, the FDA may decide to modify or revoke our existing approval or such data may impact the adoption of Barostim. Moreover, a negative perception of clinical results for one indication for use could impact the use of Barostim for other FDA approved and clinically supported indications for use.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We could also encounter delays if the FDA concludes that our financial relationships with investigators results in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial itself. Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive cash compensation and/or stock options in connection with such services. If these relationships and any related compensation to or ownership interest by the clinical investigator carrying out the study result in perceived or actual conflicts of interest, or if the FDA concludes that the financial relationship may have affected interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Even if our products are approved in the U.S. and the EEA, comparable regulatory authorities of additional foreign countries must also approve the manufacturing and marketing of our products in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S. or the EEA, including additional preclinical studies or clinical trials. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;text-indent:-0.05pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may face product liability claims that could be costly, divert management&#8217;s attention and harm our reputation.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Manufacturing and marketing of Barostim and clinical testing of Barostim Therapy may expose us to product liability claims. Although we have, and intend to maintain, liability insurance, the coverage limits of our insurance policies may not be adequate and one or more successful claims brought against us may have a material adverse effect on our business and results of operations. Further, interpretation of product liability laws may change in the future due to court rulings. It is possible evolving interpretations of product liability laws could further expose us to increased litigation risk in connection with our products. These product liability claims could, among other things, divert management&#8217;s attention from our primary business and negatively affect our reputation, continued product sales and our ability to obtain and maintain regulatory approval for our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may in the future become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and ultimately unsuccessful, and could result in the diversion of significant resources, thereby hindering our ability to effectively commercialize our existing or future products. If we are unable to obtain, maintain, protect and enforce our intellectual property, our business will be negatively affected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The market for medical devices is subject to rapid technological change and frequent litigation regarding patent and other intellectual property rights. It is possible that our patents or licenses may not withstand challenges made by others or protect our rights adequately.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our success depends in large part on our ability to secure effective patent protection for our products and processes in the U.S. and internationally. We have filed and intend to continue to file patent applications for various aspects of our technology and trademark applications to protect our brand and business. We seek to obtain and maintain patents and other intellectual property rights to restrict the ability of others to market products or services that misappropriate our technology and/or infringe our intellectual property to compete with our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">However, we face the risks that:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10.1pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We may fail to secure necessary patents, potentially permitting competitors to market competing products and make, use or sell products that are substantially the same as ours without incurring the sizeable development costs that we have incurred, which would adversely affect our ability to compete.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10.1pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our already-granted patents and any future patents may not survive legal challenges to their scope, validity or enforceability, or provide significant protection for us, and they may be re-examined or invalidated, and/or may be found to be unenforceable or not cover competing products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10.1pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Though an issued patent is presumed valid and enforceable, it may not be drafted or interpreted sufficiently broadly to prevent others from marketing products and services similar to ours or designing around our patents. For example, third parties may be able to make systems or devices that are similar to ours but that are not covered by the claims of our patents. Third parties may assert that we or our licensors were not the first to make the inventions covered by our issued patents or pending patent applications. The claims of our issued patents or patent applications when issued may not cover our commercial technology or the future products and services that we develop. We may not have the </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10.1pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">freedom to operate unimpeded by the patent rights of others. Third parties may have dominating, blocking or other patents relevant to our technology of which we are not aware. In addition, because patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after the filing of certain priority documents (or, in some cases, are not published until they issue as patents) and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for our technology or our contemplated technology. Any such patent applications may have priority over our patent applications or issued patents, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, depending on when the timing of the filing date falls under certain patent laws, we may have to participate in a priority contest (such as an interference proceeding) declared by the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;), to determine priority of invention in the U.S. There may be prior public disclosures that could invalidate our inventions or parts of our inventions of which we are not aware. Further, we may not develop additional proprietary technologies and, even if we do, they may not be patentable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10.1pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent law is constantly evolving, can be highly uncertain and involve complex legal and factual questions for which important principles remain unresolved. In the U.S. and in many foreign jurisdictions, policies regarding the breadth of claims allowed in patents can be inconsistent. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Any changes may materially affect our patents or patent applications, our ability to obtain patents or the patents and patent applications of our licensors. Future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage, which could adversely affect our financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10.1pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Monitoring unauthorized uses of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors&#8217; products and services, and may in the future seek to enforce our patents or other proprietary rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Our competitors may also independently develop similar technology. Any inability to meaningfully protect our intellectual property could result in competitors offering products that incorporate our product features, which could reduce demand for our products. In addition, we may need to defend our patents from third-party challenges, or we may need to initiate infringement claims or litigation. In an infringement proceeding, a court may decide that the patent we seek to enforce is invalid or unenforceable or that the patent in question does not cover the technology at issue. Such an adverse result could place one or more of our patents at risk of being invalidated or interpreted narrowly. Our competitors may be able to devote significantly more resources to intellectual property litigation, and may have significantly broader patent portfolios to assert against us. Further, litigation risks exposure of or compromising our confidential information.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10.1pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Any litigation or claim can be costly and time consuming and could place a significant strain on our financial resources, divert the attention of management and harm our reputation, which could have an adverse effect on our financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10.1pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be forced to enter into cross-license agreements with competitors in order to manufacture, use, sell, import and export products or services that are covered by our competitors&#8217; intellectual property rights. If our intellectual property is required to enter such cross-license agreements, it may compromise the value of our intellectual property due to the fact that our competitors may be able to manufacture, use, sell, import and export our patented technology.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For additional information regarding risks related to our intellectual property, see &#8220;Risks Related to Intellectual Property.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to retain our key executives or recruit and hire new employees, our operations and financial results may be adversely affected while we attract other highly qualified personnel.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our future success depends, in part, on our ability to continue to retain our executive officers and other key employees and recruit and hire new employees. All of our executive officers and other employees are at-will employees, and therefore may terminate employment with us at any time with no advance notice. In particular, we are highly dependent upon our management team, especially our President and Chief Executive Officer and the rest of our senior management. The replacement of any of our key personnel likely would involve significant time and costs, may significantly delay or prevent the achievement of our business objectives and may harm our business. In addition, we do not carry any &#8220;key person&#8221; insurance policies that could offset potential loss of service under applicable circumstances.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, many of our employees have become or will soon become vested in a substantial amount of stock or number of stock options. Our employees may be more likely to leave us if the shares they own or the shares underlying their vested options have significantly appreciated in value relative to the original purchase prices of the shares or the exercise prices of the options, or if the exercise prices of the options that they hold are significantly below the market price of our common stock. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our future success also depends on our ability to retain executive officers and other key employees and attract new key employees. Many executive officers and employees in the medical device industry are subject to strict non-compete or confidentiality agreements with their employers. In addition, some of our existing and future employees are or may be subject to confidentiality agreements with previous employers. Our competitors may allege breaches of and seek to enforce such non-compete agreements or initiate litigation based on such confidentiality agreements. Such litigation, whether or not meritorious, may impede our ability to attract or use executive officers and other key employees who have been employed by our competitors and may result in intellectual property claims against us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.07;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We rely on information technology and telephone networks and systems, including the Internet, to process and transmit sensitive electronic information and to manage or support a variety of business processes and activities, including sales, billing, marketing, procurement and supply chain, manufacturing and distribution. We use enterprise information technology systems to record, process and summarize financial information and results of operations for internal reporting purposes and to comply with regulatory, financial reporting, legal and tax requirements. Our information technology systems, some of which are managed by third-parties, may be susceptible to damage, disruptions or shutdowns due to computer viruses, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors or catastrophic events. If our systems suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and operating results may suffer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.07;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If important assumptions about the potential market for our product are inaccurate, or if we have failed to understand what people with HF are seeking in a treatment, we may not be able to increase our revenue or achieve profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our business strategy was developed based on a number of important assumptions about the HF market in general, any one or more of which may prove to be inaccurate. For example, we believe that the benefits of Barostim as compared to other common HF devices will continue to drive growth in the market for Barostim. Despite our review of studies reporting on the trends of HF incidence in the U.S., the actual incidence of HF and the actual demand for our product or competitive products, could differ materially from our expectations. In addition, our strategy of focusing exclusively on patients with HFrEF who are looking for an improvement in the symptoms associated with HFrEF may limit our ability to increase sales or achieve profitability, especially if there are any significant clinical breakthroughs or product or drug introductions that significantly delay or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">reduce the need for heart disease therapy. Moreover, a percentage of our indicated patients may be ineligible to undergo a Barostim procedure if they have certain co-morbidities or other disqualifying factors as determined by their physicians.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our estimates of the annual total addressable market for Barostim are based on a number of internal and third-party estimates, including, without limitation, the number of patients with HFrEF and the assumed prices at which we can sell our device. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for Barostim may prove to be incorrect. If the actual number of patients who would benefit from our product, the price at which we can sell our product, or the annual total addressable market for our product is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.07;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Unfavorable</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">global</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">economic</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">conditions</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">could</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">adversely</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">affect</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">our</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">business,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">financial</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">condition</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">or</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">results</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.35pt;">of </span><span style="color:#231f20;font-style:italic;font-weight:bold;">operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and, more recently, the global COVID-19 pandemic caused, and in some cases is continuing to cause, disruptions in the capital and credit markets, severe supply shortages and reduced hospital and clinical visits, including due to temporary shutdowns under federal, state and local mandates. A severe or prolonged economic downturn, such as the global financial crisis and COVID-19 pandemic, has resulted in and could in the future result in a variety of risks to our business, including weakened demand for Barostim, a delayed time to meet clinical endpoints and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy has strained and could in the future strain our manufacturers or suppliers, resulting in supply disruption, or causing our customers to delay making payments for our services. Certain of the foregoing have harmed and could in the future harm our business, and we cannot anticipate all of the ways in which the economic climate and financial market conditions may further affect our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may enter into strategic collaborations, in-licensing arrangements or alliances with third parties that may not result in the development of commercially viable products or the generation of significant future revenue.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the ordinary course of our business, we may enter into strategic collaborations, in-licensing arrangements or alliances to develop product candidates and to pursue new markets. Proposing, negotiating and implementing strategic collaborations, in-licensing arrangements or alliances may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenue and could be terminated prior to developing any products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. We have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#8217; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may seek to grow our business through acquisitions of complementary products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could impair our ability to execute our business strategies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">From time to time, we may consider opportunities to acquire other products or technologies that may enhance our Barostim platform technology, expand the breadth of our markets or customer base, or advance our business strategies. Potential acquisitions involve numerous risks, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">problems</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilating</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">products</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issues</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">uniform</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">standards,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">procedures,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">controls</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">associated</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">management&#8217;s</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">attention</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">from</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">existing</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">risks</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">associated</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">entering</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">new</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">markets</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">have</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limited</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">experience;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.9pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increased</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">legal</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">accounting</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">relating</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquisitions</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">matters.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have no current commitments with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired products or technologies. Our inability to integrate any acquired products or technologies effectively could impair our ability to execute our business strategies. In addition, any amortization or charges resulting from the costs of acquisitions could increase our expenses<span style="color:#231f20;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.08;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If third-party payors do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Medicare reimbursement levels are important to increasing adoption of Barostim because nearly two- thirds of the target patient population for Barostim is over the age of 65. Effective January 2021, CMS awarded Barostim a TPT payment for outpatient procedures that adds the device cost as a pass-through payment to the calculated procedure payment. The calculated procedure payment depends on many factors, including the location of the hospitals and their billing practices, and may not adequately cover hospital costs associated with the procedure. In addition, CMS awarded Barostim an NTAP for inpatient procedures, which took effect in October 2020. The NTAP is for 65% of the device cost and is incremental to the standard payment provided for the implant procedure. Hospitals are responsible for billing for the procedures to receive the additional payment when such increase in payment is necessary and there can be no assurance that hospitals will accurately perform these billing procedures. The TPT payment and the NTAP are only effective for up to three years. While we intend to request that Barostim be reclassified into a higher Medicare reimbursement level, there can be no assurance that such efforts will be successful. Any future decline in the amount Medicare is willing to reimburse our customers for procedures using Barostim could make it difficult for new customers to adopt Barostim and could create additional pricing pressure for us, which could adversely affect our ability to invest in and grow our business. From time to time, physicians and hospitals have in the past experienced, and others may experience, delays in Medicare reimbursement, which have delayed or may delay their willingness to schedule additional Barostim procedures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to intellectual property</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.14;margin:0.05pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may in the future become involved in lawsuits to defend ourselves against intellectual property disputes, which could be expensive, time consuming and ultimately unsuccessful, and could result in the diversion of significant resources, and hinder our ability to commercialize our existing or future products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our success depends in part on not infringing the patents or violating the other proprietary rights of others. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. Significant litigation regarding patent rights occurs in the medical device industry. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Whether merited or not, it is possible that third parties controlling U.S. and foreign patents allege such patents cover our products. We may also face allegations that our employees have misappropriated the intellectual property rights of their former employers or other third parties. Our competitors in both the U.S. and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use, sell, or export our products. These competitors may have one or more patents for which they can threaten or initiate patent infringement actions against us or any of our third-party suppliers. Further, if such patents are successfully asserted against us, this may result in an adverse impact on our business, including injunctions, damages or attorneys&#8217; fees. From time to time and in the ordinary course of business, we may develop noninfringement or invalidity positions with respect to third-party patents, which may or may not be ultimately adjudicated as successful by a judge or jury if such patents were asserted against us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We may receive in the future, particularly as a public company, communications from patent holders, including non-practicing entities, alleging infringement of patents or other intellectual property rights or misappropriation of trade secrets, or offering licenses to such intellectual property. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights. At any given time, we may be involved as either a plaintiff or a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The large number of patents, the rapid rate of new patent applications and issuances, the complexities of the technologies involved and the uncertainty of litigation significantly increase the risks related to any patent litigation. Any potential intellectual property litigation also could require us to do one or more of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">stop selling, making, using or exporting products that use the disputed intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain a license from the intellectual property owner to continue selling, making, exporting or using products, which license may require substantial royalty payments and may not be available on reasonable terms, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incur significant legal expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pay substantial damages or royalties to the party whose intellectual property rights we may be found to be infringing, potentially including treble damages if the court finds that the infringement was willful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if a license is available from a third-party, we may have to pay substantial royalties, upfront fees or grant cross-licenses to intellectual property rights for our products and services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pay the attorney fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">find non-infringing substitute products, which could be costly and create significant delay due to the need for FDA regulatory clearance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">find alternative supplies for infringing products or processes, which could be costly and create significant delay due to the need for FDA regulatory clearance; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">redesign those products or processes that infringe any third-party intellectual property, which could be costly, disruptive or infeasible.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business with respect to intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finally, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If any of the foregoing occurs, we may have to withdraw existing products from the market or may be unable to commercialize one or more of our products, all of which could have a material adverse effect on our business, results of operations and financial condition. Any litigation or claim against us, even those without merit, may cause us to incur substantial costs and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation. Further, as the number of participants in our industry grows, the possibility of intellectual property infringement claims against us increases.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, we may indemnify our customers, suppliers and international distributors against claims relating to the infringement of the intellectual property rights of third parties relating to our products, methods and/or manufacturing processes. Third parties may assert infringement claims against our customers, suppliers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, suppliers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products, or our suppliers may be forced to stop providing us with products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Similarly, interference or derivation proceedings provoked by third parties or brought by the USPTO or any foreign patent authority may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications. We may also become involved in other proceedings, such as re-examination or opposition proceedings, before the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property rights of others. An unfavorable outcome in any such proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing party, or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we jointly develop intellectual property with certain parties, and disagreements may therefore arise as to the ownership of the intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">in</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">patent</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">law</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">could</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">diminish</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">the</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.35pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">value</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">of</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">patents</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">in</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">general,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">thereby</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">impairing</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.35pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">our</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">ability</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">to</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">protect our</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">existing</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">and</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">future</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switched the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, in particular, the first-to-file provisions, became effective on March 16, 2013. It is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furthermore, the U.S. and foreign courts are continually interpreting various aspects of patent law. We cannot predict with any reasonable certainty how the evolution of the interpretation of these laws will affect our business. However, it is possible that changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our own, which would have a material adverse effect on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may not be able to adequately protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries may not protect our intellectual property rights to the same extent as laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which we have patent protection that may not be sufficient to terminate infringing activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products that are the same as or similar to our products, and our competitive position in the international market would be harmed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 7.2pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-disclosure or confidentiality agreements with our competitors.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of former employers or competitors. Although we have procedures in place that seek to prevent our employees and consultants from using the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-disclosure or confidentiality agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor, resulting in litigation. Even if we are successful in defending against these claims, the litigation could be costly and a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">distraction to management. If we are unsuccessful in defending against these claims, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate technologies or features that are important or essential to our products would have a material adverse effect on our business, and may prevent us from selling our products or from practicing our processes. In addition, we may lose valuable intellectual property rights.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners or customers in our markets of interest. In addition, third parties have registered trademarks similar and identical to our trademarks in foreign jurisdictions, and may in the future file for registration of such trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we were not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. In any case, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed</span><i style="color:#231f20;font-style:italic;">.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to patent and trademark protection, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our consultants and vendors and our employees. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, however, any of these parties may breach the agreements and disclose our trade secrets and other unpatented or unregistered proprietary information, and once disclosed, we are likely to lose trade secret protection. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be sufficient. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are reluctant or unwilling to enforce trade secret protection.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further, our competitors may independently develop knowledge, methods and know-how similar, equivalent or superior to our proprietary technology. Competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. In addition, our key employees, consultants, suppliers or other individuals with access to our proprietary technology and know-how may incorporate that technology and know-how into projects and inventions developed independently or with third parties. As a result, disputes may arise regarding the ownership of the proprietary rights to such technology or know-how and any such dispute may not be resolved in our favor. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those with whom they share it, from using that technology or information to compete with us and our competitive position could be adversely affected. If our intellectual property is not adequately protected to protect our market against competitors&#8217; products and methods, our competitive position and business could be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our financial and operating results</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may be required to obtain additional funds in the future, and these funds may not be available on acceptable terms or at all.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our operations have consumed substantial amounts of cash since inception, and we anticipate our expenses will increase as we build a commercial sales force in the U.S., investigate the potential use of Barostim for the treatment of other HF conditions, continue to grow our business and transition to operating as a public company. We believe that our growth will depend, in part, on our ability to fund our commercialization and research and development efforts. We believe that our existing cash, cash equivalents, short-term investments and revenue will be sufficient to meet our capital requirements and fund our operations for at least the next three years. However, we have based these estimates on assumptions that may prove to be incorrect, and we could spend our available financial resources much faster than we currently expect. As a result, we may need to seek additional funds in the future. If we are unable to raise funds on favorable terms, or at all, we may not be able to support our commercialization efforts or increase our research and development activities and the growth of our business may be negatively impacted. As a result, we may be unable to compete effectively. For the fiscal years ended December 31, 2021 and 2020, net cash used in operating activities was $27.7 million and $16.1 million, respectively. Our cash requirements in the future may be significantly different from our current estimates and depend on many factors, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and timing of our investment in our U.S. commercial infrastructure and sales force;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including product sales, marketing, manufacturing and distribution and hiring a direct sales and marketing team in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and rate of market acceptance of Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the research and development activities we intend to undertake in order to pursue product enhancements and expand HF indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our need to implement additional infrastructure and internal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire additional personnel to support our operations as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing technologies</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">other</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">developments.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To finance certain of these activities, we may seek funds through borrowings or through additional rounds of financing, including private or public equity or debt offerings and collaborative arrangements with corporate partners. We may be unable to raise funds on favorable terms, or at all.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders. If we borrow additional funds or issue debt securities, these securities could have rights superior to holders of our common stock and could contain covenants that will restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. We might have to obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to our technologies, product candidates or products that we otherwise would not relinquish. If we do not obtain additional resources, our ability to capitalize on business opportunities will be limited, we may be unable to compete effectively and the growth of our business will be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.08;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our operating results may vary significantly annually or from quarter to quarter, which may negatively impact our stock price in the future.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our revenue and results of operations may fluctuate annually or from quarter to quarter due to, among others, the following reasons:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">physician and payor acceptance of Barostim and Barostim Therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, expense and results of research and development activities, clinical trials and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in our expenses associated with expanding our commercial operations and operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of new products and technologies by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the productivity of our sales representatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">supplier, manufacturing or quality problems with our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of stocking orders from our distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our pricing policies or in the pricing policies of our competitors or suppliers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in coverage amounts or government and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">payors&#8217;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reimbursement</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">policies.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Because of these and other factors, it is possible that our operating results will not meet investor expectations or those of public market analysts.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Any unanticipated change in revenues or operating results is likely to cause our stock price to fluctuate. New information may cause investors and analysts to revalue our business, which could also cause a fluctuation in our stock price.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are required to maintain high levels of inventory, which could consume a significant amount of our resources, reduce our cash flows and lead to inventory impairment charges.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our product consists of a substantial number of individual components. In order to market and sell Barostim effectively, we often must maintain high levels of inventory. The manufacturing process requires lengthy lead times, during which components of our products may become obsolete, and we may over- or under-estimate the amount needed of a given component, in which case we may expend extra resources or be constrained in the amount of end product that we can produce. As compared to direct manufacturers, our dependence on third-party manufacturers for our component parts exposes us to greater lead times.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The seasonality of our business creates variance in our quarterly revenue, which makes it difficult to compare or forecast our financial results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that any revenue we generate could fluctuate from quarter to quarter as a result of timing and seasonality. We anticipate mild seasonality based on national holiday patterns specific to certain nations. These seasonal variations are difficult to predict accurately, may vary amongst different markets, and at times may be entirely unpredictable. In addition to the above factors, in the U.S. it is possible that we may experience seasonality based on patients&#8217; annual deductibility limits under their health insurance coverage. While historically seasonality has been minimal, we anticipate increased seasonality due to our increased focus on sales within the U.S. These seasonal variations are difficult to predict accurately, may vary amongst different markets and at times may be entirely unpredictable, which introduces additional risk into our business as we rely upon forecasts of customer demand to build inventory in advance of anticipated sales. In addition, we believe our limited history commercializing our products has, in part, made our seasonal patterns more difficult to discern and therefore predict.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">A portion of our current business is located outside the U.S. and, as a result, we generate revenue and incur expenses denominated in currencies other than the U.S. dollar, a majority of which is denominated in Euros. In 2019 and 2020, a majority of our total revenue was denominated in foreign currencies. As a result, changes in the exchange rates between such foreign currencies, particularly the Euro and the U.S. dollar, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">could materially impact our reported results of operations and distort period to period comparisons. Fluctuations in foreign currency exchange rates also impact the reporting of our receivables and payables in non-U.S. currencies. As a result of such foreign currency fluctuations, it could be more difficult to detect underlying trends in our business and results of operations. In addition, to the extent that fluctuations in currency exchange rates cause our results of operations to differ from our expectations or the expectations of our investors, the trading price of our common stock could be adversely affected. In the future, we may engage in exchange rate hedging activities in an effort to mitigate the impact of exchange rate fluctuations. If our hedging activities are not effective, changes in currency exchange rates may have a more significant impact on our results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our ability to use our net operating losses and tax credits to offset future taxable income and taxes may be subject to certain limitations, and we may not be able to utilize a significant portion of our net operating loss and tax credit carryforwards prior to their expiration.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have generated and expect to continue to generate significant federal and state net operating loss (&#8220;NOLs&#8221;) and tax credit carryforwards. As of December 31, 2021, we had federal and state NOL carryforwards of approximately $324.8 million and $6.5 million, respectively. The federal NOLs began expiring in 2021 and state NOLs began expiring in 2020. As of December 31, 2021, we had federal and state tax credit carryforwards of approximately $8.9 million and $1.6 million, respectively. The federal and state tax credit carryforwards began expiring in 2021 and 2028, respectively. These NOL and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the legislation enacted on December 22, 2017 commonly referred to as the &#8220;Tax Cuts and Jobs Act&#8221; (the &#8220;TCJA&#8221;), as modified by the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;), federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs incurred in taxable years beginning after December 31, 2020 is limited. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change NOL and specified other tax credit carryforwards, such as research and development tax credits, to offset future taxable income and taxes. We may have previously experienced, and may in the future experience, one or more &#8220;ownership changes&#8221; for purposes of the rules under Section 382 and 383 of the Code, including in connection with our IPO. If so, or if we do not generate sufficient taxable income, we may not be able to utilize a material portion of our NOLs and tax credits, even if we achieve profitability. If we are limited in our ability to use our NOLs and tax credits in future years in which we have taxable income, we will pay more taxes than if we were able to fully utilize our NOLs and tax credits. This could materially and adversely affect our results of operations by effectively increasing our future tax obligations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to complex tax rules, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are subject to income and/or non-income taxes in the U.S., Switzerland, Italy, Germany, France and the Netherlands, as well as the tax laws and regulations related to such matters. Tax accounting and compliance often involves complex issues, and judgment and interpretation is required in determining our provision for income taxes and other tax liabilities as well as the application of tax laws and regulations. In that respect, many jurisdictions have detailed transfer pricing rules, which require that all transactions with related parties be priced using arm&#8217;s length pricing principles within the meaning of such rules. The application of such transfer pricing rules, as well as of withholding taxes, goods and services taxes, sales taxes and other taxes is not always clear and we may be subject to tax audits relating to such rules or taxes.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We believe that our tax positions are reasonable, and our tax provisions and reserves are adequate to cover any potential liability. However, various items cannot be accurately forecasted and future events may be treated as discrete to the period in which they occur. In addition, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results, operations and future cash flow.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes in U.S. and non-U.S. tax laws could adversely affect our financial condition and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The rules dealing with U.S. and non-U.S. tax matters are constantly under review by persons involved in the legislative, judicial, administrative, regulatory and related governmental processes and authorities. Changes to tax laws or the interpretation and application thereof (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in U.S. and non-U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. and non-U.S. tax laws on an investment in our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to regulation of our industry</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Barostim is subject to extensive governmental regulation, and our failure to comply with applicable requirements could cause our business to suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The medical device industry is regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies and authorities, such as the EU legislative bodies and the EEA member state competent authorities. The FDA and other U.S., EEA and foreign governmental agencies and authorities regulate and oversee, among other things, with respect to medical devices:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">design, development and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">testing,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">content</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">language</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">instructions</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">storage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product safety;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing, sales and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-market regulatory clearance and approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">conformity assessment procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">record-keeping procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">advertising and promotion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls and other field safety corrective actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market studies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product import and export.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The laws and regulations to which we are subject are complex and have tended to become more stringent over time. Legislative or regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our failure to comply with U.S. federal and state regulations or EEA or other foreign regulations applicable in the countries where we operate could lead to the issuance of warning letters or untitled letters, fines, injunctions, suspensions or loss of regulatory clearance or approvals, recalls or seizures of products, termination of distribution, or civil penalties. In the most extreme cases, criminal sanctions or closure of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">manufacturing facilities are possible. If any of these risks materialize, our business would be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Barostim is also subject to extensive governmental regulation in foreign jurisdictions, such as Europe, and our failure to comply with applicable requirements could cause our business to suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the EEA, Barostim must comply with the Essential Requirements laid down in Annex I to the EU Active Implantable Medical Devices Directive. Compliance with these requirements is a prerequisite to be able to affix the CE mark to Barostim, without which they cannot be marketed or sold in the EEA. To demonstrate compliance with the Essential Requirements and obtain the right to affix the CE Mark to Barostim, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low-risk medical devices (Class I with no measuring function and which are not sterile), where the manufacturer can issue an EU Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements, a conformity assessment procedure requires the intervention of a Notified Body, which is an organization designated by a competent authority of an EEA country to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified Body would audit and examine the Technical File and the quality system for the manufacture, design and final inspection of our devices. The Notified Body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the Essential Requirements. This Certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EU Declaration of Conformity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements must be based on, among other things, the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use and that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device (e.g., product labeling and instructions for use) are supported by suitable evidence. This assessment must be based on clinical data, which can be obtained from (1) clinical studies conducted on the devices being assessed, (2) scientific literature from similar devices whose equivalence with the assessed device can be demonstrated or (3) both clinical studies and scientific literature. With respect to active implantable medical devices or Class III devices, the manufacturer must conduct clinical studies to obtain the required clinical data, unless reliance on existing clinical data from equivalent devices can be justified. The conduct of clinical studies in the EEA is governed by detailed regulatory obligations. These may include the requirement of prior authorization by the competent authorities of the country in which the study takes place and the requirement to obtain a positive opinion from a competent Ethics Committee. This process can be expensive and time-consuming.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In order to continue to sell Barostim in Europe, we must maintain our CE Mark and continue to comply with certain EU Directives and in the future EU MDR. Our failure to continue to comply with applicable foreign regulatory requirements, including those administered by authorities of the EEA countries, could result in enforcement actions against us, including refusal, suspension or withdrawal of our CE Certificates of Conformity by our Notified Body (the National Standards Authority of Ireland, or NSAI), which could impair our ability to market products in the EEA in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our business is subject to extensive governmental regulation that could make it more expensive and time consuming for us to bring Barostim to market in the U.S. and introduce new or improved products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products must comply with regulatory requirements imposed by the FDA in the U.S. and similar agencies in foreign jurisdictions. These requirements involve lengthy and detailed laboratory and clinical testing procedures, sampling activities, extensive agency review processes and other costly and time-consuming procedures. It often takes several years to satisfy these requirements, depending on the complexity and novelty of the product. We also are subject to numerous additional licensing and regulatory requirements </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. Some of the most important requirements we must comply with include:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;white-space:pre-wrap;">  </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">FDA&#8217;s</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulations</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">(Title</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">21</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">CFR);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">EU CE mark</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Medical</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Device</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Quality</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Management</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">System</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.85pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Requirements</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">(ISO</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">13485:2003);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Occupational</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Safety</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Health</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Administration</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">California</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Department</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Health</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Services</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current or evolving government regulation may impede our ability to conduct clinical studies and to manufacture and sell our existing and future products. Such government regulation also could delay our marketing of new products for a considerable period of time and impose costly procedures on our activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products remain subject to strict regulatory controls on manufacturing, marketing and use. We may be forced to modify or recall a product after release in response to regulatory action or unanticipated difficulties encountered in general use. Any such action could have a material effect on the reputation of our products and on our business and financial position. Further, regulations may change, and any additional regulation could limit or restrict our ability to use any of our technologies, which could harm our business. We could also be subject to new international, federal, state or local regulations that could affect our research and development programs and harm our business in unforeseen ways. If this happens, we may have to incur significant costs to comply with such laws and regulations, which will harm our results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The misuse or off-label use of our product may harm our image in the marketplace, result in injuries that lead to product liability suits, which could be costly to our business, or result in costly investigations and sanctions from the FDA and other regulatory bodies if we are deemed to have engaged in inappropriate promotion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim has been indicated for the improvement of symptoms of HFrEF by the FDA and the treatment of HFrEF in the EEA. We may only promote or market Barostim for its specifically approved indications as described on the approved label. We train our marketing and sales force against promoting our products for uses outside of the approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using our product off-label when, in the physician&#8217;s independent professional medical judgment, he or she deems appropriate. There may be increased risk of injury to patients if physicians attempt to use our product off-label. Furthermore, the use of our product for indications other than those approved by the applicable regulatory body may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physicians may also misuse our product or use improper techniques, potentially leading to injury and an increased risk of product liability. If our product is misused or used with improper technique, we may become subject to costly product liability claims or other litigation by our customers or their patients. In addition, if the FDA determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities to constitute inappropriate promotion, including promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. Any of these events could significantly harm our business and results of operations and cause our stock price to decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further, the advertising and promotion of our products is subject to EEA member state laws implementing the MDD, Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, as well as other EEA member state legislation governing the advertising and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">promotion of medical devices. EEA member state legislation may also restrict or impose limitations on our ability to advertise our products directly to the general public. In addition, voluntary EU and national codes of conduct provide guidelines on the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The discovery of serious safety issues with Barostim, or a recall of Barostim either voluntarily or at the direction of the FDA or another governmental authority, could harm our reputation, business and financial results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA, the competent authorities of the EEA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture that could affect patient safety or in the event that a product poses an unacceptable risk to health. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious adverse health consequences or death. We may also choose to conduct a product notification or recall to inform physicians of changes to instructions for use, or if a deficiency in a device is found or suspected. A government-mandated recall or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects, packaging defects or failures to comply with applicable regulations. Product defects or other errors may occur in the future. Recalls, which include certain notifications and corrections as well as removals, of Barostim could divert managerial and financial resources and could have an adverse effect on our financial condition, harm our reputation and reduce our ability to achieve expected revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the manufacturing of our products is subject to extensive post-market regulation by the FDA and foreign regulatory authorities, and any failure by us or our contract manufacturers or suppliers to comply with regulatory requirements could result in recalls, facility closures and other penalties. We and our suppliers and contract manufacturers are subject to the FDA&#8217;s QSR, and comparable foreign regulations which govern the methods used in, and the facilities and controls used for, the design, manufacture, quality assurance, labeling, packaging, sterilization, storage, shipping and servicing of medical devices. These regulations are enforced through periodic inspections of manufacturing facilities. Any manufacturing issues at our or our suppliers&#8217; or contract manufacturers&#8217; facilities, including failure to comply with regulatory requirements, may result in warning or untitled letters, manufacturing restrictions, voluntary or mandatory recalls or corrections,<span style="letter-spacing:-1.8pt;"> </span>fines,<span style="letter-spacing:-1.75pt;"> </span>withdrawals<span style="letter-spacing:-1.8pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.75pt;"> </span>regulatory<span style="letter-spacing:-1.8pt;"> </span>clearances<span style="letter-spacing:-1.75pt;"> </span>or<span style="letter-spacing:-1.8pt;"> </span>approvals,<span style="letter-spacing:-1.75pt;"> </span>product<span style="letter-spacing:-1.8pt;"> </span>seizures,<span style="letter-spacing:-1.75pt;"> </span>injunctions<span style="letter-spacing:-1.75pt;"> </span>or<span style="letter-spacing:-1.8pt;"> </span>the imposition<span style="letter-spacing:-1.6pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.6pt;"> </span>civil<span style="letter-spacing:-1.6pt;"> </span>or<span style="letter-spacing:-1.6pt;"> </span>criminal<span style="letter-spacing:-1.6pt;"> </span>penalties,<span style="letter-spacing:-1.6pt;"> </span>which<span style="letter-spacing:-1.6pt;"> </span>would<span style="letter-spacing:-1.6pt;"> </span>adversely<span style="letter-spacing:-1.6pt;"> </span>affect<span style="letter-spacing:-1.6pt;"> </span>our<span style="letter-spacing:-1.6pt;"> </span>business<span style="letter-spacing:-1.6pt;"> </span>results<span style="letter-spacing:-1.6pt;"> </span>and<span style="letter-spacing:-1.6pt;"> </span>prospects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new approvals for the device before we may market or distribute the corrected device. Seeking such approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA and European regulators, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Under the FDA medical device reporting regulations, medical device manufacturers are required to submit information to the FDA when they receive a report or become aware that a device has or may have caused or contributed to a death or serious injury or has or may have a malfunction that would likely cause or contribute to death or serious injury if the malfunction were to recur. All manufacturers placing medical devices on the market in the EEA are legally bound to report incidents involving devices they produce or sell to the regulatory agency, or competent authority, in whose jurisdiction the incident occurred. Under the MDD, an incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA or European regulators could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device approval, seizure of our products or delay in clearance or approval of future products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to certain federal, state and foreign fraud and abuse laws, health information privacy and security laws and transparency laws and regulations, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws and regulations could cause adverse publicity and be costly to respond to, and thus could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There are numerous U.S. federal and state, as well as foreign, laws pertaining to healthcare fraud and abuse, including anti-kickback, false claims and physician transparency laws. Our business practices and relationships with providers are subject to scrutiny under these laws. We may also be subject to privacy and security regulation related to patient, customer, employee and other third-party information by both the federal government and the states and foreign jurisdictions in which we conduct our business. In the U.S., the laws that may affect our ability to operate include, but are not limited to:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalty laws, including civil whistleblower or qui tam actions, that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">healthcare benefit program or making false statements relating to healthcare matters. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their business associates that perform services for them that involve individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization, including mandatory contractual terms as well as directly applicable privacy and security standards and requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician sunshine requirements under the Affordable Care Act, which require certain manufacturers of drugs, devices, biologics and medical supplies to report annually to HHS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">state and foreign law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These laws and regulations, among other things, constrain our business, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with hospitals, physicians or other potential purchasers of our products. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies continue to increase their scrutiny of interactions between healthcare companies and healthcare providers. The Office of the Inspector General of HHS also has issued compliance program guidance for pharmaceutical manufacturers which is routinely applied to medical device companies. All of this has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry, including for medical device companies. Responding to investigations can be time and resource consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us now or in the future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental health care programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;padding-bottom:12pt;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a material adverse effect on us.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. In March 2010, the Affordable Care Act was enacted in the U.S., which made a number of substantial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">changes in the way healthcare is financed by both governmental and private insurers. Among other ways in which it may affect our business, the Affordable Care Act:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">implemented payment system reforms, including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expanded the eligibility criteria for Medicaid programs.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">The expansion in the government&#8217;s role in the U.S. healthcare industry may result in decreased profits to us, lower reimbursement by payors for Barostim and any future products and/or reduced medical procedure volumes, all of which may have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, on April 5, 2017, the European Parliament passed the MDR, which repeals and replaces the MDD and the Active Implantable Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (i.e., without the need for adoption of the EEA member state laws implementing them), in all EEA member states and are intended to eliminate current differences in the regulation of medical devices among the EEA member states. The MDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory<span style="letter-spacing:-1.35pt;"> </span>framework<span style="letter-spacing:-1.35pt;"> </span>across the<span style="letter-spacing:-1.5pt;"> </span>EEA<span style="letter-spacing:-1.45pt;"> </span>for<span style="letter-spacing:-1.5pt;"> </span>medical<span style="letter-spacing:-1.45pt;"> </span>devices<span style="letter-spacing:-1.5pt;"> </span>and<span style="letter-spacing:-1.45pt;"> </span>ensure<span style="letter-spacing:-1.5pt;"> </span>a<span style="letter-spacing:-1.45pt;"> </span>high<span style="letter-spacing:-1.5pt;"> </span>level<span style="letter-spacing:-1.45pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.5pt;"> </span>safety<span style="letter-spacing:-1.45pt;"> </span>and<span style="letter-spacing:-1.5pt;"> </span>health<span style="letter-spacing:-1.45pt;"> </span>while<span style="letter-spacing:-1.5pt;"> </span>supporting<span style="letter-spacing:-1.45pt;"> </span>innovation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The MDR became fully effective in May 2021 and, among other things:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthened the rules on placing devices on the market and reinforced surveillance once they are available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">improved the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthened rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This regulation has not yet had a material effect on the way we conduct our business in the EEA. However, it is possible the regulation will change in the future, and we cannot be certain that future changes will not have an adverse effect on our business operations. In December 2021 we began the process of filing the Barostim device under the EU MDR and must go through a successful technical file conformity assessment and quality system audit before being certified for CE mark under the EU MDR.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our common stock </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are incurring and will incur significantly increased costs as a result of being a public company, and our management is required to devote substantial time to compliance with our public company responsibilities, which may adversely affect our business, financial condition and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As a public company, we have incurred and expect to continue to incur significant legal, accounting and other expenses that we did not incur as a private company. For example, we are now subject to the reporting requirements of the Exchange Act and must comply with the applicable requirements of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as rules and regulations subsequently implemented by the SEC and The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), including the establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Compliance with these requirements has and will continue to increase our legal and financial compliance costs and make some activities more time consuming and costly, which may adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, our management and other personnel must now divert attention from operational and other business matters to devote substantial time to these public company requirements. In particular, we have incurred and expect to continue to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 of the Sarbanes-Oxley Act, which will increase when we are no longer an emerging growth company, as defined by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and are not a non-accelerated filer. We have hired, and will need to continue to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and have established an internal audit function. We cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such costs. Additional compensation costs and any future equity awards will increase our compensation expense, which would increase our general and administrative expense and could adversely affect our profitability. As a public company, it is more difficult and expensive for us to obtain director and officer liability insurance on reasonable terms. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board of Directors, our board committees, or as executive officers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We expect that the price of our common stock will fluctuate substantially, and you may not be able to resell shares of our common stock at or above the price you paid.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The market price of our common stock has been and may continue to be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control or are related in complex ways, including:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">results from, or any delays in, clinical trial programs relating to our product candidates, including the ongoing and future U.S. clinical trials for Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new products by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes or developments in laws or regulations applicable to our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any adverse changes in our relationship with any manufacturers or suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our efforts to acquire or develop additional products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any intellectual property infringement actions in which we may become involved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements concerning our competitors or the medical device industry in general;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">achievement of expected product sales and profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture, supply or distribution shortages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in financial estimates or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">common</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">stock</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">us,</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">executive</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">officers</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">directors</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">general</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">economic</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">market</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">conditions</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">overall</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">equity</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">markets;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.95pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">loss</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">of</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">key</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">scientific</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">management</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the stock markets in general, and the markets for medical device stocks in particular, have experienced volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile or decreases significantly, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our results of operations and financial position. Any adverse determination in litigation could also subject us to significant liabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We have broad discretion to determine how to use the funds raised in the IPO and may use them in ways that may not enhance our operating results or the price of our common stock.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our management has broad discretion over the use of proceeds from the IPO, and we could spend them in ways our stockholders may not agree with or that do not yield a favorable return, if at all. We currently expect to use the net proceeds from the IPO to continue funding the expansion of our direct sales force and commercial organization related to Barostim in the U.S., research and development activities related to Barostim Therapy and working capital and general corporate purposes. If we do not invest or apply the proceeds of the IPO in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our stock price to decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">An active trading market for our shares of common stock may not be sustained.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our common stock began trading on June 30, 2021 and has a limited trading history upon which to assess whether an active public market for our shares may be sustained. The lack of an active market may impair the value of your shares or your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies or in-license new product candidates using our shares as consideration. Furthermore, there can be no guarantee that we will continue to satisfy the continued listing standards of Nasdaq. If we fail to satisfy these listing standards, we could be de-listed, which would have a negative effect on the price of our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price and trading volume to decline.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts cover us, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issues an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of the IPO, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Because we have opted to take advantage of the JOBS Act provision which allows us to delay implementing new accounting standards, our financial statements may not be directly comparable to other public companies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pursuant to the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Because we have elected to take advantage of this provision of the JOBS Act, our financial statements and the reported results of operations contained therein may not be directly comparable to those of other public companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.13;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we are unable to maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To comply with the requirements of being a public company, we are undertaking and expect to continue to undertake various actions, including implementing new internal controls and procedures and hiring new accounting or internal audit staff. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal control over financial reporting. We have developed and expect to continue to refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report following the IPO, which will be for our fiscal year ending December 31, 2022, provide a management report on internal control over financial reporting. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent registered public accounting firm, to the extent we are no longer an &#8220;emerging growth company,&#8221; as defined by the JOBS Act, and are not a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">non-accelerated filer. We do not expect to have our independent registered public accounting firm attest to our management report on internal control over financial reporting for so long as we are an emerging growth company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our current controls and any new controls that we develop may become inadequate and weaknesses in our internal control over financial reporting may be discovered in the future. If we fail to develop and maintain effective internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We have designed and implemented and expect to continue to refine the internal control over financial reporting required to comply with this obligation, which process will be time consuming, costly and complicated. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, if we are unable to assert that our internal control over financial reporting is effective, or, when required in the future, if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, or if our internal control over financial reporting is perceived as inadequate or we are unable to produce timely or accurate financial statements, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline and we could become subject to investigations or removal by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 59.75pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our principal stockholders, management and directors (four of whom are affiliated with our principal stockholders) own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 59% of our outstanding voting stock. Four of our non-employee directors are also affiliated with certain of our principal stockholders. Therefore, if they act together, these stockholders will have the ability to influence us through this ownership position and matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could attempt to delay or prevent a change in control of the Company, even if such change in control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of the Company or our assets, and might affect the prevailing market price of our common stock due to investors&#8217; perceptions that conflicts of interest may exist or arise. As a result, this concentration of ownership may not be in the best interests of our other stockholders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#39; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law (the &#8220;DGCL&#8221;) or any action asserting a claim against us that is governed by the internal affairs doctrine. The exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation also provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Anti-takeover provisions included in our amended and restated certificate of incorporation and amended and restated bylaws, as well as under Delaware law, could discourage a takeover.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace or remove current members of our management team. These include the following provisions that:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">permit our Board of Directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the authorized number of directors may be changed only by resolution of our Board of Directors and that a director may only be removed with cause by the affirmative vote of the holders of at least a majority of our outstanding voting stock, voting together as a single class;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that our amended and restated bylaws may only be altered, amended or repealed by our stockholders upon the affirmative vote of a two-thirds majority of the voting power of all of our outstanding voting stock, voting together as a single class;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that special meetings of our stockholders may be called only by the Chairman of the board, the Chief Executive Officer, or a majority of the Board of Directors then in office, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, Section 203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change in control of our company, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.09;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5f3e163e_2696_407e_9217_dc6e6f788084"></a><a id="Item1BUnresolvedStaffComments"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 1B. Unresolved Staff Comments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_57f6bdf5_dff3_449d_8fe1_86c29d8ea472"></a><a id="Item2Properties"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 2. Properties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We lease 23,890 square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and expires July 31, 2024. We intend to add new facilities as we grow and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_ebe8266c_4e01_441c_93c3_b5510955c37d"></a><a id="Item3LegalProceedings"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;3. Legal Proceedings</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the<span style="letter-spacing:0.25pt;"> </span>ordinary course of our business. We are not currently a party to any material legal proceedings.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_aeb8b893_e287_47a0_b0e1_64791b50ce6d"></a><a id="Item4MineSafetyDisclosures"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;4. Mine Safety Disclosures</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e3bd4515_f5d4_4670_82e0_b8a8f081f32a"></a><a id="PARTII"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PART II</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6670f88f_0bfc_4661_a862_653985cd3d9c"></a><a id="Item5MarketforRegistrants"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 5. Market for Registrant&#8217;s Common Equity</b><b style="font-size:12pt;font-weight:bold;">, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;CVRX.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of February 14, 2022, there were approximately 110 holders of record of our common stock. This number does not include stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Proceeds from the IPO</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">On July 2, 2021, we completed our IPO and issued 8,050,000 shares of our common stock at a public offering price of $18.00 per share, which includes 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses, of approximately $144.9 million. After deducting the underwriting discount of $10.1 million and offering expenses of $1.6 million, we received net proceeds of approximately $133.2 million. No payments for such expenses were made directly or indirectly to (i)&#160;any of our officers or directors or their associates, (ii)&#160;any persons owning 10% or more of any class of our equity securities or (iii)&#160;any of our affiliates. J.P. Morgan Securities LLC, Piper Sandler &amp; Co. and William Blair &amp; Company, L.L.C. acted as joint book-running managers of the IPO and Canaccord Genuity LLC acted as a lead manager for the IPO. Shares of our common stock began trading on the Nasdaq Global Select Market on June 30, 2021. The offer and sale of the shares were registered&#160;under the Securities Act on a Registration Statement on Form S-1 (File No. 333-256800), which was declared effective on June 29, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">There has been no material change in the expected use of the net proceeds from our IPO as described in our final prospectus, dated June 29, 2021, filed with the SEC on July 1, 2021 pursuant to Rule&#160;424(b) of the Securities Act.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_612ef035_2732_43d2_85e1_6def149da7dd"></a><a id="Item6Reserved"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 6. [Reserved]</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_afc60736_fd05_49bc_a067_4f866e63c77d"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;7. Management&#8217;s Discussion and Analysis</b><b style="font-size:12pt;font-weight:bold;"> of Financial Condition and Results of Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Overview</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular disease. Our proprietary platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the Autonomic Nervous System, which causes HFrEF and other cardiovascular diseases. Our second-generation product, Barostim, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HFrEF. Barostim provides Baroreflex Activation Therapy by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is currently approved by the FDA to improve the symptoms of patients with HFrEF and is CE Marked for HFrEF and resistant hypertension.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since our inception we have generated minimal revenue, as our activities have consisted primarily of developing Barostim Therapy, conducting our BeAT-HF pre-market and post-market pivotal studies in the U.S. and filing for regulatory approvals. Our ability to generate revenue from product sales and become profitable will depend on our ability to successfully commercialize Barostim and any product enhancements we may advance in the future. We expect to derive future revenue by expanding our own dedicated salesforce and increasing awareness of Barostim among payors, physicians and patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our sales and marketing efforts are directed at electrophysiologists, HF specialists, general cardiologists and vascular surgeons because they are the primary users of our technology. However, we consider hospitals, where the procedures are performed primarily in an outpatient setting, to be our customers, as they are the purchasing entities of Barostim in the U.S. We intend to continue making significant investments building our U.S. commercial infrastructure by expanding and training our U.S. sales force. We have dedicated significant resources to educate physicians who treat HFrEF about the advantages of Barostim and train them on the implant procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The costs for the device and implantation procedure are reimbursed through various third-party payors, such as government agencies and commercial payors. In the U.S., we estimate that 67% of our target patient population is Medicare-eligible based on the age demographic of the HFrEF patient population indicated for Barostim. As a result, we have prioritized coverage by the CMS while simultaneously developing processes to engage commercial payors. As of July&#160;2020, all Medicare Administrative Contractors have retired automatic coverage denial policies for our Current Procedural Terminology codes, thereby allowing hospitals to be paid for the Barostim procedure. Our reimbursement strategy involves continuing to broaden our current coverage and build our in-house market access team to assist patients and physicians in obtaining appropriate prior authorization approvals in advance of treatment on a case-by-case basis where positive coverage policies currently do not exist. Outside the U.S., reimbursement levels vary by country and within some countries by region. Barostim is eligible for reimbursement in certain countries in the European Union, such as Germany, where annual healthcare budgets for the hospital generally determine the number of patients to be treated and the prices to be paid for the related devices that may be purchased.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We manage all aspects of manufacturing operations and product supply of Barostim, which include final assembly, testing and packaging of our implantable pulse generator and stimulation lead, at our headquarters in Minneapolis, Minnesota. We utilize components or various subassemblies manufactured by third-party suppliers, some of which have significant lead times. Many of these components are from a limited number of suppliers. We believe that our component manufacturers are recognized in their field for their competency to manufacture the respective portions of Barostim and have quality systems established that meet FDA requirements. We seek to maintain higher levels of inventory to protect ourselves from supply interruptions and continue to seek to broaden and strengthen our supply chain through additional sourcing channels.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From our inception until the IPO, we financed our operations primarily through preferred stock financings, and additionally, from sales of our Barostim products and amounts borrowed under our current and past credit facilities. We have devoted substantially all of our resources to research and development activities related to Barostim Therapy, including clinical and regulatory initiatives to obtain marketing approval and sales and marketing activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We intend to use a portion of the IPO proceeds to continue funding the expansion of our direct sales force and commercial organization related to Barostim in the U.S. We also intend to continue investing in research and development in the near term to improve clinical outcomes, optimize patient adoption and comfort, increase patient access and enhance the physician and patient experience. Longer term, we plan to explore Barostim&#8217;s potential to expand its indications for use to other cardiovascular diseases. As a result of these investments and our commercialization efforts, we expect to continue to incur net losses for the next several&#160;years, which may require additional funding and could include future equity and debt financings.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Recent developments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since it was reported to have surfaced in December&#160;2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) has spread across the world and has been declared a pandemic by the World Health Organization. Efforts to contain the spread of COVID-19 have been significant and governments around the world, including in the U.S., have implemented severe travel restrictions, social distancing requirements, quarantines, stay-at-home orders and other significant restrictions. As a result, the current COVID-19 pandemic has presented a substantial public health and economic challenge and is affecting hospitals, physicians, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. and world economy and in financial markets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has negatively impacted our business, financial condition and results of operations by decreasing and delaying procedures performed to implant Barostim and we expect the pandemic will continue to negatively impact our business, financial condition and results of operations. Beginning in March&#160;2020, our revenue was negatively impacted by COVID-19 as healthcare facilities and clinics began restricting in-person access to their clinicians, reducing patient consultations and treatments or temporarily closing their facilities. As a result, substantially all of our then-scheduled procedures were postponed, and numerous other cases could not be scheduled. During May&#160;2020, the widespread shutdown resulted in key physician-society conferences being moved to a virtual setting, which directly impacted our planned commercial launch in the U.S.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In response to the COVID-19 pandemic, we have implemented a variety of measures intended to help us manage its impact while maintaining business continuity to support our customers and patients. These measures include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Establishing safety protocols, facility enhancements and work-from-home strategies to protect our employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Ensuring that our manufacturing and supply chain operations remain intact and operational;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Keeping our workforce intact, including our experienced and specialized U.S. sales and clinical support team;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Implementing virtual physician education programs to support opening new accounts with minimal in person interaction; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Increasing our capital resources through the completion of the IPO, which resulted in net proceeds of $133.2 million.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our hospital customers in the U.S. and Europe began to gradually perform elective procedures again during the fourth quarter of 2020. We believe the recovery of our business in the fourth quarter of 2020 and through most of fiscal year 2021 is an encouraging sign for when remaining shelter-in-place and hospital limitations are lifted. As the pandemic eased throughout 2021, we experienced the following positive trends:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Strong physician participation in our virtual educational events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expansion into new accounts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Hospitals accepting patients for elective procedures at closer to pre-pandemic levels in the U.S.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">However, procedure volumes were again negatively impacted by the Delta and Omicron variants of COVID-19 in the third and fourth quarters of 2021. We believe the challenges resulting from COVID-19 will likely continue for the duration of the pandemic. The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information that may emerge concerning the severity and spread of COVID-19 and its variants and the actions to contain the spread of COVID-19 and its variants or treat its impact.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Factors affecting our performance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe there are several important factors that have impacted and that we expect will continue to impact our business and results of operations. These factors include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Growing and supporting our U.S. commercial organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Promoting awareness among physicians, hospitals and patients to accelerate adoption of Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising awareness among payors to build upon reimbursement for Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Investing in research and development to foster innovation and further simplify Barostim procedure; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Leveraging our manufacturing capacity to further improve our gross margins.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Components of results of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Revenue</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our U.S. sales have increased since the pre-market approval of Barostim by the FDA in August&#160;2019, and the subsequent reimbursement changes in 2020. We expect to continue to drive increases in revenue through our efforts to increase awareness of Barostim among physicians, patients and payors and by the expansion of our U.S. sales force. As a result, we expect that U.S. sales will continue to account for the majority of our revenue going forward.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We derive a portion of our revenue from the sale of Barostim to hospitals in Germany and other select countries in Europe. Revenue from sales of Barostim in Europe fluctuates based on the average selling price of Barostim as determined by location of sale and channel mix, each of which may vary significantly from country to country. Our revenue from international sales can also be significantly impacted by fluctuations in foreign currency exchange rates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Cost of goods sold and gross margin</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold consists primarily of acquisition costs of the components and subassemblies of Barostim, allocated manufacturing overhead and scrap and inventory obsolescence, as well as distribution-related expenses such as logistics and shipping costs. We expect cost of goods sold to increase in absolute dollars primarily as, and to the extent, our revenue grows. Gross margin may also vary based on regional differences in rebates and incentives negotiated with certain customers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We calculate gross margin as revenue less cost of goods sold divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, but is primarily driven by the average sale price of our product, the&#160;percentage of products sold that include a full system (i.e., an IPG and a stimulation lead), as compared to individual IPG sales, and the allocated manufacturing overhead. Although we sell the majority of our devices directly to hospitals, the impact of the average selling price on gross margin is driven by the&#160;percentage of products we sold to distributors as compared to those sold directly to hospitals as our average selling price is typically higher on products we sell directly. The full system sales typically have a lower gross margin as they include the cost of an IPG and a stimulation lead whereas individual IPG sales only include the cost of an IPG.&#160;The manufacturing overhead costs of Barostim are directly aligned to our production volume and therefore the cost per product is reduced if production levels increase. While we expect our gross margin to be positively affected over time to the extent we are successful in selling more product through our direct sales force and by increasing our production volumes, it will likely fluctuate from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">period to period as we continue to introduce new products and adopt new manufacturing processes and technologies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Research and development expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) expenses consist primarily of personnel costs, including salaries, bonuses, employee benefits and stock-based compensation expenses for our R&amp;D employees. R&amp;D expenses also include costs associated with product design efforts, development prototypes, testing, clinical trial programs and regulatory activities, contractors and consultants, equipment and software to support our development, facilities and information technology. We expense research and development costs as they are incurred. We expect R&amp;D expenses to increase in absolute dollars as we continue to develop enhancements to Barostim. Our R&amp;D expenses may fluctuate from period to period due to the timing and extent of our product development and clinical trial expenses related to Barostim in HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Selling, general and administrative expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses consist primarily of personnel costs, including base salaries, bonuses, employee benefits and stock-based compensation expense for our sales and marketing personnel, including sales commissions, and for administrative personnel that support our general operations such as executive management, financial accounting, information technology and human resources personnel. SG&amp;A expenses also include costs attributable to marketing, as well as travel, legal fees, financial audit fees, insurance, fees for other consulting services, depreciation and facilities. We expense commissions at the time of the sale.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect SG&amp;A expenses to increase in absolute dollars as we continue to expand our direct sales force and commercial organization in the U.S. In addition, we will continue to increase our international presence and to develop and assist our channel partners. We also expect our administrative expenses will increase as we increase our headcount and information technology to support our operations as a public company. Additionally, we anticipate increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs associated with being a public company. However, we expect our SG&amp;A expenses to decrease as a&#160;percentage of revenue as our revenue grows.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Interest expense</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense consists of interest on our debt and amortization of associated debt discount.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Other expense, net</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other expense, net consists primarily of the fair value adjustments related to our formerly outstanding convertible preferred stock warrants, which were accounted for as a liability and marked-to-market at each reporting period. The final fair value adjustment of the warrant liability was recorded upon the closing of the IPO in connection with the conversion of the warrants to common stock warrants. Other items include losses on the extinguishment of debt, interest income earned on our cash and cash equivalents and the effect of exchange rates on our foreign currency-denominated asset and liability balances. Translation adjustments are recorded as foreign currency gains (losses) in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Provision for income taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provision for income taxes consists primarily of income taxes in foreign jurisdictions in which we conduct business. We maintain a full valuation allowance for deferred tax assets including NOL carryforwards, R&amp;D credits and other tax credits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Results of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Consolidated results of operations for the year ended December 31, 2021, compared to the year ended December 31, 2020</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,036</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,053</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,983</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 115</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,640</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,440</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,200</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 153</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,396</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,613</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,783</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 104</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 76</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,501</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,410</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,091</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,863</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,717</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,146</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,127</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,237</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 119</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,968)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,514)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,454)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 126</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,219)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,470)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 251</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,800)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,760)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">NM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,987)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,024)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,963)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 207</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (91)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (85)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (43,078)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,109)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,969)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 205</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;">NM &#8211; Not meaningful</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Revenue</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:34.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by Geography</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,147</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,733</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,414</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 428</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,889</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,320</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (431)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,036</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,053</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,983</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 115</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue was $13.0 million for the year ended December 31, 2021, an increase of $7.0 million, or 115%, over the year ended December 31, 2020.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue generated in the U.S. was $9.1 million for the year ended December 31, 2021, an increase of $7.4 million, or 428%, over the year ended December 31, 2020. Total HF revenue units in the U.S. totaled 290 and 32 for the years ended December 31, 2021 and 2020, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">HF revenue in the U.S. totaled $8.4 million and $1.0 million for the years ended December 31, 2021 and 2020, respectively. The increase was primarily driven by the continued growth following the commercial launch in 2020, which resulted in the expansion into new sales territories and increased physician and patient awareness of Barostim. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had a total of 46 active implanting centers, as compared to 11 as of December 31, 2020. Active implanting centers are customers that have completed at least one commercial HF implant in the last 12 months. The number of sales territories in the U.S. increased by eight to a total of 14 during the year ended December 31, 2021. A sales territory is an established regional area held by an account manager, typically after six months of employment. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Legacy hypertension revenue in the U.S. totaled $0.7 million for each of the years ended December 31, 2021 and 2020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue generated in Europe was $3.9 million for the year ended December 31, 2021, a decrease of $0.4 million, or 10%, over the year ended December 31, 2020. Total revenue units in Europe decreased to 176 for the year ended December 31, 2021, from 193 for the prior year period. The decrease is due to reduced procedure volumes resulting from the Delta and Omicron variants of COVID-19 in 2021. The number of sales territories in Europe remained consistent at six during the year ended December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost of goods sold and gross margin</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold increased $2.2 million, or 153%, to $3.6 million for the year ended December 31, 2021, compared to the year ended December 31, 2020. This increase was primarily due to higher sales of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Gross profit was $9.4 million for the year ended December 31, 2021, an increase of $4.8 million, or 104%, over the year ended December 31, 2020. Gross margin decreased to 72% for the year ended December 31, 2021, compared to 76% for the year ended December 31, 2020. Gross margin for the year ended December 31, 2021 was lower due to a larger percentage of our revenue units coming from full systems versus battery replacements for existing patients. This was partially offset by an increase in the average selling price.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development expenses</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses increased $1.1 million, or 17%, to $7.5 million for the year ended December 31, 2021, compared to the year ended December 31, 2020. This change was primarily driven by a $0.4 million increase in clinical study expenses, a $0.4 million increase in compensation expenses as a result of increased headcount, and a $0.4 million increase in non-cash stock-based compensation expense.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling, general and administrative expenses</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">SG&amp;A expenses increased $18.1 million, or 187%, to $27.9 million for the year ended December 31, 2021, compared to the year ended December 31, 2020. This change was driven by an increase of $9.0 million in compensation expenses, including salaries and commissions, and other employee-related expenses, mainly as a result of increased headcount, a $3.1 million increase in marketing and advertising expenses, primarily related to the commercialization of Barostim in the U.S., a $1.4 million increase in non-cash stock-based compensation expense, a $1.3 million increase related to D&amp;O insurance costs incurred as a result of becoming a public company, a $1.2 million increase in travel expenses and a $1.0 million increase in consulting expenses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest expense</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense decreased $0.3 million, or 10%, to $2.2 million for the year ended December 31, 2021, compared to the year ended December 31, 2020. This was driven by the repayment of the outstanding debt in November 2021 under the Horizon loan agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other expense, net</p><a id="_Hlk94004723"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other expense, net was $14.8 million for the year ended December 31, 2021, compared to other expense, net of $40,000 for the year ended December 31, 2020. The expense in 2021 was primarily driven by a $13.7 million increase in expense related to the increase in fair value of our convertible preferred stock warrants due to the change in the value of our common stock from December 31, 2020 to July 2, 2021, which is the date the warrants converted to common stock warrants. The expense in 2021 was also due to a $1.3 million loss on debt extinguishment in connection with the November 2021, repayment of the outstanding debt under the Horizon loan agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Provision for income taxes</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provision for income taxes was nominal for the years ended December 31, 2021 and 2020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Liquidity, capital resources and plan of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses and negative cash flows from operations since our inception, and we anticipate that we will incur significant losses for at least the next several&#160;years. As of December 31, 2021 and 2020, we had cash and cash equivalents of $142.1 million and $59.1 million, respectively. For the years ended December 31, 2021 and 2020, our net losses were $43.1 million and $14.1 million, respectively. Our net cash used in operating activities for the years ended December 31, 2021 and 2020, was $27.7 million and $16.1 million, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, our operations were financed primarily by aggregate net proceeds from the sale of our convertible preferred stock of $383.1 million, as well as debt financings. In September&#160;2019, we entered into the Horizon loan agreement to borrow $20.0 million, which was fully repaid on November 3, 2021. In July&#160;2020, we completed an equity financing pursuant to which we issued 62,500,000 shares of Series&#160;G Preferred Shares at a price of $0.80 per share, for net proceeds of $49.8 million after deducting offering expenses. On July 2, 2021, we closed our IPO for net proceeds from the offering, after deducting the underwriting discount and other offering expenses payable by us, of $133.2 million. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future liquidity and capital funding requirements will depend on numerous factors, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our investment in our U.S. commercial infrastructure and sales forces;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and rate of market acceptance of Barostim and the ability for our customers to obtain appropriate levels of reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including product sales, marketing, manufacturing and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our R&amp;D activities for product enhancements and to expand our indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our need to implement additional infrastructure and internal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire additional personnel to support our operations as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing technologies or other adverse market developments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that our existing cash resources together with revenue will be sufficient to meet our forecasted requirements for operating liquidity, capital expenditures and debt services for at least the next three years. If these sources are insufficient to satisfy our liquidity requirements, however, we may seek to sell additional equity or enter into a loan agreement. If we raise additional funds by issuing equity securities, our stockholders would experience dilution. Debt financing, if available, may involve covenants further restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additional financing may not be available at all, or may only be available in amounts or on terms that we do not deem to be favorable. If we are unable to obtain additional financing when needed to satisfy our liquidity requirements, we may be required to delay the commercialization and marketing of Barostim.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Cash flows</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the primary sources and uses of cash for each of the periods presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,732)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,096)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,183)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (311)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 111,883</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 49,783</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,960</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,371</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2021 was $27.7 million and consisted primarily of a net loss of $43.1 million and a decrease in net operating assets of $1.6 million, partially offset by non-cash charges of $13.3 million related to the fair value adjustment to our convertible preferred stock warrants, $1.9 million from non-cash stock-based compensation expense and $1.3 million from the loss on debt extinguishment. Net operating assets consisted primarily of inventory, accounts receivable and accrued expenses to support the growth of our operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2020 was $16.1 million and consisted primarily of a net loss of $14.1 million and a decrease in net operating assets of $2.9 million. Net operating assets consisted primarily of inventory, accounts receivable, accounts payable and accrued expenses to support the growth of our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities was $1.2 million and $0.3 million for the years ended December 31, 2021 and 2020, respectively, and consisted of purchases of property and equipment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2021 was $111.9 million and consisted primarily of proceeds from the issuance of common stock of $133.2 million, partially offset by the repayment of the outstanding debt balance and related fees of $21.3 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2020 was $49.8 million and consisted entirely of proceeds from the issuance of Series G convertible preferred stock. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Indebtedness</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In September&#160;2019, we entered into the Horizon loan agreement under which we borrowed $20.0 million, which is the maximum borrowing under the Horizon loan agreement. Amounts outstanding under the Horizon loan agreement bore interest at a floating per annum rate equal to 10% plus the amount by which the 30-day U.S. dollar LIBOR rate on the first business day of the&#160;month exceeded 2.2%. The Horizon loan agreement initially required interest only payments through October&#160;2021 and then 36&#160;monthly principal and interest payments beginning in November&#160;2021. In August&#160;2020, we entered into an amended agreement with Horizon to extend the interest only period through April&#160;2022, followed by 30&#160;monthly principal and interest payments beginning May&#160;2022. A final payment of $0.7 million, equal to 3.5% of the original principal, was due to be paid in October&#160;2024. On November 3, 2021, we fully repaid our outstanding principal balance of $20.0 million and incurred an additional $1.3 million related to a loss on debt extinguishment in connection </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with the Horizon loan agreement. We were in compliance with all covenants at the time the principal balance was fully repaid.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Critical accounting policies and estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and judgments that affect the amounts reported in our consolidated financial statements and accompanying notes included elsewhere in this Annual Report on Form 10-K. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable and supportable under the circumstances. The results of this evaluation then form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and such differences may be material to our consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex judgments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock-based compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain an equity incentive plan that was adopted in 2001 to provide long-term incentives for employees, consultants and members of the Board of Directors. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to consultants and non-employee directors. In connection with the IPO, we adopted the 2021 Plan under which we may grant equity incentive awards to eligible employees (including our named executive officers), non-employee directors and consultants in order to enable us to obtain and retain services of these individuals, which we deem as essential to our long-term success.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non- employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and nonemployee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We use an estimate of the value of our common stock, with the assistance of an independent appraiser, to determine the fair value of options.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i)&#160;the fair value of common stock (ii)&#160;the expected share price volatility, (iii)&#160;the expected term of the award, (iv)&#160;the risk-free interest rate and (v)&#160;the expected dividend yield.</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Fair value of common stock</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Given the absence of a public trading market for our common stock prior to the IPO, the fair value of our common stock was determined by our Board of Directors with the assistance of an unrelated third-party valuation firm. The valuation was determined in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation. For the valuation as of the date of pricing of the IPO, the fair value of our common stock was determined by our Board of Directors to be the public offering price of the shares of common stock issued in the IPO. For valuations after the completion of the IPO, our Board of Directors will determine the fair value of each share of common stock based on the closing price of our common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in our assumptions or market conditions.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected share price volatility</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Due to the lack of a public market for the trading of our common stock and a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar (guideline) companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of guideline companies have characteristics similar to us, including stage of product development and focus </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">on the life science industry.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected term of an award</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Determined based on our analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. We utilize the simplified method to develop the estimate of the expected term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Risk-free interest rate</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Based on a treasury instrument whose term is consistent with the expected term of the stock options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected dividend yield</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#8212;</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> We assume an expected dividend yield of zero, as we have never paid dividends and have no current plans to pay any dividends on our common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;) permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A discussion of recent accounting pronouncements is included in Note&#160;2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</p><a id="_14a6b553_c94e_4dc3_8fd5_791b2e8a7340"></a><a id="Item7QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Interest rate risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The risk associated with fluctuating interest rates is primarily limited to our cash equivalents, which are carried at quoted market prices. We do not currently use or plan to use financial derivatives in our investment portfolio.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Foreign currency exchange rate risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Portions of our revenue and our operating expenses are incurred outside the U.S. and thus are denominated in foreign currencies and subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Euro. Additionally, fluctuations in foreign currency exchange rates may cause us to recognize transaction gains and losses in our statements of operations and comprehensive loss. To date, foreign currency transaction realized gains and losses have not been material to our consolidated financial statements, and we have not engaged in any foreign currency hedging transactions. As our international operations grow, we will continue to reassess our approach to managing the risks relating to fluctuations in currency rates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Inflation risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inflationary factors, such as increases in our cost of goods sold and operating expenses, may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin and selling and marketing and operating expenses as a&#160;percentage of our revenue if the selling prices of our products do not increase as much as or more than these increased costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Credit risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, our cash and cash equivalents were maintained with one financial institution in the U.S., and our current deposits are likely in excess of insured limits. We believe this institution has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;8. Financial Statements and Supplementary Data</b></p><a id="_f6544c13_b3fa_4f06_a84b_bd9624ed0f89"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Board of Directors and Shareholders</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CVRx, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">We have audited the accompanying consolidated balance sheets of CVRx, Inc. (a Delaware corporation) and subsidiary (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company<span style="color:#0000ff;"> </span>as of December 31, 2021 and 2020, and the results of its<span style="color:#0000ff;"> </span>operations and its<span style="color:#0000ff;"> </span>cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:AuditorName" id="Narr_M_DJZMsxTkeoUavAhD7v8A">GRANT THORNTON LLP</ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2016.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:AuditorLocation" id="Narr_tIimdcDbokKK6crKcnkIXg">Minneapolis, Minnesota</ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">February 22, 2022</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b631dfc9_fe32_4512_9663_e305f66b493f"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedBalanceSheets_40430"></a><a id="ConsolidatedBalanceSheets"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_a954118e_803a_45fd_8f19_da53077d6187"></a><a id="Tc_dhfImiKW9k20M-O2zAWDDA_1_2"></a><a id="Tc_hfQmIRt3Xke-5u9YDURP9w_1_5"></a><a id="Tc_mi6ZYKNNB0mrPfeEuyTxSg_2_2"></a><a id="Tc_7nfJtfCKAkOYXNPVhB6IDA_2_5"></a><a id="Tc_bg4I8i7XYEmJQC6CG63opw_3_0"></a><a id="Tc_Y9t-XOXdRkSLJgjCd1Lvmg_4_0"></a><a id="Tc_S5oG5SsVBUSmUcUv7w7vvQ_5_0"></a><a id="Tc_Fs1h66C38ky9RHlAzv8lIQ_5_2"></a><a id="Tc_F1W55eZNik2Fb_Uy6N5HWg_5_5"></a><a id="Tc_AFpPZJ3DekaIgyzvcA3myA_6_0"></a><a id="Tc_JLejmmz4H0KGhmNmkOzaPA_7_0"></a><a id="Tc_X0XtyZgP_k26iHV50jkFfQ_8_0"></a><a id="Tc_4VUwDGnBjEWNJCagS7iGhg_9_0"></a><a id="Tc_Z2bDqMjue0q3a1pTvijiag_10_0"></a><a id="Tc_X72MwoDKSkS9itZ7w5yHdg_11_0"></a><a id="Tc_56s-UInWHkKJ_AlaKLaO3A_12_0"></a><a id="Tc_SrttJITqLUSzEUXcDN5aLA_12_2"></a><a id="Tc_hXvhGU_At0SX9oJONP3Jmw_12_5"></a><a id="Tc_xcvEw_k7CUal2_0xxIbtfw_13_0"></a><a id="Tc_4jx28UpHhkuWIkFK5_kVFw_14_0"></a><a id="Tc_oFG4ZPAn1kKyj98zWW4wCw_15_0"></a><a id="Tc_U1G8D5haB0uvXi0gltuWdQ_15_2"></a><a id="Tc_kJ1q-hKZ4EyCcy0t4vDVlw_15_5"></a><a id="Tc_ToDt8SeUi0S6RKlcMhQvBg_16_0"></a><a id="Tc_YOtEmQSqREG_pgVT7JII1g_17_0"></a><a id="Tc_Bqv2fqgvx06NF8NsAxrraQ_18_0"></a><a id="Tc_Ds9PW7KlLEmDLevNb8wuoQ_19_0"></a><a id="Tc_8XHWPAkcj0OguQGRjTzGAw_20_0"></a><a id="Tc_DTD8bZiN90-8kft3h3eQbw_21_0"></a><a id="Tc_qHmqZcZL4EyLAlF9lP7pcw_22_0"></a><a id="Tc_9IP4msvoVEyhx31JQ59IDA_23_0"></a><a id="Tc_4_MApxjr-0mK7IyfwQIzEg_24_0"></a><a id="Tc_ZJmOEhJ1M0iKgi0a9CS-5Q_25_0"></a><a id="Tc_HT9vN2Rvt0mBHHD0Xm6h-A_26_0"></a><a id="Tc_zIUYgD3-nUSIaBsrhSalyQ_27_0"></a><a id="Tc_fzxr81MgfkuOBkF1nm6rRQ_28_0"></a><a id="Tc_uTeTtkaAXEW_mFtPQ_kcrA_29_0"></a><a id="Tc_53m1kggmE0OYjhefW8Enuw_30_0"></a><a id="Tc_INnyR4tCnEWxzBPycTUM4Q_30_2"></a><a id="Tc_adS5E1zr70Ciaw3uRAnbQg_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_h8OSWsOnP0OiZOqtV7R9Rw_5_3">142,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_S47wP9whYkOwh78bmAczxQ_5_6">59,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_qA4t_q4bBkCJXIW8CUgrfg_6_3">2,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_mfJ-FKcD8keIxAnAfK5fYQ_6_6">1,281</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_1ylpG_oOQkWvtQwbRLghhA_7_3">3,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_19CPjcrDEkSv5rX-YXQbsA_7_6">3,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_UNqQY5Cv1UG-CYecielWwQ_8_3">2,585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_TGGqpMZfDU6pKaTXombJVg_8_6">605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_xlnfUJ82y0mkqdmWRWT2ew_9_3">151,097</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_VccJjOrLN0qi3EIteO_FiQ_9_6">64,341</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_rcE4ZXDINkuOcg9rlJRP_g_10_3">1,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_b45I2UqKu0GWH6odO-036w_10_6">410</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_rIZF944DXEuo80U841X5Eg_11_3">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_YnjbyXQ3f025WquNFfLXyg_11_6">26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_f94WY3P8FUK7ig7kYjdTaQ_12_3">152,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_hWv0nL7FR02ZWM_E0K72Ww_12_6">64,777</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_mQUnW6KKxkuY63fToS1xdg_15_3">510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_7gfWtaTRMEegBGZ9NKhQiQ_15_6">483</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_LWHXvyUx0U6GV0iuUznioQ_16_3">5,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Rw3Wq4tyIkC2UcmsjYOGog_16_6">3,583</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:zerodash" name="cvrx:WarrantLiabilityCurrent" scale="3" id="Tc_G0tpMtif5kOEDrZ8fm1KqQ_17_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:WarrantLiabilityCurrent" scale="3" id="Tc_hjEa9B-BTE-NwUCiLO9pTw_17_6">3,911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_cfMPZOKUB02gF747cTHW5A_18_3">5,908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_oUDdepy6UUKciWnz1vPOhw_18_6">7,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_73ICxiVU802Cl9zFhT_HIw_19_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_pn6F2zF7YEu_xPlO3ACSpA_19_6">19,278</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_Al3Iri-vQ0Kr7DWiLbcY1w_20_3">681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_w6GJi4ih4kiJGSh7aFl_nw_20_6">777</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_gWVnrnPAO0-a8UCxiDGiQw_21_3">6,589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_HUF3SNa_R0-WIGRPkrsixg_21_6">28,032</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Convertible preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_saCEtySRsEuZ7aVq9To-LA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_1I06B-wZP0-2Df8wiTJLEQ">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_4BrIBkChSU-0QC2bYYbIxA">10,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_WGWeMSNwQEyuE2OYQUSB9Q">237,370,645</ix:nonFraction> authorized as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_zqYKIlpoWkaUrJ-nyMhHKg">0</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_6HRjw65sUUqmEoYLNp9APg">223,541,754</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_F_D18IC5BEuK0j9gsJLwVA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_0XkIKc5vtkaAz_u2UX8LPw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_13lBHDnPvk66xXZALh-7vw_23_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_YeDeNAm_FU2ijpqXeI3XgA_23_6">329,983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity (deficit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_cB37bISmN0ix-eRShR1EvA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_OZ4MrTR96k24YrqEFzlcTw">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Ui7-b7qAmUeyMI2f9aPacw">200,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_9WBAPkP0h0S2lKpC2fvjHA">625,217,795</ix:nonFraction> authorized as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_xXIPDTIv1kCBVvAnEmzVFA">20,399,337</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_LcdkLxHOv0KeXEfMTD6Y9g">360,412</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_OiXATJAeOEWMUr6BK9NIwg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_hW0XHasF1EqKmki-9OASVQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_WGj6gh3FnkOyUn0LHJVxtg_25_3">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_xJ74FEhD8kyktkRDKPhbLw_25_6">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_OfH5HKwFDEeeX47psq2PVg_26_3">540,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_iBvGEl0Mc0qd9pDvXoJTjA_26_6">58,624</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_bnEvPkT0a02Xjtrb7Uyd9Q_27_3">394,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_XqvBOvs--EeDx6znkZg3dw_27_6">351,676</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_9D7O0cxsYEKOhbHU9tuy1Q_28_3">198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_rbWVVTP2MUWOFIbMyNSMZw_28_6">190</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_v_ylxMpqaEmp5BucbT4O0A_29_3">145,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_2wDoYhbdT0a--CvyoU8oCA_29_6">293,238</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_8Flx9k1DnUSfuv91T6Z6_w_30_3">152,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Q_E5VcrJ1U62j_qJiWrtaw_30_6">64,777</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2be85704_0c00_4b9e_9cc8_56a9eb3fc30a"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofOperati"></a><a id="ConsolidatedStatementofOperations"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b><b style="font-weight:bold;"> and Comprehensive Loss</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_579d41a3_9f33_4f4c_acf4_58e7bb942d61"></a><a id="Tc_naHFOsO6nE2kLR0xBXax8g_1_2"></a><a id="Tc_bCcNL5AvF0qYzcFmXMWjpQ_2_2"></a><a id="Tc_YlTE01G_zUSDseuOjI5JCQ_3_2"></a><a id="Tc_Wl5-wiZzZUuQsks-BSqOQQ_3_5"></a><a id="Tc_w7ukpHAqcU6tpF2HsgCprQ_4_0"></a><a id="Tc_bD_RowZ2VESChvQ9eIuSwA_4_2"></a><a id="Tc_SAuGnNwtvEmFq_AjaEz1xg_4_5"></a><a id="Tc_EpodW6isbECG7v1gO6XE1g_5_0"></a><a id="Tc_CMJnH0gZ8kex3o-WgBwW1w_6_0"></a><a id="Tc_beiCqmUm6E6Z1Gg-mvTKtg_7_0"></a><a id="Tc_pL47Gzb4l06hIo7XBwc9jw_8_0"></a><a id="Tc_QFgA69RgkkqpmGD72IVhQA_9_0"></a><a id="Tc_i2vlhcfoYka_M6IphSEmdA_10_0"></a><a id="Tc_b0CA-fCckEu_8pWmEbcyaw_11_0"></a><a id="Tc_Ka9RhdE9i02eR7IT5BhRLQ_12_0"></a><a id="Tc_cXNwd9iqO06GGVPMN_E8ig_13_0"></a><a id="Tc_2--OikY_0EKdVHBcAxVhag_14_0"></a><a id="Tc_r2pl3JttvkiB3MgJGqjORg_15_0"></a><a id="Tc__xHAH88H7EeLse5iJAhmhg_16_0"></a><a id="Tc_q30Dr_IMb0upjdC9MQ7emw_17_0"></a><a id="Tc_8QGFkpQAI0ykL3ucpybrMQ_18_0"></a><a id="Tc_0Im5Xtl5u0eRXP2qNYVJTQ_18_2"></a><a id="Tc_ztPF602KwUujtveHDN1Flw_18_5"></a><a id="Tc_QyIyFuBM50eMM5NRUQw49w_19_0"></a><a id="Tc_v8KRZPhlL0OcZLEcR4EI2g_19_2"></a><a id="Tc_S5JuhCre50m5cINRbvrITQ_19_5"></a><a id="Tc_c4Pm15NUXEirTDzyM1T7OA_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08654785%;padding-left:0pt;padding-right:0pt;width:100.17%;"><tr style="height:1pt;"><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_fqlo5WE8Wk2KnjgOdcACcg_4_3">13,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_UT-viUIQ0U-7qHNpTZl8Qw_4_6">6,053</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_O94gf6yZak2OkSYhnf1EAQ_5_3">3,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_Nfr3s8kCpUqsagqWsQU_Tg_5_6">1,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_GvdS4Z4QXk2WSNeR7qy5TQ_6_3">9,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_pAEmITIwTUGPtqjzf0xC-A_6_6">4,613</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_p17YWfVw5Ea-xJPWMJNJAg_8_3">7,501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_lwbbMuKM80OQMZ2VItnhGg_8_6">6,410</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_h-luf2cZoka-TrNJFmgnPA_9_3">27,863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_cYtEM-d4_0eGKvBtoWA2cw_9_6">9,717</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_Hor7UB5VZU2_YgNBzQlyqQ_10_3">35,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_jsI3gSGdl0qSh_Rr7rMBlQ_10_6">16,127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_MHaxuk72hkaYYr60Fk4YeA_11_3">25,968</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_5m9GvT0gKUm9UpD5OzHo-A_11_6">11,514</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_nODBMjBge0KpizVCWNeNKw_12_3">2,219</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_JbnF6SAC5UO95xO_Bussyw_12_6">2,470</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_9IF3D_C5-0WYO7AfXNtXhg_13_3">14,800</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_K6EgcBIM2Uuf_67MOJjhIw_13_6">40</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_OKDT76gBfEKxqNzCd7UvAQ_14_3">42,987</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_VTMVcqsQm0CtPgQa-Aq9Yg_14_6">14,024</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_Hbro4icpTk6Hj-zj1JPEsQ_15_3">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_iNUg8k4WAkGHyG62Q1uHOQ_15_6">85</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_CJ-1K5Z9-ky3M3bdYg46Kw_16_3">43,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YIn7544UhUGt783w6X5Mzw_16_6">14,109</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cumulative translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_OX--MWOzt0yulUlGVLVEBg_17_3">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_GSvsAotpyUOJHkg7H_-Zpw_17_6">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_cu6w1XY3MEa7tKQZyvstwQ_18_3">43,086</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_sCKl-hig2k6OvjvOg-9ukg_18_6">14,110</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_aF6ALRxPI02LXioVDDwTfQ_19_3">4.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_gq9WLOYLyk6yxPe-FAM4Ow_19_6">37.01</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average common shares used to compute net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_KTyZ9Ne5XU-y5wh-_6MUDA_20_3">10,360,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_g67npd8B7U68Bk11hogsPQ_20_6">387,083</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ec7f3727_9167_41b1_b451_81fe2d1b1dcc"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofConvert"></a><a id="ConsolidatedStatementsofConvertiblePrefe"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; </b><b style="font-weight:bold;">Equity (Deficit)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share data)</b></p><a id="_45a2d059_abac_469f_bf01_48c87d7d582a"></a><a id="Tc_56DollcYJE2AMaonQ3pN9g_1_18"></a><a id="Tc_znHgaUMj5kyCjK1MSti-9g_1_21"></a><a id="Tc_Y0o6eAiw-UatoiZiWnU5gw_2_2"></a><a id="Tc_K4CgRFYKjkCIW1ZUzTxBbw_2_12"></a><a id="Tc_qua-r50Za0GohuJsJQiFXA_2_18"></a><a id="Tc_MM7-OT8puEmxhTNy5OiVeA_2_21"></a><a id="Tc_AYI8FqqpKU-Vrf8MR3VLAw_3_2"></a><a id="Tc_H7tPS5uxFkS3ym6rKJLo0w_3_7"></a><a id="Tc_Oip-VOUa8UeXBEceVMRQUA_3_12"></a><a id="Tc_xEDA2V8Wq0SSWoogNrj78A_3_15"></a><a id="Tc_MUBksp8B_0OKv62WanaSHQ_3_18"></a><a id="Tc_D_cKBTLAy0KXABfdCkozbQ_3_21"></a><a id="Tc_dV8HQ3YPi0W6ZQTAkUMlPg_4_2"></a><a id="Tc_nP11mPepOUyRVPJHEuJPNA_4_5"></a><a id="Tc_S5rqC42kiEu1kjRaajWwdA_4_7"></a><a id="Tc_637wfpCp3Uu4oiOEuVACIQ_4_10"></a><a id="Tc_6pjYXrP74EeiTQvfhHpziQ_4_12"></a><a id="Tc_UUfQPq4jAEGrNAzXt0GzLg_4_15"></a><a id="Tc_LgAuPn5J-ECli2OXrMX4KA_4_18"></a><a id="Tc_3iXLZRIWhkabstSVORwhpw_4_21"></a><a id="Tc_K0DtMJxKvEWwIMBJGFrfkQ_5_0"></a><a id="Tc__6ia-Tlk4U6U2DhMYSg6dQ_5_4"></a><a id="Tc_bxYkFTvaSUKSu0cE1f5e1w_5_9"></a><a id="Tc_yavDR8n_iEuHjPGv_K7f6A_5_12"></a><a id="Tc_qnGwhXOQMEGYH58gPaswzQ_5_15"></a><a id="Tc_4FqBEHV3v0CuuYPjOhIQNw_5_18"></a><a id="Tc_SwrtzWHGW0W_6650BNhYSA_5_21"></a><a id="Tc_oKeIOR5PDEiXyIYQ63PGcw_6_0"></a><a id="Tc_T00ugcAZN0yOKOoBRTchRA_6_2"></a><a id="Tc_saNEjiMl1EejS8_1Yd63Eg_6_5"></a><a id="Tc_9uQT1ovyxkezQmgcU4TnUw_6_10"></a><a id="Tc_pMhy_58cO0CftuYMtmKr_A_6_13"></a><a id="Tc_cmr7zl7tlUWAhzEnmeLV7g_6_16"></a><a id="Tc_AcoKkibEjU6VQQb0zKEluQ_6_19"></a><a id="Tc_74NP7g6G4Ue8JNsW8sse3Q_6_22"></a><a id="Tc_xf6H54oW-0WLe8I8GgdT-A_7_0"></a><a id="Tc_ayQnINxCu06cTI6-5OU3tA_7_2"></a><a id="Tc_KulihQWnDkmuxcjF0x4bkQ_7_5"></a><a id="Tc_n2Z4NulYjE2FBtqgKzqleg_7_16"></a><a id="Tc_UgEL1-0kik24a-WX4tueMw_7_19"></a><a id="Tc_rQs06UAQ1Uug6TakbzMTCQ_7_22"></a><a id="Tc_K0W2IYWt9kyNXTTZs8cBkg_8_0"></a><a id="Tc_rDCEWWpC7EuwFPCVaqviCg_8_2"></a><a id="Tc_v-3yMYof10-2qKsPNTs1yg_8_5"></a><a id="Tc_aK979YHw7UGNSmVIocjTHg_8_7"></a><a id="Tc_h5s8j3VszEOta8wpSmfMHQ_8_10"></a><a id="Tc_6wwUkrtZwU6j_eauy-weJw_8_16"></a><a id="Tc_ulwDS_vHKEiUKwoDp16T5Q_8_19"></a><a id="Tc_MqKtHrAqGEe9xalZiRNdAQ_9_0"></a><a id="Tc_L1FDbaYT40evllM78k5hOw_9_7"></a><a id="Tc_Bq5IdS-j_kiBdnJbATEGMg_9_10"></a><a id="Tc_HSo6dr0EE0mNx7eC-YkVUQ_9_13"></a><a id="Tc_C2fT3Lcn90ub0kDSIsRQNg_9_16"></a><a id="Tc_tmhwSknIAEuEM3rO7TrOnw_9_19"></a><a id="Tc_3yXlotCvQUy1RNeITmd-iw_9_22"></a><a id="Tc__KrusbEWXUKCXAh2jHkPow_10_0"></a><a id="Tc_WRJ8ICjIF0CXs8-kFN2qQg_10_2"></a><a id="Tc_kKsbr9DBWUeQiyYSHaZpEw_10_7"></a><a id="Tc_pk3bxu0ePkC3KxE8gnLQEw_10_10"></a><a id="Tc_yIfreDuZIU21HKn1ywCung_10_16"></a><a id="Tc_3jH7xpEf1k6vAWOJAAJdTQ_10_19"></a><a id="Tc_wCKPEH1dkUW8Rs4aDOrzqg_11_0"></a><a id="Tc_hjoDKcEK_kOLYVmre-x2gQ_11_2"></a><a id="Tc_n7FUb7-UY0Cif55srg49rA_11_5"></a><a id="Tc_RrjJWVoXmU2uPTpyZSlRRQ_11_7"></a><a id="Tc_m5703IHgV0K6lPFhJ8epqA_11_10"></a><a id="Tc_mT4Tpu3LWUOpjRmrWPueRQ_11_13"></a><a id="Tc_amoNMFw2QUOnxDr4yryc6Q_11_19"></a><a id="Tc_kZv7f9Y4m0KsT60W5IB1rg_12_0"></a><a id="Tc_VsrETuA_iUi_VuNlhHPw4A_12_2"></a><a id="Tc_DR0RAfmP9EiywPeVziI9Lg_12_5"></a><a id="Tc_1D576JujrUmgA0lJQRdVxQ_12_7"></a><a id="Tc_iBdvOUMAlkqK3bkgdXIqpg_12_10"></a><a id="Tc_wDC0eEdDOESfizU6QIn4bQ_12_13"></a><a id="Tc_cpc067paZUiOfoujFXnV5g_12_16"></a><a id="Tc_3FEKu6YHUUWWYqS8Geb0Cw_13_0"></a><a id="Tc_Vrlsz9i-LEqmvgo1DhyZfA_13_4"></a><a id="Tc_dxNzB5rdd02oWsB-WWkk0g_13_9"></a><a id="Tc_6N9t6VmRu0ybR5u8DgfHUg_13_12"></a><a id="Tc_7mFv5RRa_UiYyC7yeLykgg_13_15"></a><a id="Tc_-CQcdP2QK0Crzp_AboGXGw_13_18"></a><a id="Tc_cXnX-zVqSUOTrxs3J9ITFg_13_21"></a><a id="Tc_HCLPVZqYDESwQEbYn_QQKA_14_0"></a><a id="Tc_2EXqtNYG9k6UDImZEbsYng_14_2"></a><a id="Tc_kSeRCv06ZEi8YOV3LJUHlA_14_5"></a><a id="Tc_UJTurKq0pEetorJv9jHa3w_14_16"></a><a id="Tc_XBhhXTXBKEOtVN7Xap-22Q_14_19"></a><a id="Tc_3n7otCGmrEGac-bE1qqkcQ_15_0"></a><a id="Tc_ZKlTBxIjN0CRjP1TYgbNcw_15_2"></a><a id="Tc_9PmCl24OAEOEvM5Om1VaNg_15_5"></a><a id="Tc_IsLWTMjmvEib4PFbMj5pWQ_15_7"></a><a id="Tc_vYviwRhjCkeLA1ylNQ97Wg_15_10"></a><a id="Tc_cfLcYJlIOEy_Ldsl0mj91A_15_16"></a><a id="Tc_3QL2ydu2zU-fmagHGwe3sw_15_19"></a><a id="Tc_XqWO7D1AjUSvRI_W8oSYlQ_16_0"></a><a id="Tc_algNG8eGcEmb19n6wBR3KA_16_2"></a><a id="Tc_lfqYm6oxiEquDBD4cpwZ1g_16_5"></a><a id="Tc_imuoqgbp6ky6Cag3kE19Sw_16_16"></a><a id="Tc_l3j0fFlhkkeXsLZr65KwJQ_16_19"></a><a id="Tc_9rhB8Qed2Ee2ONFhWsBE9Q_17_0"></a><a id="Tc_-c8gVk9Pp0i25O_Ga7x93w_17_2"></a><a id="Tc_WoPaGWcFokik-WJKlmySNQ_17_5"></a><a id="Tc_txPqjZt6t0Gt0OiTqYa1iQ_17_7"></a><a id="Tc_4ctXIDMdA0-tnYAWoAK5vw_17_10"></a><a id="Tc_OFKfWcacjk676IB7RyULuA_17_16"></a><a id="Tc_Fz3RMzLIGE2ypfiQAnmnJQ_17_19"></a><a id="Tc_ew-IJDJ3ZEi3vnzQqJPBGA_18_0"></a><a id="Tc_z2fu_bVaB0y2sxksiH7ysw_18_16"></a><a id="Tc_nZFg9X3tjkiNzdZY7X-Jaw_18_19"></a><a id="Tc_8EOamoAz2ESf316tRR9tXA_19_0"></a><a id="Tc_wNseFi7ms0KORhdNsli-9Q_19_2"></a><a id="Tc_dJTs2dvkfk6nRL8JGPRK-w_19_5"></a><a id="Tc_38UA55Q-qEGXF2gcqefAqw_19_7"></a><a id="Tc_4Pyfdg0sKUuiXsTKtktWnw_19_10"></a><a id="Tc_l0aesV_zfkWVq1m_MaRsLg_19_13"></a><a id="Tc_Kd7uLYKCa02UiWe-C2dACw_19_19"></a><a id="Tc_xOcAP80rEUKwKwuSwxQGsA_20_0"></a><a id="Tc_t4V3IP4eG0q_393ajt8cGQ_20_2"></a><a id="Tc_rsmKzj07UUO3Pq5pMSDTOQ_20_5"></a><a id="Tc_PIGluZusgE-SczN9QkPf_Q_20_7"></a><a id="Tc_oUluM-5AjkStSnFGPWDoxQ_20_10"></a><a id="Tc_xM7B_t5kHkWdhA40wRAkGg_20_13"></a><a id="Tc__oT_A0bxH0mfjWTq3Lf-MQ_20_16"></a><a id="Tc_78JcNlZXJECCjNJIhBF-Zw_21_0"></a><a id="Tc_-vqRFRt8zUah15fE4E7VVw_21_2"></a><a id="Tc_rz3qkqHt6UiZXWTf3Id86A_21_4"></a><a id="Tc_caYEqWc61U2Sq7I9NTOWIA_21_5"></a><a id="Tc_k8GhXD8fTEqw5llDym7TMQ_21_9"></a><a id="Tc_iB1GbWAz10GiUPv1p3f4ww_21_12"></a><a id="Tc_o1YZxDWUNEOC2KIIBH2Z6Q_21_15"></a><a id="Tc_wcu9kXmJM063Q5MMzlBkCA_21_18"></a><a id="Tc_Cn-kirPO2k6P-HGpZVESNw_21_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">preferred&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_p0RfPfIa3UWcDTlEg4P0KA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_lj8h8LPsCkq81YpT3x4scA_5_2">161,041,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_p0RfPfIa3UWcDTlEg4P0KA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_4tPr80hsKU2_dvMlvIsW5A_5_5">279,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6tiymcp8Wk-c2D6KmqY0og" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_TMkPlzv8fk-OXW8f8W01YA_5_7">483,931</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6tiymcp8Wk-c2D6KmqY0og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MoNsJZvVNUS1ZlE3Wn7MOg_5_10">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S5U_tTlMW0qlftdPLa9DZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EYwU2fc6Uk-r6sT2V7jk5w_5_13">58,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zeiT1HWqrEK40Ol6L2ZKYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_M0nf-2P-ckq4dlnIWIZF2w_5_16">337,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bMSZQxnqxEqCmCBMOX938g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_WCc5kdYyNEm49ubnXOiVDA_5_19">189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_hVEM63AMyUSAviWEp_dR9w_5_22">279,043</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RUHOGigFiEuJTBLQGUN3cw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_THhR-x_jj0i8R91r-LDwUw_6_7">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Repurchase of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RUHOGigFiEuJTBLQGUN3cw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="Tc_Hl0C0j4Ko0qm9yGLh-c7Mw_7_7">123,694</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RUHOGigFiEuJTBLQGUN3cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="Tc_VAC9AeQ1d0W2cDRQW5T50w_7_10">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HZTSfAFE00aFsq1LVh0T7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" sign="-" scale="3" id="Tc_c-rq3MaBhkyJb7_xNe6a_g_7_13">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HZTSfAFE00aFsq1LVh0T7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_y2HwVmyPQkiSz2MXAlu5tA_8_13">132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_MMc7_Emu5EGwRyW8gk6NNA_8_22">132</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series G preferred stock, net of costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_XAEp1PMrjEePzao7rysu6w" decimals="INF" format="ixt:numdotdecimal" name="cvrx:TemporaryEquityIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_UBnHJeEKzEO1Vg5YpQ7rKg_9_2">62,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_XAEp1PMrjEePzao7rysu6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_paNSGeDWPUyUoP89DKRbSw_9_5">49,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series G issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_XAEp1PMrjEePzao7rysu6w" decimals="-3" format="ixt:numdotdecimal" name="cvrx:TemporaryEquityAccretionOfIssuanceCost" scale="3" id="Tc_NcsnFuaYSEeQ6ztdyKdyvg_10_5">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HZTSfAFE00aFsq1LVh0T7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_63-MPfge3ku1nc7DOTf0ww_10_13">217</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_iK3WGAOKYkusQlNZJ8U2mA_10_22">217</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the year ended December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S0-dIu-pxUOkwdi2LzQL7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_PBCwQS3ZFEWtfETwBVliaw_11_16">14,109</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_EPs0bSGpWUq_EoWiJ3j6Xw_11_22">14,109</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cumulative translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yHbljhgpY0mbvZF0ftxdIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_MWV9OYyxAUiPfQKmNx7mOg_12_19">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_03wzpfppUUamnHOTUJAazg_12_22">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_gSHtkKETBkOZK6zcbuEF5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_VpZgctUewkGIABIH77hfxA_13_2">223,541,754</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_gSHtkKETBkOZK6zcbuEF5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_J6n_t40ioEGZCxIwaYGakw_13_5">329,983</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NZvrdn8yFkWAX4fnEQO45A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_D8AfL2iN30aBykMX697gTg_13_7">360,412</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NZvrdn8yFkWAX4fnEQO45A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1PXW4h03CUORJ4J6g2pKzg_13_10">4</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8bbj7mTQvkKRbK8e00U2-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yxd-8SwghU6m2Y2IRKPo5Q_13_13">58,624</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TXEPtHeAnEu5aSDgEVIuTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_i-NeqDRPSka3v6ZUefyXZg_13_16">351,676</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_k3U9zkOYDk-3HOWZzCltuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_QD_cYsn4302o2C_2noDU1A_13_19">190</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gsAU1S0EtkaKncdAlpXYUg_13_22">293,238</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_pPMRiHiDTk2ptAGpdrLWwg_14_7">59,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_l8tcX0KwjU660i8B_eHYJg_14_13">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_gKUWrvQ-L06L85w4jDJHWA_14_22">23</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_faoqboeHDUe-3IpjAzb3-g_15_13">1,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_g-EWuP3UsUKDTyGnyY6oOg_15_22">1,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_tMm46xLuVkGkTGUUvbL9bg_16_7">8,050,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_yKum0RER302psRmg6R_fgw_16_10">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_5aiqGQyDS0yQ80n6O9dzyg_16_13">133,080</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_JmTMdT-0tEOEXNXkZ__AcA_16_22">133,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="Tc_L3Im8EIrGkOC1kiK2IY-Tw_17_13">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="Tc_0LO4ueWAuU2bp_SLqOWsVA_17_22">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series G preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_nBAhCE3xjEOe547YDdUyhA" decimals="INF" format="ixt:numdotdecimal" name="cvrx:ConversionOfTemporaryEquitySharesToPermanentEquity" scale="0" id="Tc_L9r1ybUjTUuJKmQhEPqU4Q_18_2">223,541,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_nBAhCE3xjEOe547YDdUyhA" decimals="-3" format="ixt:numdotdecimal" name="cvrx:ConversionOfTemporaryToPermanentEquity" scale="3" id="Tc_TbdTbfm320GaKgWd5dyORA_18_5">329,983</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_28Bkr40qJkyJqHwNC4PnXQ_18_7">11,929,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_ZiU-CnqpwU64WxZsB4KfRA_18_10">119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_rcpsdNek4k-fiDVDXGxzWg_18_13">347,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_NbP6f51ySE-m6B_SSATgdQ_18_22">347,188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the year ended December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xQ4PL8s8EU69GgtfV_9c1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qnlLrdy7bk2dr8Wt6gkpQQ_19_16">43,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ghHWIkU_ukaVIsVZx8bYhQ_19_22">43,078</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cumulative translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ogL9DuiJFUOrmGs4jXH1PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_q8gVEK5s_UCoagIC9xXJmw_20_19">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_u3gUWTAQiUyz075wtVXpbg_20_22">8</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:19.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e__ks_GGFkytwC3zHBuP5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_iNUV9xLmIkWSE_4Z0_RDNg_21_7">20,399,337</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e__ks_GGFkytwC3zHBuP5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2BIfMN7qIUeaVSx5urAtwQ_21_10">204</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SygLLO7d6keB2YcBMuzXRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_E98sJg78MUG_cY6AX2XxBg_21_13">540,707</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NRVdw4MrM0yuymfM2lEBNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KSK2vWPL30SvCdnVSlZpOQ_21_16">394,754</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fZBmRrBVpEW4r7ljKujLsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LJN_DNN9v06W0MY8Lg2nXQ_21_19">198</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ca7rLeEiR0mT9GGRIbedyg_21_22">145,959</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:middle;width:19.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_990e7ed3_c026_49f7_9fcc_55bc0bfb4bee"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofCashFlo"></a><a id="ConsolidatedStatementofCashFlows"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_aec9e398_f1cb_49a4_9d16_6e2ec4dbf0c1"></a><a id="Tc_2QG5aUYZEk2CADPhwNRimw_1_2"></a><a id="Tc_9HCED-tva0izQQsnTQQ9zQ_2_2"></a><a id="Tc_oduEFrzoJUK0wk-g-gCZrA_3_2"></a><a id="Tc_6jpF-1fMA0GUXrle3cjkig_3_5"></a><a id="Tc_1UIu87ERzEqvh7Yn-rVk7w_4_0"></a><a id="Tc_yGHxo1BRek--zW-u9b1FVQ_5_0"></a><a id="Tc_VW15h0mBR0qJN_kYcnTFZQ_5_2"></a><a id="Tc_x6n4Do8ZXkidhaHntNQkdA_5_5"></a><a id="Tc_rX3mo7SJOkeDaW_4kflz4Q_6_0"></a><a id="Tc_5IiTY9b5TUydPUDjLB_S7A_7_0"></a><a id="Tc_kxxNQ7rB2kyn1pi0A0ROCg_8_0"></a><a id="Tc_X9Vi5KzOc0e_K1Bwiu87Og_9_0"></a><a id="Tc_apWokq-CxEKPvL16EmN-QQ_10_0"></a><a id="Tc_riHoeTDDm0Od7wxHLQ5Ngg_11_0"></a><a id="Tc_9bQ_ahoFUUW1d3Kk2GqMKw_12_0"></a><a id="Tc_XoNx-4E5nE-nQc5YIDog1w_13_0"></a><a id="Tc_gib7xGDDOE-C_tPix26Ivw_14_0"></a><a id="Tc_sgdQH3OCdUiUMxadrPgcxw_15_0"></a><a id="Tc_yhrO7bnFaECsrLvhe6C3fA_16_0"></a><a id="Tc_ntX4VEXhp0-YgxDTb6Zwqg_17_0"></a><a id="Tc_PYXbPF6ZZUe3glz_usWhjg_18_0"></a><a id="Tc__eiy16JEkkG0VMJIfcb9_g_19_0"></a><a id="Tc_4ReP2-gx4ke4tTZrvaWY3A_20_0"></a><a id="Tc_x06Ffasd0kCojGxmHBl60A_21_0"></a><a id="Tc_E3Vav5Euykup0jVqBE-wqw_22_0"></a><a id="Tc_MAGu2YdyN0yGFh28yqghnA_23_0"></a><a id="Tc_Oe4m1_oGgUqaJ7Y8OqKRhQ_24_0"></a><a id="Tc_R8NtHuHebUKAx0WY7HnWMA_25_0"></a><a id="Tc_rnYuwqjo20K1l6MqtgrbFA_26_0"></a><a id="Tc_MXe6L5PaZEac_Aibz5c-hA_27_0"></a><a id="Tc_bTumqW1i80qN4D6afZMXtA_28_0"></a><a id="Tc_EaqKQFahUkSPImc3KwBD9A_29_0"></a><a id="Tc_Zc8KaWA_fUexN4myWdwRLw_30_0"></a><a id="Tc_tWyAo6NrUUGc4xNn-_kItQ_31_0"></a><a id="Tc_wr1wmfAsc020A3GeLyTl3w_32_0"></a><a id="Tc_yMb28t9850ubFMUvuES5VQ_32_2"></a><a id="Tc_KQLcrzrUFUaPomPSAszzfA_32_5"></a><a id="Tc_abfQd1Wsp0Wf_FAk6ekC6w_33_0"></a><a id="Tc_vLeLWbsNwEeaEeskSaeQvQ_34_0"></a><a id="Tc_MkEkhEhwEkqsjWKyEDMx8w_34_2"></a><a id="Tc_AK-nUDieCEOXulcfGLrW4w_34_5"></a><a id="Tc_OYIa3ZWJB0OwS9DPD2AFGA_35_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_pLkpgD5lk02tz4e08RVAuQ_5_3">43,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_6XHYefMS_Eioco4HhE86Dg_5_6">14,109</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_o3Nt4o3SekqhKlhVkecOqw_7_3">1,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_tWFP1vShbEqzJwzN1XTVqA_7_6">132</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_cRBjNUIF4Uix3wYKiLHiqg_8_3">168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_aV4P4RcimUG_pwzh_Bfb6g_8_6">75</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of deferred financing costs and loan discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_k0wDKiCP7EOEggeoCGoShA_9_3">229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_A2sDLJTfAEe240JQx0nBnw_9_6">286</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_vD53vkKCk0G5oUE0dhSCrA_10_3">1,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc__FVR_T-v20-YcostLarHYA_10_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in fair value of convertible preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_Exyz2zQt1EKg7KCUfD-XdA_11_3">13,294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_TeY4l4d3aUWOvFOi-eZp0w_11_6">371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_AvfN-e6kRE2vGRxDjRZ1kQ_13_3">1,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_9PM0jZRvbUKoJU8QlokL-w_13_6">562</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_rarVLVLkyE-zzcKs_eDU3w_14_3">537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_8W0A27iGI02ea2PCnPFurw_14_6">1,271</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc__tBGMNdDX0KKPBzwH0ueQQ_15_3">1,980</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_1gL3zzQpUEyPEVvsibOtew_15_6">226</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_HRyMuaLK90ucCnOMuiD3bg_16_3">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_Vk82Iy_MV0CfkOiVdTL37w_16_6">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_1pEFkMjoLkOyraE3rWhUxA_17_3">2,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_-8Z7nZm1x02trNQnHsX0bg_17_6">838</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_mqn_fa-zkE2QZe8mTtt75w_18_3">27,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_d8UETZkcVkyrT34cbwAIww_18_6">16,096</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_I892wmlbrE-_2L6qKyFYJA_20_3">1,183</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_XI9t4AWJGEux_6HWX5uXPQ_20_6">311</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_c4qDiNLTK0Gq9di_DmIMnA_21_3">1,183</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_rRt4i55VC0G973rpbgld_Q_21_6">311</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from the exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_Js5M0-lCPEGvppsKgdMA2A_23_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_knsGd4EGPUChevq0yvIeAA_23_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from issuance of Series G Preferred Stock, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromOtherEquity" scale="3" id="Tc_PrA_xpnLa0Go83ee0MeY4g_24_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromOtherEquity" scale="3" id="Tc_kpTHv_CuXEu_HWyjWbasug_24_6">49,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Payments related to reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="cvrx:PaymentsRelatedToReverseStockSplit" scale="3" id="Tc_olhhAHqZlk2WLzxzkQR_Ew_25_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:zerodash" name="cvrx:PaymentsRelatedToReverseStockSplit" scale="3" id="Tc_EZFH21aZbUePBfLbZSS1zw_25_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_LpgYlBOq5EaPHR5YWx2bNg_26_3">133,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_PPON5MEM60mxrZ2NBc6qCg_26_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Repayment on debt financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_ZhW_zh-yakOonlnAjnTzzg_27_3">21,300</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_S4FE3Vo29UqPlI_eHw_A7w_27_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_KdU2ozkDe0SmLyl-lyfbMA_28_3">111,883</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_5Mpd2rC9b0utOqZEnuJxhw_28_6">49,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Effect of currency exchange on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_Y3Q3wRSoW0WoDlGfPzKABw_29_3">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_xcLRwB_Izk63OIpXCfRg0Q_29_6">5</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net change in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_tRud2zdIL0uXwBjKMO53_Q_30_3">82,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_b6PtjChRK0SPCd1XtDMSug_30_6">33,371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_GZEtAyVZg0eJI_SGiHk45w_31_3">59,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_sKehz641c0W2LwtyN5YzeA_31_6">25,741</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_TedxSG_kDU-Ye3Bn-MSKvQ_32_3">142,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Yppn0v1LWE-L2jMP8LPk5g_32_6">59,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental Information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_WB4q8Vt2vUe8qShL78lu7A_34_3">1,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_MK8NDvJfTUuJOVVZTwxK_A_34_6">2,033</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_hsWj4E601E-fBmJlflzwEQ_35_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_SxnQkjqMwUuSVw_rB5VIkA_35_6">10</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="NotestoCondensedConsolidatedFinancialSta"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_OqBBG1y5mk-Tx-z0xNEPVg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Business organization</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CVRx,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. The Company has developed and is marketing a medical device, Barostim, for heart failure (&#8220;HF&#8221;) and resistant hypertension. The Company is focused on the sale of its product in the U.S. and Europe.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that the Company will generate sufficient product sales to produce positive earnings or cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_TU9xaCWjlUqaIMoz1_x6uw" continuedAt="Tb_TU9xaCWjlUqaIMoz1_x6uw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Summary of significant accounting policies</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" id="Tb_cw0B14IkuEKGkN0S8DZeVg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="cvrx:JobsActAccountingElectionPolicyTextBlock" id="Tb_GgOJh1PGsEmljcz16IE_8g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:UseOfEstimates" id="Tb_0ah91dGRZ0Oe_Mfw2Q3uoA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_5vAgNzdsX0Cc_nDMi3CU1A" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2021 and 2020, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_PjFjwdurOUiP1cD8vdIGaA" continuedAt="Tb_PjFjwdurOUiP1cD8vdIGaA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. We do not record an allowance on our trade accounts receivable but monitor the collectability of individual customer accounts on an ongoing basis.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_TU9xaCWjlUqaIMoz1_x6uw_cont1" continuedAt="Tb_TU9xaCWjlUqaIMoz1_x6uw_cont2"><ix:continuation id="Tb_PjFjwdurOUiP1cD8vdIGaA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:InventoryPolicyTextBlock" id="Tb_lHChYZmYVUOkyl1Kukrc0g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_9LQINy_hCEOkZWinMQYHSQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#8217;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#8217;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_5U5KPXxRYEuIq0c_P92afQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non- employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#8212;Stock Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and nonemployee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We use an estimate of the value of our common stock, with the assistance of an independent appraiser, to determine the fair value of options. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_QOIyhay0E0q71R6uK7BQmw" continuedAt="Tb_QOIyhay0E0q71R6uK7BQmw_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In February&#160;2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, Leases (&#8220;Topic 842&#8221;). The purpose of Topic 842 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Topic 842 is effective for private companies and smaller reporting companies for annual periods beginning after December&#160;15, 2021 and interim periods within fiscal&#160;years beginning after December&#160;15, 2022. Early adoption is permitted, and the Company must elect whether the date of initial application is the beginning of the earliest comparative period presented in the financial statements, or the beginning of the period of adoption. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of Topic 842 guidance, whereas comparative periods and their respective disclosures prior to the adoption of Topic 842 are presented using the legacy guidance of Accounting Standards Classification (&#8220;ASC&#8221;) 840.&#160;As a result of adopting the new standard, the Company will recognize right-of-use assets of $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_y3rSgJAX9EGQxWbuV_L1FA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_8h1XLLaZZUi3QiaxRa9lKw">579,000</ix:nonFraction> and lease liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_y3rSgJAX9EGQxWbuV_L1FA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_SqiNtmJXCkKVwCfqTKPZnw">561,000</ix:nonFraction> million as of January 1, 2022. The </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_TU9xaCWjlUqaIMoz1_x6uw_cont2"><ix:continuation id="Tb_QOIyhay0E0q71R6uK7BQmw_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">difference between the amount of right-of-use assets and lease liabilities recognized includes adjustments to prepaid rent.&#160;There will be no change to net deferred tax balances as a result of the Company&#8217;s adoption of Topic 842.&#160;The adoption of Topic 842 did not impact the Company&#8217;s results of operations or cash flows.</span></p></ix:continuation></ix:continuation><a id="_32f539bb_67c4_4ac3_982a_bd76d3c40eed"></a><a id="Tc_UwXV2WM3qESWCv2K_16VsA_1_2"></a><a id="Tc_RDcy9cK9oEGK-s9DBhhdOA_1_5"></a><a id="Tc_rvM8eCQV70qufWOqxUU-HQ_2_0"></a><a id="Tc_2M4P6mylwEeuOls5UPlyAw_2_2"></a><a id="Tc_OAP5DtVOmU-TTvgn3PgUvg_2_5"></a><a id="Tc_ejvS32rc8kKm4tITSe4q2g_3_0"></a><a id="Tc_IzUNPIOg00qWZW76TcsRdA_3_2"></a><a id="Tc_9GszjloGs0a3iNrUQmEWlw_3_5"></a><a id="Tc_xetJulhawk2FkixYpVpUmQ_4_0"></a><a id="Tc_TB1YBYBS7EaGr43RkY0p7w_5_0"></a><a id="Tc_lXNNDA3Vl0i_w3e6b4jdpw_6_2"></a><a id="Tc_wOVOjQm890aSsIW5X6cZxg_6_5"></a><a id="_e1d0bd89_c340_4f30_93c0_b016a1488585"></a><a id="Tc_mrY4OCtRT0WybIvwZNkSng_1_2"></a><a id="Tc_qtUYA9uc4UaKBAxSxHV4lw_1_5"></a><a id="Tc_lbTFi930rE-4d7DHbGpumg_2_0"></a><a id="Tc_mWqongDlREK_2rgUH-CmJg_2_2"></a><a id="Tc_VKDPNo6Om0Osp4wZeduPkw_2_5"></a><a id="Tc_7QBLrgvcOEuaYg76FctprQ_3_0"></a><a id="Tc_9IxMO_2TU0-78OmtjBOnPg_3_2"></a><a id="Tc_Fmk1N0o4c0exVF7_TZ1r8Q_3_5"></a><a id="Tc_nsiaQZP1pkitHt3O-hPReA_4_0"></a><a id="Tc_B-8o6KXxykisB3a07W8XTQ_5_0"></a><a id="Tc_YIwdZaIPZ0a8qz-cVihbKw_6_0"></a><a id="Tc_UxDfcrjaGU2XYmSuXIeTFw_7_0"></a><a id="Tc_IsGItii01EGeYKHnq3QBTg_9_0"></a><a id="Tc_lNNVF6-Ju0ew-OZgY8pIsA_10_2"></a><a id="Tc_DcfZK9ZSbEm_-M8Pa2BZIA_10_5"></a><a id="_fdc13b0f_c9f8_417a_a27c_315374830de9"></a><a id="Tc_2k2IuCTOmkOg0cdWDJtlgw_1_2"></a><a id="Tc_Z5XSArr0xEK9guFgxYpbmg_1_5"></a><a id="Tc_y0M1jiWwhE-rVfMKZ8L-LA_2_0"></a><a id="Tc_rDgwgG8vskirbm1vkQNyOQ_2_2"></a><a id="Tc_m2-oDGyhgES2cwmVTLclCg_2_5"></a><a id="Tc_8ayLHW8I5kq1Q-or1or-Pw_3_0"></a><a id="Tc_7D95qOdt9Uud3bryo9cafg_3_2"></a><a id="Tc_PIr7bxgIS0yCsIqrZ7AkBw_3_5"></a><a id="Tc_W6wQQuA25Emst2pCosyfrQ_4_0"></a><a id="Tc_TV1HKUu38EK8DSEgLgQ1BQ_5_0"></a><a id="Tc_KcGs-f6hoUO7tB62RlhXdQ_6_0"></a><a id="Tc_W7JUYDlduEiUQd5hb9utNA_6_6"></a><a id="Tc_owXNxi5IREGbUsEOwEYBqQ_7_0"></a><a id="Tc_x4iftuXnokyVlPOVTCRczg_8_0"></a><a id="Tc_MHolXi_GQkii37FIdWu8zQ_8_3"></a><a id="Tc_ws3-HVcdOk-wWpe7ihverw_9_0"></a><a id="Tc_nFV94m6G2UWJX7T-bJd_8w_10_2"></a><a id="Tc_fK2XT-kFCE6c5qzP0mD8Cg_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_naEyD1XvMEeVC6Ptp1SmhQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Selected balance sheet information</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_FuHR90NPnEuO0IsCq_FF_Q" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_qU9N8iSspEaucjwSzg47yw_3_3">1,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_WeicA5opOUyHRi7HlmXbcg_3_6">1,361</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_OMa3znuybU2ZzTUsHloJFQ_4_3">482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_DvrWwtVQ1ki2--ozyePR0A_4_6">321</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_blqPL2D1QUCxyujlUKNiYQ_5_3">1,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_1FpcAIkFTEm3nLdgFRvexw_5_6">1,661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_RaIaYDS2VkC67Fcdtc6VFA_6_3">3,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_aljKQVcmikag35ApqX-XKw_6_6">3,343</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_fF84TmSM7ESMUdO-P0n00A" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_pDRh1cot40q_8Y3o2VYqGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_4SKsH-qSmkiNP4d2HhSsrQ_3_3">271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_JVTdDeParEGGJ2t4jtbpsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_2RTL8aDVhk6_GpiWPhSw2A_3_6">189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_rfzInbLWC0WZAH9zijqO7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_hFGprZPDik604R-80cfpaw_4_3">1,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_qcikURBbNkqhIs-KAt4sHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_qPftfsgG9UCZwHQdqYfj1g_4_6">1,272</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_W8mwFgZUB0-M5Mhl98X9vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_diC3-qCxCUGxGtJukhtoZw_5_3">556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_D22BP1wD10eBV-IdknkzyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_r1pY_Hp02EmZ6EjrirUP-g_5_6">516</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qbNP5EMaT0ugnnKkSC2ccQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_7Ia3grymuUiiOABzXpRPVQ_6_3">88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Hw_YMxt6zk2W-1GMsneLZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_DccK5_zAXk6fX8VfpyzEOQ_6_6">44</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_f6ItviTz1USvtPXYmohPkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_swtDEi9iEU-xA89JF-ylPw_7_3">813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_Shk5JCIfNUKOH63sKxBD4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_aEEa4n7gbkSjgLs2Q6kU_w_7_6">89</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_BFghoN7qoUGrDAujGqbG5Q_8_3">3,293</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_d3H73YxztkKQ0TyxruZbvQ_8_6">2,110</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_2QPO5WxVAUKrMVFBLFPMEQ_9_3">1,868</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_4Mihu2OHUky1PK4lpWf7Lg_9_6">1,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_y9EZ9RTbxUikTW6ELeS5DA_10_3">1,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_rXCPOJfyMU-LkWPufWh4AQ_10_6">410</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Depreciation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_o1JDPyhOTUeAKDyPk4aGJg">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_MHbHtJAP0UywkZCEQ4eyHA">0.1</ix:nonFraction> million for the&#160;years ended December 31, 2021 and 2020, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_dM8Va-kAxEqP-BzIgStDog" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="cvrx:ClinicalTrialAndOtherProfessionalFees" scale="3" id="Tc_B2VxlqJcEkKx6IoLGhmhhw_3_3">1,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:ClinicalTrialAndOtherProfessionalFees" scale="3" id="Tc_BDU27aiDw0aQaN2_hg8BXg_3_6">1,690</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_Xh97Gt_bfE-9WNAGwYpFKA_4_3">2,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_vziCottBRk2mjPBwMIroMQ_4_6">794</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedPaidTimeOff" scale="3" id="Tc_2aAwxcEge0KTQ2ICVXkq2Q_5_3">699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedPaidTimeOff" scale="3" id="Tc_dqPm-KWKKUG87RvWbwjGKQ_5_6">552</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedLiabilitiesCustomerRebateCurrent" scale="3" id="Tc_HktmTJolWESK3wHl9MgtrQ_6_3">380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_vht7j4TQk0-bg7pit-Mp1A_7_3">351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_8-tQw0ZtqEGt-A4xa4VTBw_7_6">42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_Lt3yNJ0tEEW74LclaGNwOw_8_6">356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_Flv6BwdnQkCFXvCWx8Jv6A_9_3">333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_1rd9JGEE40GE3LVhXzyyHg_9_6">149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_U2YKMYWrlUWbNpf7FI_kMw_10_3">5,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_hCx5jerb4UOPaDsWbbyR9g_10_6">3,583</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_isHupOMF2E--Cz6zrtNymQ" continuedAt="Tb_isHupOMF2E--Cz6zrtNymQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Fair value measurements</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Inputs are quoted prices in active markets for identical assets or liabilities.</span></td></tr></table></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b8882d1c_fc15_497b_b99e_4099b6b2eccc"></a><a id="Tc_QI4MMMCPs06zfw5SNeUqqQ_1_0"></a><a id="Tc_RV1YtvQcNk6PWyLVCyL2kg_2_0"></a><a id="Tc_H05VE6GgZEWwaekgD1skUA_2_2"></a><a id="Tc_dU7AoL34F0mOHAWmwKA9ww_2_5"></a><a id="Tc_7PTF2pfZKUunHnI_-0643A_2_8"></a><a id="Tc_BKE-hPhXwUSyozyNtduZmg_2_11"></a><a id="Tc_tevSnYm3RUOSA-QBnsxhsw_3_0"></a><a id="Tc_zX7Ei1o0fUSAhMnc6VW-pw_4_0"></a><a id="Tc_nWeEMclLi0-ycNTuthdUAw_4_2"></a><a id="Tc_6FJ8LjxX7EWxhjdN5g0dGA_4_5"></a><a id="Tc_dQU3g7maLk-_wTDkh5D1IQ_4_8"></a><a id="Tc_sSkizVp7cUa9jAkSwyFWGQ_4_11"></a><a id="Tc_HhdWGLRy90q-1kRKQkYC9g_5_0"></a><a id="Tc_SX0THO2Za0WMs3dRAR3hOw_5_2"></a><a id="Tc_sUWXA0JqKU-NENS7Xp1vDA_5_5"></a><a id="Tc_RswovEo8KkGWSsBtmvsD9g_5_8"></a><a id="Tc_vgCdXszUvUyE5nlpzcLNcA_5_11"></a><a id="_f52ace56_f3dd_4db9_8d2f_ba4dd40329ec"></a><a id="Tc_lbgMr3h20EW58fUfLObppQ_1_2"></a><a id="Tc_htd9_kP4Y0ykGTzxiLwonQ_2_0"></a><a id="Tc_EIAunYKRI0y5clgZdJhsPQ_2_2"></a><a id="Tc_4ls0HbrN7U-aBmB9qbtpDg_2_5"></a><a id="Tc_Rb4gxM7NbUC-i2UuaeMF4A_3_0"></a><a id="Tc_hYmL82fm4km7GX9ANilr5g_3_2"></a><a id="Tc_Qcy8iCAAeEW8W_oLzm2yKA_3_5"></a><a id="Tc_3lMM7spCkk648_hkySMchQ_4_0"></a><a id="Tc_A25HAFqidEC8HnaSjurQmw_5_0"></a><a id="Tc_72wamqvRRUylHZuHfapJRw_6_0"></a><a id="Tc_0ugxTDv2dU6qDdB0ZZAT7w_6_2"></a><a id="Tc_sJAeTNE68U-f5lgkVE-ffw_6_5"></a><a id="_6a7fd9d3_b64d_4365_9cef_43d7e82ab4f5"></a><a id="_6a7fd9d3_b64d_4365_9cef_43d7e82ab4f5_2"></a><a id="_6a7fd9d3_b64d_4365_9cef_43d7e82ab4f5_3"></a><a id="_9aa8f38a_5f33_43b4_8735_6137e519e399"></a><a id="_9aa8f38a_5f33_43b4_8735_6137e519e399_2"></a><a id="_9aa8f38a_5f33_43b4_8735_6137e519e399_3"></a><a id="_f0e0cf71_140b_4536_a84f_531779e18681"></a><a id="_f0e0cf71_140b_4536_a84f_531779e18681_2"></a><a id="_f0e0cf71_140b_4536_a84f_531779e18681_3"></a><ix:continuation id="Tb_isHupOMF2E--Cz6zrtNymQ_cont1" continuedAt="Tb_isHupOMF2E--Cz6zrtNymQ_cont2"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Inputs are unobservable for the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="Tb_WQ5ssL5PN0yJzj2bBy8TKA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table sets forth the Company&#8217;s liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy. There was no convertible preferred stock warrant liability as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:57.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible preferred stock warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_KNUV7a2UVk-AWL-jkX8qUA" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_PQhMz5hDWUuC50IQ3TVWLg_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_A_ndJ_mgvE2v6o03-Ks7wg" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_8NXFdG5nq064t6ATLmxDeQ_4_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_spHQMK4XMUiiug-F7DvVwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_ssiv9gsnp0-zuQV1FPjKbg_4_9">3,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_ARf2RRaIzk6UxSql8Of4JA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_Luhk3pskg0ar-ai-lQoW3g_4_12">3,911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_R_I0EY29n0W_Ped5vMxkzg" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_3rxOR1rgDkSz1yVqb2tDfw_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_16bB4IFwrUapwzsWJeRraA" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_xbcG3DdsA0aXIAdgZ2cpLQ_5_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W4X_2dSbnkGc95kko6HZAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_c2OHjDjcYEeaJK-sFZK9iQ_5_9">3,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D2BA-9J5XE-PbX6gbNm_aA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc__XJs55HD60apgufE-4Wbnw_5_12">3,911</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The convertible preferred stock warrant liability related to warrants issued in connection with loan and security agreements entered into in September 2014, as amended in July 2015, in May 2016 and in September 2019. These warrants were originally issued to purchase shares of Series&#160;F-2 convertible preferred stock and Series&#160;G convertible preferred stock (&#8220;Series&#160;G Preferred Shares&#8221;). <span style="color:#231f20;">In connection with the closing of the initial public offering (&#8220;IPO&#8221;), these convertible preferred stock warrants became warrants to purchase </span><span style="color:#231f20;"><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_xrHiwCtXlEGvfX5Nxy-WiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_BX9REHGdHEuMunY1rAbafw">108,406</ix:nonFraction></span><span style="color:#231f20;"> shares of common stock and were reclassified to equity.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The convertible preferred stock warrant liability also related to a warrant issued to Biosense Webster,&#160;Inc. (&#8220;BWI&#8221;), an affiliate of Johnson&#160;&amp; Johnson Innovation&#160;&#8212; JJDC,&#160;Inc., to purchase Series&#160;G Preferred Shares with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_VgmWIpZ2MkiWdk7vdQe0kg">0.01</ix:nonFraction> per share. <span style="color:#231f20;">In connection with the closing of the IPO, the BWI warrant to purchase Series G Preferred Shares became exercisable to purchase </span><span style="color:#231f20;"><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_7_2_2021_To_7_2_2021_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_LU9Pb5rH30abdxp9blQkkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_PzBH_pY_SkOmU-5BrTpaOw">607,725</ix:nonFraction></span><span style="color:#231f20;"> shares of common stock at</span> an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_7_2_2021_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_MX0otz1v_E62VZpoRgXl2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_S4AE7FirsEWqGD_My-uQLQ">0.16</ix:nonFraction> per share<span style="color:#231f20;">. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s recurring fair value measurements using significant unobservable inputs (Level 3) related solely to the Company&#8217;s convertible preferred stock warrant liability. The convertible preferred stock warrant liability was remeasured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.<span style="color:#231f20;"> In connection with the closing of the IPO, all of the outstanding convertible preferred stock warrants were converted to common stock warrants. The related liability was remeasured at the time of the IPO and reclassed to additional paid-in capital.</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_rWxrBUYGWkGi7kU1Sy_yCA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of changes in the estimated fair value of the Company&#8217;s convertible preferred stock warrants during the years ended:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_PH-M6rDzJkyqGZQxfL2QnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_hVoWlD9VHEKV8QBliQmQkQ_3_3">3,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_YzRnuQXlH02VKNNMxJ0Jag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_yVmwyQxFekOO_xokgyk9CQ_3_6">3,540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_zXBgdB9Wm0KMsLVbZrH5Gw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" scale="3" id="Tc_JPs_uMonu0qSUBSPW7AU1g_4_3">13,294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_5vT5q4Y0Gka2WmjvA6i6vA" decimals="-3" format="ixt:numdotdecimal" name="cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" scale="3" id="Tc_3mv_w-RPd02dc8l9VYthag_4_6">371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Conversion to common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_zXBgdB9Wm0KMsLVbZrH5Gw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" sign="-" scale="3" id="Tc_0YrUEldMUkmYG2fYVVpSbA_5_3">17,205</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_5vT5q4Y0Gka2WmjvA6i6vA" decimals="-3" format="ixt:zerodash" name="cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" scale="3" id="Tc_WpE7IdI1k0CS8cr8yUcIlg_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">End of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_RKtvIKc5LkyhjXn68Zj14A" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_aGF2ILlwYk2jLnAeN_yJ0A_6_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_PH-M6rDzJkyqGZQxfL2QnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_gSRP8-3LK0OkRI9IFSmCnQ_6_6">3,911</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" scale="3" id="Narr_mQbmRVCqHkOLt8SWqDgU3w"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" scale="3" id="Narr_iWOb10-kt0eEA_5P77M7ZQ">no</ix:nonFraction></ix:nonFraction> transfers in or out of Level 1, Level 2 or Level 3 fair value measurements during the periods ended December 31, 2021 and 2020.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_isHupOMF2E--Cz6zrtNymQ_cont2"></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:12pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_o4rckHCT2kiEdwrErDKtdg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Debt</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Horizon loan agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, the Company entered into a loan and security agreement (&#8220;Horizon loan agreement&#8221;) with Horizon Technology Finance Corporation (&#8220;Horizon&#8221;) under which it could borrow up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_bJIzTFWl9kmRlyHu2r6H_g">20.0</ix:nonFraction> million at a floating per annum rate equal to <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Pg0bkL4urUCnAduxdRREcA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_sUFOz1ximEyyLDO4Rtb1ng">10</ix:nonFraction>% plus the amount by which the 30-day U.S. dollar LIBOR rate on the first business day of the&#160;month exceeds <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_98TiYSuyBEyI_7e_iTGzOA" decimals="3" format="ixt:numdotdecimal" name="cvrx:ThresholdInterestRateOnFirstBusinessDayOfMonth" scale="-2" id="Narr_gydIM7R1H0Keu845MbXnpw">2.2</ix:nonFraction>%. The Horizon loan agreement initially required interest only payments through October&#160;2021 and then <ix:nonNumeric contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_98TiYSuyBEyI_7e_iTGzOA" format="ixt-sec:durmonth" name="us-gaap:DebtInstrumentTerm" id="Narr_2TR3iffmY0uJ45We4Qm_zg"><span style="white-space:pre-wrap;">36</span></ix:nonNumeric><span style="white-space:pre-wrap;">&#160;monthly principal and interest payments beginning in November&#160;2021. A final payment of $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ" decimals="-5" format="ixt:numdotdecimal" name="cvrx:DebtInstrumentFinalPayment" scale="6" id="Narr_zab2U2LXgE-MnLS0MYT5iA">0.7</ix:nonFraction> million, equal to <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ" decimals="3" format="ixt:numdotdecimal" name="cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" scale="-2" id="Narr_69z9ZDguXU6FEMbwRJQA6g">3.5</ix:nonFraction>% of the original principal, was due in October&#160;2024. The Horizon loan agreement initially required the Company to maintain cash on deposit of not less than $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ" decimals="-5" format="ixt:numdotdecimal" name="cvrx:DebtInstrumentMinimumCashOnDepositRequirement" scale="6" id="Narr_QfNZ0JPUBkyXsh9Ua886SQ">5.0</ix:nonFraction> million in accounts over which Horizon maintained an account control agreement. This minimum cash on deposit requirement was released in July&#160;2020, following the satisfaction of a financing milestone. The borrowings were collateralized by all or substantially all of the assets of the Company. The Horizon loan agreement required the payment of certain penalties if the loan was paid off prior to maturity for any reason, including pursuant to a subjective acceleration clause, and included various restrictive covenants, including a restriction on the payment of dividends. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the Company entered into an amended agreement with Horizon to extend the interest only period through April&#160;2022, followed by <ix:nonNumeric contextRef="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_mytN74qZAE-E5cluV0a_Qg" format="ixt-sec:durmonth" name="us-gaap:DebtInstrumentTerm" id="Narr_g9QO9568x0SnG22luSRODg">30</ix:nonNumeric>&#160;monthly principal and interest payments beginning in May&#160;2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Horizon loan agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="Narr_MaQGR2_tK02g5WOTB2-VIQ">1.1</ix:nonFraction> million of debt issuance costs and discounts as a reduction of long-term debt. Of this total, $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ" decimals="-5" format="ixt:numdotdecimal" name="cvrx:LegalFeesAndInvestmentBankFee" scale="6" id="Narr_QTRU1vQBuEC5UaFXeoBULA">0.5</ix:nonFraction> million related to legal fees and an investment bank fee and $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_AHM5B_OrqE2hM2md5KwcBA" decimals="-5" format="ixt:numdotdecimal" name="cvrx:IssuanceCostsOfWarrants" scale="6" id="Narr_DusszrRL2E2HX8eAgQm7mg">0.6</ix:nonFraction> million related to the warrants to purchase Series&#160;G Preferred Shares issued by the Company. These warrants were exercisable on the grant date at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_AHM5B_OrqE2hM2md5KwcBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Mk2YA30NhUm0kq5ngIWbOg">0.80</ix:nonFraction> per share and expire in September&#160;2029. The Company used the Black-Scholes option pricing model to determine the grant date fair value of these warrants. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November 3, 2021 the Company fully repaid all amounts outstanding under the Horizon loan agreement. The total repayment amount was $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_11_3_2021_To_11_3_2021_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_fNfZEgGsO0yZp9z4dnf9og" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="6" id="Narr_apMzryC7zEqP_ksoeU9NWA">21.3</ix:nonFraction> million, inclusive of $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_11_3_2021_To_11_3_2021_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherExpenseMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_ID5K4-Y0vE-LBHZCpZLEYQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_IgN76NNtp06NFEKli4p0mw">1.3</ix:nonFraction> million of prepayment and other fees, which represent a loss on extinguishment of debt and are included in Other expense, net on the consolidated statements of operations. The Company was in compliance with all related covenants at the time the principal balance was fully repaid. There was <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_C35XEWZJAU6-Xgd6ERjcqA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="6" id="Narr_UcC5_yryL0Ww9-jg5zwnPg">no</ix:nonFraction> debt outstanding in relation to the Horizon loan agreement as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_ucdU1tK7vEKOlhAsE_-zFQ" continuedAt="Tb_ucdU1tK7vEKOlhAsE_-zFQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stockholders&#8217; equity</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During 2016, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Wr3bFBKF6Uuwn1r7P4sYpQ" decimals="INF" format="ixt:numdotdecimal" name="cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_w6sgX4iwrkmrSdH6Fe1HIQ">72,125,000</ix:nonFraction> shares of Series&#160;G Preferred Shares at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_YiZ4tVb_lEOCzdR1fmlZww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_hKj3gONT5ky4lQ1bVoSW2w">0.80</ix:nonFraction> per share, for net proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Wr3bFBKF6Uuwn1r7P4sYpQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_Na1nOcYBgUqobo2fgNdcqw">57.4</ix:nonFraction> million after deducting offering expenses payable by the Company. The same Series&#160;G investors agreed to purchase an additional $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2016_To_12_31_2016_srt_StatementScenarioAxis_cvrx_OperationalMilestoneClosingMember_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_TKhCqTifZ0aCZQX-reWoVA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_xSV0ZGeYAEefV_bG80YBww">35.3</ix:nonFraction> million of Series&#160;G Preferred Shares upon the Company&#8217;s achievement of a certain operational milestone, subject to limited closing conditions. In January&#160;2019, <span style="-sec-ix-hidden:Hidden_M0BZTFHNU0ipFi78VUubmw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">May&#160;2019</span></span><span style="white-space:pre-wrap;"> and </span><span style="-sec-ix-hidden:Hidden_hGmV6LR9xUyVdc_b1EBWDQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">August&#160;2019</span></span><span style="white-space:pre-wrap;">, the Series&#160;G investors purchased additional Series&#160;G Preferred Shares, resulting in net proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_8_1_2019_To_8_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Yz5mooOlEEu0wI3NjQvG0w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_SonwLpC5MUCrnh9Naw0DcA">24.7</ix:nonFraction> million.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In July&#160;of 2020, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_n8heRn9N5UGTUj53vhPYSA" decimals="INF" format="ixt:numdotdecimal" name="cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ux9rl49xY0S1DkxojEfmJQ">62,500,000</ix:nonFraction> additional Series&#160;G Preferred Shares, at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_P2E57QTxoUSi8yLB5BySbw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_XD2SeGo3YEecTmrBMRkiQw">0.80</ix:nonFraction> per share, for net proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_n8heRn9N5UGTUj53vhPYSA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_yuNT_1WCjEaatDNpr4Lo6g">49.8</ix:nonFraction> million after deducting offering expenses payable by the Company.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0513e341_fecd_4feb_9560_380b9b1f64c4"></a><a id="Tc_9_pe1khgr0KxQbeksx6tNg_1_9"></a><a id="Tc_DYlpI13gfE2-tsZmgTPmCw_2_9"></a><a id="Tc_eNSIy68rwkWzX25q5gLE4w_3_4"></a><a id="Tc_iiHGXLUs6EugADtIncNjuQ_3_6"></a><a id="Tc_PmIxPj-fSE6C51FGq58G9A_3_9"></a><a id="Tc_LhpAr5figUSXjh9UGHIlUw_4_2"></a><a id="Tc_dnOINUlKvkqkARb7_sbfZQ_4_4"></a><a id="Tc_RVo0nCfAyUSHB_BhHfev1Q_4_6"></a><a id="Tc_dnX1PW4X4UKlykX6Hkw9iA_4_9"></a><a id="Tc_BsQDVO6AmUSXqs6Rld1iHw_5_0"></a><a id="Tc_uYbzzJcjLUm-kU8ZkoGcag_5_6"></a><a id="Tc_C-UukiEIvEG5RkzB47Pthw_5_9"></a><a id="Tc_emo0dGmfy0KflJnPidTuTw_6_0"></a><a id="Tc_0faadLq940WxCg18wxI8ag_7_0"></a><a id="Tc_feQK5_wuA0WlfelSeiwy5g_8_0"></a><a id="Tc_f3SzYlemTEKv5kx9TXqIFg_9_0"></a><a id="Tc_0_S_s7DqHkqSTcj1by-xEQ_10_0"></a><a id="Tc_ZOyFnsHooUmsr_IByMq-_w_11_0"></a><a id="Tc_-KH-RnkO6U-oY_6XS8AvaA_12_6"></a><a id="Tc_D84q66SvuEy9gW3gdbIVmA_12_9"></a><ix:continuation id="Tb_ucdU1tK7vEKOlhAsE_-zFQ_cont1" continuedAt="Tb_ucdU1tK7vEKOlhAsE_-zFQ_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On May&#160;31, 2016, holders of the requisite number of the Company&#8217;s then-outstanding convertible preferred stock approved the conversion of all preferred stock into shares of the Company&#8217;s common stock in connection with a new equity financing. Accordingly, all of the Company&#8217;s then-outstanding preferred stock was converted on a <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="As_Of_5_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_OKok4WEvikOohFGKGTT-vw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_mMz3m13AjkmjM-Mv1FBu8A">one</ix:nonFraction>-for-one basis into shares of the Company&#8217;s common stock. Under the terms of the equity financing, each prior holder of preferred stock who purchased a required amount of securities in the new financing was entitled to exchange certain of the shares of common stock received in the conversion described above into new prime series of preferred stock corresponding to the series of preferred stock from which the common stock was previously converted. All of the previously held Series&#160;A-1, B-1, C-1, D-1, E-1 and F preferred stock had similar features as the Series&#160;A-2 preferred stock (&#8220;Series&#160;A-2 Preferred Shares&#8221;), Series&#160;B-2 preferred stock (&#8220;Series&#160;B-2 Preferred Shares&#8221;), Series&#160;C-2 preferred stock (&#8220;Series&#160;C-2 Preferred Shares&#8221;), Series&#160;D-2 preferred stock (&#8220;Series&#160;D-2 Preferred Shares&#8221;), Series&#160;E-2 preferred stock (&#8220;Series&#160;E-2 Preferred Shares&#8221;) and Series&#160;F-2 preferred stock (&#8220;Series&#160;F-2 Preferred Shares&#8221;) described below. The Series&#160;A-2, Series&#160;B-2, Series&#160;C-2, Series&#160;D-2, Series&#160;E-2, Series&#160;F-2 and Series&#160;G Preferred Shares are referred to collectively as the &#8220;Preferred Shares.&#8221;</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_plyOR_vMFUyDuUasvgLhOA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, convertible preferred stock consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_CtJh2imrgkqpjB8k7gvmvA_5_2">2,454,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_d3nDhAy10Uq9T32lYgKO5g_5_4">2,454,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_n2B3pKX8B0unHyT23jqz7A_5_7">4,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_viY9fnQtxECJ2U8QnvzSFg_5_10">4,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_YCah9nj5zEGNuAGoAJ5Y5Q_6_2">2,963,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_qlYBmHJJ70eSVbHQJqgLqg_6_4">2,963,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_d1ErBi5z6EaGNsfR6w-kZA_6_7">7,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_5-0g-Sq_206-1sI76NfVgg_6_10">7,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series C&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_sBlBk-pg10KrbH44Cb3Chg_7_2">4,308,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_1s4zyblC20S2rEgmb6yLAg_7_4">4,308,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_BgTEE7Rvdkmy90p2ObZNhg_7_7">13,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_hcl3MEOrQk6ePjbz3ESOKA_7_10">13,141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series D&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_PncWUnsxakKZm_qkMbG_MQ_8_2">8,631,967</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_n7u5n2t_UEuKlfpk7yug5g_8_4">8,631,967</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_vr8RXLdH8U-8QclUniG6Mw_8_7">53,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_Q3QpYk8EcUKukiPxynATQg_8_10">53,518</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series E&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_pTfsPXsw7kySiNFLWqFNVw_9_2">12,114,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_toYjK6R--k-1eefpkJ3kSQ_9_4">10,135,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_0S8rS1rfGUykr6cPJQVlGQ_9_7">76,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_Vum97p9UD0a3WDTA5Wv1yA_9_10">91,806</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series F&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_bU7QGxkE0kSK_3-DWpFhIQ_10_2">29,773,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_hsMH79l0FEGPD6tewUui5g_10_4">29,548,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_-kmH9cmry0iuLRALB-P-CQ_10_7">41,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_9Bfaj7QAIUKG3d_X0VJAvQ_10_10">104,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc__RbSMzxmpU-zdawX0K90Ng_11_2">177,125,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_mVAtRN8Bl0SGcjXJ2wxFOw_11_4">165,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_9zApR613aEOoE01-Khixaw_11_7">132,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_p1qxMk8oo0C3bbrdH-9yag_11_10">494,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_p5bJu9TluESfrfHI2NNP9g_12_2">237,370,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_2nBEUUJiS0m3ciHI8F2XvA_12_4">223,541,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_-wm4WqIEH0WQWxrDQxlRWA_12_7">329,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_NWyx2-RrV0y2oYuHcmF3mg_12_10">770,233</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company closed its IPO of <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GImtIEFIfUmLgGy9Whzecg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Yy8xJ_ynH06JjeC7Per8IQ">8,050,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_JGMICHAQEEu3PrOrJyDdFQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_82qJcXK2IE2K0VRnB1FFpg">18.00</ix:nonFraction> per share, which included <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_OV8o_orI0kaBRnMMLVzv6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_i89rurMpyE6U5dSSOn2ENA">1,050,000</ix:nonFraction> shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for net proceeds from the IPO, after deducting the underwriting discount and other offering expenses payable by the Company totaling $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GImtIEFIfUmLgGy9Whzecg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_cJ2kFZQn9EmS4D1QUxQ63A">1.6</ix:nonFraction> million, of $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GImtIEFIfUmLgGy9Whzecg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_St6ntzXxdUCYTiozs-R-cQ">133.2</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO, all shares of convertible preferred stock were automatically converted into common stock. Series&#160;G Preferred Shares were converted into common stock on a <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_6RQJgllZt0K-iekb1XdaUQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_dc-ptkRAyU6o8iARbT7Q7w">15.819</ix:nonFraction>-for-1 basis, and all other shares of convertible preferred stock were automatically converted into common stock on a <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_sTrc01bQaECEUcHp29E6Rw">39.548</ix:nonFraction>-for-1 basis. The conversion of the outstanding preferred stock resulted in an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_7_2_2021_To_7_2_2021_Ddc3yM7430mMAAMMP8Suag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr__LnD109urkKFsr-TRYuo5Q">11,929,584</ix:nonFraction> shares of common stock. As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="INF" format="ixt-sec:numwordsen" name="cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_djCB-MmwtkalE-SL3H9jww">no</ix:nonFraction> preferred stock is outstanding.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company&#8217;s Board of Directors and stockholders approved a 1-for-<span style="-sec-ix-hidden:Hidden_33FQYq2nDUGydCuOJK10Rw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">39.548</span></span> reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on June&#160;22, 2021. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock will convert into common stock in connection with the closing of the IPO. Accordingly, all share and per-share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and the adjustment of the conversion ratio of the convertible preferred stock.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f59e6ad4_ca77_4fa8_9e3a_ca558e0ec1b7"></a><a id="Tc_6r6mu_pzjE2hMztIE5vTTQ_2_4"></a><a id="Tc_-isyxffRaU2yLSgJ0IT5hQ_3_2"></a><a id="Tc_KWeZMXqvSkawLNh3gnm6bg_3_4"></a><a id="Tc_3k71zhAi90ajwh-8OTAOyw_4_0"></a><a id="Tc_ykgxbCgfoUii5mtYdmg7CA_4_4"></a><a id="Tc_N9oY1DFpr0azVfWZc0nwsQ_5_0"></a><a id="Tc_oPRFnHDvIUeyVWy3Ji5chQ_6_0"></a><a id="Tc_GVyCYHjDFECw7wgktU6MTQ_7_0"></a><a id="Tc_XxDJSKJ_F0-9hNybxlN06A_7_4"></a><ix:continuation id="Tb_ucdU1tK7vEKOlhAsE_-zFQ_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock Warrants and Common Stock Warrants</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the loan and security agreement entered into by the Company in September 2014 and the amendment in July 2015, the Company issued a warrant to purchase shares of Series F-2 convertible preferred stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the loan and security agreement entered into in May 2016, the Company issued a warrant to purchase Series G Preferred Shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company issued to BWI a warrant to purchase shares of Series E-2 convertible preferred stock that only would have become exercisable in the event of an acquisition or asset transfer involving the Company and it expired upon our IPO.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In September&#160;of 2018, the Company also issued to BWI a warrant to purchase up to&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_dQ7ngpAoS0S1tl97Le48mw">10,000,000</ix:nonFraction></span><span style="background:#ffffff;">&#160;Series&#160;G Preferred Shares with an exercise price of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_6DwkanhKpEiPUtszTDqcsw">0.01</ix:nonFraction></span><span style="background:#ffffff;">&#160;per share. The warrant to purchase Series&#160;G Preferred Shares became exercisable upon our IPO and would have expired on the earlier of (i)&#160;an acquisition or asset transfer involving the Company or (ii)&#160;</span><ix:nonNumeric contextRef="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_oZYOOwwcKEeAvLatFPoLGA"><span style="color:#231f20;background:#ffffff;">180&#160;days</span></ix:nonNumeric><span style="color:#231f20;background:#ffffff;">&#160;after receipt of the data from the post-market stage of the BeAT-HF pivotal trial.&#160;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the warrants to purchase shares of convertible preferred stock automatically converted into warrants to purchase common stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in capital. Upon the closing of the IPO these warrants to purchase convertible preferred stock became exercisable for <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_bnP6fucus0u5PpGTSQpeQQ" decimals="INF" format="ixt:numdotdecimal" name="cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" scale="0" id="Narr_mP2OQFEpcEaUbcJlgjtlGw">716,131</ix:nonFraction> shares of common stock upon conversion at a weighted average exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_bnP6fucus0u5PpGTSQpeQQ" decimals="2" format="ixt:numdotdecimal" name="cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" scale="0" id="Narr_jAQjny_fAku5j50m7qifbg">2.39</ix:nonFraction> per share. </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_as4j6Bxl_Ui_9dgCcqS5-g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Warrants to purchase shares of our common stock are summarized below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_bxwIiabUp0unf-R8Tz_EsQ_4_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="2" format="ixt:zerodash" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_JzsnhTtdCE6KtnTbPnKqGQ_4_5">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock warrants converted to common stock warrants at IPO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="INF" format="ixt:numdotdecimal" name="cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" scale="0" id="Tc_rGD8iiXT40aMLx4I8zmOmw_5_2">716,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt:numdotdecimal" name="cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" scale="0" id="Tc_vxFGdSuBUEGZ3Jr3nZHbyA_5_5">2.39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="INF" format="ixt:zerodash" name="cvrx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_IWfwDga3P0KO9Rxh7uODWQ_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt:zerodash" name="cvrx:ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice" scale="0" id="Tc_6vgUVjFczkK-rVFT4VDhtA_6_5">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_LPFRUid40U6a3mR9YnINqQ_7_2">716,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_u96msh5Zekey9Xf4FChORg_7_5">2.39</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_C6HL133DUUquBHBM5bOiig" continuedAt="Tb_C6HL133DUUquBHBM5bOiig_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stock-Based compensation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of plans and activity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2001, the Company&#8217;s Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#8220;2001 Plan&#8221;). Under the 2001 Plan, as amended, <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_oDN2lEZu7EKFxKQVBpzLOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_u1NrnObR2Uqe8TwVbGTC-A">2,674,749</ix:nonFraction> shares of common stock had been reserved for the issuance of incentive stock options granted to employees, nonemployee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the day of grant to <ix:nonNumeric contextRef="Duration_6_1_2021_To_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_kdt0eqlvgUeFDlocBEsHgg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_unvhHJIKg0WhN8YZ0I-g6A">four&#160;years</ix:nonNumeric> and expire within a maximum term of <ix:nonNumeric contextRef="Duration_6_1_2021_To_6_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_dW1zDaWfyk2oy7oOo2LrKA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_SwpwmBv0dECEczLl6lV0YQ">10 years</ix:nonNumeric> from the grant date. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In connection with the IPO in 2021, the Company&#8217;s Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_mJX9dbF0-kOVnbsfnZIlqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_6VVmm1UfYUSqbj8gsF479Q">1,854,490</ix:nonFraction> newly reserved shares in addition to the <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_sTmU2osx-U-5lEzqPECixw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_FUBQWcPY-U-K5rFcPWsPYg">600,373</ix:nonFraction> shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan will automatically increase on the first day of each year, commencing January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_mJX9dbF0-kOVnbsfnZIlqw" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" scale="-2" id="Narr_G1xkXGU9Bki-g937qQkspQ">5</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The 2021 Plan provides for the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9eb82ce5_df0f_475e_99de_a10da6b0e7aa"></a><a id="Tc_9g3QlEuqSEixY-6wQgxF7A_1_4"></a><a id="Tc_0NHc9H6hI02EQSGA3RUrSw_2_2"></a><a id="Tc_drQ8cJTMPkSDtwt_R_jfMA_2_4"></a><a id="Tc_ptOAD2AaIEWzjRO3nGIg_Q_2_7"></a><a id="Tc_aSsQyycwWkq2EcVHfcxvDg_3_2"></a><a id="Tc_PWIIGpiHmkeL9pgsUt6h4g_3_4"></a><a id="Tc_JOZ5sMqf9Eu7zFD39L2ndA_3_7"></a><a id="Tc_8qXdXE0VakyJtGnqVs-fuw_4_2"></a><a id="Tc_eONWx4MBNE2XCoXd_Qw6Gg_4_4"></a><a id="Tc_QNQanetIDkK9WszrxGY4ag_4_7"></a><a id="Tc_kV6cgwGOfkC5NsAkJ9RUnQ_5_7"></a><a id="Tc_TxEn4XWT10WTcL1_Kg-JNw_6_0"></a><a id="Tc_Uklr4qIR_kGjGTe0RG3P-A_6_4"></a><a id="Tc_2wM_zqN8YUmKs8bUF_0SPg_6_8"></a><a id="Tc_6uAC5SvsKkSQlGx2lHrg7A_7_0"></a><a id="Tc_13WIGIgf8U2NvkpLt4ClOA_7_4"></a><a id="Tc_eyyPLSesuUesNRRTAxnlFQ_8_0"></a><a id="Tc_cN9ECqu4e0CGWoFBFkLRhw_8_4"></a><a id="Tc_4yv7cQVmJE-tJhPoiphJXQ_9_0"></a><a id="Tc_9R6qt3f8jUSm4Hl6XBTOQg_9_4"></a><a id="Tc_vpQKoQIDrEmID2a4dHX94g_10_0"></a><a id="Tc_T0e5GF7fsUG7DOngr_MlVA_10_4"></a><a id="Tc_76noYn2tNUWIY_CfS6W9wg_10_8"></a><a id="Tc_CxupjiZil0Ck4rkXG8NKVQ_11_0"></a><a id="Tc_DjW2TeA6AEmINYR2t04XvA_11_4"></a><a id="Tc_MwARelCCDkOwlnmKLvuw1A_12_0"></a><a id="Tc_4dN7RzlO80m98_fME_eAFA_12_4"></a><a id="Tc_RfG51QwnE0ah9W7ebt80hw_13_0"></a><a id="Tc_n7jOJSRYmkyjf8JcVycYRw_13_4"></a><a id="Tc_T-5eW4wYlkCZ7YKjuEClOQ_14_0"></a><a id="Tc_fvC7SGMZR0eDRkuFbCmKFA_14_4"></a><a id="Tc_8UsbKjrFokeEINUMKtm_hA_14_8"></a><a id="Tc_Im4cb-LhVUSppJY5T6bj6w_15_0"></a><a id="Tc_hwglF-pkP0SmuND9ZbUzjQ_15_4"></a><a id="Tc_B6Sh7p5tn0u3CWpifgXMUg_15_8"></a><ix:continuation id="Tb_C6HL133DUUquBHBM5bOiig_cont1" continuedAt="Tb_C6HL133DUUquBHBM5bOiig_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_bFjTgGhLakqfsDzkd9x64A" format="ixt-sec:durwordsen" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" id="Narr_TEqyo-yNjE6to0okfpRiFA">10 years</ix:nonNumeric> from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_mJX9dbF0-kOVnbsfnZIlqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_TGvtN0wfwkmLQHWqLa2X2Q">1,789,453</ix:nonFraction> shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of the Company&#8217;s common stock on the date of grant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years 2008 through December 31, 2021, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain nonemployee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as the Company&#8217;s standard form of option agreement for nonemployee directors as they have an exercise price not less than the fair market value on the grant date and vest over <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_2-T0O75ws02nTypOsGbMvw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ah-Zd2VVNEOptBkXsVtbGw">48&#160;months</ix:nonNumeric> from the date of grant.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_KMOiWbhk2Umx4Gnshmrqkw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in &#160;thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_j_GJQoavjkmatJRg0vPNcQ_6_2">966,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ZRnAfHmRck-XKoeI-fHGSw_6_5">1.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_jpxD3uHZSEmXwayeJUIzCA_6_9">2,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_eE7ki1Vx4EaOXhV5ymTSNw_7_2">517,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_LTLdkMNxyU6FleTj7qGlbw_7_5">4.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc__6Rf23Im_E657_okUdTvyQ_8_2">10,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_iZIQMih3qkS2pZ88rMGfgA_8_5">4.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EzCcG82OyUmeFpgZ5qDFKg_9_2">175</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_3pvn-Cad4UWYAeb91zNqlQ_9_5">0.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ZI5amaJZ4kCJQwHZdjWxLA_10_2">1,473,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_2xWA9B9HoECI9fSiCQkq9g_10_5">2.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_rt7h2F-FUkucdHa402wk3Q_10_9">3,745</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_IS_pJdkAIECC-xpXaQLcgg_11_2">1,411,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_wRFGYqV370WMNWyd0JYHrQ_11_5">13.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_FlaqDRDZSkWwNs599bia3g_12_2">76,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_JGX_ojgYeUWBsijlbzeDlA_12_5">11.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_8lWOIEhu30CmJwAPuODNkQ_13_2">59,341</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_N_bNHYFvB0CvLc4uhiBn4g_13_5">0.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_zCulJg8tREy2d5Jxg3uAVQ_14_2">2,749,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_RPQyER0zBUq0s_sXmhrsig_14_5">7.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_Nqgz0mZ4U0qiRhq3Ys3K6Q_14_9">16,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_seKOcb_rOU2QGs9TpYjp6A_15_2">1,060,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_aCHnilV5E0WVDLM_cKF4Dw_15_5">2.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_LAKJyenlTU2My__adfZeYg_15_9">10,303</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, stock options outstanding included <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zsm1WUir-k6VgUpvr7OdPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_Pw1MvRquaka3WmhHl4LhqA">9,993</ix:nonFraction> options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2021, the weighted average remaining contractual life was <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_lnY8OUZz5UuzF2lt3JBAbg"><span style="white-space:pre-wrap;">8.1</span></ix:nonNumeric><span style="white-space:pre-wrap;">&#160;years. For options exercisable as of December 31, 2021, the weighted average remaining contractual life was </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_K1adD9qBx0CHuNV1TqPbOg"><span style="white-space:pre-wrap;">6.6</span></ix:nonNumeric><span style="white-space:pre-wrap;"> years.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company&#8217;s Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The number of shares of common stock initially reserved for issuance under the ESPP was <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_48tuazk8rES1QsAP9ElvuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_enRtrK0BzkScYPlUeBz40w">278,170</ix:nonFraction>. The shares available for issuance under the ESPP will automatically increase on the first day of each year, commencing January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_48tuazk8rES1QsAP9ElvuA" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" scale="-2" id="Narr_cR1aG8yAUEmg88iraVAziA">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The ESPP will permit certain of the Company&#8217;s U.S. employees to purchase shares of the Company&#8217;s common stock at a price per share not less than <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_48tuazk8rES1QsAP9ElvuA" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" scale="-2" id="Narr_EDxFEAWTckqorI_gbDcZxA">85</ix:nonFraction>% of the l<span style="letter-spacing:0.25pt;">ower of (i)&#160;the closing market price per share of the Company&#8217;s common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of the Company&#8217;s common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase period commenced January 1, 2022. Accordingly, as of December 31, 2021, </span><span style="letter-spacing:0.25pt;"><ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_nw03FdpgikWG68cst93DrQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_81pqwkbg8kyGsyEfWLsgfQ">no</ix:nonFraction></span><span style="letter-spacing:0.25pt;white-space:pre-wrap;"> shares of common stock have been purchased under the ESPP.  </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ddbe76a4_b4e0_46c0_930a_8556a4231823"></a><a id="Tc_F9SRRAQeNUauZgfCVd_cmw_1_3"></a><a id="Tc_umrO3ESMuE--oj0OnMrMpA_2_3"></a><a id="Tc_N4fm5nl5tU-ckO6h7_6_9A_2_6"></a><a id="Tc_6Ctl_9yRa0ijdgnWosvJQg_3_0"></a><a id="Tc_GIh6tfNiv0KZaC8FXcOKiQ_3_2"></a><a id="Tc_A0hJqXKCRUagvm_UpJbGSA_3_6"></a><a id="Tc_XLp4_uSyikKssmKSFUP9VQ_4_0"></a><a id="Tc_AAztbzZhL0SiC-tJ_aw4EQ_4_3"></a><a id="Tc_zi-NmX8dvE66Hed5iwostw_5_0"></a><a id="Tc_255urRGYXk2ldTuk7TkqtQ_6_0"></a><a id="Tc_GQTE6-Dk8EKu7KBsWW4puA_6_3"></a><a id="Tc_au-tsI30h0SgnEY0aDn1zg_6_4"></a><a id="Tc_rxBJ4NxnGkuPEkdQYUQhwg_6_8"></a><a id="Tc_n-ImhXf0rESrdxUnfQr46Q_7_0"></a><a id="Tc_8I-6nTxOFUmNHbm-CHzprg_7_4"></a><a id="Tc_Q3fypL7Np0OWBgBWkr3BuQ_7_8"></a><a id="Tc_VD5rfHYJ9Uarl1enWy1-7w_8_0"></a><a id="Tc_TcK7j_Fc3kmWF26cGxkQaQ_8_3"></a><a id="Tc_jYnK5upJlE-a3TeMyTegUg_8_4"></a><a id="Tc_dDvx0GZfOUi5jfycdfrI9g_8_7"></a><a id="Tc_g6tJjb0O00OhBtQNLhJAxQ_8_8"></a><a id="_271d42ff_8f1d_482b_8bd2_ccb11f67ee86"></a><a id="Tc_Bj01dZwVK0O_YeJvgW3pYg_1_2"></a><a id="Tc_9Qdfg-ZUOUai3g_Vkm-F8A_2_0"></a><a id="Tc_1aoZy6W2HEilQRVin2wzxA_2_2"></a><a id="Tc_iWucWqEKGEiwYNRFK2x8CQ_2_5"></a><a id="Tc_Ic89TvXlkUeVRxH_Rd75ZA_3_0"></a><a id="Tc_utLOCT8Ng0CXNgKpWMXjTw_3_2"></a><a id="Tc_ORGu5GWXI0updm66VCgsfw_3_5"></a><a id="Tc_JkvTfQSS1k6ZS3RmXwL8NQ_4_0"></a><a id="Tc_w_47D1hmJ0Kiw83JwekcGA_5_0"></a><a id="Tc_9RDDkvPGtUynnk-woQ-dog_6_2"></a><a id="Tc_dshBXkotiUKncCsyCo4Wog_6_5"></a><ix:continuation id="Tb_C6HL133DUUquBHBM5bOiig_cont2" continuedAt="Tb_C6HL133DUUquBHBM5bOiig_cont3"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to determine the fair value of stock options on the grant date. The Company measures stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_YJRHBBFkdkm7tNN-AJMsHA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2021 and 2020. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_qmmiNkn4YUusHwTzOTRPUQ_3_3">5.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_Vwh84KnVtkOp8-VTTQPCcQ_3_7">1.98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_Pz24LA4lyUOU54enYn6jCw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_LTG1yPmjfUupHgKEXX9pfQ">2.7</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_rMwLYGHbQE6dNGAJjgqUTA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_1O3xsqjKnEyH4N9Qmo8UTA">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_dgYIHQpY50SIFkVijZlZVQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_VgWk7F-BBUKP87DWRvmu-g_4_7"> 2.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_Fm3g4MulRkuGfrsRDzx3EQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_g2BcFqVI4kCbGd-y8IYmyg_5_3">3.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_30RcSPGNvEamYzAz2-IrUw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_F65XdBF6EUWX1EIVkeFSfg_5_7"> 3.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_2jkXobQtbUSSrxs0_TbXEA">56.1</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_Yi8TZEicUEONV3ywobyvjA">63.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Tc_2GMpuEG11kOArOJDLYaCmQ_6_7">62.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_A4s_SsOTfk2AZq9HzQscHA_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_hhMGn2Acek2jQazYlmpU_Q_7_7">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_Pvi3GTzorEyZ1nJlPPADXg">0.17</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_HGE0qEW73UCHQmn_frsZvQ">1.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_vVeiDOwCykuLIUCZdtszkw">0.16</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_6nw2V1wlP0-sHfoMeju3nA">0.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews these assumptions on a periodic basis and adjusts them, as necessary. The expected term of an award was determined based on the Company&#8217;s analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. <span style="color:#231f20;">We utilize the simplified method to develop the estimate of the expected term</span>. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_mK2kEDYRWkCmYdwF-yLAOQ">zero</ix:nonFraction>, as the Company has never paid dividends and has no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_OBTtpYH5LkC8iiroqjOytQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_rITtj_g4X0aaNNHUoD6CHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_FzRQG7qK1UCIzDtk1CaiNQ_3_3">1,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Z2T5WpbvEECoGfLG7ZECvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Y-wHsQFrF0WkDrifzcwYBA_3_6">88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KP_E6votUkOpAaxA54qxHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_f8dvmVMR8Eqx-7xkQ5hzTg_4_3">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fYLvldHF7ESQu3O88FcTxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9JrWWOMylkG6xBilIvn56w_4_6">43</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_IVyA6xFKREe6yCN57Qbv9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cFT_m2bts0eamYKtXj8c3Q_5_3">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember__Rt_uAI5zEe9X0cpvPTtiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4K-UqnGcDUCFlAo8_ZkmoQ_5_6">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_iUkeTEicr0OaFxCxEShzpQ_6_3">1,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IWHhf6RSVU659LTtvXu34w_6_6">132</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, unrecognized compensation expense related to unvested stock-based compensation arrangements was $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_WpWMRS6qQk6plm6ZyVQnmA">6.9</ix:nonFraction> million. As of December 31, 2021, the related weighted average period over which it is expected to be recognized is approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_S6fQ4fZvmU6vD9j5XrKEyg"><span style="white-space:pre-wrap;">3.3</span></ix:nonNumeric><span style="white-space:pre-wrap;">&#160;years.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Early exercise of stock options</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the 2001 Plan, the Company has issued options to certain executive officers with early-exercise provisions. The options may be exercised by the holder any time after they are granted. The Company has the right to repurchase, at the original option exercise price, shares issued pursuant to such early-exercise provisions, upon the termination of employment or death of the stockholder. This repurchase right expires based upon the original option vesting schedule. As of December 31, 2021 and 2020, there have been <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_GBAq1vgtgUGuG5-Ar6ag-w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Narr_dX2FYwxpbEWlOZN6schwdw">no</ix:nonFraction> early exercises and therefore there is <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_yzrdiZL4ykShGVaP8kB8EQ" decimals="-3" format="ixt-sec:numwordsen" name="cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions" scale="3" id="Narr_ZuGQ-sREbkWSm36mkbUFEw">no</ix:nonFraction> liability recorded for the early exercise of stock options.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_C6HL133DUUquBHBM5bOiig_cont3"></ix:continuation><a id="_bbcd1f9a_28cc_4d64_a9ea_21f124c4b3f9"></a><a id="Tc_tmLB4WE8oUar7YWK7ySKUQ_1_3"></a><a id="Tc_ZzgVNuJIm0iN3XEarNBHGA_2_0"></a><a id="Tc_hKlGSGLNikKIjfttEsIy9g_2_3"></a><a id="Tc_kSJ2prYmu0SInjEC_3O57Q_2_6"></a><a id="Tc_UzWncjzUk0OtbPX9pGafUQ_3_0"></a><a id="Tc_Pv1dtBjc802tOe_32awybA_4_0"></a><a id="Tc_86cHUQ3h6UK5wiNiAlzu-g_4_2"></a><a id="Tc_AwpA7X_ERkOU0g_zj5Yjhw_4_5"></a><a id="Tc_e345MJGVvky6KeLw2MmXQw_5_0"></a><a id="Tc_Df6_-xNlk0eUoNIyDlORdQ_6_0"></a><a id="Tc_UyB-j228WUW3dlQGiFxz0g_7_0"></a><a id="Tc_xr1iIypcGUK7-ZdH93T9oA_7_2"></a><a id="Tc_4q4wx3Tr50G-9SB2cymv4g_7_5"></a><a id="_80331027_747c_4c11_b2ad_ad628b822233"></a><a id="Tc_Oik3MBHpcU-IOdYI5m-hqw_1_3"></a><a id="Tc_wSXKN0Q5p0SGgz5JPG_2Mw_2_3"></a><a id="Tc_-oWdz1QAeUGRgNlbp8zqCQ_2_6"></a><a id="Tc_MJIfxAItPkqEHFRzch-sfQ_3_0"></a><a id="Tc_O99xujbxm06J4qjSmAzNaw_3_4"></a><a id="Tc_k33Qglev5U2UF4hPUhKTNw_3_7"></a><a id="Tc_jBPO4NnB90OH77PenTgFdw_4_0"></a><a id="Tc_LQLRGk5YBEq-jkgJfpwYig_5_0"></a><a id="Tc_OxHGiDo2O0Sjd7bHWDQXcw_6_0"></a><a id="Tc_iqukv0xXXUagpEfMEdDFAw_7_0"></a><a id="Tc_F-zMKAakqka2aBlorKwayg_8_0"></a><a id="Tc_5qPvvb5Db0SzJmxylB7aYw_9_0"></a><a id="Tc__mT_R-ppwkimXbXvQfwaiA_10_0"></a><a id="Tc_hACj9gzkTki0jvfqC5wuhA_10_4"></a><a id="Tc_k4mFc5xQnk6B0IMkpdTulQ_10_7"></a><a id="_cd400586_83d6_4650_8326_79425515bda8"></a><a id="Tc_GEpEahHhSUmbbEF2n5lxtw_1_3"></a><a id="Tc_lJ2-LxpB2k-oCXHem41H7Q_2_0"></a><a id="Tc_56w4aAFXX0uks_o9sbOeIQ_2_3"></a><a id="Tc_D6Mx-mHk4Ea_jVUus7m-yQ_2_6"></a><a id="Tc_6AeyN1lcLU66lQgIagJwVg_3_0"></a><a id="Tc_yOF0jVxN2UujvSPfXWIOgQ_4_0"></a><a id="Tc_xOjGCMqKfEOkhw8YZHRyMw_4_2"></a><a id="Tc_5pR0fVC4h0ebAd7HzAkZdg_4_5"></a><a id="Tc_A3s6m7LHDUa24C706OuaPw_5_0"></a><a id="Tc_VMKpR5Zmg0O6_P-sDCo8DQ_6_0"></a><a id="Tc_4DkvOqngLkSVWbm3MN0X_g_7_0"></a><a id="Tc_8G3x6BCvvE6_KrOPDmfK3g_8_0"></a><a id="Tc_9T-wmojlPUSc8xm_Izwhcw_9_0"></a><a id="Tc_P9FZkpbGSE2KzsFuOt5jqg_10_0"></a><a id="Tc_GEZ-j22n_ke0f4PpLYEMLA_11_0"></a><a id="Tc_arRC0AFxCU-WIHmM6oN_vQ_12_0"></a><a id="Tc_ZcP44eLIT0aKX3jVFHXdQg_13_0"></a><a id="Tc_ENyTXvbMMkyG3PCWtJJhcA_14_0"></a><a id="Tc_lZZlsoLHmkuWcPzq1SdQvg_15_0"></a><a id="Tc_ffbcbQuKW0GRexLmVUwucg_15_2"></a><a id="Tc_9TY1r3HycUCCUiQvGVVgCA_15_5"></a><a id="_Hlk62564010"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_57GIGsNkoU2PJpcj01pSNg" continuedAt="Tb_57GIGsNkoU2PJpcj01pSNg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Income taxes</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, a valuation allowance was recorded against all deferred tax assets due to the Company&#8217;s cumulative net loss position. </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_-mXVFYnvLk-sPTd6ME5mFg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_XEg97La7T0aU87wlh30eRA_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_HVeZTO0fskae5gCNwRWcag_4_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_4PLXre8kP0WCPELP3dA_Qg_5_3">91</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_QvnkZpX88UyGWJsv-V8_tA_5_6">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_wiSu0tXi7UiayJrg-DikPg_6_3">91</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_U1Yuz3GvVEOEhJW0_ZlH2Q_6_6">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_GsJZHefFJU2GJ0Q6MTR6-Q_7_3">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_tm3nOpE3lU2EXarwvdc6wQ_7_6">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provision for income taxes for the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_wZPNWCzmhkWEulnjJj_tGQ">91,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_n_KICu4XLE-p4G4syjKEeQ">85,000</ix:nonFraction>, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_ZM9IjfeYb0ygWnpcJVUpHA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_iCQWFieE0EycTYW0f8rHkQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_Q8RWgrpd206g1V6eDxaEkg_3_3">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_KynKj7KFk0qiobYHLBVRRg_3_6">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_9O7R4WDdd0GwJpLD0gBXiQ_4_3">9.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_SVlZCUCNDEGCMfH1Q_6V6g_4_6">0.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development (&quot;R&amp;D&quot;) tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_TLIaVz3-Dk-iKya7FL9X2A_5_3">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_cv3smOcMs0mdtSGmuHdUmg_5_6">2.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" sign="-" scale="-2" id="Tc_4KX8AIhDiEaHtQ8t6H7k1A_6_3">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" sign="-" scale="-2" id="Tc_1gJ4WDpObkGHlLJX3-zkpw_6_6">0.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_geyeL7B7xE2pNadBZM0MDA_7_3">0.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_i7XIEq2RLEGpyo5xVV2HLw_7_6">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_WCSfWz1iJ02i0t6HhPf7Vw_8_3">2.5</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_qPBnJw2pxUGUbyhq1toPEw_8_6">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_ChAIVCEiWkebqwEPwz5gDA_9_3">14.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc__m4W6A21iUGLBXcrpYXQww_9_6">23.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_PCd_Ny5oIUK_NRpKWyRORQ_10_3">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_6CwFV2Wwm0S4ZaLTmDtZ3Q_10_6">0.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of net deferred tax assets were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_D0hiBZtysUWzh6kxBCn1bA_4_3">74,716</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_M2e-kGwxzUqO-Nu3gwnAOA_4_6">68,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">R&amp;D tax credits</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_t_RVFZDk10qQ9_VCxB9ZyQ_5_3">8,711</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_AFhsyPCfhEieYMqkWqQhEw_5_6">8,318</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">IRC Section 59e election</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsInternalRevenueCode59EElection" scale="3" id="Tc_UVAyH76YLkKsg7TTbKTkFQ_6_3">8,577</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsInternalRevenueCode59EElection" scale="3" id="Tc_V1FRc4KRSk68synM-pSiMw_6_6">7,955</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Start-up costs</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_Tbly8KhbO0OL1MzL9gxqAw_7_3">1,104</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_XUy8vBvt2kCt_iQhWAMIlQ_7_6">1,198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-qualified stock options</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_qP1ZzvCIwE6vEailttq3yw_8_3">350</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_EB7Wt096o0m9_xBIqVJ3bQ_8_6">136</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_LR156xbdlkKcQD0gx-61sw_9_3">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_NbP9GWkyakKyIDoo-O6CYA_9_6">90</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="Tc_An_qyplwvkeRPFn32c1JCg_10_3">151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="Tc_lX7Z8c8kQEyxhjS4NeuQeQ_10_6">106</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" id="Tc_QgbGkizW8UW3FImjSTvt6g_11_6">607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_r5BrMTylzUek1QrQ8JpEOw_12_3">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_pJJ77RjBx0GMC4zTo_wgSg_12_6">67</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_8pmPiYYiw0uPXQtliLIS-g_13_3">93,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_oSNHpJIb4kOiUR65D4nAFg_13_6">87,434</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_awexE_WzTUOYj48DziTj3Q_14_3">93,759</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_umMYr6ABH06OkdSe4AmizQ_14_6">87,434</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_JKUGcxHdYUifqc8o-2AloA_15_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_INPSdciyuUmZrJF_3sp_1w_15_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WXCPeSjuN0mwsFbO09y0Rg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_QEhYIeB4PkiggSV6bCCohA">324.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_z_YBcxDzik24JD_7beeSKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_jiO2RYdCP0CXoPtK_pAIUw">6.5</ix:nonFraction> million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2021, the Company had federal and state tax credit carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WXCPeSjuN0mwsFbO09y0Rg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_QkYLIYNf4Ui7pek0WJ3QPw">8.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_z_YBcxDzik24JD_7beeSKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_xsdtQR7em0m54cvsOSI3Ug">1.6</ix:nonFraction> million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits began expiring in 2028. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9e1cc25a_fa66_4c85_8dad_80518de99313"></a><a id="Tc_T-T3ArrRp0msM4DoEeMO0g_1_3"></a><a id="Tc_kv8SMO1x6kusYW3-djVs_Q_2_0"></a><a id="Tc_MuXY4RCDeEaWbU6ZnC-UrQ_2_3"></a><a id="Tc_THcCfp_0AkGRpjrEg7l29g_2_6"></a><a id="Tc_1IgnU3Q9SUai4_X6NC-bkw_3_0"></a><a id="Tc_jllgYFRJ0kWTY13xdWyqOQ_3_2"></a><a id="Tc_pj4QV2oPPEewa5E6udy94w_3_5"></a><a id="Tc_7Uz3ecOZ9U6_RIYX2RN4ow_4_0"></a><a id="Tc_Frn6cEFvSkO1ezG2uFzCxQ_5_0"></a><a id="Tc_JorFmUY8EESr55D_P6znlQ_6_0"></a><a id="Tc_NI-C1qdsZUm8FGglRU92dA_7_0"></a><a id="Tc_mB0LssrtQECBZrIcsCoN6w_8_0"></a><a id="Tc_TqA85HidS0mcKYslvz94Bg_9_0"></a><a id="Tc_BtTtm0cPSEC1uhKemA2DRA_9_2"></a><a id="Tc_HjurZgPSU02HrJ__D_O4Nw_9_5"></a><ix:continuation id="Tb_57GIGsNkoU2PJpcj01pSNg_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit the Company&#8217;s utilization of the NOLs and could be triggered by subsequent sales of securities by the Company or its stockholders.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_7cngoAIKOkWrhtic5vx8sw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_ilzE70XAXUaJ8X7_YpO4Ig_3_3">1,840</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_GuxO3En0-0Ku4LkzrrZnIQ_3_6">1,757</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_ab9dAROBN02PfhysIbjQ6g_5_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_Zv-LYhvBCUuy796NUvlGZw_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_SIJkDzWFOE2nXUeLPslK7Q_6_3">91</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_DlZqbHpn80uad3yPK-k8Ew_6_6">83</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_ylN6rRG71EGApOwVz2bC_g_8_3">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc__a-xnFwPvUu3v-kSgH0GRA_8_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_qnkRYi2MBU-4JDFe0jaahQ_9_3">1,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_vF-S66yxO02LA5qv8GbuCg_9_6">1,840</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The Company recognized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_gHSRfVTpn0eiaBveaJtwNA">61,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_43UAft3XGUSJsVwXW9sPKA">56,000</ix:nonFraction> of interest or penalties for the&#160;years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021 and 2020, total accrued interest and penalties are $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_ISLxMS25K0Gq_Sd6V7nCnA">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_rFXV23mjIUqUs3tzz1gxOw">0.3</ix:nonFraction>&#160;million, respectively. The Company recognizes accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. The Company does not expect a significant change in the amount of unrecognized tax benefits in the next year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2001 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. The Company does not have any tax audits or other proceedings pending.</p></ix:continuation><a id="_ce914ebb_f4ca_4882_93b3_e23dfc67a5b1"></a><a id="Tc_dGW4ZORpr0KPfRHnicd7AQ_1_3"></a><a id="Tc_q7OhsiEEq0O9PV4LjBdLKQ_2_0"></a><a id="Tc_zLgRDRCdbUSFeTVtNNYpQQ_2_3"></a><a id="Tc_zs-rzdmMT0yLD1f8Fnk_Qg_2_6"></a><a id="Tc_tljnNG_Cekyki5t8pdIfGg_3_0"></a><a id="Tc_h-3lfEqeEE6pM2zM8OFQqw_4_0"></a><a id="Tc_f0v7u2Te402Vw318NYa6JA_4_3"></a><a id="Tc_eEM2uvb_f0i7EFfLMPJjvQ_4_6"></a><a id="Tc_gvEF4pu2NEOF2n_0IbQvhw_5_0"></a><a id="Tc_Kc5-8coJd0WLzZLTyCS1DQ_6_0"></a><a id="Tc_odBq_cS9WUuyBhNKcCFx_g_6_3"></a><a id="Tc_oZT7H0Mv7Uu8ErzckUnidg_6_6"></a><a id="Tc_Khet1tBtHkOs2kafwsTd_g_7_0"></a><a id="Tc_DqAMVGxppkGiV3DaiuJeEg_8_0"></a><a id="Tc_kPf0iXvh-k-DZ659lvYgEw_9_0"></a><a id="Tc_ijZdIN3JeEK4bgdP3AjaRA_9_3"></a><a id="Tc_sW6PMBi7WEei-sVIE8Erqg_9_6"></a><a id="_Hlk78985748"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_tbUOOUg6z06BjtcP_65FUQ" continuedAt="Tb_tbUOOUg6z06BjtcP_65FUQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">9. (Loss) Earnings Per Share</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_pWljn0H6XEWPgJX8y9trkw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_l_AFuw4AF0KKMLVQ-QRcaw_4_4">43,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Pjr8j0QSpke0ApXrUtRsJA_4_7">14,109</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accretion of preferred stock to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" scale="3" id="Tc_yne31kNV1k2NjeU0qiCKeA_5_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" scale="3" id="Tc_b9GxYuOXJ0KFsIpYlIwdRA_5_7">217</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_0leluCxfJkiFhxuPPIHSLA_6_4">43,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_OqdA2Z3qa02pKfDmv-ALRA_6_7">14,326</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_ALfe3gyAAEun-5xAWVPJVg_8_4">10,360,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_XGVkZbuJjEm_VPNTbtKupQ_8_7">387,083</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_haduNaHsJU6XwzdDxYo72w_9_4">4.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_5AaBK9FvFkay4-xUiwrJGA_9_7">37.01</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company&#8217;s potentially dilutive securities, which include stock options, shares of convertible preferred stock, warrants to purchase shares of convertible preferred stock and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_hGUEwvMB2UGOrp6QGSXwJQ_1_2"></a><a id="Tc_N_gbnsQ7aUmd_muQ7D07BQ_2_2"></a><a id="Tc_Ti0nVPvoYkqS3zePfkRV_A_2_4"></a><a id="Tc_Fu6jf0Xd_UGhnUhG4dZkPw_3_0"></a><a id="Tc_YSRcjeXXFEyocgM8XBcTUg_4_0"></a><a id="Tc_TQCQNTD5HkmxBHoLPHgsoA_5_0"></a><a id="Tc_l9wznu0mJU2rASrcm2PH5Q_6_0"></a><ix:continuation id="Tb_tbUOOUg6z06BjtcP_65FUQ_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_TFI9OsJSCEql8Lepdyw89w" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_z1FXD3BKKUuyMZ9Pt2aLwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_meBQqngJnkuAJH-YNYo0tQ_3_2">2,749,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bk4XMJevEEOkeqMW-LrPQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ap8EFaR29UuKfyfOi65v8A_3_4">1,473,359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BejIF-DRL0aswumRwwIyHA" decimals="INF" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Guu7mxNVmUezUHmpiJsqQQ_4_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aBap4qmv00-_PB2zQLVyyw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_wV3MPOCcDE68HMW--DAjkw_4_4">108,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_PlOty7i4fUGsptJeEqXFFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8EVf31C3F0qiX5KCmrn74A_5_2">716,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_nTVDTqoC4EGDzTZXxwMKtg" decimals="INF" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_RXaHWAqNl0uRWjdebJx_Pg_5_4">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_sIVU4EK2E0GdoOrH6UNCKg" decimals="INF" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_l321eEaiVEm2ee2EUM4n_A_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_zfsXsnHsBUWf8PinLKwvcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_PgAspSVElU6MyQK8-XIngg_6_4">11,929,584</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_EBXpmlrGn0yvkJ0IlPLCkQ_7_2">3,465,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ngEXWuqF5UCwprJSGbJ6vQ_7_4">13,511,349</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7f491559_26a6_4ed1_96a8_e6d5d8a81013"></a><a id="Tc_wNADTNPo_0K8wZE8dj4vlw_1_0"></a><a id="Tc_CYUuWcJHb0WrTehPPx436w_2_0"></a><a id="Tc_7eG2IAz5fk2Hk5JH3RrLsA_2_2"></a><a id="Tc_S6nWR6wqPEWx6MbFEzFy2g_3_0"></a><a id="Tc_ZiLSTi0qNEauQqMBqkuuxA_4_0"></a><a id="Tc_yx_qrela2k-GiQG1QkGEtA_5_2"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_v3_xwdrieEqPbHFlzP80Rw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Commitments and contingencies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commitments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Operating Leases</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into an operating lease agreement for its office, manufacturing and research facility, which expires in 2024. Rent expense for the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_4R-bSkpJvUywTZ55Qlv2cw">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr__i95_ud55k6C_V2HLJg0MQ">0.4</ix:nonFraction> million, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_Mc-mXHypJU-3mj7Q4c-ETQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Future minimum lease payments under all operating leases as of December 31, 2021 are as follows for the&#160;years ending:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_OKAoxWsAxUet4sAepDrBuQ_2_3">227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_S4VfiSiVZ0O0DCHVEBzDuw_3_3">234</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_B7ykX7JLaUSx5OPbNS5DZQ_4_3">138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_pCQtjqrP_EqrUEjfxcd-MA_5_3">599</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contingencies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="3" id="Narr_a7BUF_jZZ0uMLoHBN7ZhMw"><ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="3" id="Narr_fGrJ0naGnEOwzdDWpc_Elw">no</ix:nonFraction></ix:nonFraction> contingent liabilities requiring accrual or disclosure as of December 31, 2021 or December 31, 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="Tb_J-ptQJZ0zE-kiRXpq3g1aQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Employee benefit plans</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a voluntary defined-contribution employee retirement plan (the &#8220;401(k)&#160;plan&#8221;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. The Company does not provide matching contributions to employees.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_b09MmMn80EKZO62IVbwYyg" continuedAt="Tb_b09MmMn80EKZO62IVbwYyg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Segment, geographic information and revenue disaggregation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has <ix:nonFraction unitRef="Unit_Standard_segment_dGFrNR414EyLMrXxL6FSSQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_CNESjjg2NkSWft0g-IlVew">one</ix:nonFraction> business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6966e109_9db4_4f0b_977c_c69d781d356e"></a><a id="Tc_l52G1ZChqEKp0lbfBXNdZA_1_2"></a><a id="Tc_eGkA3NDM1E2Vi3sqFQAtUQ_2_2"></a><a id="Tc_FdGCoA9i0UeLQ1OlWpHijQ_3_0"></a><a id="Tc_D65Q-xWYDU2ZrhdCxGVVoQ_3_2"></a><a id="Tc_CQHbFW_2AE-j-5KJOCVq9w_3_5"></a><a id="Tc_fC_ZsCrctkKeH_sNyuoTDQ_4_0"></a><a id="Tc_ASMLjj2eNUmGheMik37VcQ_4_2"></a><a id="Tc_yeL7-KRsZk-E9BNBV_pPLg_4_5"></a><a id="Tc_9AYnYdnok022XMBpk2MBgg_5_0"></a><a id="Tc_WLK5ELLHVUS4wUKg2KMftg_6_0"></a><a id="Tc_mCFNBeCI00uA40YrH8v1kA_7_2"></a><a id="Tc_Pwcm0cF3qkS10WBb4c7ppA_7_5"></a><ix:continuation id="Tb_b09MmMn80EKZO62IVbwYyg_cont1" continuedAt="Tb_b09MmMn80EKZO62IVbwYyg_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">and its Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_S7Orlh0S_UyqSEw9rnkkcA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the years ended:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_9YKJ16k5pUK-Co6rlduK-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_YRmmOrKJH0ucS1XRpfZ3mw_4_3">9,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_US_aqbgUY-uCkOAp8sxbW2muQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_UzUqBYQq_kK7msuRdp_rsw_4_6">1,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_DE_U05bs9aJIU6iqEyxRNqWpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_3vPCnNPL6Eext4U9GEAQ2w_5_3">3,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_DE_4mGJWS3mdUGj2uJ_PoEshg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ERNxg7M200GDF_cA5NQ07g_5_6">3,790</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_NA4nBO9IeUeJcRmeWYh52A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_G7mxPH0iMUuJCeD1PFbz_w_6_3">639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_uUcu3GeHRUyZPto-aW7cuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_4Pjn8LSEcUSt5-if3wX3pA_6_6">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_t0rXLGnRQEKBVm5yLWfh4g_7_3">13,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ" contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_N3bvNfQpLUS5Rp9_0Izcdw_7_6">6,053</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, long-lived assets were located primarily in the U.S.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d11580d8_e8af_4c84_94fb_bf2365894890"></a><ix:continuation id="Tb_b09MmMn80EKZO62IVbwYyg_cont2"></ix:continuation><a id="Item9ChangesinandDisagreementsWithAccoun"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 9. Changes in and Disagreements</b><b style="font-size:12pt;font-weight:bold;"> with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">None.</p><a id="_fffe3256_9eba_4295_a7dd_43d8dc456608"></a><a id="Item9AControlsandProcedures"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9A. Controls and Procedures</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and other procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of the end of the period covered by this Annual Report on Form 10-K.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in internal control over financial reporting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management Report on Internal Control over Financial Reporting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, for so long as we qualify as an &#8220;emerging growth company&#8221; as defined under the JOBS Act or remain a non-accelerated filer, our independent registered accounting firm is not required to issue an attestation report on our internal control over financial reporting.</p><a id="_47a3e938_0493_4dd3_afc1_bf39848ce3db"></a><a id="Item9BOtherInformation"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9B. Other Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_259cb718_dc12_4dd4_8771_fe66da1c5fc7"></a><a id="Item9c"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fc147125_0c42_41fb_a30d_6b4e3d2eece0"></a><a id="PARTIII"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART III</b></p><a id="_69989698_ac35_4d2a_9210_c2f78814cc4d"></a><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 10. Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2021.</span></p><a id="_e259b8ef_1cad_41f3_9fdd_d501dddf96c3"></a><a id="Item11ExecutiveCompensation"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 11. Executive Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2021.</span></p><a id="_cd6510c7_76c9_4fe8_8cbe_dfaf04780087"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item 12. Security Ownership of Certain Beneficial Owners</b><b style="font-size:12pt;font-weight:bold;background:#ffffff;"> and Management and Related Stockholder Matters</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">T<span style="background:#ffffff;">he information required by this Item is incorporated by reference to our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2021.</span></p><a id="_6269fd01_b169_4691_a6bd_34a8f786bef8"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2021.</span></p><a id="_86309f0e_c31c_4963_8b88_28bf6ea04963"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;14. Principal Accountant Fees and Services</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2021.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dacc696b_ff1b_461f_b6d8_88318f02e168"></a><a id="PARTIV"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART IV</b></p><a id="_811281f9_4ddd_4a0f_a543_d2908970a4e4"></a><a id="_950575"></a><a id="Item15Exhibits"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;15. Exhibit</b><b style="font-size:12pt;font-weight:bold;"> and Financial Statement Schedules</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) 1. Financial Statements:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The following consolidated financial statements of the Company are set forth in Part II, Item 8:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span>Report of Independent Registered Public Accounting Firm (PCAOB ID <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg" name="dei:AuditorFirmId" id="Narr_yJAyKEXrPE-bVlAjmn7MyQ">248</ix:nonNumeric>)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2021 and 2020</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the years ended December&#160;31, 2021 and 2020</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2021 and 2020</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span>Notes to Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">     2. Financial Statement Schedules:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">[All financial statement schedules are omitted as the required information is inapplicable or the information is presented in the consolidated financial statements or related notes.]</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">     3. Exhibits:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>See the response to Item 15(b) below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">(b) Exhibits:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT INDEX</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:88.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921089779/tm2121505d1_ex3-1.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of CVRx, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on July 7, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921089779/tm2121505d1_ex3-2.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated By-Laws of CVRx, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on July 7, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex4-2.htm"><span style="font-style:normal;font-weight:normal;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.2*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-3.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of September 12, 2014, issued by the Company to Life Science Loans, LLC (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.3*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-4.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of September 12, 2014, issued by the Company to Silicon Valley Bank (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.4*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-5.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of July 21, 2015, issued by the Company to Life Science Loans, LLC (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.5*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-6.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of July&#160;21, 2015, issued by the Company to Silicon Valley Bank (incorporated by reference to Exhibit 4.6 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.6*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-7.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.7 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.7*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-8.htm"><span style="font-style:normal;font-weight:normal;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.8 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.8*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-9.htm"><span style="font-style:normal;font-weight:normal;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.9 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.9*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-10.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.10 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.10</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-11.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Series E-2 Convertible Preferred Stock, dated as of September 28, 2018, issued by the Company to Biosense Webster, Inc. (incorporated by reference to Exhibit 4.11 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.11</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-12.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Series G Convertible Preferred Stock, dated as of September 28, 2018, issued by the Company to Biosense Webster, Inc. (incorporated by reference to Exhibit 4.12 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.12</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-13.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan A), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Credit II LLC on February 6, 2020 (incorporated by reference to Exhibit 4.13 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.13</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-14.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan B), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Credit II LLC on February 6, 2020 (incorporated by reference to Exhibit 4.14 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.14</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-15.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan C), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Funding Trust 2019-1 on February 18, 2020 (incorporated by reference to Exhibit 4.15 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.15</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-16.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan D), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation as assigned to Horizon Funding Trust 2019-1 on February 18, 2020 (incorporated by reference to Exhibit 4.16 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.16<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="tmb-20211231xex4d16.htm"><span style="font-style:normal;font-weight:normal;">Description of the Company&#8217;s Common Stock</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Lease, dated October 13, 2008, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-2.htm"><span style="font-style:normal;font-weight:normal;">First Lease Amendment, dated November 30, 2010, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.3*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-3.htm"><span style="font-style:normal;font-weight:normal;">Second Lease Amendment, dated October 22, 2012, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.4*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-4.htm"><span style="font-style:normal;font-weight:normal;">Lease Amending Agreement No. 3, dated April 21, 2016, by and between the Company and AX CROSSTOWN VI L.P. (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-5.htm"><span style="font-style:normal;font-weight:normal;">Lease Amending Agreement No. 4, dated May 18, 2020, by and between the Company and AX CROSSTOWN VI L.P. (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-7.htm"><span style="font-style:normal;font-weight:normal;">Eighth Amended and Restated Investors&#8217; Rights Agreement, dated July 1, 2020, by and among the Company and the holders listed therein (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.7#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-8.htm"><span style="font-style:normal;font-weight:normal;">2001 Stock Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.8#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-2.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Employees/Officers) pursuant to 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.9#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-3.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Non-Employee Directors) pursuant to 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.10#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-9.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.11#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-5.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Employees/Officers) pursuant to 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.12#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-6.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Non-Employee Directors) pursuant to 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.13#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-7.htm"><span style="font-style:normal;font-weight:normal;">Form of Non-Plan Stock Option Agreement (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.14<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="tmb-20211231xex10d14.htm"><span style="font-style:normal;font-weight:normal;">Employee Stock Purchase Plan</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.15*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-11.htm"><span style="font-style:normal;font-weight:normal;">Venture Loan and Security Agreement, dated as of September 30, 2019, by and among Horizon Technology Finance Corporation, as a lender and collateral agent, and the Company, as borrower (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.16#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-12.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Form of Executive Officer Employment Agreement (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.17</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-13.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Form of Indemnification Agreement between the Company and its directors and officers (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="tmb-20211231xex31d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.2<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="tmb-20211231xex31d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="tmb-20211231xex32d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1350, as adopted pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.2<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="tmb-20211231xex32d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1350, as adopted pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">21.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="tmb-20211231xex21d1.htm"><span style="font-style:normal;font-weight:normal;">List of Subsidiaries</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">23.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="tmb-20211231xex23d1.htm"><span style="font-style:normal;font-weight:normal;">Consent of Grant Thornton LLP, independent registered public accounting firm</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.INS<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Instance Document<span style="font-family:'Times New Roman','Times','serif';">&#160;&#8211;</span> the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.SCH<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.CAL<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.DEF<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.LAB<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.PRE<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">104<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit<span style="font-family:'Times New Roman','Times','serif';">&#160;</span>101)</p></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:96.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:3.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">*</p></td><td style="vertical-align:middle;width:96.12%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K under the Securities Act. The Company agrees to furnish supplementally any omitted exhibits and schedules to the SEC upon request.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4f4fb6d4_2281_490c_b9d5_d90ab0bb61c6"></a><a id="Item16Form10KSummary"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;16. Form 10-K Summary</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">None.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7b4a6c5d_e4f5_4aeb_a9f0_806f93776716"></a><a id="SIGNATURES"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date: February 22, 2022</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CVRX,</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">INC.</b></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:49.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Nadim Yared</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Nadim Yared</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="3" style="vertical-align:middle;width:88.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date: February 22, 2022</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signature</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title</b></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Nadim Yared</p></td><td style="vertical-align:bottom;width:56.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">President and Chief Executive Officer (Principal Executive Officer)</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nadim Yared</b></p></td><td style="vertical-align:bottom;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Jared Oasheim</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jared Oasheim</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Ali Behbahani</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ali Behbahani</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ John Nehra</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">John Nehra</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Geoff Pardo</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Geoff Pardo</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Joseph Slattery</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Joseph Slattery</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Mudit Jain</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Mudit Jain</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Kirk Nielsen</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kirk Nielsen</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Martha Shadan</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 22, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Martha Shadan</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.16
<SEQUENCE>2
<FILENAME>tmb-20211231xex4d16.htm
<DESCRIPTION>EX-4.16
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 2/22/2022 01:08:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Exhibit 4.16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF THE COMPANY&#8217;S COMMON STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;text-align:center;margin:0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;">The common stock of CVRx, Inc. (&#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is the only class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">The following is a description of the material terms of our common stock. The description is qualified in its entirety by reference to our amended and restated certificate of incorporation, as amended (our &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Certificate of Incorporation</u>&#8221;), and our amended and restated bylaws (our &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Bylaws</u>&#8221;) and the applicable provisions of the Delaware General Corporation Law, as amended (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">DGCL</u>&#8221;). Our Certificate of Incorporation and our Bylaws are incorporated by reference as exhibits to our Annual Reports on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">General </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par&#160;value $0.01 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Voting rights</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Dividends</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Liquidation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Rights and preferences</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Anti-takeover effects of provisions of our Certificate of Incorporation, our Bylaws and&#160;the DGCL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Some provisions of the DGCL and our Certificate of Incorporation and our Bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interests or in our best interests, including transactions that might result in a premium over the market price for our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Delaware anti-takeover statute</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;">We are subject to Section&#160;203 of the DGCL, which prohibits persons deemed &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly-held Delaware corporation for three&#160;years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three&#160;years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Undesignated preferred stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;">The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Special stockholder meetings</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;">Our Bylaws provide that a special meeting of stockholders may be called at any time by the Chairman of the board, the Chief Executive Officer or a majority of the board of directors then in office, but such special meetings may not be called by the stockholders or any other person or persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Requirements for advance notification of stockholder nominations and proposals</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;">Our Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 5pt 0pt;"><font style="font-style:italic;font-weight:bold;">Elimination of stockholder action by written consent</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;">Our Certificate of Incorporation eliminates the right of stockholders to act by written consent without a meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Classified board; election and removal of directors; filling vacancies</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;">Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our Certificate of Incorporation provides for the removal of any of our directors only for cause. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board of directors, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancy shall be filled by the stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:10pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Choice of forum</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:0pt;">Our Certificate of Incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees or agents to us or our stockholders; any action asserting a claim against us </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">arising pursuant to the DGCL, our Certificate of Incorporation or our Bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Exchange Act of 1934 or any other claim for which the federal courts have exclusive jurisdiction. Our Certificate of Incorporation also provides that the U.S.&#160;federal district courts will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act of 1933 (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Securities Act</u>&#8221;). Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. It is possible that, in connection with any action, a future court could find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Transfer agent and registrar </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The transfer agent and registrar for our common stock is American Stock Transfer and Trust Company, LLC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Listing </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;CVRX.&#8221; </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>3
<FILENAME>tmb-20211231xex10d14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 2/22/2022 01:08:28 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'CG Times';font-size:11pt;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">Exhibit 10.14</b></p><p style="font-family:'CG Times';font-size:11pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">CVRx, INC.</b></p><p style="font-family:'CG Times';font-size:11pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;letter-spacing:-0.15pt;">EMPLOYEE STOCK PURCHASE PLAN</b></p><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">1.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Purpose of the Plan</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;The purpose of this CVRx, Inc. Employee Stock Purchase Plan (the &#8220;Plan&#8221;) is to provide the employees of CVRx, Inc. (the &#8220;Company&#8221;) and its participating subsidiaries with a convenient means of purchasing shares of the Company&#8217;s common stock from time to time at a discount to market prices through the use of payroll deductions. &#160;The Company intends that the Plan shall qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Code.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Definitions</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">. &#160;</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">The terms defined in this section are used (and capitalized) elsewhere in this Plan.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">2.1.</font><font style="display:inline-block;width:20.1pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;letter-spacing:-0.15pt;">Affiliate</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8221; means each domestic or foreign entity that is a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; of the Company, as defined in Code Sections 424(e) and 424(f) or any successor provisions.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">2.2</font><font style="display:inline-block;width:22.7pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;letter-spacing:-0.15pt;">Board</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8221; means the Board of Directors of the Company.</font></p><p style="font-family:'CG Times';font-size:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">2.3</font><font style="display:inline-block;width:22.7pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;letter-spacing:-0.15pt;">Code</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8221; means the Internal Revenue Code of 1986, as amended and in effect from time to time. &#160;</font><font style="font-size:11pt;">For purposes of the Plan, references to sections of the Code shall be deemed to include any applicable regulations thereunder and any successor or similar statutory provisions.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.4</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Committee</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means the Compensation Committee of the Board or such other committee of non-employee directors appointed by the Board to administer the Plan as provided in Section&#160;13.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.5</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Common Stock</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means the common stock, par value $0.01 per share, of the Company.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">2.6</font><font style="display:inline-block;width:22.7pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;letter-spacing:-0.15pt;">Company</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8221; means CVRx, Inc., a Delaware corporation.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.7</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Corporate Transaction</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means </font><font style="font-family:'Times New Roman','Times','serif';">(i) a merger, consolidation or other reorganization of the Company with or into another corporation, or (ii) the sale of all or substantially all of the assets of the Company. &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.8</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Designated Affiliate</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means any Affiliate which has been expressly designated by the Board or Committee as a corporation whose Eligible Employees may participate in the Plan. &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.9</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Eligible Compensation</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means only the base wages paid by the Company or any Affiliate to a Participant in accordance with the Participant&#8217;s terms of employment. &#160;For the avoidance of doubt, Eligible Compensation shall not include any of the following, as determined by the Committee: &#160;employer contributions to a 401(k) or other retirement plan, any amounts that constitute &#8216;LTD earnings&#8217;, any expense reimbursements or allowances, or any income (whether paid in Shares or cash) realized by the Participant as a result of participation in any equity-based compensation plan of the Company or any Affiliate. &#160; &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.10</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Eligible Employee</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means any employee of the Company or a Designated Affiliate, except for any employee who, immediately after a right to purchase is granted under the Plan, would be deemed, for purposes of Code Section 423(b)(3), to own stock possessing 5% or more of the total combined voting power or value of all classes of stock of the Company or any Affiliate. &#160;Notwithstanding the foregoing, with respect to any Offering, the Committee may provide for the exclusion of certain employees within the limitations described in Treasury Regulations &#167;1.423-2(e)(1), (2) and (3). </font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.11</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Exchange Act</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means the Securities Exchange Act of 1934, as amended from time to time, and the regulations promulgated thereunder.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.12</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Fair Market Value</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; of a Share of Common Stock as of any date means (i) if the Company&#8217;s Common Stock is then listed on a national securities exchange, the closing sale price for a Share on such exchange on said date, or, if no sale has been made on such exchange on said date, on the last preceding day on which any sale shall have been made; (ii) if the Company&#8217;s Common Stock is not then listed on a national securities exchange, such value as the Committee in its discretion may in good faith determine. &#160;The determination of Fair Market Value shall be subject to adjustment as provided in Section 14.1.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">2.13</font><font style="display:inline-block;width:17.35pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;letter-spacing:-0.15pt;">Offering</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">&#8221; means the right provided to Participants to purchase Shares under the Plan with respect to a Purchase Period.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.14</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Offering Date</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means the first Trading Day of a Purchase Period.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.15</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Participant</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means an Eligible Employee who has elected to participate in the Plan in the manner set forth in Section 4 and whose participation has not ended pursuant to Section 8.1 or Section 9. &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.16</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Plan</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means this CVRx, Inc. Employee Stock Purchase Plan, as it may be amended from time to time.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.17</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Purchase Date</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means the last Trading Day of a Purchase Period.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.18</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Purchase Period</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means a period of time (but not to exceed 27 months or such longer period as may be permitted under Code Section 423) commencing on such date as may be established by the Committee under the Plan. &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.19</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Recordkeeping Account</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means the account maintained in the books and records of the Company recording the amount contributed to the Plan by each Participant through payroll deductions</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.20</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Shares</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means shares of Common Stock.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">2.21</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Trading Day</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">&#8221; means a day on which the national stock exchanges in the United States are open for trading.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">3.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Shares Available</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;Subject to adjustment as provided in Section 14.1, the maximum number of </font><font style="font-family:'Times New Roman','Times','serif';">Shares that may be sold by the Company to Eligible Employees under the Plan shall be 278,170 Shares, plus an automatic annual increase in such amount on January 1 of each year beginning in 2022 and ending on (and including) January 1, 2031 equal to the lesser of</font>: (i) 1% of the total number of Shares outstanding as of December 31 of the immediately preceding calendar year, or (ii) such lesser number of Shares determined by the Board<font style="font-family:'Times New Roman','Times','serif';">. &#160;If the purchases by all Participants in an Offering would otherwise cause the aggregate number of Shares to be sold under the Plan to exceed the number specified in this Section 3, each Participant in that Offering shall be allocated a ratable portion of the remaining number of Shares which may be sold under the Plan. &#160;</font><font style="font-size:12pt;">Notwithstanding anything in this Section 3 to the contrary, the number of Shares that may be issued or transferred pursuant to the rights granted under the Plan shall not exceed an aggregate of 10,000,000 Shares, subject to Section 14.1.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;">-2-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">4.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Eligibility and Participation</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;To be eligible to participate in the Plan for a given Purchase Period, an employee must be an Eligible Employee on the first day of such Purchase Period. &#160;An Eligible Employee may elect to participate in the Plan by filing an election form with the Company before the Offering Date for a Purchase Period that authorizes regular payroll deductions from Eligible Compensation beginning with the first payday in such Purchase Period and continuing until the Plan is terminated or the Eligible Employee withdraws from the Plan, modifies his or her authorization, or ceases to be an Eligible Employee, as hereinafter provided. &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">5.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Amount of Common Stock Each Eligible Employee May Purchase</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.1.</font></font><i style="font-style:italic;">Purchase Amounts and Limitations</i>. &#160;Subject to the provisions of this Plan, each Participant shall be offered the right to purchase on the Purchase Date the maximum number of whole Shares that can be purchased with the balance in the Participant&#8217;s Recordkeeping Account at the per Share price specified in Section 5.2. &#160;Notwithstanding the foregoing, no Participant shall be entitled to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font>the right to purchase Shares under this Plan and all other employee stock purchase plans (within the meaning of Code Section 423(b)), if any, of the Company and its Affiliates that accrues at a rate which in the aggregate exceeds $25,000 of Fair Market Value (determined on the Offering Date of a Purchase Period when the right is granted) for each calendar year in which such right is outstanding at any time; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font>purchase more than 4,000 Shares in any Offering under this Plan, such limit subject to adjustment from time to time as provided in Section 14.1. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">5.2.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Purchase Price</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;Unless a greater purchase price is established by the Committee for an Offering prior to the commencement of the applicable Purchase Period, the purchase price of each Share sold pursuant to this Plan will be the lesser of (i) 85% of the Fair Market Value of such Share on the Offering Date of the applicable Purchase Period, or (ii) 85% of the Fair Market Value of such Share on the Purchase Date.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">6.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Method of Participation</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.1.</font></font><i style="font-style:italic;">Notice and Date of Grant</i>. &#160;The Company shall give notice to each Eligible Employee of the opportunity to purchase Shares pursuant to this Plan and the terms and conditions of such Offering. &#160;The Company contemplates that for tax purposes the Offering Date for a Purchase Period will be considered the date of the grant of the right to purchase such Shares.</p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.2.</font></font><i style="font-style:italic;">Contribution Elections</i>. &#160;Each Eligible Employee who desires to participate in the Plan for a Purchase Period shall signify his or her election to do so by signing and filing with the Company an election form approved by the Committee. &#160;An Eligible Employee may elect to have any whole percent of Eligible Compensation (that is, 1%, 2%, 3%, etc.) withheld as a payroll deduction, but not exceeding 15% per pay period (or such other maximum percentage as the Committee may establish from time to time prior to the commencement of an Offering). &#160;An election to participate in the Plan and to authorize payroll deductions as described herein must be made before the Offering Date of a Purchase Period, and shall be effective beginning with the first payday in the Purchase Period immediately following the filing of such election form. &#160;Any election form submitted shall remain in effect until the Plan is terminated or such Participant withdraws from the Plan, modifies his or her authorization, or ceases to be an Eligible Employee, as hereinafter provided. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.3</font></font><i style="font-style:italic;">Additional Contributions</i>. &#160;If specifically provided by the Committee in connection with an Offering (including for purposes of complying with applicable local law), in addition to or instead of making contributions by payroll deductions, a Participant may make additional contributions to his or her Recordkeeping Account through the payment by cash or check prior to a Purchase Date. &#160;A Participant may make such additional contributions into his or her Recordkeeping Account only if the Participant has not </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;">-3-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;margin:0pt;">already had the maximum permitted amount withheld during the Offering through payroll deductions, subject to the limitations set forth in Section 5.1. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.4.</font></font><i style="font-style:italic;">Offering Terms and Conditions</i>. &#160;Each Offering shall consist of a single Purchase Period and shall be in such form and shall contain such terms and conditions as the Committee shall deem appropriate, consistent with the terms of the Plan. &#160;The Committee may provide for separate Offerings for different Designated Affiliates, and the terms and conditions of the separate Offerings, including the applicable Purchase Period, need not be consistent. &#160;Any Offering shall comply with the requirement of Code Section 423 that all Participants shall have the same rights and privileges for such Offering. &#160;The terms and conditions of any Offering shall be incorporated by reference into the Plan and treated as part of the Plan. &#160;</p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">7.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Recordkeeping Accounts</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">7.1.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Crediting Payroll Deduction Contributions</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;The Company shall maintain a Recordkeeping Account for each Participant. &#160;Payroll deductions pursuant to Section 6 will be credited to such Recordkeeping Accounts on each payday. &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">7.2.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">No Interest Payable</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;No interest will be credited to a Participant&#8217;s Recordkeeping Account (unless required under local law).</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">7.3.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">No Segregation of Accounts</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;The Recordkeeping Account is established solely for accounting purposes, and all amounts credited to the Recordkeeping Account will remain part of the general assets of the Company and need not be segregated from other corporate funds (unless required under local law).</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">7.4.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Additional Contributions</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;A Participant may not make any separate cash payment into a Recordkeeping Account, except as may be permitted in accordance with Section 6.3, and any such additional contributions will be credited to the Recordkeeping Accounts when received by the Company.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">8.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Right to Adjust Participation; Withdrawals from Recordkeeping Account</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">8.1.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Withdrawal from Plan</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;A Participant may at any time withdraw from the Plan. &#160;If a Participant withdraws from the Plan, the Company will pay to the Participant in cash the entire balance in such Participant&#8217;s Recordkeeping Account and no further deductions will be made from the Participant&#8217;s Eligible Compensation during such Purchase Period. &#160;A Participant who withdraws from the Plan will not be eligible to reenter the Plan until the next succeeding Purchase Period, and any such reentry shall be through the enrollment process described in Section 6.2.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">8.2.</font></font><font style="font-size:12pt;"><a name="_Ref270678726"></a></font><i style="font-style:italic;letter-spacing:-0.15pt;">Adjusting Level of Participation</i><font style="letter-spacing:-0.15pt;">. &#160;</font>A Participant may adjust his or her rate of payroll deduction contributions to the Plan as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font>A Participant may, by written notice, direct the Company to increase or decrease his or her rate of payroll deduction contributions, with such change to be effective as of the first day of the next Purchase Period<font style="font-size:12pt;"><a name="_Ref281922105"></a></font>.</p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">(b)</font></font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">A Participant may, by written notice, direct the Company to decrease his or her rate of payroll deduction contributions for a Purchase Period (including a decrease to 0%) one time during the applicable Purchase Period, with such change to become effective as soon as reasonably practicable. &#160;</font>Any Participant who has decreased his or her rate of payroll deductions to 0% and does not increase such rate of payroll deductions from 0% to at least 1% in accordance with Section 8.2(a) prior to the start of the next Purchase Period will be withdrawn from the Plan effective as of the first day of that next Purchase Period. &#160;</p><p style="font-family:'CG Times';font-size:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;">-4-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">8.3.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Submission of Notices</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;Notification of a Participant&#8217;s election to withdraw from the Plan as provided in Section 8.1 or to change his or her rate of payroll deductions as provided in Section 8.2 shall be made by signing and submitting to the Company an appropriate form for that purpose approved by the Committee. &#160;</font><font style="font-family:'Times New Roman','Times','serif';">The Committee may promulgate rules regarding the time and manner for submitting any such written notice, which may include a requirement that the notice be on file with the Company&#8217;s designated office for a reasonable period before it will be effective. &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.4</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Adjustments by Company</i><font style="font-family:'Times New Roman','Times','serif';">. &#160;To the extent necessary to comply with Section 423(b)(8) of the Code or Section 5.1 of the Plan, a Participant&#8217;s payroll deduction contributions to the Plan may be decreased by the Company to 0% at any time during a Purchase Period.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">9.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Termination of Employment</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;If the employment of a Participant is terminated for any reason, including death, disability, or retirement, the entire balance in the Participant&#8217;s Recordkeeping Account will be refunded in cash to the Participant within 30 days after the date of termination of employment. &#160;</font><font style="font-family:'Times New Roman','Times','serif';">For purposes of the Plan, a Participant will not be deemed to have terminated employment while the Participant is on sick leave, military leave or other leave of absence approved by the Company. &#160;Where the period of leave exceeds 90 days and the Participant&#8217;s right to reemployment is not guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the ninety-first day of such leave.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">10.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Purchase of Shares</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">10.1.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Number of Shares Purchased</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;As of each Purchase Date, the balance in each Participant&#8217;s Recordkeeping Account will be used to purchase the maximum number of whole Shares (subject to the limitations of Section 5.1) at the purchase price determined in accordance with Section 5.2, unless the Participant has filed an appropriate form with the Company in advance of that date to withdraw from the Plan in accordance with Section 8.1. &#160;Any amount remaining in a Participant&#8217;s Recordkeeping Account that represents the purchase price for any fractional share will be carried over in the Participant&#8217;s Recordkeeping Account to the next Purchase Period. &#160;Any amount remaining in a Participant&#8217;s Recordkeeping Account that represents the purchase price for any whole Shares that could not be purchased by reason of the limitations of Section 5.1 or under the circumstances described in Section 3 will be refunded to the Participant.</font></p><p style="font-family:'CG Times';font-size:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">10.2.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Conversion of Foreign Currency</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;I</font><font style="font-family:'Times New Roman','Times','serif';">n circumstances where payroll deductions have been taken from a Participant&#8217;s Eligible Compensation in a currency other than United States dollars, Shares shall be purchased by converting the balance in the Participant&#8217;s Recordkeeping Account to United States dollars at the exchange rate in effect at the end of the fifth Trading Day preceding the Purchase Date, as published by Bloomberg.com if available or otherwise as determined with respect to a particular jurisdiction by the Committee or its delegate for this purpose, and such dollar amount shall be used to purchase Shares as of the Purchase Date. &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">10.3.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Crediting of Shares</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;Promptly after the end of each Purchase Period, the number of Shares purchased by all Participants as of </font><font style="font-family:'Times New Roman','Times','serif';">the applicable Purchase Date shall be issued and delivered to an agent selected by the Company. &#160;Delivery of the shares to the agent shall be effected by an appropriate book-entry in the stock register maintained by the Company&#8217;s transfer agent or delivery of a certificate. &#160;The agent will hold the Shares for the benefit of all Participants who have purchased Shares and will maintain a Share subaccount for each Participant reflecting the number of Shares credited to each Participant. &#160;Each Participant will be entitled to direct the voting by the agent of all Shares credited to such Participant&#8217;s Share subaccount, and the agent may reinvest any dividends paid on Shares credited to a Participant&#8217;s Share subaccount in additional Shares in accordance with such rules as the Committee may prescribe. &#160;Each Participant may also direct the agent to sell any or all of the Shares credited to the Participant&#8217;s Share subaccount and distribute the net proceeds of such sale to the Participant</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;">-5-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">10.4</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Withdrawal of Shares from Share Subaccount</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';">Except for sales through the agent as provided in Section 10.3, a Participant may not withdraw Shares from the Participant&#8217;s Share subaccount until after the Participant has satisfied the minimum holding period requirements established by Code Section 423(a)(1). &#160;Once these holding period requirements have been satisfied with respect to Shares credited to a Participant&#8217;s Share subaccount, the Participant may request that the agent transfer any or all of those Shares directly to the Participant or to a brokerage account maintained by the Participant. &#160;The agent shall deliver the requested number of whole Shares by the issuance of a stock certificate, the electronic delivery of the Shares to a brokerage account designated by the Participant, or an appropriate book-entry in the stock register maintained by the Company&#8217;s transfer agent with a notice of issuance provided to the Participant, and will pay the Participant a cash amount representing the Fair Market Value of any applicable fractional Share withdrawn. &#160; &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">11.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Rights as a Shareholder</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;A Participant shall not be entitled to any of the rights or privileges of a shareholder of the Company with respect to Shares, including the right to vote or direct the voting or to receive any dividends that may be declared by the Company, until (i) the Participant actually has paid the purchase price for such Shares and (ii) certificates for such Shares have been issued either to the agent or to the Participant, as provided in Section 10.3.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">12.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Rights Not Transferable</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;A Participant&#8217;s rights under this Plan are exercisable only by the Participant during his or her lifetime, and may not be sold, pledged, assigned, transferred or disposed of in any manner other than by will or the laws of descent and distribution. &#160;Any attempt to sell, pledge, assign, transfer or dispose of the same shall be void and without effect. &#160;The amounts credited to a Recordkeeping Account may not be sold, pledged, assigned, transferred or disposed of in any way, and any attempted sale, pledge, assignment, transfer or other disposition of such amounts will be void and without effect.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">13.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Administration of the Plan</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.1.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Authority of the Committee</i><font style="font-family:'Times New Roman','Times','serif';">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">This Plan shall be administered by the Committee. &#160;</font><font style="font-family:'Times New Roman','Times','serif';">Subject to the express provisions of the Plan and applicable law, and in addition to other express powers and authorizations conferred on the Committee by the Plan, the Committee shall have full power and authority to:</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'CG Times';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">Determine when each Purchase Period under this Plan shall occur, and the terms and conditions of each related Offering (which need not be identical);</font></div><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'CG Times';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">Designate from time to time which Affiliates of the Company shall be eligible to participate in the Plan;</font></div><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'CG Times';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">Construe and interpret the Plan and establish, amend and revoke rules, regulations and procedures for the administration of the Plan. &#160;The Committee may, in the exercise of this power, correct any defect, omission or inconsistency in the Plan, in such manner and to the extent it may deem necessary, desirable or appropriate to make the Plan fully effective;</font></div><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'CG Times';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;">Exercise such powers and perform such acts as the Committee may deem necessary, desirable or appropriate to promote the best interests of the Company and its Designated Affiliates and to carry out the intent that the Offerings made under the Plan are treated as qualifying under Code Section 423(b); </font></div><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'CG Times';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">As more fully described in Section 18, to adopt such rules, procedures and sub-plans as may be necessary, desirable or appropriate to permit participation in the Plan by employees who are foreign nationals or employed outside the United States by a non-U.S. Designated Affiliate, and to </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;">-6-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'CG Times';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">achieve tax, securities law and other compliance objectives in particular locations outside the United States; and</font></div><p style="font-family:'CG Times';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'CG Times';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">Adopt and amend as the Committee deems appropriate a Plan rule specifying that Shares purchased by a Participant during a Purchase Period may not be sold by the Participant for a specified period of time after the Purchase Date on which the Shares were purchased by the Participant, and establish such procedures as the Committee may deem necessary to implement such rule.</font></div><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.2.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Interpretations and Decisions by the Committee</i><font style="font-family:'Times New Roman','Times','serif';">. &#160;Unless otherwise expressly provided in the Plan, all designations, determinations, interpretations, and other decisions under or with respect to the Plan shall be within the sole discretion of the Committee, may be made at any time and shall be final, conclusive, and binding upon all persons, including the Company, any Affiliate, any Participant and any Eligible Employee.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.3.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Delegation by the Committee</i><font style="font-family:'Times New Roman','Times','serif';">. &#160;Subject to the terms of the Plan and applicable law, the Committee may delegate ministerial duties associated with the administration of the Plan to such of the Company&#8217;s officers, employees or agents as the Committee may determine.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:4.5pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.4.</font></font><i style="font-style:italic;">Indemnification</i>. &#160;No member of the Board or Committee shall be liable for any action taken or determination made in good faith with respect to the Plan. &#160;In addition to such other rights of indemnification as they may have as members of the Board or officers or employees of the Company or a Designated Affiliate, members of the Board and Committee and any officers or employees of the Company or Designated Affiliate to whom authority to act for the Committee is delegated shall be indemnified by the Company from and against any and all liabilities, costs and expenses incurred by such persons as a result of any act or omission to act in connection with the performance of such person&#8217;s duties, responsibilities and obligations under the Plan if such person has acted in good faith and in a manner that he or she reasonably believes to be in, or not opposed to, the best interests of the Company. </p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">14.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Changes in Capitalization and Corporate Transactions</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">14.1.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Adjustments</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;In the event of any change in the Common Stock of the Company by reason of a stock dividend, stock split, reverse stock split, corporate separation, recapitalization, merger, consolidation, combination, exchange of shares and the like, the Committee shall make such equitable adjustments as it deems appropriate in the aggregate number and class of Shares or other securities available under this Plan, the Share limitation expressed in Section 5.1(b) of the Plan, and the number, class and purchase price of Shares or other securities subject to purchase under any pending Offering.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">14.2.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Corporate Transactions</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';">In the event of a Corporate Transaction, each right to acquire Shares on any Purchase Date that is scheduled to occur after the date of the consummation of the Corporate Transaction may be continued or assumed or an equivalent right may be substituted by the surviving or successor corporation or a parent or subsidiary of such corporation. &#160;If such surviving or successor corporation or parent or subsidiary thereof refuses to continue, assume or substitute for such outstanding rights, then the Board may, in its discretion, either terminate the Plan or shorten the Purchase Period then in progress by setting a new Purchase Date for a specified date before the date of the consummation of the Corporate Transaction. &#160;Each Participant shall be notified in writing, prior to any new Purchase Date, that the Purchase Date for the existing Offering has been changed to the new Purchase Date and that the Participant&#8217;s right to acquire Shares will be exercised automatically on the new Purchase Date unless prior to such date the Participant&#8217;s employment has been terminated or the Participant has withdrawn from the Plan. &#160;In the event of a dissolution or liquidation of the Company, any Offering and Purchase Period then </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;">-7-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">in progress will terminate immediately prior to the consummation of such action, unless otherwise provided by the Board.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">15.</font></font><font style="font-style:italic;font-weight:bold;">Amendment or Suspension of Plan</font>. &#160;The Board may at any time suspend this Plan or amend it in any respect, but no such amendment may, without shareholder approval, <font style="letter-spacing:-0.15pt;">increase the number of shares reserved under this Plan, increase the rate of automatic annual increase in the number of shares reserved as provided in Section 3, or effect any other change in the Plan that would require </font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">shareholder</font><font style="letter-spacing:-0.15pt;"> approval under applicable law or regulations or the rules of any securities exchange on which the Shares may then be listed, or to maintain compliance with Code Section 423</font>. &#160;No such amendment or suspension shall adversely affect the rights of Participants pursuant to Shares previously acquired under the Plan. &#160;During any suspension of the Plan, no new Offering or Purchase Period shall begin and no Eligible Employee shall be offered any new right to purchase Shares under the Plan or any opportunity to elect to participate in the Plan, and any existing payroll deduction authorizations shall be suspended, but any such right to purchase Shares previously granted for a Purchase Period that began prior to the Plan suspension shall remain subject to the other provisions of this Plan and the discretion of the Board and the Committee with respect thereto.</p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">16.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Effective Date and Term of Plan</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">. &#160;</i><font style="letter-spacing:-0.15pt;">The Plan will become effective on the effective date of the Company&#8217;s registration statement on Form&#160;S-1 for the initial public offering of the Common Stock. &#160;No </font><font style="font-family:'Times New Roman','Times','serif';">rights to purchase Shares granted under this Plan</font><font style="letter-spacing:-0.15pt;"> will be exercised unless and until the Plan has been approved by the shareholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted by the Board</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> of Directors</font><font style="letter-spacing:-0.15pt;">. </font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> The Plan and all rights of Participants hereunder shall terminate (i) at any time, at the discretion of the Board of Directors, or (ii) upon the completion of any Offering under which the limitation on the total number of shares to be issued during the entire term of the Plan, as determined in accordance with Section 3 and including the annual increased provided thereby, has been reached. &#160;Except as otherwise determined by the Board, upon termination of this Plan, the Company shall pay to each Participant cash in an amount equal to the entire remaining balance in such Participant&#8217;s Recordkeeping Account.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">17.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Governmental Regulations and Listing</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;All rights granted or to be granted to Eligible Employees under this Plan are expressly subject to all applicable laws and regulations and to the approval of all governmental authorities required in connection with the authorization, issuance, sale or transfer of the Shares reserved for this Plan, including, without limitation, there being a current registration statement of the Company under the Securities Act of 1933, as amended, covering the Shares purchasable on the Purchase Date applicable to such Shares, and if such a registration statement shall not then be effective, the term of such Purchase Period shall be extended until the first Trading Day after the effective date of such a registration statement, or post-effective amendment thereto. &#160;If applicable, all such rights hereunder are also similarly subject to effectiveness of an appropriate listing application to a national securities exchange covering the Shares issuable under the Plan upon official notice of issuance.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">18.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Rules for Foreign Jurisdictions</font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';">The Committee may adopt rules, procedures or subplans relating to the operation and administration of the Plan to accommodate the specific requirements of local laws and procedures. &#160;Without limiting the generality of the foregoing, the Committee is specifically authorized to adopt rules and procedures regarding handling of payroll deductions, payment of interest, conversion of local currency, payroll tax, the definition of Eligible Compensation, withholding procedures and handling of stock certificates that vary with local requirements.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">19.</font></font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;letter-spacing:-0.15pt;">Miscellaneous</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">.</i></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">19.1.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Effect on Employment Status</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;This Plan shall not be deemed to constitute a contract of employment between the Company and any Participant, nor shall it interfere with the right of the Company to terminate the employment of any Participant and treat him or her without regard to the effect that such treatment might have upon him or her under this Plan.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;">-8-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'CG Times';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'CG Times';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">19.2.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Governing Law</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;This Plan, and all agreements hereunder, shall be construed in accordance with and governed by the laws of the State of Delaware.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">19.3.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Electronic Documentation and Signatures</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';">Any reference in the Plan to election or enrollment forms, notices, authorizations or any other document to be provided in writing shall include the provision of any such form, notice, authorization or document by electronic means, including through the Company&#8217;s intranet, and any reference in the Plan to the signing of any document shall include the authentication of any such document provided in electronic form, in each case in accordance with procedures established by the Committee.</font></p><p style="font-family:'CG Times';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">19.4.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Book-Entry and Electronic Transfer of Shares.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;Any reference in this Plan to the issuance or transfer of a stock certificate evidencing Shares shall be deemed to include, in the Committee&#8217;s discretion, the issuance or transfer of such Shares in book-entry or electronic form. &#160;Uncertificated Shares shall be deemed delivered for all purposes of this Plan when the Company or its agent shall have provided to the recipient of the Shares a notice of issuance or transfer by electronic mail (with proof of receipt) or by United States mail, and have recorded the issuance or transfer in its records.</font></p><p style="font-family:'CG Times';font-size:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'CG Times';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;text-align:justify;">19.5.</font></font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;letter-spacing:-0.15pt;">Registration of Share Accounts and Certificates.</i><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.15pt;"> &#160;Any Share account contemplated by Section 10.3 and certificate to be issued to a Participant shall be registered in the name of the Participant, or jointly in the name of the Participant and another person, as the Participant may direct on an appropriate form filed with the Company or the agent.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'CG Times';font-size:12pt;text-align:center;margin:0pt;">-9-</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>tmb-20211231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 2/22/2022 01:08:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CVRx, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">List of Subsidiaries</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:41.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Name of Company</b></p></td><td style="vertical-align:top;width:4.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:53.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">State or Other Jurisdiction of Incorporation/Organization</b></p></td></tr><tr><td style="vertical-align:top;width:41.34%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CVRx Switzerland LLC</font></p></td><td style="vertical-align:top;width:4.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:53.84%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Switzerland</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>tmb-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 2/22/2022 01:08:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">We have issued our report dated February 22, 2022, with respect to the consolidated financial statements included in the Annual Report of CVRx, Inc. on Form 10-K for the year ended December 31, 2021. We consent to the incorporation by reference of said report in the Registration Statement of CVRx, Inc. on Form S-8 (File No. 333-257616).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ GRANT THORNTON LLP</font></p></td><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Minneapolis, Minnesota</font></p></td><td style="vertical-align:bottom;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';">February 22</font><font style="font-family:'Arial','Helvetica','sans-serif';">, 2022</font></p></td><td style="vertical-align:middle;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>tmb-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 2/22/2022 01:08:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, Nadim Yared, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">I have reviewed this annual report on Form 10-K of CVRx, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 22, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;"> /s/ Nadim Yared</font></p></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nadim Yared </p></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>tmb-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 2/22/2022 01:08:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, Jared Oasheim, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">I have reviewed this annual report on Form 10-K of CVRx, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 22, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">J.</font></p></div></div></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>tmb-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 2/22/2022 01:08:40 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Certification of CEO Pursuant to 18 U.S.C. Section&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">As Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">In connection with the annual report of CVRx, Inc (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2021 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission on the date hereof, I, the undersigned, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The Report fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 22, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Nadim Yared</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nadim Yared</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>tmb-20211231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 2/22/2022 01:08:43 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Certification of CFO Pursuant to 18 U.S.C. Section&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">As Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">In connection with the annual report of CVRx, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2021 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission on the date hereof, I, the undersigned, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The Report fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 22, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">J. </font></p></div></div></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tmb-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %2 9H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG*DZD7>VZZKS(<TI\K^1G0_#RRL[Z273]6U>QLY;C[1+86]R%A=\Y/&,@'N
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MM_A5F5PMPI/0"IHQDHWEN]3/"TY1BY5/BD[OR[+Y(LT4U'5URIIU;'4%%%%
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M[?I/FWT([/VSCOP/\FO5ZRJ+6_<I!1114#"O-O!(.B_$[QCH. (9VCU* #H
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MBBBH&<GXL\'MJT\6LZ/<?V?XAM!^XNE'$@_YYR#^)#^E+X6\7+KQGTK4K?\
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MHH **** "BBB@ HHHH **** *]MP9%]#5BJ\7%S(*L4 %%%% !1110 4444
M>6"35_&WQ&\0:4?$&H:3I^CB-(H;!Q&\C,,[V.#D?_6JYXD\6:KX*@L=-CN[
M#5+E+9I'>[>07$V">=D:MC@?>.!FMW6_A_HVMZP=6:2_LM0:/RY)["Y:%I%]
M&QUJ";X::%)+:RQ2ZC;26]H;/=!=LC2Q$D[7/4\DUKS1TN39F(WQ-U2[@\+G
M2="BN;C7()I!#)<[/+9.,;L8QU-)J/Q&UV&XUA;+1+-X]!@CDU+S;E@2[+EE
MCP.<<\GKBNFL/ 6BZ=+H<D N=VBI(EINESP^=V[CGK4&M?#G1-<U*ZOII+ZW
M>]14O([6Y,:7(7H' ZT7A?8+,YA/%OB/5/B9I2:2(&TJ]TB.\2VGF*C8Q&YS
MA3\XR0!T(%5['QW)I&E:A]AL);F^NO$4FG6T5S>.ZE^/F+'[J_[(KN+WP/I%
MUJFFZC$UW97&GPK!";.<Q@Q Y",.Z^U5;CX:^'[G3+FQ9;I4GOVU'S4FQ)%.
M?XD;'%'- +,Q_AS?:M=^+?&4>KN!/%<PCR(YFDBB)0Y";L<?@*[C5M.L=1LV
MBOK.WN8^FV:,./UK/\.^$=.\,W%_/927<LU\RO/)<SF5F*@@')Y[ULW/^H:H
MD[NZ&EH<1>?![P1J$89=(%HYYWVLK1G\LX_2N<O?V?=&F8FTUS4X%/19"L@'
M\J]>C_U2_04ZFJDUU#E1XOI_P2OM#F\ZPU#1KUU.5_M+3-__ +,?Y5U,,_Q'
MTN(0C0?#MY&G ^QW+P9_X"PP*[^BAU&]]0Y>QPG_  F?BNU_X_\ X?W^!U:S
MNXYOR'!I?^%J:1 /^)AI.OZ>1U^TZ:^!^*YKNL44KQ[!9G'6WQ4\$W1VC7[>
M)O[MPK1$?]] 5OVOB'1;X VFKV$^>GE7*-_(U/<Z7I]X,75C;3@]I85;^8K!
MN_AOX-O<F;PWI^3U,<7EG\UQ1[H:G4*RL 5((/<<TM<)_P *D\-1$FQDU33R
M?^?34)%Q^9-!\ :Q;#_B6>/->A]!<E+D#\& HM'N&IW=%<&-&^)%KQ#XJTF\
M Z?:]/*$_4H:4ZA\3+$?OM"T+4Q_TZ7CPM_X^,4<O9A<[NN!^*Q7^R-$$V/L
MIUJU^T9Z;-QZ^V<4K>//$5J<7_P_U92.IMIXYA^A%9&O^-?#VO:)>Z7XCT[7
M=(2YCVAKK3G&QNJLI7/(.#51BT[B;1Z)JMH]SH]Q!&<2["T9SC#CYE/Y@5SG
MAL2'6X&VQ(LEF]R!&, +*X.,8ZY!)^G4YKE/!_QCT=8?['\1ZC&ES;?NX]05
M6\FY4<!CQE6QU!%7=-\?^%-(<7$NLV\S)8QP1Q6I\V1R'<[0J]\%?SI\DE=6
M"Z-3XDD?;O!_D_\ '[_;D/E8Z[<'?^&.M=[7 ^'=-U;Q-XIC\7Z[9OI\%M&T
M6E:?+_K$#?>ED]&(X ["N^J9:60T%%%%0,*0C((I:* ((#M+1GJ.E3U%+&6(
M=.''ZT1SJW#?*WH: ):*** "BBB@ HHHH **** "BBB@ HHHH KK_P ?C_2K
M%5U_X_'^E6* "BBB@ HHHH **** .:\?^(5\,>"=3U(-MF6(QP8ZF1OE7\B<
M_A7GWPK\33VC:[H=SK*ZM-!;+?VUP9S*#^[&],DY^5L#'UKU'7/#NF^(H[2/
M4XGECM9UN(T$A52Z]-P'WA['BH+GPCHMUK,.K-:;+N*![<-$Q0%'!!! X/4]
M:TC**C9DM.]SRKQ!XP\;:M\*)/$!&GZ;:R^44ELYI!.3YNTXY^4=.,GC-;^K
M^._$6C76DZ \5G)JUQ:M=37$%I-.BIDA0L:G<6.#DYP*[0>#=$_X1(>&&M"^
ME!-@B:1B0-V[.[.<YYS5.;X>:!<6%G:R1W9>R+&WNOM<@GCW=0),[L>W2JYX
M=@LSEY?B'XH:R\,)#H=M;ZIJL\]O-;WHDC4,@&&7N <YY!]*-6^)6L>%[K5-
M/UVTL?MZV,5QIZVX?;/(Q"E.3SACVQP#780>"-$MVTIEAG9],E>>W>2X=VWO
M]XL2<MGWK/\ $O@D^)/&?A_5;@V_V'2]TC(0?,D?(*CTV@@'\Z2<+[!9G4:8
MUZ^F6K:BL2WIB4SK#G8KXY R3QFI;C_4M4M,E&8F'M6100G,2_2GU%;',"U+
M0 4444 %%%% !12$@#).!4)E>0[8A_P(T 3,ZK]X@5$;E>BJ6H6W&<N2QJ4*
M%&  /I0!#OF;H@7ZT>5(_P!^3 ]!4]':@"-(43D#)]33R,TO:B@"E<:/IEV?
M](TZTF_ZZ0*W\Q26VBZ59R^;:Z;9P2==\4"J?S J]13NP"BBBD 4444 %%%%
M !3'B5_O#\:?10!!Y#K]R0_0T;IUZJ&^E3T4 0"X X=2M2K(K_=8&E(!ZC-1
MM;H>5^4^U $M%5]\D)Q)\R^HJ=6##*G(H 6BBB@ HHHH **** *\?-U(?058
MJO;\R2-[U8H **** "BBB@ HHHH **** "BBB@ HHHH *",C%%% %>U. Z^A
MJQ5=/DNV7^\,U8H **** "D9@JDDX I20!DU6&;A\](Q^M   UPV3E8QV]:L
M*H48 P*4# P** "BBB@ H[44=J #M11VHH **** "BBB@ HHHH **** "BBB
M@ HHHH ****  C(P:KLC0MOCZ=UJQ10 U'$BY%.JNZF%_,3[O<5.K!U##H:
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M<Z[HCZCFEB;?&#0 RX?;'@=6X%/B3RXPO?O4*_OK@M_"G2K- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %.56B9E'W7JT@VH!Z"DEC$B
M%>_:H[>0D&-OO+0!/1110 4444 %%%% !1110 4444 %9/B87I\/7@L-WVC9
MQL^]C/./?&:UJ:Y*HQ W$#.!WJHOEDF:4I\DXSM>S.,TVW^S6L>H^';N6XB
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M'&L:[5H1%1<*,"G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !44L"R<]&]:EHH JH[6_R2+\O9A5E6##((
M(H(##!&14!@9#NB;'M0!8HJ 7!4[95*GUJ965AE2#0 M%%% !1110 4C*&4J
MP!!Z@BEHH 15"J H  Z 4V2*.5=LB*Z^C#(I]% K)JQ372=.1]ZV-N&]?+%6
MP H    ["EHIMM[BC",?A5@HHHI%!1143W"*<#YCZ"@"6J\TRE2B_,Q]*3;-
M-]X[%]*FCB6,?*.?6@"&.W)P93G'1:L@8&!110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 (5##! (J%K8 YC8J:GHH K[IX^JAQ[4HNDZ,"I]ZGI"JMU - "+(C=&'
MYTZH3;1GMCZ&F_9B/NR,* +%%5_*F'26C;<_WUH L457VW/]\4>7.>L@% %B
MD+*.I J#[.Y^]*:46J=R3^- #FN(U[Y^E,\^1^(XS]34JQ(O113Z *_DR/\
MZQ^/05*D2)]U>?6GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tmb-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &+ U # 2(  A$! Q$!_\0
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MTZ73Y=Q7R9&#''KD5H53TNSDT_3H;6:[FNY(P09YCEWR2>?SQ^%7* "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM7  !@# ]JSE/L-1&10I"NU1]3ZU)116984444 %%%% !1110 4444 %%%%
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MHY^IH ]'HK.M]8M[S17U.W#-&L;,5888%0<@CUXKB!X@\0QZ!!XH>_@:WEE
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MNB[JYY4H\KL;]%8'_"::!_T$$_(UL6=Y!?VJ7-M()(G&58=Z9)/5:]T^SU&
MPWEM%/&?X9%S^7I5FN4O==GLO' M)I]FGI9-.ZD=QWH VK+1+*PLVM(5<PDG
M"R,7V@]@3T%43X/TDZ*-*$<@@60RHZOAT;.<@U1L_'UG>7$40L+V,7 )M7=
M!/CLO/4^]<A#XW\01Z5?:BT5U)FZ\I T2^5$ W3KG/:@#TC1M!L]#AE2U,KO
M,VZ2:9][N?<U#<>&+"XLH[<O<(T<AE6>.3$@8]3G'>IY-6:W\._VK+:392$2
MO ,;_<=<52?Q?8+)8*%D9;N!K@.,8C0#DM_]:@#5L--MM-T];*W0^2H(.\Y+
M9ZDGOFL1/ FCI<K)FZ,"R>:MJ9B80V<YVU'IWCNPU"^MK<VEU!'=$BVGE4!)
M2/3G^=54^(UDT33G3+\6J3&&2XV HC9QR<T =)::-:66IW>H0AQ/=8\S)XXZ
M8%4]6\*:?K&H)?SR745RD?EI)!+L*CVK%@\87A\7ZE9R64WV"WMA,N%&0 N=
MQ.>A[56N_'<6IZ1%=6::C91FXA7SA$I#[B04Y..W)% &_#X,TB"RM;5$EVV\
M_P!H5B^69_5CWJ.\\$:3>7<T[-=Q)<-OG@AF*QRGU9:CO_&UI8WD]LEE>78M
M0#<RP)E8L^O_ -:J;>+/L_BB]:>YQI,-BEPHV]S^M &MJ'A+3+^6&93<6DT4
M?E+):2^6VS^Z?:HYO!6C2Z;;62)- +9S)%-#)MD5CU.[WINC^,K35=02R>SN
MK.:6/S(?/4 2KZC!IFOZO=6'BG0+6.81VUR\GG@@<A5)ZT 7]%\-6&@S7,UH
M9VDN<&5II-Y8COGUJ1] LI-3NM08/Y]U!Y$GS<;<8XK&MO'^G7%Y#']ENTM9
MY?)BNW0"-WZ8]>M.N_'EE9W[026-[]G6<0&ZV#R]Q_'/Z4 :@\-:9_PCXT1H
MF>R48 9OF'.<Y]:JVG@S3+5IW>2[N99H&MS+<S;V2,C!"^E)+XPL8(=8DFAF
M0Z80)%.,N#]TKST.>]5;SQY:6DIB73[R>2*%9KA8E!\A2,_-SZ>E &DGA?38
MUTI567&EY^S?-TR,'/KTJUIVCVFEW%[-;!P]Y,9Y=S9^8]<5CWOCFP@>T2TM
MKF^DN8/M"I;J,B/U.3^E;FEZC%JNG17L*NB2#[LBX8>H(H N4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% ",H92IZ'BL61#'(R'L:VZS]0CPRR#O
MP:N#UL3)%*BBBM20I_F/C&]L?6F44 %%%% !2,P4%F( '<U4U'4H=-A#RY+-
M]U1WKD[[4;S44DD<E+= 3M'3_P"O7/5Q$:>F[.JAA)U5S/2/<V[_ ,1Q1$Q6
MB^=)TW=A_C6,\5YJ$GF7<IQV7T_"N2&HW*R[XY2A[8KHM/UZ"2U'VN14E'!]
M_>N6M&K+67W([</5H0=J:L^[-2*TAA^Z@)]3S4U4/[:T_P#Y^%H_MK3_ /GX
M6N?DEV.AUH/>1?K=TC6FA9;>Y8F,\*Y_AKD_[:T__GX6C^VM/_Y^%JXJ<7=(
MSJ.E-6;1ZD"" 0>#2UQ>C>,]-BB\BZNU"K]QC_*M7_A-- _Z""?D:[8NZN>5
M./+*QOT5@KXRT%F"B_0DG X-;JL&4,.01D51(M<F_@N;SI7@U^_@61RVR(*
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MECDUD7O@72KZ\NKII;V*2Z;,WDS[0X]",=*Q-'^(,L?AJ35-8LYR%N_(#1H
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M!;V>H7)N+A,DL6+8!.0,GKBMFB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME\C"HK=OM#613<Z<PDC/.P'I]*PW1HV*NI4CL1BH::-H5(S6@E%%%!84444
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M/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,+Q-)BTBC'\3Y/X"N8KHO%!_P"/8?[W]*YP\*3[5PUM9L]7"JU)'"^)
MM1:[U!H%8^5"<8]3W-8E2W3%[N=CU,C']:FT^PDO[CRTX4<LWH*^PH4XT:2B
MMDCX'$5)XBO*3U;95 +' !)]!5A-.O)/NV\A_#%=?:Z?;6B!8HQGNQZFK52Z
M_9&\,#I[S.-AL=4M9!+%#*C \$5V.CZI)>)Y5U"T=PHYR.&I:56*L".HKBQ=
M..(C9K7HSTL#*6$G>,GR]4;5K>36<HDA<@]QV-:=_J5KJ-AET*7*=..M8<;A
MT##O3J^<O*%XL^IY(3M-!4<D$,H(DB1L]<BI**S-4[;',:OH'EJUQ: [1RT?
MI]*YVO2:Y?7='\LM=VZ_(>74=O>LYPZH]##8F_N3,!'>)U=&*NIR&!P177-X
M]N9_#TNFW5NLTKIL$Q/;W'K7(45,9RCLSIJT*=6W.KV+\FB:E%IJ:@]I(+5N
MDF.*H5Z3X,\3V]]9KH>IA/N[(V;HX]#[US7C#PT= OP\1S:3$F/U7VK25)<B
MG%W1STL5)UG1JJSZ>:.;HHHK$[0K6T"^^RWPC8_NY>#['M632ABI# \CD4)V
M=R9P4XN+/1Z*JZ=<B[L(IL\E>?K5JN@\.2L[,****!$-S;)<1X/##H:PY(VB
M<HPP17153U"W\V+S%'SK^HJ9(VI3L[,W/!NMDG^S;A_>(G^5=I7C4,SV\Z31
MG#HP8'WKUK3+U-0T^&Y3^->1Z'O79AJG,N5]#S<PH<DO:1V?YENBBBNH\X**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YCQ7'N:'(X9&'\
MJ\.E0Q2O&>J,5/X5[WXFCS:PR?W7Q^8_^M7BFOV_V;6KA<<.=X_'_P"OFNS*
MYVK3AW2?W'%G-/FPU.IV;7W_ /#&SX>@$>G^9CF1B<^PX_QK7JGI:[=,MQ_L
M9JY7;-WDSFHQY::04445)H%%%% $MNVV8>_%7B< GTK-4X8'T-:$A_=,1Z5Y
M&84_WL7W/:RVI^ZDNVI7CNCNP_*G]*R=:T03 W5HHW]60=_<5=J>"?8=K'Y?
MY5>,P,91YJ:^0LOS*=*=ILX0@@D$8([&BNNUG1DNXS/;J!,!D@?Q5R+*58JP
MP0<$5X,HM,^PHUHU8W04444C4%9D8,I(8<@CM6W#/JGBN^M-.GNRY'RH7/"^
M]8E26UQ+:7$<\#E)(SN5AV-.+MOL14AS*ZWZ&EK_ (>N_#UVL-QAT<9251PU
M9->N6EQ9^._#+PS[5NHQ\WJC=F'M7DTT1AGDB)!*,5)'0X.*TJTU&SCLSFP>
M(E53A45I1W&4 44HZ56'IQJ2M(SS+$U*%)2I]Q",44II*FO",)M1-<#6G6HJ
M<UJ%%%%9'6%=3X<O?/MWM)#DH/ESW%<M5O3+DVFH0RYXS@_0TXNS,J]/G@T;
ML\?DSLGH>*[KP1>F;3Y;5CDPMD?0UR.IH-R2CHPQ6EX,N?)UORR>)4(_&NBB
M^6HCR,5'VF'?D>C4445Z9\^%%%% !1110 4444 %%%% !1110 4444 %%%%
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MI;;M,MSG^#%7*H:.KQV AD&'B=D8>^?_ *]7Z]N6[L>+3OR*X4445)84444
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M#4RT:9T4M8N)[(#D ^M+3(CF)#_LBGUZQ\T%,FA2X@DAD&Z.12C#U!&#3Z*
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MB3P]I\EY+<M&^^62*5@)"%+1D%#CIQM'Y5(NBV2>5B-OW5V]XGS'B5]VX_\
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MI$(5W]<A2_7;G\:1?"\ZO;0C4G&GVMT+F&W\L9!#%MI;NHR<?AZ4 =+1110
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M]371VGAM%PUU)N/]Q.!^=;<4,<$82) BCL!6]/#=7H<E?,&]$[E73=-CT^+
M^:0_>>KU%%=B22LCS)2<G=A1113)"BBB@ HHHH **** "BBB@ HHHH ****
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M:596_*0+GU;D_K5P #@#%+16B26QBY.6["BBBF(**** "BBB@ HHHH ****
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M0JJHP !VJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ H)P"3T%%!&1@T <1JEX;V^=^=@^51[52K=U"QMHY9"D6
M.?4UG^1'_=_4UY\XN^I[%.<>56*5%7#!'C[OZFJAZFH:L:)W$HJ>"-7#;AG%
M3>1'_=_4TU%L3DD4JZ3PW>[D:T<\CYD^G>J5O96[JI:/.3_>-;UAIUI;'S8H
M0K\C.2?YUM1A)2NCEQ%6#@XLOT445V'G!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <9K-Z;R^8 _NX_E7^M9U=!J=C
M;)/(RQ8)YZGK69Y$?]W]37!.+YG<]>E./(DBE15WR(_[OZFJ;<,1[UFU8U4K
MB45- BN3N&:G\B/^[^IIJ-Q.212KH/#E[M=K1SPWS)]:J06=NZ9:/)SZFMVP
MTVTA(FCA D'0[B?ZUM2A+FNCFQ%6#@XLTJ***[#S0HHHH **** "BBB@ HHH
DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tmb-20211231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &\ <T# 2(  A$! Q$!_\0
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M2O\ H!7O_?Y*/^&BM*_Z 5[_ -_DKYY ). ,GT%)1["'8.>1]#_\-%:5_P!
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M=GT/_P -%:5_T KW_O\ )1_PT5I7_0"O?^_R5\\44>PAV#G9]#_\-%:5_P!
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M(^E? _Q0MO'VM2:+-X8$4!B9_,R)4 '9QM &>U>4_$?PK80_%@:#H*1PK>-
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MAK37U'4],\NT0@/+',D@3)P,[2<<D"N3H33V!JP4444Q!1110 4444 %%%%
M!1110 4444 %%%% !1110 44N#Z&C!]#0 E%+@^AHP?0T )12X/H:,'T- "4
M4N#Z&C!]#0 E%+@^AHP?0T )12X/H:,'T- "44N#Z&C!]#0 E%+@^AHP?0T
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MI<'T-&#Z&@!**7!]#1@^AH 2BEP?0T8/H: $HI<'T-&#Z&@!**7!]#1@^AH
M2BEP?0T8/H: $HI<'T-&#Z&@#[&_X5KX-_Z%S3_^_7_UZ/\ A6O@W_H7-/\
M^_7_ ->NJHKS>:7<Z+(Y7_A6O@W_ *%S3_\ OU_]>C_A6O@W_H7-/_[]?_7K
M3E\5>'H)GAEUS38Y$8JZ-=("I'!!&>#3/^$O\-?]#!I?_@9'_C3O/S#0S_\
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M3_\ OU_]>M#_ (2_PU_T,&E_^!D?^-'_  E_AK_H8-+_ / R/_&B\_,-#/\
M^%:^#?\ H7-/_P"_7_UZ/^%:^#?^A<T__OU_]>M#_A+_  U_T,&E_P#@9'_C
M1_PE_AK_ *&#2_\ P,C_ ,:+S\PT,_\ X5KX-_Z%S3_^_7_UZ/\ A6O@W_H7
M-/\ ^_7_ ->M#_A+_#7_ $,&E_\ @9'_ (T?\)?X:_Z&#2__  ,C_P :+S\P
MT,__ (5KX-_Z%S3_ /OU_P#7H_X5KX-_Z%S3_P#OU_\ 7K0_X2_PU_T,&E_^
M!D?^-'_"7^&O^A@TO_P,C_QHO/S#0S_^%:^#?^A<T_\ []?_ %Z/^%:^#?\
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M+_#7_0P:7_X&1_XT7GYAH9__  K7P;_T+FG_ /?K_P"O1_PK7P;_ -"YI_\
MWZ_^O6A_PE_AK_H8-+_\#(_\:/\ A+_#7_0P:7_X&1_XT7GYAH9__"M?!O\
MT+FG_P#?K_Z]'_"M?!O_ $+FG_\ ?K_Z]:'_  E_AK_H8-+_ / R/_&C_A+_
M  U_T,&E_P#@9'_C1>?F&AG_ /"M?!O_ $+FG_\ ?K_Z]'_"M?!O_0N:?_WZ
M_P#KUH?\)?X:_P"A@TO_ ,#(_P#&C_A+_#7_ $,&E_\ @9'_ (T7GYAH9_\
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M ->C_A6O@W_H7-/_ ._7_P!>NJHI<TNX604445(SXH\7_P#(ZZ[_ -A&X_\
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MCT6"TLX+6VB29## $<LX.<D=1Q7-> O!4?BV;4;B]O39:7ID'GW4ZIN;')
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MW@JTL=0OT*379G+[<_>*+C"DGTQ6HGQA:+Q=8ZVFC#RX-,_LZ6!I^9%SG<&
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MGL+/[':.Y,5OYA?RU[+N/)^M=WKE[8>*?A7HDZWEM%J^@@VLUM)*%>:'C:R
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M039&8ZNJ+YPDV^5MSVQSU]J]-_X9P;_H9E_\ S_\71_PS@W_ $,R_P#@&?\
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MD2/-\QS "-T? '4 #/45#XT\?Z7XVTNPT^'PW]CNK4+#:W#WNX1Q\ K@@#G
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M?\+?\>?]#!)_WXB_^(H^K2[A[1'UU17R+_PM_P >?]#!)_WXB_\ B*/^%O\
MCS_H8)/^_$7_ ,11]6EW#VB/KJBOD7_A;_CS_H8)/^_$7_Q%'_"W_'G_ $,$
MG_?B+_XBCZM+N'M$?75%?(O_  M_QY_T,$G_ 'XB_P#B*/\ A;_CS_H8)/\
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M^@;=_P#?EO\ "OM_ _R:,#_)H^LOL'LSX>;1-549;3KL?]L6_P *=_86K?\
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MR*"BBB@ HHHH **** "BBB@ KF?'/C*W\#Z'%JES:RW,;W"P;(B 02K'//\
MN_K735Y1^T%_R3VU_P"PE'_Z!)5TTG))BD[(SO\ AHG1_P#H"WW_ 'VG^-'_
M  T3H_\ T!;[_OM/\:^=J*[/80,N=GT3_P -$Z/_ - 6^_[[3_&C_AHG1_\
MH"WW_?:?XU\[44>P@'.SZ)_X:)T?_H"WW_?:?XT?\-$Z/_T!;[_OM/\ &OG:
MBCV$ YV?1/\ PT3H_P#T!;[_ +[3_&C_ (:)T?\ Z M]_P!]I_C7SM11[" <
M[/HG_AHG1_\ H"WW_?:?XT?\-$Z/_P! 6^_[[3_&OG:BCV$ YV?1/_#1.C_]
M 6^_[[3_ !H_X:)T?_H"WW_?:?XU\[44>P@'.SZ)_P"&B='_ .@+??\ ?:?X
MT?\ #1.C_P#0%OO^^T_QKYVHH]A .=GT3_PT3H__ $!;[_OM/\:/^&B='_Z
MM]_WVG^-?.U%'L(!SL^B?^&B='_Z M]_WVG^-'_#1.C_ /0%OO\ OM/\:^=J
M*/80#G9]$_\ #1.C_P#0%OO^^T_QH_X:)T?_ * M]_WVG^-?.U&*/80#G9]
M7G[0.D7$2J-%ON&S]]/\:G7]HC1U4#^Q;[@?WT_QKYXHH]A .=GT3_PT3H__
M $!;[_OM/\:/^&B='_Z M]_WVG^-?.U*JLWW03]*/80#G9]$?\-$Z/\ ] 6^
M_P"^T_QH_P"&B='_ .@+??\ ?:?XU\[D$'!&#24>P@'.SZ)_X:)T?_H"WW_?
M:?XT?\-$Z/\ ] 6^_P"^T_QKYVHH]A .=GT3_P -$Z/_ - 6^_[[3_&C_AHG
M1_\ H"WW_?:?XU\[44>P@'.SZ)_X:)T?_H"WW_?:?XT?\-$Z/_T!;[_OM/\
M&OG:BCV$ YV?1/\ PT3H_P#T!;[_ +[3_&C_ (:)T?\ Z M]_P!]I_C7SM11
M[" <[/HG_AHG1_\ H"WW_?:?XT?\-$Z/_P! 6^_[[3_&OG:BCV$ YV?1/_#1
M.C_] 6^_[[3_ !H_X:)T?_H"WW_?:?XU\[44>P@'.SZ)_P"&B='_ .@+??\
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MS7%O9KON)(UR(EP3D^G /Y470['9_#_Q+X)T'3R?$.B2WFHI<^;#/&N=B@#
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M_P!]BC[5;_\ />+_ +[%'//N%D<+_P *7\$?] M_^_[_ .-'_"E_!'_0+?\
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M\$?] M_^_P"_^-=U]JM_^>\7_?8H^U6__/>+_OL4<\^X61PO_"E_!'_0+?\
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M050K6\2Z!<^&=?NM)NBK/ WRR+TD4_=8?45DUV*UM#)A1110(**** "BBB@
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M$CD8/I3C-2=@<;&;1115DA1110 4444 %%%% !1110 "ONNT_P"/.'_KFO\
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MBU>]AFFA2&2,I"!NRP&.I%8B:C&OB1=2*N8A>?:-O?;OW8^N*]._X9X\1_\
M05TS\W_^)H_X9X\1_P#05TS\W_\ B:KVE.][A:1!#\5=+B^)VJ^(FT^Z?3M1
MLQ:O'E1(HPN3UQV]>]><Z])H\FK2-H,-W%I^U?+2[8-(#CG)''6O3?\ AGCQ
M'_T%=,_-_P#XFC_AGCQ'_P!!73/S?_XFE&=..S!J3/'Z*]@_X9X\1_\ 05TS
M\W_^)H_X9X\1_P#05TS\W_\ B:KVL.XN5GC]%>P?\,\>(_\ H*Z9^;__ !-'
M_#/'B/\ Z"NF?F__ ,31[6'<.5GC]%>P?\,\>(_^@KIGYO\ _$T?\,\>(_\
MH*Z9^;__ !-'M8=PY6>/T5[!_P ,\>(_^@KIGYO_ /$T?\,\>(_^@KIGYO\
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M\^,_73__  '/_P 51_POGQGZZ?\ ^ Y_^*H^KS#G1])ZM_Q[I_O_ -#5Z/\
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MT5=U>*P@U6XBTNXDN+)'VQ32+M,@'\6.P-4JU("BBB@ HHHH **** "BBB@
MKNO@Y_R5?0_]Z;_T2]<+7=?!S_DJ^A_[TW_HEZF?PL<=SZWHHHKS3H"BBB@
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M***\TZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K'\6_\B;KG_8/N/\ T6U;%8_BW_D3=<_[!]Q_Z+:FMP9\3&B@
MT5Z9S!7<?#CX?KX]N-1B;4?L7V.-'SY>[=N+#U&.E</7IOPKNXK7PYXY+W"P
MR-I?[HE]I+ 28Q[]*FHVHZ%1W,B/X=W,>F>+)[ZX-O<^'RH:'9D2YS@@]AC!
M_&N?L_"^NZA8F^L](O)[49S-'"2O'7FO:&\4Z;XG^#.O:E))%'KDEDMK>KN
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M]FF_YXO_ -\FC[+-_P \7_[Y-?</]E:?_P ^-M_WZ7_"C^RM/_Y\;;_OTO\
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M;;_OTO\ A3HM/LX9!)%:P(XZ,L8!'XXI2Q%TU8:A9EFBBBN8T"BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tmb-20211231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $^ KD# 2(  A$! Q$!_\0
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M?^5?'1ZFOL7XE_\ ).-?_P"O-_Y5\='J:[,-\+,JFXE%%%=!F%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5W2/^0Q9_]=D_F*I5
M=TC_ )#%G_UV3^8H8'W(.E% Z45Y9TA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '*?$O_ ))QK_\ UYO_ "KXZ/4U]B_$O_DG&O\ _7F_\J^.CU-=
MF&^%F53<6.-I94C099V"@>YKH9? WB"'Q7'X9DM(QJL@#+%YRX(()^]G'05B
M6'_(1MO^NJ?S%?2%]XBTU/CC::6V@:;)<LBD:F6/G+^[)X[>U:3FXO0F*3/F
MZ\LY["^GLKA,3P2-'(JG=A@<'D=:AP2< $GZ5[[H$MO_ &?XG&CQ7$WB#^VI
M6FCL+J."Y:'=\NUG4Y7KD"EM[:?4O&^MW\#7&BZ@-.B>;3=,NH&NKE]S?QE=
MJ-\J[@.>1ZTO:^0^4\!VG.,'/IBM71O#6J:_%?2Z=;K*EC 9YRT@7:@[C/7Z
M"OH5!&/B3X/O)(_*NY=+N!<-+(CR$A1@.Z@!F&3S7(_#CQ1K>JZGXJL9-7FD
MNS92+81-*%PZL=H3H 1FE[5M72#E1X_I6E7FM:K;Z;8QB2ZN'"1HS!<GZG@5
MOZ_\-O%'AC3&U'5;**&V5@A9;E'.2<#@'-:/@[^TT^,FF?VVTO\ :(O5^T&=
M@6W8[GITQ6SXCUG3=:^(G]CPZ3I>C3KK #:PGS/PY^9@?E.3SSQ5.;YK($E8
M\J*D=01]177VGPZU*_U^QT>TU+29[B\M3<J\5P71% R58A<AO;%>N>+;24?#
M[Q7;:F=0NVMBCVUQJ<\,C.=W+Q*@!1?K_C1:O&/BOX2(9 !X=P3D?W&J'5;6
M@^4^=I8FBD=&'*,5)'3(--VL,_*>.O%>NVMA/K_P?-EIGESW-GKKSSQ>:JF.
M/GYCDCCGK]:[C4+HVOBSQM/#,BR)X?C*."#A@&Z=C5.K;2PN4^:L'.,'/IB@
M EL=^E>W>!-4?5/!FH7EL][?>*I+U6NC:W<<-W)"  N&=3E1CD"N'^)TOVCQ
MJ+A]-BTZYE@C>X@2=)2'R1EB@ #$ 9%4IWE:PG'2Y(WP>\;BT-RNDQNGE^8!
M'=1LQ&,\#.37#-&ZLRLC!E)!!'0BO??&OC?2/"'B2RNXM!^UZV-,C6*\:[81
MHI!&"@X/>G_#V*^30=$U)-4U"]BN[QVN;:UFAAM[;<YW><&!9\^GO@5FJDDK
ML?*NAXG8>&]4U+1+_6+6!7LK#;]H<R %<],#J?PHN= EM?#MKK+7U@\=S(8Q
M;)-F=",\LF.!QZU[=IUS?I!\1=&\.W#17T5V);&VMY%0KG[Q0=.>_P"%82O:
M+X+\'?\ "2%3&->E-]YQ!.=S;M^/?K3]H[ARGC."!G!P>]&UO[IZ9Z5]!>-+
MBZ.B>(;>XTB>XTB1/,M+RXU*!K>/:/D-NJH"#_LY_&M"'6+G_A9N@:,;I3I=
MSH*FXMR%*2$1OC=Z]/\ .:/:Z7L'(>!?\(UJG_"-#Q#]G7^S#-Y'F^8,[_3;
MU_&LK:<9P<>N*]UT>ZUR\^%-SI_AR\E:]LM7>(Q1S*K1V^>G/\/7]:O^.$:Z
M\#ZE--/?:#%!:K#'9&:"6QNO00A<L2>/FX(_.A57>S#E/GJKND?\ABS_ .NR
M?S%4JNZ1_P ABS_Z[)_,5LR#[D'2B@=**\LZ0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#E/B7_R3C7_^O-_Y5\='J:^Q?B7_ ,DXU_\ Z\W_ )5\
M='J:[,-\+,JFXE=%+X'UV'PC'XG-HC:5)TD20%@-Q7)7J!D5SM>Y:?XGM=#\
M >"+74&672;]+FUU"'(/[MF^\1V(//YUK.35K$Q29Y'KOAO4O#L]K!J,,:27
M4"W$01P^4;ITZ'VJKIVDW>JZK;:9:PYNKF01QH_RY).!G/0>]?0]_)HUG\4;
M:%;JU-PGA\0Z7/-(I43!B%.[H&P*Q'U6?1[;P0WB;48T\31ZGB>4SJTJ6K$A
MA*ZD_*<CJ>GT-0JKML/E/%-7TB[T/4[C3KZ(1W$#E' .1GV/0UTO_"K_ !.?
M#HUW[/:?V>;?[1O^UIG9MW=/7';K6A\7UUS_ (3">34IY9=/DE=M.W3K(@3Y
M<[0"=O;TKI?^$8OS\ !;;K3SOM7]I;?M"Y\G;G/^]CMUIN;Y4^X):L\;\F3'
M^J?&-WW#T]?I4EI:2WMS'!$/FD=4S@D#)QDX[5]"P:[<Q>/_  5IL=_MTVXT
M11<P[UV.1&WWOR'6LG2!<Q>#7M_"%Q#;W<6O2?VCY4Z12>2'.W))'R8Q^OO2
M]J^P<IYQJ/P\O-*U+6;&[U72HI]*A69PTK+YVY<@1Y7)/Y5R0C=D++&Q4=2%
M) KZ!UZXA;Q#\32LT9#Z5"%(<?-\G;UK.U.;69O#GA^3P1?6<6@Q:<5OT\Z-
M8UEV_O/.0G))Y['G\*(U'U&XGB'DR%-YB?9_>VG'YUK?\(MJO_"+KXB%NITX
MS^0'# MO_P!WKCWKW[P9:&Q@T.-M3O-4TVXT_$DDE["EG%\AQ&(,99@>_7UK
ME[&]UB]^$%Y8>'M0E%]9:K(K10W*QO';<\#)'R^WUH]J^@<IXD(W9"P1BHZM
MMR!^-6=,TV;5=1MK&W #SRK$&8':I8X!.!P*^A;'48XM-T*;PUIQU#2!8B.X
MB358K>VC8C#^?$RDD]\_Y.;HCW \+: OA&>WMH8]8<ZNL%RB$)YAQN)(+)MQ
MCU&.*/:OL+E/'[SPCJ5IXR;PLOE3Z@)U@!B)V%FQCD@<<]2*9XD\-/X<U0Z=
M)?V5]<H2LJVF]O+8=5.Y1S],UWTU\]M^T>9K>Y,:2:C&CNCX#(54$$^AKH+3
M5IK_ ,2>/8;74%;Q(-T.D/-, RQ@G*1,QP#R*.=JWH%D>$>4Y<H(V+#JNTY'
MX4A4KC*D9&1D8R*^D=)NK=/''AE;ZYMF\01:1,NIR)(I;=M&T.P."W6O -9U
M>_U;56N-2O)KMXV,:-*^[:@8X4>@]JN$^9[":L=!I7PJ\7:QID6HVVF1I!,,
MP^?.D;2#L0"<XINC_"[Q1K=I/<6EI;B."X>VD$URB%9%X88-=WXS\.W?Q#DT
MC6_#NKZ>^G1V:1&*6Z$1M''7([?SX^E2>'+K0-*^%<L'B>"/5;--=:.4Q7!Z
MY \T8(+#O[UG[25KHJRN<!%\+?%4NMW&D-8P1W<$:RD2W"*K(3@%6/#<^E1>
M(_AQXB\*:>;[5;>UBAWA/W=RCMD].!S74_%%+R3XA:5>R2VT^DR"%=.DM\%!
M$"#M//WN<_0BLSXUR1R_$N\>-E=3#%\RD'M51E)M":21Y[5W2/\ D,6?_79/
MYBJ57=(_Y#%G_P!=D_F*U9!]R#I10.E%>6=(4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!RGQ+_P"2<:__ ->;_P J^.CU-?8OQ+_Y)QK_ /UYO_*O
MCH]379AOA9E4W$HHHKH,PP/0?E1@#H *** # '0 ?048'H/RHHH ,#T'Y48'
MH/RHHH ,#T'Y48'H/RHHH 3 ]!^5+@'J!^5%% !@'J!^5& >H!_"BB@ P/04
M8'3 Q110 8'H,?2BBB@ P#U /X4<>@HHH ,#T'Y4?2BB@ J[I'_(8L_^NR?S
M%4JNZ1_R&+/_ *[)_,4,#[D'2B@=**\LZ0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#*\2Z*/$7AR_P!(,_V<7<+1>;LW;<]\9&?SKQ__ (9OC_Z&
MEO\ P '_ ,<KW6BKC4E'9B<4]SPG_AF^/_H:6_\   ?_ !RC_AF^/_H:6_\
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M_P"  _\ CE>[45/MJG<?)$\)_P"&;X_^AI;_ , !_P#'*/\ AF^/_H:6_P#
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MX"_Z#+_^ <W_ ,31_P +J\!?]!E__ .;_P")J_9S["YD>@45Y_\ \+J\!?\
M09?_ , YO_B:/^%U> O^@R__ (!S?_$T>SGV#F1Z!17G_P#PNKP%_P!!E_\
MP#F_^)H_X75X"_Z#+_\ @'-_\31[.?8.9'H%%>?_ /"ZO 7_ $&7_P# .;_X
MFC_A=7@+_H,O_P" <W_Q-'LY]@YD>@4C?=-<!_PNKP%_T&7_ / .;_XFL[7?
MBG\.M?T.\TJZUF3R;F(QDBSFRI[,/EZ@X/X4*G+L',@\!>!_#VM>"-+U'4+&
M2>[GB+2RFZE!8[FYX;%=)_PK/PC_ - IO_ N;_XNO.?AGXW\">"O"PL[C6B]
M_-(9+EUM9B,]% ^7H!^I-=G_ ,+J\!?]!E__  #F_P#B:N2J<SM<E<MC3_X5
MGX1_Z!3?^!<W_P 71_PK/PC_ - IO_ N;_XNLS_A=7@+_H,O_P" <W_Q-'_"
MZO 7_09?_P  YO\ XFE:IYC]TT_^%9^$?^@4W_@7-_\ %T?\*S\(_P#0*;_P
M+F_^+K,_X75X"_Z#+_\ @'-_\31_PNKP%_T&7_\  .;_ .)HM4\P]TT_^%9^
M$?\ H%-_X%S?_%T?\*S\(_\ 0*;_ ,"YO_BZS/\ A=7@+_H,O_X!S?\ Q-'_
M  NKP%_T&7_\ YO_ (FBU3S#W33_ .%9^$?^@4W_ (%S?_%T?\*S\(_] IO_
M  +F_P#BZS/^%U> O^@R_P#X!S?_ !-'_"ZO 7_09?\ \ YO_B:+5/,/=-/_
M (5GX1_Z!3?^!<W_ ,71_P *S\(_] IO_ N;_P"+KH-)U6SUO2[?4K"4RVMP
MN^-RI7(SCH>1TJ[4<TNX[(Y+_A6?A'_H%-_X%S?_ !='_"L_"/\ T"F_\"YO
M_BZZVBCGEW"R.2_X5GX1_P"@4W_@7-_\71_PK/PC_P! IO\ P+F_^+KK:*.>
M7<+(Y+_A6?A'_H%-_P"!<W_Q='_"L_"/_0*;_P "YO\ XNNMHHYY=PLCDO\
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M&_\ GA>_^#"?_P"+I_\ PLKP9_T,FG?]_:/^%E>#/^ADT[_O[5?O/,7NC/\
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M* "BBB@ HHHH ^#J***]0Y@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "E'44E*.HH ^P?A=_R370O^O;_V9JZ^N0^%W_)-="_Z]O\ V9JZ^O-G
M\3.A;!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KQS]H@X\)Z7_P!?W_M-J]CKQS]HG_D4]+_Z_O\ VFU:4OC1,MCYRR?4
MT9/J:2BO0,!<GU-&3ZFDHH 7)]31D^II** %R?4T9/J:2B@!<GU-&3ZFDHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@#Q[_AG?P[_ -!;5?SC_P#B:/\
MAG?P[_T%M5_./_XFO8:*T]K/N3RH\>_X9W\._P#06U7\X_\ XFC_ (9W\._]
M!;5?SC_^)KV&BCVL^X<J/'O^&=_#O_06U7\X_P#XFC_AG?P[_P!!;5?SC_\
MB:]AHH]K/N'*CQ[_ (9W\._]!;5?SC_^)H_X9W\._P#06U7\X_\ XFO8:*/:
MS[ARH\>_X9W\._\ 06U7\X__ (FD/[/'AT G^UM4_./_ .)KV*D;[I^E'M9]
MPY4>!^#_ ():'XB\)Z?JUQJ6HQS7,9=DC\O:/F(XRN>U;G_#._AW_H+:K^<?
M_P 379?"[_DFVB?]<#_Z&U=?52JS4GJ)15CQ[_AG?P[_ -!;5?SC_P#B:/\
MAG?P[_T%M5_./_XFO8:*GVL^X^5'CW_#._AW_H+:K^<?_P 31_PSOX=_Z"VJ
M_G'_ /$U[#11[6?<.5'CW_#._AW_ *"VJ_G'_P#$T?\ #._AW_H+:K^<?_Q-
M>PT4>UGW#E1X]_PSOX=_Z"VJ_G'_ /$T?\,[^'?^@MJOYQ__ !->PT4>UGW#
ME1F>'M$@\.Z#9Z1;2R2PVJ;%>3&XC)/.,#O6G116;=R@HHHH **** "BBB@
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M ,"T_P ::4D[I [,\L_X9N7_ *&H_P#@!_\ ;*/^&;E_Z&H_^ '_ -LKU/\
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M_P# M/\ &CVE4.6)Y9_PS<O_ $-1_P# #_[91_PS<O\ T-1_\ /_ +97J?\
MPL'P?_T,VD_^!:?XT?\ "P?!_P#T,VD_^!:?XT>TJARQ/+/^&;E_Z&H_^ '_
M -LH_P"&;E_Z&H_^ '_VRO4_^%@^#_\ H9M)_P# M/\ &C_A8/@__H9M)_\
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M_P! [1O^_4O_ ,<J/J\Q\Z/I6BOFK_AH?Q5_T#M&_P"_4O\ \<H_X:'\5?\
M0.T;_OU+_P#'*/J\PYT?2M%?-7_#0_BK_H':-_WZE_\ CE'_  T/XJ_Z!VC?
M]^I?_CE'U>8<Z/I6BOFK_AH?Q5_T#M&_[]2__'*/^&A_%7_0.T;_ +]2_P#Q
MRCZO,.='TK17S5_PT/XJ_P"@=HW_ 'ZE_P#CE'_#0_BK_H':-_WZE_\ CE'U
M>8<Z/(Z***[C$**** "BBE7[P^M &B_AW6XK=KB31M12%%+M(UI(%51SDG&
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M]!/1O^_LO_QNCVL.X<K/(J*]=_X9X\4_]!/1O^_LO_QNC_AGCQ3_ -!/1O\
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M9N)S;K;F:0P*V\1[SM#>N.F?>O6/^&>/%/\ T$]&_P"_LO\ \;H_X9X\4_\
M03T;_O[+_P#&Z/:P[ARR/*KF_O+Q8UNKN><1C:@EE9]@]!D\?A5>O7?^&>/%
M/_03T;_O[+_\;H_X9X\4_P#03T;_ +^R_P#QNCVL.X<K/(J*]=_X9X\4_P#0
M3T;_ +^R_P#QNC_AGCQ3_P!!/1O^_LO_ ,;I^UAW#E9Y%7=?![_DIND_[S_^
M@&NC_P"&>/%/_03T;_O[+_\ &ZZ3P)\&-?\ "WC"QU>\OM,D@@+%EA>0L<J1
MQE ._K43JP<6KC47<]?UW_D 7_\ U[O_ .@FOB ]:^YM2MGO-,N;:,J'EB9
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M=9?5O_036&*P.&C0G*,%=)DSIQ47H>UT445\6<(4444 %%%% !1110 4444
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M -I_U]#_ -!:O*J]5^*'_(!M/^OH?^@M7E5?99+_ +HO5G=0^ ****]4V"E
M+$  DGH ,DTE:/A__D8M.Q_S\)_.IG+EBY=A/1%%X98AF2*1 >,NA'\Z3RWV
M;]C;,XW;3C\Z]1\1QS7&DZ]"PO4 E1T:] ,;?[,/<9_&D%E:'1SX3^U0_:A9
M[S#L;?YWW\YQC]<UYD<SO!2<>NODK)M[=+F2JZ;'F*P3,F]8)2O]X1DC\\4U
M$>1ML:,YZX523^E>I:*3'I?AJ)M0FM9 )<6PX6X(/W&.<#\JR5&H?V#J8TJW
MDMM6.H%KB&#B58ST QSC/I5+,&Y-<O6V_FUV\NGH'M#@MC;]FUM^<;<<Y^E/
M^SS[]GD2[L9V^6<_EBO2/-DAUNWD^Q?;-173MMZMNZB9&)'S+ZL/SK,\1RW>
MG'2YK?5=21Y"W[FZ?%Q&I(R"1R5..AIPQ[G)14=_/U\OS&JEW8XLVUP,9MYA
MG@9C;G]*3[/.&V^1+NQG'EG./RKMO$UYJK^.8[2TN;PA3$R0QNW!QR0![9K;
M$]W:^.=7N)EF:*.R+PB3.T@8SM]LTGCY*"ERK6-]_3R\Q>T=KV/+!&[*6",5
M'5@I('U-7;O2S;:?#?1W,<\$LC1 JK*=P )X8<CGK7</>Z7-X4UR'2 3!Y?G
MR,5(P[GE?H ,5PU_JL^H10131VZ+ NV,11[=H].N*VHUZE:6D>5)ZW]"HR<B
MC1117::!1110!UGP[_Y&N/\ ZY/_ "KI_BA_R!;/_KY_]E-<Q\._^1KC_P"N
M3_RKI_BA_P @6S_Z^?\ V4U\_B?^1I3]/\SFG_&1Y91117T!TA1110 H!8@*
M"2>@ R33GAEB ,D4B ]W0C^=:/AS/_"2:=C_ )^$Z?6N]\1Q37.CZU PO4 G
M5HVO0"C_ .S#W%<6(QGL:L:=M_\ .QG*=G8\P\M]F_8^SINVG'YTX03,F\02
ME>NX1DC\\5Z<]G:2:._A1;J$W,=H'\D(V\2_>)SC'ZYI^D$IIWAR,W\UO((Y
M"+4<+<$'[C'.!^5<TLSM&ZCU\]K-I[=;?\$GVNFQY8B/(<1HSGKA5)/Z4FQB
M^P*V_.-N.<_2N\0:C_PC]\ND026VJ?;V:YA@XE1#T QSCZ5H>:\.N)(MD;R_
M&GA;T6SJ)D8D?,OJWZUI+'M7M'OU[6_!]&/VAYM]GGW[/(EW8SM\LY_+%*;:
MX! -O,,],QMS^E=IXAEN].GTJ6WU745:4D>3<OB>-21PQ')!QT-.\0WFJR>/
M4M+6YO&57C988W; X^8@#VSFJAC)2LTE9IO?MIV!3;.(^SSAMI@EW8SCRSG'
MY4U8W92P1M@ZL%) ^IKU))[NT\9ZU<3K,T<=F7A$F=I48SCVS5&6\TN7PAK4
M.D FW51,[,I'SN<E?H ,5FLQD[>YORZWTU%[5]CB+S3#:V,%XES'/!,[1JRJ
MRG(Z\,.1SUJA5Z_U6?48X4FC@585VQ^5'MP/3&<51KT*?/R^_N:J_4****T&
M%=%X'_Y&ZR^K?^@FN=KHO __ "-UE]6_]!-<V,_W>?H_R(G\+/:Z***^!/."
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YRHHHK]
M'/4"BBB@ IPDD4861U'H&(IM% "[FV[=S;<YQGC-+YC@8#O@#'WCTIM%%A"[
MFV;-S;?[N>/RH9V8 ,[,!TR2<4E% QQ=RNTNQ7T+''Y4FYMNW<=OIGBDHHL
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M*R?]^!_C1_PJR'_H*R?]^!_C7H5%']JXS^?\%_D'MI]SSW_A5D/_ $%9/^_
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M_P#Q5']F8O\ Y]L/K='^9'<45P__  M30?\ GA?_ /?I?_BJ/^%J:#_SPO\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YC\7.NE?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tmb-20211231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &+ M,# 2(  A$! Q$!_\0
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M_47_ ,17%T4<D>P<S.T_X6WX[_Z&.X_[]1?_ !%'_"V_'?\ T,=Q_P!^HO\
MXBN+HHY(]@YF=I_PMOQW_P!#'<?]^HO_ (BC_A;?CO\ Z&.X_P"_47_Q%<71
M1R1[!S,[BW^+/CI[B-6\13D%@"/*B]?]VOJD 2QQN^2S(I)S[5\1VO\ Q]0_
M[Z_SK[=B_P"/>'_KFO\ *N;$12M8T@VQ/*3T/YFCRD]#^9I]%<QH,\I/0_F:
M/*3T/YFGT4 ,\I/0_F:/*3T/YFGT4 ,\I/0_F:/*3T/YFGT4 ,\I/0_F:/*3
MT/YFGT4 ,\I/0_F:/*3T/YFGT4 ,\I/0_F:/*3T/YFGT4 ,\I/0_F:/*3T/Y
MFGT4 ,\I/0_F:/*3T/YFGT4 ,\I/0_F:/*3T/YFGT4 ,\I/0_F:/*3T/YFGT
M4 ,\I/0_F:/*3T/YFGT4 ,\I/0_F:/*3T/YFGT4 ,\I/0_F:/*3T/YFGT4 ,
M\I/0_F:/*3T/YFGT4 ,\I/0_F:<L$3(Q*Y(Z<FEJ1/\ 5O0!7\B/^Z?S-'D1
M_P!T_F:DHH C\B/^Z?S-'D1_W3^9J2B@"/R(_P"Z?S-'D1_W3^9J2B@"/R(_
M[I_,T>1'_=/YFI** (_(C_NG\S1Y$?\ =/YFI** (_(C_NG\S1Y$?]T_F:DH
MH C\B/\ NG\S1Y$?]T_F:DHH C\B/^Z?S-'D1_W3^9J2B@"/R(_[I_,T>1'_
M '3^9J2B@"/R(_[I_,T>1'_=/YFI** (_(C_ +I_,T>1'_=/YFI** (_(C_N
MG\S1Y$?]T_F:DHH C\B/^Z?S-'D1_P!T_F:DHH C\B/^Z?S-'D1_W3^9J2B@
M"/R(_P"Z?S-'D1_W3^9J2B@"/R(_[I_,T>1'_=/YFI** 'VW%NH^O\Z*+?\
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M\$^(HI;%[33;J[U&"PCM_M'^C7%M(1U5TEY4#ID9S24(]PNST@>-=#;Q+)H
MO(Q>)$) S2H(W)Z*IW<M[8J?3?$,-S8"XU"2PLF:9H45;^.57(]&&!G_ &>H
MKC+3PYJ>G^.[?4KGP[!=0SZ?' \MHL02WF'5L'! ]Q63'X'U>XT#1;"]T=I$
MBUN6XN8GVD"%C]X\\@T^6/<+L]576M*9(G75+$K*^R,BY3#MZ#GD^U9]UXD-
MAXKM-%N[/RXKU";:[$F0[CJA7'!_$UY?=_#2Z73]>-KX<1;HZG')IY0*"L(/
M.SG@>U=CXL/VWQ5X0TJ'YKR*X^U2@')CC5<$G\:7+&^@[LZ+3?$)U#Q%J>D-
M82VYL51O,D=3YH;N ,X'U/X"MNLFT\.V%EK=QJ\+79O+@;93)=.ZL.PVDXX[
M>E:U0[=!A1112 **** "I$_U;U'4B?ZMZ (Z*** "BBB@ HHHH **** .6U[
MQF='\16FAVVBWFI7MU"9D6WEC3@'G[Y%5M:\=76A)IWVOPMJ/F7S>6D8GARL
MG]P_-C/OTK/\4>#G\1?$C2;F]TPW6CQ6CI,Y?:H?/ X(-0^-]%OH_P#A';'P
M_P"';NYL]-N5N"8'3:JC^$;VSFM4HZ"U-V^\>6&CZPVG:S:SZ=_HIN8YYG4I
M( .4!'\0Z8K7\/ZR=>T:'4OL,]G'-EHXYR-Q7LW'3-<+XZ\,Z[X]U"*T6S.G
MV%C 9XYYU1FFN".$')P!T-;]AI.I>(M L&UF;6=#O[=/+EAL+L0JY'&[Y<@@
M]J34;(+LTX/$T%QXNO/#JVTPGM;=9VE)&U@>P'7-<_)\4;)= CU6/2KR027Q
ML4@5T#%P<9R3C!-4I_ 4>K_$B^N]8TR2[TO[%''!/+*?FD P<E6!)^M<R/ 6
MN-X%L]);1I<KK1F>#>O$&[KG=TQ[YJE& KL] U+QO<Z-H9U+4_#.H6I-PD$=
MNT\+/(6Z$%6( SQS6QH^K7VH),^H:%=Z2B ,K7,T3AQWQL8XQ[U@ZSX1TC3_
M  \MA8>$VU*S>X66:SANBC9 ^\"[<_3(KE(O _B&X\.^)+:RM)=*L[UD-EI5
MS=[R IRP)!(7=Z9J;1:#4]5L]4T_4=_V&_M;KRSA_(G63:??:3BLRX\2;?%U
MOX>M+,W$QA\^YE,FU;=.W8Y)].*H^$+;R96)\&C062W2)I2T692.P"'D#KD\
M\U1TYUT[XP:Q%=85M2LX9;5C_&$X91[CTI65V.Y:N/'\1U*^M-*T/5-72P.V
M[GM%39&>X&Y@7(]!4E[X[@CU5-*TS2-1U74/)6>6"W")Y*$9&\N0 ?:L/1K'
MQ)X*OM:M;7P_)J]M>W+7-K<07$:!2W\,FX@C'J,T]-.\0^'?&^H:]#HCZI;:
MK!'YT5K,@D@E4<CYR 5]ZKEB*[+][\2]-T_4-%M+S3[ZW;51\IG"H8#NVX<9
M]?2KEGX\T^_\<W7A6V@E>YMHRSW&X>7D8ROKWKFO$7A76/&.OZ3/J6F?9(FL
M)8YG219!;2$Y3G/)'!XH\,>!+_PUX^LIPDEU:IIK)<7YP/-G9LG()SFBT+>8
M79UFD>*)]6CU6W72S'JVG3>5)9&<8;/W6#X^Z1SG%6?#6OMX@L[F9[06[V]P
M]N^R42QN5."4< ;A^%<OHEI!XB\;>,+A6D.FRK%9-)#*4\QT'SX9>?;BNQT;
M1+/0;(6=B;C[.OW4FG:78/1=QX'L*F22&KFC1114#"BBB@ HHHH **** 'V_
M^H7\?YT46_\ J%_'^=% 'Q/KG_(P:E_U]2_^AFJ%;6MZ7J#:_J)6PNR#=2D$
M0.<_,?:J/]DZC_T#[S_P'?\ PKTTU8Y[,IT5<_LG4?\ H'WG_@._^%']DZC_
M - ^\_\  =_\*=T%F4Z*N?V3J/\ T#[S_P !W_PH_LG4?^@?>?\ @._^%%T%
MF4Z*N?V3J/\ T#[S_P !W_PH_LG4?^@?>?\ @._^%%T%F4Z*N?V3J/\ T#[S
M_P !W_PH_LG4?^@?>?\ @._^%%T%F4Z*N?V3J/\ T#[S_P !W_PH_LG4?^@?
M>?\ @._^%%T%F4Z*N?V3J/\ T#[S_P !W_PH_LG4?^@?>?\ @._^%%T%F4Z*
MN?V3J/\ T#[S_P !W_PH_LG4?^@?>?\ @._^%%T%F4Z*N?V3J/\ T#[S_P !
MW_PH_LG4?^@?>?\ @._^%%T%F4Z*N?V3J/\ T#[S_P !W_PH_LG4?^@?>?\
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M>?\ 0<_\EHO_ (FC_A<OCS_H.?\ DM%_\37!T4>SCV#F9WG_  N7QY_T'/\
MR6B_^)H_X7+X\_Z#G_DM%_\ $UP=%'LX]@YF=Y_PN7QY_P!!S_R6B_\ B:/^
M%R^//^@Y_P"2T7_Q-<'11[./8.9G>?\ "Y?'G_0<_P#):+_XFC_A<OCS_H.?
M^2T7_P 37!T4>SCV#F9WG_"Y?'G_ $'/_):+_P")H_X7+X\_Z#G_ )+1?_$U
MP=%'LX]@YF=Y_P +E\>?]!S_ ,EHO_B:/^%R^//^@Y_Y+1?_ !-<'11[./8.
M9G>?\+E\>?\ 0<_\EHO_ (FC_A<OCS_H.?\ DM%_\37!T4>SCV#F9WG_  N7
MQY_T'/\ R6B_^)H_X7+X\_Z#G_DM%_\ $UP=%'LX]@YF>@0?&/QV]Q&K:YD%
M@#_HT7K_ +M?4L<TC0QL6Y**3QWQ7P_:_P#'U#_OK_.OMV+_ (]X?^N:_P J
MYL1%*UD:0;9+YK_WOTH\U_[WZ4RBN8T'^:_][]*/-?\ O?I3** '^:_][]*/
M-?\ O?I3** '^:_][]*/-?\ O?I3** '^:_][]*/-?\ O?I3** %-SM8*TBA
MFZ D GZ"C[3\^SS%WXSMR,_E7GOB\@?$_P &,V  \O)^@J+XC.NA:MH/C*+!
M6QG\BZ*\YB?Z>_\ .K4+V\Q7/1FO$3=NGB7;][+J,?7TI!?1LI87,)"]2)%(
M'UYKP;5+1[WX8:UXCG16FUG4DD3>/^62OA ?:MK7= DTCX8:Z\VF>'K1I;>/
M:=)5P6&1]_=_2J]GYBN>P)>+*2(YXG([(ZM_*G^<_P#>KSCP;H]]X?T%M5C\
M.Z&TS6*-"FE*R7$_ .'+C&3[=ZBT#Q/J7B36XXM4UVWT*:.3/]B) 4GDQV:2
M4#</]P5/)O8=STHW05PC2H'/12P!/X4U[U(FVR7$2-Z.ZJ?UKR+XG:'IJV-U
MK-C!H[;9E:]N?.8WBN"/EB.< X[&G^)M!;4]6A\0PPZ%?6UKI2;[/6)3YF,9
MR0!P<=S34$^H7/6_M8"!S-'L/1MPP?QIQN"I +@%N@)'/TKR"ZTB?QAX;\/Z
MII/ANUET\6TL?]E-.(DA=N!(N>" >?6JMIJFJV5WI4J+;7D]O_Q*K&6[D80B
M0+F60D<G^Z*/9^8KGM7G/_>_2CS7_O?I6%X4UQ_$7AZWU&2!897+(Z(VY=RG
M!VGN*VJAJVA0_P U_P"]^E'FO_>_2F44@'^:_P#>_2CS7_O?I3** '^:_P#>
M_2CS7_O?I3** '^:_P#>_2CS7_O?I3** '^:_P#>_2GK(Q1B3R*AJ1/]6] "
M>:_][]*/-?\ O?I3** '^:_][]*/-?\ O?I3** '^:_][]*/-?\ O?I3** '
M^:_][]*/-?\ O?I3** '^:_][]*/.?\ O?I3*4=1]: !;G>2%E5BIP=I!Q]:
M%N@REUE0J.K!@0/QKSGX;,B:YXQW%5)U4\$@9XKC]>N;CPUJ7B+P9:!A_;=Q
M&]EM7A5D/S_E6BIW=A7/<S?Q+C-U",C(S(HR/SI6OHU +7,(#<@F11GZ5XKK
M7AG/Q)TW1[.PT>Z6WT=56/558PC'?Y><U)XLT*2;QKX3TN#3-#DD6Q<?9I4<
MV@()S@ ;L>E'(NXKGLYO%$8D,\80]&WC'Y]*5[H1J&>9$4]"S  _B:\[U_3/
M#.B>%+1_$FCZ9)<PQM%;6-FK&-Y&[1H><Y[D<5@_\(5JEW\.M#T:ZN=.2[%\
M;D6VH3$H$Y(BXR6P" 0*%!=QW/88[L2@F.9'QUV,&Q^5/\YQ_%7F7@W5I+6W
MUJSTKPCIHU&QN5BFCTJX6*&?C[P=QU'H:D\8>)+]]-M-*O\ 3;_2?MRNUX]N
MC71CB&1L#1 C<WKV%+D=[!<]&^V((_,\^+9TW;UQ^?2A+Q9<^7/&^.NU@<?E
M7A?A[34\3?"*UT2SFM89H]2SC4-T<;X9FV@X^8D=A[UK:;9OJFF>*O"NGZ+H
M^FZM D:O<:8Y6&X&<[2V,@X!'XTW3MU%<]?%UE-XE0H/X@PQ^=.$SD9# @]Q
M7ASV-]H]OJ&E3:8FGVES_P 3"YTVWN!(([>)1E21P#(X[=@:[KP9XLOM9OI=
M.U"SL862TBNH6LI6=1&_16W=&&.W%)PLKH=SM_-?^]^E'FO_ 'OTIE%0,?YK
M_P![]*/-?^]^E,HH ?YK_P![]*/-?^]^E,HH ?YK_P![]*/-?^]^E,HH ?YK
M_P![]*/-?^]^E,HH DMS^X7\?YT4EO\ ZA?Q_G10!\3ZY_R,&I?]?4O_ *&:
MH5?US_D8-2_Z^I?_ $,U0KU%L<P4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $MK_P ?4/\ OK_.OMV+_CWA_P"N:_RKXBM?
M^/J'_?7^=?;L7_'O#_US7^5<N)Z&M,=130ZLS*K*2O# $$CZ^E8,OBE(/& T
M&:T*1O&I2[\SY3(V2$*XX)"G!S7,DV:'045S=KXNCD:S>ZM?LUK=/-$MP9,J
MLD;$;3P/O!20?PI^G>)VO[ZP@^P/%%?I-+!(TG)C3&&*XXW9R!Z8]:?*Q7.A
MHK&;Q#%''K4DT)1-+;:QW?ZSY WIQUQ3_#FMG7M)%W):-9SJ[1S6S/N,3#L3
M@9X(/XTK/<+FM16)/K%\GB==(BT^!XFMFN!.UT5. 0,;=A[D=ZH1>,)E\,R:
MS>Z:L.)7C6&&X\TL5)&>54GD= "<4^5A<ZJBN<_X2Z#_ (1D:T;639T\H.I?
M.,_=SG.?X?O>U:&@ZPFNZ7'>QQ-$&QE&89!P"<CJOT/-*S07$U?PUHFOF(ZO
MI=M>F+/EF=-VW/7%-C\,:%%HSZ/'I-HNFN=S6H3Y"?7%32Z[I,.IIILNHVR7
MKXVP-(-Q)Z#ZGTHCUW2I=0_L^/4+=[S<4,"OE@0,D$=OQI^\ EQH&D7>D)I-
MQIUO)IR !;9D^0 =.*I6_@KPQ:6MQ:V^A6,4%RH6:-8\"0#H#S4NHZQ>6>NZ
M=IT%A#-'>;LS/<E"FT9/R[#GCW%9<GBS4XM)U:^.C6Q_L^X,.P7Q_>8QDY\O
MCJ.*$I!H=5##%;P1P0HJ11J$1%'"@= *BNK"SO6B:ZM89VA8/$TD88HPZ%2>
MA^E/ADD:U22X1(I"@9U5]P4]^<#/Y5SR^*IFTU+Q+ 2?:[K[/I\0DVF;G&YF
M(PHR">AX%))@6YO!WAJYU,ZE/H.GR7I;>9F@!8MZGU-/U/PIX?UFZ2ZU+1;&
M[N$ "R30@M@=!GTJ&VUZ^NH;R%-(']J6CJDEK]J&PAN0PD*_=_X#GVJJ/%DZ
MVUTDNE@:C!=1VOD)<AHW=_NXDV\#U^7(]*JT@T.D6")(! D:)"%V!%& !Z #
MI6?/X;T2ZTI-+N-*M);!#E+=XP44]<@>M5=.\2_VB]I EFRW4KR+-'YFX0A#
MAFW8^89P!P.M6]0U.33]3L8I84-I=/Y/FY.Z.3^$$=,'I]:5F@+MK:6]C:QV
MMI!'!!$-J1QKM51Z 5-114C"BBB@ HHHH **** "BBB@ J1/]6]1U(G^K>@"
M.BFLZH,NRJ,XRQ JCKNIMHVBW6H+;_:&@7<(M^W><X S@XZT;@:%%<Y!XK%Y
M;:8]K9%Y;Y9!Y32;3%(@R4/'7/%-A\80W<5H+2T:6XECDDGA+X-L$!W;CCKD
M8 [U7*Q7.EHK"_X20?\ ".V&K?9#B[>-/*W_ '-YQUQSBF7OBA+/Q5;:*;1G
MCE $ET'PL3MDJI&.<@'O2Y6%SH**IZM>3:?I5U>00)/)!&9/+>38& &3\V#C
M\JQ4\2:DTVB(=)MA_::%B?MI/E8&?^>?S<'VH2;'<Z:BL;0]8O-5N-0CN;"*
MV6TG, 9+@R;R.IQM&/UJ6YU61-=M],MXD<F(SW,CD@11C@8QU).?RHLPN4Y_
M OA6YOGO9] L)+IW\QI6C^8MUSUZUH7&A:5=ZE;:C<:?;RWML,03NF7C'L:R
M;3Q9+</9SRZ6T.F7TODV]T9PS%N<%X\?*#@XY/O5ZTU];OQ+=:,+*YB:WA$I
MFF7:LF21\H[CCK3?,+035?"7A[7;H7.JZ/9WDZKM$DR9('I4T'AW1K6:SE@T
MRVCDLD,=LRI@Q*>H7T%9-KXS26:1KFQ-O9F*66";S@S2",X(*X&TDXQR>M;9
MN+Z31?M4-HBWC1>8EO(YQGKM+ 4/F6C#0KZOX9T/7Y(WU;2K6]>(;4,R;BH]
M!4 \%>&!IO\ 9W]@V!L]_F>28<J&]?8UHZ5J,>K:9;WT0*K,N=IZJ>X_ U'#
MKVDW&I/IT.I6TEZF=T"R L,=?R[^E%Y;!H2:;I6GZ/:"UTVRM[.W!SY<"!1G
MUXZU</S*5.=I&",]:S[+7=*U*X:"QU"WN957<5B?=@9QS6;J/B'4++6;NRBT
MF*>."S-V)!=89P,_+MV=>#WI6;8%Q_"^@R:2-*DTBS>P#F06[1Y0,>20#T/-
M6-+T;3-$MOLVEV%O9PDY*01A03ZGUJI)XAA\C2)+:(SMJ;@1*&QM7;N9CQV'
M\ZJ:=XP@U#Q!-I*VLB-'C$C,NUN.<-G#?\!S[XIVE8-#:73;);NXNA:Q>?<H
M$FD*Y,B@8 /J/:H-*T#2-#$HTK3;6R$K;I/(C"[C[UHT4KL84444@"BBB@ H
MHHH **** "BBB@!]O_J%_'^=%%O_ *A?Q_G10!\3ZY_R,&I?]?4O_H9JA5_7
M/^1@U+_KZE_]#-4*]1;',%%%% #XHGGF2*-=TCL%51W). *Z34_AYXKT:PFO
MM1T>2WMH0#([2QG:,XZ!B>_I6)I/_(9L?^OB/_T(5Z]\8-(O9-6UG4$\'0&U
M_=-_;@F;?@!0?EW[?]G[M1*34DBDKH\UO/!FL:??W%C=K:07$%L+IUDNXUS&
M>1M)/S'_ &1S7/Y'J*]^UBTLKWQGXI-U;VUP8O"BR1>:BOL<+P5ST/N.:O>%
MM#L7/AJ/3]%T>ZT"72FENKN2"*25KK9R"S?-D'L/?TJ/:V5V/E/#;'PKJ>I'
M35M!:RR:C(8[>,74>_<,_>7.4Z'KBL]M/N$U5M-?RTN5G,#!I %5PVWECP!G
MOTKV'PM:64-K\-[J*VMTN)=1N1+*J*'<!FQN/4X]ZMZ[ID L(F\0:1I=G?OX
MB1=/$4,:R3VYD&XN%SN4C/+4>UUL'+H>2MX2U9;/5;M8[>2WTID6ZDBN4=5+
M_=VD'YOPJ.;PQJT5R]O%;K=O';_:I/L<JSB./^\Q0D#'?/2O5-7@MK31?BG;
MVT4,,"W-J(XHE"J!D= .*W=-,.G>.-1TW2[33HY+KPS&\,(@C'FS 'CT.<\C
MO@9Z4>U8^4^=LCU%.1&D=412S,<*%&23[5[AX4T_2]<TJ2\\16-C::AX8OI)
M[^);:-!+$5+!2JC! 88QTP,5YWX0UNQC^)UAK&HI#;VC7IE8*@5(<D[>!P N
M1^56IWOIL3RE/4? GBG2-,.I:AHEU;VB@%I'"_(#TW '*_B!61ING3:K?)9V
M[P+*X)!GG6).!GEF( Z5Z#XI\*^);;Q'K6MW$R?V5<S[OM/VI2EW$SC:B@$E
MN,<8P,5UU_+IDWQLM_#0T'1(].A?S2T=F@:0F \,>A'/3'4"I]H[#Y3Q*?2;
M^VLOMLMK(+,S&!;@#,;..JANA/%4J]K,]U>?"%K>QM;*:"TU2>.\"V\3-!;\
MY?!Y#8/##FMOQ%HGAR/P[?QV'A_[1I'V'=:7T,5JL4;!<A_.W^:6SU!'/I1[
M7N'*?/\ 9VSWMY#:Q-$))7"*9) B@GU8\ >YI;VUDL+R6UF:(R1-M8Q2*ZD^
MS X/X5[%K5S86WB#P;H46AZ,+>^MK&:YG^R+YK'(R"W3![\<YYK2T+0+4ZWX
MFN8;>QF@AU7ROL4.G6\TJIZYE8*D?/;T-'M>H<IX)177_%#3K'2OB'JMIIUO
M';VJLC)'%]U<H"<>G-<A6B=U<EJP4444Q$MK_P ?4/\ OK_.OMV+_CWA_P"N
M:_RKXBM?^/J'_?7^=?;L7_'O#_US7^5<N)Z&M,R-(\,:9HFJ:GJ-DDHN-1D$
MEP7E+#(]!VK/U+PY<:EJ6LR-B-;BW@^RS!AE)8RQ!QU&"174T5S<SW+L<,?#
M>J7GPT.DWUG VI/(TKQ"12@8R[LANE:FM>&H=8\1:5+=6%O<Z=;0S*Z2@$*Q
M "X7\/PKI<'T-%/G86.#F\(7BQW^EZ=!%8:;>:A'*SP[/DB503A3D9+#&".]
M;.AZ-J.D:]J+S7;WMI>HDIFD6-&69>"-J #E>^.U='10Y-A8YRXAU(>-H[V/
M3'DLTLG@\X3QC+%@WW2<]L?C3_"=G>6^@FTU/3S;2>=*WEO*D@978MU4D=#B
MN@HI<VE@L,$,8B\H1KY>W;MQQC&,?E2HB1(J(H55   &  .@IU%(9Q%YH6KN
MNHZ5%9126]]>BZ&H-,H\M?ER"GWBPV\8X]Q6_H&GW&GMJAGC5#<WKS(5(.Y"
M  3CZ'K6Q15.3:L*QSVK0:@_BG1KFWTYY[6V\SS91-&NW<N/NL<G\*Q)].UR
M7P]X@M!HDGG7EV98%-W#\RG'.=W'W>_K7>44*5@L5@LEQINQXC#+)%M*,P)0
MD8QD<'\*Y:P@AU/P3%8R:>]W=6#^2]O%.(98Y4/#*Y(VG&"#D=:[*D"J&+!5
M!;J0.3]:2=@L<EI&CZCHUIJ%Z+#[5=WLJE[26_+L(P,8,KY#-R?0>]/T3PV#
M::E;ZAID5IIMU*KPZ:)=XAQU;*G"DGGY3QCK75T4^9A8X&^\(3FTWPZ9%-&+
MC!TX3A08 #M&XG!.X[CD\U<FMKB'2?#V@SN)-0,Z2. ^XHB$L23W &!FNRI-
MJ[]^T;L8W8YQ]:?.^H6%/)HHHJ!A1110 4444 %%%% !1110 5(G^K>HZD3_
M %;T 8GB'PUIOBBSAM=325HHIEF3RY"AW#I^%+XBT^:_\.75C:(&E=55%+8Z
M,.Y]A6M13NP./_X1R_MO&]E?VJH=,*M+.I< QS%0N0.X..U7++0Y;75O$ETM
MM$GV_'E.I&7^3!SZ<^M=)13YF*QP47@.WM_#^E>3H]G'J\$T3S2J%#<-ECN[
MT77A'6K^VU*]?4I(+VXN?M,=HJ1,F4/[L%R-PX'8]Z[VBGSL+(R]66\N/#5U
M'':&6\FMBGDK(J_.RX/S$XX)K"CM-9%QX88Z-(%LHV6Y/VF+]V2H7^]\W3/%
M=C1TZTE*P6.>\-6^H6]UJYO=/:U2>\:>)C,C[E/^Z3C\:"ZV/CH^?A4U"T5(
M7/0NA.5^N#G%=#2,BMC<JG!R,C.#1<+'%1>%7FUVV:/3IM/T^TN3<;7U R([
M<X\N(,50'.3G'TJ_''JH\=RWK:/(MD]LMN+C[1%U#$[MN[=CGTS73T4<S"QR
M]]X3M9-422RLHK=)"TMS.&/S,.54+G@;OF. .@JCX9TRY\.27FH:C!'86T=L
M!.WV@2"XD4DF7KQD8'/)KMJ1D5U(90R]P1D4<SM8+&+X3MY8/#=OYRM&\Q>;
M:>JAR2!^1K#L="U=!I6F2V4,4&G737!OA,I\T?-@*@^8,=W.>..]=O11S!8Q
M_"^GSZ5X>MK.YC6.9-Q=58$9+$]1586^H?\ "=-=G3F-@;,0?:/.CQN#%ON9
MW8YQTKH>E%*_4+''^'/#NH6&NRM>(GV"R5XM.(D#$J[;B2/X<#"_A76+!$LK
M2+&@=L;F Y..E244-M@D%%%%(84444 %%%% !1110 4444 %%%% #[?_ %"_
MC_.BBW_U"_C_ #HH ^)]<_Y&#4O^OJ7_ -#-4*OZY_R,&I?]?4O_ *&:H5ZB
MV.8**** "BBB@ R:ZBR\?:UINEK8V2:?;LL)MQ=1V48N/+/4>9C-<O10TGN-
M.P4444"#-%%% &M9>)-1T_P_J&BVS1):7Y4W!\L;W"]!N[#V]S631118 HS1
M10 4?A110 4444 %%%% !1110!+:_P#'U#_OK_.OMV+_ (]X?^N:_P J^(K7
M_CZA_P!]?YU]NQ?\>\/_ %S7^5<N)Z&M,QM&\1KK&K:K8#3;VV.GR",S3Q[4
MFSW4US^J:A?:9XXN]1%U.VG6D$"W-MO)01N6!D"] 5(!SZ9KN\GU-4&T>S>[
MO;ET9VO85AF5CE2JYP,?\"-<Z:3+L</>0-=^ Y-4>^U 7<<TB)+%?3(-OGD#
MA6 /'KVKKK>?3M%N5TF+^T6DD.X-*EQ<+SZRL& Z="W%-M_"NF6OAI- B$_V
M%/N@RY?[V[[V/6MLY((SUIN5P2.0LO%.JR1V-[=6%DFGW=T;4>5,YE0[RJL0
M1C&1R.M(GBG5CI+:F^GV0B>=K6WB69][R>9L4L<85?7J:GT'P@MC%;2:A<W,
M\T$LDL<!N"T$;,[$,JX'.#WS@UJ'P[IYT5])9)&M6=I.9#O5BV[(8<@@G(]*
M;<;BU.5\2:WJ9TB]TZ\A,5_;SVQ)TVX9?.C=\85B5*G@CD_C5.ZN[NSL/$=F
M&U?30;59;2"\N3+*HSAW20.V.2!C=Q75R>#M/EL;BWEN+^26XD222[>XS.2A
MROS8P /3%*/"-@\5T+JXOKR:YC\IY[FXW2!,YVJ0 %&?04U**"S,"RU2^35=
M*T>[NI3=V<DL<S;S^_C\HF-V]?\ $56\*SW-Q/I,UC+K,LA>4ZD]RTS6Y3+8
MQYGRDYQC9797/AW3KK7+76)$D%[;1-"C*^ 588PP[^U6].L(-+L(K*VW^3$"
M%WMD\DGK]32<E8+&+:>)+C6[Z2VT:VB"0/MGFO7V,N#SMA'S_0MM'UINJ/?0
M^.-# U&064_FJ;0( N0A.2>I^AXK9O='T_49HIKJUC>>(YCF&5D3Z,,'\,XJ
MEJ/AR+4=6M]2?4=2AEM_]4D$X5%R,'C:>HX/-)-#.:U+5+N;7-5N+FUU.;3-
M+D1,6=Z( G&YG*A@TAYZ=,=C2W]S-J0\0ZK%J-Y$=-5#9+#.R(/DWY9 <-G/
M\6:Z._\ "NGZA>2W$DEW&+@ 7,,-P4CN .F]1U_#%)?>$]-O[IYG:ZB2552>
M""<I%.J_=#J.N/;%/F0K,YJ>YN]7BUK4GOKNVET^WB>V2"=HT5BF\DJ#ALGC
MYL\5W&GW#W>FVEQ( 'EA21@/4J":S-0\*Z=J-T\[O=0B5%2>&WG,<<ZKT#J.
MN/;%;:JJ(J* JJ  !T J9--:#0M%%%2,**** "BBB@ HHHH **** "BBB@ H
MHHH *D3_ %;U'4B?ZMZ ,+Q)XA7PY8PW+:?>7WFS+#LM4W%<]S[5'XNEE7PA
M?R0RS6\AC7#QL4=,L!P1T/-;N2.A(JKJ-A!JEA+9W._R90 VQL'@YZ_A336@
MCB;/6[NVU#2["_N)FN+ S"Y^8_OXQ&&1R.^1^M:<'BK456UN+ZPM8[6_BDDM
M?*E9G4JNX"0$8Y'=>E:]QX<TVZUJVU:6)C=V\+0*=WRLA&"&'>J]KX1TVUEW
M![R5$1XX(IIRZ6ZL,,(QV_'-7>+%9F:/$FO'2].O?[/TS.H2I'#%Y\GR[@<E
MFQ[= *C'BK785N);K3M.$%E>+:W)BGD+.20-R KP!D<&NB&A60L["UQ+Y5@Z
MO#\_.0"!D]^M,E\/6$T%Y"WG;;NX%S+B3G>"",<<#@<4KQ[#LS$O?&<MEXA2
MT LKFU-RMNP@$S21D]V;;Y8/^SG-:'@YWDT><NS,?MDXRQR<;S0_@_3GN3+Y
M]^L1N!<BV6Y(A$F<[@N._IG%:NGZ;;Z9;/;V^_RWD>0[VR<L<FAN-K(-3D5\
M8W-VFJQ3Q64#002M]B:6:*Z&WOT (/JIX]:GE\3:M&EX;.PLGM["VAGD,T\F
M]E9 Q4<'D>I-:;>$+"5Y&N+K4;D&-XXTN+HN(0_#;,C@^YS5D>'; 17L8$VV
M\A6"7Y_X57:,<<'%.\1:E-O$LFS5W2V3;8VB7$>6.7W)NP?3\*H7'C"ZCU>T
MLVCL+..:.)Q)>O(@G+@$B-@NW(Z<G.:TKWPAIUZSDS7T(D@%O,MO<E!,@&!N
MXY('<8I]QX5LKIT$EUJ!MP$#6HNCY+[<;<KCV'0C-*\1ZEG7]3ET?0[F_AA2
M:2(+MC=MH8E@.O;K7/7DWB ^)M)"QZ<+J2WG*Q^=)Y2K\N-W&6/T KJM1T^#
M4["2RN WDR8SL;!X((Y_"D?3;>34K:_;?Y]M&T<?S<8;&<COTI)I SG[7QBW
MDZ=<ZA;1VUK<K*DDBN6\N:/)*_0@''?BJ=OK/B._\1:0T*V=M;75H\S6\S.?
MEWC!./XL?A6CJWA."\T*#1K=%-H;M9IC.^65=Q8[>.23Q]":U+W1+:\O+2[$
MMS;7%J-L;VTFPE.,HW!!7BJO$6IRNAZSJFGVL+S06TNG3:G+;%S,YF!9VP<$
M;<#&,9J?_A*]=98KB+3=-:WFOGL8PUQ('W D!S\I 'R\CK6^OARP6RBM!YWE
M177VM?WG/F9)ZXZ9)XH3PY8);P0#SMD-V;Q/WG/F$D\\=/F/%'-$=F)H.J76
MH"]@OH(8KNSN#!)Y#%D;@$$9YZ'O6O52TTZ"RN+R>'?ONY?.EW-D;L <>@XJ
MW4/?084444@"BBB@ HHHH **** "BBB@ HHHH ?;_P"H7\?YT46_^H7\?YT4
M ?$^N?\ (P:E_P!?4O\ Z&:H5?US_D8-2_Z^I?\ T,U0KU%L<P4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $MK_ ,?4/^^O
M\Z^W8O\ CWA_ZYK_ "KXBM?^/J'_ 'U_G7V[%_Q[P_\ 7-?Y5RXGH:TQU9/_
M  D5@/$O]@,95O?)\X$I\C#G@-_>P"<>U1Z/H=WIFJZI>3ZU=WT=[('BMYON
MVX'9>?\ "L75M%N[_7M8N+>-DN(8;::RF*_*94+G /OG!]C7.DKEG4:?J5OJ
M5D+R LL)=TS(-O*L5/ZBEEU*T@U&&PEF"W,R-(B'NJXSST[BO/K"TD?3=%N=
M=T.[ET__ $IIK)K5IC%*[DH6B )/&0#CC(/O4EGHRVUYH5WK&B230HEQ&@>T
M-P\ 9\PJX )&!W[=,U7(A7/0YY_),?[F63>X3]V =N>YR1Q4@92<!E)ZX!K#
M\2V\T\FCF&%Y/+U&)WV*3M4=2?05S-AX?-K9Z1>P:8T.I#57,LPB(D$;.V=Q
MZ[,8]JE130[G:ZAJL&FO:I*K.US.D"A",J6Z$^U6(+@30>:T;P#<5VS84\''
MJ1SVKSFVTY1<:6LFAW?]M1:H)+R]:S8Y7><-YV,%=N, 'CT%/M=.$(L9-<T:
MZO--3[4! +1IA'*TI*LT8!/*YPV.,]JKD0KGI!90P4LH8]%)Y/X55M]2M+J]
MN;.&8-/;%5E3I@D9&/7CTKS;Q)837CSK;:)-:M#!&;#R]),TS <\S$GRMOH,
M'ZUIR:0T6J^(/(TLQZM>P*]E>K:9Y\LAOWH&%.>Q()HY%;<=ST $-G:0<'!P
M<X-4AJL!UH:6JL93 9]X(*@ @8^O->=66D:@ME>C3H9X+DV)BDA@TB2R#MQG
M<[.0[]<$=<GFMWP[:6*>+%GTK1+C3[,:<8W:2R:W#/N'!R 2WOW]32<4@N=#
MJ&N)9:E:Z?':S75U< OLC=%"(."Q+$>O09)K4W*20&!(Z\]/K7+:KHJ7OC.W
MN_[/BD=-/E$=Q)"&"29&WYB.#Z5@Z7IKK)IZV>CW=KJ$,,PU2XDMV03$J>"Y
MXE);!&,X]J.5-!<]'#*3@,">N :Q;GQ/:PWDUM!9ZA?-;G%P]G;>8L)]"<C)
M]ADU%X.T>VTOP_9,M@EM=O HG8QXD8^C$\_@:HZ7>2>')=0L;W3M1E,EW)/!
M-:VKS+,KX.,J,*PZ?-BE9:A<MW'C.PMKFXC:SU)H;8(;BY2VS'$&&1NYW#CK
MQQ2W'B^.WOHK0:+K,KS9,+16Z,LH R2IW],>N*YZ_P!"U74;[Q!<P->QQ220
M.;!PJ1W:!<LA;&X'MPV,UO.'O=<\.WD%G/%;K%+N62(J8<I@*P['M56B*[.B
MBD,L*2&-XRR@['&&7V/O3Z**S*"BBB@ HHHH **** "BBB@ HHHH *D3_5O4
M=2)_JWH CJGJNI0:/I=QJ%R)## NYA$NYB/8=S5+Q)HEUKMC#;VFL76EO',L
MC2VW5P/X3R.*;XJMYI_"MY!"DDTI1  JY9B&'84TEH(GMO$%A=KIK0/(RZBK
M- =GH,G=Z&M"6>.&*65W 2)2S\YV@#-<#+H^IV'BVTMK*WE-A)'-<0S*ORV\
MK)@J3VRW(JM8:-Y_V.WM-$N+:\2WF35)9[<HLQ*G 9SQ*2W(/./:KY5W%<]#
MLKVWU&TBNK6420R*&5NG'T[4Z&X$RNS1R0[6*XEP,X[CD\5@^![:TL] AMX-
M-:QGB 2Y5K0P%G'?.!O^HS6';:$UYJEC'?Z:TMJ-2NY'6:(E-IQM)!XP>V>#
M2Y5=CN=_N4+N+ +_ 'L\?G6;8:U%J+$0V]QM$\D!?"E5*=2>>A[5QD>F-;16
M,6H:5<W&B6][<AK1;9I54$_NSY8!+)UQP0*BL=+OA%:BPTZXL\7-\T*O"8_*
M#+\A(_A![4^5"N>E;E^;YA\O7GI]?2JM]J5IIUH+JYF"0EU0./F&6.!T]ZX6
M.WM+?P]*EAX4G_M-8%CNVN-/<AOF&\MT\X]3@$Y]:S$T&673=8B&F37%D)[:
MXBB;2Q;JP!&\I#CKC/;)H4$%SU;>A .]<'@'<,'Z5#?WD>GV,]W*"4AC:0J"
M 6P,X&>]><ZYI?VF_P#-AL/+TA[14LT.A2S^0W.0L:LIB;/.2/QI^H:=^[OT
MU?2+_5)Y-/1-/E:Q:4J0F&&!D1MNY.3^)HY$.YZ"E_"VEKJ#$QP&'SCNZJN,
M\U7TC5QJUB+S[)+:PL?W9GD0EU['Y6./H>:K/:-+X):TEMR[G3RAA9,DMLZ8
M]<URW]B6=A#HIO\ 0&GTI;(B2V@LC)LN#_$\:C.2.-V./:DDF%ST,LJYW,!C
MGDXJIJ6J6FDV?VJ[<JA8(JHI9G8]%4#DDUQ>D>'IKG4=(76].::*&PD 2Y3S
M%CS)E5;.06 QP<UT'B:UN NEWUI:O<C3[H2O;Q ;F0J5)4=R,YQ2Y5>P7%F\
M66]M937%UIFK6YB*#RI;7#.6.%V_-M//;.10GBR&19UCTK5FNK<CSK3[.HE1
M2,AL%L%3Z@FLSQ'>OXAT"2WT^RU6,BX@/FO9M$1^\&2H<9)'4G&*L:-8W6E:
MYJ=O>BYO9;I/,AU*1<[T P(FV@*K+VP!G.:JRL!I:'X@37HA-!IVHV\#+N26
MZA5%<>V&)_2MBL7PC!+;>%=.AGB>*5(L,CKA@<]Q6U4/?0$%%%%(84444 %%
M%% !1110 4444 %%%% #[?\ U"_C_.BBW_U"_C_.B@#YIU3P!X7FU>]ED^(^
MD1.\[LT;1'*$L<@_-VJI_P *\\*_]%,T?_OR?_BZXG7"?^$@U+D_\?4O_H9J
MAD^IKT5&5MS"Z['HO_"O/"O_ $4S1_\ OR?_ (NC_A7GA7_HIFC_ /?D_P#Q
M=>=9/J:,GU-'++N%UV/1?^%>>%?^BF:/_P!^3_\ %T?\*\\*_P#13-'_ ._)
M_P#BZ\ZR?4T9/J:.67<+KL>B_P#"O/"O_13-'_[\G_XNC_A7GA7_ **9H_\
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M'_09M/\ ONO$Z*/[!H_S/\ ^KQ[GMG_"3:!_T&;3_OY1_P )-X?_ .@S9_\
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M6CQYO9ULL/YNX@(B$C/3J35SQ#\3;:-_#Z^&K:-?[)>24/)9K!$SOD86)6.
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M*+/1]6U+5-'MK8QP3W,QE<7..5C?J:K>#[B]TS5M+L/$DGBJWUJXB8Q"\O\
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M)TY.Z1V'A'48([V'3;F:RBB\S S9"8W))Z%ST'O5VTN].T>]UNTNWM]-N7N
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M&C_A2OB/_H):#_X'_P#V->;X'H/RHP/0?E1:?<+Q['I'_"E?$?\ T$M!_P#
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M3O-6L_L^7J3-2Y7J>QF)L]5_.CR6]5_.F'J:2OB3@)/);U7\Z/);U7\ZCHH
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M<44_A"6X44459(4444 2VO\ Q]0_[Z_SK[=B_P"/>'_KFO\ *OB*U_X^H?\
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M6/#T]AYT]N+>XAOMX0@'*LI3G(R>#P:T3741L:)=07NBVEQ;ZA_:$3QC%T0
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M^15\1?\ 7-*Y"NO\*_\ (J^(O^N:5QX[^#\X_FCLR[_>8G/4445J?:!1110
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M% 'Q/KG_ ",&I?\ 7U+_ .AFKNAZ-:7MCJ.IZE<3PV%@(PXMT#RR/(2$5=Q
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M_P 57-_VYJ__ $%;_P#\"7_QH_MS5_\ H*W_ /X$O_C1[_D'NG2?\*G\=?\
M0N7/_?R/_P"*H_X5/XZ_Z%RY_P"_D?\ \57-_P!N:O\ ]!6__P# E_\ &C^W
M-7_Z"M__ .!+_P"-'O\ D'NG2?\ "I_'7_0N7/\ W\C_ /BJ/^%3^.O^A<N?
M^_D?_P 57-_VYJ__ $%;_P#\"7_QH_MS5_\ H*W_ /X$O_C1[_D'NG2?\*G\
M=?\ 0N7/_?R/_P"*H_X5/XZ_Z%RY_P"_D?\ \57-_P!N:O\ ]!6__P# E_\
M&C^W-7_Z"M__ .!+_P"-'O\ D'NG2?\ "I_'7_0N7/\ W\C_ /BJ/^%3^.O^
MA<N?^_D?_P 57-_VYJ__ $%;_P#\"7_QH_MS5_\ H*W_ /X$O_C1[_D'NG2?
M\*G\=?\ 0N7/_?R/_P"*H_X5/XZ_Z%RY_P"_D?\ \57-_P!N:O\ ]!6__P#
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M#>)?^@3-_P!])_C1_P (-XE_Z!,W_?2?XUC_ -HWW_/]=?\ ?YO\:/[1OO\
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MX@9[J=F6-=K-(Q(^G/%<N,6)]E[SCNNC[KS.O NG]8CRIW]?^ 5/^$,\1?\
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M$7_0*E_[Z7_&MOPEX8UJP\2VMS=:?)%"F=SEEP./8UQ_]H7O_/[<_P#?YO\
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MN50R2,(A;JQ!+1C!W[ACKTI<\;V#E9P%%=--X42+X=6_BK[8Q>6_-I]G\L8
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M6- TGQ!;I;ZM80WD4;;D24' /KP:P?%^E:DWAB/0_#NCV\L!"+AKH0B%496
M (.[.,=>*J-KH3'>.]=NM#T>PGM]2ATT3W:12W<T E6-"I).T^X%7O"5U-?:
M6UT_B.UUV.1_W=Q;6RPJH'52 3SGUQ2S7GB%=&M;B+0+.2_S^]M)+\ (.Q63
M803^ J'PIH]]I[ZI?ZC#;6]UJ5SY[6UL^Y(0%"@;L#<>,DXZT].4.ITE%%%0
M,**** "BBB@!]O\ ZA?Q_G11;_ZA?Q_G10!\3ZY_R,&I?]?4O_H9JA5_7/\
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M/^%I>./^ADO?_'/_ (FB\PT,C_A$_$?_ $+^J_\ @')_A1_PB?B/_H7]5_\
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MG^%'_")^(_\ H7]5_P# .3_"M?\ X6EXX_Z&2]_\<_\ B:/^%I>./^ADO?\
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M'_0R7O\ XY_\357F+0R/^$3\1_\ 0OZK_P" <G^%'_")^(_^A?U7_P  Y/\
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MVC][_P @]_R*7]BZK_T#+S_OPW^%']BZK_T#+S_OPW^%7?\ A+_$/_07N/\
MQW_"C_A+_$/_ $%[C_QW_"B^*[1^]_Y![_D4O[%U7_H&7G_?AO\ "C^Q=5_Z
M!EY_WX;_  J[_P )?XA_Z"]Q_P"._P"%'_"7^(?^@O<?^._X47Q7:/WO_(/?
M\BE_8NJ_] R\_P"_#?X4?V+JO_0,O/\ OPW^%7?^$O\ $/\ T%[C_P =_P *
M/^$O\0_]!>X_\=_PHOBNT?O?^0>_Y%+^Q=5_Z!EY_P!^&_PH_L75?^@9>?\
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MDP;9TGB.V\(2ZCJ.M6/B9[E[F;S[>R%G(KHS/DB1B-N!D].3Q787/BOP=?\
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M>II*^ /."BBB@ HHHH 0Y .!D]A7*+XAU^QURPM=:TBQAM-0E:&&2TO&E=&
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M']'_ .@;;?\ ?L4?\(_H_P#T#;;_ +]BC^WX?R/[P^LKL>#Y'J*,CU%>\?\
M"/Z/_P! VV_[]BC_ (1_1_\ H&VW_?L4?V_#^1_>'UE=CP?(]11D>HKWC_A'
M]'_Z!MM_W[%'_"/Z/_T#;;_OV*/[?A_(_O#ZRNQX/D>HKHO Q'_"7V7/][^5
M>K?\(_H__0-MO^_8I\.BZ9;RB2&QACD'1D7!'XBLJV>0J4Y0Y'JFMQ2Q"::L
M3GJ:2G_9HO1O^^S_ (T?98O1O^^S_C7SIRC**?\ 98O1O^^S_C1]EB]&_P"^
MS_C0 RBG_98O1O\ OL_XT?98O1O^^S_C0 RBG_98O1O^^S_C1]EB]&_[[/\
MC0 RBG_98O1O^^S_ (T?98O1O^^S_C0 RBG_ &6+T;_OL_XT?98O1O\ OL_X
MT ,HI_V6+T;_ +[/^-'V6+T;_OL_XT ,HI_V6+T;_OL_XT?9HO1O^^S_ (T
5%O\ ZA?Q_G14T<:I&%4<#WHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tmb-20211231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &2 DL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***9)+'$NZ1U1?5CB@!]%8]UXJT2S
M.)M1@!] V:H'Q_X=!_X_<_1: .GHK @\:^'[A@J:C$">S'%:]O?VET 8+B.3
M/]UA0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M444 %%%% !1110 V21(EW.P4>IID5S#,<1R*Q] :YS7[XP"YG<,R6Z$A%ZG
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M2[= LQ_TR7^5:U '#Z<?,^(VM,?X8XU'^?PKN!TKA],&SXBZTIZLL;?SKN*
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MN>\-^-M!\4PA]-OD:3'S0O\ +(OU!KH:YG%Q=F:II[!5>Y?I&O5JG)P"35:
M&25I6_"D,GC01H%%/HHH **** "BBB@ HHHH **** $;A2:KVZJRL2,DFK##
M*D>U0VOW6'O0 EO\KNE6*K_=N_\ >JQ0!SOB/PG;:ZT=U%*UKJ,/^JN8^OT/
MK67_ &9XWD3[))J=HL1^4SJ/GQ_C7;453DVK,YJF%A.3E=J^]G:YDZ!H%MH-
MF8HB9)G.Z69OO.?\*UJ**DVITXTXJ$%9(****"RCJNE6^K6A@G!!'*..JGVK
M%2P\3VRBWAO8)(APLCCY@*ZBBN>IAH5)<UVGY.QR5L%3JS]I=QEW3M?U,;2=
M 2PF:[N)3<WK_>E;M]*V:**TI4H4H\L%H;4:%.A#DIJR(+DY"KZFDG15B! Y
M%$GSW*KZ4MT?W6/>M#4E0Y12?2G4U!A%'M3J "BBB@ HHHH **** "BBB@ J
MJ/W%Q_L-5JHKB/?&?4<B@"6BHK>3?$,]1P:EH **** "BBB@ J.>,2P21GHZ
ME?SJ2B@#B_ 4A@6_TU^&MIV7'L3D?SKM*XB4?V)\0!)]V#4$_#>/_K9KMP<C
M(H PO%M@-1T*2(CE6# CJ/>E\-:@;S3T60_O$&UAZ$=:V9HA-"\;=&&#7$V<
MCZ-KS(_"2-@_[W_UQ0!W-%(C!T#*<@C-+0 4444 %%%% !1110 4444 <UXU
MN?*T8Q*?GD.T#ZUJZ);_ &72H(O10*YO67_M;Q1:62<QPGS'_#I791J$C51V
M&* '5R%_B^^).FP=5LK=IF]B>!_.NN) !). *X[PAG4M?US6FY5Y1;Q'_97K
M_2@#LJ*** "BBB@ K*UOPWI'B*V,&J6,5PN,!F'S+]#U%:M%--IW0-7/"_$7
MP1OK"<W_ (5OG+(=RPN^V1?]UAUK/T?XK>*?"%V-.\3V4MRB<'S5V2J/8]&K
MZ$K-UC0-+U^U-OJ=E%<QXXWKROT/45TQQ',K55=?B9.E;6#L8NA^/M!\4VZC
M3KU1.WWK>3Y9!^'?\*ZF)-D86O#O$?P3FBN7O/"MXP>,[E@E?:P_W7_QK,TO
MXF^+_!5V-/\ $=G+<Q(<$3C;(![-T-#H1GK2=_(7M''XT?0]%<KX9^(7A[Q3
M&HL[Q8[@CFWF^5Q^'?\ "NJKGE%Q=FC5-/5!1114C"BBB@ HHHH **** "J\
M?[NX9>QJQ4,\9;#)]X4 -N!M9'JP.1FJDDK-'M9,'UJ>!MT0]N* )**** "B
MBB@ HHHH **** "BBF2MLC)H BB^>=V]*)OGF1*CBE**<+DDU+#&V3(_WC0!
M/1110 4444 %%%% !1110 4444 %%%% %5?W-R5_A:K55[I?E#CJIJ:-MZ!O
M44 .HHHH **** "BBB@#F_&>F27ND"YM^+JT831GZ<UH:!J::KI,-PAY*C(]
M#W%:;*&4J1D'@BN(MF;PIXH>T?C3[YM\+'HC]Q^/\_K0!W%<]XETP7$'VE!\
MR_>(Z^Q_"N@5@R@CH:&4,I5AD'@B@#G_  [JIFB^RSD"5./K70UQVKZ9+IMV
M+JWX3.0?3V/M6YI&KQWT01SMF7@@T :M%%% !1110 4444 %4=6U"/3K"29V
M ('%6IYDMXFDD8!0,\UQ<C3>*M7"+D6$+<^CGTH N^$K&1S-J=P#YMPV1GLO
M:NKJ.&%8(EC08 &*DH P_%NJ?V5X=N95/[V0>5$!U+'BI?#&E_V/X>M+0C]Y
MMWRGU=N3_.L"\/\ PD_C>&S7YK#2_P![,>S2=A^?\C7;4 %%%% !1110 444
M4 %-D;:C-Z"G5!='$84=S0 6J_(6/<U7U71=-UNT:VU*SAN8B.DBYQ]#U%78
MUVQJ/:G4TVM4!XIXF^!FUVO/#%XT<BG<MO,V,'_9?_&L#3?B)XT\!W2Z?X@M
M);FW0XVW (8#_9?O7T55/4=*L-7M6MM0M(KF%NJR+G\O2NB.);7+45T9.E;6
M.ASGA?XD>'?%"*MO=B"Z(YMYSM;/MZ_A77@@CBO&?%'P,AD=KOPS=FWD!W"W
ME;C/^RW4?C7-6'CCQQ\.[M;'7+:6YM1P$N,]/]EZKV$*FM)_)B]HX_&CZ+HK
MB_"_Q/\ #OB<)%'<BUNS_P L)SM)/L>AKLP01D'(KFE"47:2-4T]4+1114C"
MBBB@ HHHH 1E#*0>]5K=MDC(:M53FRD^X?6@"Y1348.H([TZ@ HHHH ****
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MEM?"K2RB?4YS.XY"_P (_"@"A))?^*;CRXPT-B#RW0M]*ZS3]/@TZV6&% H
MQQ4\,$<"!(U"J/2I* "L'Q5KO]C:9MA^>]N#Y=O&.I8]ZT=5U6UT>PDN[IPJ
M(.!W8^@KFO#FFW.LZF?$NK(5)XL[=O\ EFO]X^] &OX6T3^Q-(6.4AKN8^;<
M/ZN>WX=*VZ** "BBB@ HHHH **** "JT_P \Z)5FJP^:\/M0!9HHHH ****
M"JM_IUGJELUM?6L5Q"W5)%!%6J*-@/'O%/P-M+DM=>'+@VLW46\IRA/L>HKD
M[3Q;X\^&]TMIJ\$MQ9J<!+C+*1_LO7T;4%Y96NH6S6]Y;QSPL,,DBA@?SKIC
MB7;EJ*Z,G26\=#C?"_Q5\.^) D1N/L5XW_+&X.,GV/0UW 8, 5((/0BO)/%/
MP-TZ^+W.@3FRGZB%\F,GV/45QMMXA\??#.X6UU&&6>Q4X"S9="/]E^U5[&%3
M6D_DQ<\H_&CZ.HK@/"WQ;\/>(@D,\OV"\/'E3G )]FZ&N^5U=0RL&4]"#G-<
MTX2@[21JI)ZH6BBBI&%5KE<LA]>*LU!=#]V#[T -B;RI#&W0]*LU"\?FQJ1P
MP'%$4N?D?AA0!-1110 4444 %%%1RS",8'+>E #+A^!&O4TRV7$C9ZCBGQQD
M9D?[QI+;HQ]Z +%%%% !1110 4444 %%%% !1110 4444 %%%% !5:X^65'J
MS4%V,Q ^AH GHIJ'<BGVIU !1110 4444 %%%% !6!X@\,P:NOG1XBNU'#CO
M]:WZ* //++6+_0KH6>IJZ#M)C((]?>NO@UF.2#S,!UQD-&<@U/J&F6VI0F.>
M-6';/:N,NO#^HZ/,SZ9*[1]?+8_Y!H U+FY^U3M(W!/0>E.AN[BW_P!7*<>A
MY%8,>NQ[_*U"V:&4<9 Q^E:$,\$PS!<HWL3@T =;92?:K59)$7<?:K BC'1%
M_*LW3[V.*!8I6Y!X..,5HB>)AD2*?QH DP!T%%,,L8ZNH_&L^]U_3;!29KE,
MCL#DT :=96M^(+'0[8R7,@+G[D:\LQ^E8,GB75-:8P:#9-M/!N91A5]ZO:1X
M1AM;@7^IRF^OSSO?[J?[HH S].T:^\2W\>KZ\ACM4.ZVLCT]BP_I7:    #
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MCH%& *=110 4444 %%%% !1110 4444 %%%% "'H:KVGW&^M63TJO:<!A[T
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M'Z8K2K,L?W6KZC#V9DF'_ A@_JM:=:5?B;[Z_>945:"CVT^X****S-0HHHH
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MHZ-\*?"FCA6%@+F4?QW!W?I786]I;VD8CMX(XD'&U% %'M*,/AC?U#EF]V>
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M3X)\.:(!]ATJW1A_&R[F_,UT%%93K5)[LN,(QV0@4*    .PI:**R+"BBB@
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M-Q$9%/;I2VZ%F,K=3TH G10B!1VIU%% !1110 4444 %%%% !1110!P^I_\
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MM#)KVE7.GZE"5N(CL9L<$]F%3^%;N2YT<),=TENYA)]<=*3PS>R3V,EM<_\
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MJ8%:&U"]JM*H44ZB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tmb-20211231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #\ =0# 2(  A$! Q$!_\0
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M_A1_PF&A?\_Z?]\M_A0!N45A_P#"8:%_S_I_WRW^% \7Z$2 +],G_9;_  H
MW**16#J&!R",BB@!:*** "BBB@ K#\1N8($G/*KD;?4GI6Y6#XBN4C6.)Q\I
M^8U$_A&MS#TN3RHKFZF^>5CD=P*D377?*31%DZ8%54U.T163)QGD5N::VGO
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M_ER0&% TA<@^IR?Y5R]2_9I_^>,G_?)H^S3_ //&3_ODT 145+]FG_YXR?\
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MG5;:&QGNHG6X$*EBL3 D^U(#0WG^ZOY4;S_=7\JI1ZC;M9V]Q+(L G1759&
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M33WK6\H5X\H0#D=JII%<QR_:?+))/W:UL*X!9><=Z!#+>X%S#Y@!7DC!J6D
M Z#'TI:!A112'H:0')^)7 )JK&?] @^AIOB:4&;;GJ:?MV6\">BU2$R2'[PK
MI=-Z"N;B'(KI--Z"J$=19=JZ2R_U1KF[+J*Z2R_U1H$6:*** *MU]Y?I5>K=
MQLR-^?PJ']S_ +5 $5%2_N?]JC]S_M4Q$5%2_N?]JC]S_M4 145+^Y_VJ/W/
M^U0,BHJ7]S_M4?N?]J@"*BI?W/\ M4?N?]J@"*BI?W/^U1^Y_P!J@"*BI?W/
M^U1^Y_VJ!"3=5^E1U8D\O*YSTIG[G_:I#(J*E_<_[5'[G_:IB(J*E_<_[5'[
MG_:H JSVT-RJK-&KJK!P#V(Z&I:E_<_[5'[G_:H&145+^Y_VJ/W/^U0!%14O
M[G_:H_<_[5 $5%2_N?\ :H_<_P"U0(BH'6I?W/\ M4?N?]J@"X.@HH'044AG
M.^)+?+QR>HQ7*WD90JV*[[5K?S[)B!EDY%<A?0>9;%E&<5+12*"-N0&G9JM;
MN>4/:K%2,6E'%-I<T +UHI :7- "YXH!I,T47 7D]Z6DS1FBX"T4F:,T7 6D
MS1FDS0 ZHIY!'$S'TJ3-8^NW@MK1AGF@#D-1D-YK"QCD;N:TYCF7 Z 8K+T=
M3+/->.,@?=)K17DY/?FK1+)XOO"NETWH*YN(?,*Z;3A\HI@=-8]JZ.R_U9^M
M<[8CI71V@Q#GUH$6**** *MU]Y?I5>K%U]Y?I5>F(**** "BBH[C_CVE_P!T
M_P J '))'*"8W5P.,J<T+(CE@CJQ7@@'.*\/\+Z_>^%;"Y<K)-!J32"V &=L
MRG&/QR/RJYX8U"_\/VFO":YC&HO>(FZ0%LNPS@ =3S2&>S45YEIOC/Q ?[8T
M^>!)]0M+<3PD1E,Y(&"I^M6;/Q+KXT6_E^T6E[>QQJT<*(4="3SD'KB@1Z)1
M7)^#]7U#4'FBU"^M+AU4,%B0HZ>Q!KK*8!1110 4444 23=5_P!VHZDFZK_N
MU'0 445'<.8[:61>JH2/P% "^=$)/+\U-_\ =W#/Y4^O/K:*<::NL7.GQ2(7
MWO-O(F'/4'T]JVX9KW5VOIX;^2VC@.V)$ P<#.6S2&=-16+%J\H\+'4G4-,L
M1..@+=/RS5&>YUK3TL9I[N"9;B9$=!'C9GT/>F(ZBBN4MM9OFM+V^NKF.*"&
M5H8U"9+'. ?_ *U00^(=0B:\BE+NRVK3Q-+#Y9!';'<4@.RHKDS>ZY&VG,UQ
M WV_*[-F/*.,YSWHEU+6+?[99^:LLL$Z W"Q?=C9<YV^U '645FZ-<//;OOO
M([HJ<;E7:1]1VK2I@% ZT4#K0!HCH**!T%%(8I (P>E<O>6WV>YDA(^1\E:Z
MBJ.IV?VNV^7_ %B<J:&!YW>PFUNB>Q-/1PRY%7M1B\Y"&!#KU!K%AE\ERC=*
MS9:+]%(&!&:7- !2TE% Q:*,T9H 7-&:2B@0N:,TE% "TE%(S!1D]* &RRB*
M,L>U<#X@OVOKH6\1)R:UO$.MK%&T49^;I6)I=L4!O;C[S?=!H0,NQPBUMH[=
M>H&6J51TIBY9BQZGFIE7-:(DL6RY<5T^G)\HK"L8<L*ZBQBP!0!NV"=*Z&!=
ML2C&*QK&/E>*W0,#% @HHHH JW7WE^E5ZM7",[#:,U#Y+_W: (Z*D\E_[M'D
MO_=IB(Z:ZAT93T88J;R7_NT>2_\ =H P=*\,:=I6GQV:Q^>D<IF0RC)5B>HK
M.O/ .EWLE[))+.LEU<"XWJV#&X& 5KK_ "7_ +M'DO\ W:0SC8_A]ID=S)<_
M:;MII8?)DD,GS-SG)/K2V_@#3X3</)>7D\TR!/->3YE .>#78^2_]VCR7_NT
M <UH7A&ST.^FODN+BYN95V&2=LG;Z5T-2>2_]VCR7_NTP(Z*D\E_[M'DO_=H
M$1T5)Y+_ -VD\E_[M "S=5_W:CJ>2-F*X':F>2_]VD!'2$ @@C(/6I?)?^[1
MY+_W:8'/GPU!N*?:I_LI;<;;/RYZ_E4ESX?BFF>2&YFMEE $J1' >MSR7_NT
M>2_]VD,SIK*&/1Y+..#S(A$4$6?O#'2N5BTZ:\N+&&/^T=MO,LA%R,+&!V![
MUW7DO_=H\E_[M &,?#]J=/FLRS[9)3-NSRK9SD57'AB)IGFGO+B:1X6A9F/\
M)KHO)?\ NT>2_P#=H S6TN%S999O]$.4]^,<U!<:)'-<SW"7,T,TS*Q9#C!4
M8%;/DO\ W:/)?^[0!EZ9I4>FF=Q+)--.VZ21^K&M"I/)?^[1Y+_W:8B.@=:D
M\E_[M'DO_=H NCH**!T%%(8M%%% &#K>E"1&N8%^;JZCO7"WL.UR<$5ZP>17
M,Z]H8ES- N,]5%)H:.'M[LH=K]/6M!6#C*FLR\LY('.!^%5XKMX6ZG%189N4
MM4X;Z.0#)P:LAU/0YH&/HHQFB@ HS29I: #-+FF-(B_>;%4+K5K>W4_,,BF!
M?>18URQQ7-:WKZP*4C;)]!67J/B"6Z<Q6X))]*KVNF<_:;YLGLM%A$5G:/=R
MF[O,[ <@'O6B6,KC P@^Z*<S&4@8VH.BU*J@"J2$(JU/&FYA35%7[2WW,"13
M OV$&,<5TME%P.*S;.#@<5OV<) % C5L8_G7VK3JM:1[4W>O2K- !1110!6N
M6*LN#BH-[?WC4UU]Y?I5>F(=O;^\:-[?WC3:* ';V_O&C>W]XUS_ (MUN[\/
MZ2-0MK>.>..11.')^5">2,>E1:OXE>TU/1["PBCFFU!]QWDX2(#);B@9TN]O
M[QHWM_>-<\?&>@#4?L!U"/S]VW_9SZ9Z5!:>*PVJ:[#>+'%:Z9M/FKDD@C))
MH$=1O;^\:-[?WC68^NZ?&+ O. +_ !]FX/SY&1^E9;>/?#:NB-J* LYCY4\,
M#@Y]*!G3[V_O&C>W]XUB6/BK1=2O9;2UO4>:)2S#IQZY[U%:>,M!OM0%C;WR
M-.3@#! )]CT- '0;V_O&C>W]XTVB@0[>W]XT;V_O&FT4 32LP*X)Z5'O;^\:
M=-U7_=J.D [>W]XT;V_O&FT4P';V_O&C>W]XTVHKBYAM86EGD6-%ZECB@"?>
MW]XT;V_O&H8)H[B%)HFRCC(/J*I#6[$ZI+IXD)GBC\Q^/E4?7UH T][?WC1O
M;^\:QHO$=E+)$-DZ12MLCF>/",?K3Y_$.G6]RUN\S%U.UBJ$JI]R.!0,UM[?
MWC1O;^\:R;KQ#IMI,8I)B6&"VQ2P7ZD=*TD=9$5T(*L,@CO0(DWM_>-&]O[Q
MIM% #M[?WC1O;/WC3:!UH T1T%% Z"BD,6BBB@ I" P((R#2T4 <YK&B(X,D
M:Y]JXN]TI0QQPU>K$!@01D&L'5-'60,RKQ2L!Y?-!/ 3@$BHEOI(CU(^M=/?
M:=-"25Z>A%8<Y521-;?BM*PQBZTX'/-2?VZ!UQ5-X]/?NR'W%1-9V!_Y;T6'
M<O-X@0>E5)O$Q .VH#9Z<#S(32;=.C^Y"7-'*%RI-K%[=';$K'\*C72[JY.^
M[EV)5_[7@8AA1!]*A8RRGYW)%-(&PCCM;(8MTWO_ 'C2_/*VYSFG)#CM4RK3
ML(15 %/"TY(RQX!J[!:$D$B@".WMRQ!-;MG;8QD4EM:8QQ6S:VW3B@"6TMP,
M<5NVD&X@=JK6UOR!BMJWB\M.>IH$2J-H ':EHHH **** *MU]Y?I5>K%U]Y?
MI5>F(**** *NHV4>HZ=<6<P!CF0H0?<5P/@WP[K#WEU=:RC1R6MO]AM&/]WN
MWXUZ110!X^-!UE?#[>&/["S.9RW]HY&W&[.[/7-7SHVKP7_B+3AI\LJ7]LBQ
M761MW*F.?J:]1HI >71)KU__ ,(QYNAS01Z6R)*689;";<@>E4I/"M^? 6H6
MXTQC?2Z@9 NT;BN_K],5Z]10,\UUCPQ>S^*X%L+8P6S:<\)E0856V\ UAZ#X
M.OVOK"VNK'48S;2!I)7F'E#'=1UKV:B@! , #TI:**8@HHHH DFZK_NU'4DW
M5?\ =J.@ HHHH *YS6M)NY-134(U%Y'&/^/20X ]Q[_6NCHH S[F:[;16EL;
M;%R4^2)SC::Y&TMKG^V_[.>Q:&26R?S)6E#%B3]X\>M=]3?+3S/,V#?C&['.
M*0SDG2]OM-M-'-A+#)%(GF3'&P!3G(/OBIK22XTE+BQDTN6X=Y6994 *R G.
M6/:NIHH$<I;&YT=[V"32Y+DW$AD1XP"&SV;/3%=/!GR(]T8C.T90=O:I**8!
M1110 4#K10.M &B.@HH'044ABT444 %%%% !01D8-%% &?>:9'."5&":Y>_T
M,Y;*UW%1R0I*"&4&@#RB[T(\X6LJ;29$S@&O6KG25(+*,BL6XTH9/R_I0,\U
M:QD7JM,^RL/X:[R72ER?E_2JCZ6O]W]* .0%O[&I! ?0UTQTM?[M*--'I0!S
MBVSMVJS'8L>HK?33P.U6$L?:@#'@L,$<5I06>,<5HQV>,<5>AM.G% %.WM.G
M%:UO;XQQ4L%H>,#-:D-N(QD]?Y4"&VUOY?S$<]JLT44 %%%% !1110 QXE<@
MMVIOV>/TJ6B@"+[/'Z4?9X_2I:* (OL\?I1]GC]*EHH B^SQ^E'V>/TJ6B@"
M+[/'Z4?9X_2I:* (OL\?I1]GC]*EHH B^SQ^E'V>/TJ6B@"+[/'Z4?9X_2I:
M* (VA1L9'2D^SQ^E2T4 1?9X_2C[/'Z5+10!%]GC]*/L\?I4M% $7V>/TH^S
MQ^E2T4 1?9X_2C[/'Z5+10!%]GC]*/L\?I4M% $7V>/TH^SQ^E2T4 1?9X_2
MC[/'Z5+10 4444 %%%% !1110 4444 %%%% !4<D"2CYEJ2B@"A+IRG[O-4Y
M--(/W/TK;HH YPV _N_I3?L _NUTA56Z@&F&&,]4% '/"RYZ5*MF/2MT0Q_W
M!2^6@.=HS]* ,F.R8D87]*N168'+C\!5RB@!%4*, 8%+110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tmb-20211231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. V8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KBZC-PT <&11DJ.PH
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M9N(P_P#=W\USMO*J,)=5MV<&,1H-NX!AU_\ UU,]A%)JD4R684>0WWER0>U
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M% #SLB3>P'U/2@#M#<1_\]%'U-'GQ]G4_C7(CPW>2;BVH7N203@JH./PJ1=
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M9U900NC3_P#?NO5\#THP/2BX'E6_6".=(N <8^Y_]>FJ=61]XTBXW8QG9_\
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M]*ZU2,5R'BVP,!BUNW9UN+<@MCD,/>NDTN]CU"PANH\;9$#8'8]Q0!=HHHH
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M->H1C""FP'"BBBD 4444 %%%% "$9Z]*Q-1MC$Q=/7(/O6Y56]C$D##N.10
MVRNOM-NK_P 70_6K?45@:7+]GO7@.-KC*_6M\'- %>\MENK66!P"DBE2#7->
M"I)K47NE3IM^S293&>5/^?UKK&^Z:Y:)!8>.V&X!;V X7)Y*\F@#J@:6FK3J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-B'^%F]J[55 Z>E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHKK<+.0@G&.O>G9CW8W. >V:&*M&07;G@\T 8BXVC%.ITL+6[;6R5_A-,S2
M6M;13']EN0TK^;O&$'W<>M9'4X ))Z"NFTR*>'0" 8?*:0%@?OY_PH M?Z)]
MH8B:<Q^7PV#G=Z?2D0VWE0$S3!@W[Q0#A1[58,E[]L8[K8R^3@GC:5_QIL<E
MV+6U"FWV"3]V&/.?]KVI@1DVF+G]_,W_ #R/][_>IK_9B]EY4\KME=^X<*<]
M![5-))>@WH9[<[L>=C'(_P!FID6[N+W2X93"58JL?E\D+GO[T >NVBC[+&,
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M>VR)M3G>[ESG!R$_+O\ C76[11BD!!#:Q01B.)%1!P%48%3J,#%+10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4Q^HQUI]!&>#0!R_BKP^-6MFF
MB1/M4:_*Q')'I7 QK.;BT3^RT$B@KL88\S'K7LC 8Z5ROB/PG%JG^DVA\FZ7
MN#C=3 X+;-_9\Y.GIM$WS2XY4_W1[5-+%<?VFX_LJ)7,&[R1C"C'WOK52YM?
ML*O#>-<17._Y4*_*1ZYSR:'^R?:SMO+KRO+^^4^<MZ8STIB([B-UTB%VM0BE
MSB<=7]JS1C'7'X?=JY,(FLTV32&7)S&R_(/<'-52DG8+Q^M %S2%=M2C$=NM
MPYSB)AP_N:LE)?[/N#]D4()\--W4_P!T>U4;((+I?M#O#%_$T8RP^E3GR!;R
M8GE\S?\ +'M^5E]2<]: +AAF^VNITY,^1GRLC ']ZF(LHL[1C8QF/S/ED.!Y
MGL34/^C&XP+FY*E/E(3+%O[N,]*Z?P[X0FNC%=:AOCA4[A W\1_I2 E\,Z!)
M>W\E_>6:06ZMF./'?V]J]#084#%-CB1(EC10$ P *> !P*0Q:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tmb-20211231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $& 5 # 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHK UKQIX=\/ _VGJ]K XY\OS 7/\
MP$<T ;]%>,:O^T-I$$C1:1I5W>L.%>7$:D^W4_I5;0?CS>:AK]M9:EH<5G;2
MN%>8RG* ]^10![A16,_BO0HP=VK6GX2@U7?QOX=4?\A2$_3)I<R'9EK4?%&A
MZ3?)9:AJ=O;7#KO5)7P2/7]*NVVI6-XH:VNX)E/>.0-_*OFSXBZM;:_XQN[F
M$B2! L2,1P0!_B37*P!K:7S+:66%Q_%$Y4_I6;JI,OV9]C;J <U\LV7C?Q9I
MNW[-KUTRC^";$@_6NGL/C;XDM%5;RPL;P#J03&Q_F*I5$Q.FSZ HKR2Q^/.D
MR$+J&D7]N>[1A9%'Z@_I75:=\4?!^I!?+UNWA8_P7)\H_P#CU4FF2TT=C15:
MUO[2]0/:W4$ZGH8I P_2K-,04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 (3BH);ZU@&9KF&/_?<#^=>(?&?XC:MI&NIH.EW#VT:Q
M*\TD9PS$YXSZ8_G7E)\7W<B9N)YII.[,Q/\ .D[]!I+J?6=SXNT"U)$NK6H(
M["0'^58]S\3_  Q;#_CZEE/_ $SCS7R\FN7MW)LMK>21O1>?Y5;CT_Q7>']S
MI=R0>_EG^M&H]#Z!F^,>B)Q#:7<A]]J_UK,G^,ZC(@TD#T,DW^ KQ^+P+XZN
ML;;"9 >[2*O]:N1?"7QC<']^88Q_MW /\J+>8:=CT"Y^,^HDXCBT^'_>.?YL
M*Q[GXP:LV?\ B<6\8QTCC7_ UCP? _69"//U.T3Z!FK1M_@2!S<ZWGVCB_Q-
M+3N._D9EW\4;JZ5DN=;O'0CE4&./TKE+[Q7:,I%K:-(YZO,@&?R)S7=0_!.)
MKIU>ZF,8/#<#(KH;/X+^'(0#<"XF/O)@4O="[/!KK5[JZRIV1H>JQJ!3-/G%
MM>1S20K.B')C<D!OK@@U],6OPT\(VQ!&C0/C_GIEOYUL0>%?#UMCRM$T],?]
M.Z_X4[H5F?/)\7:C-Q!I5LI/]R-V_F33TU?Q;,<P:4Y]"MAN'\J^E(K*T@'[
MFT@B_P!R,+_*JU\P2"1QA=BDG\!4MI=!JY\TF>;'F7@/VB1SO4+@[NXP/I3Q
M,HR&!4^A&*CNK@-J$4A_CF9R??D_UKLUT.2ZPJ-%)G .]<<GIC/4'!Q]*[,-
M@H5Z?/)V9G6Q$J<K):'([U(X(/XTF,\ULW>D6\$IBN+81N20"O&<<<$5'!H,
M=T2D-YY3?P^8>#^-.>4S6L'<E8Z/VE8QRM1/&K#YE!]L5M2^&=50MY2QS@==
MC5G3V5[;.1/:2+C\:YI8&O#H:QQ-*6S*T(:U??;S36[CHT,A0C\JZ&Q^('C#
M2U46VOW+H/X+@"4?^/#-<\TJ[BK9!]"*8S ]^*P:G'=&ONO8],T[X[>(K8 :
MAIUC=@?Q1EHS_45U%A\?M#EPNH:7?VK=R@611^H/Z5X*>1UJ,C@TU-B<$?5N
MF?%#P=JN!#K=O$Y_AN&\H_\ CU=-;:A9WB[K6ZAG7UBD##]*^'H9C/,5=01S
M5ZVO+NR;?97=Q;L.\,A7^1K3FMN0H7V/MO-+7R/I_P 3?&6F "+7)Y5'\-Q^
M\'ZUUNF_'[7K<J-0T^UNE[F/*$_TH4D#@SZ+HKR+3OV@- GP+^QO+0]V $@_
M3FNMTSXG^$-6PMOK4"N?X9@8S^HJKDV9V%%06]Y;7:![>XBE4]T8&IZ!!111
M0 4444 %%%% !1110 4444 ?+'QU4CX@3L1UBCQ^1KSS3K&34M3MK*+[\\JQ
MK^)KTSX^IM\;@X^];QG_ -"%<-X..WQCHY_Z>D'ZTH[%/<^B_#GAFP\-:=';
M6<"A@!YDAY9V[DFML9]:4B@ 5 PSBLG5O%.G:-(L,[L\Q&?*C&XUKX%<7X:6
MW;Q5KCWFS[4)L)O/(7)Z?I6<Y--)'10IQDG*70U;?QE8W=A=7%M'(\ELN]H"
M,-CUJ_;Z[;7&@?VPO$(C+D'J,=JH+-HS^*#:PVWF7KQ'S)4^Z!Z&N+O;>]L+
MZX\*19\B[N$:(G^Z>3_3\C4.<D=4,/3J.R5NORZG27?BW4TT+3[V.VA26]E*
M*K$D = :=-KGB+2+^R75%M'AN91'MAZC/>F>.+&.+2-)MH\JD<ZQKCJ!C%5W
MT4>'_%ME<3)->64N%1W)8Q/ZU+<KFL(T73O9=3H+[Q=9Z9=W5K=12QRPIO3<
M.)?3;6KIMW->VJ3S6_D%U#!"<D?6N6\1)J6JZPZ:?:IMLXMWFRQ ^8^<[5)K
MJ-)N)[G3HI;F!H)L8=#V-:1DW(XZU.$:2<5KU+YZ5@^)+@6V@ZA,3C9 Y_2M
M[C;7&?$.X^S^#K\@\N!&/Q(%6SE1\^SH\MQ;Q)DD*2*M137=LP*R."/0U71B
MNHY1L%%X([<UIRWLUP@64JV.AVC/YU[>!@E11SU6^8;-JUW<^69W9O+7:I(Z
M#.?YFN@T*Z M0[*KY)R&'%;GPZ\(V'B.SNY+ZU,J+,$WB0J4&TGC'X5TDWPC
MM7).GZA-!UP#AU_QKI6(C!\LF<U6"FN5')R2V[[3%#Y+CJ4<X-.E>Y>#RY99
M#&1QN&?UJ[=_#[Q+:9\B2"Y7L,[6_(U5>X\0:0IAO]&FV !2RJ<8_#BM54A+
M9G*Z,UL9UQ8 *FX1R[P,#ZU>N/ ,>U#+IMS"<'=)$-ZY_"F2ZWI=YJ>GL4DM
M@LR><'4 !0>37L^FZII$\ 2RO+=D[!9 >M8UZG*E[MRH0G;5V/G6^\+QVTK1
MQW#CC^)3_6LZ30;Q/]6T<@^N#7U)/8VMVN)88I0?45AW?@C0[HD_9/*8]XV(
MKD;PT_BA8Z(U*T=G<^:)-.NK=F9K1AGJ5&:J-\O52#[C%?15U\,X6!-I>NGH
MK@$5SM_\-M40'$-O<K['!J'A,//X96-%BZB^*)XJ>1VQ49]!7HM_X%:(GS]+
MGB/]Y0<5AS>$8P?W<[H?1Q42RZ?V&F:1QM-[Z')G(IAY[5O2^%K]2?+"R^@7
MK69/IE[;G$EM(/PKGEA:T-XFZKTY;,CM;^\L7#VEU- PZ&-R*ZC3OBMXTTS:
M(]:DE0?PSHKC\R,UR!!!P5(/O3<"LK-;C>IZ_IO[0^N0$#4M+M;D=VC)C/\
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M&WD8RQ!T(QMST_.OI'&ZL>=)S2VN>PZ=XUT+4-H2^2.0_P $ORG]:Z*&6.5
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MG%9_P?L?M_Q+T[C*PDS'\*\S,I7Y4=^%=U<^MXD$<:J.B@"GT45Y1T!1110
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M(K285$P'I6JU(<3.*D&DJXT8/:HFA]*;BR+$%%3 /'G:<9&#3% \P!R0I/)
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MD!<W?7:>56O1D18U"JH51T %.HI$A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M-=%D7:ZA@>Q%%% '/ZKX+T;5@?-ME1C_ !**KZ/X!T31Y?-2W623LSCI111=
G@=2JA5    ]*6BB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tmb-20211231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %> O@# 2(  A$! Q$!_\0
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M_OL4?\)_%_T#Y/\ OL5P]%%A'<?\)_%_T#Y/^^Q1_P )_%_T#Y/^^Q7#T46
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M!,@!'R@=3FD-E<"*WE,?R7!(B.?O8.*+ =C_ ,)_%_T#Y/\ OL4?\)_%_P!
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MO^@?)_WV*X>CM18#V*QNA>V,%T%*"5 VTGIFBJV@_P#(!L?^N*T4AF/X[_Y
MT/\ UW'\C7GU>@^._P#D#0_]=Q_(UY]30@HHHI@%%%% !1110 4444 %%%%
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M:JMJNL7162%KIK93%P@VMGD?W=V*P]1>$^)4:)4C421[MI&W.1D\<5C\4<4
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M&L-(YN6#6[6YO'*E2"Y./SVXK5TL)+X=LU$%I</'.[%9Y_+V<]>M<EQ1@>U
M'<PO:/?:@\$T4UP;A2S.4Y3'(!;C&>.*J6-WI^EQ7%WYQA-S<GRUB <B-3T/
MH":Y'BCB@#IK=+>U\;Q/'+']G=_-5MPP P)Q[5BP?8<3&Y,_F[OW?EXV_CFJ
M?%+3 [9]0LSK]U&(8 _V4C[5YG+?(..N/;\*RKR]M8]#TV)[6&XD-NPWESF,
MY/8?GS7.\4O%( HHHI@%%%% !1VHI": /6M!_P"0#8_]<5HHT'_D V/_ %Q7
M^5%2,GOH89H56:%)5#9 <9&:S_L%A_SX6W_?%:=U_JQ]:Y[Q!KL?AVS@O;BW
MEDM&G6*>5,?N QP'8?W<XS0!?^P6'_/A;?\ ?%'V"P_Y\+;_ +XK"M/&NE7%
MO?7LT@MM-M[DVT5Y*PV7+#[VP#D@'C-7KGQ1H5G]E^T:M:QB[4- 2_#J> <^
MGO0!?^P6'_/A;?\ ?%'V"P_Y\+;_ +XJM%KFESZK)I<5]"]_'G?;JV67'7([
M=142^)=$?4AIRZI;&\+M'Y._YMR]5^OM0!>^P6'_ #X6W_?%'V"P_P"?"V_[
MXK-N_$^E6VF27L=W'< 6\MQ''&PS*L8.[;],8K+?XAZ*?"\NM6T@N3#'%)-:
MQN/,C\P@ 'MQG]* .F^P6'_/A;?]\4?8+#_GPMO^^*QO^$PTJW-W_:%S%9+!
M<FW4R2 F0A0Q( Y'![U%<^.=%LM>.FW=S'#&;6.YCNF<>7(')  _+KTYH WO
ML%A_SX6W_?%'V"P_Y\+;_OBJK:]I*:JFEMJ-N+YP"L&_YCD9'YCFLU/&VD7'
MB>QT*RG2[GNO/#O"P*PF)02&^N2!CT- &Y]@L/\ GPMO^^*/L%A_SX6W_?%3
MT4 0?8+#_GPMO^^*/L%A_P ^%M_WQ4]% %?[!8?\^%M_WQ4UQ9V<D@,EG YV
M@99,\4ZI)OOCZ"@"I]@L/^?"V_[XH^P6'_/A;?\ ?%3T4 0?8+#_ )\+;_OB
MC[!8?\^%M_WQ4]% $'V"P_Y\+;_OBC[!8?\ /A;?]\5/10!!]@L/^?"V_P"^
M*/L%A_SX6W_?%3T4 0?8+#_GPMO^^*/L%A_SX6W_ 'Q4]% $'V"P_P"?"V_[
MXH^P6'_/A;?]\57U349-.BA\FPN;Z>:3RXX8 ,YP3DDD # ZDUBOXYM!:QSP
MZ?>S*(FFN0@4&U17*,6R><$'IGIF@#HOL%A_SX6W_?%'V"P_Y\+;_OBJ \06
M;^(8-%C69[B:%IMX3Y%  .,]R0>@HT_Q%9:IK>H:7:[WDL AEEQ\A+9&%/?&
M,&@"_P#8+#_GPMO^^*/L%A_SX6W_ 'Q4]% $'V"P_P"?"V_[XH^P6'_/A;?]
M\5/10!!]@L/^?"V_[XH^P6'_ #X6W_?%3T4 0?8+#_GPMO\ OBC[!8?\^%M_
MWQ4]% $'V"P_Y\+;_OBC[!8?\^%M_P!\5/10 RVL[..X5H[.!&'1E3!%1_8+
M#_GPMO\ OBK</^M6H^] $'V"P_Y\+;_OBC[!8?\ /A;?]\5/10!!]@L/^?"V
M_P"^*/L%A_SX6W_?%3T4 0?8+#_GPMO^^*/L%A_SX6W_ 'Q4]% $'V"P_P"?
M"V_[XH^P6'_/A;?]\5/10!!]@L/^?"V_[XH^P6'_ #X6W_?%3T4 0?8+#_GP
MMO\ OBC[!8?\^%M_WQ65J7B0:;?-"^FWDEM&T:37:!?+C+G"CDY;WP#BF6?B
MNVN]16W^R7,5O*\J6]X^/+F:/.X#!R.AQD<XH V/L%A_SX6W_?%'V"P_Y\+;
M_OBL%_&M@-#O=5CM[AHK6Y%J$<"-I7) &-Q& <]\5M:9>MJ%A'=-;F#?G"&1
M9./7<I(/YT 2?8+#_GPMO^^*/L%A_P ^%M_WQ4]% $'V"P_Y\+;_ +XH^P6'
M_/A;?]\5/10!!]@L/^?"V_[XH^P6'_/A;?\ ?%3T4 0?8+#_ )\+;_OBC[!8
M?\^%M_WQ4]% $'V"P_Y\+;_OBD^P6'_/A;?]\58HH :MG9BUD06< 0L"5"<$
MU%]@L/\ GPMO^^*MK_J&^HJ.@"#[!8?\^%M_WQ1]@L/^?"V_[XJ>B@"#[!8?
M\^%M_P!\4?8+#_GPMO\ OBIZ* (/L%A_SX6W_?%'V"P_Y\+;_OBIZ* (/L%A
M_P ^%M_WQ1]@L/\ GPMO^^*GHH @^P6'_/A;?]\4?8+#_GPMO^^*GJ*ZN%M+
M2:X=798D+E47<QQV [F@!OV"P_Y\+;_OBC[!8?\ /A;?]\5@?\)BB++%<:3?
M07RF'R[-MA>7S20F"#@9*G.3QCFG'Q=NLTFM]'OYY1YOGPJ%!M_+.'W,3C/H
M >: -W[!8?\ /A;?]\4?8+#_ )\+;_OBL'_A-+)IXO)M+J6T80^;=@ )"91E
M P)SGIG XR*Z7H: (/L%A_SX6W_?%'V"P_Y\+;_OBIZ* (/L%A_SX6W_ 'Q1
M]@L/^?"V_P"^*GHH @^P6'_/A;?]\4?8+#_GPMO^^*GHH @^P6'_ #X6W_?%
M'V"P_P"?"V_[XJ>B@"#[!8?\^%M_WQ2?V?8?\^%M_P!\58HH O0*J0(J*%4#
M 4#@44L7^J7Z44 1W7^K'UK(U6R&I:-?6)"'[3;R1#>,KEE(!/XX-;%PI9 %
M&3FJWDR?W: //-2\!7TOA7PS864UJMYHJ*&5G>.*4^7M8[E&1SD].:Q]5^%V
MLW6FVNFVU]9):1V:Q,K-(-DHDWDCJ64],,>/2O6_)D_NT>3)_=H YSP]X>?2
M=7U[4)_(>34KP3QL@RR($5=I)'J":XO2O">L:GK%]YL=K:Z=%XCEOC*\;"X?
M;T"\8*G/7/YUZOY,G]VE\J3T- 'EEG\.M<CAAMI[O3O(M;*^M(&CW[F\\DJS
M9&!C/(%,?X;:U=Z?)!<W.F0R1Z=!80&V5PKA'#EWR.O&!C->J^3)_=H\F3^[
M0!Y=K/PWU*]FOKBWEL'EGU"2ZC\R22-D5XU3AU&0<KR,$$5/-\.]2N+*]BGO
MK2:>?0X]-65D(Q(I)+8QPO(]^*]*\F3^[1Y,G]V@#S$?#6]_X27[5)<V\EA)
M/%<N3)()4=(PN%4?*1D9!)Z=JL^'? ^KZ5K>@3W4VFFTT:.ZA1H%82SK*/E9
M\C&1W'UYYKT7R9/[M'DR?W: &44_R9/[M'DR?W: &44_R9/[M'DR?W: &5)-
M]\?04GDR?W:DEC=GR%["@""BG^3)_=H\F3^[0 RBG^3)_=H\F3^[0 RBG^3)
M_=H\F3^[0 RBG^3)_=H\F3^[0 RBG^3)_=H\F3^[0!A>)K36;[3X[;1[B" O
M)_I#2NR%H\<JK*"02<<^E8USX7U1[4QV?]FV@NK'^S[J)=[)''N)#1G@EL$]
M>YS7;>3)_=H\F3^[0!B7.C/-JNG3K+M@M;::!L$ASO4*"/IBL_P]X0_X1[6I
MKF'4+J:S:TC@CBFDW$$,Q)/'^UQ]375^3)_=H\F3^[0 RBG^3)_=H\F3^[0
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M3)_=H\F3^[0 RBG^3)_=H\F3^[0 RBG^3)_=H\F3^[0 RBG^3)_=H\F3^[0
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MMV@!<GUHR?6DHH 7)]:,GUI** %R?6C)]:2B@!<GUHR?6DHH 7)]:,GUI**
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MF61-AW'IM Q5ZW^'V@V^GW=AMO);6Y18_+EN2PA53N41_P!W!Y'?@5UNV/\
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M)MC_ .>A_*C;'_ST/Y4 1T5)MC_YZ'\J-L?_ #T/Y4 1T5)MC_YZ'\J-L?\
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M *LAL[E#^7F,G'1E.WUKJ'U:_N/AK]OCN)[6\,6//FCW,"&P6^4="/XL>^*
M.QJ/SXO/$'FIYI7=Y>X;L>N.N*\KN_%.J-H=K&EYJ$4R^?BXWKMF*XVXD"'?
M[ *,U$UQK$1O-<AN9$N;I+!+B=XPHAC="6((4E0#QT.,]* /7<C.,T5Y=:/K
M&H7VCS2:U+Y[Q7L%I-&IV2,,; Q9!N)YYP,A>*ZWP=JM[KUC<:K=!XX99!%!
M RXV;!AS^+[ORH Z2BBB@ HHHH **** "BBB@ HHHH **** )(?]:M1]ZDA_
MURU&V<'&,]L^M @HJM8K=I; 7KQO-DY*# QVJS23NK@G=#7D2-=SNJKD#+'
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M[0)2^"WRA#O')'48Q3+N^U33+F]M;759H8'U2X-Q/*2OE\ QKN"-@-R>G.*
M/6**XZ^U#51\.(+QK\0:@Z1[[E8F .6Y.-I*9'<CCKBN6U#Q7JQT2T\F[U""
MX6WF<2,R@3NK$+A@A\SIT &0<T >K>?$9S )4\T+N,>X;@/7'I4F><5Y)-+J
MUI/J&JV]W)$U]<VR7-RZA?)0PAN&"$J-W'0@5:MI-:O+[3+IM7E^VOIMXELZ
MH0DS+*I0'<HR2O4X&=N10!ZC17,>'-:O-4\-WNO3+*(IM\MK $RR1HN, =R6
M!XKC-/\ $6NW*7,46IW3>9# RRMB1HW:4!L?( #M/W><>M 'K6::CI(@=&#*
M>C*<@UYY<ZAJ-I<3:??:U?P:=#>7$7V_RP96Q$C1HQ"XP2S<XYQBNG\%!QX*
MTC?NW^1SN7:<[CU':@#>HHHH **** "BBB@1?B_U2_2BB+_5+]**!D=U_JQ]
M:PM<URS\/Z>+N],A#.(HHH4WR2N>BHHZDUNW7^K'UKD/%^CW^I1:9>Z6(GOM
M+O%NHH9FVI,,$%2>QP>#0! /B#I4=K=R7EKJ-C/:>69;2Z@V3!7;:K 9P5SW
M!K;EUBU1K01%[E;F;R5>W =4;!.6(/ XKS[Q%X5\2>+1?ZE=:=:V<YMX[6UL
MFN-V\"4.[.P& ,#  K-?1[BP\:Z4);*'3FO]86>#3K=MXA2.!D:7(&!N8@_E
M0!ZXEY:RO*D=S"[1?ZP+("4^OI5*\\1Z18QVDDU]"4N[A;:%D8,&D/;(Z>YK
MRRQ^&GB$:=J5G*4AN?L<MNMT)EVW;-)N^8*,X(ZEB2,UKW?A&^O+2UN4\):;
M:FVU6&Z^PQS*3+&J;7R<;1DXX'8<\T >AZ?JD&H1NR+)"RNR;)@%8[3@L!GE
M?>IOMMIYD4?VJ#?*,QKY@RX]O6O,I? 6O)H2OI_D6NKB\NER)./LMQD,,@=5
MX8#U%,U#X<Z@GBB$6,(?2U^RK#,LJHULL/7L6R>ORD Y.: /5Z*** "BBB@
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M>@#NK36M,O8/-@NX#&LS0C<P'SJ<$ 'WI+G7-*L[.>ZDO;?R86"2E&#;23@
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M110 4444 %%%% !1110 4444 %%%% $D/^N6H^]20_ZY:C[T %%%% !1110
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M&S=FC^TK/ ^"P:.,.N"IQCFK"_#^P6QFLS?7AB:-8XN5'E*KAP.!\W('WLY
MQ4EKX$T^VWDW5S(9#*SYVC)DC"-C XX Q0!5L_',IO'6^TRYCM]EJ3(D?$!F
M0'Y^?[Q[=JU_$/BNQ\.7$5M<I)+<2(TGEQE00BG!;)('7H.IJ*+PA;+8SVTM
MY<S&;[/OD;;N/D@!>@] ,U/KOAFVUR\BO&N)K:ZC1HO,B"G*,<E2&!'7D'J*
M ((O&-E<2@VMK>7%F%1I;R.+]W#N7>-W?[I!/'&:@/CJQCMWN+BPOX(C";BW
M+Q?\?" @$H >OS X.#@U.?!]LLS>5?WT5K*$^T6J282<JNT%CC/( !P><5"/
M ]HT/E3ZA?7$<<7DVRRN#]G3<"0O'/W0,G)Q0!(OC&%LPKI>H'4!.8!8[!YA
M(4/NZXV[2#G-5Y_'^G10B5;*_E183-/LBY@4.8V##/4,","KUWX5@N+Z6_AO
M+JUO7G$RSPD90[ A4 C!! Z&H4\%Z?':3VZS7)$]OY$CLP+,3)YC.3_>+$Y^
MM $;>,[52&N([BQ\F=HYXYX<MM$1D!R#P"O/?TQ1<>-H+.R6XN])U&W9Y%2*
M.6-5\P,"0=Q.T<#N0:LWGA'3[^ZFFN'E<3/O>/(P?W7E8_[Y/YU!)X.$]H8;
MC6]2G;Y0C2LK!5 P%VD;3]2,T ;]G=)>V4%U&KJDR!PKC! (S@U/5+2=,@T;
M2K?3K8N88%*J7;).22<GZDU=H **** "BBB@"_%_JE^E%$7^J7Z44 ,N!N0#
M('/>JWEC^^M6+K_5CZU4H D\L?WUH\L?WUJ.B@"3RQ_?6CRQ_?6HZ* )/+']
M]:/+']]:CHH D\L?WUH\L?WUJ.B@"3RQ_?6CRQ_?6HZ* )/+']]:/+']]:CH
MH D\L?WUH\L?WUJ.B@!_EC^^M22H"X^=1P*@J2;[X^@H /+']]:/+']]:CHH
M D\L?WUH\L?WUJ.@8(R""/44 2>6/[ZT>6/[ZU'10!)Y8_OK1Y8_OK4=% $G
MEC^^M'EC^^M1T4 2>6/[ZT>6/[ZU'10!)Y8_OK1Y8_OK4=% $GEC^^M'EC^^
MM1T4 2>6/[ZT>6/[ZU'10!)Y8_OK1Y8_OK4=% $GEC^^M'EC^^M1T4 2>6/[
MZT>6/[ZU'10!-$@$H.]33?+']]:(?]<M1]Z )/+']]:/+']]:CHH D\L?WUH
M\L?WUJ,D 9) 'O10!)Y8_OK1Y8_OK4=% $GEC^^M'EC^^M1T4 2>6/[ZT>6/
M[ZU'10!)Y8_OK1Y8_OK4=% $GEC^^M'EC^^M1T4 2>6/[ZT>6/[ZU'10!)Y8
M_OK1Y8_OK4=% $GEC^^M'EC^^M1T4 2>6/[ZT>6/[ZU'10!)Y8_OK1Y8_OK4
M=% $P0>4PWKU'--\L?WUH7_4-]14= $GEC^^M'EC^^M1T4 2>6/[ZT>6/[ZU
M'WQGGKBB@"3RQ_?6CRQ_?6HZ* )/+']]:/+']]:CHH D\L?WUH\L?WUJ.B@"
M3RQ_?6CRQ_?6HZ* )/+']]:/+']]:CHH D\L?WUH\L?WUJ.B@"3RQ_?6CRQ_
M?6HZ* )/+']]:/+']]:CHH D\L?WUH\L?WUJ.B@"3RQ_?6D\L?\ /1:910!H
M1C$:C.>**2+_ %2_2B@".Z_U8^M5*MW7^K'UJI0 4444 %%%% !1110 4444
M %%%% !1110 4444 %23??'T%1U)-]\?04 45DNSJ+QM"@M @*R;OF+>F*M4
M44DK"2L8WBO8?#%ZCWWV$2*(_M!SA"S <D<@'.">P)-<>FJ_\(['?VMO%#8W
MKF!5%O.;FW.XD;E#$;7(!X8XKO=5O++3],N+G4<?9$7$H*;P02!C'?)(&*PH
M+_PI!I-RD>FI;V(=1+"=.\M9'8X4!-OS'-,9QS>(=5U-]/U2:1)QIHOW\A5&
M)GA,>UCL;&<-[@<^M6#XEU_4+*-);^V@ O+&3ST:-OEDE *D(Q 7H>3DC@UW
MFDSZ/>K+)IUO$JV\C1,X@\L!N P!QST ./3':K2:1IL<$EJFGVBPS-N>(0J%
M<^I&.: ,+0]?U#4?$$VDSI&'T\2?;65<!B6_<[?3*Y;\*ZFL;0[>PBGNY[.X
MENI+UO.>=EX(7Y H( &%QC%;)XZ\9]: "BC^M'4D=QU]J "BDR, Y&#T.:6@
M HHZYQSCK[4'@9/ ]30 44>OMU]J3( R2,>N>* %HJG/JMC;7'V>6X59O,CB
M*8Y#/DJ#]<&KF1C.1@]\T %%5FO[9;A[?>6FC9$=$4DH7^[GT'O5GU]J "BC
MOCOUQ1Z^W7VH **KVM[;WHE-O)O$,K1/QT8=15B@"2'_ %RU$V<' R<<"I8?
M]<M1]Z!%:QDNI;8->0I%-DY53D8[59HHI)65@2LCD/%ULM]JVGP[[2=XXI)/
M[/O)FA28<?,KC^(>A]:YR\\:W&G:-:?V5<,B6]IYKQ7.R1CB0J TC,,K\IP5
MR3P:[7Q#>Z!&]O9ZU:+>-(#)%"UIY_ ZMC!QUJM>:MX6C2V>\MHAMMS)$)++
M)BB!V],?*"1@#O3&<A_;&KZ;J5Y/#,DD^I7[Q"5MH\I$C5@@WL%YW?H:MV_B
M'7YKPZE]JMB4TKSS:)AEE"RD,RD'KM!/&?2N]6STZ]L0C64#6\P$ABEA'/H2
MI'6J^K6.G-I["5X[/"?9H[F)%#Q!\#:I(.,],4 ,\-ZK+KFF-J; "VGF<V@
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M2T?T/:LO4+#2?[6MII6*2V[?;3;01C]Z_*+*V!EB,G'/\J -N,.L:+(P:0*
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MQ6FWR&V"-HFRR<@L1_=Y%=SX7TBZTB/5A=;,W>I374>QL_(YR,^] &]1110
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M/-_V$_[YH\W_ &$_[YH CHJ3S?\ 83_OFCS?]A/^^: (Z*D\W_83_OFCS?\
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M]A/^^: &;CC&3BDR:D\W_83_ +YH\W_83_OF@!FX^II,U)YO^PG_ 'S1YO\
ML)_WS0 PDGJ325)YO^PG_?-'F_["?]\T ,W'U-5;FPM;R[MKJXA$DULQ:%F)
M^0D8SCUJ[YO^PG_?-'F_["?]\T ,W'&,G%)4GF_["?\ ?-'F_P"PG_?- $=%
M2>;_ +"?]\T>;_L)_P!\T 1T5)YO^PG_ 'S1YO\ L)_WS0!'14GF_P"PG_?-
M'F_["?\ ?- $=%2>;_L)_P!\T>;_ +"?]\T "_ZAOJ*CJ<2?N6.U.HXQ3/-_
MV$_[YH CHJ3S?]A/^^:/-_V$_P"^: (Z*D\W_83_ +YH\W_83_OF@".BI/-_
MV$_[YH\W_83_ +YH CHJ3S?]A/\ OFCS?]A/^^: (Z*D\W_83_OFCS?]A/\
MOF@".BI/-_V$_P"^:/-_V$_[YH CHJ3S?]A/^^:/-_V$_P"^: (Z*D\W_83_
M +YH\W_83_OF@".BI/-_V$_[YH\W_83_ +YH CHJ3S?]A/\ OFCS?]A/^^:
M(Z*D\W_83_OFCS?]A/\ OF@".BI/-_V$_P"^:/-_V$_[YH MQ?ZI?I12QG,:
MG '':B@"*Z_U8^M5*MW7^K'UJI0 4444 %%%% !1110 4444 %%%% !1110
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M61SCWP<4 ;UIJNGW]Q/!:7L$\T!Q*D;@E#[BD76-,>]FLEO[8W4"EI8O,&Y
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M%NGV^BV&JE)VAO2-BA?F08RS,/10"35/Q1X>N-5UBRO$T^SOX88)(GAN9VC
M+$'(*]>E4[/P--/#:VVKWTPM[2T-O MG,4QO8EP3CE0-JCV6F,V]1\126>JO
MI]MI5Q?21P+.[Q2(H"G./O$9Z5$/%D=W%9'2=/N=0FNH!<^4C+'Y<><98L<
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M;R+4?/?S47<#@)C&<9'XU=C\'7,3PZJ+Z8ZR+S[7(AF/V<[CAE"X_P">?'U
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M/8T ;4OB+18+2"[EU6S2WN"1%(91A\=<?2J:^+]);5]0L6N(DCL$1I[EY5"
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MY[[["3QC?L+[OIQ5=/ ^D+;R0EKIQ(\KNSRY8M(@1SGW"CZ5/_PB.F_VK'J
MDNP\<XN5B$Q\KS-A3=M]2#0!BR_$B&&RLKB32Y8WO(?M,,;R@$PX^]D9Y)Z"
MNPL;N/4+"WO80PBGC61 XP0",\CL:QY?!^FR6=C;QRW=N;*W^S12P3%7,6,;
M6/<<5N00);6\<$0(CC4(H)R<#WH DHHHH **** "BBB@"1?]0WU%1U(O^H;Z
MBHZ "CJ<444 <1/\1K9KFZMK*S>9D\V.%]WWI$!ZC'"Y4\YK)TOQMK-FDEWK
MZM]G2VMRB*B+YLLPRN2"<#&?P'-=<OA#34NY9DDNUCD:1_LPF/E*[@[F"^IR
M?;FG2>$M+EM7@99MK) @82$,GDC",I[,/6@#.L_'/]IQI'IVDS7-\2^ZW60!
M0J $L'/!'( ]ZB3Q9?MK$]O/I\MO$EW%#"OREW+0O(4;GC[O7Z5IMX/L3#&!
M=Z@MPCNWVM;@B8[@ P+>A '&.U/@\):;;7T-U$URIB>.18S*2N^-&0,<\YVL
M<\\T 9E[\0]-M;>WD2"20SQ1NH) "N^?D8]B-IS]*W- UN'Q!I8O88GB^=HV
M1NS+UP>X]#5%?!>C+;W,<*S1M-=_;/-CEP\4O3Y#V')XZ<FK]AHXTTP);W5P
MT,:R&197+M*[$'<Q/<8/YT 9FI>,H-,\01:7+:DJ\T4)E\U<[G( (3J1DC)J
MLGCR(*9KG2[F"V:.9X)-RL93&VUEP.F21C-7KOP;I=YJDNH2/=+)).ERR)-A
M#*A!#8_ <=*E?PII+VT-O+'(\,4<T:JS]I3ELGUST]* (]!U?4=1UO5;6_LC
M9BV2 I"S!B-X8D[AUZ#Z5G'X@VJ7MW;RV+CR(9IDV2J[.(\9! ^Z3GBMO2-
MM='FNYXI[J>:["":2YE+LP4$+].#BLR/P%HT;,!)>%?+EB6-I\A$D^\ ,?KU
MXH T-&UU]3FNX+FQDL9K9(YBCN'S&X)5LCZ'(K"MOB9IMP\I^RS>2(V>%E.Y
MGV]B/X2>V3756^F6]K?3WD8;S9H8X7W'(*ID+Q_P(UD1>"](@CEC9KI[5HVC
M6WDN"8X5;KM';V].U "/XEU".2&T?P]<KJ4[-Y5N9EVL@4$MOZ<9 QZU3;Q[
M&8A-!I-S)%'")KEBZJ8!YAC88[D,IX'I5W_A#; A9#>ZD;M6W)>&Z/FJ,8V@
M]-N.V*F3PCI$-G-:QI(D,UNMLP\PYVAM^<GN6))/?- %<>+U-R'_ +-G&FO<
MO:1WNX8:5<_P]=N5(SZUGKX_E-J+EO#]TL7V:.]+&5.(&.-WU_V:UQX1TQ;X
MW.ZY*>:TZVQF/DK*P(+A?7DGTR<T\^%-,-F;0B;RC9)8GY^?*4Y'X^] %"/Q
M5,\\MI9:?<:C=+-,60%8]D:$#OUY.!W-1S^.8H]8_LPV;1/(6BC=Y%+"01E_
MF0<@<$9J_-X0TZ4EXYKRWE9Y':6WG*,PD(+*2/X3@?2JT7@31;>ZCEC>Z0),
M9HX?/)17*E6(!Y.0QZYH HZ)XQE80MJI7RIH[?$JKM6-V@\P[O8X.*ZO2[X:
MGI=K?")XEN(Q(J/U /(S^&#7.ZMX*MKC1&TFSVK!<M D[S.=RQQ8 V8_BP,?
MB:ZM%5$5$4*B@!0.@% #J*** +\7^J7Z441?ZI?I10!'=?ZL?6N ^(\FS3])
M2ZDDBT:34$34W1BN(L' 8CD*6QFN_NO]6/K5)T26-HY$5T8896&01[B@#QZ^
MU:V\-:KJL_@FXB_LF*U@-UY3F6WBE:4#*DD@$J6S@T_7O$^HZMJH%MKD5MIU
MKX@AMXYHP-A0QYRS9P1G/L:]8CL+*&U:UBL[>.W?.Z)(E"'/7(Q@TATZQ: P
M-96QA)!,9B7:2.G&.U 'G-EXWU61M1O'U.UFN(_M@BT-8,R+Y7W&W#G!')SP
M>U9T_CO7K7396M=9L]4>2PANS/' ,6DCR*IC8#KD$\'GBO6DM+:.X:X2VA6=
MQM:58P&8>A/4TV/3[**.2..SMT21MSJL2@,?4C')H \RF\3^*=/U&Z675(KF
M&QUBULFC^RA3,DP!.3VQGC%9\'Q"\3S_ -I2K<6496*Y813@?Z(4<*I(7+=.
MNX=<=J]@-M;DDF"(EF#$E!RPZ'ZCUIJV5HDLLJVL"R3#$KB, R#_ &CW_&@#
MDOAUXDO=?LM1CU&<S7-I.$+[4Q@J" &0E6_"NTJ&VM;:SB\JUMXH(\YV1(%&
M?H*FH **** "BBB@ HHHH *DF^^/H*CJ2;[X^@H CHHHH QO%&H7&F:(UQ;2
MI S311/<.NY8$=PK2$>P/TKS\>(M4LI;N&QU6WG2XU&16U)W2-#MC4A06RH)
MY^N.*]7D\L1MYI41X.[?C&/?-0+!8R6_EK%;- 0&VA5*D>N.E 'GTOB7Q)-I
MLM['?VT+6ME;SLD<7F),SNRGDX." #Q5F37M6M]6ET>]UZ&SBBGF4ZG+"HW;
M55ECP?E!^8GW KN7-EEE<V^2OS!BOW1Z^PI)18R*!-]F996# /M(<]CSU- '
M P^)?$-Y92Z@+R.!+2VM9FA$ (G,DC*3D\J"J@CZU5O_ !/JMQ/KFGMJ:CS+
M>Y^S&V"L(M@R,CAT( (.1@DC!KTEVM [I(8-^S<ZDC.T=R/050L=7T6_NW%I
M+;M-)#'(S[0/,1RP7G^+[C<>U '(#Q#JEOH]Y=G6E:&!K>T@98D(8NB$N6)Q
MGDC).*S!XHUBX@L=1.HJ[VEW>PK&-I%R5A#("5X)Y(X_"O3REA%');E;54V[
MI(L*!M'<KZ57M+S2KV%)K=86M_+6X27RP(\= 0>F>/J* .!L/%^NR6S"?4[$
M12M;[[Q)$E-F)&()8* H''&XY!ZUM>'9I[GP?XCDBU'[1-]KO/+O(Q]["#!
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M+*D08X+,PR!CZ"ET_4[/4[-+JTG5XG&1G@@9(Y!Y'(- %NBHQ<0,4"SQ$O\
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M8SK;+LN9RZ(TL\%N3%$7^[N/49_'% %_5;&0>'YM/TN!(S(!$JIA5C5CAF_
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MMXX$R?E"D!R"1D"NK^S2>WYT?9I/;\Z .0D\$6O]KF\M[EK>%W222!8(VR4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tmb-20211231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (7 W$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*MP:9=7-C->1(###]\YY_*JE=QIEJ+:&PM7FMUCEB?SXWE <EQQQ^ HZ <HF
MF2OI@OPZ>69A#MYSG&<_2F:A8R:=>R6LK*SIC)7IR ?ZUN&!K;PRT##YH]2V
MG\!5'Q3_ ,C%<_1/_0!2O_7W#&0^'K^>"&5!#B9=T:F50S#V%9DD;Q2-'(I5
MU.&![&NTMK6TN4T#S9W2=(=\487AR#G&>U5;.>\6XFOY;A+6&>[V-$80[,WI
MR.*?6PNESDZ*[6]D.FZ?J\EJL:,E\ I* [<@= 14EWB*:[U"*./[6MC'(IV
MX8D@MCI2O_7R'8Y&;3Y(-.MKUF0QSE@H'48..:J5W-F?[4AT62]"RN3*V"H
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MD_[X- #VO[I_L^9F_P!'&(L8&SG-65U[4T,I6[=3*VY\ <GUZ<'Z53^S3_\
M/"3_ +X-'V:?_GA)_P!\&@":;4[RXBFCEG+),XDD&!\S>M/76=02Y6X6Z<2J
M@C# #[H[8[U6^S3_ //"3_O@T?9I_P#GA)_WP: +,^L:C</$\MW(SQ-N1NA4
M^V*+G6=0O#&;BZ=_+;<H(  /K@56^S3_ //"3_O@T?9I_P#GA)_WP: )FU.\
M8W),Y)N<>=P/GIPU:^&W%P?DB\E?E'">G2J_V:?_ )X2?]\&C[-/_P \)/\
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MD_[X-'V:?_GA)_WP: (J*E^S3_\ /"3_ +X-'V:?_GA)_P!\&@"*BI?LT_\
MSPD_[X-'V:?_ )X2?]\&@"*BI?LT_P#SPD_[X-'V:?\ YX2?]\&@"*BI?LT_
M_/"3_O@T?9I_^>$G_?!H BKJ? ?_ "')_P#KV;_T):YO[-/_ ,\)/^^#73^!
M898]:F+QNH^SL,LI'\2T@/0****0PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "L?0O]?JG_7VW\A6Q6/H7^OU3_K[;^0H
MV**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+IVH7-M-)-+8Q^9) 8)$?!Z'!7.">X&*BL?%5OJPT6XBO#9K=[]UM-:OF4A
MQ <@8 SG=T- '4T5C6GBO1+ZY6WMK]7D8,4^1@LF.NUB,-CV)J'3?&OA_5KB
MU@LM0\R2Z#& &%T#XZ@%E SQTZT ;]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "N5^(.JPZ9X89)IUA%W,EMO;H Q^8_\
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MS]L8&XTU=/V^7]T#^+K^E)_U^/\ P _K\O\ @E!O'%W<:C%9Z9HGVMI--34
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[G\36A3>^A*"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK'T+_7ZI_P!?;?R%;%8^A?Z_5/\ K[;^0H V**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .0UG_D?M*_ZY+_Z$]=?7(:S_P C]I7_ %R7_P!">NOH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBL2WO[I_&%U8-+FV2V#JFT<-\O.<9[F@#;HHHH **** "BBB@ HHHH ****
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M-U>EA:VTLQ7EO+0MC\JR5:J]FSI>!PL5=P1T7_"?ZS_<M?\ OV?\:/\ A/\
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M1[>K_,'U##?R(ZG_ (3_ %G^Y:_]^S_C1_PG^L_W+7_OV?\ &N7"LQ 4$DG
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M2(L-RAU(R/6FZU9;MBC@\'+:*-B7Q'?7FI0ZG*(?M$ "H%4[<#)Y&?<UH?\
M">:O_=M?^_9_QKF(O]4WUHKDS#%5J;AR2:NOU/$E0I>VJ+ET3.G_ .$\U?\
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M_C1_PGFK_P!VU_[]G_&N<BMYIRPBB>0JI9@JDX'J:CI_7L4OML/84OY4=/\
M\)YJ_P#=M?\ OV?\:/\ A/-7_NVO_?L_XUS%%+Z_B?YV'U>E_*=/_P )YJ_]
MVU_[]G_&C_A/-7_NVO\ W[/^-<Q4L%M/<EA!"\I5=S!%)P/6FL=BF[*;#V%)
M=$=%_P )YJ_]VU_[]G_&C_A/-7_NVO\ W[/^-<X()3"9A&_E!MI?' /IFHZ'
MCL4MYL/84OY4=/\ \)YJ_P#=M?\ OV?\:/\ A/-7_NVO_?L_XUS(!)  R3VJ
MQ_9]YYRP_99O-9=RIL.2/7'I36,Q;VFQ.A26Z1O?\)YJ_P#=M?\ OV?\:/\
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M<'@ GH.:6/2-%ED,L>R4+;22200W!8*RD8PV,\@USXUO41+!(+DJ\ (C(4#
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M.DWTLOQ\NUNYUMXD4WAK5-2@ 6.\6%F4?PR!_F']?QK"T;38+Z*5IK74)BK
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MK7KFC@Y1VG;^O4].><TZGQT4_5_\ \/N[ZZOY?-NKB29_5VSCZ>E5Z]XHI/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU>P7/1:*\Z_X6Q;?] F7_O\ #_"C_A;%M_T"9?\ O\/\*/J]7L%ST6BO.O\
MA;%M_P! F7_O\/\ "C_A;%M_T"9?^_P_PH^KU>P7/1:*\Z_X6Q;?] F7_O\
M#_"C_A;%M_T"9?\ O\/\*/J]7L%ST6BO.O\ A;%M_P! F7_O\/\ "C_A;%M_
MT"9?^_P_PH^KU>P7/1:*\Z_X6Q;?] F7_O\ #_"C_A;%M_T"9?\ O\/\*/J]
M7L%ST6BO.O\ A;%M_P! F7_O\/\ "C_A;%M_T"9?^_P_PH^KU>P7/1:*\Z_X
M6Q;?] F7_O\ #_"C_A;%M_T"9?\ O\/\*/J]7L%ST6BO.O\ A;%M_P! F7_O
M\/\ "C_A;%M_T"9?^_P_PH^KU>P7/1:*\Z_X6Q;?] F7_O\ #_"C_A;%M_T"
M9?\ O\/\*/J]7L%ST6BO.O\ A;%M_P! F7_O\/\ "C_A;%M_T"9?^_P_PH^K
MU>P7/1:*\Z_X6Q;?] F7_O\ #_"C_A;%M_T"9?\ O\/\*/J]7L%ST6BO.O\
MA;%M_P! F7_O\/\ "C_A;%M_T"9?^_P_PH^KU>P7/1:*\Z_X6Q;?] F7_O\
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MWH660?4&HE"4':2 V:*:CB2-77HP!%.J "BBB@ HHHH **** "BBB@ HHHH
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M /KW]J[2\UAA8ZY,GEV=V((%7R[D2,Q#<G< ,G'6K$.J ZXX2^17N-( W>:
M&FP,9/\ >ZTW5E9V7]6N%CSG[-/M9O)DPO#':>/K38X9)B1%&[D=E4FO0+69
MY_#KVFHW(M?)20_:;>]4^:Q[.G4G/&:P?"D:@7EPM]+#+$%VPQ7"PF49Y^8@
M\#TQ5JIOY"Z'/+;SN2%AD)!P0%/!I5MIV9E6"0LOW@$.1]:]$U[4X[:+7I;"
M\CCD>Y@9&BD&3\HR1BK#O;G6I[^'4VW;X0\,-TD2D;>78D'=]!4*L[7M_6G^
M8WH<''HKR^'I-5$IW)<BW\@)DDD9SG/Z8K.6"9R0L3L0<$!2<&N\U"[B32]8
M-E/")8-6%PJAP,J .1Z\^E/UME7[)%ITZVT^LSK>-(S;/+7:!R>WS;C1&J^V
M_P#DO^"#_K^ON.!>VN(\;X)5R<#<A&32-!,KA&B<.>BE3DUZ8;Y+?Q!8075Q
M')IMNC)%-)<*S23$??;DX]O2FIJ47VN."XB@MKD6\ZVUQ)?+.=Y QEL#'?&:
M/;/L%CA;W17L=%L=0>0YNG=?**8*;<=\\YSZ5;M?#D']GVUWJ>J1V(NR?LZ&
M(R%@#C)Q]T5>\32S'PQH\-W=)/=I+-YF)0Y&<8R14EW;IXBT713:75LCVD)@
MG264(4Y^]SU'TI\[:U?4.QSNHZ1=Z9JDVGRQEYHS_P LP2&!Y!'MBA-&OY-.
MEOEMG\B)PCG'()]NM=S=ZK#J5QK TB\BBO<0QQ3,XC+HHPVUC[UGVEWJ#^'-
M5LWU)3?+<(QS<#E,?-@YYI*K+EUWT_0#BO)E\OS/*?R_[VTX_.M+6-#ETJ2!
M0[3I+;I,7$9 7=GCOZ5V7VR,7!N#>0?V'_9^P0>8/O[,8V=<[N]3/?;;FVN7
MOX3I"Z:$EB\X'<^T\;>N>E)U9=@7]?@>:B&4Q^8(W*?WMIQ^=#0RHF]HW53C
MDJ0*]*?5+1-'MWLK:&>U^P^7(C7RQJK8^;,9!R??O7->+-1>6'3+6*YWVZV4
M):-6R X7O[U<:C;M8$5])\/66K)'#%K,:ZA(I9;8P-C(!."_3.!1:>&HS81W
MFIZDEA'-*T4 ,1D+D<$\=!GO6IX?TYM.THZI;O;2ZE.I2!7G11 IX+$$\MZ"
MFRPC7O#FE6T-U;I<V,LB3K+*%X8@[AGJ..U2YOFLGI^0D4X/!TS7M_:7%_;P
MRVB,X099I0%W @<<$8YJ+3O#45U96=Q=:DMJ;V4Q6Z"$R;CG')!XYK>_M2TN
M_&FI3QSIY*V#PK(3@.1'CC\:70+M[31]+73Y+*5#(7O%NI0&C.<?+D_+QSD5
M//.WW?J-G#WUI)87T]I*5,D+E&*G()%:NB^&_P"T[&XU"ZO8K&P@8(TSJ6RW
MH .M6-72$6^J&Q6SELOM8VSR-F?_ (#SROX5>T1H-5\$W>B"Z@M[P7 F03/M
M#CCN?I5N;Y+^@/<P9M$EEU"2WTEGU.-%#>;!$1U]1VJ>Q\,7=[8:A-B5+FS*
MK]F\HEG+''KQ^5;MA9M;^'=0T:WU"U34?M"2EEN JLF!P&Z''-:FM:O:R6&O
M&UO$,RPP1ET?!=@?FQZU+JRV7]; M3S_ /L?4OMOV+[#<?:0,^5Y9W8^E._L
M75/M$D'V"X\Z-=[IY9RH]2*]#N+ZWN9+ZVAO84O;G2X5BE,H&6 Y&[L:1-2A
MMK.2W-]$U];:0R22K*#E]P( ;N11[:782U_KT_S.+/A+5ET674WMW1(I"C1,
MA#X'5NG3_"ET/P_;ZIIU[?76H_8H+0KO;R#)G/L"#6I9W$FH> +Z'[:OVI;P
MRLLLVUF3:,XR>>_%2^#)%_X1_685%E)/(8]D-VX"/SWR13<Y)2\K?H/L<]K^
MAG0[F%!<I<PSQ"6*55*[E/MVK)KO]<=9]6C-O_9MQ<#3\7$<LF88B,<1\]?0
M9-<!5TI.2U W/!O_ ".&F?\ 78?R->W:M#]HTB\BQDM"V/KCBO$?!O\ R.&F
M?]=A_(U[T0""",@UQXSXT",[09O/T&QDSG]RJG\./Z5HUB>%LII+6QZV\SQ?
MD:VZY!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7-VO_ "4"]_Z\Q_-*Z2N;M?\ DH%[_P!>8_FE '24444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\^^)?^1HU;_K\E_\ 0S7L7@AT?P;INS&!
M&0<>NXYKQWQ+_P C1JW_ %^2_P#H9KH? WC&/0F:QORWV*1MP<#/EM]/2O2K
M0<Z2L(T/$MY;VOQ!U);CQ"VCB73(U!5$8S<M\OS*3^6#78^"&D;P=IOF6?V0
MB+:(L$< \'!Y&1SSZUKVVH6=Y");:ZAFC(SN1P16'XA\::9HENZI/'<7F/DA
MC;=@_P"T1TKSX0D_=2&]7<\Y^(TD3^,;@1XRL:*^/[VW_ BN4J:\NI;Z\FNI
MVW2RN78^YJ&O7A'EBD2%%%%6 4444 %%%% !1110 4444 %%%% !1110!)#,
M]O.DT1 =#N4D \_0U-?ZC=ZI=&YO9C+*0!D@# '0 #@#Z55HI65[@%%%%,"[
MI6EW.LWZ65H%,S@D!FP.!FG#1[OR+Z4HJBR8+,&.""21Q^5:?@IBOB$,#@BW
MF(/_   UOW<L&I>#=2U>(J)IUBCND':1#U_$$&L9U'&5O3\QK4\^IT<;2R+&
M@W.Y"J/4FMWP]#:2PS&X32F(88^W7#QG\-O6J.M)#'J3+ MHJ;1Q:2&2/\">
M:OF][E$2WGAK4[&\M+26 &XNEW1QHVX]<<TMUX>N;22.-[FQ:1W\LHEPI*'_
M &O2NPTUXTU7POYA )TZ14YQ\QW8K'O]#BN=$-TFFSV5_P#:Q!'$[$F?/< _
MSZ5DJCO9_P!:V#^OP,;4/#UYI]DMXSV\]N6V&2WF$@5O0XZ5DUUNM6TNA^'1
MHZP3NS2B6ZN/+81AL<(IQ@X]:Y*M*<G)7&%%%%:""BBB@ HHHH **** "BBB
M@ HHHH **** -SP;_P CAIG_ %V'\C7O5>"^#?\ D<-,_P"NP_D:]ZKSL9\:
M&C$T;]UJVKV_I.)!_P "&?YUMUB1?N?%]PO:>V5OQ4X_K6W7(,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YNU_Y
M*!>_]>8_FE=)7-VO_)0+W_KS'\TH Z2BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /GWQ+_ ,C1JW_7Y+_Z&:RZ]0M_!FF^(-<UJ6YDN8VCNF_U+@9RS9SD
M'TJ[_P *KT3_ )^]0_[^)_\ $5Z4<5322%8\BHKUW_A5>B?\_>H?]_$_^(H_
MX57HG_/WJ'_?Q/\ XBG]:IA8\BHKUW_A5>B?\_>H?]_$_P#B*/\ A5>B?\_>
MH?\ ?Q/_ (BCZU3"QY%17KO_  JO1/\ G[U#_OXG_P 11_PJO1/^?O4/^_B?
M_$4?6J86/(J*]=_X57HG_/WJ'_?Q/_B*/^%5Z)_S]ZA_W\3_ .(H^M4PL>14
M5Z[_ ,*KT3_G[U#_ +^)_P#$4?\ "J]$_P"?O4/^_B?_ !%'UJF%CR*BO7?^
M%5Z)_P _>H?]_$_^(H_X57HG_/WJ'_?Q/_B*/K5,+'D5%>N_\*KT3_G[U#_O
MXG_Q%'_"J]$_Y^]0_P"_B?\ Q%'UJF%CR*BO7?\ A5>B?\_>H?\ ?Q/_ (BC
M_A5>B?\ /WJ'_?Q/_B*/K5,+'D5%>N_\*KT3_G[U#_OXG_Q%'_"J]$_Y^]0_
M[^)_\11]:IA8\BHKUW_A5>B?\_>H?]_$_P#B*/\ A5>B?\_>H?\ ?Q/_ (BC
MZU3"QY%17KO_  JO1/\ G[U#_OXG_P 11_PJO1/^?O4/^_B?_$4?6J86/)8I
MI(7WQ2/&V"-R,0<&E6>9(GB65UC?[R!B WU'>O6?^%5Z)_S]ZA_W\3_XBC_A
M5>B?\_>H?]_$_P#B*/K5,+'D5%>N_P#"J]$_Y^]0_P"_B?\ Q%'_  JO1/\
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MTD0.C*RGH5.0:=7FUIXHUK3V32H;32!,NKC3_P!U')'%M*;MP&YB#GZU-/\
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M@ HHHH **** .;\,_P#(6U[_ *^S_-JZ2N;\,_\ (6U[_K[/\VKI* "BBB@
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M43#(9O3CMR?:@/Z_K\"O_P (/9MICZ?-J>K3P[D:'S;@$VY0Y79\O;WS2?\
M"!Z:;>YC-WJ!DN+M+QIS*/,650 "#MQVZ$'K3KOQWI5K/<Q+!?7/V>".XD>W
MMRZB-QD-G/H._P"M0R>-3_PE5CI=OIMU/:75MYZW"*.0<8(R?NC/)I]?Z_KH
M'3^OZZFYJ.BVVJ26+732,MG+YRID;78 @;ACG&<]N:HZAX0TW4+F\G+30&[L
MFLIE@*JK(3UQM/S#L?TI+/QEI5[>0P1?:!'<.T=O<O"1#,RYR%;OT/L<<5B:
MIXT:[OM &C_:TM+K4U@>X: "*>/#9"D^XZ\=*25W;O\ KH#=E?M^FIKWO@G2
MM0DB>X>Y81V!T\*' !C)!STSNRHYZ>U1+X#TPQ:@EQ=7]T;^V2VF>:4%MJ9V
MD848//TXZ=:U=6UZTT>2UAE2>:YNF*P6]O'OD? RQ ] .I-<]X=\57<ND:E>
MWEMJ%Z8]3F@CB@MP9(XUQ@$#'3WYHO?^OZ[AM;^OZV)KKPQ<WWB+1C.H>PTD
M;TN99=TL[8X#   8//X"M"[\)6E_J\5_>7M_.L,PGBM))@84D'1@,9X],X]J
MRKSX@1"70WTS3[J^M=29QOC0!AM!RH!(^8$'(-:]WXKL[#5+>RO+6^@%Q*L,
M=S)!B%I&Z+NSU/TIZ_UW J-X&LQIPL(=4U6"W+.TB13J!('8L0WR].>HP<=Z
MTKWP[8WOAW^PCYD-EY:Q@1,-RJ,8P2#Z5!8^*['4)9_)@O!:P[\WCP$0G9][
M#?@>U4W\<V#6\C06M\96MWN+57@V_:54<E"3R.0><'%*]D%KLWK[3;?4=*FT
MVY#-;S1&)P#@E2,=:YV;X?:;/ 8GU#4\/:?8YF$RYFC&=N[Y>HSQC'OFJ#^,
M+^X\'67B9;::TCA:-[J&1!LFC; )0\G SD'BMWQAXBD\->&;C58+1[IHP,*/
MNC)'+'L*&K7O_7]7!:V2$3P?IZ)J*B6YQ?VB6DOS+PB*5!7Y>N#WS5/Q=X>O
M;[P*^A:0L<C[$B!GEVG:O?('7@>E6V\76L26J26-_P#;+B(RBS2'=*J#@L0#
M@#GUYK2M-9L+W2!JL,X^QE"YD88V@=<@]",&A];@NECB8/ >HK!>BY\NZGO+
M;[*\UQJ4CO%'_=3,6 /KFKU]X5U._P!*TZQ>"TB;3E46MU#?R)-&57;D-Y6,
MXZ\8]JU8/&6G2V,]_+;W]M91Q^8MQ/;%4E4G V=SG(P,9-,G\<:7:65]<7<-
M[;M9Q":2":#;(8R<!E&<$9]Z&"1BKX+U:+33:6LWV5WE:6:ZAU2033,1@ER8
MB#^7TK)N/A[K2ZKI L%AL[6RMYHS+;Z@ZR;G.22QCSDGV(KK)_&MLUMJ0MK*
M_P#MEI;?:%AEM]C.AX# $CC/7H:P_#?C=H[6*36Y-3>>XLFO )+:-8]JX+>6
M5.2.1UHZ_P!>8=/Z\A\O@*Y;2+/3X;:WMFLW:2"[@U*59U=OO-N\ODGOQ3KG
MP3J=W96L4KYNK5F:*_\ [6F^T MU^?R^GMBMH^.-.%M:3_8]3V7DWDVX-HP:
M0[=V0#R1CO\ _KIEIX_TB[>V58;^,3W)M"\ML56.;.-C'L<^F:=G<.ES,N_!
M^JWEQIER66.YTY2D<\>IRB213R5=C$2P/?I2-X+OWT"_T8PVOV>]N&N'?[:V
M]'+;LJ?)P,$<<&M?Q;XIF\-R:6L.G37?VR[2!B@' .>!R,MZ#I64OC633_$6
MO#4(;][&VBMY$BCMMQMPRDN6(Z=NI/3BENOZ\A[?U\A=0\'W^H:5I]B;>UMV
MT\8M;FVU"2.:/C!(81=^_%1S>#=5N+73XI9 \UC/Y\5T^J2M,6(P<L8CP1QC
M%;M[XSTJSD*XN;C9 MQ,UO"7$,;=&<]LX/'7VJ'QIK4^G>$?[3TVX*LTD)61
M$#Y1G&< @YR#3ZW\Q=#(TO0/$:^,;WQ+<Z?I<,TT0@6'[4YP!U;(3DG ].E=
M1K'A^UUF6TN));BWN[1BT%S;/M=,C##D$$$=016=+X[TNWBO7N+>_A-DT8F2
M6#:RJYPKX)^[GO\ I4VI>,]+TR2Z25+F3[,\,;F&+>"TOW0.>3Z_6EV#NR$>
M!-,6Q:W2YOUD^UM>1W0G_?1RL,$JV.F.Q!JV_A>WFMK**XOK^X:TN5NEEFE#
M.[CIGC&/8 5%#XSTE[>_EG^TVCV&WSX+B$K(-WW2%[[NV*I:IXZ@L](U*>"P
MO/MUG!YQM)XMC%#G#]?N\<D=/2B]@M<N'P;IQU'[=YUUYOV\:AC>N/,V[<?=
M^[CMU]Z2X\%:7<K>B1[G?=78O1*LFUX90,!HR!QQZYZUCS>,+TZKX>E^QWT-
MO>0RM-:" .\A" @C&3CGKD>]:\?CC2I[.UF@CO)IKEG6.UC@)FRGW\KVQWR:
M+6T_K^M!)WU_K^M1\OA"VN+*&&XU+4YKB";SX;UYQYT;8QP<;0,=L8JWHGAZ
MUT%[Y[>>YF>]F\^9KB0.=VT+P<#T_P CBJ!\<:4XM!:1WEY-<HTBP6T!:154
M[6+#C&#Q5?\ X2RSL=5UDW5Y>2+;M;HMH;8#8TBY54Q\S%N^>AH'8NR^#M,F
MN=4>5[EX-3'^E6ID_=,V -P&,@\#O4VE>&K72[TWOVF[N[KRO)26[EWE(\YV
MK@#C]3ZU?TZ__M&T\_[+=6QS@QW,>QQ^%9"^,K 7=Q:W%K?VLT4#W"K<0;/-
MC3[Q3GGZ'%&P;C-3\$:=JEY>W#W5]"+T)]HAAE 21D^ZQ!4G(QZX]JDG\&Z=
M<+K:O-= :PD:7&'7Y0B[1M^7CCUS67J?Q!6#2+/4-/TC4)X;BXCB#2P&,$-C
MD9(SUP.Q(-68/%5I;ZAK<U[=WB1VB6[-:S0*/(+KD*NW)9CW![]*!^8ZX\ Z
M7<7$LGVJ_C262*:2&.4!&DCQM8@KUPH![>U27OA][&WU>7286NIM3/[VVN)@
ML()&"PXSZ9&:L1^++5FM%GL=1M7NYQ;Q+<0;"6()!Z].*R-?\6/]MT^WTR:2
M)H];AL;O<BX=6!) SGCISP:+7]W^NG_ %>VO]:7_ ."2Q> ;=_"FEZ+-?W<'
MV)EF9[5E'F2#NV]6!&3GIZ5?N/"4-W9VT=SJFIR75K(TD%]YJ+/'D8(!50N,
M=BIJ2Z\56ECJT-A=6E_#YTGDPW#P8BDDQD*&SU.#BLO1O':7D.KSZCI]S96]
MA<21><R94A<84X).\YZ 47O=_,+6.GT^R_L^S6W^TW%R023+<2;W8GU/^'%9
MO_")Z6]EJEG.DD]OJ4[3SI(W1CC[I !&, CO4(\::2D%V]T+JS>U19'AN(2K
ME6.%*@9SD\<54TKQ!=ZEXXGLC%=6UHMBLHM[F$(P<L1N]>GO1N_Z_KH&R_K^
MNI;LO!UG9R33M?:C<W<D!MTNKB</)#&>R'&!]<$\<TW0?""^'Y(OL^MZM/;Q
M@@6T\D9C.>Y"H"3^-9LGBZ;3/%NO07B7MQ8VL4#HMO;[Q"""68D=N!W/3BM7
M_A,](Q?MOEVV5O'=,=O^LC<$J4YYZ8^M'F'D5M8\-7>J>,+74$N[BTM8[)X6
MEMI0LFXL#CD'C%./@+2$2V2UDO+188'MCY$V#+&QRP<D$G)).1@U+XJ\32:!
MX5;6(+&6=L(1&1C;N(^]SQU_.LNZ\6WD'BNQ0V>HBTEL)9FLEMPTI=6 !.,X
MXSWQS1;IZ_JP\_ZZ(U4\&V$3:7)!=7L$NFP?9XY(Y &DCXRK_+@C@=,&H?\
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MGO<VL3/NF<F)".[E>=OKBB_45NAEW_AS6O[;UFZT^2Q,.JP1PN9V<-#M4C(
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MTO5HF$L"O;$MC]X@) ;\1BN!'A3Q)%8-<QVDOVRR86%JH8?-!AP7'/3]X/\
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M #:NDKF_#/\ R%M>_P"OL_S:NDH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH @6\MVO7LQ)_I"()"F#]T]\]*
MGK#N1Y'C&SEZ"XMGC_[Y.?ZBMR@ HHHH **** "BBB@ HHHH **** "BBB@
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MXXY-3)XUB&K:K:W6G7%I;Z;:_:99YF&6'.,*,]<'J<^U '4T5RNF>+[BZO\
M3X+_ $:2QAU-2UE*TZN7PN[#J!\AQSU-=53:L 4444@"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOPS_R%M>_Z^S_ #:N
MDKF_#/\ R%M>_P"OL_S:NDH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Q-=_=7NDW/\ <N=A/LP_^L*VZQO%
M"_\ $F:4=89$D_)A6NC;D5O4 T .HHHH **** "BBB@ HHHH **** "BBB@
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M4.IB<X;'(Z5T5>+S?Z^3_>/\ZRJU'"UCEQ-:5*W+U/3?^$NT/_G^_P#(3_\
MQ-'_  EVA_\ /]_Y"?\ ^)KR^BL?;R.7Z[4[(]0_X2[0_P#G^_\ (3__ !-'
M_"7:'_S_ '_D)_\ XFO+Z*/;R#Z[4[(]0_X2[0_^?[_R$_\ \31_PEVA_P#/
M]_Y"?_XFO+ZOVNC7UW )HHE$9. SNJY^F3S35:;V0UC*KT21Z#_PEVA_\_W_
M )"?_P")H_X2[0_^?[_R$_\ \37F+HT;LC##*<&FTO;R%]=J=D>H?\)=H?\
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M)\K/0Z***V.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSLP4*"<X'05G)WL14FG%),2NH\!_\AR?_KV;_P!"6N7KJ/ ?_(<G_P"O9O\
MT):TH?$:X+^)\CT.BBBNL]4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_#/\
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M^?P_]^G_ ,*/^$NT3_G\/_?I_P#"CV-3^5_<'MZ7\R^\VZ*Q/^$NT3_G\/\
MWZ?_  H_X2[1/^?P_P#?I_\ "CV-3^5_<'MZ7\R^\VZ*Q/\ A+M$_P"?P_\
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M?P_]^G_PH_X2[1/^?P_]^G_PH]C4_E?W![>E_,OO-NBL3_A+M$_Y_#_WZ?\
MPH_X2[1/^?P_]^G_ ,*/8U/Y7]P>WI?S+[S;HK$_X2[1/^?P_P#?I_\ "C_A
M+M$_Y_#_ -^G_P */8U/Y7]P>WI?S+[S;HK$_P"$NT3_ )_#_P!^G_PH_P"$
MNT3_ )_#_P!^G_PH]C4_E?W![>E_,OO-NBL3_A+M$_Y_#_WZ?_"C_A+M$_Y_
M#_WZ?_"CV-3^5_<'MZ7\R^\VZ*Q/^$NT3_G\/_?I_P#"C_A+M$_Y_#_WZ?\
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M7:8U5A)V31UE%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML57F@ET?0I[5HI&N+K:TIVG;$HZ#/KS41JMI=_Z\S65&*;[?UY'/4J(TCJB
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MT>,L R$@C([$5-)J>H31M'+?7+HW!5I6(/X9KIGM;/4)=+LIXI/-DLEVRJ^
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MMO=-N6.(O]K^;L!D8],USSE2[%1A2>!Z"M8S4FTNAE*FXI-]1****L@****
M"BBB@ HHHH **** "BBB@ HHHH **** "NH\"?\ (;G_ .O9O_0EKEZZCP)_
MR&Y_^O9O_0EK#$_PI&V&_BQ/0J***\,]X**** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tmb-20211231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -0 TH# 2(  A$! Q$!_\0
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M[-M/^>7_ (\?\:/[-M/^>7_CQ_QJU5+5=4M='TZ6^O9-D$8&2!DDDX  ]<T
M/_LZT_YY?^/'_&C^SK3_ )Y?^/'_ !JK:ZW;7.D2:GY5S%!&&++-"4? ZG:>
M:L:;J$&J:=#?6Q8PS+N0L,''TH =_9UI_P \O_'C_C1_9UI_SR_\>/\ C69<
M>*=/MM,%].EU&C2^2D;0,)';.,*O4UJ6-VE]9Q72)(BR+D+*A1A]0>E "?V=
M:?\ /+_QX_XT?V=:?\\O_'C_ (U88A5+$@ <DUSA\::3'8P7D[2Q6]Q<&"*1
MDX8@XW>R^] &W_9UI_SR_P#'C_C1_9UI_P \O_'C_C5/6O$&G^'[-+J_E*QR
M.$38-Q8GT%+%KEG)JT>FJ7-S)")U&WC:?>@"W_9UI_SR_P#'C_C1_9UI_P \
MO_'C_C4%UJ]K9ZI9Z?.72:[W>2=ORD@9(SZU27Q7I;2^2&E\[[6;/RO+.X2#
MV].^: -3^SK3_GE_X\?\:/[.M/\ GE_X\?\ &LNZ\5Z9:_;C(TQ6Q94F98\@
M,>@![U=U+5[32K:"XN2XCGE2%-JY^9NE $_]G6G_ #R_\>/^-']G6G_/+_QX
M_P"-9&H^+]/TW5)-.DAO9KF-%=EM[=I, ].E2P>);.>ZLH3%<0F\5C%Y\10Y
M!Z$'O0!I?V=:?\\O_'C_ (T?V;:?\\O_ !X_XU:'2B@"K_9MI_SR_P#'C_C1
M_9UI_P \O_'C_C5JB@"K_9MI_P \O_'C_C1_9MI_SR_\>/\ C5JB@"K_ &;:
M?\\O_'C_ (U%<6%M';2.L>&520=QJ_4-W_QYS?[AH =!_P >\?\ N#^55+>!
MIXR[7$X.XC"OQUJW!_Q[Q_[H_E45C_Q[?\#;^= "?8O^GJY_[^4?8O\ IZN?
M^_E6J* *OV+_ *>KG_OY1]B_Z>KG_OY5JB@"K]B_Z>KG_OY1]B_Z>KG_ +^5
M:HH J_8O^GJY_P"_E'V+_IZN?^_E6J* *OV+_IZN?^_E'V+_ *>KG_OY5JB@
M"K]B_P"GJY_[^4?8O^GJY_[^5:HH J_8O^GJY_[^4?8O^GJY_P"_E6J* *OV
M+_IZN?\ OY1]B_Z>KG_OY5JB@"K]B_Z>KG_OY1]B_P"GJY_[^5:HH J_8O\
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MNG?\>$?X_P S5J@ HHHH **** "BBB@ HHHR* "BC-% !1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !1110 5#=_P#'G-_N&IJAN_\ CSF_W#0
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M?_CWE_W#_*DMO^/2'_<7^5 $6F_\>$?X_P S5JJNF_\ 'A'^/\S5J@ HHHH
M**** "BBB@ HHHH **** .2^)'_(GR_]=X/_ $8M=;7)?$C_ )$Z7_KO!_Z,
M6NMH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN_P#CSF_W#4U0W?\
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M%_WV*/M=O_S\1?\ ?8H FHJ'[5;_ //>+_OL4?:K?_GO%_WV* )J*A^U6_\
MSWB_[[%!N[<?\MXO^^Q0!-14(N[?_GO%_P!]BC[5;_\ /Q%_WV* )J*A^U6_
M_/Q%_P!]BC[5;_\ /Q%_WV* )J*A^U6__/Q%_P!]BC[5;_\ /Q%_WV* )J*A
M^UV__/Q%_P!]BC[5;_\ /Q%_WV* )J*A^U6__/Q%_P!]BD^UV_\ SWB_[[%
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M S8Z^@SFM(]#6?J\_D:>Y,"3;R$V.<+\QQDGT% &?874LE[8BY\J:1UE&_8
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MP/YZ%PZJ20>".06;VYH T-,OO[0LEGV&-MS(Z'^%@<$5SWB;_D<O"7_7>?\
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M: .DHHHH **** #%)@4M% !BN2\3#_BL?"7_ %WG_P#1==;7)>)O^1R\)?\
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MJ\CKUSX'_P"OUC_=B_FU 'L5%%% $<__ ![R_P"X?Y4EM_QZ0_[B_P J6?\
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MIKJJ "BBB@ HHHH **** .2^)'_(G3?]=X/_ $8M=;7)?$C_ )$Z7_KX@_\
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M@#0UJYA@M8A<K%]FDF5)FFP$1>3DY^@'XUGZ!;Q6-[Y5M%"EO=0F941,%%#
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M /S^W/\ W];_ !JK14N,7NA.*>Z%)+$DDDGDDTE%%4,*]<^!_P#K]8_W8O\
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MN4/\C653>/K^C(GO'U_1FW6?=_Z\_05H5GW?^O/T%:ED%%%% !1110 4444
M%20?Z]/K4=20?Z]/K0(TZ***!A1110!%<6\-U"T,\2R1-C<C#(/>J7]@:3_T
M#;;_ +]BM*BI<(O="<4]T0VUK!:1>5;Q)%'G.U!@9J:BBJ2MHAI6"BBB@ KP
MCXU?\CE9_P#8/3_T9)7N]>$?&K_D<K/_ +!Z?^C)* /.**** "M2#_D6[O\
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MZZVN3\3?\CEX1_Z[S_\ HN@#K*AG*K#*7;8@4EF]!CK4U0W"H\$BR*61E(8
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MS_L(3_\ HQJ^IJ^6?%G_ ".6N?\ 80G_ /1C4 8]%%% !1110 4444 %>N?
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M >3?\*.MO^@[+_X##_XJC_A1UM_T'9?_  &'_P 57K-% 'DW_"CK;_H.R_\
M@,/_ (JHF^%<,%RFB#5I&6Y4S&7R!E=O;&:]>K$NO^1QL/\ KVD_G6579>J_
M,BILO5' _P#"CK;_ *#LO_@,/_BJ/^%'6W_0=E_\!A_\57K&:,BM2SR?_A1U
MM_T'9?\ P&'_ ,56IX<^%,/A[7K;5$U:2=H"2(S %SD$==WO7HFX4M !1110
M 5#=_P#'G-_N&IJAN_\ CSF_W#0 Z#_CWB_W!_*HK+_CV_X&W\ZE@_X]X_\
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MG_80G_\ 1C5]35\L^+/^1RUS_L(3_P#HQJ ,>BBB@ HHHH **** "O7/@?\
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MCW_GQT'_ +^R4 =9BEKDOM'CW_GQT'_O[)1]H\>_\^.@_P#?V2@#K:Q_#/\
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M[$]ZI0V>I^7/8ND:PR2NS7._)96.<;>H../PH U9K^&&U6X;)5\;%499R>@
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M ./>7_</\J2V_P"/2'_<7^5 $6F_\>$?X_S-6JJZ=_QX1_C_ #-6J "BBB@
MHHHH **** "BBB@ HHHH Y+XD?\ (G3?]?$'_HQ:ZVN2^)'_ ")TW_7>#_T8
MM=;0 4444 %)M )(')ZFEHH **** "BBB@ K#E_Y'6#_ *\6_P#0ZW*Q)?\
MD=8/^O%O_0ZRJ[+U1%3IZEZ]U?3M-*"^O[6U+_=$\RIN^F3S5:ZU&>6T6[TV
MYT]K3:6-Q(^]#CL-I _'-:NT5D:CIM]=:A#<VUW:HL2D+'<VK3 -_>&)%P:U
M+!=6NF_LTFP:-+H@2,[ >62I. .I/%;%8U[8ZM<_9"FH64;P,)&+63L'?!'
M\T8'/3D^]:ZDX&[!/?% #J*** "BBB@ HHHH **** "BBB@ I",TM% "!0
M!@#THQ2T4 )BC%+10 F*,4M% ";11@4M% !1110 5#=_\><W^X:FJ&[_ ./.
M;_<- #H/^/>+_<'\JBL?^/;_ (&W\ZE@_P"/>/\ W1_*HK'_ (]O^!M_.@"S
M1110 4444 %%%% !1110 4444 %<EXF_Y'+PE_UWG_\ 1==;7)>)O^1R\)?]
M=Y__ $70!UM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F,4M%
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M?=$2CX)((&<@C<V.>] %W3;X:A9+/L,;[F1T/\+ X(KG?$W_ ".7A+_KO/\
M^BZZ'3[,:?9K KESDLSGJS$Y)_6N(U&UUFW\=>&WU+4XKN)[B?R42W$9C^3N
M1UXQ^5 'H=% Z44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %8?_ #//_<-_]JUN5B?\SS_W#?\ VK657IZD3Z>IMTF*6BM2Q,"EHHH
M**** "BBB@ HHHH **** "BBB@ HHHH CG_X]Y?]P_RI+;_CTA_W%_E2S_\
M'O+_ +A_E26W_'I#_N+_ "H BTW_ (\(_P ?YFK55=-_X\(_Q_F:M4 %%%%
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=_P#'G-_N&IJAN_\
MCSF_W#0 Z#_CWC_W1_*HK'_CW_X&W\ZE@_X]XO\ <'\JBL?^/;_@;?SH LT4
M44 %%%% !1110 4444 %%%% !7)>)O\ D<O"7_7>?_T776UR7B;_ )'+PC_U
MWG_]%T =;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'/_P >\O\
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MAH =!_Q[Q?[@_E45C_Q[_P# V_G4L'_'O%_N#^516/\ Q[?\#;^= %FBBB@
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M_</\J2V_X](?]Q?Y4 1:=_QX1_C_ #-6JJZ;_P >$?X_S-6J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N03[>8M5$.J6%O!]JFRDEL
M6DZ\_-Y@'_COYUU]4)='TR6=IY-.M'F8[B[0*6)]<XH YIKF34OL5M;:7-/:
M0VJEXUD4%&9<+RQ&<#G-7)[R6\\!ZF;B,QW,5G/%,C'E65"#72)$B$E452W)
M(&,TUH(F616B0K)_K 5&'XQSZT +;?\ 'K#_ +@_E4M(    , >E+0 4444
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M@?A6\.E,2-(UVHH5>N%&*?0 4444 %%%% !4-W_QYS?[AJ:H;O\ X\YO]PT
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M#(+ ]:[:B@#GK#2-/M_$MU-%IUK&\<<8C=(%!7@C@XXKH:** "BBB@ HHHH
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M ,]T_P"^J )J*A^UV_\ SW3_ +ZH^UV__/=/^^J )JAN_P#CSF_W#1]KM_\
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MY%'D0_\ /)/^^14/E7G_ #\K_P!^Z/*O/^?E?^_= $WD0_\ /)/^^11Y$/\
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M@M?^>(_,TGDWG_/RO_?%'E7G_/RO_?N@!?L%K_SQ'YFC[!:_\\1^9I/)O/\
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MK)&P9&&0P.013JPO!VF7>C^%+&QO7W7$:G< <[022%_ '%;M !1110 4444
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M73?^/"/\?YFK5 !1110 4444 %%%% !1110 C,%&3TJM+J-G#:?:Y+F);?\
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MF7ZZE8K<!"C9*NA_A8<$5<HC)25T"=U=!1113&%%%% !1110 4444 %0W?\
MQYS?[AJ:H;O_ (\YO]PT .@_X]XO]P?RJ*Q_X]_^!M_.I8/^/>+_ '!_*HK'
M_CW_ .!M_.@"S1110 4444 %%%% !1110 4444 %<EXF_P"1R\)?]=Y__1==
M;7)>)O\ D<O"7_7>?_T70!UM%%% !1110 4444 %%%% !1110 4444 %%%%
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MY3R3TH X[2GTR.6*UDL+HWJL-[ESEFSRQ&[\:[):Y6WB,ME:6\6EL;@.A-X
MFPX()D#@Y.1_.NJ% #J*** "BBB@ HHHH **** "BBB@#F/ W_(*O_\ L)W/
M_HPUM:M_R#)O^ _^A"L7P-_R"K__ +"=S_Z,-:NNW$5MH\\LS;(UVY8_[P%
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M-W_QYS?[AH =!_Q[Q?[@_E45C_Q[?\#;^=2P?\>\7^X/Y5%8_P#'M_P-OYT
M6:*** "BBB@ HHHH **** "BJMYJ%G8;#>7=O;ASM4S2!-Q]!D\T7>H6EA&L
MEY=P6R,=JM-($!/H,F@"U7)>)O\ D<O"7_7>?_T775JP=0P((/(([URGB;_D
M<O"7_7>?_P!%T =;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'/_
M ,>\O^X?Y4EM_P >D/\ N+_*EG_X]Y?]P_RI+;_CTA_W%_E0!%IO_'A'^/\
M,U:JKIO_ !X1_C_,U:H *IW-XL-Q;6[!B;EF12,<84MS^5,GU:V@C=R7?8YC
M*QKN)8#) ^@!_*H[FV35%L[JWN2GEGS8I$ (8,I'?V- %33]/Y<6^L:@4@E*
M-&PB"Y'4?<Z?2MP=:Q[73I;*5L:H?WTID961?F)Z@5L#K0 ZBBB@ HHHH **
M** "BBB@ HHHH YCP-_R"K__ +"=S_Z,-3^-O^11OO\ MG_Z,6H/ W_()O\
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M0 44AI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG_X]Y?\
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M%"^_[9_^C%JG\/O._L&Z^T^7Y_\ :%QYGEYV[M_.,\XS5SQM_P BA??]L_\
MT8M 'D-)2T4""DHHH L6'_(0MO\ KJO\Q7K=A_R-NK_]<H?Y&O)+#_D(6O\
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M:** "BBB@ HHHH *Y+Q-_P CEX2_Z[S_ /HNNMKDO$W_ ".7A+_KO/\ ^BZ
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MA.Y_]&&I_&W_ "*-]_VS_P#1BU!X&_Y!5_\ ]A.Y_P#1AJQXV_Y%"^_[9_\
MHQ: /(*6BB@0E%%+0!/8?\A"V_ZZI_,5ZW8?\C;J_P#URA_D:\DL/^0A;?\
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M_P"A5L55L+*+3[-+>'.U<DEN22>I-6JFG%Q@DQ05HI,****LH**** "BBB@
MHHHH *AN_P#CSF_W#4U0W?\ QYS?[AH =!_Q[Q?[@_E4-E_Q['_?;^=30?\
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MM[.69/+RBEOWK;5X]3@X_*DT[_CPB_'^9IFIVSWFG3PQX+LN5!/!(.<'V.*
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M G'#$@D#C(%16NA+;I=0F0F*>((3CG/.3^9)I8+'49)H!>S6[06[!T$2D,Y
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MH&">6J3,3">8G7JOL:LVY<SGSP/."XRO1ESU_/\ G0!<%%%% !1110 4444
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M?PS_ ,@C_MO+_P"AFLW_ !%Z/]"'\:^?Z&Q5"\_UWX5?JA>?Z[\*T+*]%%%
M#))4AC:21PB*,EB< 54_MC3?^?Z#_OL5<=%=2KJ&4]01D&L62TMO^$FBC^SQ
M;#:D[=@QG=UQ6524XVY3.;DK6-F&:.XB66%U>-NC*<@T^FI&D2!(T5$'15&
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MKJ8S3N7D/5C456KVU*5^H5UGPT_Y*!I?^\__ * :Y.NL^&G_ "4#2_\ >?\
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M%7__ &$[G_T8:L>-O^11OO\ MG_Z,6J_@;_D%7__ &$[G_T8:G\;?\BC??\
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MK-_Q%Z/]"'\:^?Z&Q5"\_P!?^%7ZH7G^O_"M"RO1110 5DR?\C5#_P!>C?\
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M!_2H!YDDGRX2XCX![./\YJ6SV,[O'E0?OH>S?YS^5 %ZB@44 %%%% !1110
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M;SYD;J,?\"% &LM.I ,4M !2$XI:KWD,L\!2&Z>V?/$B*K$?@P(H CO-4LK
MJ+J=8RW0')_E1=ZK964<;W%PB+(,H>N1Z\=JQM1O?LDR6$\LQ+0_O;P6C.S
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M0_\ 7HW_ *%6579>J,ZG3U-:BBBM30*D@_UZ?6HZD@_UZ?6@#3HHHH ****
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MR 3SUKI!619>(;2\A@<1W"F95(4PM@9]\8_&M<')H =1110 4444 %!&:**
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M,[R1@J#]]#V;_/\ *H&">6J3,3"?]4Z]5^M6;<L9SYX'G!, KT9<]?S_ )T
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MM%<E_8'B_P#Z'C_RDQ?XUI:+IVMV4TK:IK_]IHR@(GV-(=A]<J>: -NH;O\
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M:H;O_CSF_P!PT .@_P"/>+_<'\JBL?\ CV_X&W\ZE@_X]X_]T?RJ*Q_X]O\
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M93D&@!U%%% !1110 4444 %%%% !1110 5#=_P#'G-_N&IJAN_\ CSF_W#0
MZ#_CWB_W!_*HK'_CW_X&W\ZE@_X]XO\ <'\JBL?^/;_@;?SH LT444 %%%%
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MPT .@_X]X_\ ='\JBL?^/?\ X&W\ZE@_X]X_]T?RJ*Q_X]_^!M_.@"S1110
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M '%_E2S_ /'O+_N'^5);?\>D/^XO\J (M._X\(_Q_F:M55TW_CPC_'^9JU0
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M%;R7#J UR)F1E^HP=V/PKH$!"@,<G')H =1110 4444 %%%% !1110 4444
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MQ)=3+&I.!G))_ <TZUO+>\A$UO*LD9.,CUK+7:OBR4W'5K5!:ENG#-Y@'O\
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M_P"/2'_<7^5+/_Q[R_[A_E26W_'I#_N+_*@"+3?^/"/\?YFK55=-_P"/"/\
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M ,>__ V_G0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/N*T(8EAA2)<[44*,G)P*@^Q?]/5S_W\H^Q?]/5S_P!_* +5%5?L/_3S<_\
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L!-/_ ,>\O^X?Y4EM_P >D/\ N+_*H38@C!N;@@]1OJRB".-4&<* !F@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tmb-20211231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20211231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )2 Y # 2(  A$! Q$!_\0
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M-=9_PB%G_P!!5O\ P'/^-'_"(6?_ $%6_P# <_XT <F[O(VYV9CZL<T^*>6
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M!S_C1_PB%G_T%6_\!S_C0!R1))R3DU(]Q/)&(WFD9!T4L2!^%=3_ ,(A9_\
M05;_ ,!S_C1_PB%G_P!!5O\ P'/^- ')JS(P96*L.A!P:&9G8L[%F/<G-=9_
MPB%G_P!!5O\ P'/^-'_"(6?_ $%6_P# <_XT7 Y-69&#(Q5AT(."*D-S.TGF
M-/(7QC<7.<?6NH_X1"S_ .@JW_@.?\:/^$0L_P#H*M_X#G_&@#E1-*H8"1P&
MZ@,>:02R",QAV"'JH/!_"NK_ .$0L_\ H*M_X#G_ !H_X1"S_P"@JW_@.?\
M&@#EHIYH<B*62//7:Q&:3S9"FSS'V?W=QQ75?\(A9_\ 05;_ ,!S_C1_PB%G
M_P!!5O\ P'/^- '*-+(ZA6=F4= 3D"B.62%MT4C(WJIP:ZO_ (1"S_Z"K?\
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M7;2$S( I SD\]?SK#,\QB$1ED,8Z(6./RKKO^$(@_P"@FW_?C_Z]'_"$0?\
M03;_ +\?_7H X])9$#*CLH;J <9HCEDA;?%(R-ZJ<&NP_P"$(@_Z";?]^/\
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M'_UZ/^$(@_Z";?\ ?C_Z] ''M+(R!&=BHZ*3P*?'<SPJ5BGD13U"N0#76_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 5HP?\ 'C'_ +QK.K1@_P"/&/\
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M5J* +/D0?\_ _*CR(/\ GX'Y56HH L^1!_S\#\J/(@_Y^!^55J* +/D0?\_
M_*CR(/\ GX'Y56HH L^1!_S\#\J/(@_Y^!^55J* +/D0?\_ _*CR(/\ GX'Y
M56HH L^1!_S\#\J/(@_Y^!^55J* +/D0?\_ _*CR(/\ GX'Y56HH L^1!_S\
M#\J/(@_Y^!^55J* +/D0?\_ _*CR(/\ GX'Y56HH L^1!_S\#\J/(@_Y^!^5
M5J* +/D0?\_ _*CR(/\ GX'Y56HH L^1!_S\#\J/(@_Y^!^55J* +/D0?\_
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MJ* )?+C_ .>@_*CRX_\ GH/RJ*B@"7RX_P#GH/RH\N/_ )Z#\JBHH E\N/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_? H^VR_P!V/_O@4 5J*L_;9?[L?_? H^VR_P!V/_O@4 5J*L_;9?[L?_?
MH^VR_P!V/_O@4 5J*L_;9?[L?_? H^VR_P!V/_O@4 5J*L_;9?[L?_? H^VR
M_P!V/_O@4 5J*L_;9?[L?_? H^VR_P!V/_O@4 5J*L_;9?[L?_? H^VR_P!V
M/_O@4 5J*L_;9?[L?_? H^VR_P!V/_O@4 5J*L_;9?[L?_? H^VR_P!V/_O@
M4 5J*L_;9?[L?_? H^VR_P!V/_O@4 5J*L_;9?[L?_? H^VR_P!V/_O@4 5J
M*L_;9?[L?_? H^VR_P!V/_O@4 5JT8/^/&/_ 'C5?[;+_=C_ .^!5V*=VM4<
MA<DGM2&1T5+Y[>B_E1Y[>B_E0!%14OGMZ+^5'GMZ+^5 $5%2^>WHOY4>>WHO
MY4 145+Y[>B_E1Y[>B_E0!%14OGMZ+^5'GMZ+^5 $5%2^>WHOY4>>WHOY4 1
M45+Y[>B_E1Y[>B_E0!%14OGMZ+^5'GMZ+^5 $5%2^>WHOY4>>WHOY4 145+Y
M[>B_E1Y[>B_E0 0?ZT?0U%5B&5FD ('?M4?GMZ+^5 $=%2^>WHOY4>>WHOY4
M 145+Y[>B_E1Y[>B_E0!%14OGMZ+^5'GMZ+^5 $5%2^>WHOY4>>WHOY4 145
M+Y[>B_E1Y[>B_E0!%14OGMZ+^5'GMZ+^5 $5%2^>WHOY4>>WHOY4 145+Y[>
MB_E1Y[>B_E0!%14OGMZ+^5'GMZ+^5 $5%2^>WHOY4GGMZ+^5 "S=$_W:BJQ)
M*RA< <CTIGGMZ+^5 $5%2^>WHOY4>>WHOY4 145+Y[>B_E1Y[>B_E0!%14OG
MMZ+^5'GMZ+^5 $5%2^>WHOY4>>WHOY4 145+Y[>B_E1Y[>B_E0!%14OGMZ+^
M5'GMZ+^5 $5%2^>WHOY4>>WHOY4 145+Y[>B_E1Y[>B_E0!%14OGMZ+^5'GM
MZ+^5 $56;3JWX5'Y[>B_E4UO(7+9QQZ"@#.U/_CZ'^Z*IU<U/_CZ'^Z*ITQ!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %:,'_'C'_O&LZM&#_CQC_WC0 M%%%(84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!+!_K1]#452P?ZT?0U%0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 2S=$_W:BJ6;HG^[45 !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5FTZM^%5JLVG5OPH H:
MG_Q]#_=%4ZN:G_Q]#_=%4Z8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "M&#_CQC_WC6=6C!_QXQ_[QH 6BBBD,***
M* "BBN/\;^-_^$-N]&62T\^VO99%G=<[HD0 E@.^ 23["@#L**Y_6O$?]G7.
M@);I'/%JMXL DSP%*,P8>O3]:9H_B8W.L:KI&J11VE]8'S0-WRRVY^[("?Q!
M]#0!T=%<+)X[N_\ A&)O$$=@GV*2^CM[+>2&EB:0(9#Z9))'L*W?&&O2>&/"
MM]K$4*S/;*I$;' .6"_UH W:*Q?%.N/X?T5KJ&$3W<DJ06T!./,D=@JC]<_A
M3_#&M_\ "0Z!;:@T7DS-NCGAS_JY%)5E_ @T :]%8>NZ])I&IZ):)"L@U&[^
MSLQ/W!M+9'Y5FR>,)DL_%T_V6,G0@VP9/[W$6_G^5 '7454TN[.H:397K*%:
MX@24J.VY0<?K5N@ HHHH **** )8/]:/H:BJ6#_6CZ&HJ "BBB@ HHJMJ-T;
M+3;FZ50QAB9PI[X&: +-%<CX,\;Q>+/#DM_Y @O+=29K<G[O&01[$55A\=W
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M44 %%%% !1110 4444 %%%% !1110 5HP?\ 'C'_ +QK.K1@_P"/&/\ WC0
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M%[&"'8?="GG.>U>HH-J*I); QD]37(^"O"VGVGA'1#>:1;QW\5K&9"\0WJX
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M%E;N=%UJ6.XNIEZ1%3\X_P"!#%:7CRRQJ?AR<Z1/?V-I,WFPP1!R%VX'!(H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 4-3_X^A_NBJ=7-3_X^A_NBJ=,04444 %%%% !1110 4444 %%%% !1110
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M10!9^PS_ -U?^^A1]AG_ +J_]]"JU% %G[#/_=7_ +Z%'V&?^ZO_ 'T*K44
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M-;B0 9"[6 )V^N,"O3* "BBB@ HHHH **** "BBB@"6;HG^[452S=$_W:BH
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M!/X5-7"ZY\.8]6N-/DAO6M8[.)$,:/+B4C ^;$GW=FX>OS<D]*[B-!%&L:C
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MU_.O2,CUHH \UC^'OB#39KJRT;6[2VTBYN#/^\MMT\.3DJAZ$?6O18H1';)
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M* "BBB@ HHHH *T8/^/&/_>-9U:,'_'C'_O&@!:***0PHHHH **** "BBB@
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M\Z,P_P!U_P ZBHH ES#_ '7_ #HS#_=?\ZBHH ES#_=?\Z,P_P!U_P ZBHH
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M[<XW;1G&?PK@?!/Q+3Q7!J+W.GBQ:RB$Q7SM^Y,$YZ#TKM?$O_(EWW_7K/\
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MI]D7E<V=N7EQYC>4N7QTSQS4HMX5E$JPQB0+M#A1G'IGTJ7:WH?RHVMZ'\J
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M'TH 2BEP?2C!]* ))NB?[M15+*#A./X:CP?2@!**7!]*,'TH 2BEP?2C!]*
M$HI<'THP?2@!**7!]*,'TH 2BEP?2C!]* $HI<'THP?2@!**7!]*,'TH 2BE
MP?2C!]* $HI<'THP?2@!*LVG5OPJM@^E6;7JWX4 5;^YFBN J.5&T'&*K?;K
MG_GJ?R%2:G_Q]#_=%4Z8%C[=<_\ /4_D*/MUS_SU/Y"J]% BQ]NN?^>I_(4?
M;KG_ )ZG\A5>B@"Q]NN?^>I_(4?;KG_GJ?R%5Z* +'VZY_YZG\A1]NN?^>I_
M(57HH L?;KG_ )ZG\A1]NN?^>I_(57HH L?;KG_GJ?R%'VZY_P">I_(57HH
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MZCSY/[U1T4 2>?)_>H\^3^]4=% $GGR?WJ//D_O5'10!)Y\G]ZCSY/[U1T4
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MHH **** "BBB@ HHHH **** "BBB@"6#_6CZ&HJE@_UH^AJ*@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@"S)_QX0_[S56J2]N([31A<S'$4(>1SZ
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M^M'T-1U+!_K1]#45 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI^=;5,04444 %:,'_'C'_O&LZM&#_CQC_P!XT +1112&%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-S?)&XPRI(^5R.W !_&NLDABF $L:.!TW*#BG@8&!TH **** "BBB@ HHHH
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MK$?,W2H/.E_YZ-^= "_9I_\ GDWY4?9I_P#GDWY4GG2_\]&_.CSI?^>C?G0
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MXT;V_O&@!?*?^Z:/*?\ NFDWM_>-&]O[QH 7RG_NFCRG_NFDWM_>-&]O[QH
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M2+D9]:8'CL5C<Z?;>,EMYM-ALCI,ADLK*Y:412;>&&0 .,]^]4+WP]8Q>'/
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M8_\ >-9U:,'_ !XQ_P"\: %HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %%%% $L'^M'T-15)!_K1]#4= !1110 4444
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M$2Y6UA>-[8,0 P)9MZ@D9X!KHDU_2Y+?49UN@8M-+"[;8W[K:H<]N?E(/&:
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M-NSGUSFNS\'::=-\++#]CN;1I7EE,-S.)9 68G+$<9/7';-='3))8X0&DD1
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M/7+:AH][!I>J1Q-K#7$S:A,))2OEE0[#^#/''-7;[0]0DTGQ^B6,ADOI<VP
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MRSPK J-Y9Z9!)(SW6M[P=8*_B.\U1;370OV5+<76KS'=)\Q8JL9Y '7<?[Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>tmb-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/22/2022 1:07:58 PM-->
<!--Modified on: 2/22/2022 1:07:58 PM-->
<xsd:schema targetNamespace="http://www.cvrx.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:cvrx="http://www.cvrx.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails">
        <link:definition>40302 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails">
        <link:definition>40303 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails">
        <link:definition>40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" id="DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails">
        <link:definition>40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>40901 - Disclosure - (Loss) Earnings Per Share (Basic and Diluted Net Loss per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails">
        <link:definition>41002 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureBusinessOrganization" id="DisclosureBusinessOrganization">
        <link:definition>10101 - Disclosure - Business Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" id="DisclosureSelectedBalanceSheetInformation">
        <link:definition>10301 - Disclosure - Selected Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>10501 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10601 - Disclosure - Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10701 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShare" id="DisclosureLossEarningsPerShare">
        <link:definition>10901 - Disclosure - (Loss) Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>11101 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregation">
        <link:definition>11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" id="DisclosureSelectedBalanceSheetInformationTables">
        <link:definition>30303 - Disclosure - Selected Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30603 - Disclosure - Stockholders Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30703 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30803 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables" id="DisclosureLossEarningsPerShareTables">
        <link:definition>30903 - Disclosure - (Loss) Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31003 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables">
        <link:definition>31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" id="DisclosureSelectedBalanceSheetInformationNarrativeDetails">
        <link:definition>40301 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" id="DisclosureFairValueMeasurementsNarrativeDetails">
        <link:definition>40401 - Disclosure - Fair value measurements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>40402 - Disclosure - Fair Value Measurements (Liabilities Measured at Fair Value on a Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails" id="DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails">
        <link:definition>40403 - Disclosure - Fair Value Measurements (Fair Value of Convertible Preferred Stock Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" id="DisclosureDebtNarrativeDetails">
        <link:definition>40501 - Disclosure - Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>40601 - Disclosure - Stockholders Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" id="DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails">
        <link:definition>40602 - Disclosure - Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails" id="DisclosureStockholdersEquitySummaryOfWarrantsDetails">
        <link:definition>40603 - Disclosure - Stockholders Equity (Summary of Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" id="DisclosureStockBasedCompensationNarrativeDetails">
        <link:definition>40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" id="DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails">
        <link:definition>40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails">
        <link:definition>40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>40801 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>40902 - Disclosure - (Loss) Earnings Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails">
        <link:definition>41201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Schedule of Segment Reporting) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:element name="WarrantLiabilityCurrent" id="cvrx_WarrantLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" id="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="JobsActAccountingElectionPolicyTextBlock" id="cvrx_JobsActAccountingElectionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LabEquipmentMember" id="cvrx_LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ComputerEquipmentAndSoftwareMember" id="cvrx_ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClinicalTrialAndOtherProfessionalFees" id="cvrx_ClinicalTrialAndOtherProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedPaidTimeOff" id="cvrx_AccruedPaidTimeOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ConvertiblePreferredStockWarrantLiabilityMember" id="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BiosenseWebsterInc.Member" id="cvrx_BiosenseWebsterInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LoanAndSecurityAgreementMember" id="cvrx_LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HorizonTechnologyFinanceCorporationMember" id="cvrx_HorizonTechnologyFinanceCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdInterestRateOnFirstBusinessDayOfMonth" id="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentFinalPayment" id="cvrx_DebtInstrumentFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" id="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LegalFeesAndInvestmentBankFee" id="cvrx_LegalFeesAndInvestmentBankFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IssuanceCostsOfWarrants" id="cvrx_IssuanceCostsOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtInstrumentMinimumCashOnDepositRequirement" id="cvrx_DebtInstrumentMinimumCashOnDepositRequirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Seriesa2RedeemableConvertiblePreferredStockMember" id="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Seriesb2RedeemableConvertiblePreferredStockMember" id="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Seriesc2RedeemableConvertiblePreferredStockMember" id="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Seriesd2RedeemableConvertiblePreferredStockMember" id="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Seriese2RedeemableConvertiblePreferredStockMember" id="cvrx_Seriese2RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Seriesf2RedeemableConvertiblePreferredStockMember" id="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesgConvertiblePreferredStockMember" id="cvrx_SeriesgConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OperationalMilestoneClosingMember" id="cvrx_OperationalMilestoneClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OtherCountriesMember" id="cvrx_OtherCountriesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandOneStockIncentiveAwardPlanMember" id="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonOfficerEmployeesMember" id="cvrx_NonOfficerEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficerEmployeesMember" id="cvrx_OfficerEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockOptionsWithEarlyExerciseOptionMember" id="cvrx_StockOptionsWithEarlyExerciseOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LiabilityRecordedForEarlyExerciseOfStockOptions" id="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsToPurchaseSeriesGPreferredSharesMember" id="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EmployeeStockPurchasePlanMember" id="cvrx_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandTwentyOneEquityPlanMember" id="cvrx_TwoThousandTwentyOneEquityPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryEquityIssuedDuringPeriodSharesNewIssues" id="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityAccretionOfIssuanceCost" id="cvrx_TemporaryEquityAccretionOfIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ConversionOfTemporaryToPermanentEquity" id="cvrx_ConversionOfTemporaryToPermanentEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConversionOfTemporaryEquitySharesToPermanentEquity" id="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PaymentsRelatedToReverseStockSplit" id="cvrx_PaymentsRelatedToReverseStockSplit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsToPurchaseCommonStockMember" id="cvrx_WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" id="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" id="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" id="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" id="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsStartUpCosts" id="cvrx_DeferredTaxAssetsStartUpCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" id="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" id="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice" id="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsInternalRevenueCode59EElection" id="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedLiabilitiesCustomerRebateCurrent" id="cvrx_AccruedLiabilitiesCustomerRebateCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>tmb-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/22/2022 1:07:58 PM-->
<!--Modified on: 2/22/2022 1:07:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637811320778805524" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637811320778805524" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637811320778805524" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637811320778805524" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637811320778805524" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637811320778805524" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637811320778805524" xlink:to="us-gaap_AccountsReceivableNetCurrent_637811320778805524" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637811320778815936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637811320778805524" xlink:to="us-gaap_InventoryNet_637811320778815936" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637811320778815936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637811320778805524" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637811320778815936" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637811320778815936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637811320778815936" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637811320778815936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637811320778815936" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637811320778815936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637811320778815936" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637811320778815936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637811320778815936" xlink:to="us-gaap_LiabilitiesCurrent_637811320778815936" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637811320778815936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637811320778815936" xlink:to="us-gaap_AccountsPayableCurrent_637811320778815936" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637811320778815936" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637811320778815936" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637811320778815936" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantLiabilityCurrent" xlink:label="cvrx_WarrantLiabilityCurrent_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637811320778815936" xlink:to="cvrx_WarrantLiabilityCurrent_637811320778825858" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637811320778815936" xlink:to="us-gaap_LongTermDebtNoncurrent_637811320778825858" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637811320778815936" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637811320778825858" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637811320778825858" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320778825858" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637811320778825858" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637811320778825858" xlink:to="us-gaap_CommonStockValue_637811320778825858" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637811320778825858" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637811320778825858" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637811320778825858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637811320778825858" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637811320778825858" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637811320778835948" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637811320778825858" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637811320778835948" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637811320778835948" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637811320778835948" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637811320778835948" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637811320778835948" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637811320778835948" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637811320778835948" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637811320778835948" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637811320778835948" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637811320778835948" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637811320778835948" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637811320778835948" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637811320778835948" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637811320778835948" xlink:to="us-gaap_OperatingIncomeLoss_637811320778835948" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637811320778835948" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637811320778835948" xlink:to="us-gaap_GrossProfit_637811320778835948" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637811320778846022" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637811320778835948" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637811320778846022" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637811320778846022" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637811320778835948" xlink:to="us-gaap_CostOfRevenue_637811320778846022" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637811320778846022" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637811320778835948" xlink:to="us-gaap_OperatingExpenses_637811320778846022" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637811320778846022" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637811320778846022" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637811320778846022" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637811320778846022" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637811320778846022" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637811320778846022" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637811320778846022" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637811320778835948" xlink:to="us-gaap_InterestExpense_637811320778846022" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637811320778846022" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637811320778846022" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320778846022" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320778846022" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320778846022" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637811320778855907" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320778846022" xlink:to="us-gaap_ProceedsFromOtherEquity_637811320778855907" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320778846022" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637811320778855907" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320778846022" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637811320778855907" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PaymentsRelatedToReverseStockSplit" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320778846022" xlink:to="cvrx_PaymentsRelatedToReverseStockSplit_637811320778855907" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637811320778855907" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637811320778855907" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637811320778855907" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_ShareBasedCompensation_637811320778855907" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_Depreciation_637811320778855907" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637811320778855907" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637811320778855907" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637811320778865924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637811320778865924" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637811320778865924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637811320778865924" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637811320778865924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637811320778865924" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637811320778865924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_IncreaseDecreaseInInventories_637811320778865924" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637811320778865924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637811320778865924" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637811320778865924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637811320778865924" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637811320778865924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_ProfitLoss_637811320778865924" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637811320778865924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320778855907" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637811320778865924" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637811320778875923" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637811320778875923" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_637811320778875923" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryRawMaterials_637811320778875923" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_637811320778875923" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryWorkInProcess_637811320778875923" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_637811320778875923" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryFinishedGoods_637811320778875923" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637811320778875923" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637811320778875923" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637811320778875923" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637811320778875923" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637811320778875923" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedBonusesCurrent_637811320778875923" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_AccruedPaidTimeOff_637811320778885911" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637811320778885911" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_637811320778885911" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_InterestPayableCurrent_637811320778885911" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_637811320778885911" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_637811320778885911" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637811320778885911" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_637811320778885911" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_637811320778885911" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_637811320778885911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_637811320778885911" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_637811320778885911" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637811320778895873" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_637811320778895873" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637811320778895873" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_637811320778895873" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637811320778895873" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_637811320778895873" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637811320778895873" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637811320778895873" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_637811320778895873" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="us-gaap_DeferredTaxAssetsOther_637811320778895873" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_637811320778895873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_637811320778895873" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637811320778905867" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_637811320778905867" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637811320778905867" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_637811320778905867" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_637811320778905867" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637811320778905867" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637811320778895873" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637811320778905867" order="9" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40901 - Disclosure - (Loss) Earnings Per Share (Basic and Diluted Net Loss per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_637811320778905867" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_637811320778905867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_637811320778905867" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637811320778915942" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637811320778915942" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637811320778915942" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637811320778915942" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637811320778915942" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637811320778915942" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>tmb-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/22/2022 1:07:58 PM-->
<!--Modified on: 2/22/2022 1:07:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureFairValueMeasurementsNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails" roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentInLeaseNoncurrent" xlink:label="us-gaap_NetInvestmentInLeaseNoncurrent" xlink:title="us-gaap_NetInvestmentInLeaseNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_NetInvestmentInLeaseNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsAbstract To us-gaap_NetInvestmentInLeaseNoncurrent" order="9" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis_1" xlink:title="dei_DocumentInformationDocumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_1" xlink:title="dei_DocumentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_DocumentInformationDocumentAxis_1" xlink:to="dei_DocumentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_DocumentInformationDocumentAxis_1 To dei_DocumentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConversionOfTemporaryToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cvrx_ConversionOfTemporaryToPermanentEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityAccretionOfIssuanceCost" xlink:label="cvrx_TemporaryEquityAccretionOfIssuanceCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="cvrx_TemporaryEquityAccretionOfIssuanceCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of significant accounting policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cvrx_LabEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetUnderConstructionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair value measurements (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_BiosenseWebsterInc.Member" xlink:label="cvrx_BiosenseWebsterInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvrx_BiosenseWebsterInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" xlink:label="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements (Liabilities Measured at Fair Value on a Recurring Basis) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Fair Value Measurements (Fair Value of Convertible Preferred Stock Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Debt  (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cvrx_LoanAndSecurityAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_HorizonTechnologyFinanceCorporationMember" xlink:label="cvrx_HorizonTechnologyFinanceCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="cvrx_HorizonTechnologyFinanceCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth" xlink:label="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentFinalPayment" xlink:label="cvrx_DebtInstrumentFinalPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_DebtInstrumentFinalPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentMinimumCashOnDepositRequirement" xlink:label="cvrx_DebtInstrumentMinimumCashOnDepositRequirement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_DebtInstrumentMinimumCashOnDepositRequirement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LegalFeesAndInvestmentBankFee" xlink:label="cvrx_LegalFeesAndInvestmentBankFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_LegalFeesAndInvestmentBankFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_IssuanceCostsOfWarrants" xlink:label="cvrx_IssuanceCostsOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_IssuanceCostsOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders Equity (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_SeriesgConvertiblePreferredStockMember" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_SeriesgConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OperationalMilestoneClosingMember" xlink:label="cvrx_OperationalMilestoneClosingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="cvrx_OperationalMilestoneClosingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_BiosenseWebsterInc.Member" xlink:label="cvrx_BiosenseWebsterInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvrx_BiosenseWebsterInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" xlink:label="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesa2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesb2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesc2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesd2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriese2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriese2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_Seriese2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesf2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_SeriesgConvertiblePreferredStockMember" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="cvrx_SeriesgConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_StockOptionsWithEarlyExerciseOptionMember" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="cvrx_StockOptionsWithEarlyExerciseOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvrx_NonOfficerEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvrx_OfficerEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="40902 - Disclosure - (Loss) Earnings Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Schedule of Segment Reporting) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cvrx_OtherCountriesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>tmb-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/22/2022 1:07:58 PM-->
<!--Modified on: 2/22/2022 1:07:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantLiabilityCurrent" xlink:label="cvrx_WarrantLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_WarrantLiabilityCurrent" xlink:to="cvrx_WarrantLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_WarrantLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of warrant liability classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_WarrantLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_WarrantLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 10)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, $0.01 par value, 10,000,000 and 237,370,645 authorized as of December 31, 2021 and December 31, 2020, respectively; 0 and 223,541,754 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible preferred stock, Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.01 par value, 200,000,000 and 625,217,795 authorized as of December 31, 2021 and December 31, 2020, respectively; 20,399,337 and 360,412 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, convertible preferred stock, and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares used to compute net loss per share, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Shareholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated and other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConversionOfTemporaryToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ConversionOfTemporaryToPermanentEquity" xlink:to="cvrx_ConversionOfTemporaryToPermanentEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Temporary to Permanent Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Temporary to Permanent Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series G preferred stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xlink:to="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Temporary Equity, Shares, to Permanent Equity .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Temporary Equity, Shares, to Permanent Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series G preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series G preferred stock, net of costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues" xlink:to="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of securities classified as temporary equity that have been issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Series G preferred stock, net of costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityAccretionOfIssuanceCost" xlink:label="cvrx_TemporaryEquityAccretionOfIssuanceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TemporaryEquityAccretionOfIssuanceCost" xlink:to="cvrx_TemporaryEquityAccretionOfIssuanceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TemporaryEquityAccretionOfIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TemporaryEquityAccretionOfIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion of issuance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TemporaryEquityAccretionOfIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of Series G issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchased During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchased During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series G preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series G preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of Series G issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing costs and loan discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on debt extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment and other fees,</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in fair value of convertible preferred stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Other Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series G Preferred Stock, net of fees</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PaymentsRelatedToReverseStockSplit" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PaymentsRelatedToReverseStockSplit" xlink:to="cvrx_PaymentsRelatedToReverseStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow related to reverse stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Related to Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments related to reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment on debt financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of currency exchange on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Organization [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected Balance Sheet Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected balance sheet information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Loss) Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plans [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment, Geographic Information and Revenue Disaggregation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment, geographic information and revenue disaggregation</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:to="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation And Consolidation Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement presentation and basis of consolidation</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:to="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to JOBS Act accounting election.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JOBS Act Accounting Election [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JOBS Act accounting election</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Measured at Fair Value on a Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of the Company's Convertible Preferred Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Warrants to Purchase Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Provision for Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Taxes at the Federal Statutory Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Net Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes to Gross Unrecognized Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect, Period of Adoption, Adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work-in-process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office furniture and equipment</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LabEquipmentMember" xlink:to="cvrx_LabEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to lab equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ComputerEquipmentAndSoftwareMember" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to computer equipment and software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetUnderConstructionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital equipment in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial and Other Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trial and other professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bonuses</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_AccruedPaidTimeOff" xlink:to="cvrx_AccruedPaidTimeOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of paid time off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Paid Time Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid time off</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued liability relating customer rebate classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Customer Rebate Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer rebates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" xlink:label="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" xlink:to="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to warrants to purchase series G preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Series G Preferred Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Series G Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_WarrantsToPurchaseCommonStockMember" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants to purchase common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_BiosenseWebsterInc.Member" xlink:label="cvrx_BiosenseWebsterInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_BiosenseWebsterInc.Member" xlink:to="cvrx_BiosenseWebsterInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_BiosenseWebsterInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Biosense Webster, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_BiosenseWebsterInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biosense Webster, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares converted from warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Outstanding, Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant outstanding term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from level 1 to 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from level 2 to level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer into level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer out of level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xlink:to="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to convertible preferred stock warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock Warrant Liability [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">End of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning of the period</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" xlink:to="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of changes in fair value of liability measured at fair value on recurring basis using unobservable input (level 3).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Changes in Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" xlink:to="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of conversions of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Conversions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion to common stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LoanAndSecurityAgreementMember" xlink:to="cvrx_LoanAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to loan and security agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan and Security Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIBOR [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lender Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Lender [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_HorizonTechnologyFinanceCorporationMember" xlink:label="cvrx_HorizonTechnologyFinanceCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_HorizonTechnologyFinanceCorporationMember" xlink:to="cvrx_HorizonTechnologyFinanceCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_HorizonTechnologyFinanceCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Horizon Technology Finance Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_HorizonTechnologyFinanceCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Horizon Technology Finance Corporation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth" xlink:label="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth" xlink:to="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of threshold interest rate on the first business day of the month.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Interest Rate on First Business Day of Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate on first business day of month (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term (in months)</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentFinalPayment" xlink:label="cvrx_DebtInstrumentFinalPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DebtInstrumentFinalPayment" xlink:to="cvrx_DebtInstrumentFinalPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DebtInstrumentFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of final payment of debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DebtInstrumentFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Final Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DebtInstrumentFinalPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of final payment on original principal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Percentage of Final Payment on Original Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of final payment on original principal</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentMinimumCashOnDepositRequirement" xlink:label="cvrx_DebtInstrumentMinimumCashOnDepositRequirement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DebtInstrumentMinimumCashOnDepositRequirement" xlink:to="cvrx_DebtInstrumentMinimumCashOnDepositRequirement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DebtInstrumentMinimumCashOnDepositRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of minimum cash on deposit requirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DebtInstrumentMinimumCashOnDepositRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Minimum Cash on Deposit Requirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DebtInstrumentMinimumCashOnDepositRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum cash on deposit requirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs and discounts</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LegalFeesAndInvestmentBankFee" xlink:label="cvrx_LegalFeesAndInvestmentBankFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LegalFeesAndInvestmentBankFee" xlink:to="cvrx_LegalFeesAndInvestmentBankFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LegalFeesAndInvestmentBankFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of legal fees and an investment bank fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LegalFeesAndInvestmentBankFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Fees and Investment Bank Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LegalFeesAndInvestmentBankFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal fees and an investment bank fee</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_IssuanceCostsOfWarrants" xlink:label="cvrx_IssuanceCostsOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_IssuanceCostsOfWarrants" xlink:to="cvrx_IssuanceCostsOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_IssuanceCostsOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of issuance costs of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_IssuanceCostsOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Costs of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_IssuanceCostsOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total debt extinguishment cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_SeriesgConvertiblePreferredStockMember" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_SeriesgConvertiblePreferredStockMember" xlink:to="cvrx_SeriesgConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to SeriesG Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series G Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OperationalMilestoneClosingMember" xlink:label="cvrx_OperationalMilestoneClosingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OperationalMilestoneClosingMember" xlink:to="cvrx_OperationalMilestoneClosingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OperationalMilestoneClosingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to operational milestone closing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OperationalMilestoneClosingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operational milestone closing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Warrants Converted To Common Stock Warrants At Initial Public Offering Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesa2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember" xlink:to="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series A2 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A2 Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesb2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember" xlink:to="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series B2 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B2 Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesc2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember" xlink:to="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series C2 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C2 Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesd2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember" xlink:to="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series D2 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series D2 Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriese2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriese2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_Seriese2RedeemableConvertiblePreferredStockMember" xlink:to="cvrx_Seriese2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_Seriese2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series E2 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_Seriese2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series E2 Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesf2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember" xlink:to="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Series F2 Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series F2 Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Liquidation Preference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants, Outstanding</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice" xlink:label="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice" xlink:to="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants or rights outstanding, weighted average exercise price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrants or Rights Exercised, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_StockOptionsWithEarlyExerciseOptionMember" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_StockOptionsWithEarlyExerciseOptionMember" xlink:to="cvrx_StockOptionsWithEarlyExerciseOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to stock options with early exercise option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options with early exercise option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Stock incentive plan 2001.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2001 Plan</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EmployeeStockPurchasePlanMember" xlink:to="cvrx_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESSP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to two thousand twenty one equity plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares available for grant</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based payment award, term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued/purchased under ESPP</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of automatic annual  increase in shares reserved for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Reserved For Issuance Automatic Incremental Annual Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual incremental percentage</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Permitted To be Purchased, Minimum Percentage Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of End of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of Beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xlink:to="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of liability recorded for the early exercise of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Recorded for Early Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability recorded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled / Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of December 31, 2021 (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of End of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of Beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled / Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of December 31, 2021 (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term, outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, exercisable (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_NonOfficerEmployeesMember" xlink:to="cvrx_NonOfficerEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_NonOfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to non officer employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_NonOfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non officer employees</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OfficerEmployeesMember" xlink:to="cvrx_OfficerEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to officer employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Officer employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general &amp; administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research &amp; development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal, State and Local, Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, federal and state</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, total current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax at federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development ("R&amp;D") tax credit</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rate change</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D tax credits</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xlink:to="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount after allocation of valuation allowances of deferred tax asset attributable to Internal Revenue Code 59E election.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Internal Revenue Code 59 E election</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IRC Section 59e election</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DeferredTaxAssetsStartUpCosts" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Start Up Costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Start-up costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-qualified stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued vacation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Derivative Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrecognized tax benefits at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrecognized tax benefits at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross increases: Prior year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross increases: Current year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross decreases: Prior year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Accretion of Redemption Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of preferred stock to redemption value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase redeemable convertible preferred stock (as converted to common stock)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible preferred stock (as converted to common stock)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Excluded potential common shares from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liabilities accrual amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OtherCountriesMember" xlink:to="cvrx_OtherCountriesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OtherCountriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to other countries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OtherCountriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other countries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>tmb-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/22/2022 1:07:58 PM-->
<!--Modified on: 2/22/2022 1:07:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureBusinessOrganization" roleURI="http://www.cvrx.com/role/DisclosureBusinessOrganization" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformation" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureDebt" roleURI="http://www.cvrx.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockholdersEquity" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureLossEarningsPerShare" roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregation" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationTables" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureLossEarningsPerShareTables" roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureFairValueMeasurementsNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails" roleURI="http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockholdersEquitySummaryOfWarrantsDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="tmb-20211231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637811320779475566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637811320779475566" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637811320779475566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637811320779475566" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637811320779475566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637811320779475566" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637811320779475566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637811320779475566" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637811320779475566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637811320779475566" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637811320779485566" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637811320779485566" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637811320779485566" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637811320779485566" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637811320779485566" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637811320779485566" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637811320779485566" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637811320779485566" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637811320779485566" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637811320779485566" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637811320779485566" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637811320779485566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637811320779485566" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637811320779495925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637811320779495925" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637811320779495925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637811320779495925" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637811320779495925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637811320779495925" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637811320779495925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637811320779495925" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637811320779495925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637811320779495925" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637811320779495925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637811320779495925" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637811320779495925" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637811320779495925" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637811320779506141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637811320779506141" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637811320779506141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637811320779506141" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637811320779506141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637811320779506141" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637811320779506141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637811320779506141" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637811320779506141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637811320779506141" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637811320779506141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637811320779506141" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637811320779516282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637811320779516282" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637811320779516282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_637811320779516282" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637811320779516282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_637811320779516282" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637811320779516282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_637811320779516282" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637811320779526107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637811320779526107" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637811320779526107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637811320779526107" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637811320779526107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637811320779526107" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637811320779526107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637811320779526107" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637811320779535974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637811320779535974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637811320779535974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637811320779535974" xlink:to="us-gaap_AssetsCurrentAbstract_637811320779535974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637811320779535974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637811320779535974" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637811320779535974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637811320779535974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637811320779535974" xlink:to="us-gaap_AccountsReceivableNetCurrent_637811320779535974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637811320779535974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637811320779535974" xlink:to="us-gaap_InventoryNet_637811320779535974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637811320779535974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637811320779535974" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637811320779535974" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637811320779535974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637811320779535974" xlink:to="us-gaap_AssetsCurrent_637811320779535974" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637811320779545685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637811320779535974" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637811320779545685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637811320779545685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637811320779535974" xlink:to="us-gaap_OtherAssetsNoncurrent_637811320779545685" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637811320779545685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637811320779535974" xlink:to="us-gaap_Assets_637811320779545685" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637811320779545685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637811320779545685" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_637811320779545685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637811320779545685" xlink:to="us-gaap_LiabilitiesAbstract_637811320779545685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637811320779545685" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637811320779545685" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637811320779545685" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637811320779545685" xlink:to="us-gaap_AccountsPayableCurrent_637811320779555987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637811320779545685" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637811320779555987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantLiabilityCurrent" xlink:label="cvrx_WarrantLiabilityCurrent_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637811320779545685" xlink:to="cvrx_WarrantLiabilityCurrent_637811320779555987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637811320779545685" xlink:to="us-gaap_LiabilitiesCurrent_637811320779555987" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637811320779545685" xlink:to="us-gaap_LongTermDebtNoncurrent_637811320779555987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637811320779545685" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637811320779555987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_637811320779545685" xlink:to="us-gaap_Liabilities_637811320779555987" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637811320779545685" xlink:to="us-gaap_CommitmentsAndContingencies_637811320779555987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320779555987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637811320779545685" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320779555987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637811320779565959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637811320779545685" xlink:to="us-gaap_StockholdersEquityAbstract_637811320779565959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637811320779565959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637811320779565959" xlink:to="us-gaap_CommonStockValue_637811320779565959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637811320779565959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637811320779565959" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637811320779565959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637811320779565959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637811320779565959" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637811320779565959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637811320779565959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637811320779565959" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637811320779565959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637811320779565959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637811320779565959" xlink:to="us-gaap_StockholdersEquity_637811320779565959" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637811320779545685" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637811320779576025" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637811320779576025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637811320779576025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquitySharesIssued_637811320779576025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637811320779576025" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637811320779576025" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesAuthorized_637811320779576025" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesIssued_637811320779576025" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637811320779576025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesOutstanding_637811320779576025" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637811320779585906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_CostOfRevenue_637811320779585906" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GrossProfit_637811320779585906" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637811320779585906" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637811320779585906" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637811320779585906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637811320779585906" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637811320779585906" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637811320779585906" xlink:to="us-gaap_OperatingExpenses_637811320779585906" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637811320779585906" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InterestExpense_637811320779585906" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637811320779585906" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637811320779585906" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637811320779585906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637811320779585906" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637811320779595876" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637811320779595876" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637811320779595876" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637811320779595876" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637811320779595876" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637811320779595876" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637811320779595876" xlink:to="us-gaap_StatementClassOfStockAxis_637811320779595876" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637811320779595876" xlink:to="us-gaap_ConvertiblePreferredStockMember_637811320779595876" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637811320779595876" xlink:to="us-gaap_ClassOfStockDomain_637811320779595876" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637811320779595876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637811320779595876" xlink:to="us-gaap_StatementEquityComponentsAxis_637811320779595876" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637811320779595876" xlink:to="us-gaap_CommonStockMember_637811320779605908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637811320779595876" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637811320779605908" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637811320779595876" xlink:to="us-gaap_RetainedEarningsMember_637811320779605908" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637811320779595876" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637811320779605908" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637811320779595876" xlink:to="us-gaap_EquityComponentDomain_637811320779605908" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637811320779595876" xlink:to="us-gaap_StatementLineItems_637811320779605908" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779605908" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320779605908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637811320779605908" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConversionOfTemporaryToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryToPermanentEquity_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="cvrx_ConversionOfTemporaryToPermanentEquity_637811320779605908" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity" xlink:label="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity_637811320779605908" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637811320779605908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637811320779605908" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues_637811320779615891" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityAccretionOfIssuanceCost" xlink:label="cvrx_TemporaryEquityAccretionOfIssuanceCost_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="cvrx_TemporaryEquityAccretionOfIssuanceCost_637811320779615891" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320779615891" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637811320779605908" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637811320779615891" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779605908" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockholdersEquity_637811320779615891" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_SharesOutstanding_637811320779615891" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637811320779615891" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637811320779615891" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_637811320779615891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_637811320779615891" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_637811320779625874" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue_637811320779615891" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_637811320779625874" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637811320779625874" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637811320779625874" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637811320779625874" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637811320779625874" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637811320779625874" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637811320779625874" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_637811320779625874" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_637811320779625874" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637811320779625874" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637811320779625874" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637811320779625874" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637811320779625874" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637811320779625874" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637811320779625874" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637811320779635942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_NetIncomeLoss_637811320779635942" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637811320779635942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_637811320779635942" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637811320779635942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_StockholdersEquity_637811320779635942" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637811320779635942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637811320779615891" xlink:to="us-gaap_SharesOutstanding_637811320779635942" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_ProfitLoss_637811320779645725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_ShareBasedCompensation_637811320779645725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_Depreciation_637811320779645725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637811320779645725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637811320779645725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637811320779645725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637811320779645725" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637811320779645725" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637811320779645725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637811320779645725" xlink:to="us-gaap_IncreaseDecreaseInInventories_637811320779645725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637811320779645725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637811320779645725" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637811320779645725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637811320779645725" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637811320779656062" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_637811320779645725" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637811320779656062" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637811320779645725" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637811320779656062" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637811320779656062" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637811320779656062" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637811320779656062" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637811320779656062" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637811320779656062" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637811320779656062" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637811320779656062" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637811320779656062" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity_637811320779656062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637811320779656062" xlink:to="us-gaap_ProceedsFromOtherEquity_637811320779656062" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PaymentsRelatedToReverseStockSplit" xlink:label="cvrx_PaymentsRelatedToReverseStockSplit_637811320779665619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637811320779656062" xlink:to="cvrx_PaymentsRelatedToReverseStockSplit_637811320779665619" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637811320779665619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637811320779656062" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637811320779665619" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637811320779665619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637811320779656062" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637811320779665619" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320779665619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637811320779656062" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637811320779665619" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637811320779665619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637811320779665619" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637811320779665619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637811320779665619" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637811320779665619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637811320779665619" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378113207796656191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378113207796656191" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637811320779665619" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637811320779665619" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637811320779676245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637811320779665619" xlink:to="us-gaap_InterestPaidNet_637811320779676245" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_637811320779676245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637811320779665619" xlink:to="us-gaap_IncomeTaxesPaid_637811320779676245" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureBusinessOrganization" xlink:type="extended" xlink:title="10101 - Disclosure - Business Organization" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637811320779676245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637811320779676245" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637811320779676245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637811320779676245" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" xlink:type="extended" xlink:title="10301 - Disclosure - Selected Balance Sheet Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637811320779676245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637811320779676245" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637811320779685875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637811320779685875" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebt" xlink:type="extended" xlink:title="10501 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637811320779685875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637811320779685875" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10601 - Disclosure - Stockholders Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637811320779685875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637811320779685875" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637811320779685875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637811320779685875" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637811320779685875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637811320779685875" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossEarningsPerShare" xlink:type="extended" xlink:title="10901 - Disclosure - (Loss) Earnings Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637811320779685875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637811320779685875" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637811320779695910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637811320779695910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="11101 - Disclosure - Employee Benefit Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637811320779695910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637811320779695910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" xlink:type="extended" xlink:title="11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_637811320779695910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_637811320779695910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_637811320779695910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_637811320779695910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_637811320779695910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cvrx_JobsActAccountingElectionPolicyTextBlock_637811320779695910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637811320779695910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_637811320779695910" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637811320779695910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637811320779695910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_637811320779695910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_637811320779695910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_637811320779706224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_InventoryPolicyTextBlock_637811320779706224" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637811320779706224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637811320779706224" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637811320779706224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637811320779706224" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637811320779706224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637811320779706224" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" xlink:type="extended" xlink:title="30303 - Disclosure - Selected Balance Sheet Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637811320779706224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637811320779706224" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637811320779706224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637811320779706224" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637811320779706224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637811320779706224" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair value measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_637811320779715986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_637811320779715986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637811320779715986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637811320779715986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30603 - Disclosure - Stockholders Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_637811320779715986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_TemporaryEquityTableTextBlock_637811320779715986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637811320779715986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637811320779715986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637811320779715986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637811320779715986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637811320779715986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637811320779715986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637811320779715986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637811320779715986" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637811320779715986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637811320779715986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637811320779725909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637811320779725909" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637811320779725909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637811320779725909" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_637811320779725909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_637811320779725909" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables" xlink:type="extended" xlink:title="30903 - Disclosure - (Loss) Earnings Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637811320779725909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637811320779725909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637811320779725909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637811320779725909" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637811320779725909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637811320779725909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_637811320779725909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_637811320779725909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of significant accounting policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637811320779735918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637811320779735918" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637811320779735918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637811320779735918" xlink:to="us-gaap_TypeOfAdoptionMember_637811320779735918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637811320779735918" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_637811320779735918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637811320779735918" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637811320779735918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637811320779735918" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637811320779735918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637811320779735918" xlink:to="us-gaap_OperatingLeaseLiability_637811320779735918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_5" xlink:to="us-gaap_Depreciation_637811320779735918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryRawMaterials_637811320779735918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryWorkInProcess_637811320779735918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryFinishedGoods_637811320779735918" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637811320779735918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryNet_637811320779735918" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637811320779746020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637811320779746020" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637811320779746020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637811320779746020" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637811320779746020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637811320779746020" xlink:to="us-gaap_OfficeEquipmentMember_637811320779746020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637811320779746020" xlink:to="cvrx_LabEquipmentMember_637811320779746020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637811320779746020" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember_637811320779746020" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637811320779746020" xlink:to="us-gaap_LeaseholdImprovementsMember_637811320779746020" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637811320779746020" xlink:to="us-gaap_AssetUnderConstructionMember_637811320779746020" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637811320779746020" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637811320779746020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637811320779746020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637811320779746020" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637811320779746020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637811320779746020" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637811320779755985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637811320779746020" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637811320779755985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_637811320779755985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedBonusesCurrent_637811320779755985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_AccruedPaidTimeOff_637811320779755985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_637811320779755985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_637811320779755985" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_InterestPayableCurrent_637811320779755985" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637811320779755985" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637811320779755985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637811320779755985" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair value measurements (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_StatementTable_637811320779766023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637811320779766023" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637811320779766023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637811320779766023" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637811320779766023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" xlink:label="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637811320779766023" xlink:to="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_637811320779766023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637811320779766023" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_637811320779766023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637811320779766023" xlink:to="srt_CounterpartyNameAxis_637811320779766023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637811320779766023" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637811320779766023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_BiosenseWebsterInc.Member" xlink:label="cvrx_BiosenseWebsterInc.Member_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637811320779766023" xlink:to="cvrx_BiosenseWebsterInc.Member_637811320779766023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637811320779766023" xlink:to="us-gaap_StatementLineItems_637811320779766023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779766023" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637811320779766023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779766023" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779766023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637811320779766023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779766023" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637811320779766023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779766023" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_637811320779776053" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779766023" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_637811320779776053" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779766023" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_637811320779776053" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637811320779766023" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_637811320779776053" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements (Liabilities Measured at Fair Value on a Recurring Basis) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637811320779776053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637811320779776053" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637811320779776053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637811320779776053" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637811320779776053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637811320779776053" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637811320779776053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637811320779776053" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637811320779776053" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637811320779776053" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637811320779776053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637811320779776053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637811320779776053" xlink:to="us-gaap_FairValueInputsLevel1Member_637811320779776053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637811320779776053" xlink:to="us-gaap_FairValueInputsLevel2Member_637811320779786011" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637811320779776053" xlink:to="us-gaap_FairValueInputsLevel3Member_637811320779786011" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637811320779776053" xlink:to="us-gaap_FinancialInstrumentAxis_637811320779786011" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637811320779786011" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779786011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779786011" xlink:to="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_637811320779786011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637811320779776053" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637811320779786011" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637811320779786011" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_637811320779786011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_637811320779786011" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_637811320779786011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Fair Value Measurements (Fair Value of Convertible Preferred Stock Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637811320779786011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637811320779786011" xlink:to="us-gaap_FinancialInstrumentAxis_637811320779786011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779786011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637811320779786011" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779786011" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779786011" xlink:to="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_637811320779796032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637811320779786011" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637811320779796032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637811320779796032" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637811320779796032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637811320779796032" xlink:to="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue_637811320779796032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions" xlink:label="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637811320779796032" xlink:to="cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions_637811320779796032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6378113207797960321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637811320779796032" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6378113207797960321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Debt  (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_637811320779796032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637811320779796032" xlink:to="us-gaap_DebtInstrumentAxis_637811320779796032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637811320779796032" xlink:to="us-gaap_DebtInstrumentNameDomain_637811320779796032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637811320779796032" xlink:to="cvrx_LoanAndSecurityAgreementMember_637811320779796032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637811320779796032" xlink:to="us-gaap_VariableRateAxis_637811320779796032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637811320779796032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_637811320779796032" xlink:to="us-gaap_VariableRateDomain_637811320779796032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_637811320779796032" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_637811320779806023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637811320779796032" xlink:to="us-gaap_FinancialInstrumentAxis_637811320779806023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637811320779806023" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779806023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637811320779806023" xlink:to="cvrx_ConvertiblePreferredStockWarrantLiabilityMember_637811320779806023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637811320779796032" xlink:to="us-gaap_LineOfCreditFacilityAxis_637811320779806023" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_637811320779806023" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_637811320779806023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_HorizonTechnologyFinanceCorporationMember" xlink:label="cvrx_HorizonTechnologyFinanceCorporationMember_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_637811320779806023" xlink:to="cvrx_HorizonTechnologyFinanceCorporationMember_637811320779806023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637811320779796032" xlink:to="us-gaap_IncomeStatementLocationAxis_637811320779806023" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637811320779806023" xlink:to="us-gaap_IncomeStatementLocationDomain_637811320779806023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637811320779806023" xlink:to="us-gaap_OtherExpenseMember_637811320779806023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637811320779806023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637811320779796032" xlink:to="us-gaap_DebtInstrumentLineItems_637811320779806023" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637811320779816041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637811320779816041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637811320779816041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637811320779816041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth" xlink:label="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth_637811320779816041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth_637811320779816041" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637811320779816041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="us-gaap_DebtInstrumentTerm_637811320779816041" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentFinalPayment" xlink:label="cvrx_DebtInstrumentFinalPayment_637811320779816041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="cvrx_DebtInstrumentFinalPayment_637811320779816041" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_637811320779816041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_637811320779816041" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DebtInstrumentMinimumCashOnDepositRequirement" xlink:label="cvrx_DebtInstrumentMinimumCashOnDepositRequirement_637811320779826033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="cvrx_DebtInstrumentMinimumCashOnDepositRequirement_637811320779826033" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_637811320779826033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="us-gaap_DeferredFinanceCostsGross_637811320779826033" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LegalFeesAndInvestmentBankFee" xlink:label="cvrx_LegalFeesAndInvestmentBankFee_637811320779826033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="cvrx_LegalFeesAndInvestmentBankFee_637811320779826033" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_IssuanceCostsOfWarrants" xlink:label="cvrx_IssuanceCostsOfWarrants_637811320779826033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="cvrx_IssuanceCostsOfWarrants_637811320779826033" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779826033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779826033" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_637811320779826033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_637811320779826033" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637811320779835688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637811320779835688" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637811320779835688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637811320779806023" xlink:to="us-gaap_LongTermDebt_637811320779835688" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders Equity (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637811320779835688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637811320779835688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637811320779835688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637811320779835688" xlink:to="us-gaap_StatementClassOfStockAxis_637811320779835688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637811320779835688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637811320779835688" xlink:to="us-gaap_ClassOfStockDomain_637811320779835688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_SeriesgConvertiblePreferredStockMember" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember_637811320779835688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637811320779835688" xlink:to="cvrx_SeriesgConvertiblePreferredStockMember_637811320779835688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637811320779835688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637811320779835688" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637811320779835688" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637811320779835688" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637811320779835688" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637811320779835688" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637811320779835688" xlink:to="us-gaap_IPOMember_637811320779846149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637811320779835688" xlink:to="us-gaap_OverAllotmentOptionMember_637811320779846149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637811320779835688" xlink:to="srt_StatementScenarioAxis_637811320779846149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637811320779846149" xlink:to="srt_ScenarioUnspecifiedDomain_637811320779846149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OperationalMilestoneClosingMember" xlink:label="cvrx_OperationalMilestoneClosingMember_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637811320779846149" xlink:to="cvrx_OperationalMilestoneClosingMember_637811320779846149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637811320779835688" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637811320779846149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637811320779846149" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637811320779846149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637811320779846149" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_637811320779846149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember" xlink:label="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_637811320779846149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637811320779846149" xlink:to="cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_637811320779846149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637811320779855792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637811320779835688" xlink:to="srt_CounterpartyNameAxis_637811320779855792" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637811320779855792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637811320779855792" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637811320779855792" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_BiosenseWebsterInc.Member" xlink:label="cvrx_BiosenseWebsterInc.Member_637811320779855792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637811320779855792" xlink:to="cvrx_BiosenseWebsterInc.Member_637811320779855792" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637811320779855792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637811320779835688" xlink:to="us-gaap_TemporaryEquityLineItems_637811320779855792" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637811320779855792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637811320779855792" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637811320779855792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637811320779855792" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637811320779866236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637811320779866236" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637811320779866236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637811320779866236" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637811320779866236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_SharesIssuedPricePerShare_637811320779866236" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637811320779866236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637811320779866236" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637811320779866236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637811320779866236" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_637811320779866236" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_637811320779866236" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_637811320779915575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_637811320779915575" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_637811320779915575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_637811320779915575" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637811320779915575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637811320779915575" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637811320779915575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637811320779915575" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637811320779925968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637811320779925968" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779925968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779925968" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637811320779925968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779855792" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637811320779925968" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637811320779925968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637811320779925968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637811320779925968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637811320779925968" xlink:to="us-gaap_StatementClassOfStockAxis_637811320779925968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637811320779925968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637811320779925968" xlink:to="us-gaap_ClassOfStockDomain_637811320779925968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesa2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637811320779925968" xlink:to="cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_637811320779935969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesb2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637811320779925968" xlink:to="cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_637811320779935969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesc2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637811320779925968" xlink:to="cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_637811320779935969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesd2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637811320779925968" xlink:to="cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_637811320779935969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriese2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriese2RedeemableConvertiblePreferredStockMember_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637811320779925968" xlink:to="cvrx_Seriese2RedeemableConvertiblePreferredStockMember_637811320779935969" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_Seriesf2RedeemableConvertiblePreferredStockMember" xlink:label="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637811320779925968" xlink:to="cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_637811320779935969" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_SeriesgConvertiblePreferredStockMember" xlink:label="cvrx_SeriesgConvertiblePreferredStockMember_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637811320779925968" xlink:to="cvrx_SeriesgConvertiblePreferredStockMember_637811320779935969" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637811320779925968" xlink:to="us-gaap_TemporaryEquityLineItems_637811320779935969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779935969" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637811320779935969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779935969" xlink:to="us-gaap_TemporaryEquitySharesIssued_637811320779935969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779935969" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637811320779935969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320779935969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779935969" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637811320779935969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_637811320779945957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637811320779935969" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_637811320779945957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Stockholders Equity (Summary of Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637811320779945957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637811320779945957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_637811320779945957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_637811320779945957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised_637811320779945957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="cvrx_StockIssuedDuringPeriodSharesWarrantsExercised_637811320779945957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6378113207799459571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6378113207799459571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779945957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779945957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_637811320779945957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_637811320779945957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice" xlink:label="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice_637811320779945957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice_637811320779945957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637811320779955954" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779955954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779955954" xlink:to="us-gaap_AwardTypeAxis_637811320779955954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637811320779955954" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637811320779955954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637811320779955954" xlink:to="us-gaap_EmployeeStockOptionMember_637811320779955954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_StockOptionsWithEarlyExerciseOptionMember" xlink:label="cvrx_StockOptionsWithEarlyExerciseOptionMember_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOptionMember_637811320779955954" xlink:to="cvrx_StockOptionsWithEarlyExerciseOptionMember_637811320779955954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779955954" xlink:to="us-gaap_PlanNameAxis_637811320779955954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637811320779955954" xlink:to="us-gaap_PlanNameDomain_637811320779955954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637811320779955954" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_637811320779955954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637811320779955954" xlink:to="cvrx_EmployeeStockPurchasePlanMember_637811320779955954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_637811320779955954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637811320779955954" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember_637811320779955954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779955954" xlink:to="srt_RangeAxis_637811320779966022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637811320779966022" xlink:to="srt_RangeMember_637811320779966022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637811320779966022" xlink:to="srt_MaximumMember_637811320779966022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779955954" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637811320779966022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637811320779966022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_637811320779966022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637811320779966022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637811320779966022" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_637811320779966022" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_637811320779966022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_637811320779966022" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637811320779976071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637811320779976071" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637811320779976071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637811320779976071" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637811320779976071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637811320779976071" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637811320779976071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637811320779976071" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions" xlink:label="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_637811320779976071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779966022" xlink:to="cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions_637811320779976071" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779985953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779985953" xlink:to="us-gaap_AwardTypeAxis_637811320779985953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637811320779985953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637811320779985953" xlink:to="us-gaap_EmployeeStockOptionMember_637811320779985953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779985953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637811320779985953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637811320779985953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637811320779985953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637811320779985953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637811320779985953" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637811320779985953" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378113207799859531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378113207799859531" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637811320779985953" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637811320779985953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637811320779985953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637811320779995938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637811320779995938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637811320779995938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637811320779995938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637811320779995938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637811320779995938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637811320779995938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637811320779995938" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378113207799959381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378113207799959381" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637811320779995938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637811320779995938" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637811320779995938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320779985953" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637811320779995938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637811320779995938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637811320779995938" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637811320779995938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637811320779995938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637811320779995938" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637811320779995938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637811320780006115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637811320779995938" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637811320780006115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637811320780006115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637811320779995938" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637811320780006115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320780006115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320780006115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637811320780006115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320780006115" xlink:to="srt_TitleOfIndividualAxis_637811320780006115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637811320780006115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637811320780006115" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637811320780006115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember_637811320780006115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637811320780006115" xlink:to="cvrx_NonOfficerEmployeesMember_637811320780006115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember_637811320780006115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637811320780006115" xlink:to="cvrx_OfficerEmployeesMember_637811320780006115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320780006115" xlink:to="srt_RangeAxis_637811320780015990" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637811320780015990" xlink:to="srt_RangeMember_637811320780015990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637811320780015990" xlink:to="srt_MinimumMember_637811320780015990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637811320780015990" xlink:to="srt_MaximumMember_637811320780015990" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637811320780006115" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637811320780015990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637811320780015990" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637811320780015990" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637811320780015990" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637811320780015990" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637811320780015990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637811320780015990" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637811320780025938" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637811320780015990" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637811320780025938" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637811320780025938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637811320780025938" xlink:to="us-gaap_IncomeStatementLocationAxis_637811320780025938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637811320780025938" xlink:to="us-gaap_IncomeStatementLocationDomain_637811320780025938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637811320780025938" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637811320780025938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637811320780025938" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637811320780025938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637811320780025938" xlink:to="us-gaap_CostOfSalesMember_637811320780025938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637811320780025938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637811320780025938" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637811320780025938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637811320780025938" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637811320780036045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637811320780025938" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637811320780036045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637811320780025938" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637811320780036045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637811320780036045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637811320780036045" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637811320780036045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637811320780036045" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637811320780036045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637811320780036045" xlink:to="us-gaap_DomesticCountryMember_637811320780036045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637811320780036045" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637811320780036045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637811320780036045" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637811320780036045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637811320780036045" xlink:to="us-gaap_OperatingLossCarryforwards_637811320780036045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637811320780036045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637811320780036045" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637811320780036045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637811320780045969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637811320780036045" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637811320780045969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_637811320780045969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637811320780036045" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_637811320780045969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637811320780045969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637811320780036045" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637811320780045969" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_637811320780045969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_637811320780045969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_637811320780045969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_637811320780045969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637811320780045969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637811320780045969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637811320780045969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637811320780045969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637811320780056051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_637811320780056051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637811320780056051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_637811320780056051" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637811320780056051" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_637811320780056051" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637811320780056051" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637811320780056051" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637811320780056051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637811320780056051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DeferredTaxAssetsInternalRevenueCode59EElection" xlink:label="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="cvrx_DeferredTaxAssetsInternalRevenueCode59EElection_637811320780056051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_637811320780056051" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637811320780056051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637811320780056051" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637811320780065887" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_637811320780065887" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_637811320780065887" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsOther_637811320780065887" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsGross_637811320780065887" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637811320780065887" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsNet_637811320780065887" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefits_637811320780065887" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_637811320780065887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637811320780065887" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_637811320780065887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_637811320780065887" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefits_637811320780075932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40901 - Disclosure - (Loss) Earnings Per Share (Basic and Diluted Net Loss per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637811320780075932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637811320780075932" xlink:to="us-gaap_NetIncomeLoss_637811320780075932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637811320780075932" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_637811320780075932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637811320780075932" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637811320780075932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_637811320780075932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_637811320780075932" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637811320780075932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_637811320780075932" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637811320780075932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="40902 - Disclosure - (Loss) Earnings Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637811320780075932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637811320780075932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637811320780075932" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637811320780085968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637811320780085968" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637811320780085968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637811320780085968" xlink:to="us-gaap_EmployeeStockOptionMember_637811320780085968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637811320780085968" xlink:to="us-gaap_WarrantMember_637811320780085968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637811320780085968" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_637811320780085968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637811320780085968" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_637811320780085968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637811320780075932" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637811320780085968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637811320780085968" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637811320780085968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_OperatingLeaseExpense_637811320780085968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_637811320780085968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_ContractualObligation_637811320780085968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637811320780095943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637811320780095943" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637811320780095943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637811320780095943" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637811320780095943" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637811320780095943" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637811320780095943" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637811320780095943" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637811320780095943" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Schedule of Segment Reporting) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_637811320780095943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_637811320780095943" xlink:to="srt_StatementGeographicalAxis_637811320780095943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637811320780095943" xlink:to="srt_SegmentGeographicalDomain_637811320780095943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637811320780095943" xlink:to="country_US_637811320780095943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE" xlink:label="country_DE_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637811320780095943" xlink:to="country_DE_637811320780095943" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20211231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637811320780095943" xlink:to="cvrx_OtherCountriesMember_637811320780095943" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_637811320780095943" xlink:to="us-gaap_SegmentReportingInformationLineItems_637811320780095943" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637811320780095943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_637811320780095943" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637811320780095943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637811320780105923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_637811320780095943" xlink:to="us-gaap_NumberOfOperatingSegments_637811320780105923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726165328136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CVRx,&#160;Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1983744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9201 West Broadway Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">416-2840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,477,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, Minnesota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001235912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726166255624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,072<span></span>
</td>
<td class="nump">$ 59,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="nump">3,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,585<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">151,097<span></span>
</td>
<td class="nump">64,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">152,548<span></span>
</td>
<td class="nump">64,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,398<span></span>
</td>
<td class="nump">3,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,908<span></span>
</td>
<td class="nump">7,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,589<span></span>
</td>
<td class="nump">28,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.01 par value, 10,000,000 and 237,370,645 authorized as of December 31, 2021 and December 31, 2020, respectively; 0 and 223,541,754 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">329,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 200,000,000 and 625,217,795 authorized as of December 31, 2021 and December 31, 2020, respectively; 20,399,337 and 360,412 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">540,707<span></span>
</td>
<td class="nump">58,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(394,754)<span></span>
</td>
<td class="num">(351,676)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">145,959<span></span>
</td>
<td class="num">(293,238)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders' equity (deficit)</a></td>
<td class="nump">$ 152,548<span></span>
</td>
<td class="nump">$ 64,777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liability classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726165300888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">237,370,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,541,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,541,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">625,217,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">20,399,337<span></span>
</td>
<td class="nump">360,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">20,399,337<span></span>
</td>
<td class="nump">360,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169283704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 13,036<span></span>
</td>
<td class="nump">$ 6,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">3,640<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">9,396<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,501<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">27,863<span></span>
</td>
<td class="nump">9,717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">35,364<span></span>
</td>
<td class="nump">16,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(25,968)<span></span>
</td>
<td class="num">(11,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(2,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(14,800)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(42,987)<span></span>
</td>
<td class="num">(14,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,078)<span></span>
</td>
<td class="num">(14,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Cumulative translation adjustment</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (43,086)<span></span>
</td>
<td class="num">$ (14,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (4.16)<span></span>
</td>
<td class="num">$ (37.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used to compute net loss per share, basic and diluted</a></td>
<td class="nump">10,360,054<span></span>
</td>
<td class="nump">387,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726162996552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Convertible preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated and other comprehensive loss</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balances, Beginning at Dec. 31, 2019</a></td>
<td class="nump">$ 279,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balances, Beginning (in shares) at Dec. 31, 2019</a></td>
<td class="nump">161,041,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series G preferred stock, net of costs</a></td>
<td class="nump">$ 49,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series G preferred stock, net of costs (in shares)</a></td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_TemporaryEquityAccretionOfIssuanceCost', window );">Accretion of Series G issuance costs</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balances, Ending at Dec. 31, 2020</a></td>
<td class="nump">$ 329,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,983<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2020</a></td>
<td class="nump">223,541,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,541,754<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Beginning at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 58,708<span></span>
</td>
<td class="num">$ (337,567)<span></span>
</td>
<td class="num">$ (189)<span></span>
</td>
<td class="num">$ (279,043)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Beginning (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Accretion of Series G issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Ending at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">58,624<span></span>
</td>
<td class="num">(351,676)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="num">(293,238)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ConversionOfTemporaryToPermanentEquity', window );">Conversion of Series G preferred stock</a></td>
<td class="num">$ (329,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity', window );">Conversion of Series G preferred stock (in shares)</a></td>
<td class="num">(223,541,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balances, Ending at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">133,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series G preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">347,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series G preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,929,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Ending at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 540,707<span></span>
</td>
<td class="num">$ (394,754)<span></span>
</td>
<td class="num">$ (198)<span></span>
</td>
<td class="nump">$ 145,959<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,399,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Temporary Equity, Shares, to Permanent Equity .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ConversionOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Temporary to Permanent Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ConversionOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_TemporaryEquityAccretionOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Accretion of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_TemporaryEquityAccretionOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726166285128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (43,078)<span></span>
</td>
<td class="num">$ (14,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs and loan discount</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of convertible preferred stock warrants</a></td>
<td class="nump">13,294<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,279)<span></span>
</td>
<td class="num">(562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(537)<span></span>
</td>
<td class="num">(1,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,980)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,187<span></span>
</td>
<td class="num">(838)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(27,732)<span></span>
</td>
<td class="num">(16,096)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,183)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,183)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from issuance of Series G Preferred Stock, net of fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_PaymentsRelatedToReverseStockSplit', window );">Payments related to reverse stock split</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering costs</a></td>
<td class="nump">133,161<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment on debt financing</a></td>
<td class="num">(21,300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">111,883<span></span>
</td>
<td class="nump">49,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of currency exchange on cash and cash equivalents</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">82,960<span></span>
</td>
<td class="nump">33,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">59,112<span></span>
</td>
<td class="nump">25,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">142,072<span></span>
</td>
<td class="nump">59,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">2,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PaymentsRelatedToReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow related to reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PaymentsRelatedToReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726168968808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business organization</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Business organization</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CVRx,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. The Company has developed and is marketing a medical device, Barostim, for heart failure (&#8220;HF&#8221;) and resistant hypertension. The Company is focused on the sale of its product in the U.S. and Europe.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that the Company will generate sufficient product sales to produce positive earnings or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169041704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Summary of significant accounting policies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2021 and 2020, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. We do not record an allowance on our trade accounts receivable but monitor the collectability of individual customer accounts on an ongoing basis.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#8217;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#8217;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non- employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#8212;Stock Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and nonemployee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We use an estimate of the value of our common stock, with the assistance of an independent appraiser, to determine the fair value of options. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In February&#160;2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, Leases (&#8220;Topic 842&#8221;). The purpose of Topic 842 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Topic 842 is effective for private companies and smaller reporting companies for annual periods beginning after December&#160;15, 2021 and interim periods within fiscal&#160;years beginning after December&#160;15, 2022. Early adoption is permitted, and the Company must elect whether the date of initial application is the beginning of the earliest comparative period presented in the financial statements, or the beginning of the period of adoption. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of Topic 842 guidance, whereas comparative periods and their respective disclosures prior to the adoption of Topic 842 are presented using the legacy guidance of Accounting Standards Classification (&#8220;ASC&#8221;) 840.&#160;As a result of adopting the new standard, the Company will recognize right-of-use assets of $579,000 and lease liabilities of $561,000 million as of January 1, 2022. The </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">difference between the amount of right-of-use assets and lease liabilities recognized includes adjustments to prepaid rent.&#160;There will be no change to net deferred tax balances as a result of the Company&#8217;s adoption of Topic 842.&#160;The adoption of Topic 842 did not impact the Company&#8217;s results of operations or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169063992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Selected balance sheet information</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Selected balance sheet information</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,361</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 321</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,661</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,343</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 189</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,272</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 516</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 89</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,293</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,110</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,700</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 410</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Depreciation expense was $0.2 million and $0.1 million for the&#160;years ended December 31, 2021 and 2020, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,690</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 794</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 552</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 356</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,583</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169017080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Fair value measurements</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8212; Inputs are quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8212; Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8212; Inputs are unobservable for the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table sets forth the Company&#8217;s liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy. There was no convertible preferred stock warrant liability as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:57.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible preferred stock warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,911</p></td></tr><tr><td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,911</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The convertible preferred stock warrant liability related to warrants issued in connection with loan and security agreements entered into in September 2014, as amended in July 2015, in May 2016 and in September 2019. These warrants were originally issued to purchase shares of Series&#160;F-2 convertible preferred stock and Series&#160;G convertible preferred stock (&#8220;Series&#160;G Preferred Shares&#8221;). <span style="color:#231f20;">In connection with the closing of the initial public offering (&#8220;IPO&#8221;), these convertible preferred stock warrants became warrants to purchase </span><span style="color:#231f20;">108,406</span><span style="color:#231f20;"> shares of common stock and were reclassified to equity.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The convertible preferred stock warrant liability also related to a warrant issued to Biosense Webster,&#160;Inc. (&#8220;BWI&#8221;), an affiliate of Johnson&#160;&amp; Johnson Innovation&#160;&#8212; JJDC,&#160;Inc., to purchase Series&#160;G Preferred Shares with an exercise price of $0.01 per share. <span style="color:#231f20;">In connection with the closing of the IPO, the BWI warrant to purchase Series G Preferred Shares became exercisable to purchase </span><span style="color:#231f20;">607,725</span><span style="color:#231f20;"> shares of common stock at</span> an exercise price of $0.16 per share<span style="color:#231f20;">. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s recurring fair value measurements using significant unobservable inputs (Level 3) related solely to the Company&#8217;s convertible preferred stock warrant liability. The convertible preferred stock warrant liability was remeasured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.<span style="color:#231f20;"> In connection with the closing of the IPO, all of the outstanding convertible preferred stock warrants were converted to common stock warrants. The related liability was remeasured at the time of the IPO and reclassed to additional paid-in capital.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of changes in the estimated fair value of the Company&#8217;s convertible preferred stock warrants during the years ended:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,540</p></td></tr><tr><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 371</p></td></tr><tr><td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Conversion to common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (17,205)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">End of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,911</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were no transfers in or out of Level 1, Level 2 or Level 3 fair value measurements during the periods ended December 31, 2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726251042536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Debt</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Horizon loan agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, the Company entered into a loan and security agreement (&#8220;Horizon loan agreement&#8221;) with Horizon Technology Finance Corporation (&#8220;Horizon&#8221;) under which it could borrow up to a total of $20.0 million at a floating per annum rate equal to 10% plus the amount by which the 30-day U.S. dollar LIBOR rate on the first business day of the&#160;month exceeds 2.2%. The Horizon loan agreement initially required interest only payments through October&#160;2021 and then <span style="white-space:pre-wrap;">36</span><span style="white-space:pre-wrap;">&#160;monthly principal and interest payments beginning in November&#160;2021. A final payment of $0.7 million, equal to 3.5% of the original principal, was due in October&#160;2024. The Horizon loan agreement initially required the Company to maintain cash on deposit of not less than $5.0 million in accounts over which Horizon maintained an account control agreement. This minimum cash on deposit requirement was released in July&#160;2020, following the satisfaction of a financing milestone. The borrowings were collateralized by all or substantially all of the assets of the Company. The Horizon loan agreement required the payment of certain penalties if the loan was paid off prior to maturity for any reason, including pursuant to a subjective acceleration clause, and included various restrictive covenants, including a restriction on the payment of dividends. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the Company entered into an amended agreement with Horizon to extend the interest only period through April&#160;2022, followed by 30&#160;monthly principal and interest payments beginning in May&#160;2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Horizon loan agreement, the Company recorded $1.1 million of debt issuance costs and discounts as a reduction of long-term debt. Of this total, $0.5 million related to legal fees and an investment bank fee and $0.6 million related to the warrants to purchase Series&#160;G Preferred Shares issued by the Company. These warrants were exercisable on the grant date at a price of $0.80 per share and expire in September&#160;2029. The Company used the Black-Scholes option pricing model to determine the grant date fair value of these warrants. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November 3, 2021 the Company fully repaid all amounts outstanding under the Horizon loan agreement. The total repayment amount was $21.3 million, inclusive of $1.3 million of prepayment and other fees, which represent a loss on extinguishment of debt and are included in Other expense, net on the consolidated statements of operations. The Company was in compliance with all related covenants at the time the principal balance was fully repaid. There was no debt outstanding in relation to the Horizon loan agreement as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169324984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stockholders&#8217; equity</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Initial Public Offering</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During 2016, the Company issued 72,125,000 shares of Series&#160;G Preferred Shares at a price of $0.80 per share, for net proceeds to the Company of approximately $57.4 million after deducting offering expenses payable by the Company. The same Series&#160;G investors agreed to purchase an additional $35.3 million of Series&#160;G Preferred Shares upon the Company&#8217;s achievement of a certain operational milestone, subject to limited closing conditions. In January&#160;2019, <span style="-sec-ix-hidden:Hidden_M0BZTFHNU0ipFi78VUubmw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">May&#160;2019</span></span><span style="white-space:pre-wrap;"> and </span><span style="-sec-ix-hidden:Hidden_hGmV6LR9xUyVdc_b1EBWDQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">August&#160;2019</span></span><span style="white-space:pre-wrap;">, the Series&#160;G investors purchased additional Series&#160;G Preferred Shares, resulting in net proceeds to the Company of $24.7 million.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In July&#160;of 2020, the Company issued 62,500,000 additional Series&#160;G Preferred Shares, at a price of $0.80 per share, for net proceeds to the Company of $49.8 million after deducting offering expenses payable by the Company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On May&#160;31, 2016, holders of the requisite number of the Company&#8217;s then-outstanding convertible preferred stock approved the conversion of all preferred stock into shares of the Company&#8217;s common stock in connection with a new equity financing. Accordingly, all of the Company&#8217;s then-outstanding preferred stock was converted on a one-for-one basis into shares of the Company&#8217;s common stock. Under the terms of the equity financing, each prior holder of preferred stock who purchased a required amount of securities in the new financing was entitled to exchange certain of the shares of common stock received in the conversion described above into new prime series of preferred stock corresponding to the series of preferred stock from which the common stock was previously converted. All of the previously held Series&#160;A-1, B-1, C-1, D-1, E-1 and F preferred stock had similar features as the Series&#160;A-2 preferred stock (&#8220;Series&#160;A-2 Preferred Shares&#8221;), Series&#160;B-2 preferred stock (&#8220;Series&#160;B-2 Preferred Shares&#8221;), Series&#160;C-2 preferred stock (&#8220;Series&#160;C-2 Preferred Shares&#8221;), Series&#160;D-2 preferred stock (&#8220;Series&#160;D-2 Preferred Shares&#8221;), Series&#160;E-2 preferred stock (&#8220;Series&#160;E-2 Preferred Shares&#8221;) and Series&#160;F-2 preferred stock (&#8220;Series&#160;F-2 Preferred Shares&#8221;) described below. The Series&#160;A-2, Series&#160;B-2, Series&#160;C-2, Series&#160;D-2, Series&#160;E-2, Series&#160;F-2 and Series&#160;G Preferred Shares are referred to collectively as the &#8220;Preferred Shares.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, convertible preferred stock consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,454,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,454,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,909</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,963,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,963,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,526</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series C&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,308,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,308,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,141</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series D&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,631,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,631,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 53,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 53,518</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series E&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,114,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,135,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 76,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91,806</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series F&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,773,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,548,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 41,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 104,783</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 177,125,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 165,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 132,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 494,550</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 237,370,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223,541,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 329,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 770,233</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July&#160;2, 2021, the Company closed its IPO of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which included 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for net proceeds from the IPO, after deducting the underwriting discount and other offering expenses payable by the Company totaling $1.6 million, of $133.2 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO, all shares of convertible preferred stock were automatically converted into common stock. Series&#160;G Preferred Shares were converted into common stock on a 15.819-for-1 basis, and all other shares of convertible preferred stock were automatically converted into common stock on a 39.548-for-1 basis. The conversion of the outstanding preferred stock resulted in an aggregate of 11,929,584 shares of common stock. As of December 31, 2021, no preferred stock is outstanding.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company&#8217;s Board of Directors and stockholders approved a 1-for-<span style="-sec-ix-hidden:Hidden_33FQYq2nDUGydCuOJK10Rw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">39.548</span></span> reverse stock split of the Company&#8217;s common stock. The reverse stock split became effective on June&#160;22, 2021. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock will convert into common stock in connection with the closing of the IPO. Accordingly, all share and per-share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and the adjustment of the conversion ratio of the convertible preferred stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock Warrants and Common Stock Warrants</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the loan and security agreement entered into by the Company in September 2014 and the amendment in July 2015, the Company issued a warrant to purchase shares of Series F-2 convertible preferred stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the loan and security agreement entered into in May 2016, the Company issued a warrant to purchase Series G Preferred Shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company issued to BWI a warrant to purchase shares of Series E-2 convertible preferred stock that only would have become exercisable in the event of an acquisition or asset transfer involving the Company and it expired upon our IPO.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In September&#160;of 2018, the Company also issued to BWI a warrant to purchase up to&#160;</span><span style="background:#ffffff;">10,000,000</span><span style="background:#ffffff;">&#160;Series&#160;G Preferred Shares with an exercise price of </span><span style="background:#ffffff;">$0.01</span><span style="background:#ffffff;">&#160;per share. The warrant to purchase Series&#160;G Preferred Shares became exercisable upon our IPO and would have expired on the earlier of (i)&#160;an acquisition or asset transfer involving the Company or (ii)&#160;</span><span style="color:#231f20;background:#ffffff;">180&#160;days</span><span style="color:#231f20;background:#ffffff;">&#160;after receipt of the data from the post-market stage of the BeAT-HF pivotal trial.&#160;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the warrants to purchase shares of convertible preferred stock automatically converted into warrants to purchase common stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in capital. Upon the closing of the IPO these warrants to purchase convertible preferred stock became exercisable for 716,131 shares of common stock upon conversion at a weighted average exercise price of $2.39 per share. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Warrants to purchase shares of our common stock are summarized below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock warrants converted to common stock warrants at IPO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.39</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.39</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169011624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stock-Based compensation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of plans and activity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2001, the Company&#8217;s Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#8220;2001 Plan&#8221;). Under the 2001 Plan, as amended, 2,674,749 shares of common stock had been reserved for the issuance of incentive stock options granted to employees, nonemployee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the day of grant to four&#160;years and expire within a maximum term of 10 years from the grant date. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In connection with the IPO in 2021, the Company&#8217;s Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was 1,854,490 newly reserved shares in addition to the 600,373 shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan will automatically increase on the first day of each year, commencing January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The 2021 Plan provides for the </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of 10 years from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2021, there were 1,789,453 shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of the Company&#8217;s common stock on the date of grant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years 2008 through December 31, 2021, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain nonemployee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as the Company&#8217;s standard form of option agreement for nonemployee directors as they have an exercise price not less than the fair market value on the grant date and vest over 48&#160;months from the date of grant.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in &#160;thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 966,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 2,256</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 517,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">4.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (10,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">4.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">0.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 1,473,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">2.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 3,745</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,411,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (76,294)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">11.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (59,341)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">0.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 2,749,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 16,262</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 1,060,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">2.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 10,303</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, stock options outstanding included 9,993 options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2021, the weighted average remaining contractual life was <span style="white-space:pre-wrap;">8.1</span><span style="white-space:pre-wrap;">&#160;years. For options exercisable as of December 31, 2021, the weighted average remaining contractual life was </span><span style="white-space:pre-wrap;">6.6</span><span style="white-space:pre-wrap;"> years.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the IPO, the Company&#8217;s Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The number of shares of common stock initially reserved for issuance under the ESPP was 278,170. The shares available for issuance under the ESPP will automatically increase on the first day of each year, commencing January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 1% of the total number of shares of the Company&#8217;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The ESPP will permit certain of the Company&#8217;s U.S. employees to purchase shares of the Company&#8217;s common stock at a price per share not less than 85% of the l<span style="letter-spacing:0.25pt;">ower of (i)&#160;the closing market price per share of the Company&#8217;s common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of the Company&#8217;s common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase period commenced January 1, 2022. Accordingly, as of December 31, 2021, </span><span style="letter-spacing:0.25pt;">no</span><span style="letter-spacing:0.25pt;white-space:pre-wrap;"> shares of common stock have been purchased under the ESPP.  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to determine the fair value of stock options on the grant date. The Company measures stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2021 and 2020. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.7 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.1% to 63.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 62.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.17% to 1.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.16% to 0.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews these assumptions on a periodic basis and adjusts them, as necessary. The expected term of an award was determined based on the Company&#8217;s analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. <span style="color:#231f20;">We utilize the simplified method to develop the estimate of the expected term</span>. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be zero, as the Company has never paid dividends and has no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 43</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 132</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, unrecognized compensation expense related to unvested stock-based compensation arrangements was $6.9 million. As of December 31, 2021, the related weighted average period over which it is expected to be recognized is approximately <span style="white-space:pre-wrap;">3.3</span><span style="white-space:pre-wrap;">&#160;years.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Early exercise of stock options</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the 2001 Plan, the Company has issued options to certain executive officers with early-exercise provisions. The options may be exercised by the holder any time after they are granted. The Company has the right to repurchase, at the original option exercise price, shares issued pursuant to such early-exercise provisions, upon the termination of employment or death of the stockholder. This repurchase right expires based upon the original option vesting schedule. As of December 31, 2021 and 2020, there have been no early exercises and therefore there is no liability recorded for the early exercise of stock options.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169332232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Income taxes</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, a valuation allowance was recorded against all deferred tax assets due to the Company&#8217;s cumulative net loss position. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provision for income taxes for the years ended December 31, 2021 and 2020 was $91,000 and $85,000, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.0)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development ("R&amp;D") tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.7)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of net deferred tax assets were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">74,716</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 68,957</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">R&amp;D tax credits</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,711</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,318</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">IRC Section 59e election</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,577</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,955</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Start-up costs</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1,104</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,198</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-qualified stock options</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">350</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 136</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 106</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 67</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 93,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 87,434</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (93,759)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87,434)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, the Company had federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $324.8 million and $6.5 million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2021, the Company had federal and state tax credit carryforwards of approximately $8.9 million and $1.6 million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits began expiring in 2028. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit the Company&#8217;s utilization of the NOLs and could be triggered by subsequent sales of securities by the Company or its stockholders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,840</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,757</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,840</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The Company recognized approximately $61,000 and $56,000 of interest or penalties for the&#160;years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021 and 2020, total accrued interest and penalties are $0.3 million and $0.3&#160;million, respectively. The Company recognizes accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. The Company does not expect a significant change in the amount of unrecognized tax benefits in the next year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2001 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. The Company does not have any tax audits or other proceedings pending.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169361784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">(Loss) Earnings Per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">9. (Loss) Earnings Per Share</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (43,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (14,109)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accretion of preferred stock to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (217)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (43,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (14,326)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,360,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 387,083</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (4.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (37.01)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company&#8217;s potentially dilutive securities, which include stock options, shares of convertible preferred stock, warrants to purchase shares of convertible preferred stock and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,749,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,473,359</p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 108,406</p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,929,584</p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,465,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,511,349</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726256498168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Commitments and contingencies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commitments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Operating Leases</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into an operating lease agreement for its office, manufacturing and research facility, which expires in 2024. Rent expense for the years ended December 31, 2021 and 2020 was $0.4 million and $0.4 million, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Future minimum lease payments under all operating leases as of December 31, 2021 are as follows for the&#160;years ending:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 227</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 234</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 138</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 599</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contingencies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been no contingent liabilities requiring accrual or disclosure as of December 31, 2021 or December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169361784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee benefit plans</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Employee benefit plans</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a voluntary defined-contribution employee retirement plan (the &#8220;401(k)&#160;plan&#8221;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. The Company does not provide matching contributions to employees.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726168948328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic Information and Revenue Disaggregation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment, Geographic Information and Revenue Disaggregation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, geographic information and revenue disaggregation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Segment, geographic information and revenue disaggregation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">and its Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the years ended:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,733</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,790</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,053</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2021 and 2020, long-lived assets were located primarily in the U.S.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726165255928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock', window );">Statement presentation and basis of consolidation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_JobsActAccountingElectionPolicyTextBlock', window );">JOBS Act accounting election</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2021 and 2020, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. We do not record an allowance on our trade accounts receivable but monitor the collectability of individual customer accounts on an ongoing basis.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#8217;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#8217;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non- employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#8212;Stock Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and nonemployee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We use an estimate of the value of our common stock, with the assistance of an independent appraiser, to determine the fair value of options. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In February&#160;2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, Leases (&#8220;Topic 842&#8221;). The purpose of Topic 842 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Topic 842 is effective for private companies and smaller reporting companies for annual periods beginning after December&#160;15, 2021 and interim periods within fiscal&#160;years beginning after December&#160;15, 2022. Early adoption is permitted, and the Company must elect whether the date of initial application is the beginning of the earliest comparative period presented in the financial statements, or the beginning of the period of adoption. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of Topic 842 guidance, whereas comparative periods and their respective disclosures prior to the adoption of Topic 842 are presented using the legacy guidance of Accounting Standards Classification (&#8220;ASC&#8221;) 840.&#160;As a result of adopting the new standard, the Company will recognize right-of-use assets of $579,000 and lease liabilities of $561,000 million as of January 1, 2022. The </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">difference between the amount of right-of-use assets and lease liabilities recognized includes adjustments to prepaid rent.&#160;There will be no change to net deferred tax balances as a result of the Company&#8217;s adoption of Topic 842.&#160;The adoption of Topic 842 did not impact the Company&#8217;s results of operations or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_JobsActAccountingElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to JOBS Act accounting election.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_JobsActAccountingElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726170145480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,361</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 321</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,661</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,343</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 189</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,272</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 516</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 89</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,293</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,110</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,700</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 410</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,690</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 794</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 552</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 356</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 149</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,583</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726168928920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table sets forth the Company&#8217;s liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy. There was no convertible preferred stock warrant liability as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:57.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible preferred stock warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,911</p></td></tr><tr><td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,911</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value of the Company's Convertible Preferred Stock Warrants</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of changes in the estimated fair value of the Company&#8217;s convertible preferred stock warrants during the years ended:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,540</p></td></tr><tr><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 371</p></td></tr><tr><td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Conversion to common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (17,205)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">End of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,911</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726168200152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, convertible preferred stock consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,454,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,454,686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,909</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series B&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,963,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,963,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,526</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series C&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,308,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,308,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,141</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series D&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,631,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,631,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 53,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 53,518</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series E&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,114,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,135,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 76,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91,806</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series F&#8209;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,773,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 29,548,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 41,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 104,783</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series G</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 177,125,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 165,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 132,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 494,550</p></td></tr><tr><td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 237,370,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223,541,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 329,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 770,233</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants to Purchase Shares</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Warrants to purchase shares of our common stock are summarized below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock warrants converted to common stock warrants at IPO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.39</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.39</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726170206232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in &#160;thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 966,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 2,256</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 517,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">4.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (10,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">4.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">0.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 1,473,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">2.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 3,745</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,411,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">13.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (76,294)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">11.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (59,341)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">0.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 2,749,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 16,262</p></td></tr><tr><td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 1,060,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">2.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 10,303</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2021 and 2020. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.7 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.1% to 63.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 62.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.17% to 1.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.16% to 0.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 43</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 132</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726162844952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Provision for Income Taxes</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total current</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Taxes at the Federal Statutory Rate</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.0)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development ("R&amp;D") tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.7)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9.0)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development ("R&amp;D") tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14.7)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.6)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Changes to Gross Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,840</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,757</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,840</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726168202936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (43,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (14,109)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accretion of preferred stock to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (217)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (43,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (14,326)</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,360,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 387,083</p></td></tr><tr><td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (4.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (37.01)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,749,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,473,359</p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 108,406</p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,929,584</p></td></tr><tr><td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,465,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,511,349</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169326680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Future minimum lease payments under all operating leases as of December 31, 2021 are as follows for the&#160;years ending:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 227</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 234</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 138</p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 599</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726168950168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic Information and Revenue Disaggregation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment, Geographic Information and Revenue Disaggregation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the years ended:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,733</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,790</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,053</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726170249880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies (Details) - Cumulative Effect, Period of Adoption, Adjustment<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 579,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">lease liabilities</a></td>
<td class="nump">$ 561,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726164854504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726165201464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="nump">$ 1,593<span></span>
</td>
<td class="nump">$ 1,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 3,880<span></span>
</td>
<td class="nump">$ 3,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726162866568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,293<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="nump">1,868<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">1,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Capital equipment in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726166321064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ClinicalTrialAndOtherProfessionalFees', window );">Clinical trial and other professional fees</a></td>
<td class="nump">$ 1,607<span></span>
</td>
<td class="nump">$ 1,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonuses</a></td>
<td class="nump">2,028<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_AccruedPaidTimeOff', window );">Paid time off</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_AccruedLiabilitiesCustomerRebateCurrent', window );">Customer rebates</a></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Taxes</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 5,398<span></span>
</td>
<td class="nump">$ 3,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_AccruedLiabilitiesCustomerRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liability relating customer rebate classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_AccruedLiabilitiesCustomerRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_AccruedPaidTimeOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of paid time off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_AccruedPaidTimeOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ClinicalTrialAndOtherProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ClinicalTrialAndOtherProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726165346776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Transfer from level 1 to 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Transfer from level 2 to level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfer into level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer out of level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember', window );">Warrants to Purchase Series G Preferred Shares | Biosense Webster, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of common shares converted from warrants</a></td>
<td class="nump">607,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of common shares converted from warrants</a></td>
<td class="nump">108,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvrx_BiosenseWebsterInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvrx_BiosenseWebsterInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726165415208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 3,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Convertible Preferred Stock Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">3,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Convertible Preferred Stock Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Convertible Preferred Stock Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">3,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Convertible Preferred Stock Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 3,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvrx_ConvertiblePreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvrx_ConvertiblePreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726162849400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value of Convertible Preferred Stock Warrants) (Details) - Convertible Preferred Stock Warrant Liability [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning of the period</a></td>
<td class="nump">$ 3,911<span></span>
</td>
<td class="nump">$ 3,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue', window );">Change in fair value</a></td>
<td class="nump">13,294<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions', window );">Conversion to common stock warrants</a></td>
<td class="num">(17,205)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">End of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of changes in fair value of liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of conversions of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvrx_ConvertiblePreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvrx_ConvertiblePreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726163081832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 03, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Prepayment and other fees,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,325)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cvrx_HorizonTechnologyFinanceCorporationMember', window );">Horizon Technology Finance Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cvrx_ConvertiblePreferredStockWarrantLiabilityMember', window );">Convertible Preferred Stock Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_IssuanceCostsOfWarrants', window );">Issuance costs of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Horizon Technology Finance Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth', window );">Interest rate on first business day of month (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_DebtInstrumentFinalPayment', window );">Final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal', window );">Percentage of final payment on original principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_DebtInstrumentMinimumCashOnDepositRequirement', window );">Minimum cash on deposit requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_LegalFeesAndInvestmentBankFee', window );">Legal fees and an investment bank fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Total debt extinguishment cost</a></td>
<td class="nump">$ 21,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Horizon Technology Finance Corporation [Member] | Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Prepayment and other fees,</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | LIBOR [Member] | Horizon Technology Finance Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DebtInstrumentFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of final payment of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DebtInstrumentFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DebtInstrumentMinimumCashOnDepositRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of minimum cash on deposit requirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DebtInstrumentMinimumCashOnDepositRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of final payment on original principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_IssuanceCostsOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance costs of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_IssuanceCostsOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_LegalFeesAndInvestmentBankFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of legal fees and an investment bank fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_LegalFeesAndInvestmentBankFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of threshold interest rate on the first business day of the month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cvrx_HorizonTechnologyFinanceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cvrx_HorizonTechnologyFinanceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cvrx_ConvertiblePreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cvrx_ConvertiblePreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726162065704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering', window );">Preferred stock warrants converted to common stock warrants at IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice', window );">Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock (in shares)</a></td>
<td class="nump">11,929,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering', window );">Preferred stock warrants converted to common stock warrants at IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice', window );">Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember', window );">Warrants to Purchase Series G Preferred Shares | Biosense Webster, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs | $</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="nump">$ 133.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember', window );">Series G Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of Redeemable Convertible Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.8<span></span>
</td>
<td class="nump">$ 24.7<span></span>
</td>
<td class="nump">$ 24.7<span></span>
</td>
<td class="nump">$ 24.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember', window );">Series G Preferred Shares | Operational milestone closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of Redeemable Convertible Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants converted to common stock warrants at IPO.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvrx_BiosenseWebsterInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvrx_BiosenseWebsterInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cvrx_OperationalMilestoneClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cvrx_OperationalMilestoneClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726164974536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders Equity (Schedule of Convertible Preferred Stock) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">237,370,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,541,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,541,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 329,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesa2RedeemableConvertiblePreferredStockMember', window );">Series A2 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,454,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,454,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,454,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesb2RedeemableConvertiblePreferredStockMember', window );">Series B2 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,963,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,963,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,963,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesc2RedeemableConvertiblePreferredStockMember', window );">Series C2 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,308,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,308,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,308,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesd2RedeemableConvertiblePreferredStockMember', window );">Series D2 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,631,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,631,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,631,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriese2RedeemableConvertiblePreferredStockMember', window );">Series E2 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,114,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,135,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,135,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesf2RedeemableConvertiblePreferredStockMember', window );">Series F2 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,773,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,548,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,548,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember', window );">Series G Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesa2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_Seriesa2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesb2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_Seriesb2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesc2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_Seriesc2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesd2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_Seriesd2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriese2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_Seriese2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_Seriesf2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_Seriesf2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cvrx_SeriesgConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726165280936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Summary of Warrants) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants, Outstanding | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering', window );">Preferred stock warrants converted to common stock warrants at IPO | shares</a></td>
<td class="nump">716,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants, Outstanding | shares</a></td>
<td class="nump">716,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice', window );">Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">2.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding, Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding, weighted average exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants converted to common stock warrants at IPO.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726163224088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,749,441<span></span>
</td>
<td class="nump">1,473,359<span></span>
</td>
<td class="nump">966,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,912<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,341<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember', window );">2001 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="nump">2,674,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember', window );">2001 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued/purchased under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage', window );">Annual incremental percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage', window );">Minimum Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,854,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,789,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage', window );">Annual incremental percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember', window );">2021 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm', window );">Share based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock | 2001 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvrx_StockOptionsWithEarlyExerciseOptionMember', window );">Stock options with early exercise option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability recorded for the early exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of automatic annual  increase in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvrx_StockOptionsWithEarlyExerciseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvrx_StockOptionsWithEarlyExerciseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726163058376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Summary of Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of Beginning of period (in shares)</a></td>
<td class="nump">1,473,359<span></span>
</td>
<td class="nump">966,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,411,717<span></span>
</td>
<td class="nump">517,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled / Forfeited (in shares)</a></td>
<td class="num">(76,294)<span></span>
</td>
<td class="num">(10,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(59,341)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of End of period (in shares)</a></td>
<td class="nump">2,749,441<span></span>
</td>
<td class="nump">1,473,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable as of December 31, 2021 (in shares)</a></td>
<td class="nump">1,060,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of Beginning of period (in dollars per share)</a></td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">13.31<span></span>
</td>
<td class="nump">4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled / Forfeited (in dollars per share)</a></td>
<td class="nump">11.25<span></span>
</td>
<td class="nump">4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.39<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance as of End of period (in dollars per share)</a></td>
<td class="nump">7.93<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable as of December 31, 2021 (in dollars per share)</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 16,262<span></span>
</td>
<td class="nump">$ 3,745<span></span>
</td>
<td class="nump">$ 2,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable as of December 31, 2020</a></td>
<td class="nump">$ 10,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (in years)</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable (in years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of End of period (in shares)</a></td>
<td class="nump">9,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726166267656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,411,717<span></span>
</td>
<td class="nump">517,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">56.10%<span></span>
</td>
<td class="nump">62.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">63.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.17%<span></span>
</td>
<td class="nump">0.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">1.44%<span></span>
</td>
<td class="nump">0.18%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember', window );">Non officer employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember', window );">Non officer employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember', window );">Non officer employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember', window );">Officer employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169163672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,912<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general &amp; administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,468<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research &amp; development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169132200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">324,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169316872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components of Provision for Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Provision for income taxes, federal and state</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Provision for income taxes, foreign</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for income taxes, total current</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726168083272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development ("R&amp;D") tax credit</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent', window );">Uncertain tax position</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Deferred rate change</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(14.70%)<span></span>
</td>
<td class="num">(23.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726161998184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components of Net Deferred Tax Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 74,716<span></span>
</td>
<td class="nump">$ 68,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D tax credits</a></td>
<td class="nump">8,711<span></span>
</td>
<td class="nump">8,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_DeferredTaxAssetsInternalRevenueCode59EElection', window );">IRC Section 59e election</a></td>
<td class="nump">8,577<span></span>
</td>
<td class="nump">7,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cvrx_DeferredTaxAssetsStartUpCosts', window );">Start-up costs</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Non-qualified stock options</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Accrued vacation</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">93,759<span></span>
</td>
<td class="nump">87,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(93,759)<span></span>
</td>
<td class="num">(87,434)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DeferredTaxAssetsInternalRevenueCode59EElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to Internal Revenue Code 59E election.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DeferredTaxAssetsInternalRevenueCode59EElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Start Up Costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169168488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at beginning of year</a></td>
<td class="nump">$ 1,840<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases: Prior year tax positions</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases: Current year tax positions</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Gross decreases: Prior year tax positions</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at end of year</a></td>
<td class="nump">$ 1,939<span></span>
</td>
<td class="nump">$ 1,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169455000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Share (Basic and Diluted Net Loss per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,078)<span></span>
</td>
<td class="num">$ (14,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of preferred stock to redemption value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (43,078)<span></span>
</td>
<td class="num">$ (14,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">10,360,054<span></span>
</td>
<td class="nump">387,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders - basic</a></td>
<td class="num">$ (4.16)<span></span>
</td>
<td class="num">$ (37.01)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726166272184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Loss) Earnings Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">3,465,572<span></span>
</td>
<td class="nump">13,511,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">2,749,441<span></span>
</td>
<td class="nump">1,473,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase redeemable convertible preferred stock (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">716,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock (as converted to common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,929,584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726162998424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent liabilities accrual amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726165638888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Future Minimum Lease Payments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">December 31, 2022</a></td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">December 31, 2023</a></td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">December 31, 2024</a></td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139726169089592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic Information and Revenue Disaggregation (Schedule of Segment Reporting) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 13,036<span></span>
</td>
<td class="nump">$ 6,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9,147<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">3,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cvrx_OtherCountriesMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cvrx_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cvrx_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>tmb-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:cvrx="http://www.cvrx.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tmb-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_P2E57QTxoUSi8yLB5BySbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_YiZ4tVb_lEOCzdR1fmlZww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_gSHtkKETBkOZK6zcbuEF5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesf2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriese2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesd2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesc2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesb2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:Seriesa2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_p0RfPfIa3UWcDTlEg4P0KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_GBAq1vgtgUGuG5-Ar6ag-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RUHOGigFiEuJTBLQGUN3cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_OV8o_orI0kaBRnMMLVzv6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_nw03FdpgikWG68cst93DrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_Ddc3yM7430mMAAMMP8Suag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2021_To_6_22_2021_os5QyOYe3E-ZHagmcHHjZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2021-06-22</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NRVdw4MrM0yuymfM2lEBNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SygLLO7d6keB2YcBMuzXRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fZBmRrBVpEW4r7ljKujLsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TXEPtHeAnEu5aSDgEVIuTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8bbj7mTQvkKRbK8e00U2-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_k3U9zkOYDk-3HOWZzCltuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zeiT1HWqrEK40Ol6L2ZKYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S5U_tTlMW0qlftdPLa9DZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bMSZQxnqxEqCmCBMOX938g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e__ks_GGFkytwC3zHBuP5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NZvrdn8yFkWAX4fnEQO45A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6tiymcp8Wk-c2D6KmqY0og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_JGMICHAQEEu3PrOrJyDdFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zsm1WUir-k6VgUpvr7OdPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_sTmU2osx-U-5lEzqPECixw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_Pz24LA4lyUOU54enYn6jCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_rMwLYGHbQE6dNGAJjgqUTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_Fm3g4MulRkuGfrsRDzx3EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_30RcSPGNvEamYzAz2-IrUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_dgYIHQpY50SIFkVijZlZVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_dW1zDaWfyk2oy7oOo2LrKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_kdt0eqlvgUeFDlocBEsHgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_2-T0O75ws02nTypOsGbMvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_NA4nBO9IeUeJcRmeWYh52A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_9YKJ16k5pUK-Co6rlduK-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_DE_U05bs9aJIU6iqEyxRNqWpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_uUcu3GeHRUyZPto-aW7cuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_US_aqbgUY-uCkOAp8sxbW2muQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_DE_4mGJWS3mdUGj2uJ_PoEshg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_pDRh1cot40q_8Y3o2VYqGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qbNP5EMaT0ugnnKkSC2ccQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_f6ItviTz1USvtPXYmohPkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_rfzInbLWC0WZAH9zijqO7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_W8mwFgZUB0-M5Mhl98X9vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_JVTdDeParEGGJ2t4jtbpsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Hw_YMxt6zk2W-1GMsneLZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_Shk5JCIfNUKOH63sKxBD4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_qcikURBbNkqhIs-KAt4sHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_D22BP1wD10eBV-IdknkzyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_8_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Yz5mooOlEEu0wI3NjQvG0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2019_To_5_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_dLnUJPKZnUehAo0SsgSNng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_814Td6NHJU2LA3ME4089rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_12_31_2016_srt_StatementScenarioAxis_cvrx_OperationalMilestoneClosingMember_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_TKhCqTifZ0aCZQX-reWoVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:OperationalMilestoneClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_6RQJgllZt0K-iekb1XdaUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_OKok4WEvikOohFGKGTT-vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GImtIEFIfUmLgGy9Whzecg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_11_3_2021_To_11_3_2021_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_fNfZEgGsO0yZp9z4dnf9og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ogL9DuiJFUOrmGs4jXH1PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yHbljhgpY0mbvZF0ftxdIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_z_YBcxDzik24JD_7beeSKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WXCPeSjuN0mwsFbO09y0Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_y3rSgJAX9EGQxWbuV_L1FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xQ4PL8s8EU69GgtfV_9c1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S0-dIu-pxUOkwdi2LzQL7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_C35XEWZJAU6-Xgd6ERjcqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_3_2021_To_11_3_2021_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherExpenseMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_ID5K4-Y0vE-LBHZCpZLEYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_spHQMK4XMUiiug-F7DvVwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_A_ndJ_mgvE2v6o03-Ks7wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_KNUV7a2UVk-AWL-jkX8qUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_ARf2RRaIzk6UxSql8Of4JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W4X_2dSbnkGc95kko6HZAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_16bB4IFwrUapwzsWJeRraA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_R_I0EY29n0W_Ped5vMxkzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D2BA-9J5XE-PbX6gbNm_aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_RKtvIKc5LkyhjXn68Zj14A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_PH-M6rDzJkyqGZQxfL2QnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_YzRnuQXlH02VKNNMxJ0Jag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_mytN74qZAE-E5cluV0a_Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Pg0bkL4urUCnAduxdRREcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_LU9Pb5rH30abdxp9blQkkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvrx:BiosenseWebsterInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseSeriesGPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_xrHiwCtXlEGvfX5Nxy-WiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_oDN2lEZu7EKFxKQVBpzLOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_MX0otz1v_E62VZpoRgXl2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvrx:BiosenseWebsterInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseSeriesGPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvrx:BiosenseWebsterInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseSeriesGPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BejIF-DRL0aswumRwwIyHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_sIVU4EK2E0GdoOrH6UNCKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_z1FXD3BKKUuyMZ9Pt2aLwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_PlOty7i4fUGsptJeEqXFFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aBap4qmv00-_PB2zQLVyyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_zfsXsnHsBUWf8PinLKwvcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bk4XMJevEEOkeqMW-LrPQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_nTVDTqoC4EGDzTZXxwMKtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_rITtj_g4X0aaNNHUoD6CHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KP_E6votUkOpAaxA54qxHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_IVyA6xFKREe6yCN57Qbv9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Z2T5WpbvEECoGfLG7ZECvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fYLvldHF7ESQu3O88FcTxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember__Rt_uAI5zEe9X0cpvPTtiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HZTSfAFE00aFsq1LVh0T7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_Rj3REBVBCEmO0bZWuNdaXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_14_2022_fw8KXFtSr0qiXvq0PQOA0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_98TiYSuyBEyI_7e_iTGzOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_n8heRn9N5UGTUj53vhPYSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Wr3bFBKF6Uuwn1r7P4sYpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cvrx:SeriesgConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_XAEp1PMrjEePzao7rysu6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_mJX9dbF0-kOVnbsfnZIlqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_48tuazk8rES1QsAP9ElvuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_bFjTgGhLakqfsDzkd9x64A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_bnP6fucus0u5PpGTSQpeQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_yzrdiZL4ykShGVaP8kB8EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:StockOptionsWithEarlyExerciseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_AHM5B_OrqE2hM2md5KwcBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_zXBgdB9Wm0KMsLVbZrH5Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_5vT5q4Y0Gka2WmjvA6i6vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cvrx:ConvertiblePreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cvrx:HorizonTechnologyFinanceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_nBAhCE3xjEOe547YDdUyhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_segment_dGFrNR414EyLMrXxL6FSSQ">
        <measure>cvrx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      id="Hidden_0htmWiR1l0-oVHAWAyf0UQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      id="Hidden_SkOF68hLmkeEGP9aOGLNCA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_c0jPe0diSkSfNdsCtMjVQQ_2_1">0001235912</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_7RP57kWlCk6ddKyIPE4a4A_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_wXUsJX2ik0WeER6vF0Ufkg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_Ae5QhOk9ck-_TG9LL4v7nQ">false</dei:AmendmentFlag>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Hidden_5pg87fbRIkKIPG2d7UU4QA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Hidden_byZi4mWJc0C6vryvKDO1NA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Hidden_CHwWvOCpqkalJ4DpOnMy7w"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Hidden_eK-8jgn7QEO0ypzWDE_TsQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Hidden_ViAT-p-9bUmfp12LJKjAFg"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Hidden_hwtDLgJumE2RaB-hUrfXrQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Hidden_OiXATJAeOEWMUr6BK9NIwg"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">20399337</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_dLnUJPKZnUehAo0SsgSNng"
      decimals="-5"
      id="Hidden_hGmV6LR9xUyVdc_b1EBWDQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">24700000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2019_To_1_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_814Td6NHJU2LA3ME4089rw"
      decimals="-5"
      id="Hidden_M0BZTFHNU0ipFi78VUubmw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">24700000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_6_22_2021_To_6_22_2021_os5QyOYe3E-ZHagmcHHjZA"
      decimals="3"
      id="Hidden_33FQYq2nDUGydCuOJK10Rw"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Hidden_F_D18IC5BEuK0j9gsJLwVA"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Hidden_0XkIKc5vtkaAz_u2UX8LPw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">223541754</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Hidden_hW0XHasF1EqKmki-9OASVQ"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">360412</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ"
      decimals="INF"
      id="Hidden_GlL9e5dCzU2TRSGzqgA9yQ"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2454686</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ"
      decimals="INF"
      id="Hidden_WIbgbBDQSUeSK852Ql0xGg"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2963069</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg"
      decimals="INF"
      id="Hidden_I2CPLNNNTEqPHzyLFDHo3A"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">4308394</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA"
      decimals="INF"
      id="Hidden_HR3YeE_xcUa647uDv07mmA"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">8631967</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ"
      decimals="INF"
      id="Hidden_v3NMNR0jRkSXP-mwxlXtBw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">10135320</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w"
      decimals="INF"
      id="Hidden_jPTbjUbrSkaozDE6EHAXtA"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">29548318</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA"
      decimals="INF"
      id="Hidden_39tfPm6F3kCPPgcE17HUrQ"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">165500000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Hidden_-Y-YqAH9UEGLKbzC_205Pw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">223541754</us-gaap:TemporaryEquitySharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_rnceL-N0AkCak25DB5-qTQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_J9uOqC2b70KBk9PrwiKM1w">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_sbR2giYieUaGXdK2OkNKVw">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_mjVJNflkAEizYVIpC4yWxw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_m0lTdPD4IUubzHDH0pVBIg">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_Eg0qEVN1gUiHcb5WmoCRNA">001-40545</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_qJAUExItTEumVenFrjtv3w">CVRx,&#160;Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_O7LYxyuvmEigNGOkxQ93Ag_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_IDfBNfMXK0-OOaJntp7EHw_1_1">41-1983744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_LFXUeru2OE6ftqGyPJox2g">9201 West Broadway Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_aYHUsx4sD0ChL8vpch9e7Q">Suite&#160;650</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_ezCo47NrDUmKVSQT53Pn8w">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_kHK1XsndZ0iapAuoofbrBw">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_Z_XEBlJPJ0OMR7RAvYlizQ">55445</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_A7N1E_gDC0KnMkZsPaDW8Q">763</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_twAzHAs3i06eIEMb89G7gw">416-2840</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_95cD_i0Mq0yQGQnA-2RjmQ_2_0">Common stock,</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_68n6rB2Rm0u-lBYR1kCJQw_2_2">CVRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_NvPfn1NRFkqT2FdSYJzh-A_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_yP0-SsDDxU2GaeTZ4cSHiA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_x6sfvGnOUEK9IQ7s34vIAw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_y1gH9d7IpEeUAQg5qX5X2Q">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_dFM91SVZW0Cn6nsNWs2qwQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_EKZH7No1rEmuKdyY2l1MGw_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tc_gvWbonJtM0ido3LN18FU8A_3_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_n0Rx-D-LkkWE2_z6OMdkkg">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_bQm3YWrk70KUTR_XBTSZ0g">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_-NLVwVooMkamF_ADfV59PA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_yZjEbaI4mk-4l79p0bH-lQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_Rj3REBVBCEmO0bZWuNdaXw"
      decimals="-5"
      id="Narr_Se9ONxU8pki0Mlck1E6EFA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">9600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_14_2022_fw8KXFtSr0qiXvq0PQOA0A"
      decimals="INF"
      id="Narr_RtTZxl9gmkC_pmejKwn2tw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">20477600</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_M_DJZMsxTkeoUavAhD7v8A">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_tIimdcDbokKK6crKcnkIXg">Minneapolis, Minnesota</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_h8OSWsOnP0OiZOqtV7R9Rw_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">142072000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_S47wP9whYkOwh78bmAczxQ_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">59112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_qA4t_q4bBkCJXIW8CUgrfg_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2560000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_mfJ-FKcD8keIxAnAfK5fYQ_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1281000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_1ylpG_oOQkWvtQwbRLghhA_7_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3880000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_19CPjcrDEkSv5rX-YXQbsA_7_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3343000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_UNqQY5Cv1UG-CYecielWwQ_8_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2585000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_TGGqpMZfDU6pKaTXombJVg_8_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">605000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_xlnfUJ82y0mkqdmWRWT2ew_9_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">151097000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_VccJjOrLN0qi3EIteO_FiQ_9_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">64341000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_rcE4ZXDINkuOcg9rlJRP_g_10_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1425000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_b45I2UqKu0GWH6odO-036w_10_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">410000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_rIZF944DXEuo80U841X5Eg_11_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">26000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_YnjbyXQ3f025WquNFfLXyg_11_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">26000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_f94WY3P8FUK7ig7kYjdTaQ_12_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">152548000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_hWv0nL7FR02ZWM_E0K72Ww_12_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">64777000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_mQUnW6KKxkuY63fToS1xdg_15_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">510000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_7gfWtaTRMEegBGZ9NKhQiQ_15_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">483000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_LWHXvyUx0U6GV0iuUznioQ_16_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">5398000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_Rw3Wq4tyIkC2UcmsjYOGog_16_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3583000</us-gaap:AccruedLiabilitiesCurrent>
    <cvrx:WarrantLiabilityCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_G0tpMtif5kOEDrZ8fm1KqQ_17_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</cvrx:WarrantLiabilityCurrent>
    <cvrx:WarrantLiabilityCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_hjEa9B-BTE-NwUCiLO9pTw_17_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3911000</cvrx:WarrantLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_cfMPZOKUB02gF747cTHW5A_18_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">5908000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_oUDdepy6UUKciWnz1vPOhw_18_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">7977000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_73ICxiVU802Cl9zFhT_HIw_19_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_pn6F2zF7YEu_xPlO3ACSpA_19_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">19278000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_Al3Iri-vQ0Kr7DWiLbcY1w_20_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">681000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_w6GJi4ih4kiJGSh7aFl_nw_20_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">777000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_gWVnrnPAO0-a8UCxiDGiQw_21_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">6589000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_HUF3SNa_R0-WIGRPkrsixg_21_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">28032000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Narr_saCEtySRsEuZ7aVq9To-LA"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Narr_1I06B-wZP0-2Df8wiTJLEQ"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Narr_4BrIBkChSU-0QC2bYYbIxA"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Narr_WGWeMSNwQEyuE2OYQUSB9Q"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">237370645</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Narr_zqYKIlpoWkaUrJ-nyMhHKg"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Narr_6HRjw65sUUqmEoYLNp9APg"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">223541754</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_13lBHDnPvk66xXZALh-7vw_23_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_YeDeNAm_FU2ijpqXeI3XgA_23_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">329983000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Narr_cB37bISmN0ix-eRShR1EvA"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Narr_OZ4MrTR96k24YrqEFzlcTw"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Narr_Ui7-b7qAmUeyMI2f9aPacw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Narr_9WBAPkP0h0S2lKpC2fvjHA"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">625217795</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Narr_xXIPDTIv1kCBVvAnEmzVFA"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">20399337</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Narr_LcdkLxHOv0KeXEfMTD6Y9g"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">360412</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_WGj6gh3FnkOyUn0LHJVxtg_25_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">204000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_xJ74FEhD8kyktkRDKPhbLw_25_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_OfH5HKwFDEeeX47psq2PVg_26_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">540707000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_iBvGEl0Mc0qd9pDvXoJTjA_26_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">58624000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_bnEvPkT0a02Xjtrb7Uyd9Q_27_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-394754000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_XqvBOvs--EeDx6znkZg3dw_27_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-351676000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_9D7O0cxsYEKOhbHU9tuy1Q_28_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-198000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_rbWVVTP2MUWOFIbMyNSMZw_28_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-190000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_v_ylxMpqaEmp5BucbT4O0A_29_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">145959000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_2wDoYhbdT0a--CvyoU8oCA_29_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-293238000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_8Flx9k1DnUSfuv91T6Z6_w_30_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">152548000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_Q_E5VcrJ1U62j_qJiWrtaw_30_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">64777000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_fqlo5WE8Wk2KnjgOdcACcg_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">13036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_UT-viUIQ0U-7qHNpTZl8Qw_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">6053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_O94gf6yZak2OkSYhnf1EAQ_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3640000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_Nfr3s8kCpUqsagqWsQU_Tg_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1440000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_GvdS4Z4QXk2WSNeR7qy5TQ_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">9396000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_pAEmITIwTUGPtqjzf0xC-A_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">4613000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_p17YWfVw5Ea-xJPWMJNJAg_8_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">7501000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_lwbbMuKM80OQMZ2VItnhGg_8_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">6410000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_h-luf2cZoka-TrNJFmgnPA_9_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">27863000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_cYtEM-d4_0eGKvBtoWA2cw_9_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">9717000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_Hor7UB5VZU2_YgNBzQlyqQ_10_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">35364000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_jsI3gSGdl0qSh_Rr7rMBlQ_10_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">16127000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_MHaxuk72hkaYYr60Fk4YeA_11_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-25968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_5m9GvT0gKUm9UpD5OzHo-A_11_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-11514000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_nODBMjBge0KpizVCWNeNKw_12_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2219000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_JbnF6SAC5UO95xO_Bussyw_12_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2470000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_9IF3D_C5-0WYO7AfXNtXhg_13_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_K6EgcBIM2Uuf_67MOJjhIw_13_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-40000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_OKDT76gBfEKxqNzCd7UvAQ_14_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-42987000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_VTMVcqsQm0CtPgQa-Aq9Yg_14_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14024000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_Hbro4icpTk6Hj-zj1JPEsQ_15_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_iNUg8k4WAkGHyG62Q1uHOQ_15_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">85000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_CJ-1K5Z9-ky3M3bdYg46Kw_16_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-43078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_YIn7544UhUGt783w6X5Mzw_16_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14109000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_OX--MWOzt0yulUlGVLVEBg_17_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-8000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_GSvsAotpyUOJHkg7H_-Zpw_17_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_cu6w1XY3MEa7tKQZyvstwQ_18_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-43086000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_sCKl-hig2k6OvjvOg-9ukg_18_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14110000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Tc_aF6ALRxPI02LXioVDDwTfQ_19_3"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">-4.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="2"
      id="Tc_gq9WLOYLyk6yxPe-FAM4Ow_19_6"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">-37.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="0"
      id="Tc_KTyZ9Ne5XU-y5wh-_6MUDA_20_3"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">10360054</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="0"
      id="Tc_g67npd8B7U68Bk11hogsPQ_20_6"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">387083</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_p0RfPfIa3UWcDTlEg4P0KA"
      decimals="INF"
      id="Tc_lj8h8LPsCkq81YpT3x4scA_5_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">161041754</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_p0RfPfIa3UWcDTlEg4P0KA"
      decimals="-3"
      id="Tc_4tPr80hsKU2_dvMlvIsW5A_5_5"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">279983000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6tiymcp8Wk-c2D6KmqY0og"
      decimals="INF"
      id="Tc_TMkPlzv8fk-OXW8f8W01YA_5_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">483931</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6tiymcp8Wk-c2D6KmqY0og"
      decimals="-3"
      id="Tc_MoNsJZvVNUS1ZlE3Wn7MOg_5_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S5U_tTlMW0qlftdPLa9DZw"
      decimals="-3"
      id="Tc_EYwU2fc6Uk-r6sT2V7jk5w_5_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">58708000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zeiT1HWqrEK40Ol6L2ZKYA"
      decimals="-3"
      id="Tc_M0nf-2P-ckq4dlnIWIZF2w_5_16"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-337567000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bMSZQxnqxEqCmCBMOX938g"
      decimals="-3"
      id="Tc_WCc5kdYyNEm49ubnXOiVDA_5_19"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ"
      decimals="-3"
      id="Tc_hVEM63AMyUSAviWEp_dR9w_5_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-279043000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RUHOGigFiEuJTBLQGUN3cw"
      decimals="INF"
      id="Tc_THhR-x_jj0i8R91r-LDwUw_6_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">175</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RUHOGigFiEuJTBLQGUN3cw"
      decimals="INF"
      id="Tc_Hl0C0j4Ko0qm9yGLh-c7Mw_7_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">123694</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RUHOGigFiEuJTBLQGUN3cw"
      decimals="-3"
      id="Tc_VAC9AeQ1d0W2cDRQW5T50w_7_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HZTSfAFE00aFsq1LVh0T7g"
      decimals="-3"
      id="Tc_c-rq3MaBhkyJb7_xNe6a_g_7_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HZTSfAFE00aFsq1LVh0T7g"
      decimals="-3"
      id="Tc_y2HwVmyPQkiSz2MXAlu5tA_8_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">132000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_MMc7_Emu5EGwRyW8gk6NNA_8_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">132000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <cvrx:TemporaryEquityIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_XAEp1PMrjEePzao7rysu6w"
      decimals="INF"
      id="Tc_UBnHJeEKzEO1Vg5YpQ7rKg_9_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">62500000</cvrx:TemporaryEquityIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_XAEp1PMrjEePzao7rysu6w"
      decimals="-3"
      id="Tc_paNSGeDWPUyUoP89DKRbSw_9_5"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">49783000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <cvrx:TemporaryEquityAccretionOfIssuanceCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_XAEp1PMrjEePzao7rysu6w"
      decimals="-3"
      id="Tc_NcsnFuaYSEeQ6ztdyKdyvg_10_5"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">217000</cvrx:TemporaryEquityAccretionOfIssuanceCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HZTSfAFE00aFsq1LVh0T7g"
      decimals="-3"
      id="Tc_63-MPfge3ku1nc7DOTf0ww_10_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_iK3WGAOKYkusQlNZJ8U2mA_10_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_S0-dIu-pxUOkwdi2LzQL7w"
      decimals="-3"
      id="Tc_PBCwQS3ZFEWtfETwBVliaw_11_16"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14109000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_EPs0bSGpWUq_EoWiJ3j6Xw_11_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14109000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yHbljhgpY0mbvZF0ftxdIA"
      decimals="-3"
      id="Tc_MWV9OYyxAUiPfQKmNx7mOg_12_19"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_03wzpfppUUamnHOTUJAazg_12_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_gSHtkKETBkOZK6zcbuEF5w"
      decimals="INF"
      id="Tc_VpZgctUewkGIABIH77hfxA_13_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">223541754</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_gSHtkKETBkOZK6zcbuEF5w"
      decimals="-3"
      id="Tc_J6n_t40ioEGZCxIwaYGakw_13_5"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">329983000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NZvrdn8yFkWAX4fnEQO45A"
      decimals="INF"
      id="Tc_D8AfL2iN30aBykMX697gTg_13_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">360412</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NZvrdn8yFkWAX4fnEQO45A"
      decimals="-3"
      id="Tc_1PXW4h03CUORJ4J6g2pKzg_13_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8bbj7mTQvkKRbK8e00U2-A"
      decimals="-3"
      id="Tc_yxd-8SwghU6m2Y2IRKPo5Q_13_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">58624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TXEPtHeAnEu5aSDgEVIuTw"
      decimals="-3"
      id="Tc_i-NeqDRPSka3v6ZUefyXZg_13_16"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-351676000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_k3U9zkOYDk-3HOWZzCltuw"
      decimals="-3"
      id="Tc_QD_cYsn4302o2C_2noDU1A_13_19"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_gsAU1S0EtkaKncdAlpXYUg_13_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-293238000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw"
      decimals="INF"
      id="Tc_pPMRiHiDTk2ptAGpdrLWwg_14_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">59341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA"
      decimals="-3"
      id="Tc_l8tcX0KwjU660i8B_eHYJg_14_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_gKUWrvQ-L06L85w4jDJHWA_14_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">23000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA"
      decimals="-3"
      id="Tc_faoqboeHDUe-3IpjAzb3-g_15_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_g-EWuP3UsUKDTyGnyY6oOg_15_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw"
      decimals="INF"
      id="Tc_tMm46xLuVkGkTGUUvbL9bg_16_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw"
      decimals="-3"
      id="Tc_yKum0RER302psRmg6R_fgw_16_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">81000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA"
      decimals="-3"
      id="Tc_5aiqGQyDS0yQ80n6O9dzyg_16_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">133080000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_JmTMdT-0tEOEXNXkZ__AcA_16_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">133161000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA"
      decimals="-3"
      id="Tc_L3Im8EIrGkOC1kiK2IY-Tw_17_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_0LO4ueWAuU2bp_SLqOWsVA_17_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <cvrx:ConversionOfTemporaryEquitySharesToPermanentEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_nBAhCE3xjEOe547YDdUyhA"
      decimals="INF"
      id="Tc_L9r1ybUjTUuJKmQhEPqU4Q_18_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">223541754</cvrx:ConversionOfTemporaryEquitySharesToPermanentEquity>
    <cvrx:ConversionOfTemporaryToPermanentEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_nBAhCE3xjEOe547YDdUyhA"
      decimals="-3"
      id="Tc_TbdTbfm320GaKgWd5dyORA_18_5"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">329983000</cvrx:ConversionOfTemporaryToPermanentEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw"
      decimals="INF"
      id="Tc_28Bkr40qJkyJqHwNC4PnXQ_18_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">11929584</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m90jBbBZbkKs8Tld0oqtzw"
      decimals="-3"
      id="Tc_ZiU-CnqpwU64WxZsB4KfRA_18_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">119000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gZJ80Pyn7UOZd6gXgQc9uA"
      decimals="-3"
      id="Tc_rcpsdNek4k-fiDVDXGxzWg_18_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">347069000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_NbP6f51ySE-m6B_SSATgdQ_18_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">347188000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xQ4PL8s8EU69GgtfV_9c1Q"
      decimals="-3"
      id="Tc_qnlLrdy7bk2dr8Wt6gkpQQ_19_16"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-43078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_ghHWIkU_ukaVIsVZx8bYhQ_19_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-43078000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ogL9DuiJFUOrmGs4jXH1PQ"
      decimals="-3"
      id="Tc_q8gVEK5s_UCoagIC9xXJmw_20_19"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_u3gUWTAQiUyz075wtVXpbg_20_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e__ks_GGFkytwC3zHBuP5Q"
      decimals="INF"
      id="Tc_iNUV9xLmIkWSE_4Z0_RDNg_21_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">20399337</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e__ks_GGFkytwC3zHBuP5Q"
      decimals="-3"
      id="Tc_2BIfMN7qIUeaVSx5urAtwQ_21_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SygLLO7d6keB2YcBMuzXRA"
      decimals="-3"
      id="Tc_E98sJg78MUG_cY6AX2XxBg_21_13"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">540707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NRVdw4MrM0yuymfM2lEBNA"
      decimals="-3"
      id="Tc_KSK2vWPL30SvCdnVSlZpOQ_21_16"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-394754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fZBmRrBVpEW4r7ljKujLsQ"
      decimals="-3"
      id="Tc_LJN_DNN9v06W0MY8Lg2nXQ_21_19"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_ca7rLeEiR0mT9GGRIbedyg_21_22"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">145959000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_pLkpgD5lk02tz4e08RVAuQ_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-43078000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_6XHYefMS_Eioco4HhE86Dg_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14109000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_o3Nt4o3SekqhKlhVkecOqw_7_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1912000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_tWFP1vShbEqzJwzN1XTVqA_7_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">132000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_cRBjNUIF4Uix3wYKiLHiqg_8_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">168000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_aV4P4RcimUG_pwzh_Bfb6g_8_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">75000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_k0wDKiCP7EOEggeoCGoShA_9_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">229000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_A2sDLJTfAEe240JQx0nBnw_9_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">286000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_vD53vkKCk0G5oUE0dhSCrA_10_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-1325000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc__FVR_T-v20-YcostLarHYA_10_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_Exyz2zQt1EKg7KCUfD-XdA_11_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">13294000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_TeY4l4d3aUWOvFOi-eZp0w_11_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">371000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_AvfN-e6kRE2vGRxDjRZ1kQ_13_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1279000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_9PM0jZRvbUKoJU8QlokL-w_13_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">562000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_rarVLVLkyE-zzcKs_eDU3w_14_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">537000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_8W0A27iGI02ea2PCnPFurw_14_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1271000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc__tBGMNdDX0KKPBzwH0ueQQ_15_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1980000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_1gL3zzQpUEyPEVvsibOtew_15_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">226000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_HRyMuaLK90ucCnOMuiD3bg_16_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">27000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_Vk82Iy_MV0CfkOiVdTL37w_16_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">46000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_1pEFkMjoLkOyraE3rWhUxA_17_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2187000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_-8Z7nZm1x02trNQnHsX0bg_17_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-838000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_mqn_fa-zkE2QZe8mTtt75w_18_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-27732000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_d8UETZkcVkyrT34cbwAIww_18_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-16096000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_I892wmlbrE-_2L6qKyFYJA_20_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1183000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_XI9t4AWJGEux_6HWX5uXPQ_20_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">311000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_c4qDiNLTK0Gq9di_DmIMnA_21_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-1183000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_rRt4i55VC0G973rpbgld_Q_21_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-311000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_Js5M0-lCPEGvppsKgdMA2A_23_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">23000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_knsGd4EGPUChevq0yvIeAA_23_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_PrA_xpnLa0Go83ee0MeY4g_24_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_kpTHv_CuXEu_HWyjWbasug_24_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">49783000</us-gaap:ProceedsFromOtherEquity>
    <cvrx:PaymentsRelatedToReverseStockSplit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_olhhAHqZlk2WLzxzkQR_Ew_25_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1000</cvrx:PaymentsRelatedToReverseStockSplit>
    <cvrx:PaymentsRelatedToReverseStockSplit
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_EZFH21aZbUePBfLbZSS1zw_25_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</cvrx:PaymentsRelatedToReverseStockSplit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_LpgYlBOq5EaPHR5YWx2bNg_26_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">133161000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_PPON5MEM60mxrZ2NBc6qCg_26_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_ZhW_zh-yakOonlnAjnTzzg_27_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">21300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_S4FE3Vo29UqPlI_eHw_A7w_27_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_KdU2ozkDe0SmLyl-lyfbMA_28_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">111883000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_5Mpd2rC9b0utOqZEnuJxhw_28_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">49783000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_Y3Q3wRSoW0WoDlGfPzKABw_29_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-8000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_xcLRwB_Izk63OIpXCfRg0Q_29_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-5000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_tRud2zdIL0uXwBjKMO53_Q_30_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">82960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_b6PtjChRK0SPCd1XtDMSug_30_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">33371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_GZEtAyVZg0eJI_SGiHk45w_31_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">59112000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ"
      decimals="-3"
      id="Tc_sKehz641c0W2LwtyN5YzeA_31_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">25741000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_TedxSG_kDU-Ye3Bn-MSKvQ_32_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">142072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_Yppn0v1LWE-L2jMP8LPk5g_32_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">59112000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_WB4q8Vt2vUe8qShL78lu7A_34_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1706000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_MK8NDvJfTUuJOVVZTwxK_A_34_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2033000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_hsWj4E601E-fBmJlflzwEQ_35_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_SxnQkjqMwUuSVw_rB5VIkA_35_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">10000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_OqBBG1y5mk-Tx-z0xNEPVg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;1.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Business organization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;CVRx,&#160;Inc. (the &#x201c;Company&#x201d;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. The Company has developed and is marketing a medical device, Barostim, for heart failure (&#x201c;HF&#x201d;) and resistant hypertension. The Company is focused on the sale of its product in the U.S. and Europe.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that the Company will generate sufficient product sales to produce positive earnings or cash flows.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_TU9xaCWjlUqaIMoz1_x6uw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;2.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Summary of significant accounting policies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement presentation and basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;JOBS Act accounting election&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2021 and 2020, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. We do not record an allowance on our trade accounts receivable but monitor the collectability of individual customer accounts on an ongoing basis.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#x2019;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Accounting Standards Codification Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#x2019;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize equity-based compensation expense for awards of equity instruments to employees and non- employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#x2014;Stock Compensation (&#x201c;ASC 718&#x201d;). ASC 718 requires all equity-based compensation awards to employees and nonemployee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We use an estimate of the value of our common stock, with the assistance of an independent appraiser, to determine the fair value of options. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In February&#160;2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, Leases (&#x201c;Topic 842&#x201d;). The purpose of Topic 842 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Topic 842 is effective for private companies and smaller reporting companies for annual periods beginning after December&#160;15, 2021 and interim periods within fiscal&#160;years beginning after December&#160;15, 2022. Early adoption is permitted, and the Company must elect whether the date of initial application is the beginning of the earliest comparative period presented in the financial statements, or the beginning of the period of adoption. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of Topic 842 guidance, whereas comparative periods and their respective disclosures prior to the adoption of Topic 842 are presented using the legacy guidance of Accounting Standards Classification (&#x201c;ASC&#x201d;) 840.&#160;As a result of adopting the new standard, the Company will recognize right-of-use assets of $579,000 and lease liabilities of $561,000 million as of January 1, 2022. The &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;difference between the amount of right-of-use assets and lease liabilities recognized includes adjustments to prepaid rent.&#160;There will be no change to net deferred tax balances as a result of the Company&#x2019;s adoption of Topic 842.&#160;The adoption of Topic 842 did not impact the Company&#x2019;s results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_cw0B14IkuEKGkN0S8DZeVg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement presentation and basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock>
    <cvrx:JobsActAccountingElectionPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_GgOJh1PGsEmljcz16IE_8g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;JOBS Act accounting election&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). As a result, the Company has elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.&lt;/p&gt;</cvrx:JobsActAccountingElectionPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_0ah91dGRZ0Oe_Mfw2Q3uoA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_5vAgNzdsX0Cc_nDMi3CU1A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2021 and 2020, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_PjFjwdurOUiP1cD8vdIGaA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. We do not record an allowance on our trade accounts receivable but monitor the collectability of individual customer accounts on an ongoing basis.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_lHChYZmYVUOkyl1Kukrc0g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company regularly reviews inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_9LQINy_hCEOkZWinMQYHSQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sells its products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. The Company&#x2019;s revenue consists primarily of the sale of its Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Accounting Standards Codification Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. The Company recognizes net revenue on product sales when the customer obtains control of the Company&#x2019;s product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_5U5KPXxRYEuIq0c_P92afQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize equity-based compensation expense for awards of equity instruments to employees and non- employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#x2014;Stock Compensation (&#x201c;ASC 718&#x201d;). ASC 718 requires all equity-based compensation awards to employees and nonemployee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We use an estimate of the value of our common stock, with the assistance of an independent appraiser, to determine the fair value of options. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_QOIyhay0E0q71R6uK7BQmw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In February&#160;2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-02, Leases (&#x201c;Topic 842&#x201d;). The purpose of Topic 842 is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Topic 842 is effective for private companies and smaller reporting companies for annual periods beginning after December&#160;15, 2021 and interim periods within fiscal&#160;years beginning after December&#160;15, 2022. Early adoption is permitted, and the Company must elect whether the date of initial application is the beginning of the earliest comparative period presented in the financial statements, or the beginning of the period of adoption. Under the alternative modified retrospective transition approach, the reported results for 2022 reflect the application of Topic 842 guidance, whereas comparative periods and their respective disclosures prior to the adoption of Topic 842 are presented using the legacy guidance of Accounting Standards Classification (&#x201c;ASC&#x201d;) 840.&#160;As a result of adopting the new standard, the Company will recognize right-of-use assets of $579,000 and lease liabilities of $561,000 million as of January 1, 2022. The &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;difference between the amount of right-of-use assets and lease liabilities recognized includes adjustments to prepaid rent.&#160;There will be no change to net deferred tax balances as a result of the Company&#x2019;s adoption of Topic 842.&#160;The adoption of Topic 842 did not impact the Company&#x2019;s results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_y3rSgJAX9EGQxWbuV_L1FA"
      decimals="-6"
      id="Narr_8h1XLLaZZUi3QiaxRa9lKw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">579000000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_y3rSgJAX9EGQxWbuV_L1FA"
      decimals="-6"
      id="Narr_SqiNtmJXCkKVwCfqTKPZnw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">561000000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_naEyD1XvMEeVC6Ptp1SmhQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;3.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Selected balance sheet information&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw material&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 321&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,272&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 516&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital equipment in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,293&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,110&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,868&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 410&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;Depreciation expense was $0.2 million and $0.1 million for the&#160;years ended December 31, 2021 and 2020, respectively. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses consist of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Clinical trial and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Paid time off&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 699&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 552&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest payable &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,583&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_FuHR90NPnEuO0IsCq_FF_Q">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw material&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 321&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,880&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_qU9N8iSspEaucjwSzg47yw_3_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1593000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_WeicA5opOUyHRi7HlmXbcg_3_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1361000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_OMa3znuybU2ZzTUsHloJFQ_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">482000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_DvrWwtVQ1ki2--ozyePR0A_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">321000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_blqPL2D1QUCxyujlUKNiYQ_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1805000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_1FpcAIkFTEm3nLdgFRvexw_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1661000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_RaIaYDS2VkC67Fcdtc6VFA_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3880000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_aljKQVcmikag35ApqX-XKw_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3343000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_fF84TmSM7ESMUdO-P0n00A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,272&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 516&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital equipment in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,293&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,110&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,868&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 410&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_pDRh1cot40q_8Y3o2VYqGA"
      decimals="-3"
      id="Tc_4SKsH-qSmkiNP4d2HhSsrQ_3_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">271000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_JVTdDeParEGGJ2t4jtbpsw"
      decimals="-3"
      id="Tc_2RTL8aDVhk6_GpiWPhSw2A_3_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">189000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_rfzInbLWC0WZAH9zijqO7Q"
      decimals="-3"
      id="Tc_hFGprZPDik604R-80cfpaw_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1565000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_qcikURBbNkqhIs-KAt4sHQ"
      decimals="-3"
      id="Tc_qPftfsgG9UCZwHQdqYfj1g_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1272000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_W8mwFgZUB0-M5Mhl98X9vQ"
      decimals="-3"
      id="Tc_diC3-qCxCUGxGtJukhtoZw_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_D22BP1wD10eBV-IdknkzyA"
      decimals="-3"
      id="Tc_r1pY_Hp02EmZ6EjrirUP-g_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">516000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qbNP5EMaT0ugnnKkSC2ccQ"
      decimals="-3"
      id="Tc_7Ia3grymuUiiOABzXpRPVQ_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">88000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Hw_YMxt6zk2W-1GMsneLZQ"
      decimals="-3"
      id="Tc_DccK5_zAXk6fX8VfpyzEOQ_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">44000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_f6ItviTz1USvtPXYmohPkg"
      decimals="-3"
      id="Tc_swtDEi9iEU-xA89JF-ylPw_7_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">813000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_Shk5JCIfNUKOH63sKxBD4g"
      decimals="-3"
      id="Tc_aEEa4n7gbkSjgLs2Q6kU_w_7_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">89000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_BFghoN7qoUGrDAujGqbG5Q_8_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3293000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_d3H73YxztkKQ0TyxruZbvQ_8_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2110000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_2QPO5WxVAUKrMVFBLFPMEQ_9_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1868000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_4Mihu2OHUky1PK4lpWf7Lg_9_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_y9EZ9RTbxUikTW6ELeS5DA_10_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1425000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_rXCPOJfyMU-LkWPufWh4AQ_10_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">410000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-5"
      id="Narr_o1JDPyhOTUeAKDyPk4aGJg"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-5"
      id="Narr_MHbHtJAP0UywkZCEQ4eyHA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">100000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_dM8Va-kAxEqP-BzIgStDog">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses consist of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Clinical trial and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Paid time off&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 699&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 552&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest payable &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,583&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cvrx:ClinicalTrialAndOtherProfessionalFees
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_B2VxlqJcEkKx6IoLGhmhhw_3_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1607000</cvrx:ClinicalTrialAndOtherProfessionalFees>
    <cvrx:ClinicalTrialAndOtherProfessionalFees
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_BDU27aiDw0aQaN2_hg8BXg_3_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1690000</cvrx:ClinicalTrialAndOtherProfessionalFees>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_Xh97Gt_bfE-9WNAGwYpFKA_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2028000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_vziCottBRk2mjPBwMIroMQ_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">794000</us-gaap:AccruedBonusesCurrent>
    <cvrx:AccruedPaidTimeOff
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_2aAwxcEge0KTQ2ICVXkq2Q_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">699000</cvrx:AccruedPaidTimeOff>
    <cvrx:AccruedPaidTimeOff
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_dqPm-KWKKUG87RvWbwjGKQ_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">552000</cvrx:AccruedPaidTimeOff>
    <cvrx:AccruedLiabilitiesCustomerRebateCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_HktmTJolWESK3wHl9MgtrQ_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">380000</cvrx:AccruedLiabilitiesCustomerRebateCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_vht7j4TQk0-bg7pit-Mp1A_7_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">351000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_8-tQw0ZtqEGt-A4xa4VTBw_7_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">42000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_Lt3yNJ0tEEW74LclaGNwOw_8_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">356000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_Flv6BwdnQkCFXvCWx8Jv6A_9_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">333000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_1rd9JGEE40GE3LVhXzyyHg_9_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">149000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_U2YKMYWrlUWbNpf7FI_kMw_10_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">5398000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_hCx5jerb4UOPaDsWbbyR9g_10_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3583000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_isHupOMF2E--Cz6zrtNymQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;4.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Fair value measurements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2014; Inputs are quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2014; Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2014; Inputs are unobservable for the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The following table sets forth the Company&#x2019;s liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy. There was no convertible preferred stock warrant liability as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Convertible preferred stock warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The convertible preferred stock warrant liability related to warrants issued in connection with loan and security agreements entered into in September 2014, as amended in July 2015, in May 2016 and in September 2019. These warrants were originally issued to purchase shares of Series&#160;F-2 convertible preferred stock and Series&#160;G convertible preferred stock (&#x201c;Series&#160;G Preferred Shares&#x201d;). &lt;span style="color:#231f20;"&gt;In connection with the closing of the initial public offering (&#x201c;IPO&#x201d;), these convertible preferred stock warrants became warrants to purchase &lt;/span&gt;&lt;span style="color:#231f20;"&gt;108,406&lt;/span&gt;&lt;span style="color:#231f20;"&gt; shares of common stock and were reclassified to equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The convertible preferred stock warrant liability also related to a warrant issued to Biosense Webster,&#160;Inc. (&#x201c;BWI&#x201d;), an affiliate of Johnson&#160;&amp;amp; Johnson Innovation&#160;&#x2014; JJDC,&#160;Inc., to purchase Series&#160;G Preferred Shares with an exercise price of $0.01 per share. &lt;span style="color:#231f20;"&gt;In connection with the closing of the IPO, the BWI warrant to purchase Series G Preferred Shares became exercisable to purchase &lt;/span&gt;&lt;span style="color:#231f20;"&gt;607,725&lt;/span&gt;&lt;span style="color:#231f20;"&gt; shares of common stock at&lt;/span&gt; an exercise price of $0.16 per share&lt;span style="color:#231f20;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s recurring fair value measurements using significant unobservable inputs (Level 3) related solely to the Company&#x2019;s convertible preferred stock warrant liability. The convertible preferred stock warrant liability was remeasured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.&lt;span style="color:#231f20;"&gt; In connection with the closing of the IPO, all of the outstanding convertible preferred stock warrants were converted to common stock warrants. The related liability was remeasured at the time of the IPO and reclassed to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth a summary of changes in the estimated fair value of the Company&#x2019;s convertible preferred stock warrants during the years ended:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Conversion to common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,205)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;End of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;There were no transfers in or out of Level 1, Level 2 or Level 3 fair value measurements during the periods ended December 31, 2021 and 2020.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_WQ5ssL5PN0yJzj2bBy8TKA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The following table sets forth the Company&#x2019;s liabilities that were measured at fair value on a recurring basis by level within the fair value hierarchy. There was no convertible preferred stock warrant liability as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Convertible preferred stock warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:57.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_KNUV7a2UVk-AWL-jkX8qUA"
      decimals="-3"
      id="Tc_PQhMz5hDWUuC50IQ3TVWLg_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_A_ndJ_mgvE2v6o03-Ks7wg"
      decimals="-3"
      id="Tc_8NXFdG5nq064t6ATLmxDeQ_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_spHQMK4XMUiiug-F7DvVwQ"
      decimals="-3"
      id="Tc_ssiv9gsnp0-zuQV1FPjKbg_4_9"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3911000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_ARf2RRaIzk6UxSql8Of4JA"
      decimals="-3"
      id="Tc_Luhk3pskg0ar-ai-lQoW3g_4_12"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3911000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_R_I0EY29n0W_Ped5vMxkzg"
      decimals="-3"
      id="Tc_3rxOR1rgDkSz1yVqb2tDfw_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_16bB4IFwrUapwzsWJeRraA"
      decimals="-3"
      id="Tc_xbcG3DdsA0aXIAdgZ2cpLQ_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_W4X_2dSbnkGc95kko6HZAg"
      decimals="-3"
      id="Tc_c2OHjDjcYEeaJK-sFZK9iQ_5_9"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3911000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D2BA-9J5XE-PbX6gbNm_aA"
      decimals="-3"
      id="Tc__XJs55HD60apgufE-4Wbnw_5_12"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3911000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_xrHiwCtXlEGvfX5Nxy-WiA"
      decimals="INF"
      id="Narr_BX9REHGdHEuMunY1rAbafw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">108406</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg"
      decimals="2"
      id="Narr_VgmWIpZ2MkiWdk7vdQe0kg"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_7_2_2021_To_7_2_2021_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_LU9Pb5rH30abdxp9blQkkQ"
      decimals="INF"
      id="Narr_PzBH_pY_SkOmU-5BrTpaOw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">607725</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_2_2021_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_MX0otz1v_E62VZpoRgXl2A"
      decimals="2"
      id="Narr_S4AE7FirsEWqGD_My-uQLQ"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_rWxrBUYGWkGi7kU1Sy_yCA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth a summary of changes in the estimated fair value of the Company&#x2019;s convertible preferred stock warrants during the years ended:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,294&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Conversion to common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,205)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:76.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;End of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,911&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_PH-M6rDzJkyqGZQxfL2QnQ"
      decimals="-3"
      id="Tc_hVoWlD9VHEKV8QBliQmQkQ_3_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3911000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_YzRnuQXlH02VKNNMxJ0Jag"
      decimals="-3"
      id="Tc_yVmwyQxFekOO_xokgyk9CQ_3_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3540000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_zXBgdB9Wm0KMsLVbZrH5Gw"
      decimals="-3"
      id="Tc_JPs_uMonu0qSUBSPW7AU1g_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">13294000</cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue>
    <cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_5vT5q4Y0Gka2WmjvA6i6vA"
      decimals="-3"
      id="Tc_3mv_w-RPd02dc8l9VYthag_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">371000</cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue>
    <cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_zXBgdB9Wm0KMsLVbZrH5Gw"
      decimals="-3"
      id="Tc_0YrUEldMUkmYG2fYVVpSbA_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-17205000</cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions>
    <cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_5vT5q4Y0Gka2WmjvA6i6vA"
      decimals="-3"
      id="Tc_WpE7IdI1k0CS8cr8yUcIlg_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</cvrx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_RKtvIKc5LkyhjXn68Zj14A"
      decimals="-3"
      id="Tc_aGF2ILlwYk2jLnAeN_yJ0A_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_PH-M6rDzJkyqGZQxfL2QnQ"
      decimals="-3"
      id="Tc_gSRP8-3LK0OkRI9IFSmCnQ_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3911000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Narr_mQbmRVCqHkOLt8SWqDgU3w"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Narr_iWOb10-kt0eEA_5P77M7ZQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_o4rckHCT2kiEdwrErDKtdg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;5.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Horizon loan agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In September&#160;2019, the Company entered into a loan and security agreement (&#x201c;Horizon loan agreement&#x201d;) with Horizon Technology Finance Corporation (&#x201c;Horizon&#x201d;) under which it could borrow up to a total of $20.0 million at a floating per annum rate equal to 10% plus the amount by which the 30-day U.S. dollar LIBOR rate on the first business day of the&#160;month exceeds 2.2%. The Horizon loan agreement initially required interest only payments through October&#160;2021 and then &lt;span style="white-space:pre-wrap;"&gt;36&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;&#160;monthly principal and interest payments beginning in November&#160;2021. A final payment of $0.7 million, equal to 3.5% of the original principal, was due in October&#160;2024. The Horizon loan agreement initially required the Company to maintain cash on deposit of not less than $5.0 million in accounts over which Horizon maintained an account control agreement. This minimum cash on deposit requirement was released in July&#160;2020, following the satisfaction of a financing milestone. The borrowings were collateralized by all or substantially all of the assets of the Company. The Horizon loan agreement required the payment of certain penalties if the loan was paid off prior to maturity for any reason, including pursuant to a subjective acceleration clause, and included various restrictive covenants, including a restriction on the payment of dividends. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2020, the Company entered into an amended agreement with Horizon to extend the interest only period through April&#160;2022, followed by 30&#160;monthly principal and interest payments beginning in May&#160;2022.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Horizon loan agreement, the Company recorded $1.1 million of debt issuance costs and discounts as a reduction of long-term debt. Of this total, $0.5 million related to legal fees and an investment bank fee and $0.6 million related to the warrants to purchase Series&#160;G Preferred Shares issued by the Company. These warrants were exercisable on the grant date at a price of $0.80 per share and expire in September&#160;2029. The Company used the Black-Scholes option pricing model to determine the grant date fair value of these warrants. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 3, 2021 the Company fully repaid all amounts outstanding under the Horizon loan agreement. The total repayment amount was $21.3 million, inclusive of $1.3 million of prepayment and other fees, which represent a loss on extinguishment of debt and are included in Other expense, net on the consolidated statements of operations. The Company was in compliance with all related covenants at the time the principal balance was fully repaid. There was no debt outstanding in relation to the Horizon loan agreement as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ"
      decimals="-6"
      id="Narr_bJIzTFWl9kmRlyHu2r6H_g"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Pg0bkL4urUCnAduxdRREcA"
      decimals="2"
      id="Narr_sUFOz1ximEyyLDO4Rtb1ng"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.10</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <cvrx:ThresholdInterestRateOnFirstBusinessDayOfMonth
      contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_98TiYSuyBEyI_7e_iTGzOA"
      decimals="3"
      id="Narr_gydIM7R1H0Keu845MbXnpw"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.022</cvrx:ThresholdInterestRateOnFirstBusinessDayOfMonth>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_98TiYSuyBEyI_7e_iTGzOA"
      id="Narr_2TR3iffmY0uJ45We4Qm_zg">P36M</us-gaap:DebtInstrumentTerm>
    <cvrx:DebtInstrumentFinalPayment
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ"
      decimals="-5"
      id="Narr_zab2U2LXgE-MnLS0MYT5iA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">700000</cvrx:DebtInstrumentFinalPayment>
    <cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ"
      decimals="3"
      id="Narr_69z9ZDguXU6FEMbwRJQA6g"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.035</cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal>
    <cvrx:DebtInstrumentMinimumCashOnDepositRequirement
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ"
      decimals="-5"
      id="Narr_QfNZ0JPUBkyXsh9Ua886SQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">5000000.0</cvrx:DebtInstrumentMinimumCashOnDepositRequirement>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_8_1_2020_To_8_31_2020_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_mytN74qZAE-E5cluV0a_Qg"
      id="Narr_g9QO9568x0SnG22luSRODg">P30M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ"
      decimals="-5"
      id="Narr_MaQGR2_tK02g5WOTB2-VIQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1100000</us-gaap:DeferredFinanceCostsGross>
    <cvrx:LegalFeesAndInvestmentBankFee
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_L1JoieMoH0aMPa4vaDCsMQ"
      decimals="-5"
      id="Narr_QTRU1vQBuEC5UaFXeoBULA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">500000</cvrx:LegalFeesAndInvestmentBankFee>
    <cvrx:IssuanceCostsOfWarrants
      contextRef="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_AHM5B_OrqE2hM2md5KwcBA"
      decimals="-5"
      id="Narr_DusszrRL2E2HX8eAgQm7mg"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">600000</cvrx:IssuanceCostsOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_AHM5B_OrqE2hM2md5KwcBA"
      decimals="2"
      id="Narr_Mk2YA30NhUm0kq5ngIWbOg"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="Duration_11_3_2021_To_11_3_2021_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_fNfZEgGsO0yZp9z4dnf9og"
      decimals="-5"
      id="Narr_apMzryC7zEqP_ksoeU9NWA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">21300000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_11_3_2021_To_11_3_2021_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherExpenseMember_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_ID5K4-Y0vE-LBHZCpZLEYQ"
      decimals="-5"
      id="Narr_IgN76NNtp06NFEKli4p0mw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2021_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_C35XEWZJAU6-Xgd6ERjcqA"
      decimals="-5"
      id="Narr_UcC5_yryL0Ww9-jg5zwnPg"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_ucdU1tK7vEKOlhAsE_-zFQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;6.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Stockholders&#x2019; equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Initial Public Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During 2016, the Company issued 72,125,000 shares of Series&#160;G Preferred Shares at a price of $0.80 per share, for net proceeds to the Company of approximately $57.4 million after deducting offering expenses payable by the Company. The same Series&#160;G investors agreed to purchase an additional $35.3 million of Series&#160;G Preferred Shares upon the Company&#x2019;s achievement of a certain operational milestone, subject to limited closing conditions. In January&#160;2019, &lt;span style="-sec-ix-hidden:Hidden_M0BZTFHNU0ipFi78VUubmw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;May&#160;2019&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; and &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_hGmV6LR9xUyVdc_b1EBWDQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;August&#160;2019&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;, the Series&#160;G investors purchased additional Series&#160;G Preferred Shares, resulting in net proceeds to the Company of $24.7 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In July&#160;of 2020, the Company issued 62,500,000 additional Series&#160;G Preferred Shares, at a price of $0.80 per share, for net proceeds to the Company of $49.8 million after deducting offering expenses payable by the Company.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On May&#160;31, 2016, holders of the requisite number of the Company&#x2019;s then-outstanding convertible preferred stock approved the conversion of all preferred stock into shares of the Company&#x2019;s common stock in connection with a new equity financing. Accordingly, all of the Company&#x2019;s then-outstanding preferred stock was converted on a one-for-one basis into shares of the Company&#x2019;s common stock. Under the terms of the equity financing, each prior holder of preferred stock who purchased a required amount of securities in the new financing was entitled to exchange certain of the shares of common stock received in the conversion described above into new prime series of preferred stock corresponding to the series of preferred stock from which the common stock was previously converted. All of the previously held Series&#160;A-1, B-1, C-1, D-1, E-1 and F preferred stock had similar features as the Series&#160;A-2 preferred stock (&#x201c;Series&#160;A-2 Preferred Shares&#x201d;), Series&#160;B-2 preferred stock (&#x201c;Series&#160;B-2 Preferred Shares&#x201d;), Series&#160;C-2 preferred stock (&#x201c;Series&#160;C-2 Preferred Shares&#x201d;), Series&#160;D-2 preferred stock (&#x201c;Series&#160;D-2 Preferred Shares&#x201d;), Series&#160;E-2 preferred stock (&#x201c;Series&#160;E-2 Preferred Shares&#x201d;) and Series&#160;F-2 preferred stock (&#x201c;Series&#160;F-2 Preferred Shares&#x201d;) described below. The Series&#160;A-2, Series&#160;B-2, Series&#160;C-2, Series&#160;D-2, Series&#160;E-2, Series&#160;F-2 and Series&#160;G Preferred Shares are referred to collectively as the &#x201c;Preferred Shares.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2020, convertible preferred stock consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,454,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,454,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,909&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,909&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,963,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,963,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series C&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,308,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,308,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series D&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,631,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,631,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 53,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 53,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series E&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,114,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,135,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 76,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91,806&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series F&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,773,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,548,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 41,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 104,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series G&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 177,125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 165,500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 132,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 494,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 237,370,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223,541,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 329,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 770,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;2, 2021, the Company closed its IPO of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which included 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for net proceeds from the IPO, after deducting the underwriting discount and other offering expenses payable by the Company totaling $1.6 million, of $133.2 million.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the closing of the IPO, all shares of convertible preferred stock were automatically converted into common stock. Series&#160;G Preferred Shares were converted into common stock on a 15.819-for-1 basis, and all other shares of convertible preferred stock were automatically converted into common stock on a 39.548-for-1 basis. The conversion of the outstanding preferred stock resulted in an aggregate of 11,929,584 shares of common stock. As of December 31, 2021, no preferred stock is outstanding.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the IPO, the Company&#x2019;s Board of Directors and stockholders approved a 1-for-&lt;span style="-sec-ix-hidden:Hidden_33FQYq2nDUGydCuOJK10Rw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;39.548&lt;/span&gt;&lt;/span&gt; reverse stock split of the Company&#x2019;s common stock. The reverse stock split became effective on June&#160;22, 2021. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock will convert into common stock in connection with the closing of the IPO. Accordingly, all share and per-share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split and the adjustment of the conversion ratio of the convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred Stock Warrants and Common Stock Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the loan and security agreement entered into by the Company in September 2014 and the amendment in July 2015, the Company issued a warrant to purchase shares of Series F-2 convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the loan and security agreement entered into in May 2016, the Company issued a warrant to purchase Series G Preferred Shares.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company issued to BWI a warrant to purchase shares of Series E-2 convertible preferred stock that only would have become exercisable in the event of an acquisition or asset transfer involving the Company and it expired upon our IPO.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In September&#160;of 2018, the Company also issued to BWI a warrant to purchase up to&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;10,000,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;Series&#160;G Preferred Shares with an exercise price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.01&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;per share. The warrant to purchase Series&#160;G Preferred Shares became exercisable upon our IPO and would have expired on the earlier of (i)&#160;an acquisition or asset transfer involving the Company or (ii)&#160;&lt;/span&gt;&lt;span style="color:#231f20;background:#ffffff;"&gt;180&#160;days&lt;/span&gt;&lt;span style="color:#231f20;background:#ffffff;"&gt;&#160;after receipt of the data from the post-market stage of the BeAT-HF pivotal trial.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the IPO, the warrants to purchase shares of convertible preferred stock automatically converted into warrants to purchase common stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in capital. Upon the closing of the IPO these warrants to purchase convertible preferred stock became exercisable for 716,131 shares of common stock upon conversion at a weighted average exercise price of $2.39 per share. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Warrants to purchase shares of our common stock are summarized below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common Stock Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock warrants converted to common stock warrants at IPO&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Wr3bFBKF6Uuwn1r7P4sYpQ"
      decimals="INF"
      id="Narr_w6sgX4iwrkmrSdH6Fe1HIQ"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">72125000</cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_YiZ4tVb_lEOCzdR1fmlZww"
      decimals="2"
      id="Narr_hKj3gONT5ky4lQ1bVoSW2w"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.80</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Wr3bFBKF6Uuwn1r7P4sYpQ"
      decimals="-5"
      id="Narr_Na1nOcYBgUqobo2fgNdcqw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">57400000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2016_To_12_31_2016_srt_StatementScenarioAxis_cvrx_OperationalMilestoneClosingMember_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_TKhCqTifZ0aCZQX-reWoVA"
      decimals="-5"
      id="Narr_xSV0ZGeYAEefV_bG80YBww"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">35300000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_8_1_2019_To_8_31_2019_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_Yz5mooOlEEu0wI3NjQvG0w"
      decimals="-5"
      id="Narr_SonwLpC5MUCrnh9Naw0DcA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">24700000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_n8heRn9N5UGTUj53vhPYSA"
      decimals="INF"
      id="Narr_ux9rl49xY0S1DkxojEfmJQ"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">62500000</cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_P2E57QTxoUSi8yLB5BySbw"
      decimals="2"
      id="Narr_XD2SeGo3YEecTmrBMRkiQw"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.80</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_7_1_2020_To_7_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_n8heRn9N5UGTUj53vhPYSA"
      decimals="-5"
      id="Narr_yuNT_1WCjEaatDNpr4Lo6g"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">49800000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_5_31_2016_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_OKok4WEvikOohFGKGTT-vw"
      decimals="0"
      id="Narr_mMz3m13AjkmjM-Mv1FBu8A"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_plyOR_vMFUyDuUasvgLhOA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2020, convertible preferred stock consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,454,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,454,686&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,909&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,909&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,963,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,963,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series C&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,308,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,308,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13,141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series D&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,631,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,631,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 53,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 53,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series E&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,114,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,135,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 76,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91,806&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series F&#x2011;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,773,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 29,548,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 41,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 104,783&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series G&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 177,125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 165,500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 132,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 494,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 237,370,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223,541,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 329,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 770,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ"
      decimals="INF"
      id="Tc_CtJh2imrgkqpjB8k7gvmvA_5_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2454686</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ"
      decimals="INF"
      id="Tc_d3nDhAy10Uq9T32lYgKO5g_5_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2454686</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ"
      decimals="-3"
      id="Tc_n2B3pKX8B0unHyT23jqz7A_5_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">4909000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesa2RedeemableConvertiblePreferredStockMember_xkhtB0rsq0uLDX2udNBaRQ"
      decimals="-3"
      id="Tc_viY9fnQtxECJ2U8QnvzSFg_5_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">4909000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ"
      decimals="INF"
      id="Tc_YCah9nj5zEGNuAGoAJ5Y5Q_6_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2963069</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ"
      decimals="INF"
      id="Tc_qlYBmHJJ70eSVbHQJqgLqg_6_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2963069</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ"
      decimals="-3"
      id="Tc_d1ErBi5z6EaGNsfR6w-kZA_6_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">7526000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesb2RedeemableConvertiblePreferredStockMember_NcuTWSSMs0yHIZpBMMAiwQ"
      decimals="-3"
      id="Tc_5-0g-Sq_206-1sI76NfVgg_6_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">7526000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg"
      decimals="INF"
      id="Tc_sBlBk-pg10KrbH44Cb3Chg_7_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">4308394</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg"
      decimals="INF"
      id="Tc_1s4zyblC20S2rEgmb6yLAg_7_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">4308394</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg"
      decimals="-3"
      id="Tc_BgTEE7Rvdkmy90p2ObZNhg_7_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">13141000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesc2RedeemableConvertiblePreferredStockMember_GZaxJ273hEWzzleC8wJPmg"
      decimals="-3"
      id="Tc_hcl3MEOrQk6ePjbz3ESOKA_7_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">13141000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA"
      decimals="INF"
      id="Tc_PncWUnsxakKZm_qkMbG_MQ_8_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">8631967</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA"
      decimals="INF"
      id="Tc_n7u5n2t_UEuKlfpk7yug5g_8_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">8631967</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA"
      decimals="-3"
      id="Tc_vr8RXLdH8U-8QclUniG6Mw_8_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">53518000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesd2RedeemableConvertiblePreferredStockMember_Zs1U1Li1CUG8yvuoRnYulA"
      decimals="-3"
      id="Tc_Q3QpYk8EcUKukiPxynATQg_8_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">53518000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ"
      decimals="INF"
      id="Tc_pTfsPXsw7kySiNFLWqFNVw_9_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">12114211</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ"
      decimals="INF"
      id="Tc_toYjK6R--k-1eefpkJ3kSQ_9_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">10135320</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ"
      decimals="-3"
      id="Tc_0S8rS1rfGUykr6cPJQVlGQ_9_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">76826000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriese2RedeemableConvertiblePreferredStockMember_WiDelDVs2k6E-9JuzLV8mQ"
      decimals="-3"
      id="Tc_Vum97p9UD0a3WDTA5Wv1yA_9_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">91806000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w"
      decimals="INF"
      id="Tc_bU7QGxkE0kSK_3-DWpFhIQ_10_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">29773318</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w"
      decimals="INF"
      id="Tc_hsMH79l0FEGPD6tewUui5g_10_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">29548318</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w"
      decimals="-3"
      id="Tc_-kmH9cmry0iuLRALB-P-CQ_10_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">41663000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_Seriesf2RedeemableConvertiblePreferredStockMember_4mu5XpcT7kWSrkAgUDIm5w"
      decimals="-3"
      id="Tc_9Bfaj7QAIUKG3d_X0VJAvQ_10_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">104783000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA"
      decimals="INF"
      id="Tc__RbSMzxmpU-zdawX0K90Ng_11_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">177125000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA"
      decimals="INF"
      id="Tc_mVAtRN8Bl0SGcjXJ2wxFOw_11_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">165500000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA"
      decimals="-3"
      id="Tc_9zApR613aEOoE01-Khixaw_11_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">132400000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_DejQB4DJS0SI6RIdWel8hA"
      decimals="-3"
      id="Tc_p1qxMk8oo0C3bbrdH-9yag_11_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">494550000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Tc_p5bJu9TluESfrfHI2NNP9g_12_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">237370645</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Tc_2nBEUUJiS0m3ciHI8F2XvA_12_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">223541754</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_-wm4WqIEH0WQWxrDQxlRWA_12_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">329983000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_NWyx2-RrV0y2oYuHcmF3mg_12_10"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">770233000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GImtIEFIfUmLgGy9Whzecg"
      decimals="INF"
      id="Narr_Yy8xJ_ynH06JjeC7Per8IQ"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_JGMICHAQEEu3PrOrJyDdFQ"
      decimals="2"
      id="Narr_82qJcXK2IE2K0VRnB1FFpg"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">18.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_OV8o_orI0kaBRnMMLVzv6A"
      decimals="INF"
      id="Narr_i89rurMpyE6U5dSSOn2ENA"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GImtIEFIfUmLgGy9Whzecg"
      decimals="-5"
      id="Narr_cJ2kFZQn9EmS4D1QUxQ63A"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_GImtIEFIfUmLgGy9Whzecg"
      decimals="-5"
      id="Narr_St6ntzXxdUCYTiozs-R-cQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">133200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_cvrx_SeriesgConvertiblePreferredStockMember_6RQJgllZt0K-iekb1XdaUQ"
      decimals="3"
      id="Narr_dc-ptkRAyU6o8iARbT7Q7w"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">15.819</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="3"
      id="Narr_sTrc01bQaECEUcHp29E6Rw"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">39.548</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_7_2_2021_To_7_2_2021_Ddc3yM7430mMAAMMP8Suag"
      decimals="INF"
      id="Narr__LnD109urkKFsr-TRYuo5Q"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">11929584</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="INF"
      id="Narr_djCB-MmwtkalE-SL3H9jww"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg"
      decimals="INF"
      id="Narr_dQ7ngpAoS0S1tl97Le48mw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">10000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg"
      decimals="2"
      id="Narr_6DwkanhKpEiPUtszTDqcsw"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_30_2018_srt_CounterpartyNameAxis_cvrx_BiosenseWebsterInc.Member_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember_PcadjQR0T0K8F3ioAdhVEg"
      id="Narr_oZYOOwwcKEeAvLatFPoLGA">P180D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_bnP6fucus0u5PpGTSQpeQQ"
      decimals="INF"
      id="Narr_mP2OQFEpcEaUbcJlgjtlGw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">716131</cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering>
    <cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_bnP6fucus0u5PpGTSQpeQQ"
      decimals="2"
      id="Narr_jAQjny_fAku5j50m7qifbg"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">2.39</cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_as4j6Bxl_Ui_9dgCcqS5-g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Warrants to purchase shares of our common stock are summarized below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common Stock Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock warrants converted to common stock warrants at IPO&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Tc_bxwIiabUp0unf-R8Tz_EsQ_4_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="2"
      id="Tc_JzsnhTtdCE6KtnTbPnKqGQ_4_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="INF"
      id="Tc_rGD8iiXT40aMLx4I8zmOmw_5_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">716131</cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering>
    <cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Tc_vxFGdSuBUEGZ3Jr3nZHbyA_5_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">2.39</cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice>
    <cvrx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="INF"
      id="Tc_IWfwDga3P0KO9Rxh7uODWQ_6_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</cvrx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <cvrx:ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Tc_6vgUVjFczkK-rVFT4VDhtA_6_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0</cvrx:ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Tc_LPFRUid40U6a3mR9YnINqQ_7_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">716131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="2"
      id="Tc_u96msh5Zekey9Xf4FChORg_7_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">2.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_C6HL133DUUquBHBM5bOiig">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;7.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Stock-Based compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Summary of plans and activity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2001, the Company&#x2019;s Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#x201c;2001 Plan&#x201d;). Under the 2001 Plan, as amended, 2,674,749 shares of common stock had been reserved for the issuance of incentive stock options granted to employees, nonemployee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the day of grant to four&#160;years and expire within a maximum term of 10 years from the grant date. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In connection with the IPO in 2021, the Company&#x2019;s Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was 1,854,490 newly reserved shares in addition to the 600,373 shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan will automatically increase on the first day of each year, commencing January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of shares of the Company&#x2019;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The 2021 Plan provides for the &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of 10 years from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2021, there were 1,789,453 shares available for future issuance under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of the Company&#x2019;s common stock on the date of grant. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years 2008 through December 31, 2021, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain nonemployee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as the Company&#x2019;s standard form of option agreement for nonemployee directors as they have an exercise price not less than the fair market value on the grant date and vest over 48&#160;months from the date of grant.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of stock option activity:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in &#160;thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 966,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 2,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 517,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;4.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (10,178)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;4.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (175)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;0.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 1,473,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;2.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 3,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,411,717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (76,294)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;11.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (59,341)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;0.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 16,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 1,060,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;2.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 10,303&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, stock options outstanding included 9,993 options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2021, the weighted average remaining contractual life was &lt;span style="white-space:pre-wrap;"&gt;8.1&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;&#160;years. For options exercisable as of December 31, 2021, the weighted average remaining contractual life was &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;6.6&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the IPO, the Company&#x2019;s Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The number of shares of common stock initially reserved for issuance under the ESPP was 278,170. The shares available for issuance under the ESPP will automatically increase on the first day of each year, commencing January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 1% of the total number of shares of the Company&#x2019;s common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The ESPP will permit certain of the Company&#x2019;s U.S. employees to purchase shares of the Company&#x2019;s common stock at a price per share not less than 85% of the l&lt;span style="letter-spacing:0.25pt;"&gt;ower of (i)&#160;the closing market price per share of the Company&#x2019;s common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of the Company&#x2019;s common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase period commenced January 1, 2022. Accordingly, as of December 31, 2021, &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;no&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;white-space:pre-wrap;"&gt; shares of common stock have been purchased under the ESPP.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation expense&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to determine the fair value of stock options on the grant date. The Company measures stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. The Company accounts for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2021 and 2020. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value of options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;non-officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.7 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;56.1% to 63.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 62.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.17% to 1.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.16% to 0.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews these assumptions on a periodic basis and adjusts them, as necessary. The expected term of an award was determined based on the Company&#x2019;s analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. &lt;span style="color:#231f20;"&gt;We utilize the simplified method to develop the estimate of the expected term&lt;/span&gt;. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be zero, as the Company has never paid dividends and has no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general &amp;amp; administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, unrecognized compensation expense related to unvested stock-based compensation arrangements was $6.9 million. As of December 31, 2021, the related weighted average period over which it is expected to be recognized is approximately &lt;span style="white-space:pre-wrap;"&gt;3.3&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;&#160;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Early exercise of stock options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2001 Plan, the Company has issued options to certain executive officers with early-exercise provisions. The options may be exercised by the holder any time after they are granted. The Company has the right to repurchase, at the original option exercise price, shares issued pursuant to such early-exercise provisions, upon the termination of employment or death of the stockholder. This repurchase right expires based upon the original option vesting schedule. As of December 31, 2021 and 2020, there have been no early exercises and therefore there is no liability recorded for the early exercise of stock options.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_oDN2lEZu7EKFxKQVBpzLOw"
      decimals="INF"
      id="Narr_u1NrnObR2Uqe8TwVbGTC-A"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2674749</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2021_To_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_kdt0eqlvgUeFDlocBEsHgg"
      id="Narr_unvhHJIKg0WhN8YZ0I-g6A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2021_To_6_1_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_dW1zDaWfyk2oy7oOo2LrKA"
      id="Narr_SwpwmBv0dECEczLl6lV0YQ">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_mJX9dbF0-kOVnbsfnZIlqw"
      decimals="INF"
      id="Narr_6VVmm1UfYUSqbj8gsF479Q"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">1854490</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_sTmU2osx-U-5lEzqPECixw"
      decimals="INF"
      id="Narr_FUBQWcPY-U-K5rFcPWsPYg"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">600373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_mJX9dbF0-kOVnbsfnZIlqw"
      decimals="2"
      id="Narr_G1xkXGU9Bki-g937qQkspQ"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.05</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_bFjTgGhLakqfsDzkd9x64A"
      id="Narr_TEqyo-yNjE6to0okfpRiFA">P10Y</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_mJX9dbF0-kOVnbsfnZIlqw"
      decimals="INF"
      id="Narr_TGvtN0wfwkmLQHWqLa2X2Q"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">1789453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_2-T0O75ws02nTypOsGbMvw"
      id="Narr_ah-Zd2VVNEOptBkXsVtbGw">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_KMOiWbhk2Umx4Gnshmrqkw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of stock option activity:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in &#160;thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 966,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 2,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 517,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;4.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (10,178)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;4.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (175)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;0.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 1,473,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;2.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 3,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,411,717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;13.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (76,294)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;11.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (59,341)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;0.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 16,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:51.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 1,060,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;2.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 10,303&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ"
      decimals="INF"
      id="Tc_j_GJQoavjkmatJRg0vPNcQ_6_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">966146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ"
      decimals="2"
      id="Tc_ZRnAfHmRck-XKoeI-fHGSw_6_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">1.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ"
      decimals="-3"
      id="Tc_jpxD3uHZSEmXwayeJUIzCA_6_9"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2256000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="INF"
      id="Tc_eE7ki1Vx4EaOXhV5ymTSNw_7_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">517566</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="2"
      id="Tc_LTLdkMNxyU6FleTj7qGlbw_7_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">4.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="INF"
      id="Tc__6Rf23Im_E657_okUdTvyQ_8_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">10178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="2"
      id="Tc_iZIQMih3qkS2pZ88rMGfgA_8_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">4.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="INF"
      id="Tc_EzCcG82OyUmeFpgZ5qDFKg_9_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">175</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="2"
      id="Tc_3pvn-Cad4UWYAeb91zNqlQ_9_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="INF"
      id="Tc_ZI5amaJZ4kCJQwHZdjWxLA_10_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">1473359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="2"
      id="Tc_2xWA9B9HoECI9fSiCQkq9g_10_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">2.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_rt7h2F-FUkucdHa402wk3Q_10_9"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="INF"
      id="Tc_IS_pJdkAIECC-xpXaQLcgg_11_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">1411717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Tc_wRFGYqV370WMNWyd0JYHrQ_11_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">13.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="INF"
      id="Tc_FlaqDRDZSkWwNs599bia3g_12_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">76294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Tc_JGX_ojgYeUWBsijlbzeDlA_12_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">11.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="INF"
      id="Tc_8lWOIEhu30CmJwAPuODNkQ_13_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">59341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Tc_N_bNHYFvB0CvLc4uhiBn4g_13_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">0.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Tc_zCulJg8tREy2d5Jxg3uAVQ_14_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2749441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="2"
      id="Tc_RPQyER0zBUq0s_sXmhrsig_14_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">7.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_Nqgz0mZ4U0qiRhq3Ys3K6Q_14_9"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">16262000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="INF"
      id="Tc_seKOcb_rOU2QGs9TpYjp6A_15_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">1060820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="2"
      id="Tc_aCHnilV5E0WVDLM_cKF4Dw_15_5"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_LAKJyenlTU2My__adfZeYg_15_9"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">10303000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zsm1WUir-k6VgUpvr7OdPg"
      decimals="INF"
      id="Narr_Pw1MvRquaka3WmhHl4LhqA"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">9993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_lnY8OUZz5UuzF2lt3JBAbg">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_K1adD9qBx0CHuNV1TqPbOg">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_48tuazk8rES1QsAP9ElvuA"
      decimals="INF"
      id="Narr_enRtrK0BzkScYPlUeBz40w"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">278170</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_48tuazk8rES1QsAP9ElvuA"
      decimals="2"
      id="Narr_cR1aG8yAUEmg88iraVAziA"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.01</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_48tuazk8rES1QsAP9ElvuA"
      decimals="2"
      id="Narr_EDxFEAWTckqorI_gbDcZxA"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.85</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_nw03FdpgikWG68cst93DrQ"
      decimals="INF"
      id="Narr_81pqwkbg8kyGsyEfWLsgfQ"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_YJRHBBFkdkm7tNN-AJMsHA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2021 and 2020. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value of options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;non-officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.7 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;56.1% to 63.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 62.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.17% to 1.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.16% to 0.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Tc_qmmiNkn4YUusHwTzOTRPUQ_3_3"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="2"
      id="Tc_Vwh84KnVtkOp8-VTTQPCcQ_3_7"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_Pz24LA4lyUOU54enYn6jCw"
      id="Narr_LTG1yPmjfUupHgKEXX9pfQ">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_rMwLYGHbQE6dNGAJjgqUTA"
      id="Narr_1O3xsqjKnEyH4N9Qmo8UTA">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_dgYIHQpY50SIFkVijZlZVQ"
      id="Tc_VgWk7F-BBUKP87DWRvmu-g_4_7">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_Fm3g4MulRkuGfrsRDzx3EQ"
      id="Tc_g2BcFqVI4kCbGd-y8IYmyg_5_3">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_30RcSPGNvEamYzAz2-IrUw"
      id="Tc_F65XdBF6EUWX1EIVkeFSfg_5_7">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Narr_2jkXobQtbUSSrxs0_TbXEA"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Narr_Yi8TZEicUEONV3ywobyvjA"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc_2GMpuEG11kOArOJDLYaCmQ_6_7"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="4"
      id="Tc_A4s_SsOTfk2AZq9HzQscHA_7_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="4"
      id="Tc_hhMGn2Acek2jQazYlmpU_Q_7_7"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="4"
      id="Narr_Pvi3GTzorEyZ1nJlPPADXg"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.0017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="4"
      id="Narr_HGE0qEW73UCHQmn_frsZvQ"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="4"
      id="Narr_vVeiDOwCykuLIUCZdtszkw"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.0016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="4"
      id="Narr_6nw2V1wlP0-sHfoMeju3nA"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Narr_mK2kEDYRWkCmYdwF-yLAOQ"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_OBTtpYH5LkC8iiroqjOytQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general &amp;amp; administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_rITtj_g4X0aaNNHUoD6CHw"
      decimals="-3"
      id="Tc_FzRQG7qK1UCIzDtk1CaiNQ_3_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1468000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Z2T5WpbvEECoGfLG7ZECvw"
      decimals="-3"
      id="Tc_Y-wHsQFrF0WkDrifzcwYBA_3_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">88000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KP_E6votUkOpAaxA54qxHA"
      decimals="-3"
      id="Tc_f8dvmVMR8Eqx-7xkQ5hzTg_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">420000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fYLvldHF7ESQu3O88FcTxA"
      decimals="-3"
      id="Tc_9JrWWOMylkG6xBilIvn56w_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">43000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_IVyA6xFKREe6yCN57Qbv9g"
      decimals="-3"
      id="Tc_cFT_m2bts0eamYKtXj8c3Q_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">24000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember__Rt_uAI5zEe9X0cpvPTtiQ"
      decimals="-3"
      id="Tc_4K-UqnGcDUCFlAo8_ZkmoQ_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_iUkeTEicr0OaFxCxEShzpQ_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_IWHhf6RSVU659LTtvXu34w_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-5"
      id="Narr_WpWMRS6qQk6plm6ZyVQnmA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">6900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_S6fQ4fZvmU6vD9j5XrKEyg">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_GBAq1vgtgUGuG5-Ar6ag-w"
      decimals="-3"
      id="Narr_dX2FYwxpbEWlOZN6schwdw"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_cvrx_StockOptionsWithEarlyExerciseOptionMember_yzrdiZL4ykShGVaP8kB8EQ"
      decimals="-3"
      id="Narr_ZuGQ-sREbkWSm36mkbUFEw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</cvrx:LiabilityRecordedForEarlyExerciseOfStockOptions>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_57GIGsNkoU2PJpcj01pSNg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and 2020, a valuation allowance was recorded against all deferred tax assets due to the Company&#x2019;s cumulative net loss position. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of our provision for income taxes are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Provision for income taxes for the years ended December 31, 2021 and 2020 was $91,000 and $85,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development ("R&amp;amp;D") tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of net deferred tax assets were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;74,716&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 68,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;R&amp;amp;D tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 8,318&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;IRC Section 59e election&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,955&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;1,104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Non-qualified stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; -   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 93,759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 87,434&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (93,759)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (87,434)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021, the Company had federal and state net operating loss carryforwards (&#x201c;NOLs&#x201d;) of approximately $324.8 million and $6.5 million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2021, the Company had federal and state tax credit carryforwards of approximately $8.9 million and $1.6 million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits began expiring in 2028. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit the Company&#x2019;s utilization of the NOLs and could be triggered by subsequent sales of securities by the Company or its stockholders.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The changes to our gross unrecognized tax benefits were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,757&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross increases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross decreases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The Company recognized approximately $61,000 and $56,000 of interest or penalties for the&#160;years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021 and 2020, total accrued interest and penalties are $0.3 million and $0.3&#160;million, respectively. The Company recognizes accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. The Company does not expect a significant change in the amount of unrecognized tax benefits in the next year.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2001 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. The Company does not have any tax audits or other proceedings pending.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_-mXVFYnvLk-sPTd6ME5mFg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of our provision for income taxes are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_XEg97La7T0aU87wlh30eRA_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_HVeZTO0fskae5gCNwRWcag_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_4PLXre8kP0WCPELP3dA_Qg_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">91000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_QvnkZpX88UyGWJsv-V8_tA_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">85000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_wiSu0tXi7UiayJrg-DikPg_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">91000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_U1Yuz3GvVEOEhJW0_ZlH2Q_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">85000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_GsJZHefFJU2GJ0Q6MTR6-Q_7_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_tm3nOpE3lU2EXarwvdc6wQ_7_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">85000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Narr_wZPNWCzmhkWEulnjJj_tGQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Narr_n_KICu4XLE-p4G4syjKEeQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">85000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_ZM9IjfeYb0ygWnpcJVUpHA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development ("R&amp;amp;D") tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_iCQWFieE0EycTYW0f8rHkQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development ("R&amp;amp;D") tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Tc_Q8RWgrpd206g1V6eDxaEkg_3_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc_KynKj7KFk0qiobYHLBVRRg_3_6"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Tc_9O7R4WDdd0GwJpLD0gBXiQ_4_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.090</cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc_SVlZCUCNDEGCMfH1Q_6V6g_4_6"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.005</cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Tc_TLIaVz3-Dk-iKya7FL9X2A_5_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc_cv3smOcMs0mdtSGmuHdUmg_5_6"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Tc_4KX8AIhDiEaHtQ8t6H7k1A_6_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.002</cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc_1gJ4WDpObkGHlLJX3-zkpw_6_6"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.005</cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Tc_geyeL7B7xE2pNadBZM0MDA_7_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc_i7XIEq2RLEGpyo5xVV2HLw_7_6"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Tc_WCSfWz1iJ02i0t6HhPf7Vw_8_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc_qPBnJw2pxUGUbyhq1toPEw_8_6"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Tc_ChAIVCEiWkebqwEPwz5gDA_9_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.147</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc__m4W6A21iUGLBXcrpYXQww_9_6"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.232</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="3"
      id="Tc_PCd_Ny5oIUK_NRpKWyRORQ_10_3"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="3"
      id="Tc_6CwFV2Wwm0S4ZaLTmDtZ3Q_10_6"
      unitRef="Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g">-0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_D0hiBZtysUWzh6kxBCn1bA_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">74716000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_M2e-kGwxzUqO-Nu3gwnAOA_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">68957000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_t_RVFZDk10qQ9_VCxB9ZyQ_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">8711000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_AFhsyPCfhEieYMqkWqQhEw_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">8318000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <cvrx:DeferredTaxAssetsInternalRevenueCode59EElection
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_UVAyH76YLkKsg7TTbKTkFQ_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">8577000</cvrx:DeferredTaxAssetsInternalRevenueCode59EElection>
    <cvrx:DeferredTaxAssetsInternalRevenueCode59EElection
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_V1FRc4KRSk68synM-pSiMw_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">7955000</cvrx:DeferredTaxAssetsInternalRevenueCode59EElection>
    <cvrx:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_Tbly8KhbO0OL1MzL9gxqAw_7_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1104000</cvrx:DeferredTaxAssetsStartUpCosts>
    <cvrx:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_XUy8vBvt2kCt_iQhWAMIlQ_7_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1198000</cvrx:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_qP1ZzvCIwE6vEailttq3yw_8_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">350000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_EB7Wt096o0m9_xBIqVJ3bQ_8_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">136000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_LR156xbdlkKcQD0gx-61sw_9_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">91000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_NbP9GWkyakKyIDoo-O6CYA_9_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">90000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_An_qyplwvkeRPFn32c1JCg_10_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">151000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_lX7Z8c8kQEyxhjS4NeuQeQ_10_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">106000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_QgbGkizW8UW3FImjSTvt6g_11_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">607000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_r5BrMTylzUek1QrQ8JpEOw_12_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">59000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_pJJ77RjBx0GMC4zTo_wgSg_12_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">67000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_8pmPiYYiw0uPXQtliLIS-g_13_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">93759000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_oSNHpJIb4kOiUR65D4nAFg_13_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">87434000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_awexE_WzTUOYj48DziTj3Q_14_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">93759000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_umMYr6ABH06OkdSe4AmizQ_14_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">87434000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_JKUGcxHdYUifqc8o-2AloA_15_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_INPSdciyuUmZrJF_3sp_1w_15_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WXCPeSjuN0mwsFbO09y0Rg"
      decimals="-5"
      id="Narr_QEhYIeB4PkiggSV6bCCohA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">324800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_z_YBcxDzik24JD_7beeSKA"
      decimals="-5"
      id="Narr_jiO2RYdCP0CXoPtK_pAIUw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">6500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WXCPeSjuN0mwsFbO09y0Rg"
      decimals="-5"
      id="Narr_QkYLIYNf4Ui7pek0WJ3QPw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">8900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_z_YBcxDzik24JD_7beeSKA"
      decimals="-5"
      id="Narr_xsdtQR7em0m54cvsOSI3Ug"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_7cngoAIKOkWrhtic5vx8sw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The changes to our gross unrecognized tax benefits were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,757&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross increases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross decreases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_ilzE70XAXUaJ8X7_YpO4Ig_3_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1840000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ"
      decimals="-3"
      id="Tc_GuxO3En0-0Ku4LkzrrZnIQ_3_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1757000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_ab9dAROBN02PfhysIbjQ6g_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">10000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_Zv-LYhvBCUuy796NUvlGZw_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_SIJkDzWFOE2nXUeLPslK7Q_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">91000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_DlZqbHpn80uad3yPK-k8Ew_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">83000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_ylN6rRG71EGApOwVz2bC_g_8_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">2000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc__a-xnFwPvUu3v-kSgH0GRA_8_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_qnkRYi2MBU-4JDFe0jaahQ_9_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1939000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Tc_vF-S66yxO02LA5qv8GbuCg_9_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1840000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Narr_gHSRfVTpn0eiaBveaJtwNA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">61000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Narr_43UAft3XGUSJsVwXW9sPKA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">56000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-5"
      id="Narr_ISLxMS25K0Gq_Sd6V7nCnA"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-5"
      id="Narr_rFXV23mjIUqUs3tzz1gxOw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_tbUOOUg6z06BjtcP_65FUQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;9. (Loss) Earnings Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,078)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,109)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accretion of preferred stock to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (217)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,078)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,326)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,360,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 387,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share attributable to common stockholders&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4.16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37.01)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The Company&#x2019;s potentially dilutive securities, which include stock options, shares of convertible preferred stock, warrants to purchase shares of convertible preferred stock and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,473,359&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase redeemable convertible preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 108,406&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Redeemable convertible preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,929,584&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,465,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,511,349&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_pWljn0H6XEWPgJX8y9trkw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,078)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,109)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accretion of preferred stock to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (217)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,078)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,326)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,360,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 387,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share attributable to common stockholders&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4.16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37.01)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_l_AFuw4AF0KKMLVQ-QRcaw_4_4"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-43078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_Pjr8j0QSpke0ApXrUtRsJA_4_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14109000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_yne31kNV1k2NjeU0qiCKeA_5_4"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_b9GxYuOXJ0KFsIpYlIwdRA_5_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">217000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_0leluCxfJkiFhxuPPIHSLA_6_4"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-43078000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_OqdA2Z3qa02pKfDmv-ALRA_6_7"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">-14326000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="0"
      id="Tc_ALfe3gyAAEun-5xAWVPJVg_8_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">10360054</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="0"
      id="Tc_XGVkZbuJjEm_VPNTbtKupQ_8_7"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">387083</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="2"
      id="Tc_haduNaHsJU6XwzdDxYo72w_9_4"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">-4.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="2"
      id="Tc_5AaBK9FvFkay4-xUiwrJGA_9_7"
      unitRef="Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww">-37.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_TFI9OsJSCEql8Lepdyw89w">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,473,359&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase redeemable convertible preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 108,406&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Redeemable convertible preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 11,929,584&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,465,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,511,349&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_z1FXD3BKKUuyMZ9Pt2aLwA"
      decimals="INF"
      id="Tc_meBQqngJnkuAJH-YNYo0tQ_3_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">2749441</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bk4XMJevEEOkeqMW-LrPQw"
      decimals="INF"
      id="Tc_ap8EFaR29UuKfyfOi65v8A_3_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">1473359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BejIF-DRL0aswumRwwIyHA"
      decimals="INF"
      id="Tc_Guu7mxNVmUezUHmpiJsqQQ_4_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aBap4qmv00-_PB2zQLVyyw"
      decimals="INF"
      id="Tc_wV3MPOCcDE68HMW--DAjkw_4_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">108406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_PlOty7i4fUGsptJeEqXFFA"
      decimals="INF"
      id="Tc_8EVf31C3F0qiX5KCmrn74A_5_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">716131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_nTVDTqoC4EGDzTZXxwMKtg"
      decimals="INF"
      id="Tc_RXaHWAqNl0uRWjdebJx_Pg_5_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_sIVU4EK2E0GdoOrH6UNCKg"
      decimals="INF"
      id="Tc_l321eEaiVEm2ee2EUM4n_A_6_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_zfsXsnHsBUWf8PinLKwvcw"
      decimals="INF"
      id="Tc_PgAspSVElU6MyQK8-XIngg_6_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">11929584</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="INF"
      id="Tc_EBXpmlrGn0yvkJ0IlPLCkQ_7_2"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">3465572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="INF"
      id="Tc_ngEXWuqF5UCwprJSGbJ6vQ_7_4"
      unitRef="Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g">13511349</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_v3_xwdrieEqPbHFlzP80Rw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Commitments and contingencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Commitments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into an operating lease agreement for its office, manufacturing and research facility, which expires in 2024. Rent expense for the years ended December 31, 2021 and 2020 was $0.4 million and $0.4 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum lease payments under all operating leases as of December 31, 2021 are as follows for the&#160;years ending:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been no contingent liabilities requiring accrual or disclosure as of December 31, 2021 or December 31, 2020.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-5"
      id="Narr_4R-bSkpJvUywTZ55Qlv2cw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-5"
      id="Narr__i95_ud55k6C_V2HLJg0MQ"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_Mc-mXHypJU-3mj7Q4c-ETQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Future minimum lease payments under all operating leases as of December 31, 2021 are as follows for the&#160;years ending:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 234&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_OKAoxWsAxUet4sAepDrBuQ_2_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">227000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_S4VfiSiVZ0O0DCHVEBzDuw_3_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">234000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_B7ykX7JLaUSx5OPbNS5DZQ_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">138000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Tc_pCQtjqrP_EqrUEjfxcd-MA_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">599000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw"
      decimals="-3"
      id="Narr_a7BUF_jZZ0uMLoHBN7ZhMw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg"
      decimals="-3"
      id="Narr_fGrJ0naGnEOwzdDWpc_Elw"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">0</us-gaap:ContractualObligation>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_J-ptQJZ0zE-kiRXpq3g1aQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;11.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Employee benefit plans&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sponsors a voluntary defined-contribution employee retirement plan (the &#x201c;401(k)&#160;plan&#x201d;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. The Company does not provide matching contributions to employees.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_b09MmMn80EKZO62IVbwYyg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;12.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Segment, geographic information and revenue disaggregation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;and its Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the years ended:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,790&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,036&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2021 and 2020, long-lived assets were located primarily in the U.S.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="0"
      id="Narr_CNESjjg2NkSWft0g-IlVew"
      unitRef="Unit_Standard_segment_dGFrNR414EyLMrXxL6FSSQ">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Tb_S7Orlh0S_UyqSEw9rnkkcA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company derives all its revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the years ended:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,790&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,036&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_9YKJ16k5pUK-Co6rlduK-Q"
      decimals="-3"
      id="Tc_YRmmOrKJH0ucS1XRpfZ3mw_4_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">9147000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_US_aqbgUY-uCkOAp8sxbW2muQ"
      decimals="-3"
      id="Tc_UzUqBYQq_kK7msuRdp_rsw_4_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">1733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_DE_U05bs9aJIU6iqEyxRNqWpQ"
      decimals="-3"
      id="Tc_3vPCnNPL6Eext4U9GEAQ2w_5_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_DE_4mGJWS3mdUGj2uJ_PoEshg"
      decimals="-3"
      id="Tc_ERNxg7M200GDF_cA5NQ07g_5_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">3790000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_NA4nBO9IeUeJcRmeWYh52A"
      decimals="-3"
      id="Tc_G7mxPH0iMUuJCeD1PFbz_w_6_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">639000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_uUcu3GeHRUyZPto-aW7cuQ"
      decimals="-3"
      id="Tc_4Pjn8LSEcUSt5-if3wX3pA_6_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">530000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      decimals="-3"
      id="Tc_t0rXLGnRQEKBVm5yLWfh4g_7_3"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">13036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_0EAbEqw75kK05jlDmpvh0g"
      decimals="-3"
      id="Tc_N3bvNfQpLUS5Rp9_0Izcdw_7_6"
      unitRef="Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ">6053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg"
      id="Narr_yJAyKEXrPE-bVlAjmn7MyQ">248</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<5K\)9ORWG:G08(LU3+9!@-!$HGR/WO>=L1! #T60+<!]%6 ZQ\)\+8!7MT
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MJ54U[VF;&TYW]6O".\HY+>K++8E%"R4%Q.\;2OG3C7SSV+TM/_\74$L#!!0
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M\ 6A#P.@II.HB3U@1DC+]L:U#.'1ZT*_9^?6N(_\PN)1Z]L,V\#5JH2[90G
MJ0.O>0V"\Z6&X(D'S[?J3^BD!6 M2;A;D[Z^1J"#J'V]Z9,XIDT=#=GA<31M
MH[86)SQY4P,F8'?I-W06N%80W"TARX-*=M!9O$VSL:\2?8PGM,E/P(SBE@U-
M:CTAW7KBQ35$3P@V\04A!#MDU@Z[%@[R@G T@EIW&J\+*JD5@W0KQE+)A//T
ML@Y4.MBC7"5"7U0WSZ%I*&56[FT'%&;+5PKB4>7;M+0+I)82TBTES]$+K0]
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M9[]K87\SRZ=A5BG\% DN/]\^+."#D<&\X(;@^;/S/%^^N;1MA^8Q1JLW+V%
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M8>.-6%QX4X9;J)GQWA3A[Y)D1I8)\'UN<)ZK%ZR@O98\^QM02P,$%     @
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M*(UI./BA+;+ER^U2%6G+L+7F94UB*":**E?W0IB(E:H,(Y8%/40XMS0(:NP
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MT:4LT]W&?! G,\M*$H\/L8+YJ9W'CWEGOAO*6MS02V1R?R-Z,42W%QY(4+D
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MG#A=AD&M*OM!TU+5:/[MSXW@L $MP/Q*J3H,Z(#V"[<W_P%02P,$%     @
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M81BZS9/IB-9=C&"3@\/G=..CC6):QB(5/N QXLK LN["1>D&<D%AE=XP3;[
MX/X_!>9+ _70^6:$?J*\M8<T;=!'0<B^>_IX"UBX*&=9(A:(!X"081JTI[,@
M;.;,:1B,=KMW8%"C>.7\E@ Z2N49,3[MW'W/L_SLIO/&04V,F".:>14&LZ;,
MP;A:?T;)M.64QLADBSQM0O6?$_6>TK+K8 S#9FN_.4A8M B&M),FQS 85.N;
M+9(ZP\<K+I<M]@^:B8:L!SO6UYX0-6S#\8HF&M;E.>T/Z@I[%&@WRG?UYW']
M^;7_[Q&ZQ$+$'-V]7P7(QFV%9@U_=OR_:9'Z6X7Y2!&68W19(9>^9,9<ZPV"
MSIKKI([)DV%W$HUK&^-I=S::L#)W:IG3%&.*I%'+[B":L@]WU^R^;'!',V!5
MM]L\/II,&KL3%&)$":/MVR)'YYJ6^Z-N% [;=F=3]E')MU\+GF)X !5$%7]!
MDY $33Z#4=CD,AA3?4$CVHV#%OA:" \L3X_.FC:8A>PJCG6!5S_PF+<J'HV:
M=%%(MVXCP$N-'M-<MJC_MK$S#B?L5ZQ"NO%FU 2Y\:3,VK8\:2@TZ$Y:>$PG
MW>%@R'X[@AL[+'<L6C#2,WGCHO:8+,?ZF->F[X$NMUMO2=F*)Q5J[]HL^5RR
MG=(E_?#LXZ]_-VX9G;VAVWB.[<"CP $.FPMV,N@/@RE.4FGJ#$E=R!BQN]QH
M:T6VLA!C+"-++AD\YD*3' @[58M#.GA9#Y\,@]?8H%9?]W5OJCG%>KNG9(3%
M]@5*'KSB18K78:R5 ,>>SQ:[NC^JML[9*N,;/,],,?\=Q:(VCI/8$I&%I2(3
MUA^OS2]J+4&;E<BW!7EWS/C^CVK$?%.AXV#:=UTDTGZ0%K1$UG?8Q\B"K)X
MO41$&W>I;O',];)=;WODG&+9\2I6O:7QAMMYS#"I+,,0I4\E-(UAFF%'D](2
M;]L884AZW,2N#,=!MEZ!0Q'4M:$.L5.QFPF2@-T7U'EMW]'X59U?JR)-O/:M
M@UVQ;VXZXDQ.FL6.%@UOM5@N07N+H1<,PC!AL.$IN.@R@*)@2X9/>*(>J=1@
MH[<=B*Y4BE%4&L8+:[8]^5)3RA:2&GML)_XHP:=LR_X*+<-/SVB S3K&O)"2
MPAUM1D-1#4.C[G08[CU/L 'P3'%$T< -_!=JWVJ!+G!WU3OGEC+>K+Y;6-\.
MPR_@TE*%IX-2BP3^]UJ<MK3_6S5>X"!,ZU;7S :S@ZZZ2M,R<PP<YMYE8L%V
M[[IE8@K,DMAG)N $YC#7T;EA8@Z(%?3\A6(&)UXC$E?B=LG:,BSL T]-GB<U
M8%R;M$=CMT:F@M /C*7,S0&!R67UMTWR3RO(\U^OK.N!>-FM53+0@9T0-)R?
MT.BU5[EJ&VV5JV$'\]PU&E*T4$+(U'#G+O*H#.S&'6^Y[8<$*FL@S1-/) I\
M#:"WZ'2.I:,V.57S']F99ZKP7 _':WE4PJ-/S6 W!]9NQ:I2JYN?@_N@*N8U
M@3DA+ 8R-_5=O#XKT"AYNJW@9*E%^;7J=X1\DPA7/PG4D<"'QT*K#/T:1BB?
M5L5RA541DP/UT4 _!%"CYK^]\((ZB0+#R8<71FB*YIB7]Q765;-Z[:[5>->
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M5'TKKQ=&KMU-F$J:[M7N,:</&53V .UGDJJM65@%[:?1XE]02P,$%     @
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M')1!604\SZ4T>\$ZZ$;O^=]02P,$%     @ FF%65/_!,V]V P  -@H  !D
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M^"/XX#,?=V/2C2D\*,L$# KO\D57ZW]T( >M'_TL3JY&=]*SMW'\S;H%.:S
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M\*8TG^3^%]'EXP),9:G=+]JWNKXW06FCC:PZ8XB@*NKVGS]V=1@9Q*\9T,Z
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M88=2\!(JS65%%,S.!Y?T]22U\]V$SQQ6NO=,;"13*>_LX'UQ/@@L(1"0&XO
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M,O:BF#Z./1H_,U:*JY[%8R^.:0\H\\?1C@*A2#(-N]J&AHN5ZKWHU O2P$.
M1YE,=J('7A1$![0OZ;0O^6'MN]2H42W?3S9M1B)+ PJW,\!N@F8)3][8UG_'
MN&I[\SO9U+OD\C"+QW)I7)9J)>]Y =HY7JVEB[5:-+/N[]?N9<MZWI88$H>R
M%O(!T!X5P&$H$,Q!],)<VC"=5 "9"(:;#29$XG:Z5N<:M<AR*F4! CDJ-_4!
MF,(UM;OFCG6T#FUK^#]-R?]$_[O<[YOO:/4&FPK[\KS$OB")G\:["M(?CWJ-
M5^-9SJX#UHZ38I>P8_>=GMH_&IZVHTI6)W(V0\E7O47KR/J97<W4WU:'_I3_
MY'F_U\C?KXO];YV[>XFUQ05NXYN] #F_=-PC/R8OMW#2T$_Q=0=1<%ON6#H/
M',3C/1HI[P#8?+GA^NYDI@"PE#%PT(:H_O8<^#1S5*@?[Z*"WU/W'1]&Y.4!
M64D[64D/-O0-Y')>\7\PKKUG.!MYI6&76AP&?_>L+O3<7.N950\H ATQ=PH[
MF3IB>9\8-,2L3C>BI/__V<QU[-MMJM^=4_8W["UNA"A$'IE#A9TJR"M6UJ>$
M%2C.W)Z%[:6IWY!>G(YZX]&(W(!&%OFB-2W@'J]Z-5[<S!;=N"<1<839PY)"
M.9A+66BBI=@^0X8;5=AN54MGC->-_H8?[BJS8>^"5(*:NVN@QN595J:Y*W5O
MNYOF97/!VDQOKJD?F)KC>9,(F*%IX&>X!:GFZM<,C*S==6LJ#5[>W.,";\N@
M[ 3\/I/2K ?607?_OO@74$L#!!0    ( )IA5E1J88XW/@0  ),1   9
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M3R/?ZU[\[?>O0&6>68)Y@60%TN:FQ3C1D<@4Y:$Z/1 SJ:MV/'*528F^O-B
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M4=&& /)7QOBM$1+T.WKZ&U!+ P04    " ":8594!KX%<NP"  "N!@  &0
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MEO@,@+(&N+^2TKQ/;*?I'Y;L'U!+ P04    " ":8594#<(A97(#  !C#0
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M00/L/(SVP4UO&XO$SM@.A='^^+UV0Q*&Q'2UVY<V3GSN/3[7/G9RO);J7B<
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M.,E(SA.: T:6EX-W\.V=/U8*I<2?"=GPQC50H3Q1^D/=S./+@:<\(BF)A(+
M\M\+N2%IJI"D'S\UZ*"VJ12;UUOT]V7P,I@GS,D-3;\GL5A=#L(!B,D2KU-Q
M3S<?B0XH4'@137GY"39:UAN :,T%S;2R]"!+\NH__J47HJ$@ VU70%H![2G
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MJO;S\CJD;$BV+RX(GIF4+"T>=P3'A&L#]7[#F#PV] #UI=3B'U!+ P04
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M!1U,>:KHA8L;(Q>NG1Q+@\VINYP#3T#9"?A\*J79W=@%RG\D!O\!4$L#!!0
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MJ3]C+.1ZY(7>=N&!+W*R"WX\K-@"'Y&>JYDR,[]527F)0G,I0&$V\F[#F\G
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M:F JKNJ&74](5J[GS269#NJ&N;GC4%D#\SV3DK83NT%[:\9_ 5!+ P04
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M%EB/@K(3<#R7TAP:=H&VPIW_ 5!+ P04    " ":8594PQD#-X #  !8"P
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M".55[;.@[1A9NYOUO31X3W?- I]2H*P!SB\EKF?7L0GZQ]G\?U!+ P04
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MAXF^CH$P!GI_P;G:3$R ZH(W_@M02P,$%     @ FF%65-DX1<4= P  #A(
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M=HIW(K93/-> ^/,&'FGJKS86!SRP*F"] _']<:"G_#YQ#%7%M&%/,(ZD*89
M+_I[-$F0["3P\=<'>TKB.$W]"&!^!7&,(? TX@BF #1@2!PWY^#!>11NSJEP
M^PO0Z#=02P,$%     @ FF%65)>*NQS     $P(   L   !?<F5L<R\N<F5L
M<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\
M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M96QS+W=O<FMB;V]K+GAM;"YR96QSS=D[3L- %(7AK41> )/[F/!00D5#B]B
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MWA'UCO^I=RZG7<K7GN\U/O\_J2[G>]/U\9?E]\G1JW+!.<!O^\<O4$L#!!0
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MZ_[)3SX!4$L! A0#%     @ FF%65 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " ":8594E[DA2NX
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ FF%65-S/'O/0 @
MJ@D  !@              ("!-Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( )IA5E1>=]<5@00  )L/   8              " @3T7
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " ":8594Y?8;
MP'$&   Y'P  &               @('T&P  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ FF%65!(7"#U(!@  \!@  !@
M ("!FR(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )IA
M5E0IRY5Z&0,  )\&   8              " @1DI  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " ":8594:[ET%IX*  !M&@  &
M        @(%H+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( )IA5E1AJD#9U L  .TF   9              "
M@==2  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ FF%6
M5/9<ZG[@!P  UAD  !D              ("!XEX  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " ":8594[FN,;(<$   F#0  &0
M        @('Y9@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( )IA5E1CG+1HD0,  &<(   9              " @;=K  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ FF%65!3Q:(7& @  + 8
M !D              ("!?V\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " ":8594LA_;#DD$  !B"@  &0              @(%\<@
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )IA5E3_=1N2
M*@L  *<>   9              " @?QV  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ FF%65"2*(K[V P  A@L  !D
M ("!78(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " ":
M8594_\$S;W8#   V"@  &0              @(&*A@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( )IA5E1^MV%9_ ,  .L*   9
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M970R-BYX;6Q02P$"% ,4    " ":8594!KX%<NP"  "N!@  &0
M    @('+G@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M )IA5E1FB=/.3 (  ,$$   9              " @>ZA  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ FF%65.'4^]PV @  *04  !D
M             ("!<:0  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " ":8594&20-]G("  !D!@  &0              @('>I@  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( )IA5E0-PB%E<@,
M &,-   9              " @8>I  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ FF%65-0H((OH @  F @  !D              ("!
M,*T  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " ":8594
MW6J@.D\#  #K"@  &0              @(%/L   >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( )IA5E356J5,]0(  '(,   9
M      " @=6S  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ FF%65%FG%Y7X @  KP<  !D              ("! ;<  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " ":8594*Z%1;]D$   6$P
M&0              @($PN@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( )IA5E3362_:_ 4   (<   9              " @4"_  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ FF%65([=PW-O
M!0  VQ\  !D              ("!<\4  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " ":8594ES$48M,"   -"0  &0
M@($9RP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( )IA
M5E21H]/,"04  " 8   9              " @2/.  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ FF%65'HTW,?!!   H!(  !D
M         ("!8],  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " ":8594HA@[/0,$  "=$   &0              @(%;V   >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( )IA5E0INU.Z5@,  ( +
M   9              " @97<  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ FF%65 ;OCX(= P  . H  !D              ("!(N
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " ":8594)$&V
M4I$"  !!!P  &0              @(%VXP  >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    ( )IA5E29^2R'.P,  .T*   9
M  " @3[F  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MFF%65,,9 S>  P  6 L  !D              ("!L.D  'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " ":85946:%]?<T"   :"   &0
M            @(%G[0  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( )IA5E3I^C2J' ,  (D(   9              " @6OP  !X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ FF%65'KHT,)6 P
MJ T  !D              ("!OO,  'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " ":8594I7>9-%D"  #,!0  &0              @(%+
M]P  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( )IA5E3>
MY)FM+ (  $X%   9              " @=OY  !X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ FF%65'"4N40( P  [ D  !D
M     ("!/OP  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M" ":8594V3A%Q1T#   .$@  #0              @ %]_P  >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( )IA5E27BKL<P    !,"   +              "
M <4" 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )IA5E1*\+7^8@0  )XC   /
M              "  :X# 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ":
M8594?'[I&]0!  #&'P  &@              @ $]" $ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ":8594*F32ILH!  ";'P  $P
M            @ %)"@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /0 ]
+ *(0  !$# $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>129</ContextCount>
  <ElementCount>374</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Business Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureBusinessOrganization</Role>
      <ShortName>Business Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - (Loss) Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossEarningsPerShare</Role>
      <ShortName>(Loss) Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation</Role>
      <ShortName>Segment, Geographic Information and Revenue Disaggregation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Selected Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</Role>
      <ShortName>Selected Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Stockholders Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30903 - Disclosure - (Loss) Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables</Role>
      <ShortName>(Loss) Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossEarningsPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables</Role>
      <ShortName>Segment, Geographic Information and Revenue Disaggregation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails</Role>
      <ShortName>Selected Balance Sheet Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair value measurements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair value measurements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Fair Value Measurements (Liabilities Measured at Fair Value on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Liabilities Measured at Fair Value on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Fair Value Measurements (Fair Value of Convertible Preferred Stock Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value of Convertible Preferred Stock Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureDebt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Stockholders Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Stockholders Equity (Summary of Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails</Role>
      <ShortName>Stockholders Equity (Summary of Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Components of Provision for Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes (Components of Net Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40901 - Disclosure - (Loss) Earnings Per Share (Basic and Diluted Net Loss per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>(Loss) Earnings Per Share (Basic and Diluted Net Loss per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40902 - Disclosure - (Loss) Earnings Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>(Loss) Earnings Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies (Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="tmb-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Schedule of Segment Reporting) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails</Role>
      <ShortName>Segment, Geographic Information and Revenue Disaggregation (Schedule of Segment Reporting) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="tmb-20211231x10k.htm">tmb-20211231x10k.htm</File>
    <File>tmb-20211231.xsd</File>
    <File>tmb-20211231_cal.xml</File>
    <File>tmb-20211231_def.xml</File>
    <File>tmb-20211231_lab.xml</File>
    <File>tmb-20211231_pre.xml</File>
    <File>tmb-20211231xex10d14.htm</File>
    <File>tmb-20211231xex21d1.htm</File>
    <File>tmb-20211231xex23d1.htm</File>
    <File>tmb-20211231xex31d1.htm</File>
    <File>tmb-20211231xex31d2.htm</File>
    <File>tmb-20211231xex32d1.htm</File>
    <File>tmb-20211231xex32d2.htm</File>
    <File>tmb-20211231xex4d16.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tmb-20211231x10k006.jpg</File>
    <File>tmb-20211231x10k007.jpg</File>
    <File>tmb-20211231x10k008.jpg</File>
    <File>tmb-20211231x10k009.jpg</File>
    <File>tmb-20211231x10k010.jpg</File>
    <File>tmb-20211231x10k011.jpg</File>
    <File>tmb-20211231x10k012.jpg</File>
    <File>tmb-20211231x10k013.jpg</File>
    <File>tmb-20211231x10k014.jpg</File>
    <File>tmb-20211231x10k015.jpg</File>
    <File>tmb-20211231x10k016.jpg</File>
    <File>tmb-20211231x10k017.jpg</File>
    <File>tmb-20211231x10k018.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="528">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tmb-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 129,
   "dts": {
    "calculationLink": {
     "local": [
      "tmb-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tmb-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 449,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 23,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 27
   },
   "keyCustom": 32,
   "keyStandard": 342,
   "memberCustom": 23,
   "memberStandard": 29,
   "nsprefix": "cvrx",
   "nsuri": "http://www.cvrx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "role": "http://www.cvrx.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Debt",
     "role": "http://www.cvrx.com/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Stockholders Equity",
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stock-Based Compensation",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Income Taxes",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - (Loss) Earnings Per Share",
     "role": "http://www.cvrx.com/role/DisclosureLossEarningsPerShare",
     "shortName": "(Loss) Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Commitments and Contingencies",
     "role": "http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Employee Benefit Plans",
     "role": "http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation",
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation",
     "shortName": "Segment, Geographic Information and Revenue Disaggregation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Selected Balance Sheet Information (Tables)",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables",
     "shortName": "Selected Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair value measurements (Tables)",
     "role": "http://www.cvrx.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair value measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Stockholders Equity (Tables)",
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - (Loss) Earnings Per Share (Tables)",
     "role": "http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables",
     "shortName": "(Loss) Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)",
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables",
     "shortName": "Segment, Geographic Information and Revenue Disaggregation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_y3rSgJAX9EGQxWbuV_L1FA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of significant accounting policies (Details)",
     "role": "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_y3rSgJAX9EGQxWbuV_L1FA",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails",
     "shortName": "Selected Balance Sheet Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails",
     "shortName": "Selected Balance Sheet Information (Schedule of Inventory) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvrx:ClinicalTrialAndOtherProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
     "shortName": "Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvrx:ClinicalTrialAndOtherProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair value measurements (Narrative) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
     "shortName": "Fair value measurements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D2BA-9J5XE-PbX6gbNm_aA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Fair Value Measurements (Liabilities Measured at Fair Value on a Recurring Basis) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements (Liabilities Measured at Fair Value on a Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_D2BA-9J5XE-PbX6gbNm_aA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_PH-M6rDzJkyqGZQxfL2QnQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Fair Value Measurements (Fair Value of Convertible Preferred Stock Warrants) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails",
     "shortName": "Fair Value Measurements (Fair Value of Convertible Preferred Stock Warrants) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_cvrx_ConvertiblePreferredStockWarrantLiabilityMember_YzRnuQXlH02VKNNMxJ0Jag",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Debt (Narrative) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
     "shortName": "Debt (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_LineOfCreditFacilityAxis_cvrx_HorizonTechnologyFinanceCorporationMember_C35XEWZJAU6-Xgd6ERjcqA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Stockholders Equity (Narrative) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "shortName": "Stockholders Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
     "shortName": "Stockholders Equity (Schedule of Convertible Preferred Stock) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityLiquidationPreference",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Stockholders Equity (Summary of Warrants) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails",
     "shortName": "Stockholders Equity (Summary of Warrants) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_6_1_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_oDN2lEZu7EKFxKQVBpzLOw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation (Summary of Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
     "shortName": "Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_yM5uFd1nnESr30gCjwugww",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes (Components of Provision for Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails",
     "shortName": "Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_HZIENGe-IUW0ZnSFQiZo0g",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes (Components of Net Deferred Tax Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_OUrsTPtvWEOUr4jpM--Fmw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_nkbsxwg9L02EwBAO85CEWQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - (Loss) Earnings Per Share (Basic and Diluted Net Loss per Share) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails",
     "shortName": "(Loss) Earnings Per Share (Basic and Diluted Net Loss per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PreferredStockAccretionOfRedemptionDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_p0RfPfIa3UWcDTlEg4P0KA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)",
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_p0RfPfIa3UWcDTlEg4P0KA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - (Loss) Earnings Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "(Loss) Earnings Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_1-EHN6_-p0WvbhSGq9cj0g",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Commitments and Contingencies (Future Minimum Lease Payments) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies (Future Minimum Lease Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_G6Nye9gB_EepvKBYPND_Lg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Schedule of Segment Reporting) (Details)",
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails",
     "shortName": "Segment, Geographic Information and Revenue Disaggregation (Schedule of Segment Reporting) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_dGFrNR414EyLMrXxL6FSSQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_pJPMSkFAzUafDar_JR2WjQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Business Organization",
     "role": "http://www.cvrx.com/role/DisclosureBusinessOrganization",
     "shortName": "Business Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Selected Balance Sheet Information",
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation",
     "shortName": "Selected Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yWuTv1Ht3kOnvC-OW8Jtbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 54,
   "tag": {
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_AccruedLiabilitiesCustomerRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liability relating customer rebate classified as current.",
        "label": "Accrued Liabilities, Customer Rebate Current",
        "terseLabel": "Customer rebates"
       }
      }
     },
     "localname": "AccruedLiabilitiesCustomerRebateCurrent",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_AccruedPaidTimeOff": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of paid time off.",
        "label": "Accrued Paid Time Off",
        "terseLabel": "Paid time off"
       }
      }
     },
     "localname": "AccruedPaidTimeOff",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.",
        "label": "Basis of Presentation And Consolidation Policy [Policy Text Block]",
        "terseLabel": "Statement presentation and basis of consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvrx_BiosenseWebsterInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Biosense Webster, Inc.",
        "label": "Biosense Webster, Inc."
       }
      }
     },
     "localname": "BiosenseWebsterInc.Member",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding, weighted average exercise price per share.",
        "label": "Class of Warrants or Rights Exercised, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsExercisedWeightedAverageExercisePrice",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvrx_ClinicalTrialAndOtherProfessionalFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.",
        "label": "Clinical Trial and Other Professional Fees",
        "terseLabel": "Clinical trial and other professional fees"
       }
      }
     },
     "localname": "ClinicalTrialAndOtherProfessionalFees",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to computer equipment and software.",
        "label": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_ConversionOfTemporaryEquitySharesToPermanentEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Temporary Equity, Shares, to Permanent Equity .",
        "label": "Conversion of Temporary Equity, Shares, to Permanent Equity",
        "negatedLabel": "Conversion of Series G preferred stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfTemporaryEquitySharesToPermanentEquity",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvrx_ConversionOfTemporaryToPermanentEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Temporary to Permanent Equity.",
        "label": "Conversion of Temporary to Permanent Equity",
        "negatedLabel": "Conversion of Series G preferred stock"
       }
      }
     },
     "localname": "ConversionOfTemporaryToPermanentEquity",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_ConvertiblePreferredStockWarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible preferred stock warrant liability.",
        "label": "Convertible Preferred Stock Warrant Liability [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWarrantLiabilityMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails",
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_DebtInstrumentFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of final payment of debt instrument.",
        "label": "Debt Instrument, Final Payment",
        "terseLabel": "Final payment"
       }
      }
     },
     "localname": "DebtInstrumentFinalPayment",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_DebtInstrumentMinimumCashOnDepositRequirement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of minimum cash on deposit requirement.",
        "label": "Debt Instrument, Minimum Cash on Deposit Requirement",
        "terseLabel": "Minimum cash on deposit requirement"
       }
      }
     },
     "localname": "DebtInstrumentMinimumCashOnDepositRequirement",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of final payment on original principal.",
        "label": "Debt Instrument, Percentage of Final Payment on Original Principal",
        "terseLabel": "Percentage of final payment on original principal"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_DeferredTaxAssetsInternalRevenueCode59EElection": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to Internal Revenue Code 59E election.",
        "label": "Deferred Tax Assets Internal Revenue Code 59 E election",
        "terseLabel": "IRC Section 59e election"
       }
      }
     },
     "localname": "DeferredTaxAssetsInternalRevenueCode59EElection",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_DeferredTaxAssetsStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Start Up Costs.",
        "label": "Deferred Tax Assets Start Up Costs",
        "terseLabel": "Start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartUpCosts",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent",
        "terseLabel": "Uncertain tax position"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to employee stock purchase plan.",
        "label": "ESSP",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of changes in fair value of liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Changes in Fair Value",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInFairValue",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of conversions of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Conversions",
        "terseLabel": "Conversion to common stock warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversions",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_HorizonTechnologyFinanceCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Horizon Technology Finance Corporation.",
        "label": "Horizon Technology Finance Corporation [Member]"
       }
      }
     },
     "localname": "HorizonTechnologyFinanceCorporationMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_IssuanceCostsOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance costs of warrants.",
        "label": "Issuance Costs of Warrants",
        "terseLabel": "Issuance costs of warrants"
       }
      }
     },
     "localname": "IssuanceCostsOfWarrants",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_JobsActAccountingElectionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to JOBS Act accounting election.",
        "label": "JOBS Act Accounting Election [Policy Text Block]",
        "terseLabel": "JOBS Act accounting election"
       }
      }
     },
     "localname": "JobsActAccountingElectionPolicyTextBlock",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvrx_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to lab equipment.",
        "label": "Lab equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_LegalFeesAndInvestmentBankFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of legal fees and an investment bank fee.",
        "label": "Legal Fees and Investment Bank Fee",
        "terseLabel": "Legal fees and an investment bank fee"
       }
      }
     },
     "localname": "LegalFeesAndInvestmentBankFee",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_LiabilityRecordedForEarlyExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability recorded for the early exercise of stock options.",
        "label": "Liability Recorded for Early Exercise of Stock Options",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "LiabilityRecordedForEarlyExerciseOfStockOptions",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to loan and security agreement.",
        "label": "Loan and Security Agreement [Member]"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_NonOfficerEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to non officer employees.",
        "label": "Non officer employees"
       }
      }
     },
     "localname": "NonOfficerEmployeesMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_OfficerEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to officer employees.",
        "label": "Officer employees"
       }
      }
     },
     "localname": "OfficerEmployeesMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_OperationalMilestoneClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to operational milestone closing.",
        "label": "Operational milestone closing"
       }
      }
     },
     "localname": "OperationalMilestoneClosingMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to other countries.",
        "label": "Other countries"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_PaymentsRelatedToReverseStockSplit": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow related to reverse stock split.",
        "label": "Payments Related to Reverse Stock Split",
        "negatedLabel": "Payments related to reverse stock split"
       }
      }
     },
     "localname": "PaymentsRelatedToReverseStockSplit",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants converted to common stock warrants at IPO.",
        "label": "Preferred stock warrants converted to common stock warrants at Initial Public Offering",
        "terseLabel": "Preferred stock warrants converted to common stock warrants at IPO"
       }
      }
     },
     "localname": "PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.",
        "label": "Preferred Stock Warrants Converted To Common Stock Warrants At Initial Public Offering Weighted Average Exercise Price",
        "terseLabel": "Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvrx_Seriesa2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series A2 Preferred Stock.",
        "label": "Series A2 Preferred Shares"
       }
      }
     },
     "localname": "Seriesa2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_Seriesb2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series B2 Preferred Stock.",
        "label": "Series B2 Preferred Shares"
       }
      }
     },
     "localname": "Seriesb2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_Seriesc2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series C2 preferred stock.",
        "label": "Series C2 Preferred Shares"
       }
      }
     },
     "localname": "Seriesc2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_Seriesd2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series D2 Preferred Stock.",
        "label": "Series D2 Preferred Shares"
       }
      }
     },
     "localname": "Seriesd2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_Seriese2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series E2 Preferred Stock.",
        "label": "Series E2 Preferred Shares"
       }
      }
     },
     "localname": "Seriese2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_Seriesf2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Series F2 Preferred Stock.",
        "label": "Series F2 Preferred Shares"
       }
      }
     },
     "localname": "Seriesf2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_SeriesgConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to SeriesG Preferred Stock.",
        "label": "Series G Preferred Shares"
       }
      }
     },
     "localname": "SeriesgConvertiblePreferredStockMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Term",
        "terseLabel": "Share based payment award, term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of automatic annual  increase in shares reserved for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Reserved For Issuance Automatic Incremental Annual Percentage",
        "terseLabel": "Annual incremental percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Permitted To be Purchased, Minimum Percentage Percentage",
        "terseLabel": "Minimum Percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvrx_StockOptionsWithEarlyExerciseOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to stock options with early exercise option.",
        "label": "Stock options with early exercise option"
       }
      }
     },
     "localname": "StockOptionsWithEarlyExerciseOptionMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_TemporaryEquityAccretionOfIssuanceCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Accretion of issuance cost.",
        "label": "Temporary Equity, Accretion of issuance cost",
        "terseLabel": "Accretion of Series G issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfIssuanceCost",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_TemporaryEquityIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued during the period.",
        "label": "Temporary Equity Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Series G preferred stock, net of costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvrx_ThresholdInterestRateOnFirstBusinessDayOfMonth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of threshold interest rate on the first business day of the month.",
        "label": "Threshold Interest Rate on First Business Day of Month",
        "terseLabel": "Interest rate on first business day of month (as a percent)"
       }
      }
     },
     "localname": "ThresholdInterestRateOnFirstBusinessDayOfMonth",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvrx_TwoThousandOneStockIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Stock incentive plan 2001.",
        "label": "2001 Plan"
       }
      }
     },
     "localname": "TwoThousandOneStockIncentiveAwardPlanMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_TwoThousandTwentyOneEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to two thousand twenty one equity plan.",
        "label": "2021",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityPlanMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_WarrantLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of warrant liability classified as current.",
        "label": "Warrant Liability, Current",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiabilityCurrent",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvrx_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants to purchase common stock.",
        "label": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvrx_WarrantsToPurchaseSeriesGPreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to warrants to purchase series G preferred shares.",
        "label": "Warrants to Purchase Series G Preferred Shares [Member]",
        "terseLabel": "Warrants to Purchase Series G Preferred Shares"
       }
      }
     },
     "localname": "WarrantsToPurchaseSeriesGPreferredSharesMember",
     "nsuri": "http://www.cvrx.com/20211231",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r60",
      "r62",
      "r117",
      "r118",
      "r260",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r124",
      "r132",
      "r137",
      "r216",
      "r377",
      "r378",
      "r379",
      "r411",
      "r412",
      "r441",
      "r444",
      "r446",
      "r447",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r259",
      "r297",
      "r343",
      "r345",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r555",
      "r557",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r259",
      "r297",
      "r343",
      "r345",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r555",
      "r557",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r259",
      "r297",
      "r334",
      "r343",
      "r345",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r555",
      "r557",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r259",
      "r297",
      "r334",
      "r343",
      "r345",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r521",
      "r555",
      "r557",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r117",
      "r118",
      "r260",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r133",
      "r137",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r190",
      "r191",
      "r329",
      "r330",
      "r556",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r329",
      "r330",
      "r556",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r133",
      "r137",
      "r242",
      "r344",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r195",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r489"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r27",
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r46"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r21",
      "r531",
      "r544"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r234"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r66",
      "r67",
      "r68",
      "r546",
      "r565",
      "r569"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r65",
      "r68",
      "r74",
      "r75",
      "r76",
      "r121",
      "r122",
      "r123",
      "r430",
      "r560",
      "r561",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated and other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r377",
      "r378",
      "r379",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r125",
      "r126",
      "r127",
      "r128",
      "r137",
      "r205",
      "r206",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r244",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r409",
      "r410",
      "r411",
      "r412",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r485",
      "r525",
      "r526",
      "r527",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r347",
      "r349",
      "r383",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Employee stock compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r311",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Accretion of Series G issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r311",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "negatedLabel": "Reverse stock split"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r349",
      "r369",
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r97",
      "r279",
      "r287",
      "r288",
      "r478"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred financing costs and loan discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Excluded potential common shares from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Capital equipment in process"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r173",
      "r178",
      "r185",
      "r212",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r425",
      "r431",
      "r459",
      "r487",
      "r489",
      "r529",
      "r543"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r59",
      "r113",
      "r212",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r425",
      "r431",
      "r459",
      "r487",
      "r489"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r350",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selected Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r39",
      "r99"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r99",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r468"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r110",
      "r113",
      "r140",
      "r141",
      "r142",
      "r145",
      "r147",
      "r155",
      "r156",
      "r157",
      "r212",
      "r245",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r294",
      "r295",
      "r300",
      "r304",
      "r459",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r318",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Warrants Outstanding, Weighted average exercise price",
        "periodStartLabel": "Warrants Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Warrant exercise price",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Common Stock Warrants, Outstanding",
        "periodStartLabel": "Common Stock Warrants, Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r241",
      "r534",
      "r550"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r243",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26",
      "r489"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value, 200,000,000 and 625,217,795 authorized as of December 31, 2021 and December 31, 2020, respectively; 20,399,337 and 360,412 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r332",
      "r333",
      "r346",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee benefit plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r70",
      "r72",
      "r73",
      "r80",
      "r537",
      "r552"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contingent liabilities accrual amount"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Number of common shares converted from warrants"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r294",
      "r295",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible preferred stock",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r82",
      "r113",
      "r212",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r459"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes, federal and state"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r406"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes, foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r406",
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes, total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r273",
      "r280",
      "r281",
      "r283",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r112",
      "r119",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r285",
      "r286",
      "r287",
      "r288",
      "r479",
      "r530",
      "r532",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48",
      "r112",
      "r119",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r285",
      "r286",
      "r287",
      "r288",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r48",
      "r112",
      "r119",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r312",
      "r313",
      "r314",
      "r315",
      "r476",
      "r477",
      "r479",
      "r480",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term (in months)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs and discounts"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "verboseLabel": "Preferred stock warrants"
       }
      }
     },
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r402",
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences",
        "terseLabel": "Accrued vacation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Non-qualified stock options"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r97",
      "r232"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic and diluted",
        "verboseLabel": "Net loss per share attributable to common stockholders - basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "(Loss) Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of currency exchange on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r115",
      "r389",
      "r417"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r389",
      "r417"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r389",
      "r417"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Deferred rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r389",
      "r417"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r389",
      "r417"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development (\"R&amp;D\") tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r74",
      "r75",
      "r76",
      "r121",
      "r122",
      "r123",
      "r126",
      "r134",
      "r136",
      "r154",
      "r216",
      "r311",
      "r316",
      "r377",
      "r378",
      "r379",
      "r411",
      "r412",
      "r446",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r560",
      "r561",
      "r562",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r97",
      "r292"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Changes in fair value of convertible preferred stock warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r271",
      "r285",
      "r286",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r450",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r449",
      "r450",
      "r452",
      "r453",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r271",
      "r335",
      "r336",
      "r341",
      "r342",
      "r450",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r271",
      "r285",
      "r286",
      "r335",
      "r336",
      "r341",
      "r342",
      "r450",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r271",
      "r285",
      "r286",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r450",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Transfer from level 1 to 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Transfer from level 2 to level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r454",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r454",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value of the Company's Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Transfer into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Transfer out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "End of the period",
        "periodStartLabel": "Beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r271",
      "r285",
      "r286",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r282",
      "r309",
      "r437",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails",
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r97",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment",
        "terseLabel": "Prepayment and other fees,"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r81",
      "r113",
      "r173",
      "r177",
      "r181",
      "r184",
      "r187",
      "r212",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r459"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r78",
      "r173",
      "r177",
      "r181",
      "r184",
      "r187",
      "r528",
      "r535",
      "r539",
      "r553"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r390",
      "r397",
      "r401",
      "r413",
      "r418",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r135",
      "r136",
      "r172",
      "r388",
      "r414",
      "r419",
      "r554"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r77",
      "r171",
      "r475",
      "r478",
      "r538"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r93",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r46"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r57",
      "r489"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r58",
      "r107",
      "r153",
      "r228",
      "r229",
      "r230",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw material"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r113",
      "r179",
      "r212",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r426",
      "r431",
      "r432",
      "r459",
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r113",
      "r212",
      "r459",
      "r489",
      "r533",
      "r548"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock, and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r113",
      "r212",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r426",
      "r431",
      "r432",
      "r459",
      "r487",
      "r488",
      "r489"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r44",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r44",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Debt Instrument, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "LIBOR [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r270",
      "r284",
      "r285",
      "r286",
      "r532",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r95",
      "r98"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r69",
      "r71",
      "r76",
      "r79",
      "r98",
      "r113",
      "r125",
      "r130",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r143",
      "r173",
      "r177",
      "r181",
      "r184",
      "r187",
      "r212",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r448",
      "r459",
      "r536",
      "r551"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r138",
      "r139",
      "r144",
      "r147",
      "r173",
      "r177",
      "r181",
      "r184",
      "r187"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r132",
      "r137",
      "r151",
      "r205",
      "r206",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r244",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r409",
      "r410",
      "r411",
      "r412",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r485",
      "r525",
      "r526",
      "r527",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office furniture and equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r173",
      "r177",
      "r181",
      "r184",
      "r187"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Organization [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureBusinessOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r46"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r423",
      "r424",
      "r429"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other expense, net"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Underwriters option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Total debt extinguishment cost"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payment of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r350",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockAccretionOfRedemptionDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accretion of the preferred stock redemption discount during the period.",
        "label": "Preferred Stock, Accretion of Redemption Discount",
        "negatedTerseLabel": "Accretion of preferred stock to redemption value"
       }
      }
     },
     "localname": "PreferredStockAccretionOfRedemptionDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Proceeds from issuance of Series G Preferred Stock, net of fees"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r86",
      "r372"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r69",
      "r71",
      "r76",
      "r91",
      "r113",
      "r125",
      "r135",
      "r136",
      "r173",
      "r177",
      "r181",
      "r184",
      "r187",
      "r212",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r423",
      "r427",
      "r428",
      "r433",
      "r434",
      "r448",
      "r459",
      "r539"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r41",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r40",
      "r233"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r235",
      "r489",
      "r540",
      "r549"
     ],
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable convertible preferred stock (as converted to common stock)"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment on debt financing"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r386",
      "r523",
      "r583"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research &amp; development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r316",
      "r380",
      "r489",
      "r547",
      "r564",
      "r569"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r121",
      "r122",
      "r123",
      "r126",
      "r134",
      "r136",
      "r216",
      "r377",
      "r378",
      "r379",
      "r411",
      "r412",
      "r446",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r169",
      "r170",
      "r176",
      "r182",
      "r183",
      "r189",
      "r190",
      "r193",
      "r328",
      "r329",
      "r524"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Taxes at the Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r349",
      "r368",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r349",
      "r368",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Recognized Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r15",
      "r34",
      "r35",
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r41",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r180",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r180",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r350",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r354",
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r318",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrants to Purchase Shares"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r396",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Changes to Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment, Geographic Information and Revenue Disaggregation [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r167",
      "r168",
      "r173",
      "r175",
      "r181",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, geographic information and revenue disaggregation"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationScheduleOfSegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, general &amp; administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable as of December 31, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable as of December 31, 2021 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled / Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r356",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance as of End of period (in shares)",
        "periodStartLabel": "Outstanding as of Beginning of period (in shares)",
        "verboseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance as of End of period (in dollars per share)",
        "periodStartLabel": "Outstanding as of Beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r348",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled / Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r365",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable as of December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances, Ending (in shares)",
        "periodStartLabel": "Balances, Beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r110",
      "r113",
      "r140",
      "r141",
      "r142",
      "r145",
      "r147",
      "r155",
      "r156",
      "r157",
      "r212",
      "r245",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r294",
      "r295",
      "r300",
      "r304",
      "r311",
      "r459",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r53",
      "r74",
      "r75",
      "r76",
      "r121",
      "r122",
      "r123",
      "r126",
      "r134",
      "r136",
      "r154",
      "r216",
      "r311",
      "r316",
      "r377",
      "r378",
      "r379",
      "r411",
      "r412",
      "r446",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r560",
      "r561",
      "r562",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Shareholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r154",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r274",
      "r311",
      "r312",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock (in shares)",
        "verboseLabel": "Conversion of Series G preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r25",
      "r26",
      "r311",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued/purchased under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r311",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r26",
      "r311",
      "r316",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r53",
      "r311",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series G preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r311",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r311",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r25",
      "r26",
      "r311",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r25",
      "r26",
      "r311",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r31",
      "r32",
      "r113",
      "r203",
      "r212",
      "r459",
      "r489"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances, Ending",
        "periodStartLabel": "Balances, Beginning",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r295",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r316",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Selected balance sheet information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r16",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r245",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255"
     ],
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balances, Ending",
        "periodStartLabel": "Balances, Beginning",
        "terseLabel": "Convertible preferred stock, $0.01 par value, 10,000,000 and 237,370,645 authorized as of December 31, 2021 and December 31, 2020, respectively; 0 and 223,541,754 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively",
        "verboseLabel": "Redeemable convertible preferred stock, Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Aggregate Liquidation Preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "verboseLabel": "Temporary equity share price (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "verboseLabel": "Preferred stock authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued",
        "verboseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balances, Ending (in shares)",
        "periodStartLabel": "Balances, Beginning (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityScheduleOfConvertiblePreferredStockDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series G preferred stock, net of costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r16",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r282",
      "r309",
      "r437",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsFairValueOfConvertiblePreferredStockWarrantsDetails",
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r125",
      "r126",
      "r127",
      "r128",
      "r137",
      "r205",
      "r206",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r244",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r409",
      "r410",
      "r411",
      "r412",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r485",
      "r525",
      "r526",
      "r527",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r387",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Gross unrecognized tax benefits at end of year",
        "periodStartLabel": "Gross unrecognized tax benefits at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Gross decreases: Prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases: Current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases: Prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants to purchase redeemable convertible preferred stock (as converted to common stock)"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant outstanding term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares used to compute net loss per share, basic and diluted",
        "verboseLabel": "Weighted average common shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossEarningsPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r586": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r587": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r588": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r589": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r591": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r592": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r593": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r594": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r597": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r598": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r599": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r600": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001558370-22-001539-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-001539-xbrl.zip
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MDLZC@Q:IC]Z'QZ*9?&1C&)ZSI^4J8[3%!.DY8'C6.3Q\^,M_ 5!+ P04
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M_,<]RA?#%JW>NS 86T"K_[=A^SB'+ZFTNO)8Q%::X>I0M64>G&3J PAPCC
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M^#-N1 S+(<%@>T/0$_%)*,0V_=D;A5G+27"/W4AL9<%,[%2DV:)I<UXP=-N
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MJ,A_44;^I,$C=N<!]>ELE6@"?$'9DK+8\:A7CC4Z0U"+ML*6J;H:^$%83./
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M UJ-3LJ_'"?$2X]V__A_4$L#!!0    ( )IA5E2V76";O&D  /'Z!@ 4
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MZ9T74G5 'J#]RAZ='&IMC3A0-80>=[ZF,72B.$@TI;91%:=(QM%:BOZ$ G]
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MF^_>D9V7DB>HMK1BX\SJN^_X__A0]/[#WU8?_O;=ZJ]__@OQ]OECDH;_$/M
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M"@9!"P$'>]5L^+Q.^6.9 5]!OZ'I':PTZ^UT=_1&#@@#S=!Q>DO5%3$\#-7
MWDDMQHHD*1',Q X28>P(YX?BB,YDQN@\F%/M,9$W84R")(J\-",L1Q/[/M,L
M8PT_V3*#IQ10R=5F=@I]79.XPU!N@NRDVO_3LV5+KV5AIDKM#JP\[+(<C%1*
M;@\;!0M2\T"!A]85[\3!8I?;F]8&PX'/NA5NFIIW:.P:U\3YCB%FJGHL$<^:
MZO9BF6B^-!P[D-HZAKD\$S2EPCK8%4ZGNREN6=+^$+/:-76-5]?UL:@A-FIV
M6R)RM2C>"U]2GZ5A6)OHUH%,8H+F]I!]]0\W'/B,2\#9-#-/LXM#4RI>;45,
MKKO9 &93:YU1+)G8\4V',IMV.!S/.G1V<[I^X.*L7D_D0]L ]17'\A>X(#M$
M>CN']Q$NQ,YH!,-55S<HH+F\V-UC.5&OLZS8T7P943[!JIH<W4B6$F=06'?=
MT&7H=JZ@J5LO+635*V>*IDL*56L+2,=ABN8*W12:ZJR-N8S-_M6BGBY+B]*>
M5:*N]DN*5[OSY;:@G7II:'CD3J"S]J+ K"?#V;P RF==K\6Q>%ZAZ^BP?&]]
MB:%4D$>ZH5F:!\X'D4",!Z::C%A2RY(H#/ALNF+.+V5?L_DD?^2AZ\'!6>]B
M/M%X3S\RYX&Z=B#.+V'^>+9GL;ZE:546&A[#9?\7J*]KF5%"'D8CS-.\OCF8
M#.)P&J.-^05/SI/ ST-*KN0+8TM*OG(1\Y*UNPM<#HWD:HG>A<KB-'8J.+LM
M<YNQX:4P@3)':[9!#GZM*C6G!U(#Q(#5+J?YZ)[QNZ%31IM&NC^%2ILD"3+"
M<A>7L_(?TR3+;M)DK:P#T6R!/(I:U)%C2/H:<02U26GJ;)P6$<3<W!&RK\VN
M59LY7Q,1\XIX<U$\'=@SX>UJCSR@>E5M/"6B:HPXV/IE-G76BC(I23NOF3B'
MLN5SFB[+)-[2C#(G?SR)@W,V:D?)#M8$"J65"75W'^2!JJ5R<YK<T0%QP.K)
M;3ZK$]2+\GT5_3*&7<UO9],YJ.F[7&BF$2.Z^9'&#%8BIO9)L WC$, *2B=V
M1[)V9^0A/<P(C=5DK9Z(@WR@ L9E3@2;%2D8\0AHLG(;^'/;82/9P6NPPI1N
MZV8W^$-<J5IG6HTX<-6RVDNCW<QC[6LFEE.3H\P90ZC55<_ZS-%HN91P.U:O
M->#J9DL(N19IQP==HU2?X\BSJ" 0$?M;2;5)[##N+F.6"M"L9XIZW IYO"G4
MDF/MH GB.%-):NJ");UI,LSOA4(QW<#!B*[PFDPOVJ[7W,\^?T[BI(D@W5'6
MVPEYT.DI??0$M+('XI#4%-QX%.2U667ZU7!8L'!T3W$6O8OP79&8NEP*J@?]
M\JQ#&.^9RO7AKE.Z3M+B6-F]]TRSBV<V:4W2((R]].4RIUO^8C:<DDCX/+=$
M*"4@3LD1.7K,8.[F\#\9.\2X-8?6YL.WE/#71\"$@/*1R@<N8HF(7,@5:0I%
M2JG<3!PPFYE/0 H3AL*$.0C@'&F9&8IQY)3&5'TN1-UZ$0BG5/,8G8Z:HD<6
MM<0C48$1+J<KY$U!VW(.-&3B,HVN-VGR%&8,'@B+SL[@G!/&[.LIUA]W\VJK
M<;1U8A]FNB&8FGZF>>\:ZV$;Y,#:JI(,IXT&B$&T74Y3MX/739I)U8P/*?1.
M)>WKVO9ZR3Q .8\N<Z]?M5R>^LBRQG 3G^U3YCC^RWWJQ9GG0T9[$@?\7Q'/
M;T^"_[O/<CC+4;Y=<Y.D_(N6E[&[UAIFE $YR#GY28X6Z^82 #%(N['#N"6U
MSE>P"L%)*3F11.<',B3A22V]_'S6BA0ZH!IBEO5+G8FGN> 'RB6#>Y40;FLH
M'!JQYUV_[A[(L59#W8,""JKFB'%,1^H1I01T7MU;S0H7?5G<? 9QG-V53Y26
M)=9.O2STX8AO&.US9=6B_E[(HUI3;3FR>[H@CFY=R4T=NGJ"MZH@N"*<AYNA
M?FIURSE972EP11Z ASB[+KBX6K>:7WGB'>"V+]6.*9[ (F^%A1P"W2\LS7MD
M%CAA1O0V]/-^^T#3ZS4WDE0Y1P__C(DAA\5Q1I+1THP28A =J9!IO)5L2<&7
M",:0-!W7*'<*NXX-]-8K#%3"C[#.'FJ""%#:,7YPC@0O>+OVL7832F6_$."X
M5-KI^*U'_:)?G7V1H_0@$R@*?*D[(L;@8?)/4,R+1^+AD]0HRGI5<IY%7I85
M]CEY#E7;>EWME^+^*E5;7?ZP\1+<7"FSL6L#0>[(_,6#7X&H2Z^5%3Q/MEX8
MJ]9CVAHB]U.U<HT%PZ-6B#VS0UA;+BG(.G7*^GV4ZHD0+MPG"OF8<L6PKQ=V
M=]53N[G8W=D%LR-K2CXBAU"]L>.J?!@:A5UD12)5@Y7W)(9D3B<S4O1!'L9:
M*K=F2&T=$(>PGMS&:]HBMZ^IND^6#O3LS)=4;9$[;Z>*C<V8MH:(G;5;7EM.
MBB-[JLK2]^1+Q^V0>Z=2-<4+"@O(@E2RVG@WP*$3G@1!""=FO.C&"X/+^,S;
MA;D7=3ID7Q_DSJFELNRHG1T0.ZV>W*8.7%,G.T;^;1@37S!P6DHP9ZA.@W)S
MM]./E8V1.W"WDLVJ@6TM$;MLC\#&ONK[XIP@A9)YZ]!W6I!6DD9UV+(;?P?T
M1^[*@TW1P&7=SH@=?K@.-F( =G 3?L;9QW3$CNF;4B;L.17_O8P/GC:^3:+H
M8Y)^\5+5>9.!))"'AXE!#F[$:O=''"1&:HRX=\B9D#<ENZ\)RVTJCM5F)C E
M!5>C>62^?>"1\.Y]$0?^4_I<K#_"%<_K=<7T/KFAZ=:+JT6< TL-ZXG4ZPW4
M!V<?T,VQCP<)@V F#+^C8/X+6EJ"YK>(X4AYY=EPE+QD5;CY-Y,LPK<%.U(#
MS'U=WIT9[F@:THS\:&-78@"T"5W$$3USF.NCLCC(TS)+-_QUDE@D%.II9!L5
M!/GZ0=,6E" 8<!*M=?!@Z)PF4N$I>1.6)T:/BK',.-DZM F()IZT/M^G8;QA
MQ@F3X&<OVM//] O_1K41;$@**2;;,) \"3.A@W@R-DH=X^(WQW##0TDP)H(S
M$:Q7A#.'*Y-?1(.)"ESTG21Q8BD@XS'?[D(@7B02&OA)EALM^+3G=P<*'^LJ
M@%<%)Z8TD.+(*)-4F=U0 MCS.F-]C*'CD9*XN@J449_QRB$L?#A/&:Y#6 _-
M2%XA#!497?[HY>31>Z+D@=*8A )I H$T.2.ZX^+.G/C-;[[#=:]VR"VS/U>8
MZ\8XP\%V;/*G!;PGOI_2G&>^I83PC*F&R=0]%P2R/>JKH%71;6& VJ>%O0RL
MX@3.'9:1 %[N%A,Q6, ]^$UEA8;.%>8UE,>UA7A\_\UD%[&/"E)X'&F6[KW$
M3A*(9["FFEC>4929_LG>KJ*M"P$\1Y'N4BN,V=8.>3 H56L<]C]LA-BAU;*:
MNFR9SDLT)QG2Q!SJ(NZL'&U?O5,O@M&**7@A;NMW9.46];S+O31WI>DIW81Q
MW*/LK#>.U,MA_+OK'2_Z?_%,4S_,E!5F3.A@!RA3TS1O*PTD@AG@C'4Q!L#^
MY671I.!,*M:.GIZ=W4(E);ZJQDV1[%P_S*>P@H!5"Z#236B9J*)A' U8Z:"R
M/%S146949O46_@[X=30:9T6-X#1E%/D]3?+P0N1V-]X+__@$)@6K$G)6%>9D
M,)T0HKMZW<.!)2M*DV=OIN@[A_9'\(LIO;NE.V;K1W#BHU&IRY0]_98 M#JJ
M'^%J5R?L,*HE^[AT3&+1FI,Y!;])]:^)BYTD%'='N]06T&=@KZKC@H.\J;QN
ME(M>"PWS ^$GBW/!!V.@6[* .M*1#.SU^P[9?:*X8LQMP7-7.<6]A9,569C3
M.YH^A3X5=KNE?K*).96NO& &ML@19R[#-Z^^3\L3,=K-IKKQ3NS-Y=FJ?9Y8
M3R57I-I]@@<#80N82)*XF2ZA-^W%=A<E+Y06P.M+$KC.MPR/:+^2,]G&A["7
M?NIZGL/#"SA4/?\I:CD'JP[S)>LUY>9Q?>"E<^G)$!46<\3:S C:R]D+!@;;
M)UV[D,'UV=^Y32&*_8L#X:X>0)A)UX$XN*0I*JAQMXM"U1,(@XD@QT@SHPR>
M#%84$&.FH2+FE=(J=G [5BJ<!AQA[Z[@69XIX&Q=K7'-;)Q;"E=FRYE6UJ:Y
M^VR*9Y?RA6*IB/-==:/((&/5H8D<5ZR83'>JUDL0,>K8T6O"J5WS^KI<I[R6
M U5F-Y/IIBN3,L<<T#)LZ1-=)FX--)KV7/(5(M=0Q::<>RX.N^8R7M,POOKQ
MB<E/48V=U6(!^J5-<H4]Y4N *L@?21(YX-LPF-%TN(4>8K"WHM9L4V4AQ(I4
M"U5G;>OQZ.;.D]@.]\U<57GCJR3+/B8I#3?QV9ZA;.R_W*=>G'D^Z'(2!_Q?
M$=]\K>W[F>;7ZWOO6?%#3,8,.<9-:V09_:;AA!@7)U;8-.JY6*0A%Q&"D3<@
MVM<K4DA'2O&()!\O!2Y)2&H184.'K_$S,=VDSDA-?B;JJ(.E<\ER7L4)PSMN
M+$?VLL>/4?(ETW_KN:T+<L3345CQLO-1>\3HHR7VB'F/ZAUG8$8X-QRO-[,@
M!I%NTN0I#&AP^O)3QO*H^'I'4Q:%\>:$0< 3GPWV>+T1(>2Q8&X<.4*&4T$<
M-R.4,8TF&#5YV)1,X3K?&^#+YB]?DXHUJ7EWQ-8\(ZT#,W$3K3FR@!>3I+*+
M5S'[P2'2,%NLPQQ2#87-&@V0(\.Q,G+$U]\BCN06(<=$Z$&.S/X9[7DID)LD
M%8EPGJ?APS[W8*TT3\AG9N4DSIF<$32[C%E0T;DK?4UD#,?O_C263> P=^R'
M$66"U>G^?6)GV)^(%?+PG]+ RB512WP00]*DZEI:0JW$(D>H!U\O+5%9@LG3
MRN1Q@:WP*?SM@[7WPL#H$AZ^RW9Z>.-&-1]5-4:.A-U*'A6 .VJ)&(UZ!+91
ML*3U@ADD1N#7%\_ U/(E?.U=]HF4A\V:0GDDM\#.Z8X!3-@5G =-D(=DFT)R
M(,K?(PZ_5C%-_4XFYB:@)E,'5A5W*0Q^^0O??8 KG3O'R^8G6YCU_<,3!9,_
MAK''!O!XPS=F3^+@/,S\9!^K#T[H=T<>C$,-T<C^-?LB#N+!*ABGC!(CB(AS
M^I ?'&+@P5%Q=)1NN[)'4!ZY6I<\BQM&8)0H\6(2%+P=HL:/7AAG,.6@V75\
M\0RY_#[,'L4V#?RB"JOJ]$..$]JJRP#1VPDQ,NC+;AH"P*&<F;,@:/(H,<+5
MR:;IU0?BH'< 2$@;'-Q@W_0JWZ1T5\RHZA?9UY1F*X>@]M$+4WZQHE[5N%[_
MXL&,3YG_]/5!#F9:*LM UMD!,8CIR6WJSD!=W"623A$!<)4<W,3QM$J?/<)*
M"*_ N@;]G[C^/4?MOR@,XO2AE'J%E$%>WK>1,J0_\O ?;(KN9U$4G1'#PG =
M+#^%(FTU<'[.MQGFLXB$']*&@+ "G^N$WD,8.=\<.#;(B2^F?K?4I^$3[))K
MV[*UZ^) 0FV ;GPX[K<H:.@0WS(JE)Q(S<K5]&<6,U3ZIDI]G4;\)4MH8L9.
M?6>XK\_B8KQ%Y>[@ECHL*JK;Y+8<SA(+/&%L5V]!ZP55U/)%AC X+V8@Q2[M
M21SPVQ4BF]$VER:QQ<7Y$"-U X .I44APR"%+$-&P;L\6L 38G'A2?#%@R.S
M6*DT!Q74,VG5T.?WH/)BYH *@,JTYL9[,9HEU/T6!RL*U?7F!T6G18&%2O:I
M9@8%'RR+!+;5K_3<M>OI.J[3/</)>H%BB)V.NRXQNA4&Z WP@WY+BW&5^/;#
M'#@1B16B2+=MA%+;<G1?Q"U+A<$&$4 >^,.-87:;$C$(&"@QX^W):3 AR;VH
M"Q-FMDGOU0%\< 'K(9F-2]G=A)8)'QK&T8"1#BK+@Q,=92:"E8HUIKM.#LQT
M>"D[K.R"XXY2<0$%JFOY?]^'*;TI3I+?,(7SDSBX* ^3*VPZB !R9!ENC,:E
M;^W>B)'$0 GCQ;>"%:]+)YB1DMN*<'XKOB!WH;K/,-?JY)Q&D=XJ1'>I0Q\_
M1P,P?K 8;@RS] ,Q6!@H,6.Z@6H6,Y5-&K.8MN0"'UQ4EU[&SF*Z"2T3/C2,
MHP$C'526!R<ZRDP$*Q7K!<QBIC33X2RFOD.&9!:3)CZE0?:1"<=OF%_OX-Y;
M=O%,4S]DYE$E=AK]D..(MNH']:FZ.R%&"7W9S4\%" ["UT59[(()J;@X*U,U
MJ_+Y(R6TH'WT?'HB>".)>WXN!"9B^8N&\9JM%Q3C+6JJ(EMJNI!X;I/8CB.+
M0TZ"M/O0G4[/4'I?LBI9?U/=EKIKO#4)-R--HC??/O"(?/>^B$?_*7VN5DEN
M:00+*E!-BK]$IWP84K\7TO@<J#;$J687Q_$:)/X>)&RKB3-4 U._OF=##Y_=
M)OL<4D^2"EZB(-C1&X??3!+5;< UEP&J]=';6O'R<4>'SUK.KG[W[XXD^R@K
MC<!+2I B<4-HC 2J?D@1;[#JJMRDM=-"LI1NV>V,X_([T8*+B'GWN<L<VL.T
M0\YD-%[*=H@#MV71B>QZ?97$FWN:;CN*U70T1Q[U?8K*P:YJBSC&>T4V=>Z:
M,/@MD'[+0F[KM/[,],I6M6>JU<)%[$6,7G7%'\?#C6&VYX XU@V4F'&/ =76
MY50VX9.[G623MET%AY!QP?(+/[]>7SS[O*3$+8/4ZQ@L!/^#U9LG+Q*3H"Q/
M0Y\!+GQQ$@?-#Z26"L-/PPDY"$UH7AFM)F"#&-:FU-8TUH5,D/F44A$0"](#
M8+42X"AQ7)%:&/$E'( Z_$SJX&92A-O6?ODV(2V-SNSME\;D?U"U!6>$V5$&
M$\]9']\F*MZ>D7\:81K%;SF[$,C!V<V/(N/VO!(@AG1'AAAS5,0"I*^($)VT
MW&24'Y=J#BE"!S?9\\)^)YZ!"].%KW!@F.)'>N6P;1V%7RNH8L'(27!NQY'H
M(NY</'1OOE:P(EY.*%1P61.AQH06NLN]-%^HC1[H)HQC&#Z9I5ZHE[I\)&N_
MVT7\X2,O J'A:>3+>)VD6_':>,]3V]J]D2/W0#,TWM72ZXH8C8=J8!H4,I_Z
M(6XBL7)^N-N)*20&;DOBBA=@;[PP8.FIPD+'K9"'MD*M9DF;1A/$H:J2U+Q0
MC:!'@. *IG/%Q.[,VX7,-\-_T*!Z&G@U8[6*_@HV=@W!X8@7HV.QR*9D[8\A
MSUN?*MG2>^^99J"CT@R'K=!'8ZM:!P6FY":HH[%=TA%EH^ U6TZ01Z2SZE!6
MU3J,+:YD#N0=QM=UNO'BXH&NLR3.DB@,Q!@?!S?,K.7QV^J5,"]B<XZ<C]E]
M%R9MT48>RU9-*". %<*(<<.N?J9A>;K/PIAF&9'%Z<C EQ*<\(A?E&3[E-[3
MY_PT4I\$GH#-:P[9#L-:B]X6'J\UD+M4-8UI6: 5:8C$EZ-DH6#UJ1*+U'*1
M6C#R*XA&N&R.9N3H3%S!9B))YO*I7U%3ETW*;IAM_/YR#IT=D.-7O[*-!WR5
MK1%CBH;0YJM.VZV7OO#+B>$F#M>A[\4YJ3F2DB6.-$ 2\M@J?8.[=F?D+C_,
M"(V5::V>B$-AH +&8=$7"\X'P;D,4>-#)MG$JVVR*W@Z!(53+X)[27>/E.;%
M_<=ZF.\;^[0[(P>%84:004&O)V)0&*B <2S0B/)M_X(?X0PU-ZL<;>#*II%L
MTCM2#B.!/#1,#*+:S^WKCSA,C-2PLIW9#!B)'X:!=%:KE!#R4%@DXQ8):PC!
M\"RZ_N#9TP4Y+N@HW/HF^K*&1RVQ33U:>A']$_6 ME@Q0C$2MFG>-_3U]5F@
M3W<.;IT=%N;5]H!:<FM<P]4,:C]QM;=2-#L,8;@!7ZO:,QPI&R,/VFXEY6AM
M;XDX3'L$-G54((MCC&DJV#>ZJ%LORD4[1Q1%T\4XJ3TXY5Z*:N]L2DU=5@;@
ME1M[1H>C1LA#KEVIQE7Z1@O$ :80U'@:#66G'I,H8.[^IZ*&*([10)9,R/4Y
MR:G^^#"D/W+W'6R*QI*;;F?$3C]<!ZOQ ,QP#3ZN#$);BPS/F2-6*O(:??#X
M*5_L*S8KSJ!<WMVCEU*0/BCK;/9-=L8218X?=HS62$Q'442,-)84&Q5M;T^!
M-I'9XQB2M8US*ANG=R(WFNIK";]NLQG%7SO)UQ" /9H91R#0?LNCFQ34R4F:
M0C$)_K?[L=^YA108A>$^E_;Z9G</Y("BH6[KG:]%+7?J2&WE+AB*H;5%V[YQ
MLZ?+\GRX<\3K:K\L+[:'Q+4;XYJ=SJ&TZRN.%UX*54:@NA4?;/M63-7-D0=J
MGZ*-551%6\0!VBNR<;G*@C 4>R.<-(Z1YE#AOF&FJ_W"7+=S@%$V7I#SVD/9
M-N]U/JY,I^Z;JR3+OB;'6KNL$9ALMV$NUI=B-JWCEP1H##<$M*<Y0VD@#V@C
MDS1J_@TA@#CPS?0PKC%1<^,771O\<(QJ6@;I&^H&$WD-X=(Y* ZCL/2 L3>>
M=$<,JLF:8\OX,D.GA\_684R#4QJS/_(;IAV8@S]F>I,P?*-Y*(YPRBWTC_=;
M)(\<=&P;LGD>S@YMQ$!E747C&<!V%R4OE)*"$>&<T(SVU;8#LTXIJFP2C;%^
M" GD06=BD(-Q7KL_XN Q4F/$2%;OS\-0IHH8#$/\?&:IK/!06&$']%T>)*0;
MP,M;NDM22#7ZRBZKFR,'@3Y%&Z<"%6T1!W>OR.9723GA%?F1)IO4VSV&?N,J
MNBA5_T1C<87)VVQ2>(,2S;&<0\,,.".KU7-A;J][+K:_VX*"89*CGX('J9C@
MFKC.:((5V=30$!Y 0UI 0]" !A,\R+<//,;?O2\BG+]'?^IE87:]ENNQB8EZ
M7:Z-5ZMY$?]?%?-C:2%% 2LF EP81<@Q4@2)O]^6 MO\W<??9JH1(UD?%3MZ
M@;=,<B_D[W7D"7D ,?D3)W(I10BRZAM?EOF;29"G#7?=6O&TU+Y18O)$+"Q*
M52@%7_)K\5]G$.W66E6)2ETWLH?5_YX\9">^5$?L JJ45)IV8O. OIBQ>*@)
M*NS5[8@=:P?K,0^V_OOUZ1V\+"$WI(5D,^/H;!:J=)8J#Y:\D*#D_+9H^?T=
M3EY_RNCU^B++0Y914]73AD>-D )@MU+R[+/9 O%$4R&HJ1<R<ORU[)+@"DW.
M,JW"M"3H^-%1R, .GF?MS$R&]D4>F(-,</A8:&]'Q&$\3/Y1C]'P\P['3QXC
M"_.9#8+H[>'[U MHN:=<Y!W9+?4ID^TAHL($"JOI]D4. X-,(,. 5D?$,#!,
M?E.O+PF3FC*>P'=F J>WRYX8Z"1ISQ*Q1G/D@=VG:/-&67M;Q.';*[+YI:J"
M,+Z!>GJ='09FL:W\D3DQG+R$G>1?POSQ;)_ER19.?.F$ZV BR(/8S"AR: ^C
M@#C@#14Q#8GRE /\'J1D2+XPCJ1DB0<8'-DFI7ZRB4/'RV9U@0?Y<-?UKMAE
MN61!%N?A$^6'NSI3>C-*R"%DA'D:9T2&DT$,)F.TF:R<"A8T<6(<?)54/M,O
MTB-(:1*S/WU1NEKGD,D(,L@1Q=0P,IP,I8$82XQ5,8T5QK#Q?EB#);Y9R^SV
M@76&@^?$&EQ=YBK^(PWV$;U>5U.NLWV:LK_N85VD]Y"J?G?D&#+4$(U41+,O
M8LP8K(+QN%HP@HTW:66C8$9^Y>S<8X1;>S@$!(:'<#;E!7*I'"ZD_'T?[@"E
M^J! JR-R$-!77@[__EZ( W^ \*8N7K)8\4M7N;B/5;)!$_$S&$*.]9)=TQHK
M\IFZ?&&@ACV6(:5[&ER%WD,8A3D\MSHL(= @@!P-AANC/2GHZXT8'0R4L!$<
M!3,B<4.#$XY-<O$,2Q%.SRI5CW-)FA>OX@77,9OLL$2)37+X&?,^O#"EA1PZ
M1IFH]=VZ(800 \HX?4P#J7[G;M7 E)(S26)2\2;B1@<6O'%CL58K>3F17@R$
M:QN'5EL(*OT4)P\93?G1C\MXM\_9URRH62^^QFL3M :P>D68-M3 II"GR^>5
M(.)@=6<$S!61I2-</-*4;Y&8ZL#FD._ECY3O.WGQRY\RV.]_8K/%$*QWPU"3
MIO C\#TJ\HL'>W9NCZW2[2Y)O?1%O'>D-5/LZX,<#;54;AQ/[>J &)_TY#9U
M^HIZ];X=$HB85FUY9M<1VRA6@MK?,RM1YSJ]#3>/_2\)C:&'' I&FZI]V6@@
M,<00,EXG&W&F?#YP50VA)$F)$ $-#CFTW7Z[!6!FIJOLDR?DAJGXR!J(&MPX
M]J[;#PAQ@XE30G"--WS234VL$%X.:(TTG@*]#*DN \;&*C?1D;T5$>Q7I.2/
M$<><&>]P,"BL51D+&985/_#)%R\-9// '%&4;,FR_59\9HQKHY@L$./&&[4/
M[\PY+ S[+"AJ)93;,!%D6C6B/%N12C B288:(9&86#;73V!GE@>>4Z;1-HPI
M7ZKZ$?+#M^=>3DES':OQ$Z  V+(([AU-GT*?M@]')Q$7!HZ9KV_%K9)_L)^#
MIF$B7O'4QUK[_!8#NQ.9NAV!+3-;!!A/I?-D^6EQ?"$H*E'LPMR+0!J6L6[A
M<#1"-,9FXYH\43Y)7I@9!=Z"8$D,Y]SA,&WQ^F0A8%'F?&#V:D)Q,9AI;*YV
M5!Q,;A&X9ZZ5G17[DKLXM5V]]%I(0-X4,GR-$,[F-UW37#=I\A1F %+K)"7R
M:\\HT.IBO8:Z>T^TLLTM2VH/]GR'P941R<7@E;G!%&G<8'J+0*P1:MF K(J]
M#%<@ =8C&DXM=V 39C_Q'+V7\\GN1QK0U(L(%#/>PWT=;DD4\'5>[!\S>=FD
MG?)WX\S/\ ^EMAC0,C)3.UX-(K4(J#+3R 9*E9PY.@G>?**(^Q[ O/9J9E.?
M:=YF-118]%.<5E-5)EJ17&:W211]3%)8TAP(1P8$%X-(IL9J!Z6AU!:!2\9*
MV8 FF3D/M)(] ?ZD$  A.LUNM;-'6.[C9T5^3),L4YL.!4H=/EP/AWY]AN#G
M8;3/Z5"(&DIM,?AD9";%#&\(J44@DYE&5N9U!6?"6(N=T!4_CN_SO*G@CQ"5
MYK78L44@;[H"<-J5=D,!1B=Q'@8@(IONWL$U!)Y!7CS[T3Z@@2BGM]WM\V*G
MX="* VYGVV.T& BS;5S%;6]+7!8!?-:5M7):01**U%*14JRRA&8E6#N0(D1-
M-.:V9&*'F'M%V4297C/X]Z BUQ5E>I63]I=/7@X:Z9T6-J.$'#5'F$>&10,R
MB'%OC#;&%[$Y3SC86W EG&U]+?-E14K6:!#+A:'D$>#C/H>7USZ%<;C=;X7%
MRO,H.&:=AP_D2F]:G[X47PXXSCN0&G+P&6DFQ0'=(:00@]!8C:P<N3UZ?5KB
MO2(/+U4++(B$TFHX:PE?IV(%[S*66X2Q'^X87L//J;#Q6)K(4<F*R31+#O<3
M1(Q0=O0:^;H/@-)=[L6!EP89^6D7P%D'?NB4"T#"N%FRN)"A *PCE)HQ-$^"
M_[O/<FZNCTG:8<R3YU#U*.=0&LA#S\@D<J@-(H XM,STF"*4?@4.+L/DGG&X
M7I\$";]:\HEN'VBJL)JB*7*G[U*P45BDI1UB%^X4=Q)//4^V7AA;]-4LS24_
M9?\Z]%'VT6]G^^T^\F"!3!Q@$W<!:LWK4&[U74,22'UZC$' UTWZ(XR!46H8
M[\=7#(M3H"LB>/*U\H+KBM1\%S@MN0IC>IG3K2H?LD$7:6A9-YV-*4I%%&$0
MVM=MDG=3H!9-WUP%1"%<%I>96'.=EY>AN5[_E%%^%%%A_+X^R(--2V4YD#H[
M( X2/;E- ^!H4X,S>)NLWS(6XBBKF^7":=6NM-PS+3W7!W85VS1:EI%;+RID
MC]14!VO5=#%A>BRQM0"M2&.(2WMZ1GR',*H/[6-X$/S6^_*)36#3T(M4>:VJ
M+?)8[%2Q]1UPN2'B..R6U]0[I7>R&%U2$5Z) ]:.W_ZVJBKHMRVH88C!7Y+T
M]\N89>8^S7J#\+#Q4J*P5<G6,&RT7$(<M@ML(1"!,$S,"M(X0M&NMD#M;1B_
MW0EZ&,+Q8QB'V2,-?DR2H#<<#QLO)1Q;E6P-QT;+)81CN\ 6PK$D3#AE'-%H
M5]E*PPV00W&(3?UD7L<ID0'=D0?L4$.TGTOK[HLXJ >K,.7[D2[7/Y7JG[[
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MR/IUICRM#1?DB^HTY[C50OS14FISX)'NJY2QV6N0Q)<QF\ ^>/'OU^LU36D
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ML+*F(92GJ<PTT6_1SNF50VB'>6U": N;5PRA7=IB@%!)OAI'[0+H]\+*,=W
M7M.4$#J%L<_@M$04,1-^6QKKU0!JL1H"M6<F/736QN>5@ZG2M#:A](C)*P92
MM:X88%22;M)#9Y-GH?;-7+ZT2FO*Q1FJ<^KS^L7DP[L5 8A[); JK8;\0L/-
M(QLP3IYHZFUHN?S,3TS#2LEZKL55?4%>.3";_S@3+<IJ2O&*H7V$,3!@?^/
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ME@NLQ>"('*[.'J&HT&5\$7O\R>S1.T9*@J\ JKJ--12HVJDM'*9ZE)H>I(0
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M)%%1B:-9<7][!NQ=<&]P3O%<3B(I*_*L;$7F,Q,-Q7)4FJ+HYU'O&HE V?<
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MES("I*@:J' ?P2K!\'B. &7--LF5J[]476U@("71(A#:$:N?(7 !_8!$1_P
M>-<#T*WG?&(K>69AK23;3D1;2EZ.9 ,L_TPUWM7$0)<+:H."5GL]0;H,N#=S
MZ7NOV'J$Y(TN:K3$-FO\<PBFAPS)U];3%PA\F5;L]!J1:F0(<Z6U?/T&D ,#
M\("@ [*/0?(U8"*H25L&H4H9^49&'J>DDX>N*.V3* Q"VYM";_X,T)(!JKIJ
MYN"G$:4=Q"'U#Y7,?Y\[5[L#K\ ]?/;IGT?/F%,!IB\8+XD16'? (MI.D<5?
M3@]&0P63&M(["'/2&%U'"6L.6Z*+U<X>H$N*] X"IS1"5^[(_ <,%]\]_R4
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M5]K!N*\%>E>\->F\7_*R5O"XY=!*% 1M2_&].6Y?)H.>CSZQ6+AN&*Q(V:\
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M04%I&4&E V8ZE[K"""H=@*3*(H(>N2^!APK#&]NA%'.6.E9Q[>#4?*V3(M&
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M7F3 R>GAR7G/,F\FL[+P^20:(.,)7A+'KNO3H[C)BGGAK[:\N1B0(UF_U2%
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MMA=HJ:-7D=M"<\A<V@BM,0O&2Y+J91R&"+Y$(5G&G_T'*A<Q#-6W8SBH&C)
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M&0\TF\+9Z'QTW*\6;"_PBH6T4VX9$ S9,IN"!K#I5L05.^A:;A@ "Z.R*6@
MTGK0--C%JF*, 7CM*)N"!LC9&0K* )1CD@$H&LS- !UPN>-EMR,6&G#77^%A
MTZ/ONC<^(A^[/R3,=:8?NKM!6Z<GA77\5*2@-7-/FW$X/F3(RR-QYP?F:F=
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M'<7[7.F3T>\11:+OYG42R5#;X9[/CMWQU-Q8GR;"XO'P'S[Q5M('V+!Z2?;
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MHSSU^N&\S\+T!@>T6K+%SDUB) XY$1H\;!#9^VJ&/RP0&XB:,:P*\J?YUSL
M_-FRZ*  7'4J,"@)XYDXA*ZLGW7"4=<X DPR\<)4>E76A$]?$S5+^']15Q]%
MZLEM722$>U0@>=FF5$S,=66^\L#/KXI76CH4;MRK;MG$YNX1:WU*'M?%T<G.
M?*2/GH<=(X.;(,7&W'_SI[P E;(<;;>P8;YE8ZF\0:6\OI&)=13$Y\AG)IX]
MRHLGM;B1"3=4W@XIF=N&,,I>7$T)Y87?1GG7C9MW)IXWU@%O1.=Z6W-/2A!
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MR""1R5P+C+[A&(+$+O/1/IX15"R]#0QCZ,1X(T@"TP\N$O0K-]_L7O0IX)"
M0]XLRUTE[\ETYK5#B!),;; Q""$S1U\=@[WM>MM#,B0X(\ZM+M3> 1;0!HH7
M(SWA,LC0(3[DN51])"M@GA,BUGM4S!-"&&'"CB)X&<ASK3#7/FV>4G?2&V1*
M[2<WO$-F=Z/#2\$)129>B@07>JX-202\$O#*&WG%Y10?2YA((3 ",\>0:4R
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M3@C4X9H/=<WC2L('H7&\_$"C^B@9'K]M#]]^],>SQT6(R9'ES=WI.%@<2CC
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M7QCL9N4E5\3'!Y!YV:2G&:&_4FM+ZW;1D3>C-])3T?2LV$:.>)H'A+\=FMH
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MH%MEQZ@U*/*7@_#DS?L$OANY:WEYZPY_0#)4,%[B2*IF/7H!@Z -TK6QAE(
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MUN <M8C;V,<_^8UL=%%&<1$RR?3PR 1;%ZP[J:&=\ \45K"CSK+,L?7.T_.
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MIVI4,KT\C^F>6I)>4@=$/C.&W-<WFUO\(^ *#A4#6PG0)W'B41P7.AG(-$N
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MG%M:_ZJ1\&06EU@'A9%C K2?N=<L/'V$)C$_#[S1Z9\<EXG_FV+5-)('Y^L
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M*_1XB?$:-'2I/QO+7'Q &IZ=618[/EM+XZNU<X6.4^=$TJFH7&Y T'T4*2P
MDX3?I!,=06_M#LWM!&D^0BJXHB;2O*#/*H_?TK446XOERV<GL<72CRM(O".3
M"KLNE^1RSDA>US&I8U[ICJ^&+L?%!NYZV^8Z,9$,],1.3@R:"F:$E!&Z%4.1
M3RUGRBXF\B7XO0%+R*_B&AA^W(H!NA+63*(!0T^6\[BY*<#U8DE91M(LF71E
M+LHZ:2Z(B>;0=.WNIJMS#89TO9>BO4,2/28N KNM"D'0\:'CQ$U:[*@9/9D,
M'\A9*6[&%NK;N T1,H=5-9]#QCGQ7<BV 3$&OBBJ!<96%U*!@=&!,$OW6ME%
MMMPLH-0/NBE"LX4^"G=<9(/6!YF5RA%[D47(3^M&.G-G.F"FR#]Z3<"\HN2F
MQL/0^3#>M,+X-OY.U\W+=JD]W^E['G[GPS8J[ /,YO =CU8,\7I7+:#XI69H
M(6DN$&+ _R"[W$K[N?2M"&MTQO,A%Z';4+LSV0GAEU9TJ7]2RR-VB8,3<-(X
MM=A0T(!+!*\(^]]Q0"%.!S^2N&T]Q42Y#9Q-N0A3N!SW?5]%0VP1JH"N)Z>O
M*^/0YA^EC*N'QPC"PT(3K>+&G\DV),6^$;^PE9$M/KC\9("N"9"-P.7ED7E%
MB<0SQA)WN8Z'FH)]-Q[ARV:A$ID>1<W)S@KV]E!+S*-_DU=?2>)OJR0G*GI+
MP4TWF16<U>S%^BL;I0YYY&;!GX*3S)Z\;*36*0&D%@W=ZY_<+ %G[7CX(R:$
MR3M4J7[]D[CY:F!<UH,^B],^0,:-E=^UG@I#14"3F7.8DQK#(J:Y4&BPQ![O
M!X1XQ#)P^W?<H5A.K07RFVNDW"=!ST#Z8-0>:&'WM 2P0!ZQ(2)2W=!D\][8
MB1C[O*HY ;P>6=XE%I>'+K:L4SKJDN&F8C7CVI-LOAPOT2PR5YCTLME&R\>F
MFZVMPK,U_9I4.(\3KMW@7DAXPAAS7YMT@J]9[VG9(I].6^%/F>.%^;<<-;AS
M7K8T6":%MZ15/'%:;%Q20MD"XM?9')"Y83J<Q [4@7I0R5K(#J%P'F:^MN4K
M-D'$A.UIGP,[W$6Y,6#'!IC8HSMOH/QI39D%Z7S%X0=2U>F*_-$U3B-Z4@)H
M60MO1N7:7/8/KUW";V'/LU[;0>0C'9*JVYZ4;)C+HT<K;JG4=9.YT4%59/:(
MVGP5!9JS .X]X^%1S,HMQ1K2 .F99%=*-@;E7BE+8.@L)C%@JF6\7I0LOJ2'
M00" =[APHCGL7-]M@_1,&Y=DC]0FZ>LITZAP6!!TB7'G[^NY=W5QF)O?<VX6
MRE0+16V0&32@GY5.#G^V?>P7 I"M:I?A;FNDQMSD6SW0(+$S1U70,C[(F'0Y
MG<0FT5JC+@-,(,4S,<6CMT-4:+5_:'4?(.Z*C/EDL%OW#M-).PIM8!H(9G0I
MUGM\!W=T!$B^H&M\ELPA7P3D89QRU<#VT>$KR0(B)$F(&H:=!S>&IN9I9Z%2
M"?U4=I9^_8 XVHLE U^F07,240_M07!-&"59#&AN=I+M+" .HOXRW%B2!P&Y
MHI!M!:#Q=B+:&L9SRS)+$1%3[?RZ> H>D1)2J0D@;B[S98NH] 7\F^-E">]5
MZKEA#:DG.8D!(&MN*=8;I;9N667IP;ZRM*\LW>K*TF?HZW>=61[[ZBI]D2>J
M@6-^SKKE YQ'Z+I6W)2, [$"2,0*B'N>>T0L3A,E8:='KV8'9F.#X#KS_><;
MI#;WG,-WG4*6?!K:W[([,XRY%-K!"@U*D.!K'7NJZJ]8;/[[S>M!N"4)6FOS
M2OKQ4\*%'4W[F>M#Y?8"BKTQX2A =YH8#UYZ%D LHJQ*!GD'XCE:#R=SC353
MUA/7^26)0]_@J!-,>VG_BJ4]2?!%Q+04B2Z1?RWI6:C-W1B*=9,AN1:!;GC"
MJVRY;)-7,H'L1WCR.5T0U2C0."=-**%RE*/\C6!<6TZT7F<PDXBQ0XEX*PL0
M8-1PY3KX.?23)N^;Q>( FV"EV !5R.7 SE@H=\T:/$[Q9W!7O2"'VEVQ='RD
M22\MXF?.!EE+3E]WX#O@1U- %UFW^]K^K'[%9Y6EV\!F7QF_^^0-R<T9Y[*?
M:%G<4B"*12M0R@6; ##< LC(LCADXWII]H5;KT?^K%QI44:G/F:8KNT[>N]D
MS_9"N!="".$3TL0'?REG[SAK@_XW[GC\!BG(DA:1MRJ$+'C?QISMKH$NU7^6
M\RW*<_RSX99X;;J(:>8HNLA'QT&SL@8WE,PN*1HW:D]^@%.+5"7#PTF#A?;R
METMFYX486R7='E<. \X"+>.TS9>Q!">0*RWN)/\NY]P?(_S@R##39JW=L )/
M0Z#O1SA P37(@%)5,3]5%,-2#C%O:A-9J^1AD5$^+QN&49X(<A2N---Y7)Z+
MES_OS<;^Q)H(/R=_">@=[%$!T_N3#RO+*OVKVEC17<YJBUD6=6FFH2+/K5FN
MJK+*-TLE8PWU<"U'VE)/(SZ\N()@4*OD,"_:O&?2.BZ.Q(5H52?7S^%QI)9J
MDW,RP=-,*^OOX<89*0ZO*:3JN+F&GK78J*X1YL_=*Z-/Q=NCPR>O;!_B']2;
MQ.4 J]2("@.2SXQ+%0H ^4$KV[D:*5.YU:%^2SYH&\9[\ HB+"BKO\[IOTX[
MOC#^)FR#08=8.'FY\A?/O>]<"WP77DCRXG0MD(:^95<[1*SR:147U8![%?85
MJ[!Q+/$8WR4=<UT$C#RP''<"F*7UQ00*0]L<=DY>MCK<AJ^Z\8Y<Z=CBU)H?
MN\ \GF 2@YHR74TV?)K<]W]@,D7'$+<>S]K,W5S$_H!\Q0=D -OJ [S+$SEY
M.D(O7_3C[>7"%8T"ZU)DK\?DZEQ [.L $(X>Y7F1"V* M2\SP46[@=CS+ XM
M?:&$%YK-21NH\N"8>/A!MP@YC0QD7[YCQBCNH\EUB"FNYCV+*165*"Y&1EB!
M2C/KV_VY^HK/U:QI-3G)$>D2BEH[7])VF/>=LQ0N>ON8+<H"AJ4-N5 //ZZ,
M,1+&8A4=RRT"5,9JJD5:$??FH=-5DS<"F*4]L_%TX1ND-S9C3I[ 4%D/H/KP
M6Y?>'XVO^FAP:UA2.K70@")(SV8 <8Y H+_6Y3_[,/CXTLAMZ5A\\^NSE]].
M '&M8Z:6X8_?WD99,"<IR:Y/N><:??AF.T8 \JMF2JL=7X]V+3_+28HX@_3-
M?]+BGGV[%_FO6.2' J16P$B!-JSYR75059N?%O5,D# %87:$=;E3-X,O$[K.
MM3,HT"1-#*V7A#S1U)'L"9G]P9%C@LKYS1'7H[VT?EEIW8G_Q5!1YQ%W<\1U
M0?-6 @^6(EQ/BR^*%W:X6XK'>RJA&D,_YRWKD/UAWR&[[Y"]U1VRC\%GK3"O
M;@#"POFD'AVB#",&2GB=@@H;3AB$RILJ$J_AA!-UM-EIA(WGDM&;+5ZI-Z]-
M10*>3,RU8,.%!,8N6..HTZ3QR_D!K@M,;3XBSK#FT!Q&_]KJ MO!<.JA;%*:
M4YD1,:93T!>7==F=N3QI2&+RHF5D"Q",;V43O%/.JQNK#RUS7"2RP 7WI^-.
MY$7)$TOZN[.R0S<Q_S+.G? %\"L>)^D&J:H,&56/T2?3*-WN1K=MW)J Z]C-
MZ.G[2A)9?1U_C&"]73)V^@MN'O <\;  '1Q'U8UCX$ZZ=K=1<UHKXCXBY#GK
MUP=SIAOBN>1FJR%)MB-];$]NK+*IKB;28."7W2;[?"M#0I#OC>38Z27)\%%?
M"^418PY57#K26?;-\#*^+[*O_0A-,N2%C,;P-]PG944Q@9\V&&-T19%/G044
M[T&YBA]1T^X);!W+I&SCK%%8PW67,EK&MBT&2YBL0G]-:<-E K,=^'/+NLBV
M7M6P32RN(NT4+4(V29=JKOXP"."1IJ;J2;A:'6'E!@86F9#J16KH)DTD71V2
M%V>-IVV3#X@2PY%SQ--+08"Z*!PLRQALPT6!<[QM"MY_4 'F'N#2$W9>MR:T
M?@QQ6H.GS88OBH^>)%B1 &M/FR3?V8]/[,/'+Q<^7N2:6BC6:S2Q]]S Q <E
M_(;QB8:\Y39&C,8&<X$HW*S(V%+<QZ9ZGT/[BL5*[57FX*F'(@2?8,DNZ5H[
M4UEIUX;5M\-SV4O55RQ5ZNH*>IOSP+C3K 6PCHR3=RI#ZV;-OR.G6GUJ%W?M
M!>DK%J2V6$CW(GKS:)<M[Q"F,12O,68EDC#",S(@EF&LV3"% F2@N1#9[?76
M7MS^PXP@R]&01+C;EB?']UA1A#S?",CL*4"4YH\GD%YI<\7OF(>)&PUXB&@I
MJ*/A6BS+B?VD3]T<4=Q7B[YT.;\MEX#G)WGHBAG2AG^P[G+C<!=>ATI7R.(X
M9"!-])R</+ERF$*]3S9D'U4>54T<B8G)MA8::"XF3T\F/].'I$]"NH?"1"$%
M8%4>:1PH+N/V"(KKF3)/CO[@P@+&8]<T_+&RZWJ%$.7%GN9U^2]-(\]F3 AO
M *.3GPO ]@$'V](8])2>\2BN HWI7;<TML"N.># @*[U-X'GG$]^:ABM\.GH
M5X3O,0 X N]XA&9QT!>Y+ JEYP.=[:"@4*#I=GUFDC#$:N+1TWG.*69/9Z4M
MB;BR4K_YXJ8G?J$SACD$>JA=D,YMQ(</;"SA6@'[B#0@0]WMS+QO$A8DS)#2
M6XRI>'W'AY/?!'E1?\Y&]DQV.G+:B5#"&N@V<636XDWSP).)#[-$J^CP_0.+
M;$1,+/)UP,3=\*"%NN=TV7M'Q\<VN;C]Z1?/VY/G^K'O[W;B\^>MHP^13"!+
M?W[V;/*-QXLNJN;B6R5$#;S)94U"J[WH"VE&QW'"8QP_1D_+O<?ZDR=DS5)Z
MUGSP\Y1E-B5P';TD-U$%S09VG@!+FN1RM5@6VPMP\@(SI^\F^%@^F#$*R">&
M+SQYZ;BV!P3JSV1"G=PN@WQ]\I)VW4!?)54LJ.N>L1O8>RTNE,O7AT<K##9%
M,B/.G]'#:6URND6U+.^=W[F?W-HJ,IZ1W3/F\<BQ(#!V(A/:X!:-1F UJYC>
M1QCD#(3Z+/\7(]Z6]9F1$\FQ5)*H0-D$B.-B?IBL.LX;!9YH*XV1I(95IMBL
MAP.QP^,.),]K*#QPFSSO]E=>)E])5I-O09F'9IBT9@AH5R>R$3'XTT@.K8Z=
M,(0%2P,3LJ.1YS!J5< YA;/NNGH230&IO4D*\Y9UYORX[\S9=^;<ZLZ</QY#
MG?PZ^2M#:8EC_.>1X.3+X-G]4D^>K-I2B:D?9.P,_B@.[$G/D[;T7*_RMBIS
MJ02SLS-7?^GUB+\DQM&[_% 'YCFA@,ONR\_Y1FYY3^]I@QJG9$89':_B@JX&
M<N:>1?A3>CK!7I76$[GKUJ_A/<-)F@N;A7O4>T?WCC+7T!%"VFDQ8PHFIEW?
M.)3L9,T_\)KIU$Y^);L.0-@Z<YR#8>=FI,7(==%.H';5%@:XPPX. B;_>/1[
MV!8ASK"KL3:3!Z0M'P]5R@%'L$&VT5[U9(SIF&6R.ZN\Q;#WBB/.F?A7XAF"
MV&-8IE^TM!47#8?&,S*178A% 7 X#'!J3U"<PY6(3I"SX]K32FY!57B"D;*N
MFW/E!1]*D:((25&"@]2</2V&(!Z$IDE7N+U>'PN78*^7]A!E-:#HL:&C$S"(
MQT+E"!(FB^.$M%O@OJE@GV7\<EG&UYJZ<M2>*2 ^9QA( =$*28^%/$<(:[R3
MK'YT>H[VU92]=*FR+4)8# <M#1U'0L.A69CW8>!LG(&-D^6,+K27N;W,!8C^
M)%J/N0'M'4Z&[85 %*VNQ>XH/XZ7V462!/FPT[8FSPU0B_0K9-;=&'$'GHC)
M[*R8O5,?0]K.]Q+\%4OP27"ZB]]7 &"3#&MG3<R):ZK#C]LLB6:BI7'UH%^9
M@=:!A2PQWO#=%6QE$53N6/UK+YM?L6R^7$;69O(69T4N8<18_79]1OKW%&1;
M,B2.(<;9&8]E:&Z9 LV#OBM::0P3EF#]FD2</ A>IA/@0D:VE\*O6 I?:<'I
ME*N01>LR$C,8Y9"V$/0Y3B1S%7@>L -.?GWVY.>39]_ZZI7*'Y/I);B2BP+(
M!B =UBR CM2B3L&3!6UQQK52!/X1\Z"I8Z-9?IZ7E2_2GORZ'P?_NH7XS9KD
M]90S?I.VKYS!=JDBAZ;!2; #7TWS$RMH00-D-;V24V JNM%N^)?:,%+2)YC&
MJ9!F-(8BI,?F*2OAJT,N"Y(_8OIO5O^1SB&-9ADC$L/0*F&++@0])X&*PW0]
M,JA)L;F;N"ZE;_R_3W[]%@GG[W[\_L%HB5UKTS\_>QTJTYH3#MG@D([E'#6I
MG5 L= GKDU^WEN0*X$\YOB@K]ZM'][_[_MYW)R=/+U^4E<O1+[!]D:/O[C]\
MP%?YEI/3#.AEP/#G3O:L)\DEH9&>YW77%I0+S'7H/\JVFWE:NWBU<7->62#K
MQ.4*;5W)YXT0FY-$<PIY*6U.$2PU+D?S!4LT=O&@Y?#S72"'3]+>5:G\9I8\
M=_UH[:5-:Y)4W[H-O>=&<$9MD'!>=FV_"N._PJZ93[IETW M/E8@P@0BO;+O
M)*NO&XPL/@8R0;]FWY">08L7Y-GD.-MKL\ENI%)8P<*Y8G]?;.&@FT7OVA9+
MI5L])V4\=Z0M'6^[U#G&U(8GT)4>BF7.<^7!)J:?!@#I6N1(<5"S"1?H=%6F
M$<GLHJ5*.&MY-3V**'GX!+/0W:3R^HTK'E[>@&FM+:\_^S.DM>^'5O<O89?^
M?(#?7/*<Y>Z'_--_:,,;7?[?ORNOK \LJ0Z-[!TTXQ#)X#WMB$GWH^I+-@V^
M*56I*=$BR.<E9N(UIQ1Y0Y)?QV9:J"+?G#DV(O\1*\VV$VEX^."+O*\,EL+S
M26E0"VGF!.5ICHT\%R8WQK-S;@-NT? -#'+,8FG3R\0N+\G.^?0(/U%^*BOH
M-AUPZ1=;CYH8PN'KGO4MZJY(.LH1>_GFE\GQ_>\?/LB&3[V%0J4$15853XB&
M'870G.NBS2K=TNZST1@-@GCM+7T?A='89BM$!5/+RD:_+69GDL5_SO5;Z=RU
MSC3^P$\EA1&G^,0)F9Q>^;-#KV[\)5;RFJ7@-K8Q/=RW,>W;F&YU&Y-81%.7
M@J8Z:(8'M'WFV-,7 [!M-^L0 ")VZV(H[)"060=5 L0:I;4O 4K$^@AD6%NE
M&NF'[U(7>#":\19\F<DG"IF[WS9[//30YA>3?F5QV\Z9#U'GBT7Y>S+C80V_
M1@*FP"AC#3)PM,=F*H81^]WR?J_8<UR*Y\CNTJ]_N4+_\4W)=O:_2'KR5GO!
MCJ45C&=O!F]407W8>3O0$0[S_BY*)F1K(LTKYDQFS6E-]YV;U_?K7R;?D,ND
M5<F_\4Q-T=:3EZP1ZOFW&C?]5U\7LI3[1UC+_</)4R_X<?+HY-<#=Y>MIJB1
M14G(:,XJ+4A]U-VWOG2+Z ;#0Y%&GO$.QNN#G6'.4301!B?M9\4.DE/U(DG]
M2N[V=4PP/1$(T6_XBY9(>?'ZB:5WH"ZX9:TM7-O=*==)M)&0NQPY_8;#G?;L
M#UXZ@Z0+L[Q1J8_YZ=H\%IE4@P/VFZQD>-E2R(YL7'5T1^B)LIUNNZ5\XJR7
M)!9U.[0XWA5S2R]-6=-^XP?*Z-T\,4]62N;!L=6*.B_A6YVBZXI5CCAEWG1=
M&1&[)#D2!<K-I3W!<NER-A[RZU^>AI<4SK@]23!)AY,7S06G4\16 /B2<Q#2
M6'C9"63\+3+9BJ\79F-@XB9\<WSV<)*&C3J"TZ]YP,0>X^*LH6MV9RA-0,?G
M \V^+=JT(TV)C":/RE?XR&NK!]./KX3T2BY-RP4^4E(PWFS%D4%U[$W(QYB0
MT<:D*S0D.T='QUNDTHE&",,T15_TF0&)_K<;!61DC''XBI$A2.VA+MJE*07W
M?=,*%./-VG)*:O>,==RV&V/D#QVGGV,R\G6Z&CO#M(9WFKO=6M>RX/8ST>]Q
MC<^%3DEAY#C5P3,^.$?9)>LN^3HYA:7<6J3NFG_49+3(OH32@@RE88TC+VSW
M".JVPBTQZDLAG.CL_VR:>?SV*\7%ZR;?(-GP_?&#!]^&++>;F]*4QT@/$]GP
M_:'_B$/_:D>GV!4>^R<ZP+!MW<='UNM^6: ;;A?&)1"F+2G%I\F$VT<X 6A=
MG3NY(&(M<F D"Q<C-5<+%[Q0X6(ZY;PBHP!9=+,SR-N56713"4A *=1GKE_#
M]&C,+DJ)7P8^,<]9\1BHEMFP=G*%JH.J7(A2:\O"]!P\@-,<^3<KPY3MI=U1
MAY-=TH"90&X6*&'U%]EDVJ_AC'&U28;F,XN=,>B@Q#@I'F? :.7$(+L9LTT,
MN,UX![C63M;-0ZPL 9T?F]AN<,B4]D2SOL9^(GR8D00E!0$.>K9;]ZPZONM7
M\SQ1P$7,T^E*AYX07NMIGP,W)<(%E$,U&:**SG=NJ-NRQ,9.2?,NA'_3.CIX
MFO.B !&[AM>S=\(WR@BJI$J+E71;L 0CGVT=2" 6X_E3M,=%Z8*_RF06?)>=
MTZ#/>P1:69K;C?@18GM MZ1OQOY2*I]9J."!AU",AW+5\.(I0D)SE*;+I=LE
MW3'?CLI?\;1*@%1B (0FL+9*WOHLYY71'V@58CB_XZ)<VNN?ASNX[955"97X
M;&,71#ZC4A0G2>^3A]$/2,8UDX[V7&8LAZ5L]1?H<%!44)G6!7T4+\,:QP3:
M/@_G9NO9F+^5X9-#L9B1#G 6;$S(!HB0JPZY:'ZH ;KK0'ZM_V+5<K#"+GM$
M,I:S)(?"7AX_LB=#H<-)$E3^*X+1,@)IP*NF=70>]IH]D(WC9]S9JJP*C*60
MPIN]3?]PF_ZWICZ( ?<56O*7"X.\O03P]N37W9BW%R/([N/#?0H/.B"QRCR
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MZLE_]955>!\].K8L)'T/LD<.3-%J=8)^U*MR7$U_;LE_[ Y-5,7VN#\E=XJ
MDK&%./1)XYY@GUX6J'YQKD,A3::<!$+[= F# UR2R_!"AC-$8DE<SQU0T UP
M#C,7N#1G Z=%B*N21NQ+)>!P\B2E\K/G=T\HZ\!A5)0ZI0G$7Y'"P#''=!/8
MIW#@4!NM69EVJ,CS*Z+;56S13U$QUHIWKJ-YR%UB61SQ2:MF..XN%O1O,"R%
M5]<LH1*6@#0-U(@(#EW$F6D9*KE\<DV4X=O\HI[4).G-1;41GJ@ML8\^'+^Y
MIENQ<YB\+A10I7C&W3\*_6+-]?G$/%M)T"TX4TVGD%^G6$.&(Y4IR#6;#SX[
M!CXZ84(KPX3$9YBWA@]K(N*NL*.=D@(UDUC.P-TV943JJC@-K0]^O$$M'K-(
M<PU.C+2:JBXQ9%:"VF:.F[7T$EBU+$1\YPV>%KG\A52321>$MP.K%A\GR19@
M;\""9?"3:1MT+J=EUK/(NJ3(B(Q-XHD?2!@ML)#6AR47O\7J" ;N"@F%25D)
M!NT'G[B7=;<N\KG((;ZK@[!(T449"V56S8-+R2!G7X2BX\T!_Y=[ <K0$8"_
M]LM>@B178N%=XI()*QJC<FGIDZ*?2$C>Z#3(C+SSM1[JQ%R?V;X5H9@#T5C[
M;9>WDJL\E>*L,%8I20G0D^"_),\8,]")0):=$SA1Y(K#/^*6P%/C%+Y&%=D'
M6+[@G @1+S=QN'@HDTQL)Y*!H[N)DF#M$P+@3JJ;[L+N;%7,3R/<K]Z(!5@.
MZLQVC+ZJ=V7$8=^ECROR&9)61T?H?CCYF>*>!DTFN00TSDO2T"1X@-V04&V$
M&O[R_4$%@TL)G,?6, K4;13(]A7T$-:@'B^_W6YX9:$+>H[O/I40[ F=FV^L
MAA\@V^ZT6_8_MO%;^S.^\RF3F.PAF;0"S'&!>PG-HLWDWXZ/CK*CHZ-8&0CO
MF71SU=OGR"GF^AC2/J(K_6$3D\!HKRG!$ZX*7-. ^TT;NI#R%&R%-4QM*[_A
M:S^<N(W@RVA??WC0D!RVN_LP(/P5N6C>R,'S*Z1=6]*9-1=3/G)\)"[BILC9
M'+X1'X;CNO-T07$MZ'GLPA"=F!'F/=2"D$R)XC8CT9%?MP586)_%6(>3OY:&
M?_"!5@-2@1W+N0Z,>5!'D"B*Q?ITK.AJ51[U&>&Q 'CN@IOB@KKDGC_N?KX0
M=PQM?A=Y6UBT"0$8O0.*"-!934W.BM6CHRZ,Z93=J\0.5!OY$!L)[V8!-C[,
M)X6T4>*)P=BH'R%>$T>$W6)C,-GK+>_>>;?I<8LP/L%3F6[\^TXH !70I[3>
M)<P%JS&W,5%^9V(HDN14I,R-70G.O4809MXI0GCQ;G.0R$(8@(H!$&.+K]EB
M;AF"8!PW>)D4J[7S Q:)#2=8FC8Y9>R]M0CQ2H H:NS1%=6"OK,)E?&[K;'?
MOM^&O2>YQ3N]Y3] E\2T%[O1,FH,IC0^SW'05?]8S+/W6U_-'ONQ""UVVT,X
M^:5/Q2602XO;!Z:D=!&8MI4B^SPL0]AY(6(LX=+;FR,BJ:2.OGNY.Y?%A />
MIRE"N"Y)/M V2=\!XVY:V X04#KDR->M&/(48FU[9_=#]L'?[ ->L.C:B <O
M#W4+2W/?'^U+<_O2W*TNS=$ET6O?B<6&U13W!R/'4;FI[N0T=E4 +#B7S CI
MZ%[^KD &:XXP=2!K'K'[<ZT0<#!HH=H<!8<P >%[GJ/IKD8<.M$LE^N9NVU(
MDXB:?/-S#GG-'64GIJSIC_Q+U?:TM9-UOHS]SV5'+VC*[!(M7*:>LQ@YMU9V
MZW$KN^U0[]#PFC2K&5=%/64G2G![SC1/I^TB,XK[@U>MJSF<O$JBI9TWQ3U=
MQ&'5#PEH0OCF"I:7!G JT5R(S9>DDSM#T([#,"/6'\[DLNDDBR@S[)DE_D-/
MI.24L*0T$')7)>]AT2,QN!T!'4Y^\5CEF,PZ>B19F>>HA)\X+YK+%J"HYPVB
MY^'/AAK \Y,X)94)FGK-+8;S,$ O-(R:U"+O67X:2=1_4'("62"ID/&M)PPZ
M/^\^1)R@0J":8O@LN=P+]=79.0H2F_97IGQ<&M!HM@ES^#ECCEO-,J(MA#>;
M(:V<>'8<*/2:F(6V[$;<NNRS^'70N%I:W"U]XG<Y:>3ML61"*%UXBC%M9D5[
MJCL88V?<\@/;+Y1ONO//T9'77NQWZ@E'[UQ2R8D#ZYY!MURS)/:A:2'KY=XY
M:=65&IK;.1S%7@"2WB]>601\H!4S8_+"91-E$BW=)$SRU4BFBV(LM;-U"1UA
MR49+?W[0&M;;[T]A\=76A7G(> 9"K9L5R+\='V?'#X^1N;EW+[O_P_W+--^:
MC'%5F((3"%P91RT"J(3%55LYFI'2=JS+7%;;OM,6F0^#)/E^MI2BV*^@?H\?
MT?N1M]JYUWBIS66%M9,78D3H8H1FNFD^C'O]D<LO>5^QTJVKX@,I&9 SM(GR
MSQ,U9SQ),FB5P-?9KK"J#2T]>2=WEQ7RM[=U'Z)VZU9!$SEW$W&E8JN:L>L9
M0DF]E3V,58==3\'J0C,]]:+J,7$"DQVO%.HSY+C"]$D__+RP7A/Q9D<J!K%I
MQ)2X.^Q:1G E-:M/XRH]0N7V[I\>[5MX61OHS:N&7 UU_D&@,@/IBOTJ'*M'
M/\3.AI>OGL2Y8J0:9H DG7OXQ2W;IB4EC8#,<J4'+V1F=_57%;^C#JY9IWQ-
M<K!::\Y'_E: QG-V1CZ Q#_6O;C9EMVUG4/OSYBGOY5KO&Q9RVGQKW_9K <7
M2"M7O+KLOJYU;*K3(8+>:MN6S$6*-7?7XQ-<:TOFKL7QZ2\7&X-%FNGBK$D,
MD.TKX$*JO\1U5LR@B#\A S3R-[W<9:Y!=,"X+M+4M?1:1+]O7E0E7&9V!&(&
M<($AE>%.==GV80]ED&%*;K3X< .KH7=:S?S,\F*MPY'!"=MA-0+M5JUR.[ON
MQ0^ZC<$3C&OA2ZZ;)A1 SMD" 16YVMCD']]V(U,9^*?0#1>_@WM ?$%,&*[+
M;K1!V'.2"Z1.Z (Y^34BAG;&-@EHA;+C"2Z['O?W 0;G?/M>?;W(R]:7+$(O
M<=+C*VIQ&^\S<I\YT-?W/M36]+7K6N:-1 E,[*RV.W_</EF H3!Z"AAMW7GJ
M;,=N:#1IZP7DBL916L:2WRY8:F[&ZII,6OV0(]>:52)HP];U8(0&37*^A0@%
MJ0+=IMVL617A 200EJI@I1R:H0J5=*.+RI+BT\!!">7F$<=>7N[7X<O'SKU*
MVBQ;U]:2P]/#4$'!N[-PI<U+.NA3D-K0 X^&6W5O/Z@%WH&?N]ZWM/+R*@Q
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M_9'>T#;][9E1A!1Z5R'4HDAQSID-3MI [AA:5>V?PYSB>]NJM)%[2^RC^4+
M"^@K]ECEG/&Q9(,2UZ(VC;=#N7GH+IE"85F_[=#)L]?%?;C#MR6IG:"&_+N.
M77))XF:AHWTX3D[7>NN=*?)?0#Z7C$R@CN2M$;W8.9V,(HN].JTR#_[:D00
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MA)MS2C@%]NGD$\-)['&_8_3B0J 6  EDN+Z37*;HFR) PNDN,O:N>D!TJJ<
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M@6%^;$MC"+PI5)8"$((XVS$+R\CW/EXIW=/$OA<%4 ZRGIQ$I6"*3Z]/&CX
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M#D9"#<0TAY-?5XU26A:>B,@>*'.:?&M!FY4"CNAS ?)A H@S:X<HBTK:,MI
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M@S@VV3GI@W^PYV,6C([?TCDE Y=;3E&J+EG:"Z8NF)RB.(.#8]?K-"\PJ2F
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M_/G,.$XGDME@4 :1X&7A&2@2:>!G/>D92?LQ;=\%O9DVBY^=G#=5ST$UE@^
M[=$W(]RII!,K"@?XDK_0RR3U!S*-7"'^PJO0^POPMQ00_/-T^D#'FJO$*9;=
M(8&B/]R[<\Y'LHJ_:4.K]E_Q)G#>K4I8Z#JIJB!:82R(H&C"Z]7Z+VM"^50V
M06GPZ#%%FWR8#\KZ "@/^/7Q8YWRS_ >./1$PK[XO9CURM(\CW&+Z#\!9M*
M-_RUY?C8EAEI@.C7,'L"HDX;T#:5("F(O7(BPCE*.@5Z382)[I)X<M',8C\E
MDSU/\I>BX>EPSTVL,O#BSIL+Y4>4L#KCRA);[N06$C+C@(;Z R@(Y4^V GQ!
M-9/EWBUX:_D5HT0D%232D9P-K=<X/4+OLV9FO<'1E.@Q41Y@Z)/7' E)E#];
MK$A;3#?;)].TD#==OU@D[$'P74'6_<$X(I.=$>J5X=../V*T?H$*6PB4L>'0
MR$)C&*-BB$NK7-OR%I2@HFG7CUUWQ!98TB!,'\!]<$REFCUB)RF'#("3&M=X
MAI$_5)*XAE!5CP?;,JQM=;.S@FFYY)'&:S!B?SKR&:O8E/'8)8@B]@7[LN O
M[V8,+_78)8!R>PN+;:!7_[F48MR8$7O]&#]\9V4ZQ7'-P^NU0IROSJ+1%%%!
M8)!DWQAF5DBF$';$\Z>O9X15QQ-^=>7L7:V1;"SM!HTAC-GA-YQX*P4G*WZ8
MC]%Y4XJA8,<.G@NGY5>X[*IH5E6RA\R4K:"T4!S)6Q5!]MY3&ENUJ,K&BTDM
M,YO0SP?-8L&N9-]6_*'(MVGA/3_PV#EYG)ZP<HM1CX&54HW &M3.S&/'VC3_
M!_UV:; RR2E?!)R6A''#/YZ'="_FD)^49]63YTDUOSQ%XL18SYLEZ.,4U\_6
M]5C3Q2'AZ.Q&0N@7=@QE=J6P(N'DN["\"A.HRJ-:-G/F->,:GL&(:D)E?W<>
MKY/ !URZ*,\&^O81%U5NV:6Q(OH<!.:"#X/:7I=Z#S#,K,N9-8?43%_;&U%S
M8]7GEC=_S?H^OALN8/ND;DPRTCZUI]ATNEQM 53'KAR*@GSTMRRL)&3I,6YC
M7>[>OBZWK\O=]KI<"(TL>4$>H'-NRN6RK^7?"P3>Y."=D[N$_D]5+ +$1F<;
MY-B6\.+V(8[82"/1?T6?FM^@GC?KG"U-$&.U5KG-^;>B[E(JO+L=?PG8'!(7
MP2T.928U.%/X 6M0IKO79Z&"9/$_*4GI=7Y,ZVUQA$9R4(%I9H,A^23.9*J^
M'\^O^,C)</O2F#&4%;,DU^%:96CUIU4S98+)D#FC37Q7K%&5)*-JL8=S8\S9
MSY&D&0)"^@5LD\0(WP"Y"G,4>--F.;"B"S\"&D-Y'9Q_;>4\N(RICDCYF/,C
MWH(LU<#Z=B3&)70- A.79MU$G!8,%['TLD9SAFA<T6$[X $6Y]OY_-:L9\?!
M.$+1QZ7;*D$75W_H_'?LD)3,</Q64G'FXHQZ-L-,]\#'T7*\OFW-C 8&6V3M
MI-/S+#[-8B+VJ*AU]"S ,WH^3A+865M."Q6#LK-,Q6OZ\^2Y]+I9EJ*3EWKG
M=- 7Y&J7<J32VPA$:8S<="Q<*]_FH;H"(+^R]/!&P7'^^'C:/Q6BD&R_XI:Z
M-Q+5>4:I?LW9J)@(#3$9M[L)B:9+,\#$]CIB*4$<-.E,<2?!T3S9D$LQX8:&
M>2P/W3_.-)M+.NO>T?$]]$5/2<'1&RR$'L4U3^,Z3.PR+UE[55"<\=R+L=$@
ME%MORFG/AT,"&%Z8^/MG9>A\C462&;H\TQ<_M:2?<QE@^JP9.\4WQ?.G5] <
M038DW WI96.FB4$?\A(YRI;+T%Q4_![^*:%MYT=/)0V:7]QQW^/I8!Q7,E1C
M^\!]--QI7 6*\48@@^$2%O1FT';,^;2ZJ0_BG*^E '$1QS$M_B&(VG@CACQ!
MN:@$RPFRL\CVDO/$%#R1\FXWN.2P%/W\Z:LGB73I>]8$<"<O%=W-GTB,W4PK
MS0]8@[U?;LKHS8&=/*0^2$;V;1W8<PUE=MVDG@]9)XJMV&>9E>=J=@?=;V'+
M_0;00DA=-K6=Q9+4W7DY[X$.O( KC^1D_"[)&CJ;%K9/= &Z8W&*$U:4_^HE
M 68G7)K DO2LJ>QHN$.7GXH*+<^<I7DQS:7I"$?;)6;P@B2)?+?/W*764,[5
MI(\-V%[M8CX.+DQ9<Q(>49BSE8QDK=HO*=Y 7?/!UN^J*'Z]=.-[LHM/G-W[
M M-Z(>@LI4 EE,P6WUU.R2SM$(QB44M'GG(T>Y0*H7NV#X]=34F@I?'8*G1Z
M)>ZN&1Y+*=U$TO-13(QK'=+>R_O-E?=036[%<T"!=JVIA$7S'I%GL J>U M=
M5WLYV\O9>Z:@F<]!!J>$;FTO,GN1&169/'0)(+5&?SPPX*C='1C>,NXE:R]9
MHY+% 7?!H\H@Q^[R^3G%O3HX$/[&96>.R LC.N*RE$\/AQDR*9V1G\:44'NA
MVPO=J-!9;*Q$>AM.30"89H(!;L-)N';HN;T,W5P96I]I%VP9BJ^QS^CR''1(
M0:(3[&:@'.Y%[>:*6FP"J#O#QM@+RUY8QAVJB+ V[T/N?9W3);E+M"IG/'*=
M%"]BNS17;.2CDVG>MM;?C*+97N+V$O>!EG"T<3\6@^@39A?)T]=:TCY^W O?
M)PA?-VM)RTG*?<OK6N>_!^Y75#G'25]]Q74ATT>QD#WH(*=+@B54JZR-3B'T
M>PG=2^BXA(9^AY"Q6*&\S?,MB_R\ 4Z$#-IQPB.O][G[O3#M%*:&G+MVLLHW
MTBNQF55[:=E+RP=6T(V]7 @8ZHX<+*2_ I:HMJ-4D].^Y&'%^E+ANF73._?W
MTSO[Z9TO.[VS5[][]3O6P)2?MH6.G@K6!-HZ!.9J5I3G_,ZZT'!MC946UD@W
M:K<A[7W-1"-[Z;NYTK>=EG%MVU51GZ[/-ICNU89?R0R*##JZA;UX[<7KP\3+
M<,T&8QIY/>B<S+5';9-IP+O)%*<#P)H,7+ZY=I://8/=;1(]5F,H4B2IYTLX
M.3Z -O$*ANON?^)PG< />AQ^:>#/,3,K/ :>-(+1LIKZ  <R!6_:B2T8Q@S&
MQ^<$@X6Y!(KV\\_,?<$11/+TNZ9BO@,6'9U[<U!L93WO28) B @P%YM($^06
M#VXG:62#VA5.$AE\XKY*!<; "&[GL7G':1-X),^-S*WE&@Q_R-?(6_F08F+S
M=XT^*605,1%4@%7B:N=67L3= A.RHE*573$<WVH4[&BRRCOF*)MA]DZV8C@1
MSGA @BM@Q+I":$$A'IU[^@0==BT.31G@^+3L*L7.#3-9-J<8N^Y7I)]Y2O&I
MNQ3?F73$Z2G@#7)D0J)(!"S%78+! ^6GIXR&NRZ\<*R:"\:PBR^: 1/7S$^"
M4_K/ON"]&A6/= K]</(DU!L8^.]R,>2Q+P& 86E0A"EV[-873?O.YO88J(6_
MRW.:,YC?[O^S]Z;-C1Q9ENA?@?6;9R:91;(RI2HMI;$VR]8RRGZMDD8IF3X'
M  <92B "%0LIU*]_]]S%_7H@0"9521%,Q=A85XH 8G&_[GZ7<\\YXJH$-Y+P
M'VDG.[^14C?H"&5O3!-:=9%L+3:+,MVBBL<H80Y?3E9(D9/P&/JER*;-:(2U
MY:[:+0?:KO@G8.->66$&?-RA9R2S()B5$<>_EB*[3DVG8V%-[?H(MD -&%P;
M>F8FD=.46QL[ZZ "_YHP"426)&\1X3<ZD^.5P0AW QYI>W@KE>K2=SVT[UTC
MW!^XX^<Z3-(V(83Q#&<6%9H;H$MY8V;VAQ$C[^I!3[\QZ3C\9^&+\V:,AXRT
M&5A=;062-B6!%V:V<E^M[6VT.9=NRZO+5SZ9?''$)^I*G$8EK(P0VIH:F?2*
MC XJJAD=+"'AX"21R(V;T!.]^%B.2?JH6E:;8@>&VZXL#NVR!TU:$)X]U_/=
M\AFIE.%V>]_F2\='9-<_;0(9;49]@BXC(QFY8GY9?I>1]$725=)=F_9 ;)3O
MVZK.GN*G?$R,R8#?G+D(=K1%0OP"I^!F *U)%#D;J8$-_7[HH]:I'"W!H;[E
M9.%S9[0ZLA0<ESGR2Q^JL%T+]:@J+S$TLQAK9BB=6:)*W,A/F$G;+0W/DTE;
M#<4:NVXDH65_/H(A)'*_J)EU329K-B9MBBIRQ^G$J)Z!Z[.*"%]"8G"C:]9O
MW<:M[JQ8)0FR*7N_S?0;.:]U V#O@2EE!-PQWB.#D4SKTS*<J<XVI9R&H [B
MU"KQ^@%>QJH=JKY094'K/KT4[3 GCF)4DV,=!M[EQRH>_OGC_IYMY"/> *>N
MP+>C3;TM10<3/NA[/>>O:J'X'1T"([H8&U)5D[29](<R>!::Z]&O]3ARHD4&
M^&:<FQY.,N]W'J3IB(NU6:,P3O2])C;)?+TJ0G['\1;YDS)VKZ0\(_3+(?>#
M-,0\3"A-6MK /)3;S\W?2X#_OEGE'RC^0182*525D9>G6^,5,(2LU/C7#9.2
MF*"S3<5D*L+QH7!M5'116Y"GT,I@L\U$+\*V"S>@K$@RK4MOM-Y5RKE2C=&[
MRQ[VX=UQ?L9M]0:'IML#Y(!.V_71X.;,<F[(XM P1P[3JZ;767R#0?JMA&)V
M86M:<ST0V:8XF#GI2^05ELQ*)VL.GHGJ9=G5)-F0*2NP>(%& P6$L9+_931S
M>0J'0XBU'B!K!*H\4WI5BL;W&L!?++XU&G\P\0JI;"EQ[:$9)!,@>JW3SPW%
MHF@0N6HIQ=D4_,C&9#[E-U^]S$<R!COB:E6=&XG1$5IM[GZ2BL4P4(R5*5\F
M=D"5;..O8:][BE2V?YW!,#,8YJE3V2K?%K<7L'Z:+/ZD*DU[$+8]*!I&S=CP
M&SG!C("S'9L7,K8 OZ=<++Z,7/9!?@ UN$[(),&XA]1KI_&5>=0K[IKI',4V
M!:]TI@5ERK,TMJDC@FXL>/;6&";J,3*.)R#E\DP3JITUY..U_BN\_.G9M]\L
M]M5UTQL!?R1P5:Y>E(DX1N1Z44M>&J??^2"RK#OB1LTKZXV%JVS,4R:",-B9
M40D\(\_LX8O#HZK>BQFH<.;58EK8Q>+5C_\%71ER#58B=5[U/<N^?_VS4@UP
MOB[UBR19 .?E^L_5498M Q%WY@0FY<9"$YJ:=H1@_0%R<K0H06:(;(Q<8NU^
M M]- _G196FWN()3_YCXB'D)/*$E$&, -=A0MV0#S+/-B!O^+Y:MWW+)CU-1
MY+#7<.4EW<K?U)_KJ75LF;-%SA9Y3XMLVI&@B[<Q[4S(-]/'A23.5O84K4R-
MJ@W]T&I:!'YTDJ 41Q:BS)JEB$4F[(6SQ<T6=T^+<S5(7!"!%7+K=;0K2XPS
M&[Q*ZJFNN^.-UF L"4^QSH3(>"^#T%U)?LJG2C5!I93JS*D%8LD8+ZZ:9Y;[
MJH*[.(?&M@*@2<?AJ"V28@']-$D^CCQ2R8^A2#O[IO.*N5\#?P4]:,&&5/M(
M7UVB;GG99'D:L36X!.NVO"D4'X*O:,VJOH2!(Z7.5YV-<#;"MS/"#";"[/0,
MQ2@[  QYA\WY!WD3G*K]S&8WF]U]4E,.\CJM;[D.*];R!70Q[I'!M#K'1<<B
MUFY%QYT/\J/*I#'RU':Y=522E;23_IA%+'9E78LPIC6,]U$B)'O6U-18G,Z#
M73:-D_*,1!B%YMDL3\=IB5&B+E?L9/WPKU\N=J)V(Y+5,5]GG9)>8D1@Q]F!
M(B*U\WJ=U^O]UVO>"S):=EQ1LJY>K?64=%(<NDJU853Q&<MFM1HXX28K;;;&
MV1K?SAI=4:*JNWU($MU31X-$CA[[2O\R"*-NK>I'#_4:Q<LW(6H97@?5O\!5
MNJ$3O>%V :7 JC:\Z/B6LRG/IOQVINQ(*S=A#0W)0HYT]D<F273Q\="'U/XE
MQM_&!J'9^F;K>SOK8V1MM4L85L9#HC\/>F7703)WS-7&AE-V@OV%5CV#MM%B
M%X53NW+#R;L663UZQ-5<%ILM\1Y8!0F9U@$XS 6[B^6:CF<NR7*;,>USC,,V
M2^-.+S,ULKLSMK;GL[6=G;71R=GQ"T)!=M]4M>Z B&=VH3\#$H5<J30/WEDT
ME)L[@5] 'Q2*'!>+[R>S(_\.ELX76VY##[\-_AK%%H/7&ZI8V[;2J>-;*FZD
MLPT=UVMQBES3.SY)'GQQ%T#=E%DG .OV=7E']#_1C;F58[]%=+I6%"/C+CN3
MU#Y2]/8]S]((LMF04\8]>PJ+C,FLNH]0>3\?(QBC=+:\H756"QJ1OG_0FA4M
MP':)_3!"+N6QQAK?Y9+\QVDD.("?ZR#1C/9%P):D^N;-)AWNTBF/>SQ;ACIL
MJCY&^$4"N[LVEM]A<:8F*#DM;23@3\K6P]'M%9*).)P9V\IU\R;DZ->(G>>(
MSL/9[T#57BR^(W^\8:1_F:R7P?+QR]&X;  PI$T=QJMCB)V)[JZ#R#]'-HQ-
MS.LE@*XREMA]M@=KKV VB=3+HC=Y[SJ'QETJVMZ)SL50,\%#B&4,9^2RO:RM
MZ,N$!;$#*Q-/DOTJ3T;;9'(&*W5'<!*+10GI\KS017.8'B%T?2HOVU8@!7#)
M']-W]FWHRXB!%O^GB!]?FAPZ_L V:CVJ:ZM4.Z'F/+7+]1A=K(NAERY7O=3H
MFU7?A>WF8O%#2XN=MJ5Q'IYMT)\I>OS@O6B&KCDJZ+AC!<TS*+I7'7Y(OT/F
MG,:-MSKFV1#-8RZP8Z/%_TK/&P\H'6G=E2!2ZRYBQ?^"==HWJS<+69(\"RNT
M':^20!8O9#Q.M=*N0!/R]C,KV<A#/-"R6P%*0*]Z0V.,;Z=I7![R<<MR_\"]
M'[17>Y&\V-3<?)NU=-Y<^' [;;&,.I^TV D3.S:O^&COTL 48\\,+W0?W9K>
MUN;LY[^&A@[%-;B<+IYB1]'?YHZBN:/HJ7<4G<=Y_O5UJ+$'9NVO</FB[^.[
M:FVS^?KKE\JH*&FJ$TT+N5)9E,(SV6"AY6!'POH:.-K)2@?2Y0TWUC&XQ"?E
MAVLZIT5\L7AI[F;J6@?.[:",&3E+G712@9[MNME>3U1^1UP&Z*,@0S8J'* Y
M I.CX9PMM)D?9%PMH]H+?;Q1:W(<P^3NNX&B8V2JI#+R!T9<'\U*)09#I\=3
MNWO+!G@:)Z[I='E#[GOGR!XQ)/*A4S&=V=^?/;]X_K?CW>T=LD,I9<P&C39&
MN[*MC!%EM2VKG7H>XF$O@]+H%F1F2 TYG@<,T8M/OR 3[5EA66<R3GH;]H.X
M(@_<M?[=[8LUT0RZ""IV.?HO4+#?EGL+M)D014J$IX:*[']+BPNLU9HY*"+#
MB7!:F09!X7Y;D7_,S 'BE47V-VXWC!7-^*W$ >>@L#%)RNWJ-;O]3+V7.MQM
M.I=,J]U'0MJA<[XC_1/5 ,38MU)7W,)2L?A&&-Z*"0?T>.!8'X:Y^(2H+N<-
M6"N)'=VZ7[0#3=8E'/N>^].;CM8I[?0!VZ0 )_W]NEMN*-9L5'39W";N(%2'
M122.$QU3$8??^#DYU-VRCOBF.4E2#RQ=]W:+B:,FN6&UP]F1S85E(G)NH[3F
MBLC<LHY/*&QCD> @\2 UR][(><Q@L_/4$P]D0_!^;\\/2M2G6W%N_\N [FGS
M!-CQ@?T.56_[4,]3W2J[?H@Z)@R^&<3CH+79'W(2O&5(K=N%Q. <I^]LRP0:
M%'L!V=-0>YH,:=S.N;LX=H0)&P&%YV:*/'2\O;6!(NDK''"MM:0[P\L9Z,9<
M*#%[EXA;TN*;X@ 2.R[<KFLCQE6CNX<LV_*,G>-HJ7'(^J!D<NR"<MX42PZ5
M5^[<#YSIP&;8#<M?F7&T48:L2*C$W]3-E2F5F(RU[K/MC=ZH99</>$BE[9,=
M:G)@%AP4'N_$,:LFEV$7424WTVD5*0GP5%M0\?.':Z8FY)L*D,%L&]L8WRX>
M<N^A'Y@]!:HWNN060F[;R<H'CRU*!Q,$C%U883W$!60SJ<-H&><\IA)'&_=)
MC#TQJ,J([&G(P2_(3L*FVFJ29YJK$Y]'0Y+<4<I&H[L'[4"ENO?JW3C^+P[H
MP&8.B\\OX+<\K,Q6<GE)7(X?L@OAS:E3S SS[0R<EY-2JDLJ;!DS6FJI[--)
MS<:&%:E*34)J]K?J^,BD@]O 8OG[_H6+7QOLB+=L1TH0A4[]">_CO5X1GER)
M@Y54X<((S_P;+AWZR0.@#)Y?O)AQ!K\39Q!C;*%@UHTZT<GIED2^2<.N/I?S
M]BC&]D+4PTN^XCI,VFWTKSBR_7:^*]^0/\<EQ%98]>/'O!65'!(N<?[JG;@F
M4.ZX@D,;BE2^4,>@0&AH6T,+X+79LCV[KQ#@\X6M4BZ_ L&.N)LW;T6\JMO:
M+6B+>5G-RRI;5G"2RBV%ZNO#LTMR!)BEVYWN*/%9D*!_-@^T&^AT)EL5)3'G
MA0JVI:*5LZ(CMR!G92L8EQ1@J=$6ZJ)> VW@HYV1OP5 BF:H#U;J:L,S4!Q6
MM90#*;@K15U@79@SH-_<H&"D[<5#'9]@&P3%TDNN:&(OF!?2O)#>=B']) E+
M%!RZ;HBKB ,[A/@4;<I"\$$S)BR2Z&H.<MVB5KF.(EC(Q(6U([.D[7_9-N5Z
M>Q!/GDG9S)'F]%9*U&:G6G2GNXI&HFRUXU^;57GY(6W!]54??X[X1+F!2;!7
M(8D!1;[@-R%R#_-UG0?/Q^;HWH+#T@_C8J07CE !SOI9><B>Z*>CAR@I_&K[
M>(QJE"9Q,P[]FZ WD.I_V_7Q>:T+L39-GO@$'$7X^92@.M19F.^"*\&VY0\]
M<8&)L.[F*D3;,7.0C8DA(S&-XX,>+3B-LCCY9-N J,<1">YQ??8U<(7W1I_W
MDQE , ,(WC=]WMD5..4*G)</L&E#6 .4UV@E#_YF15[E.IUGNO5K9BQFP*9.
M--Z=Z7IHCA0&U6VS>J.9>Y4'T3.%[#%<ET)T/4J,T2TTA@SQC"UORG:,8EX&
M,/-,IQS'24VFKS74QPAV 7CQ8:]X6NYG'ICN@H9@H -VNWCQV6)'HW=%W]WT
MJNVVJ;9:-H[8[K9J&%2W;E:#@#8^:+@:NNA0S%E!P:2(;S2^"4<*?)HB(M=A
M^E"RG/:B^,GH#1WXDN(33"%+:M%S(G%\2;]%T<6PA^NJXQ.:VP(28?DRH<@E
ME2^N&4\G/I?,[ZG4[GCZ[/RGS8O\+VD>B!\[V9:IZT4KBJ,9'8JIKS=C7R6O
M=EFA-V_TU?QP2O6.W!T9(<#>\92IH*+8TK(V2T9N%K)ZFA@7:SM^S 5++D9G
M;>1/%IKJ9VNJQ:E2(BHU,&=NK$6W(4/MI%W9-1;P75$D+*QM0GRE(P:-,HTM
MSQ&YE1\8<1:CC\B*&$@DV) 5[1!TZP^9DZ-T?BZ_[0^I;O13S-U_#\<_+#[
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MU:&_:=HWTE +,[)U4$0GA<M4[> .#I4FLC^JMS-RU:H.'T^%,9-(D8R'1W^
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M8OG9YA/PWTJL)9QL21.RT[50+HTN.H79CN7)HVA$D\>T\BP$,H04C$_*!QS
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M=3:/E!N_JCI /#MZ\_X&(/ZANV6$T[K+F5/*=EGU>NA[Z:$,P2::EWH"GN)
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M-)VG^A<$KY*[*>QL9(C,P&@J]D0Q%!0.""JZ..61N!2J-K%&;V2_91!SYK7
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MM#!$_"8?D"0*,]1R+5HCEM@H//E*@J^<3(CX8ORIE"H?%2E-D\Z'HP?C#;@
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M3;*.KT4JL5M\_-E';!8??_:Q":BQ__G*J/A^U!#\RT:TZUY\_MDGDEG8B3I
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M6LVOY+MU*.DD63%Z2G)E@XIJ;4("?*MYRU9E-$-2;=YN,YXCV=MMT$TV?"D
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MV&7&?9?291-1^XO7H,>8?A9&;4MSP3J0J\!7B[3[0%?6 D875#[:"K@SNZM
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M72;R%?P#)59N,NK9B>2]AIB1A+3-[R94IC&>Q5KO) !SE*D<8R.CR:LZZIM
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M^M*H3=(&(&(#!D+(]4V$'C$=O9XWK#U:( :S$'/UD-B+Q5=#[%U%$G/=7Z6
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M2YJ*JKN"L\UD?S](*^*S+X,*+W\_]&BH[Q"KB=;OJZA-!F^2'125Y)8"-#H
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M0\%?>IU.SWN$?R>-O_/SXF/TA^[/CVU1\;,D"#9>I'[\Q?N,,>DCT,M!?_S
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MNS[3VXN9LJR>HI4;J=BW/4Q*W4&<IB=9D6'G&W7374L.JQU*I FRS!L^?ET
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M-9VQX"4G%7;+3.@*XH5DJ>UL,2E2--%R*QANZ.WVV$6]R#Q-_LCEYV$Z";9
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M4^8#NBX95Z.[=6'I*,]+PRUQF3F\U2#T%6R^^AI(ES8!FYPBXAXL%JTKVI;
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M&&%J[^/&JQ=8*+(AJ>7$3>%;^O=9>)HP=GX1A,ITMJ0F! 0_SNVNQDFY]:W
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M0%(57>')-Q\$(5AT\ JGOL]5G1$B-:CIN"MO+VG16-+NI\CNXT!K/*P46A^
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MZ4*T8*F"L04*ITE43'6,@#68)2$4:GL%.H)/FL$AK!@X-OFN_9BC-L;A+5M
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M0Z >FKI;Y O4A12C<.RK7"^%O:;AA2^=DV;<0Z1\ACK2EYFQC*AT<6Q*=T@
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M*@I7MW-5?6M!V9+YZ=>PI-H>7')^XS29>MW=OGD<- [XB;X$_"], I8R9A7
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M_"W#M)]!K[758:L@FX#U0'?F2*%#AM_QTGMO=NZ(GX#KZ[./6F*1.QUTK_,
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M 6[S'1,O&>8^D*<_ X8/T@<'CC#>2 (F5>%T"'*.N%Y#C@TY.N3(D0\@DL5
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MD9^$:;"!@>.Y9YT*XS"=LE9M/ZN\MD;U(%%5A/R)&[K%/^Q-%7I18M""0=R
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M3(@W5F_-<G@+K%RV,56=G&"V5[333PWZS9$+P<I L)(4>1^G_X8#PJNQ?UQ
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M$R.0IEF,DC$5PV1JQ &94]6T3#,*!T;D6"4QY6'_UK/0^OEB1X&B?U5OP=X
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M=F%A:SW&<$="ML"N<%UD^@*NRW3T[=E:V2IB^C!M@@UIIWIZ9MW#US)S8I[
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MHTD2:]62,U:&!D+%$LJH*V]KM)_7<,L2V@Z)Z=GIVM?7ZW,;&<0'U(N@.%9
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MU#]^RDK.[\A6;5<M%01BNQ@;3=Z:6^5P"E%Z@76J5,Z5R0"[Y,K:-9?E1J;
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M?;/\N69[AP$/"4N9!_0]O.];!\P7MJ,X6R$$^]YG(/J>"Y<=,"90A0'#@S_
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M75Q_9SQS+.+=FYK0<+%1N[#H24M9L'M&F9PR_7!3"]N@O;FIW5JY2=:?^[.
M$RN0\)S@";.0*PGE*783_]#J9P<+;$<#3FH_^!N^V"1<>V9HB7]@X?_N>U?Z
MPEO0WB5W5>9_9LP 2?E-<_$0+4!<_ IQ@OM72H>@ 1+G+[KUAN&"^Q?S?0P
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M0"%_,.9OY>3S.\8\@$L=K!,M>ZY8P=/#3^!;]B]X2$P<&/#_1T?,GM1N\/M
M8SMS9?:3ACM\%$ 4ZBP(OBS,'PC0]23=RGLD_&<&G:*[$N8#R!R' 19HI*QB
M!"-3W)B5N;&JRC0]4K'1>$2- 'C8O_4LM(ZH\]?T5C#/;+>U.?0X*-6S>Q6S
MGWI F #^+M"RSQ334V:8:X^SBCO)S^S#[)_^*#KV:>C:/>=2WUC9JYDGS^>9
M^+&H4"""N2;"R3[E9%Q]NO\N6<$N8?O!XS7W1WK:0<84H'* Y-+R&%='@8PI
ME,QI.",S@  JI8W&F(K_Q"588]4LT(HT& HFD>5SC<FZWC+F:]C^Y->17#$K
MY%+>2L&,7;/I6IUFD]LU92(ZTM9\(>_L[+)4P=9F2D_IV:'#RV1T)#-=Y%/X
MN,9C!:GOS "I3DU##T;2OX[$I9*?9H763EBN)NS 2CE=DUW+E(S].G);*&YL
M/-,"9BJUZZ5\;H3GNTV9CH[L]G!Z@LTS+6Q9KLOF0+4Z^2$<&9GGAK&HG)T>
M]DU#FRA%RZLW38T/1D;FZ?3)N<VVRZ()<DI/ILSQ;$<U92;Z=KID= ;<B.Y(
M6ZTAY:;5C-QF>9F-CC0WFWJ3=3*$N;7PA8'Q6$O,ZG(Z.K+/=0VZLA-5#,@5
M/+,V IJ)NLQ%1RJ+GFTN4]F-4&FLJC@CS.LI>$D+%AWJ&$4;='*Y.29J['I3
MK#;INJ[+.!X=RHV:LC*Q\Y+4PS6R8A*%9:VRAIE8T:G:]4V*$FA+2%E-E1Z4
M<K:.!T/)Z%#=&+&;0BXG"JFL[#6,#<&45L'0$\QW=:U9),6L)AE2;:-H3D-7
M-\'0$]S?3AR1'5EY1<BZ3G4U 4R6'/,R?H)5EM>GND)_LL!2 WV3ZXR8X7H9
M4. $KQJ#_JB19X9#"9#Z;"?[;F\RU>'%PI&A,C"V.%,63+. =6OETE@=<;(.
MKQ2(#*5:H$&D] UE LKK#)V5TAN0/.S;$QFZP9C\6'$US,S:T\)F7LS,&(R'
M:6>1H0+955:TX&]-?X%-N\N,D%HOUS)Q@ELUON 3 VU;Q[:%_(1(;Y?ZQ J>
M>H);(J#FN&P7=&FIE-E!6EQ66I- 3YS@5BM=]XI^$8RD"K_!>@.V:/5JP5-/
M<,NQ!OYZ.;4)K(+/F-K2TYU1/AAZ@ENU/F"J=$,9"HHJ\\9H1ZNI23#T!+=&
M'7^^[.%&&EO6J1RCC(>UOA<,/<$M05E6FGEE(IGM1FFNDI5U)L<%0T]P:ZBF
M*TJ/E\<2V-2I^;:GK5O5M4R>X);7V_(V4W<DJ:!2F[J5DLV2UX1YBY&A:P=?
MS\>\&Q@0&$\60'7;F9'!4T]P:UL;$6F/2].8/\K7I)4OM.E !9(G='6E656=
MG2/E):5ASQMMWMWM A0$0R.J31F-FQK><Q=8;RSG>9,!9I8))G!"!E954.V-
MW/I: (H 7+.M@.8JF, )&:B9@CD1)FO!7+K37F4KY&J;]!H.C<R5KZ0L*6>
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M@O"65<!@AKQ4-9K/]O8?2 :R;;M0?<1200^@E$BQ<JR]*TF#5S$>TX&#&LQ
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ML0P5YV^"[Y21YU\R#!'KO7 Y4+0!!#49R]&!3H%-.U \40/W.WB"CCN7.$
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MX1+XNE!X ^&6G=Q"WRRX=<J\O-4'(XXA+ZR$'\BK/&2,GC W$%3ZO^.C##7
M1P-^B6OC^S.[=P6(N>L>61_A+#1#]]\4#T5OV'Z\I( ;XDLX>W$8Z5T\E)8L
MO(B'Q_#A!(*AX]$$=DG,)O"_&9"1AFBC98</!OCL+TZP"R?Z@R-^E7+P<OJG
MUYZ"L&8,J8)' )-0T7"#0)]EX/.&4S8$&6OBP;D69/7<'B5R.%PFD!?@SXA8
M_ ;H.VPEVG=A;PW52/(3/^>4:()5*(K1,G3X4?#)^N4XKDZKZLUYCV")18;L
MIMU:)M_13L0UGFYW@YX,Y,#0'3_8:1\,%5Z02QTMV.03*X&IY?*6YPN.%$$&
M<O>;(%NV;;CDIUL,3(P>J,<$0<5C=527P-Y!LH_EV22U!V4DDYFN91J^JW[7
M E$Y%OO\V@9[@1D%EJ'BCUOHXZVM'P)J1BBG?RB@W4;ELK?(BN.2<5^0PT"@
M7?M?J++?A^PS*'I7$+>$;$3 ":.[?^R9R%9EN#;<0T%%( 7%:8S<H1AH?^Y^
M,(M?L]()>?2Q4\B_H(%:*P"=T;M$=3%^BLQEJ \<>QY2KNX.%PE@]SZ"?@1H
M$'R7: ?VD27XQ-$@5L!1[$-5]K]C:4'7D6#IXX@=*I" /0\[=ZM/+F0JY'/%
MKBQ9VST:J'8S&=U,]=NC"@MO[).ZB['8$LB+P6&"E B$Z@[$LO@N"F$KQ&M0
M)O>#=Y"<CB-KT,]B<,C(2#V%\PHB<+8=XNT-UX# JA%\+UP.9TM3>$4#8 U"
M,_?Q$J=").*Q0"LYZCKH!9U?P;3N8H-=B!.OPN70_?=I6/ !R$8)50O;##86
MT[VO:6-3(R_,XP'(!W$<V]@+M)EH';>6@7 $Y-;"M*<>R96QO(8.%H#8[,3D
M=Z$?,B*?W9#$W=4B>^^>Q"_;[MS!F]#ALU_%O0"A HF'O+P="#8$G)0( QX3
MCD2\7=!G-DG<^<04"O7:+WKP0AVL=C[30UL#UDA#.C0^GXU9PMT#!NSL?R^3
M4M0_5BDN."HY1GQT@U")DF&]<' R:]GF;,OA"JYO>5L&%5_\$C&M&1/LQ[['
M!N8[SJ.MGG3/C'-LN;,>3=TA5R=+S,'5]/0[KJ:WMKB'(;^+5J\U&]B 04NW
MNZB>]L_T)L0S+CLGQ_4Z/YD,9+HC\^LNGU-KJU__I#*Y.$$<7U5_#J^C37GC
MIM2#5?-.;D=O(3<=[7Y<4&K#56&VZ-?:$QUM1YH\O1U0$E$Q).$]N.=U)%'$
MR"V0HX/]62__H6?PB_GY<Y&?/_+SW[J?_P7/_8MJTN45H_#ZAB^!0?D@@:^!
M_?K'#QY%OEPH33DK$)A@ ]<',JR<.)U/'P\ANTH0E0A;[H'<OP((<(HP)* '
M(H1_S1"+!%,4D[TML I;(VNQ".#PT/T6AU^';C@<RAVGC,(GI:/].Y^1GD19
MQ,%;,NQ,<$YVO!4 #\U#3Z\PAO* '(/PT3=^ @*.IF8I.C>=<NF,D.22O$!S
MN2S%<U,QDQ9I(4D ( ;9!_AM&IK!:CRD1@UZP?9&A255X\CTT&;0@?JT9;<H
M>#FAEC/8<BUAYXKY^5QLH9:IIRVM92,+"IUAAEBXLU%KL1X,$I4.1W'$TY94
M(]E.:YZZ8H';4NW4H*UZS JV/'I[BVFGBLZPI0T2_?Y2TNFV-%A*L.71V\'C
MLD=3EI!5:EK2J?9[(+F@)(X^?GMU,VBVJRV)(!:CR2B3[@MV5V1@RZ.WY\KV
MYE$URC;!TW+3&G0T=J2N8,NCMZ^!<^^J<WZE4"5%7C^80W.@=;CD\=O[>?(A
M_Y#O95B^;"7IKO) F)D5ESINJ8Z;S2)##U5"YE8T2$^3CZ*YXM+'XURUAJW'
MCI;-$7S/KHY2X[0P64NPY>$X.4"*Q%3,YCB!3A)<<D837(X6"&Y*D&F>3&:S
MJ>S1S#3K(=DJ.-T^,?*FU>5JTE1ZNG2*4A;.X(')N4)RP-?RS+JWK@R3<+5.
M4(HZ[9?D'$U8;"(I9HJ5:=ET->D4I6BCA:%+1;7+UCC*D@:51$&[ETY1RK!6
M;#>-=$LC6K:97$V Z+:5U2E*R73R=4M:"BW6Y1^D3+HD.*;5.44IN>JZT>*H
M_H!(9+(MS7G,M_2V=(I22II"-@DC*1!@/2QEN/Z$M+*=4Y0"%46^,VF3IB([
M%8=N)>;M+F!.44H^D372M?':4V0[3_-$9I0=]SNG*.6ANA(G?+4](?CL8I,0
MAO)\6D.4<M1RL"[.!.N1+P^H\8/6<\=5T"^MN,P)+K'+54>6"9(M@X=:15_0
MG7Q?XG(GZ+39');2B7N7 *M$:R(]9,TJPA+B>)F*PFQ2RTUZ4U;C$HULFZ?R
MDRIN^H129Z) TE-BQ@FY699+DAF>XZF,P-%DBLXDLS0A@MP1JBA4U2WT6YH"
M>5L01\5[1Y56IRAUDAKW&,LBUFPM)[DE"?+K5)-.4:I'-,A'>;2:LPEK.&O4
M)MEZHLZ<HE2K**VD<G9I*[(UU<BETFEZK<XI2M6HA%$L>W.)[5'"2AOVZX):
M.(EI6=ZK5T;9:DI9D)V$89&&E6BO3E%JIIA++5JBDQNX(CVU/",G\+.3E-JN
M6IGI6JKV"*]@5Q?6),,H^9.8-DJO.AV7H5*L9CN463!L;V:=QK0A6:D-7#K+
MUK+%'BO5I0Z9/TFI-:%L)V;IN3%H99Q\FNJJ\['8.46IH\S]X*&HBBXK#SIB
M:C[-N4Z3@2W33UL:JW%S+:>J7;8\'=AL:\4^Y!>=4S2]3LHSQQWKAN(-U79K
MV"]TA8W$98];-BJ&.I:Y<D>193I3JHHC-[OIP);T$?;:=*(R%,26DEB-3)"1
MYTM@K4[QB5X:YI):NDP-1O?C3#\QO1>Y[.HDG\QJU+B?4$H%-BVD%ILVH16S
MD$1"?')QCW&H0$?>%Z!ZR-*Z3UES(K^!SK->D1PO&RP8%M)MQR1[VOS851QE
M+'CNSC_]M3,6;*]I'MCFPU;S3\A4L"-H80Y% A6T9KN0VH)O\\?*X3$QE]Q*
M-T<TVSKKMHBJ75API1)W\;B'@Y#?@W"_@P@KWOE]C:2%'\^[]38>#PT$&2@"
MXP12N 5?4=\2)+:&\*YC;+_P32'XFP.+";'G]*#-L47*L;8#"UY(^C-_8[IL
MZJ6,J2$30JASY#M&.MYVR;9_8WWZMV]<6L%%>M6HL_N=1Z'.K@/^WK+JY2TY
MQ!V1.FTE"#WW=@H)V>?^. %O[L4$O!?>DX [\(N/MN=';TN*C+;EYK8E=Y?.
M1-MR<]L2@=B-;DL$8C>X+1&(77);7B\@L]V?MPG%G[4&V:V>>G"!Z$I%(5Z&
M\S]=DNQK*_)2>&.X%.%A6<(GQ@>HJ*$%^7^_J%\?70?RPB4FLB]%![Q_:0[#
MWF@R_LS*1%014<7?)\Q9[T;-SRO7_2JQO'@)\R\<:FFXL&_1_C>Z;?D%^../
M#Y(P6;SS'#D;UWPNQ9R1JY#U]HL :T0X-T8XQ'NQ]\B&^_EEE,/S[?(KE&(-
MH![/Q@^W-<7/J,R&E/?;6H7SE&A%VN]-EF@-3_7<Q=R"L.^]YZ^<;GH@)^4Y
M%IC+6OZAW2QR]3^IWA8XWB S-@)>M$_4<%L,<LVLW+--EG>%QU5O(R4S'@JA
MP&654[F7:K-&'!UQ=,31SW TP;4&EMUO.\L1"S\E'\U&(E%"-TDOS-$C( M,
MRC!; Z_2E3,551M/!10^A8HRQNDT><9JRY]K*1L9EI*0]81I&2AMUK<3O:^(
M0I\XY3,6@'W9COX-0>9R8@/BK:K>]CGK!,JT&CR]T5UO.J FF_[ KJC&?0D%
M5$*Y(9F]2/WEB#DCYOQ*S'DY"> UYBPNK='*&79(1:82"6/C@7:70''Y4 2@
MJ3,+ +<EP)9DW<]CC?-U1;K*I765S[/#71N[;F_RMP5WEY-%MCQ=1BQ] NZF
MZJ)=IXID9U!8>^ZC.J@UY0=T90/;,+)$*K)A1+@0X<*W$X->PP6R9 I,52GU
M68W6ZZ)4ZB[!&EU/Q9:0]!]:0FXY;.A;A 7=Y)0QW!VP-PW96S1<=$7D!L#M
MC ;<3Y[E;:'8Y:2;9BAET1Z[NGR5?RCVJ*%22&=*@N@(Z6$)71F%,@T=SV:/
M<^1$'!UQ=,31MR"7G.9H7GVL=8:")BN\1*<8<S%.C'%B V24B=/)ESRM![=+
MG^:XNME[DY>^!MNV4/H9QT.9OAU&%U&I15RR[/@"[*R43?:U7B/#]AH#L95H
M$SI!7+S$XM^H.J<_1IPQ"&P'&,>9?:(KL=%]UQ-3_(JW+**K8M]M6Z*K8C>X
M+=%5L9O<E@C$;G1;(A"[P6V)0.R2V_*U#=?1?=?7[HM$-QN?79KHOFM$%=%]
M5S.Z[WKZ((FN+4;W72/"N0'"^6[W75NS&2J<-W,M'9?W.[3U1[%FT7VYZ+[<
M&P(LMJ6/GG7KY;V^9P)<\&C;UF>]78N@LI%9[,Y)P7"2Q(++/M &-7Q8E)D/
M.W:?'5#9,D[&WR=[-;N26/0T16ZVDR)5F?=LG)6?AOB7>2GL+(*(""(BB'@V
M8N-\$'$_[(M%T.8MMER^IYSDHS,U[8_'?KP;(JANOY[EB\.YDN;*ICQJSWLK
MB@ENZ69SW^:.;IV?7D 4^H&@]GT"YG\49KU/K!&6UIJ#+/,4K:S9IJI/ZZ,"
M,9HPE=Q&?ERT,IWKH=6\5#:M2;LH*VDBV4UD"6%F\BO_MB\93Z4O>,,F8O6(
MU;\&J[]//'F.U1>"K RZ^6E36<RK=J+&.$F[<D567[1GSLR6RKE!8;*J=,3%
MP^R1E/R[PV2<RKQTM?_+6W)0I4,750S?B2Q^27-CYJQX"T1ZVC?6TRY_+?!'
MH>$'!)\M]^T:P,:]@/4"=!QEM55)F@SR1**1:LS57':<6UX1'46Y0"<6A75A
M4%Z7G7M7F3O&9.5?-4ZETI%E)T*,"#&N)S^] 3&*%)5ODZLB28#\,%$5%5W9
M>%>T!5ND^<!53()BM4F:?;1D:]!.2/XEY!3Y$F)\,4,/JH8]-U0158ZVC"6N
MMQCE9(O4P)^F!G[,D;5CGVJ(>[8JX;393K$-OD^XDJ[7E%Z!$H0K"CV9*D]+
MEJ>Y UEN,?G-V.RVAQW_+G(V&YE^(I[_Z3S_,<_42SQ?67$/C;63WBC4*$&6
M&[8.ZI,K\GQ1$&HI;L.,E?1LG!W.3&_#MCK^;>5D\EO;@'@3!4J&3$"R'CMW
MBMG;FO(-J7-1WJ@H;]2?R%&,;0-GH,-E+!BZ[5@N'EH JK-TU5G*_0TYZ"V=
M]OA!,^9MY>,I7-X-JO;**;)R3F8'B363S=V7$I[:7G$9+$B14:K]"&XBN/E:
M(MR+<-.;*ZG[0G76'-1:E31MU];Y8O**<,.S+)_4,])4Z3U*=9OJI)4!A^ &
MRG#?*,0HRGP7J:>1>GK5Y'7OAJ)\29H;S<S"&)2M(N,^EA?3<JK#9?UT=M0E
MRPQ%;!JQZ==@T[-GI'N_>YNN9.B']<91:AVB[ZTM=S)=(C:%$@,5)\F7LDY^
M><-/'=CV[Q@C"*[FJKP#1+CLI@57%J>JPX% O&; &6WP%Y%R%BEGD7+V1068
M$)<70TP./ZL ?8!@R81X_5D@/76SH]-NI4;K(3.H68UA*5\OM1MLA\L%U0C2
M%W2814@2(<G-3?ZVD.3L,M8%D239D.<NU:H,%(]LUY*J.9IEZA)$$AR*G2'^
M3!J[Y310D14GRG8>93N_:0GJ62 [G?W<R[&37+<_70]DI3]*LW702Q49CB1\
ML2A)15?((A:/6/RF1)MWLK@U+K1;]S.O,4C4E5';G8WF2::#6!S%#+UN._IR
M]0TNP2GI';6$I<D86)M MT%LQ=NQ_STS&7VT&$.(JE+OH*KPO'94E/:IJ,E;
M%F>0]\6V-V_U!X"I%;VVDN3+]]*O?XB[X[N',;CFZM8Z=^F%(0X6AN (EIFR
MBU4FI=2(U*-:U,SEG+C@PC0JTXISS[2)@;=2)@6VDP1>A4$+<YQ29K<P\/6H
MN(2O9GJ M^P8T$4@QK9Y$6,T&8^AC<9KB"86CUG -H& DN>JWEWL*L4\>L(<
MB*X*6C.H45DN$.LRCWE0!G8? <-Q40^QD1WR"859LXMV(K^I2CVG:$A7*.H1
MC'#+E?:VDD=4R",JY'&Y]-%/-SW4\.W['26]_W[[\$.SW-_8/OS8M/8WM@\1
M+MW*/D2X= O[$.'26??AQATKST_ZQQ34^#NJE?#FM?A.)3.B?3_SOG_MHABH
MQV]?!>,-<!]5+_@31OFZ=2XBTK@\:7SM2A:PRX(JZVAX,0=U@CT AC,'%KKP
M/@.V#:5U^/4,@.]Q]?VVHA*O.>UOGH7^RX71H/1EO[?<UT?KP>AB"[%>.\1Y
M)<AXIVY34<.UNK@76*6V3E>->GFNS><KO[X$&4\3F>\98AQQ;\2]MQ$A\V?<
M6QQ0&5XNK@B^PS<I;BYE\V,I*/T03^?.?,GJFG2:-W37/J.L\!.@Y9IS_':W
M,[_<N1^Z-H!"2 *&*;B6=?H.P'B>RY0=;CIC$[E1DRFO'LQ2C?$K+U!Q@OH.
MZ?<BYHN8[]IW=M[$?,N-7(![D>\JE/;8SJ\:5<MH=/Q:")G<-\J"![ML\[(8
M<V0-Q(S9+%(7OK2Z\!,2DW^YDQ_K# 'R(&;K0UYKS6:G;A#SS&HML!(@:OT.
M52T,Q\J"ZOA%!M*YEQ(W1=P:<>N/YM;S:OAOXE9QT=82M5&M-BAG,]WE:+IZ
M+-<Z08+_U)G+)5W5-^#:D-R %;/ E'<BK?YF%8OKS_&G:2 7$0)"%URVK-;%
MG/:\0E)1'*U_;Z@CME>C5Q4UUY <*\C$3V=?,AQ&+!NQ[(VQ+)HB2?W]E97F
M/K^./.-?7/S^+%;\T7+ZI>SI55V YRAFRQ?,>G,G\YCL=Q0B,94RINPD&B;)
M^&G8Z=3Q7=J(P2,&CQC\-FSV;V+P;,+IK(B)LV#+3H))KOGDL)\/$I\GO[!&
M7D41BL!V8B;OX7O;D7P?R?=?1[Z/:#2BT1NCT2]V"&X/@+:/_\^?@'6']IKW
MA,.RHTRR+JA\N;EJK?Q$WO2+=:J_GA*.X^XB&?W[)LV]BH_L]K/D?EG='#/H
M*:/W<^A54I?I_$K4.TJA-%X61NOL_3+-^"FT:?J;UDF+F#]B_L]G_K.++.]F
M?M(2<_=EEDT299:N#^?CC>=5MEFODW]6MNRF4C-\B]0+MS''VTIY>]X+.[>?
MX_;+"B;O@:4!]5!K/(PL=3":-LU9IE3EE,8J2&"=BM.Y*!(_8M^(?3_!)? F
M]IT7UJE'8$V3@U:;+]JCZ=3KYJ0@.34=3V5?TBH^,SUUJ*'Y]JQ5UQWC&T=U
MZ13")5ZVAKSJ@J)L"ZIANQ:PC[,&RW;%-5N-$L4F$H5->F,Y34\+*%?6(3TQ
MS@OM.-2,/,HQ_+8TNOX/OPFT?B^;V!#78CO;LZ"9O2@.'J02#K[:)KD]2HOA
M/XQ:GLB2D;Q[+GW*5Q@](JG8$M%43 ,\HBB4_]X^D?9C"P^72 J/1A=@=&A
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MR_*KHO2]%J_BA,=3ST\<;,5L=XJ2!@=$'\HFC/+U^MF,0PSP(N\<<$SH'!2
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MWZ=R[B+..:DW:(T-K9$T\ZAHCXU$8TF6\FZ6^?6/H8,C 30!QY2 /\2F*)?
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MQI]-FE]O2=)S7E*030U)64 (<I"">3;3Z@O- 1Q\)6[FA6;?:@[&O_[0./Y
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MTY\-LM9U;.28'KT#]A0@EPR#RK2']B]&NJ+H[KJ$"R_ZI%XSZ(;3WJB\[16
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MW LJ!C<OKAH6/VH5(60TRLU:1\ZG5RP_RO$F5VZ3_6GKVY 8H2Z#B9M=/"\
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MA)K)'=)X2B;-6F$T3D-L.;D'$0++/6R<7/>B70"-[V#1+K"K<S6K=O7;&FM
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M]53_F6<F=N&8,@IL^&N-$(-RNYC)Y&515A-VO1Y)EVM6,?T+ ]#E,V#WMNF
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M':OH=E>-;KO)HE.>U*\_\2B]7]+M:*A_37D=S^157=FLOVPW$9^)QX6 >C.
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M9;-?LRX^6+_J9"3RK^3G=3-XA-IM5[SNT*-6;/0T5UEZGDM-XX]FA5F.7T#
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M/PB-FY*:>Z@ -6W?7U9@OU[\%5[H2O%"&^3RA7PVQ^?]'_9=':$B68CDQVX
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MV28Y[PG#G(B"+PR=WOI0V,G?*I!L$,1+ZK)CX$I2N#8OG4^AP 0J;-\!SA@
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M_XH#]2PC!V$CP:(;R\R-$)).5 82XBS!@XVR9D7"8Z8*!:::<<C-;^.3.N\
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MN=UX;4/:O4)!4TI&#KCKR^ .V9#X#U8C'&DA_I39TDPL%F1\^F>O;[^\+_1
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M<8GP<'%P<,D(7^ 349'34%.14U+2,G RT=*QTU-2,O.SL+]]Q\/#0\,D*"K
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MBD=A[0.JRT[:>1:^W$@UA>@S,O7QW@-NNQBK3._Z"UZ\KD!V3O9<^!N'<,I
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M.('!H\BK" KWI\?UP]?=#) ;,H' R,9\CVFDB8#)_]M4/4P9">J:X#8P\:D
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MN9::80B_1W+ZB]T 8DSO^B/$ [Z72X7#.\.W4<I%_; XS;5SU >[B#>?OXK
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MQ>+W7EF8^9F]G1B[1.T,/,L>7_MR3$Z27M-+@P(K#* 9/KHER@Q_A!=5OVO
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M<2.+<'SCD6;:9@9\<&=NEV]+OWS'P(.E/1K"N#_S)]]F;UW3C3LAB=.L:C=
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MP%K%HWS2XR,]OI*?!/L[+E^W%P-?0V_$HQ0_?HQ$9K3H6!NN;QE7OH9,419
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M+I7B44'P!Q'5V7Q2REY_,:5OF/D^@IUTTE:JWJ[34E_!44M,/5)DR ?LEOW
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M"O5U/D;Z>$K%R/<E*0Y63=R-;2]:+[[56:*[5=?KDCIOV'3Z?C$%1MQU8T#
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M(#&G] _=)SQ*O6WY)A+ZHO/?"2MFWW\!4$L#!!0    ( )IA5E1B.,C_W3T
M -->   7    =&UB+3(P,C$Q,C,Q>#$P:S P.2YJ<&?MO =4%%O:+EQ(4D$P
MD*,*"!)%<FS10Q814!J)"BA)0'*F!0,( @(B2FHD9R1G6G+.2<DYAR8WT.$6
MSLP9\<P<G>_.K'^^]=]VE8M=5?O=;WC>M+NJ<5]PX\!I)3E%.0#O& #@@?\
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MD9>S M+J:?:\/K<KU/.C!J 3S R#"_I\Z[P%*2-*W0:#[6\4'FR2*+2]':X
M/C,ZKT"-UOO#LE W?NN15'0X0 G9V#F>S[ES R!^RG([(29:H(VAYR9WH%$M
MG-PAF\24SC$GQ85H] #@?JQ<J[1Z<OPI7L-'*4[F$\Y7I^K6G!B3DI.U6RQH
M/TR5.1'42V^>2G-F,%G2JR]:YY)9UPR>]+B*;?S*TW)BF5WUJOH&^XD2Q>J'
M=^5I&"+F*FDMQ*F\7-+TENC>]K?9/-JQ:6!,5XY&M4PS\0=&;_8'FMF6K5)!
M+VL[$RF/D1LLV3@_DSU@]'_[_@-;N^WUJ5U8W>N@E'8.GXG5CY!GS+5+;B8[
M;"QB1@W$Y]>CJY[J&A%\FJ/-]&#60%;XU+3!9$+UX2OBSYO7@Y.E@8!*7?18
M+5BL.TDMO5&E6,I90'Q=2!OAR0*.LTIRJ)?)+%*3UEC?,DN^Q&YLK"9+^?&"
M+-B @=ZDI-9[F_@+A 0Q'3%OL+T"EO!"#MN-[KQ@:VCQ$390A&WM&QB(A+R*
M)KD?Y\<I]ZOPHYR"YZNB_5P-,##8BG"V438#)@XVK=&- Y8.<(!9@9GRU&\M
M1G-TH./C?XL#J9;C(8NS7,Y/KRI-4)Q['?*$D[,DH8VQ,MM$,..LZ)S<(ZFG
M#T)OX,>6H"PG_57,\C\L&RGG/![0$LCJH=N^4'I6BK/<DV"=8"%!DBJXC2E+
M:5#2CHOK3"\_]JS8TKP'5S\+*FBB!7[.^86UP_&($2/'[C7APBOK+YSW30B>
M>L8.T(X;,$03?\9>Z$GH-?*&\7E&!29\"O8Z]6DJD%\K]=80M;%M^.CIOBW,
MU26U"%&Z_OZEY9 FBD54>*=1MGZ^'DI$)[=O:X57QU@DXK496[[9><MFT!:L
M]FB+U,YR@V2P-2*QXM:7$CY0\_A-B7LM]JKW>UKW)P*H 0V;*;Z31:\?HQ5Y
M5O+A7P<Y,X0[B50&:%@,I^\;L7^Q46E77*:2#W'VJ8F ORC02%KL/&YUG;BZ
M^+[,O P#'8+8:]L??JH00;\ !K]%LCF+^9K+V 5U6_I.!Z%.U$&M.+6_I$#\
M(E6HI'AFJH5+IA7;U>:N;5(#4V)XLC:W25=#U4';1178K:#;,0M6_2/E;9]Y
MB7J>UT\%BC5(F6TJ-7)G&>JAI?N7+1];6;'VG"69);$"(R+_@\UZNYAG)2MW
MW!4GI#2J0^N(4G?NOKL[?);^;=C3[0NJM"LQ!5^=W^F1JR'AS_-;8.?,5*2C
MZ"2>'0SS[K2OE70Z80L^K&L>*/>5*U,E)IKWAW<I6@53/I>>YN!OGV&TJQ?X
M[>&EOJI$H^=Q?ES7OX7HLNQG8QL:]O!=L ZX)E0]X(!TPRI9A6(W#R-F$HR$
M;GA_V#[.J]MO\];3_TUYYQ4."%95Q@'9:YBDOF6'(VZ3>=G=],-C]RDPDL?>
M/^)ACT )XB^!_S5M?R]4UM+X+OKM"#L&[,DZ3STI&'%G OTX,@$'E.. ?;Q4
M>'5]D701(T>L?5QY3^RO=I?K:R@3&!E(4><N>NJP70%[7B?D&H:PP* =@KU4
M\=*O9["C1#+EY_=)91SX<$JZ86G':A!;5'TP4;"N KO%:+0$V#U:0C>#P#XF
M^T%<D(7T1',0T]'I04>)6WPQC1_L*+:-;T <G9\ R6OPN<9^H'/GK_>ETJ_"
M$YGZ/6K"F(C'<8"W-K-O.7ORX@#=NWB& ?YPXZ"606E#T>:Y BM8C03*">L]
MF#W'#*9BO?#JM;U+@^R8)Y!]>JC!7<X\===7LEH_EQ)N(3TU(Q]TE)H\6@#A
M YOG2</:X(!UH65!M16383&UJ3%D.Y81[#4*T_<:_M+5D:Y-C.V3F".B8&@5
MMU,4;O=VR>XX[QZ9+GB4MGZ-[#?Y:&.8NLXC5Y^9).@HLWX:3*ISX2]^'=I^
M1:(_FD+3<CCVG_I"BGEI_X>/GT,7PW?ZU20>0XO?G.=Y/7YN#.B'HKF9B4%A
MVT ,C6O# H2H=DBBV2C!'JNZ"@G#D ZJ8@F348?E-'$5#M@2,(.@J.!3JN_T
M7MC;OX6*_'!>_@=J#+G+U/**LG8PY"=W4) ;PJ%@FV>&!?OC[XFW\%;].C%=
MIUI5O""F!>%"=C5AZ=^PCCB O75D(_BU%5.!$Y:*_!D8+QYUPY \D/H@E)8T
M.5@M1RJ"/6<^#J S4Y1((&O=Z$ ]F@%/IX!D0?J/X[&T);!Y<P@*++N'N'K!
M-N(^"H)]:0EV"<=ZT*#Y7SP#8;5/FP]'DZBN9THEJKL8NIB@!6Q!WGIA2'P<
M4'BXN36,V!)B1H,9>B5L\<_E7>'TX5;E!F%E9;!/%X0%8#N'NT_AV)?Q.. I
M,R:W0O4G<D@EWIYY-0-'MK6 :X!K?R;'?I4_PA T]<\-*)^?QI CF7=$<GIM
M%$VIW,?X07#J]8?8KK(#X;6<E0VL^M=ZK*O]9$7>4:Y*(-3.'34BV@,O$HL&
MMA;4QS3.WFQZDG!Q^4'HO%@R79AU2I2A'3.R;>E_RJ/RX%WF_T(]<1QA:!OR
MXZ*0H_#9";OQCOT=K$:$#W-*'@< D(.'5BC(N"\R^56F4/ DOL..K6K8CE1D
M[O&E\JGL1,>Q/X-.MP-GP2.&''$EKL@?8!E_5!5Y,^&&68$A?K,_0?.WOG&!
M(\OZ)YK\UAW^Q\E9>/8OD@R9KEHF*<8&.['Z?M5DBNTVRVRPU>:(>_.W3N?W
M@W(3BA:$^"'F&>-A8ZFPP\WO3BPG&&H= W" 9^+AOG91WZR\N'187*4Y:#2?
M=2@&/]_Z8)OOV]XQ'7.=P199%V*M%X&V#4IO%>O:ROPYR;<>^@_:@Q)-LR,0
M$Q_1=\%:984>BU'^Z[;UT246-\GL/;CN#>XDV5N2;:I3Y8Z0F+8&D(J.-HM/
M23]C1V;'@/(?)7*9?N?%NG*J9H^@>L+]9Z1@5I]6,G]>$\V4BK2 8GM1,#.Z
M01521^//;&]>*]DJ<BU?)1Y8T']AP+L 81 :(;_I<ZLGWY**1$OF!%T='RTK
M?,]LT7SMJ$ABMR,M/UY.^#494O?+&_XU<67=^W# *?+)['UBT['=18/#+RZ.
MJA3ZWBY^09MK-AME"J.$=4K(X0"$.ICTFHE73DUFX(#&OY^1SKXR)]^=KTG]
MS"$]Z(RSO$I?5C=KS"+/:LXQ"H;@>D6I"@O'7//VNA<4:@K'_":D.9V'U) B
M/BM\6U]X'KVS^$A"$F;XT5' )C_04TU?^0>^M.7>)F2]LE78U_3;2_\!#C^R
MEIW>JCO_*S?^E6-HF\$?D .KN8%*QWH-BF#VPP^_$-EV\?EU;,Z/G47K6,:A
M(FLTB\0=AJMXL=U)@IKWY!I4TD-W<UL:*EP%-3LE%=HLZ/B!,(X2XNY*P]Y*
M(0OMBKX7;:L!<4T\ST<]RF@2]PP(8!VJ&]<RF5&FUD<8+Y+35#RAPBR/"1G"
M.LOB />3TDV6.$#R(@ZH)'2?^'.;JGYZO]>U!?O*@YA[;K#[.7[YW=AF-=_!
M.+3]CP[THQJ6+S',[T/^-D-M1]EZ;X(:@^2:(_]1MY ?(;AS#D0<\]]F<!RP
M%:&1_E@4Y:;/S[S8[02H^Z"_3:#P^%WH];67.(#:88P&5<AS"=MQRX_HU7#^
MF>+'*8V+TYYA?>YWURL3QRW/MN^J>/>;L9=L:.FFGR;JE[1\T$%)%O6VQ#7H
M@_:<]?^ HS#/:L,Y>3#]&!?B@)@SL+%C0;DZL([CB#4O ]$?5?:C,3Z!'C6/
M _XV0?YO=LB.^H/*_H"U+S?%_CV6@T:@5=8I?7RVX62RPA]L+NCT%1-QW,EX
M>BQ1!KO;*IHM_N/2&2L:4YH%&2T/V;#^<<W]&OZ^)_P,PAIN8/.VT@)HV1W9
M!3TD3I6?K0[L?T5_U5LMV+:R'GX$'8< %OFGZ.#T> Z&KGCLWU',_+MN*Y_\
MS.<>7/DOMT98MS/YE(BOI-H4">/%G9:;@:.V51$TTZ17$M;#68H2V>7,=,6Z
M5F!_%$!M$<IGDJ0[7$]1KB:08O7<*V*O$]LY>I3XE>3+RR*L1?_01?9J?A(#
M$0_X_POP^"]'$C?X:SX>>PB)P5AE3$^"#6,+J;D6?KW+,I? A'Y^1(?7XYN:
M/;7O&L^/<  *\NK%*_I"=NL'M46.W4,=B?/9%&EJO36\QZ5@,XG0;D_1I?U+
MX=9)7\S$!1W[EPJHF]^NXP 89\7KDL>\#G:+G/\@^_T!O]+9_)O_.%'^@?W]
M\IIH9J4N Z&?8;-OEN$_D<8D _TXLJ9._Z7?O'M0LW2-CF]BQ(K+L3A4KE>=
M0GV%15N!\HY=B,U3*1 7S]UT#OA+L V][D_+6A'&H5;#)F+U_(';*XAS&067
M5U:S>#+*5=A*%])+W?1DU5L!'T?4>@C_0(P%RZ1FF<G#9--"=94LGMI!"@G"
MF+B+13,*]%-5(QWZ<O*4K\U%#(?5)K>@LA,*/+/OYMJ[^(2H\=Q+[GLE:Y%+
MYM_ J]IBM5^[N7ZW,-':A7AH[BK+A0V*(:%BV0Y5GC!'+"W3;,%L?^V0\H=/
MION)??%Z.@M%>3J\=H*.JXW\ [/X%(6NO.DIM0]S>_BLXHFM4#PQLAU)=^BV
MQY[W8\\7N)$L=:S<2#@>-3C,MD_"95^SNFG4P>XDVBB( _";,CN2HKE-U]P^
M=J2K<)=FODSHCX%*W/.5(^"5OD].E.= 5Z+$'MB0L"B@+*EFMFO-AMB?UF)X
MCQ@%W!$!UWB2A=ML+[SYG'&Z^?0RJ0N^E,"*?MY'5(T2<K7((U[&(4/?Q75N
M,-.*>T0O&_7EXMN0$^JJ^G8#E'F6\?.EC66=9QL.%!:<@B/]%7A;.7MNCB'@
M+(3/;QR7>.)AZD W0LPI>=&O:V!Y!63T]**PX[F]G2>Z30Q7IQGGR? :QS$6
MX@7:;[YM2\6G)"0RR@(>SY!E6,6L%SA ?^Q  &J@ZW.XDU)*C7&#+;?I>;CD
MH3YT%I[DB$LP"<)V,6^P+2!VSAA@J+8W'3Q8#GZ#-88GX8 OLK MG8&VOI$;
MX_PQ$[(4FK6'13T5]S*?T(F;FIKAU%?Q0M[\UGU:ZDEL7WBGT/M5]:]; 3(F
M#MS!0AE>[\D22(V]]'! U?FVS"5??PD),W5"'1=AA0;;<2Y'ZQM+>O+/5[(S
MI%EUA##9OI9W%HH(Y;(]V=^,DR[?)QH="WC(&2#LKU8JJ;2KW"O8[8VM7NRL
M=/3WU9;ZLC5,9)YH[0S7+NB_5&2AZ)"L54.$[450LYX+*KU&PU30^55+]=('
M\AWA4+>$$9J72Z^V]BZ=8_"8>7^9@SS7:PW:VMVK.7##ZX[)$]_$]U&$^*P1
M!0Z)YL)\='H+NXYK?/L%$437<<#-0-C)O+B&M*)7/.>4A@>3!X&GWB<V!:J:
MIK(S7=?\N265$YR5Y;O6+I3UK<E]9.S=#VC]\%*,9L)0D6:.5C(FVDS)T>P8
M5-)U2::?.[.M;C049GUL.T0'*LO\BB:%O6?-TM!/QU_"U^C](_:02[>G,"'R
MD!=N\@'3I17(F/@,YY#ZW1N](8N0O*^%*9LWW+RO$ORV N!%>05N*4_QG*N-
M<, F"[J^?B<,/6-^ML85VA)X5R5XJ,[;EK9$D@QO,O&.8\7+R:"S,:-N]R+H
M?8U?WJU7_XVS1G*#7(C1=2X0+98 /Z6_M$;A[\3^=?:9N@7BBCD?WU6.ZT\^
M2AC%4DX[V(1?+>'1XHCS^WAH<:9P)!]6Z3?F[34^[#-]GX/?P 8@&0PT [O8
M'O/-#B_8AOIY')#M MNBVX(,LF-EI?BP",1.)!0$Z^L ZL\=4:9Q?@L"WY[=
MXNP'V^(+RJJ'SS%#B]'0\MZ0M3M%@9MUQWKC\(]ID7^:PA<+%VO(9C1GDQ#T
M4YKS5M,?6H?66CR"Y,J59,JPEC[6RO$[CFW=(U[CMZP1G?.;EJ:IF2R+W%LI
M%UXQP[\J-+-135/K'_IZ/ 96*B::D.R\2<Q;*$K'-=3@FY51><$Y]'8WFBNS
M7$0X%<]"PHYT$>QW=2G?3+$R,#C.EN  7SK'2.O)2 .40L&(HW%$%9NLLV'$
M[,@K'*")3MF6SN<,=_PD&O- UE'\?N" 7F'XYYXE*-0T\-%5+=G9^NA!(=*O
MHAW)YEM!9W073X\X4]]5D<8!ZJ4OS6@2IX\Q7K<M$>6X*CQN,U @HMY*H4H4
M5U%6!^VX%)X HCE4[V7/@99@Q*7,G-S8.?Z M"=$<J?NE?3;Z]W77LI.8;QF
M-F ]K:=J,1UT5</W0=5!E?3ZRHO=U)V8&S-@;-@*\HTAR>MZS-9G%*I!+7_;
MPD4%.[85![6)D,1[T>[A63"[G6 ,]E+F5;(4&J>A1[;NB[7_^&6GA@5B T"
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MK9&U9\.6BN44T.OZ43N.(:9K$[*ESX<;3)F;C@_5(IRCIIBSS/9E+B<[VPK
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M.$Q "%ASL@EJYJJ9LDD/[L JLIN7"LB@K84)@#N<%+K6^<P'!=+#UAX?Q*%
MAP9'";BG-1\\/=%R2U" LT,K,8?OP%8)!7QKUEIN\0^%CB8,[L7)CJOO7:"
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M*T=W*DULY"^)M2[IK3+L!=,N].QM14MU",=B9FXO$H0J%L5(Z>4:OQ]Y:KL
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M@= L;_@#W)'0\5-6TM;$/AGFP9J,XW!'\Y26I7EM/<*U7"L]1.<]92R"9U
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M0ML\4"!J%'S"#F[;.-EZ0!(ZU7[S2%W+2W?'??G<Q"7UN,[SR89$AN]C@Z%
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M;J5M"P5\UZB'\SDY>B@@US+V>;YD.MPZU-$HX),5^@M*!_=+[#J2?3P!HH,
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MII/B-V0G*'XF<9(OV\*VP<HI)5J[')&+Q#$0;>(O(N[@W,P<)E'A46A0H;W
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MS?K->NSJNRC9FMJ!]?2^^YE?<./8F6V<&#@C];7-C0F;0G1;=;4+Y.^W+"(
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MHH>,L%# @_^S4^*'8O&\\A=S\R"L7AA/.C6ZB11WTLDNR1R.2G46"T*UP:Y
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M#M02CY"P;2;DM6[Y(P@3DE#WSPP"_XD"K;>GZ/[@VGH^>!<!F09O/TB(V<&
MM\E@OS*G9UGGX@"7 X/>D'S0%?</3_W8VH+=XFUU=$]1KR0GQO4=HKQW2*;5
MOG+;#PCBF&HE"=7171UCG7//)YDY;A?B8L_7:KB.1:B"PR=7&(</Y'@ 4H_W
M%4?:4!R.-/")V8+3'_(K.E +^XT6MB$-[:YLS$4&58Q7T13Z/!984\(U189C
M"5C#&H./!?:SHW[B/,OOG/_O6O]IK1<M?NAKF:8)UTHJ8V>;4A[/2TDNKHSH
M51V>:I.#SCG I:;=&ZW;]JWI&33SR>Z+0I2D3FJG?-2J.TU X2!$](<9^'BZ
MRA/Y.O*[M0IZ>4<3]_ETD>[_@;>(<3W0?W86Q5H-/9)7$:$=76GK2I9F>R.1
MWIJTVO==WDV]42:^\!%5EI_<*6A8G0Y'GP,WDV[?OKOYT<O!+Z',!X\#ERE+
M%#M;;'6"\]J_O"G>9\I$7EE=TZSZUBO0OJ9NR4W0&"T:U6BTT,+Z@1AX%6PC
M\E5A&]5X\ZN&Z5LX4\FXYDG6E]T!:N9F9_D$EK7)O&4OUNV6M^)R-XK3U<T.
M+]59>=7'%+3L=-TCB$_G2Z)X+7&2K3<V&Q45$SR/N%[RR2[23 AB/,A\R1O5
M!78EH9_;#"7:>.::ZV]@WS #>Z>KVE^TG%+XJ9C2N:CL[0KC>:>S:H3T!OII
M>#-Y :1[0[F@6,\$@H19YZK@!V<C[I(=U5IDS>4ZRB%>U#-=7H8'8"9KWM2E
M&Z,<>@H_(SZ<N<^1B2?"NF/^<7LJJ&B-E$6SISB()& O5WU(VEP==",@JH"H
M%>YNX\E>5=]+[T'G^"II;4=[)5RK4W\>5.6C1,"B+KGR_.G#+S4IH&<JV^?*
MDT<%#K' J\#G4LZ%* NCA0<7S^D12C29-,UND"AN+[TK4N!7@(6.*0LU7Q9H
MZQ OC.:1OJ5Y$NZM&;O49$ZR15X=51UR,C&$A)]WE'ZK6 !Z.<7RU=_J8SLM
MK]@Z+7TN%FC(HS"%6S8M-%X9+0Z6M[=DZ!,_6';C;R9[_KR&=#LJM#!]]7BQ
MT-'V7'B:=.ZMDJ>&47')4!>F9QO:3ZH1=F.:_=9O!4=X>#;@5XKD,VM:<U1-
MP?:N#(C8>333+,KS7(-*[[X\#:^#I_*M&(JFJW(70X-3$>$)_G#?Q3GH3%KK
M8J^ MMD!G)=D0H%L>6*398@M\-JYOEL>72#O[N' 2 P(]@Y6RB40%3BX  M(
M+XX52S,Q5*'1H[=M,EN6Y-WV?[O?NLDE0++"/30IV]G4D2]GQZI'%'Y/^S64
MB-X96OD Z9>&#)HE?\L:OFF9W)^[F1*]I!1[U6#<'S^JWJ<E:4VNS=S@BDR\
MK@=XV 'Q<B>(ZLV!/KXJA4XS@LOG:Z&/'POACD"G8JW;8IRYN<.EH0/XZBMK
MRB&JFS:Y-Y<_/1NJL$:JB9[[Q!B9IK;L3"6J$H6:',_=>[<AX LZLA&:-F:1
ML.'8+$<X#6VVU7%Q.YYG*QB\A!&J,2G9> IQPG_YTMZ[[KA_,?%ET1-++X8U
M6J<T@UB_ZJA6\\RDA"Z&1[<Y^!- B(A/^W5-IK &P8I>P0D%JUR'E1QKKZ[H
MR*EK#X'@M^]?VZ_4=JI6((Q]QQJWD:']LH,I XP8L4J_Z 5:@08KF]? $PA\
M11D<)J!]O[_I"FUT8J9GC&H5U?OBHG>L(=ZMI)4L#*+*5J^^_,BI:F2"G^UO
M*_V>C^G9]4 L'#%-3IQP1N6I5R,LG&!XZQ:QFD:#T%+UFZ%W^](R+5MLZ(/G
MJ"4'YR=6I\?&%7C\4] /<.$45:WN_ASOKL9NX![D'62'&4F"J3+$F.O82H%]
MKY<I28$,_/Z]]/,!)2F[V+_'%49_6D-_@\2%#E<[Q3 5I3O0@S+>P,2="_VP
MM6P(QUY!V&$K1)M,RWJ;U147@NFZ>"R?'B;P5[^?HZ5RXC4TSA-@SGL'6XM5
M911#@N]@3-;;89-Z]CA<S#R3_D,@/T5+\.4J4BS XAF#)CE2E>0_F?0*VV&&
MD$AX[ M\R,A*S7LM/OWWI%W^?Z3K7S\G057:8<S<FFA$[L Q1GEP\^,#ELNH
MCRG77!ASUNV>V%!-EK<MS]>45FU;OB'YX*_49Z7;'E+&UW3M C$JVR=\N?8@
M[5J*?I,7I;],855)_]X(%%(X+[MIW?_T4@>=F)P)*)_VRK2!@6UD9&!]?Q5+
MUN14<=J 93JH-'JI Q8H&VE@7@[SEY @T!ZHTB>8%TTMJ7@$7Q6M\*LIHR+H
M?3N]L9!^KK,C*3[ZH,EHQ8NY_%M91;0]]VALE_N]Q8X6XX^5SA>6,K2<L[2&
MZ/*A"6==.V/'S(^UMB"7V_4"K[\H&ZNTJ;OW;4&6+C]2B<TW80<^J6_[2I]X
MY<'3:'7&%Q<23,-87\X4CDJ+.F?FB&M96*'%P",^IQXE,\&N[9*5D\7>D6TE
MP[&R<%"0J5'[^H//UQTZ,=:IDU9H_>V6N5B)[1[#85\>2\S BKNY1)6HV^I-
M ?>23@J;1/:K%^UDZ_"^Y)+2U9647MEM_VJFI)F]O)%9VP:]C]G.Z#H;[^WS
M7D):;- =0BT==(%*U/JSB4#>>OF<^@%_WD<MT9+^HC<R>G<.LQ1#N!4&'@GH
M5;BM6*9+E%6(P?F:2L\3;X^RY-,[I!X=,/H*Z1"5U83B,:89%>CP!Q%-&)Y;
MOLE9QE!V5[9V4EI!SU14*[:DT#(M)[Q!L#$99%I8=/L.,#<5N+(N[C44:W&%
M]%SZU2(>[N@QU8AQ2B.N*T^S=Z<C6^&01_,O*R+@QV)EH:/Z[Q]E2!")@.3C
M- -&IGQJC^.'*AP;Y*TIG6L@/(J;#^]&\P!SUS29'BCXU/5/(-VT=;J.2?S>
M,$F:O*")T0M-Z6"_^*W[JJ!N#=)/8KX"H2W)GC+(K#8;HLL\#+Q1#;6CJ5LY
M_"KG=36@:/2EI1!$5%L,)9Y8*OP^D)+=P-^*$A'!Y_I]-F.*=H''K.9R:;Q9
M-/Q%0J*I7,X5^MMG0-.\UUCCSX1'*#YV@EXZGA23'[6<K0A<8;%,-K'//QF^
M2N]^"/WF(57S1G/%(G?H7)6Y]6WUPQ16I77V-IF.W'%5SBQ%<\=,!8FH+X6E
MX:7<L$]5,JMG:N]T/S[8SP!=+_L<6*0DI<[VJ[&:*Y(XOU_HYC5F:0R*/S>K
M;B5L24Q$;XF_E/AHW>L:%F@-FN8]1L0<Y=JZZ4 =VA64SQ!^.EA[9EGI).31
M-KK2/;&B7H^N@&A\.!3*V&;-OTEA[F;8V&EB_?(M6$"@Y[7<JP]G% G?7D4\
M)2?0H2,7WHB&6:!XX4VA3!T[^95B)>M=DTZ;7>QA3<T2][O6UN^>Q#VV!%O'
M'19 *W=#);& HE6QD^*[RUK+*Z;VC,G]US-+&%]D<SFM W":+WCX<PQ$A/2!
M.-U-$F>PY?5/'=S@32H/I6XLE'[?44GYGHSA/0M%^'M2.<CTIYPO56-?1[2T
MU<?2.H;R7>.&A(CM([[8"5\(7LS31M_5K)9<Q<MX<J.\0%[ZQE'P;3_B,Z'<
M95H;\P;[<Z#/MK-SDBG9VB?O> _\WA6.+2ZUUW-L=HF@RENJ2>(%1%#62)3_
M">+7R; 2G&TO@TPQ_7)*!+WB_970Y$#.#W_+B)H3US3/7#DH=4O5X1K<:+CX
M3;V.GD ^ 41E=_G[8<YG\\;A8\^)4!_WW/&1\0<&D5/:<'6Z@%3[9DJ":S+*
M:J&#PY/+A[1A 5Q6FXS\&2-9$>SWKB?8UQK-42O%NP]R:\H,,P_'J6WO'3 Z
M',Q.SM)MS! 1<K0]BP].(#]7I.!(D9^L?<\]&:ZEN<H$IQ#7IWH(&!Y>U2<<
M4#G^OCT9[,!PB9/JHP+/4K0ZR"E;+-^H=IW/)=?,O\:'F#WY_8_1R$87!)ZG
MR8 ,O\"H3 X3()YA[L4ZGSA:+^A$*V&.R->^M(=@\,-X<#1OD7_^(UGK=#_J
MLE#,)"AB"W6%5'KOB9*R>H>Z+M16Q0(M% L+IFU>>B3Z^%;3HKPU?5KIF>66
MX:&"HC@8J8SQI=7HBABXGEW=AN$9S?ZK"6#B?DFQ[L GZ19AHQ? QK>VC@+=
MEH:J3/L;OT8QB*VYZV:8NP]![/(G:)07P@0K((KR&)8JU90'IJFYG0E^EI9
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M7'-&92D.$N'N$)CHMLC:BE9"^%<MDXH/J@=QXLL^!+M4-@N/$B1]!X.L+^K
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M6U[_4,D:ZCQ.[X929=%.A\TBH7NJ_990:!ZCWH72R\WYKPD-GQ+8.B80PG?
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MQ1Z)UH@'S9VVETH#>&5YSC"QY:&*]S_8M;YZ%RW"GGIBJX4,6K&;L?(NAE5
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M?]PIPV7(4DI<)&,%"XQJ)*1Y:)PWBFX;Z[BK]*'FB?3YNA90LOQ]3;&4.N;
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MW[1_?2,,]#(Q/S12*@3(<\BS3)91]Q&8%O+[_"IK1W.&"':<(+GN]:ST[,*
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MKT<NRBY;9GWK?RY WK?SQN<AT.]77;T>$\>2Z!3'5(+ZS22UJ;*1:M\&W/>
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M?(:IM2]QS>A!1#(+]-:A1'L=J,#@VYJ>BK8Q?)#)@B+\)CA8W_-SOKL$ODZ
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M]!4,1@>[$RTWB&\CICKE<6 @VO "$!L&2T1M:E8)"R@G\+<K_!V%0L%%NP+
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MB!%Z,B4*[^3!E>)X"ATM\;EM7X[6.[K\(-*:;$15DZ C;2RQZ,6@QRD]0CB
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MY',?7/")_RO'N9C? M.9_M(4R4?3U%7*++UCN:^EUN_M= Q9 W]:P'>WDLI
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M$BJH\'&[70Y//'>$,_,,DJ<&BN1!7T0R"O1R^RT:$J[?D9RB".V<-6'NTW+
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M/&?O??<Z]U8_[X^:56..>JMJ5(U1-1OU [4$W%-55%$$0&@  +K[ :A90![
MQL3$PL3 QL+"PL'!QL4G)<#'P\.G)+E/1$I+14]'2T5#P\#"R\; Q,U,0\,N
MRL'-QR\D)$3/)BXM)B#%*R@D\,=+0#@X./AX^!0$!!0"C#2, O_EA&H'B+%!
MA& ;,(@)0",&@8E!J$Z _JZ=&*"_)."O"80&1L? Q,+&P<6[JU!W#T #@<%H
MZ& ,#'3TN]*@NW( G1B#A)%?#O.^M@46DSNI0&A"#C;SX^JO9#JC^RR"EAZO
M<7 ?D%-04CUD96/GX!02%A$5$Y>0?Z*@J*2LHJK[3$_?X/D+0ROKES:V=O8.
MGJ^\O'U\_?S#PM]$O(U\%Y68E)R2FI;^(2,W+[^@L*BXI+2F]G-=/:*AL>E;
M1V=7=T]OWW?DV/C$Y-2/Z9GEE=6UG[_6-S:W#@Z/CD].S\XO+O_@!0+ H+^E
M_R4OXCM>:.CH8'2L/WB!T'S^J$",CL'(CTDBIXUEX7Z?22 4F_1Q0D[U5QQF
M09U],DN/4=P'+$++#P_^H/879O\Y8J__6\S^3NP?O&8 ?##H;O# Q  $.+MD
MSPW!_1]%Z<J6H-L(%J8"):<D+E"M\%*IXL6@!T.L(J^1W;=/MMN:288U,0^]
M&]2K:2MCW>S JE$YCJ5&"X^1"@R,BAJ*V*7[CJ<& K]5 D@$^!-DJ8[U#4YW
M$EZK/%WB?CZ?L-TEL?B\KF&VQB)54M8BU@ZL$55),.X#BM:@X/C:]12'&0Y(
M1,EE& +LN5'_=4ASUAW7RMD=RD;MYC'P=YG3WUMD$=ECN<?\U'>>%9,=#&OT
MCEU0U'U=JNZ^N)_H )E6#K-H)6B21\1\V.(RA=[CM \.K'*9F\7=7;J,=RB:
M.?[9G &RSM&_U\^Z2]TV8TE[>K6QDWH^[TKR"=O]VU545D!_R><R?;5LWA?&
M'/%>Y>>[SC,_"QZH-FIHKXE#Y)!Y6=B38E(?>48U>PG<.ERDV=$<9W<4%WY)
M2_/:Q*>B@!<4U)$]JD&-XP6MOF;:68Q46+-,T=F50C\F)[<FN7R=/A2QM.&7
M8^]DSCM\]K"'!UHZJB"8:(=L75L@X4>RM/II'F?>[YCW>QA69SYS/:"U_,XE
MEJ%XSX6&E>OQPB:O%8D"@Y=T%V-J<;YNPM^Z5/INC!GL5_5GK(W7*8;]I39Z
M7I#'$FJJKIUP4>[6L>+68 A&X!?1EI9/-A5<J3O$\WFROLB,"@O]BADB*>YB
M\9;.NO1CDXLPY9=Z$C^;%3X4,+\XZ%E_6,J7IH>PQ>2G(F@.L9A" 5.ZTN$Z
M#@E/4RV4XA?]/.1V9&E)!BDI#72 8=,4\EDXPOGJ24"3\YR@<8O^5-7,;+E[
MX]5C/]?LY74X:U:)<S'%2_[7#\4,$'/ST-:GA-6[L'>O^P3RZ ;<,YS24@\2
MVJR?'O=;"8>6Y_84I\W09LKBL 2$$6\$Z&&C>Y_%]Q4;B:8NV)"E>4OH@"L=
M9Y_OTZT(#S-[GA0XIB,A_#^UBG)XOE8P.W84IV4[//F.;ZGLL^S9@T1XN=]_
M8:B6B'8S]O,GE Q&T%#!'(]&:Q:]1C^9,<4'H_ZE1S#VR:9133+H<<"'A;GW
MUGSW,#LBZ#H0R$3LF-8F^/$C9BE&"[$AZD\WDKK@BOL](;/=@M&_0J5>UE^\
M;_ ,<8PQX=+VL;,FP7@7/!(N:G"<2TT]U1R[D5_BQBA G/1:!?+H$$:XPD;8
MG!(&WE2P\76V-GG S"D@2=)E5-R7&T\UKJT D/X9NFI>JT(?N^U Q\]LGM(0
MQ\'I;,6Z !4%/I$ W=!A5<"0 S3(\\\B_PF0#<\)#U:T'#W,ZR<M)O?(RC;<
MX!1X*[X2(DXKL;"%M!F$=Q\:H=<;L'S2\QGQXGJ>>8B@<Z%-4$02>IY/N=P[
M^RKD)#-]J84%<75U]Q%"L,[-QK'U$R>-7TX*5\3Y":F1IW [1<G94S/O5ZPQ
M@BGS+(;%8(2/;X<.3ZPRG09L?@!6PP(>D&_EZB\]2_RF,.?: ^'%']9EZL9^
MRWRY\1<)8@?S"+FS9J,KOF"R!NH[QL<-S3)?!@F'(UM"" Z:LY2%$;'\+ZB0
M-YGP$V(D)IK\[==M6:KOGDD:A8H>(:=244'_Y1[Y TH"?O%-MM01@B\>+5_9
M6R%B]06X&4(HO."E[&!"38*981IMC6YE2W1..HEQQ^5(A<]5+4/RQ;CNWZT*
MN:"D5@LAXIM2$B^G[YL\>(/)C\@>JH!:L26A^;T]DR:4F"P4A_&R@\FO\/H4
M' ,B5-(89"3IQH?/%9>X!#Y'/RV)D#[:-NJ\OY!D?QUDAQ93\8&@-4-V2:7*
MBEM<6$T9;6%K=]RM^"HY@&J.N=6J-W>QD_T<9!-''PDC"$6FQM-$(T= "J1:
M?P L5:V4*I@11 HBC@D"R:PT.AL>GGCA+".R;6C1HOU/*ZI>^U.%EN?XX<=1
M/6 3[P*L[!$>#N0&;M\'WCSCT+YF:[7A:ZQ&'*VDJN1?:;17_.@=]"IQI-&1
M*BVM0 &^H='(H$02/JO'H#FQ/5F:]G'7GP?@#KX'JRZ/;7W-DH]T[3T:Q@/+
MWE%FR2I+AG$%7.FC@&D&@0_1JF84\]$94;020POZJ13:E(V6F!RAPW,+\WXU
MTRZ="8+B@5 BAQ*;*9\S'7)O=MR0P"68&^0MV33U\S7+GZ2I%)9*+/YWL_'X
M+&U0I'IOR.-NM<^XG6Q%S M6\_VX3[.%M<@6:B*27LF:#<I$*/<W?'J& BS"
MK"J3Z*:N.EP-,[480+( /JXL6RK_9"A%T:@L-N9HJ (/*:"M\#<(Q[*#5'J$
MY;4GG3X7/T5XECM(^D#>6#DL\!@%5!=MCE W_]HH.S/8UG-J89A"*&D?H'^Q
M:X!>6!<15\+.8-A?EMDGA3]&F.!I*(;0^!VY07!;Z>(J%S D(NK6CK)YD7RP
M .LI-7QB>9)\Y>(H/C)%@'0?YC^");5 9J!3LS439OTZV*Z'>2,Y>__=D](<
M+[5]LO=HA@(>T"6RT94T&BTL[E>T-A/OJJ<*F,7Q/"F2]H>+D"7#%;YIB@M>
M!-*\%ECOS/LH;K-3O ,4&&,T'8 NI)2V15DQL4R?\E#/TN0/%T'CW=IE+EJ%
MSOW[MMY%7-RR^-GN"\4]Q5NW-$],M#$&"]W7<_K,GHY@64MHZW'O+;4A7NRL
M&2C2^$<A9#%(M?\!1H9G@B:S1O&L64)L,!NT'&>-#M?KH*\H (H!&,]Q>!HG
M?[DG)4FV:B1]B%9D[S)=EM=-Q2HK:FZ;\Y(I1/20?4[:$?^\4I$2XJQI>C(T
M>*"I\&[6H9_%XGL:7CN,\,I->M.#*_IMSV0<26^] 7ZT0!$X0=.,=E94C3JN
M'1?XS=Y;\>1\A?YBO^GZ#?W^)_FQW^3BQ^VY[5[3I-8&S"@ I]/LF*@)!;0I
MW)4JH #9J\JK-2TLDP1%!0_(/YYH_[GF W!%;WYOA=KM_<@O&_1>*" P"K(L
M]OXV],SLK!=&6.LV;"A:"7<?.3]%>JQP41?RUT]=^%,E]JQ@OO,_['YI5_@N
MJDG@4Y@LK9LX94%%H.\713"]/>2LKP %A'<HHH#L[.M7(Y@W9*%W2B-B4  $
M<KZ9=WN?@/HV&'HP)DM]K(]US4HE>GV- E8+X\Z?"KE>7*" 'G7 =2(@7<?7
M.D*[250'^[3\3T5"Y\V*;+<RFC>'=F@0?,=3'[A[ 7PD];#W=Q)PB$59$4]L
M:N8JDU3@>U'73!DW76G!/P?3#7=:X[M<I8_Q9NZZ%(&NKJ& 1<P0"5PN\-_;
MHO2/=H2(;I03_4,A_7ZZW>+1$0J(S0 6<ZL@RWRC7];740"M$/2;11YT>/A6
MP@X<'-7^)\JC?Z(+([C\_ZV:_+LIB7[>H=AS'9A]M89D>R]DZR7G#;(*C9<5
M HUH/^LNLHH[OPJ[O2*%VC]' <-S]&<_8'C)X2NE_\CG2Z2D7=_<64%0%-#8
MX#_:X#_%O^+L@OWJ ]/G5J9=UT1B$/YLR2UQU43YJV1UFY/=BO2U6D#DREV6
MED?4?QTNT6!&Y5 S+"3!FU),[2PW)ZB<;RFTURP$FK>)_Z1OFAG@Z&J!+[CE
MILY93,"LW&BEYKY"P#E_VGHL69U9>M<;G,!8;Y[P<#;%!BS[N(5XUKYT9S5&
M5.SY+U<O>5E:.2D#QE5G?WI"N9=0;I*^=Q,R&M,G)4;=\2B@7Y(ZC2['D<MT
MXC,*(-T@F1'^O#4;:ES)&#K()_G1Z$U37907.@XI'V8A-X9[JBF/D1&[N;/,
M1OKX(S"RZ&X4D)!++!/HHE#(MBC^'ZSIR6/A^:#;KE?WSF;U<P_JD]<)K2/]
M:ZB S9H_3)\$0KJ!9-VKYZS43+>L["I^\30TKS%\O6B('6TQ/:^5>ORL?'M'
M8VAHZ,7/++ZH(C:WE:I >IE&;UY78?'0NH3AZ>1"PF%=6=H0AF-8O,28UG6+
M/MM[8;E"NYKO:8_Q(J@MQ/IX?H!DJ<.C];UV<T=5&>KCAAJ8=]=!P74QRV6M
M&HNR@HY3[L*C&/71:'E5PIZ:S37U-0'][R-37\@E]+F?:Z'#[8LU0G>]'M5F
M-5M0@ ^D[<N%Q<C46\<-'%KUIO"5QKV$?\JP'+SY5>O%$+7TU2;\MX+8?&QX
M1H%MF8.$R=Y'UP"!FGCO9FLZR2A+:63WI63#.7[-(_R8<:IZ0G\#^H)M+BA!
M%IPD7!"1(D&TYS]E^I9+V:KXSW%.835 HH%AI5G6&_M$*\)X]6$QV"5JJ'H<
M8XBL3072)/?K,\Y*"*88V8!O4B?KU.W#2<HTK70+;47OJVS5L0/,0J%,JI7?
M'AM?V,^D(88=^][1&W%EB]=G4V8RRA#.K!^_H9?CH)SE+X1?\V8OXJ[Z&X/M
M7[HT'M--M ''.?ZZUEZR:C2 8*(=FJJ%FS@;6B./6A?\-,FQP$AZ/*^,,.R@
M=+1CA58N+MN3%#BJ85EH#])4!78(.J%'HTKCH^L]T^.WPKUQ! LJ#?4Y 8ER
M8IRPU?T2<MEQ!H8>J)NFV$(Q"D"&2-0E:(H7A?48KIQM709V&O,E"O;RHQ7=
M7D@%*]:]NC'OCUGEFG_K6BS-#@Z,'A><[7+'Z^#$BHG 3=!1W-IL5&8X9LJ4
MI1&Z?(D"(BJI]IXN\GP03V0>FMDZOE&E59QG?:WWDCE>(FS#8;7X)6? %%X
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M(2?A[YZ\M]S%&NC29,W3Q'"<-"R:97C==?C1.U&6?JA57;8'SLLQ1R22K7[
MXF#M+#+YV+?3.2GN>PZ);^R\#]3:''3-<-\T.W13$:N '-RW>Y+IW8W5%,2T
MBC>U1I99=!ZFI8SW_K%\M=/!0FNJ;^)S.E$MO>377.OSLDJ8K3[.Y!G,+PC)
MK,5(L;<@R\SCT/7^$]*WG8;OL&[P$,45[,8V6J+JT7<>@>Z3*6IK-RH7G.Z'
M0J )N\NV J$:0[G\/L:X-"]*(&NBH>H\PC+G53QH]]JR21/X,2NW7,SV#N(G
M-L]\/[&[J9Q(E5=PZ.W;:WE!B]^_M:"^G\;R]C5*W/DS',OL* A@+-9K_B>5
M3[KM^>YFB^:**SBT\(/KR3"3V-#RSQR,.(NIC)ESKUP'_Z!DA,2;WT<L/6?\
MO9YU 08*%>>.F@<LQ!W%[W 59]/Z/5INR>#.SK3PSVZ*A+WC['U]70SD18!-
M"PI8$4DHW-*9Q?G5%( "FIU=T4,]@C3)-JRM?A"I=K;M3V9#X3-;M>79#O4H
M0/_[&E&G%A;1R_U5G5HDS6#I!U:NQI2OEM*U60X_T\)<'GY6^U+7P7@8^3Q:
MB?+L5RMQ\CTYVL9RY=TQE:9$\J#)\+4J^JUWO^U#UR3J>A.'?B&-[!B3:>'5
M?-^5(,B:ES]<US-9N"FUW7R[,0)XJY<&V3I)A-=TA'25OVPS,41<<]%!WF8H
MIC VCS]ZF<6GM-L+=C]>\CR&R4L]LF>1H:B/"<7<6A-8+Z:KVR3&9Z#[I"\<
M4_F1VT>=* 7=OAX[LGMT.VI&XT,78VQN%#OP5Z 5'%@X<NC(S7ZM%#[@VG*8
M7%5/&!.?*Y9E*^0:-T8CW%5ZS#5T/>:WT@AG-.[!64I:G+J^U)4U&\W:D'<^
M_4"]0XDQB]:L(!Y-;_:M=N>X(<]\5PT"5;6-].+/M_,AEPLQS[$:/HL#7]N#
MAA8&9E! ],J8P5FJ"%2JH]IB>_N'@3/)#D6W6(5N^Z5]V%/16J+C]]U'S[-@
M=-G#D!BOABZ N0HL?IFMNERYZRHE7]9OC[_WX"-.1_*MX*9A,.]$5O> /-;E
M9NRH?HMD 3PUD\(B[6H@Z/E)(?J,_GM'*]=Z2;>0H^B3RZQ?=?HL<N&R6##2
M V1J/,$,AW)O06X(LV_"E&.QQ8:"[7!!=ZGAO#?=ZF0=!_8@8"[G^3"_9=TF
M^.4Q_$?^"V;"(H8)KFW9+1,EZ1ZX;E5C0, ;A(N557< %3!7BO".7YA50=^@
M$J5@F(A7P$J0I8E[6P&I.>$XYLAF)-S D4HYKJA3[O*@XZGBHZAK]O9J0##4
MB^-+;^<C]ZS&N1F;XJBM97_0QKG+DMO]=PZ,_YO@B.[T+IHTK3I3<[V-/K=T
M<Y_:AQ$0] "CS=%)71[TLZ(J]2P--B^O9L?1"!W5M,8K>"KU=#$"(SP:]N[\
MSN.]/;5XR2EI%H2W=^[:@E^;'3TS*#1KI<2!?";BTZ@\64\&T@)Q3^P41HCP
MD[YSW$5!4W>QY135X,[ K4ESP\U*R?/V.4)QLB)/X9VL4.[BPR#8/:5/F$I"
MH):* .2N3%VWJ>_K4V]YAUDF["?I-&FG99R7&3,11*]$O8@0;)NRM%J>6<E+
MFF2]L]L^:KY,T6JOT*VK9L <9W X[I91*R_7NZ-?-&MTK7;@9\?"/^D>C@D%
M&76[;5YZ-GR)WVVP&](C;PO:'GOT2 %>JVR0%26M;K711O&Y9IQU8D#.=5=I
MCT(+D^2:$ZE(-+-;(SZT=]LJ=I>C[!<>'.WKPVBZK5NTBGK<LN8%PVUR#J=R
M3O9.[8_,H]:OT %%_=LAM<O73RMI%!1WT^Q>A3I_]VB76#V1ZF!;F_/*S+A+
M@\M-LG\&X+RS]EJOKHZZP.I(U)JNSG)FB)WQL'?.*,UFJV<A]7N?<_S:7DK;
M5=:)8_^F+&6BKX^Z-W=5^M&X8I=<"<\QC\2,'*=11/PK'W'A @5 U/)2)P1+
MU?#OQOT7 Z^;^X;G9^T2E7^;TNW[8'CHRK2 C4?J+=:L<.TJ5U?M"%L?"G@1
MWE/AQCD<L=,VF#/+RZ>*!N4$?K1WN=V*$045V_LKLW#OOAAV ];I]VDGYDXK
MI!*"5DN,<SAL79BP;@K%(1H@4M"8X>/J)Y%A#L7M8$2=)M?OQST(H02B9!*_
M8F%Q='T2?NEJ61K6(L_312HC>1G<H@%R2(H_*;;.0[K7+?VR[^J(R.<T9)GX
M8_V$MXBC&0K;W7*C./Y^:!5N6ZG:.>X<_=1$VH.HU47/Z$=G/-^N."DPRU7Y
M>;8,!9#+GY0%*9C;>]QDG2R)S:QRG<#W/67)]GA2MR:?TZ E<N@0>)KB)CIJ
M!Q1H? P>9-6E_*EY<>-8[MKDF/H.XVWL#Q>0J[F8<9;JH1VX%#,UX_/6_S4C
MY*P;3#90J=&;DVGH>I$;(@ZW1"*[IXEYR/K77"W=9(K@HNH!4/ZTW_V-%HL-
MRL;T3AG3X^4%+>^==-.?^P#W@F%1 YI$TBU6OQ&:I/G."?5A+4'\H>>Z8":<
M@JOGA[_-#]<>+PKE'_SFW%:Q=;9 W[3!B4^*\/!.V#.,WTA08M&@[(W!=98Y
M,0F4&5!5\V)NAT6NSF .7*UF !V.Z73BA1E(3&\Z%XOD?>A,C^H(LE!4Y#YS
M#VD"I^M,1>?Z 9E[B[!359-<^HLQ*S+MX5;-0GL??8O$@!RAEVY - =]/$R1
MV<Q^H)^XBIH23S L6K1 R=7']F<[2ZV72GH9O7#L@ ^\\EP1_J8\'NW<+_";
MYY!]W_+YO8H7TW(0CC,8?C'OLDJFD[,524_\(/.2\S#<21Y:]'RV&\[TI%P4
M@Y+YB$P]D#>^4P?O@W9ZYL!W:K?C-7UXVT=G5U<:M'MZY&"W03!'!PJX;[0G
ME73ZO"'::D\4[K1T7(SD"^&LF#A&*\S_VXGR7Z#."^KB,)><=+Y93UQA-PCJ
MS':'EIS",+ZT'49&D#URN^:\#,@(SGYY:O?.9E'08]<_2;VF1F0Y2\<Z\\(6
MTJMW/"1.,X+&&1]4<JS]SX>)?P6-:">64I)ZK=/MI6FI> _E#8&WR+OZ2>%C
M+:Z( SK>0)^B)[]5.0/S1@ZAI5/!8=A?5 &:975WF0>?%APE!B[P"]W(6B/<
MKP>]#31K9I2.=:"J*\'TG:.%,$I_XYWA$5Q@-]D<M_/@V8)BTI<&B]!M(^O]
MX+J!\U+M-55:>4[9 0'!U[XP?"C(*)&U&>)OCW.-X;.-;*A\.U*S6</OFHQ
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M:@J '$^Y)U&ZYQ;7I_%K-HS9VEQGSZ$U,;;M;1,]1B#+#CSP<U18768IW5J
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MCS(G;R@7#A9,#U*H,"@":_@^A5B4W&-]976Y<U*IHX]ZN\T;K]T'O2?9'\Q
M/OK0>F9/YB0I5B=H&T[SM8IM&C"]892-!+3;24,2H]AA:/\'$*&F_Q]02P,$
M%     @ FF%65/>)*'7P,@  B30  !<   !T;6(M,C R,3$R,S%X,3!K,#$T
M+FIP9YUZ=5#<WY=EXQ(TP:UQ=V@<&@D>W#W!:=S=0I#@[NY.<(?@!)=&@KL&
M=Y]\I_:W4S4[NS6S]U/GK_OJU3OOU3UUZW//V^+;!@!+3DI6"@ #"P# _/T
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M$/,VV:_NS4PD(TJ[Z+,9/4EK57+$#"/\-S3#<L#RV50ONTBXH;S?3)#NG-N
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M&OUKI8O-N00^UN%-;"SN!RZ2O.(VVW^Q>F<N:*D<KS02X 1Y+"4%%'+A*W1
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M4LR XW@E;P$7.6FNXVP']NM.Q'F:_NZQ_18#A3-@S=GVQX3081W%(H+[J&S
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M$&9H-BD4!6RB3?(&P '2O0%TVR*G,]4B]X'!486/9%Y_RQPD++@W]2SFBB%
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MESQZ3F[=L"M@8YA:['<HJ PIK.$WM.JE(D28E'_ "^<":E'/OR]7R:MU33[
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MOT?A@QHF3>@C<TF3B.X-(T/Q%)#!(W3CMK-04$ASSS+T0GK<X7(90F2ZF,X
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M"NZ1/D[O7JFNFB;4\QU*XA@$0LN#E0$ 3#E=^MQ_C(?_%3#??O\;4$L#!!0
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M0EPG\.)5-H_A%OYD][R6\_OD3/EU[GH446KN8;'6KF)1)[+!B%872<!^+_N
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M,LQJGX/<!#R&&DT+.L9XODT& >UZBAV**5-V]D? ?#2CL"MRM$YOD+;_Y@7
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M>G%[I4BOO3,T5\"07L<[J@2C0,G!-^&D9">M0=2-PQ6/@%&1&X5:P9MOWB\
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M.S;7F2FM]E$1")\/V_9V)%[>&I&/C/3;>(9VI2;C1O63&2,+#:+DMXG([WY
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M"%PE<MH#6,D:[\:V>$9,@)X[JE?![L3?3WY0/W3W$G=%,;R+=',Q@41_ORE
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M^/XOZMXR**ZF71<>'((%=PL0@@S!W8-F@@<=( 2'87"7! D$'2P,+L%M<)<
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M>J''6O@WC(BI;B4M%80A0YW@N&[]<.<\O<3PAH.:CU7N1]*#R1]WY,T?TK9
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MVJWJINE4$8NZ2!)5IA]$2-J[]T*)FULI-=JX]P@V>?TMJ"*&4%@EKLO$NK9
M>@U*;./FO096 9W4=-OB'6?SD=SHQV\ )/^MLR9XT7:6)(M1@;3ZTV>4)FCD
M><5JTP/GB#M"6R-8M3JT2W?Z) \VD@>J$0AC2_O(R/&56Y&W+HSR65GN/APY
M<J _Y,UZU;.;W/?\]5/[I6) %, (Y19%AC[!&8(_)3/5UY:=,!*6< -&M_B
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M *6!7I3^_E$:K+C4^9P ON-6T3P3)**N)[Z5D]^((Y39/CJ]DG&37I79"Z(
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M:K"T+#"Q1B,6H5);X;FOZ_6@?3)IPK+5M>F%-)OIY>,;")UTGV41N8W.P-E
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M&_MOGAO:D@I-\W%$@>O8.6*7D8(LYAZ!FR6R)<.IKU+Y!I@FY^8)2@*0MJ4
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M]$WPUY+>/*,8,AX)%SRT@F2C">LS\8&(FU@,TW7U!/3G.YJ8[7)##X45#P$
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M46^/9)C*UPF#HX<RGN*NZ60;["&:F5<XWK E4!J!E;7-G1M,+:7G3K?Z5A5
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M&VGH>:5$<?V<JBVA$]^87B^WEQP3Q:R2"5+E]5KSGFAZ<.]ER$NL6OAIS3V
MWY_<RCUMJC7CC%0:3BXR/E\\JJ@PF_TM#H_.:VG:M2\$]B950H-CP*JB!-7S
M7 9<6?JK_8%JFYV-N#0F5Q5"2$K30N:T^_N>F(F.Z#0<"H=;KOOF?JR+'8D<
MC>66-!L5(=90SC5"GO[8VTOMF_,!-MXA1,+)LSW@Y)4=CH3#B%ZR>+?U][Y+
M"B98+H9,!R>H[! 3A&WSUS3A,"N3MUCRF($=0!PRO]7N-*X\MR.UHEDF@Q<)
MY#S=$>+Q.Y.:RBM@4GP/;I8I+FVJR5I5,TH'\97,'IOOXJ.)6/GG7X7 ^KJ]
MJ?ZF=.63!*.X<^*/]O@B-LP1KO@\H=.DHU&HI.E<J&"0'./M$H4#;10[585B
MNB$"NI<P#7V[(+9(*>] #)02=[;1MYXU,!#:9:*!2!1EP''_8. LQBM!+OP(
MZ-N023&:^QWZ,67<9;Z^SC:$IYM_NE\1;<3PX=M1L3QV4I/XB,QZ-GE:,,7M
M2H5^T= X$?WEE9U>/+;27'> &EN!:'F"BOO[T%/;O$FNZ?5*3/->)R_B,M.+
M]%YA%+!*F2-=KR)YA3V-G&5) .!%,DI(LW7K1K>PIIW%,#5:N'P]-&'6]J=2
MB2"2(&:V.E"&2F-K3*VW,GUYZBK=NVQ:8$[6T6D#CS6>V6,=VK6I3LE[10+6
MB8!=^DC1IS#A^C2E7Y3E0YQ#Y$<5.V@/=9@.Z:,E')7(\^VV.#OG<?VJZ2-/
M5[*N'K# =!YJL.^5_U)D@V 3R :?[B7*:NI0T/T9L_2PTWO> >/?2ZMI3AX\
MFDJP(F[)CE^1ZS!<;C#2,0)8.OS17-43TZ+)B@=:7E ?BH=0XIIA*2YDI8Q:
MNB,;^*L_%B$TVS3P$TK/@6]SR?5>D#]53Z,J8[_7$:UD\V/_P7_M0CR,Y"9K
M?>E74&<G2IS53=UD*+E -3F"FTKZTQ'0!0U81-G1VQ7"V=FY,K4N,(CF$*4Q
M"*74V,91\_+QXSD40\!4G'<;/Z+LLETEG$"_XE_R]7:3$R@9+%E2DA6MQ%*.
MY&]1^VXD$>@0NX6NE?XXM"MJF0U&4F+,C3>VG<(O":W0MU:2]X N"B0](>*D
MWAQ.4<>#F>JT *HU,S,C6+I:J:F0>%9L+=*XOH8DCQOQ.DN4J:QY/8"[)BR]
ME/T>+8=NF.@YC->>Z]O8!SY>%;LI?C[M\H<5'LYC;%G_=>Q)Z/HJG:ZW%G3^
M'V;N!%DY7V7%KP"U"24W-/)[_(W=:OJHE5Y$MV,^!=G);")J7AYHPSB47>PX
M)9&W5>1Y$?A?7NA@*?7*W.R8'/<*N[W<OJRPM9A@JJ9@CZL2:!C8S$Z!].*T
M:"?VU<5Z+Y_7)3\JM.9XE:7D1,U4M8=1+I 8/!V2.W%U5TKH;X0L4MWL0*'W
M*J"NKNXVKV>W(6[5@D=V1[U^TM]1?%G$_M8^"T\F[?Z1&H/8 W_43MJACJAD
MH-N;$-10E.GZ-K'7;JDKOLK[<;O2<N8L[%&6Z&I"9U1%%/3'Y$D)E_#*]/J>
MO5SM*FL$-T*)$N@$W&(]\R_/7@OSWOG'I=)!9@R/#.8@</;I*VC2X=&PEHS@
MA!W[<@#T%EM!9@?D91%;$DLV5&8M/_ NV<9^??9-':6P<S(&$RS% )%U,U.>
M8V<7R-A-:\G\ZVJ*H^(9Y&@+%;R5EI5U+EPEL)<Z$(Z[M^XYNQ/!,ZG]UWSQ
MPEG_;G;:KO:2\X-X*4GGAIO#;[0F/P!3Q$A#URLV#+U^R!9V8H/'$H_FZJ8.
M)XDKP'J]4W\R8-Q^+C2KM +D'F27N\N'/!][&A_@QQ>UYMY7 &$[U ZVG;6<
M@II*:HZ$^B_919\(VG;Y[_RVCSC1>V@?@2'$[2A/<_@'L^@;&4R2#+>5(MF?
MVS4>66.Z+=?4GMK\("5:?@&?X?8H<WD%^L7W?Z.''R/1\F9/;1<WR"_=3D=]
M7W^A9QXOAUHTAFG6>;P039"^X<EG0/ZER?T:NSQR0][XL:&JH;$V5)<U5"E?
M<5[O_#$=]I)"?8^[/GU:HVH\5EH')@W_!P=R=CPQ4:Z!&TAAM[CHQ,+-MO *
M0ACW*&59B1'@*\:4($5J53T[9_"RT-JD[H6%/:\QWE9V&05.24.1G(ED$]E(
M[W>4ZUG6&9*_6NK[2,M!0[?'JF0#^B.,@1*D4 H1IG;M*1L"&_IF.>"9!$,D
M/I_VG_\@^ADQ%@M&%+38L)_BNS48;/"N2KC>%&,=RG\Y4!:W3AYY+DUA[A,R
MP&AY)/BH0LZYL2*Z5H7C VR2>LL2WO!=EN:MK),JWA71J<F$083W[*8W6F)&
M]KE3CCS3.P+^#ZE+&+//'\'DS"O"!2VJLTZLM1<M@NEMTR\^9!!<:7:L<-&O
M<QO2O?\S/8/!1TH<1[\1(/BW.,VOR+2XW;*R,6:%URU9-HX0]#^UI9/HGQ?T
M-/R[;-5_?J^4*R'IWCV@IS'QTC89+BX#>W9&I+1Z6NZN<M";8W='%S$K;X,_
M(OX9"2_NLATOCOOXU&FV?@?1\C;B 3B4W,KLW/JTR08A9C7:#JVFA#*)-?1(
MTFA87_BD?P0:W/SAG!\S;B^AY__6M9)-H,AE^+=T@N$5@.4FLP9<)LM:UCPA
M)U@IQU*98.(FK8>WA :V/7F#L>V);DU?X6!)6JY.0R'5)RVR=-'3;&F8C%CM
M#A_-HK((=29N@"5;5_XAEHDJR3H3%7;4*V0H X[0)[[$ZC:3[#E6#,@%3[><
MY6B+/:1V CNWL6DYZS;+A\"UKXPX=KOE,J=T10<>VFMJIJYDY27,RB4*SJZW
M/\;)'YER-.$",'Y4J/X,*5R^ -V$/CC&"J-CB0FM@^E"[LP5EZ#V1.$2LI%&
M F(^"N,W_LQ:.V?BI:B?VVGDV0_$6TN!FM<UI&Q>UB5.^/W2LW.;<?8<B/GL
M32EWV3T -)=O[.GLS#6L0\X_>TE$8N8D/-+'60^4A/5"Z'%!\[*&*7H40_:2
MOX[Z;+GUC%-YZRVD'3QQ*O*]L)YS[=%Q>IZ.)+<56"^PI7^8&+JM5O9DC,,R
MKM+XU!G<>Q@<X%'J?M +XT&EENZMZ\%*..+L,(U10AC>O-+/36=T2L??NL&'
M#AX"2DW:;\'92)[G%Q$KRLYD+<-QM5R]#'C!L;V5H$Y4R'38*HTK_,BNHB+/
MV]+V\1:,+WB&EL0P3(YAW7YG#W-,9,*'$95!L>.3AA@3"JR=]_MM:[AJ%2TC
M*A%DG=\7=HI6ZZ1 ZM21^ML:C%B%T@:]?3>0B,QYD=:B&@'YLWBUL 9S-1VJ
MN&'SYVXHZ7%K'$YV/^?@IZ$(D)?&"./.#\1T$YQ7Z[BJ;>PMM,=JSOX<G:T.
M2W2XW'OR _\4D^_&9O)O7BW5^CD]Q311_,]%W'W3)E!1^;X)S.IF'>(\X?%:
MD9(,F!+&71M9QJ,)KYPL7XI9\;0,VOH)"5;$&7T<4-\OX8W,&Y=K7[^A,_4V
MMR^!C:2#@#TG-7(T\8,9IOE.74J'+W-6N/COKA";/J_<:;MLE9][)^+56!'(
MG)IXGE1H_(ST3_DKN.O94QAZRC+AP_"TQLH"%O.IX3.V"1<5AE2T7*'55:UV
M%MG$VKAY^$E3I9TEUGO>1Z$'SHD9R (-U:O%#>;D0Q,; 0,4Z(\<7U4\K1IK
MM3PB]([DNEU::U21ZDJ'+!<T_[>5\>"T;"%%J&=8G+;_;/MYI:35J>@]X!19
M\?$EXD\%^<%LMUT2@0V?3/,KL=<TY0*HA(FK(_^--W\]S?.C%\-.V_ Z7$W.
MGWVUSQ,>1YL$?N?5R!+%KOAK2#8)=56AMVEZ^H)"!$Y,U<55'[?^_/J68YP>
M@5+^59ZU\++^*UF,MC3XT?:C;8% +:VVT^-GD\?1.C)3U+/=:?H0J./+$L<-
MT/RZFWRA_0);/)SV(U*2<E)JF3UFY(4E@GL]:&_/-LH^7/&UPO4'9JG "IF?
M#U7;)3;::5BO]GA_LZ.?U/)W.J^N<5)RBD:O^3$I/^Z<GG(0W\PM>[K,-.-O
M[EK[W7"+C.TV:PKKCZ7QJ;*68J/2:+1AOAR^LC^XK?\!\9[.K3?;%X(745N:
M^OHPY!\A=COS<,>$"%7'+-CH=J.R<-(*5/],:(+<^?F9X_!@:?4[?IJ8+_%1
M7CKYDQ1NPBE_PSUML#J9<3ZE\2[KNC #B5OHI"IXCAB,=JZVC2_^E_:^,RBJ
M;DVW$1%!E" (*%%0R3GG(%EH<@X2%)J6G&.C( @"+2 YYYQS%LE94C<YYYPS
MW;<]=^[,Y]3]G'/FG+DSM^K\6%7=57N_];QQ/>_:>Z_U?-A"2)!\;-BJH=FY
M/H&B/OF+*-K[<TUSWP:&*A?=J'2(E1W1DJ5:]R-K,D9I8(_SG4F'7<:J=3:Z
M;"_KP*HH\QB]B:WNA42/UJ%U+1'O5!>GE6G9GJ?JD:$D"6NI ^Q:1M\%^F'9
MRRWN49I1NI:@ Z&J[\9L-&M4CTC6[X!_Y&0.S\%@Y*B:T[9Z36/J@>N[.'QB
M$:-PJ[&4&3I+17OG6IKQ/07A :WF?0?RC.9W9<;&EJD!_7?(B,F.;^:1@";P
M>$[JYFZ+10%4L&$_<[U^S,J*&3(TU]IK:KTMID8US7X9%-XK/\K"VD!R!%)M
MI4@D+-6_2+7-[L;&Q4RE"3K&IO_)!$6/,"N;4>3(/HEHV(;IF%QUV%6Q(<)@
MFDML:;=4$$@TJ&MQ65*VWY0T*334G3GK:R>B!084\*(G)"QK9:G(0:+G><XN
M$"^^KL\^:*JJ"1I4@^I&;\/+]*G]93'*5V)\P^LO,,/B'HK!C8><$E\ *YH>
MJX&&VS$:US]UE277E98=:A7/<F^.J@RW>%F["1]XW1ILP_*R+*M<\3.F)7AN
MPOAH.!BK:RV[4&^$BW%C]G)YO+Q=-.#U!^+7(B# NYRS92V(0SK(I5K.R2EK
M8M VV5[GM:;3)0$'PSX)"3F=^RP2 $,"5I]E%MY8(61(W5(M>9.Q4X:6H&\.
M)R1"'E9Q]! S )ONYCAY>-S8*)9$W;\#-C7VP#G4[2TA#7/_V-+2J1*W:Y$U
M,W.]2UM1NNH^&'!BH#1H6!^@&$[M)9P<:3'E@O_D0Y\8'QF$(5YK?[1:A J^
M&JW4 )9+*V<3#I."< BW1<[\%&,8(D6=!+H#7?182$^4>,%\?Z5%1T?%3%:7
M S\#ZWW]B^K*YXGIED.3KFK ".DHXN'=YF%4/<&O]-\7[\;D+WZ5!MW:1>^I
MP,6<T]/7GK)4*!2J(L;ELBX3/S51VHL7=$GP[7K1:#D!FER-F#<0F1QH3Z_G
M):F_^VFX0"HF2GE"=49@K1 UN:#/KD5++A2:B-[5EX!QRMG&K4T]XIU8%1(?
M70MF4<)%)S+5VD<4YAMLP?'&A4"V5?8RA!FX7-+VW1L[AA%2Q%.7&S8_1(L[
MUF)=H9)C3EW<];T&#'IVP@F:0U,\/P[+>D@2T(/1M)R #^0<BC8+>>+MGOE=
MJK,A >E$FB"BH\.UX%!<[G5"94KX"D*&=3ZG,L?*YJ'&4<-[NBOJ6EF8?;RT
MRS; :6.V+H@N:Z8%XS^S=>8_B"C]O>.]#?/DR79;\L;=#Q(QHHYG@_)));LR
M84M/^-WO?3:'(B[X$6G5OWN5J/- ND&(>^$J1 VE <BBAT&R^>WI6^P[MG;P
M81\>NB*PXH'P=-RR+D]Y!A)@;@B\IX@6N@PD"ZJ9YC66I1%FU[/*U<[Y&M\E
MZHCUQ<V7 <4M*%[KII4[]GN\&CNN'"UD60)K#@YT6O-W\F^<CZUG![FV?>D)
MIU[O^@;M4[[]58L;\[.F#8ZE^Y(.46CWJ@:T?S".AM:<;XG6 ]9>E6W#G<'1
MS\0FN_XQ#21.IVW&:@FHES+N7)2E;">NXZ2U*RQ@EQUI2'DSG?!\VAWG9&\X
MO?: LSU_T]V31X%1>S+C:G+!]$&?TD,FMD:!B%D? 6R&/*-O-, *11R.+_5+
M'+Z5GZYJ]VXLB^J+)M=U-<:6BY_(X2@^_6:&/6Q:@IH<E8\Q<G.EU"I'G\;=
M>QN;]L%M20N/%,TX+.%!['4>--!3QFJA__'F19N#(O8=!1LN1EDY -KHB<A7
M831P::645MP!L^-:0UV;'*&T'(<](5I$O^FY:3O^>8!L% )L9[KR:HA#CHZO
M4T+I#L?=19\-AY2T%.*J3/+VOF>F? ZK./1GQWE:=5V5D:_L.KGKVFDCY%\H
MF][E/'-/;LU\OHVE/YI65B%LJ&C>JAE76L[6V'?K336!-0T-E365TV*YE9 !
MPY;:AGM'C.-&>B6XS4Z@+P2/CY\*A\+=X21K+#&&66-H9$C_8W/(JAL3"XNC
MCM5QH80*4>5$HDX@_Z2ND&?*4JCBJR3N3Y:3A86P1#N03=;D39;.JG$4V1(V
M)QPS=[ 2X,2EQ9CEVK2XB00 /R !TN$=Y(H*.O(C^='?=UMS**D[A16=U"=+
M_M;\^N_.J38XQ,DC8QH)L%\S%ND3O?Q>M?6D_1X20/#VJY/_RXA#8]WUJ3"]
M472Q!W^65D6LBX*R,%VNIU@K/INVW7;+;<,F7(*A$K[KC!5IH;GO5]T71BMW
MY)$ _1$K5AK_3H7P>ZH'A.%R^B'MZD??@P:\F,V;:JT$I1*I?%MW\U?UB#C[
MUC#Y-VT%CPSKI1A!-EO%%Z$W/]<:W*P:0PKPSC6G0;S,F4P/K&GT-&^6-U.U
MW)>VNA?K1 -@#GJN\C+A$X59M;4U\=U.4^4LMNSCK[&WUO.LSXX()FAZK1X=
M0M"GSA4=KT9'5V*>C0C12G]>W769^_$!;6-+9<ZBV"7;U?_@>()B\T@C='8Z
M1FDY4)[.N!-]CPR>KR)UTGPR<OT^2122*>?%&V2U/&SNI8DXH"X/FS<AH-50
M>8[PL07JQBN7-C34P8XOF';[HB\K,VM-[Q'Q;%0SUV>)J!E62F%-SL%M#C%S
M5QX709^=)BXR5HUD>-3/:#*"G2WDS$)TB&V7WOMT<F/<^$57Z496#D0X\>3;
MY=%Z>T:M^-G: *P@NSODC6!X7MV<GO#5!%/*=)J-6<N"ZYJP8) "<&ODNAG/
MYA+17(C+X"O6U'B <=*4:L==V;KY5'OJBCM#1#>LW&S*1^-;!WLG5_O(RFBJ
M_^R97)V7[I+!C(L=<RTUM0Z6,N55O40H7_'K-+\=&]9SRF5</23   GH6Q:R
M>I"=?P,5&S$QJ'[PO"[<H)?XJQ_Y1Q]1UWDO3GW-O&H8C\! 1.[4IX'4@JG7
M>HQE'&PX+1QHUC3\E_ R#85^E@'$ZL#B*B6''C]."4';NW?X">B^+<(6NA!#
M\'6 0V_QL9M-425]Q0V'AQ>G<M+ $,VAO(V&R;"L5LE.Q(9F S!C\#[\$['\
M"+EQU5![ Q;.RSMNVM&,FW9PHDUU%13Q^Y94S7\V1K5_]F%G=Z&\OB;TGNLP
MHVNJ*8TMX(E=V UCI/\P!,\5TJ;EHR]2[V9A,D6+2_ R0-!$\9OY]!GWAKKR
MB553&A2E&*Z0$6\;ZT(B!^S[+@G7!H%'9XU?1XX*&YYY+NWI<2[S.]/&AH/&
MV7RPLQ5+EH)8[A,;BV&V6O%0:3E^HKDA21@"LB_:]2@@P14BW]!X(!+-5S_&
M4M'(0(POER,1YMGN_%&92.[;IJ*[,*&:]6*)BA2A__^[I[Q_[\!@-IR> 1';
M,D29!_L EN-Z2@\,P\@_UND;?(TU5=XT<?#OI,ETU%@\@A1'W"Q=;S%4DC&;
M1C_452_L'3V>.U>H$+U H"H<$ EH^WD(J7, $B Z=X&%!)S''5XR4MK01&]5
M"M*@.B*6'TC VA420"V*!#R4N7XV27F-!$"67R !B^#>]?2I+I%ZM3)A203!
M#BX"TGSX$ DXX()\-TA% @;/$!(0Q/.&IN+)=3C<%BLM\*79/&==D7>LT(A&
MUJFD=D_QR[!UT?UH"\C1#<J4R4A 8/H?Y7"OLH0\*6-KI6_)&CX])(9;.LOD
M_"(:^HL>\$1=4+16J5!)VH6%K4X"W6 VM\;7?")A\9:L+45'2CC#Y*E,-A+P
M&P'10PI3748&N1,4J?_.)O_.#H8FI?7^#!D?2?G(,7B2J[]X.6>;N0?\8IR?
M9W/62R(!R7O7?DC M:*;%V%C@^\_S*A=+U<D=P3E)I^0F6\IU52'P]X&*:?"
MBV"WO4V2JZ.-;YRS3F4R?Z_LB)]UUP!AI&'& PR*68G+':6NX[U?+H$YAWG8
MY+C.'B["@!S/*[Y993C2;^EC.%&@H[RUC*(JVW.7!+"O>;6"G)XBSYU>] Q*
MI@4QFE;\(^;#7]]-9_SER[^_>_.X_W T&-J<'$(:((D>4JX-<ULH75V1 (&U
M-D>A:Y>)BT09_VN&NF %-W=M,>_EU_/-M2*1I1!17\?XR+)&\%USX[9W'*TB
M3<DACE\DHDX/6DG0:)3S,%.(.EU)C</WVOR=@F?O*XFSS/-:?9M*?J=9DA45
MH"& Y\?ST' _^-X[>-U;,70'J80/PIHU>:<IA$4 #+MSDP:(:J#QZ&X:L"Z\
MA/(5C"@E*F>Q?3B8F>Z$ 2Z>KS?HE+D!M'K8C1< &L=J-4^*'!S=-YR9HM=F
MR0H$JI!]%+_.IQTK&-"68\P>72]D2O>_SR&Z?;YVI<!6XX87WK $0 (>,/0Y
M5VGV9K=5.8\PP3E>#CXUB[S_OM\^T,.%H*S3@8/QL,6,BA?VQ4"?H2-?*$7:
MA>J!M]JF,,,HW%1#D]XB-(M>=4XA"J.JVG5$Y=#']2@L CX;H1TT JRL=2VP
MB@T9>9D9L1O26*I?/5F$';;6^^&J:];-QJBXD:G:A3-7Q_K9ET?3DK5"ES<@
M_@V;K12!35CU2?%%(KC];?A,ZTVRQ4L>!8'PA*AO6X-*EECO(HN,ZZHK*M1Y
MP$PY!U%B<C34,NZKBBM#;TT=V)GJ2?:$BE-/3[.93R8YRF:4"O)+\*EOLV:/
M3,;G) .WC,[1=M+'(+KDOK2:O.X9FE4E\Y.T]4(-'X J4*!E-ACTP'$<"2A/
MB[3NYGV@O,+?@GY54_3.R!"K8<&)+]IZ!F$\ WUUJ<J\,TF39O J;SE*A1JM
MJ<(A?^=&W[K"2-+[>F(CJDI"D!'T,G@JP[$7KQ!!V&\], (L-26T,-RU.B"S
M#_/!I4A('BZ)6@C\I&1HD2XD/6 7.N^N/AF:,NFWCM!M)[.@">7FQT[+[.9Z
MH<DL+'R_480$+C.R;"!P+SIN(3TLB:/3VLMR)BD:1S<C["8)IO"BCIW>M;>Y
MYK9C9VZ1*YB8?<-V0FSO;LC$YTYJC/+QQ;QV#Y=;D?Z;%BV"G^3N=I\LYB?Q
MZD)T;^43AI<.#\P:!?3AZ[:M1Q<2L^]2NZUM[6DNCSB>/SZUL\$WBWUH[-=%
MY.S['6JDNP0[W" :8WFK0MW[GOH)M+F086Z6MI_!8*"L&F=1 NLRCA"N<F5Q
M8@3+?KEA:@7R<+!Y0QC$$J:L+VV?DM/5LE:H7ZM>]EGW VS@D;K%A"G[[H!=
MDC!C*#@_0%,S2;5H*H:8CWG3:V,1<?#&36IZ48;$G("LY$QXPR'_5E$TRG-'
MO+N%3^,E0,S,*<%2!+&>XSIF@_9/4C/W*:\#7OR?@SYJ-UBM5_PDGXT.XJV'
M4#.(8J][8J**23<2L#71?/RLD)YKS='*/RY249 B0(I02V[];SWQX_\VR.;\
M(<O,Q1#X!,+*X-F_(P=?_Z9-:OXS0^MS/Z()> 8]*K8H)HZ_\4S>HUS3/P\-
M2 Z]$N4<\>0LZ,P#E:;S7;V2?R0EK"0XO"F"_X,;O.#AE=G"/,!FMJ* *]WR
MI)D,'BO)57482!V6;C?T=1Y6=EZNHWWJE2^R(FT1\L9*(HF;;M+B^+Z6:M60
MXP@-D4%^%5VGPSB:H0I3"%,Q34)Y>-O5R*[U+NLSCNF^P]K=3N[[;U2S!?GS
MX:?%W2@CZ<00<\40K&E6^JM\=0,8;S+:J(VRLG('<KTQ"QWM>:I^ERU=&!P?
MI.6O'L4SN6Z/FUH(AN(K.EQU5%3J!?NNY7E>4(: 2!EU4 $@E3_>R!*135E5
MF!/[O,1I>N!;P!IF*"JI1PHJ[\VHE#+,B 5=57MF"Y=J\XI0U]2$:CS:?SG"
M!C+DINJ&&EI$MVEQ]'O1!U'!+? /DJ,I$L8<I&'<IU\CX9#SYWYQ%$GF]270
M 6+-'VY9JJU@_.!@;^ZGXR">Q_TAS1%<X3WXB+=/I&6V^M\J+"K$FGQQ8V,:
MSHZFW<SV8,W6+;8K&+3+F9K]*A6.H:&,UC(EPZ5F!#_Y$2T LOC\V$^SW#5E
MJAT_B,9NI6:0=,87*KZCY2F3-SUEI+]AZQ?:KTX53-7!#BNU.;G3U'BE%4%&
M\#!BY1:'0\+1;)&!J[_>>-"TKFY#0?VK*Q%/;]<<X$R)A^RLIG-M-.;E.1(P
M2SE07_LZ=,\@=)<):R>Y)]%+O;AG;KAF1WISUDMRH"*@Q\]J,@-M9$.3^@!C
M]'%!]7KIWE<KQS40X1)MA4DF7TO%55JPG0SW@MR;PR^EO=O,T&_JU5%150?Y
MXN[F)K;B'R,H _,.]/LQ.I/OQ2S?_M([F5DW6LRJ_*R_+SR''RW43B4S."(D
M\>?*+[PL,7,_*AU?>\S4XAM#RL.H70]88(V'E_>(7##KN"Z7YF>+5FNRB#W]
M-MY#\>SIB;Q<N9XHT]'7:T$U250U4B'!>-QMH%(64J5]42'-// A3XAZN!:B
M"&0!UU(QZG\W3#>\\_DBKX=GIWMK$QSS)3>R!X?>]/TZHRJS;>?K*JBI%<,=
MIO;J-]V[MFX%V:\'^@CI7J#8FOD+#WQ54#MM6U'Z-\@A6?*_G&Z^LI7S2PFI
M2#UX/-\<>"C\((BNJ'SL?\#7=W_W*+H#O&6)2\-65]5">V*S7W09%"NNX,#P
MU51UNA-%O;]CY$ &QXI7YQ9DKJET ZYO=!%6"*)U0G4/$E(OI6C3021@X=:H
MZ-HF_,AF/QV!QRR)\"Z$\" !V,?8=*=LN+G#VVXHGONOMQ)"_DVBX7LIB@ZT
M$P$#*(KO^MU31K'B?*/^YN_0<[%*W(O+RNNI:\8?=.GCWT2R%4K7D(#]]Y:4
M1R?@B^IS%23@[B,4A175;(Z'?'3'(/0@P1S=<!9" OZ(0/3?D!6+I4%- 9>)
M++_3267[-:5:YO@1BMG_*P"Z7Y UW@H2#D;?=*RG@/R"@/+?H&FEJ,B4^OQ7
MF:;@W$@I6OY HS]C('3+4HX^P;[' V[SAVU*&-*5V%VDOZY+Q#<HA0?1Y?/\
M5\3H$E>A2:<\C#NS(:;#K.Z9M_2[^>J4PI^-!/#B6O1L V7B"O4\876CZ;=;
M:KK\K U3::6H[F9(=&T?"9C+_HMK_OC/NR/[L+G&<#;ZZ#^\5#@$N *Q]7 W
MZFLZL@YJ^]E-_=R1IA4)\$[^B[/^^/>46S3RIF5G \)QU5_'^!#5-SU$0'!O
M+B'[Z7_\/3Z*T#K#K,Z\[MWC62\ _E&-7W2"FJI=&$U3_!/F/V'^$^8_8?X3
MYA]@;OVR9Z;.KP(9!64;JT>%;-P<+*\6P:_N3,I()%4DTK<;9'%K$C@KDK]!
M]0!Q?V^G]7-0R!1"NNQ1+*")%D770E3R)^'7 :RH!F\1>',75NPOQ%=7_N1S
MPF=UOF_SM<>#F1X-!]F*\C+OMU=4TX.5[(..%:!XKD#)>B\!MYV=E4_H3]UP
M)-!_E&-\NU94R#GW> 4K^-C_)9 <[N@@&5)\THFYI7_0*=ZH&:!>\E!!)G=U
M5#WB^^E1-TY^Y9))@?#=G*V*^7&ZM*#7?\VZ,9%UJV+=:(99%=1Y*(IV'FW7
M,M.QCLQ>_]Q&HZJJ5[\*AMTHOVQ^"7-ZN_0D75Y9+3$VP,.4V^\[_:DU#0WX
M#LEE$'.!>8/<+!&&L>)>1##VW-#V;D'%CK3QNU85*4F".NO7&0E?[EN67@E.
M#^ 3K&_T'+&TA%QLRKR"<13!/JM9&(\6S":/A6('[04%AC\9"^)M$G")B1'O
M/>BBJ*B2-]23VTT5=S^UCY6D4K65QB(44HS<YOY8CW)ZH6C?0OBP&[-9K6RW
M_U/T9N.D2)'DS!E+JZ=3#)3,+NQOL0'7X/22T9-[@P\L[65\.>IVM!?)T.'!
M[AJ4..G=5OEI].9@3PST< ?%L6BF9)OSVWGLUCR;;XPVM-RM6QU(L)$ IS%?
M^FLI<1"8>6?4^0?@S9<%<;ZB. 5GWU9=K\QC3BZHK>Q'",SJM*#_OH:0AG5>
M:-#SUT2(PV *W$:^,6OFTUJ.C*_1B4%&$RXF>CE]KX7SHK\^_(&[IKY5+D?3
M.'S"V/)>0$^( *J/7X$PZJF=><KW)DZ<B^?0IP%KC1UMT$1@Y*/FB$V*>D:$
M/*N#0-'T!F_5%TFN'Y$ZH7CFM,F9<OF=.&K2U/ZS5%IAMU>5O3.."Q/Y?VA;
MA'#>3SLIT[ZA[TF7DWOXV'*7J;UFJ)C99(XM$$@J^727]'1+:N"S&]C2FMS4
MXJM/!S^ZU>52YKM- 4=>&O7$G>P/KK0]73MA],PC)->E&JL?#"@EDL;2PHI8
MJBJR05,$H;XB#:/2^2 71$/_&VGZICEXV*!J&E=HCD^4J0^F@Y[($S#AZ)<9
M&]R!D2]XMNZKY2S]U9-8%02?D("-5-+!!3T'CP$>MN4SMR*@"-3+2@A/#NO(
MG/0E)NU($9?>E'9K';7$U#T:?^S9 '+&M+(P8N4?P7ZW8$5YP+-0L3R>*OBC
MND=%U>P"I 8$;$L8R2^R"XUW,F_<Q^?&VY$ /9 #RYIT0V45[X/2"K&%.)1J
M(N<;.B<_],6?AZ7V6IB&9=<RC/",5'&3W_%RRXM[R7.8T>3X*/R+M-"5_V?*
M5Q1@V5'/(J :OYI^#Z,DTZTVM-$#K5T4++!FS9N0-%5TDN7[U5NA7_OE^8:/
M,]@E/K__Z*_V=&T3K"_Y/"1#SH96E0LNA=.)LA)Z$K"0(+X,G",15Z^Z_B;Q
M\0&SW^'=)=7Z#PT^[!0U6\J3&V>\I?VT^+NR:A[AMH"B=-72JE%NO<SP6:=;
MN.PLU=<^&/.F).URV<QQ&T<ZDT82IH\&AA-X%,*ZA1S)&5D+1/1.N"_K5JLE
M ],2-@FDE5M\:.^0XS;RU(6*I071^_Q5BS0J\\"+^X/_>@[VR:CK0X2D Q+P
MEX.PM4T@'VG>\1Z8N!,1JAB2[OT7U$EWUH]#:JU1'G8]X=ZUW&NZ?RB:<.#\
MC#/= J*_]@LU)CNG(_^.8='S!^H:=11*CRRY9RZAP[K<!YV?/8?31%GFG'=C
MQB=R11X'4-SS=;DLY^I@!;+V6=6<MEL:GBN(CQ8G7>XI!H$# 0^6J_LP7P7/
MCTWEUS,_^L:Y[4\"QWKL(^ (T(HFG/WL,!:AH%7ZS;4=7TB&7:D@J/^D$PG(
M*[$<2'6]]$_EGDYVEQX0QC2^T+ \RVWOP.)<V^R6MY9%%=H?/K_I=&^!/03C
M&^?,J^.L&CTKF*$]\5P$4UVJ%DF\E-\WQ6_ 1G(N4/&Q6))\C%=$?*+N13%)
M2(#L\*2%X:;!L!GQI/R#%:@8(Z9&+KCZ^EZ\=/A7C6HDP-<T.JWN2E&D ZY7
MQFA-RL(\<4K*^Y&*(J!9/C<+5!7WL7./Z3'?\Z]ILM: #DPQW-GTJ<)MT?Q>
M<,*,"'WF!W%:#B%K 0YVS".BS S0OL'FL-ZK>T_3PWQ#9>0KWV2!!L'9BLZK
MW+'+#]I+'F"B"S=5JN83I?\\8NNIJ3Q0X\8*\59FJAC5]8KNJ%V,=\:NDH]?
MGF3=%*TYAIP&NLBS4\_:+\W!ZKA^,$_J!6:]-_:GBPQ3[&*XH#7WYB-35]W0
M-7NZN_-D!T_R,6\T66TK.U5(ZPAEH4Q5@,E-B-(J4X31MQ]"X?H=&FA^Y6S?
M3Z=VCK.YXL)QJ^IGBF-X+I9+IH5Y70I%\2L\CJOPPR@G:*AYG8_[0;-34Y;$
M424"LE]:35XPE%&HLV)CGF1LTD: :\:>3\F=7BO)/\G_[#7[\K"]P;B*7Q_J
MJ;;SHB%(7Z=70/;:Y!%5=34YV'E0;F0OKF/!))S/G(.QO?D%0\:'^V\GGS5V
M--J0L7?C,%/IN\7:%%G>9!B,!<_P2[VPQT2,@)82$;"WK*6T@M76Y.]/3G-T
M%6)8)J7=3&LU!6/"R7@]DVJ+,E)"F=G1:%DRY@GLO4]4Q]ZE.HU:=XE8-+.O
M";U>S>)6<ZX^<9 ; O%"-OM:% +3"6['21'@\.%(+^QMJ<!UG@=F98Z-XF4G
MVI9AR#[V"K 6^.">,.H@";KYF-UQJF>P^YC#Y3";CU]X76-QYTU-(A;8V?[X
MB*N0H,W,X7&"'Y,M;A&C\V)'OQ-HQ^KX@E;!:]:4NV,(J@H4UZ4W-C86OKQG
MPWX?FH N8GMW&?T&5'=0N?U,0JOR.M0$M-?'5C$\'5/79A!O0SDS>)QFH(2P
MZ+.?T^\*&3/4I$*0%HYSY>O5*\C%]#S%Z^6467WX/8G0/%M709@&V/ H6H*>
M@#1*><@MEE_EBWCFSNMJ/4@+$D!]1=J("O-]T;Y5BT(OI8$AQWS&+>TD5OY$
M'=(S1V$'S8J=I_<2A1NN-(,DT7O)LHRC.M.<VO7RB2C>2J2_8%%_W3#<A2=4
MU'('[]$+B]/C7,20EP<3>$U_\.E-2VT,--.F-0-4)MQ8ZB_.!/.&Q-#.\W .
M)V=.3FI;QCD:JC6V_8A]5;]_1WR)Z$'%N^U*%JYGF;-0!.9%S/,C]8;[:+4-
M":^C@NMYT8ND5 K[T1$29T8G'4;+E@:"LA\VV_\"ZEXO6<?_!L6KRM;T03U3
M4&>K> /Q]F$[%P;IT!(3.C55<&B;^K"EN]]0!<I8=;P8NC^-512[\^X$R[&>
M?C&B/[S;N:?8)T;5W65#HR,@6](*>WJ0H*$D^DC7-H-BW' Q>TIFAQE2?,@X
MKK#=*+K0W(<BM8'Q$E5S&V^?QL-8XT%&RL+"FQ4."@_V6&046\%6)AS"]YUL
MK*,?CJ=S^M09OU8)6B,]WE$I"LLJGYHB,3MZ6W9T/<CI,RZ<HY%6;01+W:;=
M,;\!(<P9I1Q/=942K"NV^!?"Y5A2CW3%GP.Z7@"\B:(S0?NS1OI,[0TY-&[R
MN2L^.[H>VEO+YMMOLF-C@4&DYE]D<&QHDH*"Y*X_.D;%22>[5E7_]+BJ <KC
M5"E=5&.)# -#+%Q34RCG\LD7!%_5F9ES$Q2%NT-TD8 PN]8J6)WH.>6JW;&6
M5/8&CTM5U9EBK>FGYDF$]3<STQ'N07[5;75CN7EW;!BGJA6+OVK68H37R[0@
MAJ[?+AUM"F&A8JSV7QZP%!G606]!NJPAEZ<V-UA@'.!^AI4_@@DHD1;$V"H\
M_P]8S$3O.BF^>&"$FCC;DB_Q\[CG9EV?"O9.["H>T4=)>S5IVD4D..6(+@"@
MB ^H^<T[X!Q>2F;PC#!>"&3,R,\3UM->L*E,)5N<K4'N&U<H/'H&;')+DCXQ
MC=M& OYPTQ 2</<VY!@?<G4LVO$Q,"5QY!IMP>Z^3G';PGK1$@+O+A*P_A0)
M.%N'A%#N^\@@ >+$2$"SY+5E4[5,K:A:X=0AGSMC#:I#NB5Z>;?YYI)R2>::
M"A\U#TLA 7L_D(#'(M4R-5Y*U39=OY=G<3E#L7 B,--,$Y!6#ST7HT$"4CZC
MVKU4!!?D.QKES6TCQ WN0?J6HT? Z);S=2A%T*[HGZD!+1S:I?P?#HU?D%EI
M"ZCS:.8+4\PL*3HZM%#NICK'*]=:Z%H@5^Q62"I0)31R](_R?P$HV68\57_]
M6?N=A*91;"]/N2><3=\M1>Y69+ ? &TC*%)(,J<S)#REU<9HIKC'JV:Q#OBG
MN*<6FC,HM5!-]*NEG>(B9A;$&$[\FV[^SF)#AEYP],!0E&M7<'C^"LL=]X.@
MC3^/G8# UD:CY7OW/^EYF[/?U.>X(5P2.,O?SOA:SRG6M',[Q8\FKNC@D1(R
MLD;5RU*,MSN)_F+C7]P$8T,"AG'S%R%9]L319\1[3_3Y3!]OZ].14'Z4NRGT
M.(TINCT>18N?"_#ZP>Z[96#TJUO_:/R1R_Y[J*+@TU3XJ1$)4(L6&#N;I(F1
M3TV[377W5G P!7M0+D9;U!F]W4.3EU;?EH3@YK]XZQ>C,2EBE/],#ERG\X3B
MT\:]Z/+^)YYS?)[IU$<)4/F(*P_E.4:WW%A9<PK=^61]TT+'N3_54&&+!+*!
MNWF>O)'P WZ"QMB[*FUF&M[QC);2FB\G0KM15BB,SFQN]7X/UOU-K*+\W\5F
M!^6E^(DG\'A @]NC:W>ME@"7 W(2*R;I34Z/!$RY( &@*_&OI$+-="MWL"_Q
M@[6 ?ZZ@ERGN#=5ETXM+<R;N^/DACC["]OJW8P#/&9F:3(&Q@\1G1V)FFE)H
M &5<?1R3NM]D DHYS+$#T1&^"U;SJ&%&+5OC3U%2W^:3&L9B3GK/"V$8D<X,
M)!W*!(2G YP&HK_QGFN"X!!" A7E+D:Q/5FE[A$R##WHG<3AV18+=L%J\W#N
M>ZY+LBM&,\'49JIBQ]WDC-F_27<@?@!DOU7;4W[JB.]*;^JS8'*%V)79V@N
M;U*#1B:\$N.3]#.#5'G<F2*)I'2^#0/>/P?VXX#$I?EGL(?.Q?:QU.8PW</N
MNY7G9MER9[XIM@.46S";639U$324,UF?KLD@'$A*-(H$_%DN4VJCYF!9D>)
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MH/)[0:%! AOK7$?/#U3U8 TIT#6NS=0$A"AH[]U' JP*]OO;SX_K$.HH%&_
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ME;TZ0)(NU8QO)#+48/C#5]@CL@B%_%ZG4,W'K8Y7Y6PY2L--4&&UGX=N7LN
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M(^0QHQ G7A1,;[&P_Y4]!3E*!NTIHXT5V/AOYI39J0/G,FA-78G0B-#Q-E_
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M_","KZ,?=38BWX&EISQRD]E'6SND\(JJS%O*S*P/<^.%2G/<ZIO##H:))B6
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M>4)-X_(5<L[8?.<' A:ZW(5-5!T;L >9XSWBM/0#+DBBA4A+ 6)G% ^APDD
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M2GDPPZ]4@]O4K@<Y@L/V8Z"3BOO!"(\!4&9 FZBV ^M-/TB1H=4G[E)02>7
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M$3(%56L-= <6^T&&]!D:XNO7@Y]K"* \PJ[>$D<1XA/>R4OY:/5.:$,$\W<
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MK8^8<3L5Y^NVDC3:H[Y/&Z?W:$/)R,W7<(P"!=N1=(VVV^KKO/:U.<K?_^1
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MWGN-*63J3J*AR?J4;%GC??\%A^L:@OE57AUD17"CTXK!VD:IDSHJQZ"LUI-
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M()Q\"VITL'.%>]'\=JGT^U!=U%4:0LGCR@ 7PSF_$SH$]@J0SQFP20CCXJ_
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MVT"F+.168$F"U7BX#++_S*+R[4WD$@$_18/5*T=S&RLB%[">K1BQ\42RO^-
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M=,;5DC*#JZ9,,_K>Y>%7 3=Q\^0"B( E#6JN$Z=-=3;^A*>(-CH$F-M>V%Y
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M%ZA@YH#UQJ4Y#^S_38&IDMT;8-EDI&'K]?P%G7%_".UO#R7T['%0 '*98M;
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MSB4"&:6)PH(B[!GAQSO3][V;([9VY,_2F]6C2PI99TL\A.14UJQ1B7R$/PW
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M_AX^_;\..&KX%[U?_L6G8*L/>_C+BOEC=BKJK,9!+<E[- D+V[I)KJ8B <!
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MXQ+<M8/USV=WOGO_^7+OFWGOS<Q:[_2J5:?VJ7-J>^U=58V81BP"!$_D%.4
M)&0 0+K] 8@90 ; 0$-#1T/%0$='Q\3$P,(AP<7!QL:A)"+&)Z&EHJ>CI:*A
M86#F8F5@Y&"BH6%[>(_C 0\_/S\]J["X$*\8%Q\_[R\?0<+$Q,3!QJ' Q:7@
MO4-SA_=_^4*T 808R.J@:! 2(X!,B 0B1$)T O2W>*(B_7H!OU](R" 45#1T
M#$PL[-L.-00 ,A((A(P"0D5%0;E]ZG/['$ A1"6ZPR.-1JQFBL[H2,+K'Y.!
MP?2HXC.I^L@!,]\+IP!,+#)R"DJJNRRL;/?N\PL(/A02%I%Y+"LGKZ#X1$-3
M2UM'5T_?S/REA:65M8VSBZN;.\3#,_!U4'#(F[>AL7'OXA,2WW](RLS*SLG-
MRR\HK*RJKJFMJV]H;._H[.KN^=+;-SHV/C$Y-?T-MK2\LOI];7UC<^OPZ/CD
M].P<_N/B%[J0 !#2']>_2Q?A+5W(*"@@%/1?Z$)"=O^E R$*ZAT>-")I-713
M1V)&7G\,DD<Q&16?,9GXU ](7SB-8)$Q\R_=/?R%M%\I^]<("_@/4?8WPOZ-
M+AB  T*Z%1Z($) $3B4)X:GG"N-=-<W:.\$/?L0H"C-?$&[J21ZD;*4=MP_=
MP!UN[G]8B?J!7W;]RF3--BF7*1\!O-[71 "I9-#S#NBA)K3=O1 ZA"UYN?0)
M7OA](QTOZX:X1>,&HH< %G 10)<: L"<+T  8AP(8#\8 2P7)6;ZB43!GYVJ
M_%BR1 #>#Q$ J?P5JV?>U4$5 FBE1@"AI<:AP);DDNB$Y'I0VO7!PI46_9\1
M:O!D _U/0*,S6;&UKM*@%_P-/$/A).\;_^2?CQA/F/TJ/^?]1P!-,1TO[9_1
M@#;VK*GUPU*=?^ICRI>+A#\F+-0COW3@Y*&HHJO\8^=_0%6K?T2*]A^&_P>>
MZ7"KA+*F:H4*S.Z\0B](QTO\9^BD-E?6E]<_,)(S>P>XQ>+3!TE>"N[OT-L?
MJ7RKBN)C*@$<_HX_?\=:IQ-5]/_?%_\C.#^#9(??<WDYR\O+$R-%^_#GO84=
M'#CGVJ61R>,'2>4]QVZ',]!' &EDM]T3KZQ ,O^,XK3F\H:QM2/[3)[>\,5H
MR-7]%L#U[Y3D'^2M*P@#S\TU5WW&A&1>[F LOQZS7ZWP&G^=;+Z4QA0*S/]?
MT>HT'%X57AFBO9C!";I</Q&3GW8O1@!PV9JR'X<.EYO0[O3Z85=1%?:A&O-C
M0[D/IOUT@26 +0+X2ZDZGR<\)"/^\5"-8K7[5B-(C?];F#[:E')32[!UR1(W
M#1,O@7R?Y)?":J3Q_PNZ*?MS[3!L(?DI&J>^/8_'74D6;&WVTN:9V:X& +N?
M\-[4Q-J]T1;)W?[0,D,L$!YY/^<_-_K)_GT5]H'I>6.WO1[*DP' 9>$_0XJ5
M=9U%VP*&RC?_[JO(:J26?\;>0,%D=P=KVMGR^ "5^A\T$_H_5Y-8"O/Z#W?>
MNBNL8XDK RYI/T/U=.[CV4,T[/=?G9!BLP-5"ZO*M=2_0@"<."E:R9\*5-L3
M8J /N?K\HLVU@S?P!W%2?WU=TJ09R2&_$[>6:: 4+>O_67WX;Z*6_[/1*$$
MV/" ??W8[_9F08^EG_RPD3<\[96(7R?]!@%=^YQ?%MS:F?IASU7(U$T]]['
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MS$N\REZ+_"RK^8)A =,Q(#.4[2]+:7\;_?;^ISF5-=N(?[NW?G /LG(CLXT
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MD\OPLQ6"?[644$BN=$N>1UC^X:?]R$+9LA_</@)]/%RK<E_:1]E**GDK[>Q
M5>TUQ71WW$DBN#X"M&R1Q=T!)=QJ+(L6,'JP*U40)#KN\3C\W.Q"1^-0BTXE
M6'^9,<&,Z#E;KV2S_A&NB?0G!Y(-D<>$"AQBTK9YBF[('WUWW<HEI3!O\]7A
M5CKXS1D">#SE<*7G"+;G[X_!;BQM:W82^?CQT,@RI-DQ'9+I 3YI&CWN;H+=
M8[*:<<C'06*:;S;0'CG%'B#N7IN<MU""DE!_4".^FX$FI4#;QDS?WJB"+XL>
M*F:7>*;?FN?C:)O72P\S[GW^UCV+34Z,)J#M9'=7BGJ>"UZ1I6?56.S)DD63
M5%*.+#["$_'^ 0K:QC.^-O[>F_N?3<L@SD^:L%#G,E6@#^1^4&;.9DC13D=Z
MZ:31/AD<6ZS9?VTQNH?6 F;W&+E^GY*MW/25,_Q5O<EHH[CV&BY^UP*^0(3<
M/:)N3N8>C@!&N!D>P(#78"I%>[5 V,R-5NQ2-Z[80LXXWEG!(V'A&(G^]'Q3
M$7K(WIYD7WP!'LPO$@-7/JJH8@9O?$5#7[9-@GOE?&:-\'9U=;2(># >$L\<
ML^J?**SN<P Y(>VS]HQ/"[["7,;'M!4!=VR/]?(6^J0D[SY=P5BJV!Z$4@&G
MNR;=^GA! L7ZD>G1R?4PA6>8>.GFT?+CVIZ0;84I,8'B^0W]=[:<$4U-XIU/
M,XFKH[_6ST6*XDU\-MAP=S-F@;\T*V@;57*P?9A$ZXXB-)M^+40?)*I:&^.M
M<:ACCD.FS :&?>1Y@+,ROLZ/M""]PBFI=&"?4K2=]!'W[#5% L8,\<-+[(B%
M'!L(M!.F$LHQOZW82-P=4?%9O3ADN&!5)Z;RUK6GX0ELSUAGC^XPNC9@4SK<
M2Z;6C>HX*9,YT*[)LZUK;)F/SQ+/J7@/@HSL7&J8Q44V0TT\@1VVS%#@EY*
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MU+T\P0P/QO=+QZIL ;R*,)ZI,8%QM7_#XS];K#XC +K;5*+95J3Z^6UN1($
MYOF!:C79.T%_=!%0(S E8=OVXWF6Z4=P/YB#Q%[\F3!_>"A\-J/<B9<O\!:,
M92W+09'/(4+C=&_\5P5&)J!4>(XA+KW_*%\5V0_8 '(R_Q9_WPV\MKJ@"LWY
MK?H;6,CD+<PMK<@:YIK374*7[,L5.-W+T/?!!]>99TO_+&+%" N?RAKF<SS
M&F>9/T-$2W'.)!;5WL+4Z4LY)J:5>QVB&93Z8&9DI+;R86%J=_F)2;"^8%21
M3$&O<[X-N2HTWW8FD"%J Q=PA+GF9JW8IA':U-'=;1E=*V^V L<*U\H2%8@U
MG@^*3N:6%6V100G%Q+%L.!TQQRQBI:E?"'_0V3?+ 6\M8%=SZFC4-UN7E23L
M!+HZ. A^66.Z;*^)"G2)VDT1U5!8572!XS83%IDB$P9@]/ C+9]11;VM\6&&
M1XY<27,53MV-SHJJ1$7? P_ED4X:]13"HY;SSA[#:L[2;"Z>:BCC5B<KO,"3
M.EEO<9%?D@\93!][ZS YD7L\$#KX&/7XX^[%E#1]T,E&L_H\HPJ_<4U]7?=^
M-,-FM\C-[4@Z:Q<(8,G]+6>9@&C#E.(XCB-?;^SV&([7U#.R8_DI;_2<SX7&
M+2WCJ#GX]T0KLZ+2=XW*X3Z9N$PZ8SROAFUB/UC.L2B8S4&6L\9NZ*RU^38U
M:B:N.R_,>.H\<N>F*E;2=]A  ][B.;UY"_"+,]PG)TKF1N3GS<+LY\GCD=VE
M7&6%6XWH?M5RXWLE8UJ/IMS5>M\:(D-PMXWCT .JDQU+[![2'PK=+:UB..GI
M[R$UWE]:>^NQ-" IZU"=K>\KT2^B^-9,HJE""N\@.(8K2##C.>PJZ>/]I<Q0
M]P4.T$AR06EN P+ @4LJ'U3."F2IB _TVZ>N+9U_69^=DOZ;.A,-C$C.Y1?J
M-;)>UI ")+>6]$MQE"2VXY_3D*JM:IT@?E;OE6TK_-'<HR-=,L6)> $>(G7(
MY9?*5S%6(V3LB)IRVL"H\*T<J=N#)G)BBX[A8"]YV>?>R:XZ,3..#'(>3K@(
M@1?5NDM:$(SK0Z'!%K&1C<CKR1[!Y:/%+Q4^J(#3/-IPIPFYMR8"@)%'G E&
ME(\Z<NTN0*=HBZ8FXJ?N?P[)%RXU5D':+%DN:):F'=@A)\>NA60FVCEYYSC)
M^V)>V9I(CW VBV?WY.DKBD5W?_V<%^=UU1D7!Q]&HP]U+7FH>?#P+6K$#M]U
MZKQNSO2WZ4M/>E];_U%7['Y9N!$8]VN%M"/V6S/M.X8H*TPM;OIY[1$@S0E[
MA_"ILVVWRSWP[AZ6/,]VWV1JRZ(XM7'YV*ZALO5U2E2EHLTEU1V_!_AYR'Y"
M+2J=20DI*PLT+2U?8^5?YO0P$R3TR5V2,^,7##@9WQVQUU@*CEC&CO"]V/.1
M6\:T#/!PEU-"[K"Z(6H1*C,:E:#;\!0X/9V5M$E5VD AI[=._$K$]4#QRZ"*
M9R\""!)?ZJXC&S6T<3+(#E!X89N60.<<1-&6CJ>D/^XJ20#?UQU+.1VQS96E
MFNG*D1@HUA%=2)63?W*B$N*N/S$5N!OYB;KDRFXDP?OE.'U\I'@AI]?29$SI
MEJ7:0_):'16*8&N.M:.OO6.XVUTN(A(QEAG6VA?@UQ:B5N0V]X0EU7VLD$__
M70\^-?+X'&C^C#?2?;\N!OWJ"K\OK0 !] PC !<MD>=Z1PP((,W_A]JJ- *0
M!!T5CJLR#OW6+8H1_P></EX[TX_C!P%TJ.TJ__>^6C9LR/^OS__5/J5=-"\F
M@&C"N$%VEG^;S(*5O_<@ ''T[_*)]%<G]/&RLH#2?U.(XN^UVH@4V9W'1.9"
MK*3T"6G'P[Z:Y= 2>ADU59160^@O30]'!# D_4-3\W\ !/4M(89AJU#N[Q"U
MAX\1@%MF.J9W/0)83[^5XPH"2 T\RL__[PL2^PU4Z.6JQ5E3I_6DRGKB$Q:0
M\6\>HN&/6^V7F^QFK]H6WTP'2+SK5)&%U+4[4-@0-NMK-_#'RN87]9LZLEMR
M9!>Q0'$0P,6V1EOK_98*N*6UQ]V6^2(?\94.JGNSG7'=BANH@&<):8=U&B'J
M1&DKMTLOIX.+K;,C/W4'NFI.O>1ZB25]&!H[6.0"BF^<FP8]DF%C2(@;QB\C
M0=K4U"'-]I92BI#1JI@XV73ICQ"9G?M2^<"NJT?,?55+E/[MO,L9L?'&%%F2
M<09W/-AM!X-YG3KDN:,47:"LQH2K*)A:J6'<@?YE2R.Y\PY[>#7\W0WXW45J
MD+MIKDF]DE<#!A-K[M(T%;"_449?VS1>,Q1^_L"H([^D)HP[D41C5Z&-"6_1
M5?ODO.S1H60(=(FA[@W4:E[/0]AN1F)TUCT==XO]BR^UE3M527'2P'Q#@>CT
M%I%<^8>W\IJ?@2COR8&H3@_7L_J J4?-9"/5%2HN%. H4&":Q@#@R4FZKH\?
M1M7?EO3TC(PJ.$=\IE(N5G"-)M6H$4FYX; YZ3S 6S,39B2I-@:>%=D?'-5<
MO!4"TL:)-GY ;L+*YZ2G8PJC"F=;>M.K<0;C_T?7]XW=#RTOGQG0$HTI-B7
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MDP](\6R&=L*CEBA<]H&M1-O"K3B*"8Q(VUQS29%(Z6WC#$=;U%ECK4Y%#J]
ML&-,M!/^NNQ ,7G"OH,SEA+V]:IC-!0+6&R6ORY8QG]#YD8E.H,ZG$GNG!S$
MD>KB5XB,_JKIO8_U#9%(0N"*LH;LQ/QLBAJTNN0K4.A H:<)6MBK<5?3G^G@
M'Y/%8JXB>/E*V D-S0>2J:1[MR'T^Y)<$LV;5:;X(73T>3]A>BH$\*5K<>$2
M"P'L/BSU7;F1-B&5B$( V>TM$K:ZK+&L"<SN077=NN8%FS%JR=B/ZNZ#,V><
M;YK!],TK-!>'78 EQ'-OGA,D4^L18YG4S43SLM4266 0W=NBMDC$B IFI*+2
MVCU9+J^@)@6@(4$YW$JH@)^<RF(7-4$ ,5YJ"*#,_4:NVKHTC-DN,B,F&$,<
M(QV?,7)P1>; (FQY3E#0*0&9]A$* D@HC_:U\RS3W[S"M 877C&/E92:$1D,
M@1E>FHZ3V^S$PC!V@RH?A0%&F0\D##U?A'GI<G*.SL^3A))0:$K[H8_Z":4%
MZ7MKW] D[53U.W-VQHA5"JZQA=B4^@"D<8N?L+N*8#93*@4VVNN7VDMN!K.5
MW"C._O,M@O,P;(7F(D@L<R\X_P&OYZ@![+--<>U!]I.O1@$X+Z,T3M/QF:H:
M$Z4/SD/M[')CE6925';<!ICLW2P!\U0XJ:7:J)C\DBTGM6;*R5G-"*564"5O
MT^-9"45QX0%/]S.CJ*2[E\RBG:E6X$!1!-!R6K 6S/[&F#)+C\DQ6(X21175
M=E,=3+2F.\TK7G7K(4B%RKC'/JWJP6T1@,G"E9;G: ?5HSN::A1&&< *73SR
MYJ0B;;.M+8&2<R,I%@_E*=T[I#ZXZ(W< B4"F#J!7G 5V7):I)%P&.CS8$N6
MUWW#6?7PM?"U;[8DG>FR12'J9U9C%.MQ"<]"C2K(+SOIIU5'PKW.?L@3&%V9
M_QP7@,P71BMG0X(X_,"TIT4O7W-?5"I2GUWZL,/ 8,Z=#((9&1J>J"79MOQ$
MI7(#YBH#(=E* FV&0"NFC"Z#GQU$/RZ1EZT]1.\4=U=N1&%N-!<U=)7#Z7QP
MCM9"ED%6SCEF^";Z61]I=L]7J0T^*3J])4X9U09X%FUP8;@ [L,GMM;F3&\=
M6;1ZQ@ELE0R'BW/A5=E[VH1&4E,/"0*/E)CE,;Z*QC2V@';<V@_F,9@N%8V"
MC3X)+CP=K2G&=TKDQ**,>5+\VBG]%!A&QUWI1QUO-EW<EDNU(EUM_+'H%/X@
M;#@THQ3N)$[=)4$<+X#[:+7EDFLF.9"!OLG>;RI;T19EK(L_AJD?D^4ATUV^
M*1)E6]2.[N-'L?SR3F24,$]S5?0DO9GM5K:ITQ9G92^0J>"N"*%+^$SFTV#V
M "$+EKH;FMG9KBR5]"T\JDOY][ &^LX4M9 *=<G[V^"2YU7^IK5O&=]Z,N(@
M*=(6$QKVOXK.'&!#E@<E]#Q- E:?(X#8#@\$\/P- C@QTR'/@_8*'$A>AQ,B
M@ VGJ0IL7=211D+65!W3.'H>DZ<7FDJYNB7-#SBS&=E,OD8@XS Y?SD12P*Z
M#^$M$LB3P6F?=B5?@IMNXZ+;C!EIP$FD:(,3/Q ].&EZ/@PNE@&.6,:A?^@F
M#'(P/"]38R ,X,55K1JN+I'8W"OAO[1BA;8P._HI TY0?#NP\GZH/0P#MG+I
MNX'YY+L?.@5ZG<:/*0_5SV#4N@^KCV-^E)K[9%&_/V6=S_U-+XIAK@[M15K)
MSTK@JJBX*C<2(9>95?9S694IXTL)@@P7-'];#=9+#!UZ*9+?3S&-M-WU0$R^
M0[]EK2RCPR/_2BZI_?NW0(,JG%),T#'-E$G!5E)D2AD<JQO7V*#(:^'A4+*8
M82E!$?WGHIB#;,Y,N"<VK<K27-?I*!]92I9A.8?"EB@>>^$$)W>- R$$7;5N
M9+VZKM:Z>5J!?J/_"!5]+&@YFMPEBEQO\ZSUWK@ [I,]+Q])54A?7^"YI2,2
M<:H<A%0@K7- 8@T!*%>D*8]S<@E@(DM5=?E)=U-+?)PB]UI2?K;=82SP=DGP
M:*!$8*+\0P#FN# #,F253OQ08UND.ZL$TM]V-+]1:5V8"$'61DUI-9H&949*
MB@#CGPYIQSW1(UFJ)KCIEMO!%3_\D)!ZE\0+ST-N[NHKVF;J;PE.'=;,\CSF
MSHTB[!<<:4HK]2B^QX^KN_&)D)&,V*&E<<ZNR>/=RP92TKG6AF5:\@XZ<C#R
MUJC2PP"EL+R>A#=AX8%;TJN>PVB#!<O8[^-Z3,PGN''."(KDP@%=O-FKX)Q
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MIJ\R1Y7S9Y!"9;I=A0+T42XT[,C5.D"(RH,$?\?#?G=D0QUB8;1GN\*!-Z[
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M%&GF[C;RT#*@NN<C6#Q$9JVE:SNNX&XVL4_\Y'V7>S/<*7FO9UX^7]_#;V]
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MM%2+YP7P[4N+(NY\T34L8?VB9ECSZC.=)T>^HWKT9U_KMTN8TZ["G$;OU-I
M-]#I/&WIQ ))3$;4)Y#';;M/4#+:X)_/R)K"JJ!F6$6,^,CWC)C0"<7V/N@V
MS7,/CP!5Y:V^OHK45IR0(C NCUV9L?H^T;-)X877<>$'H!%)ETNKHC>2I[["
MF/G.69^4U RR_E"?BT=[PC*;D8!#(-E<N&>7<4H9/4=AU8AHI]79\N)>I76K
MA^_IQ$C'JT;2T872WNK:DGT?PO*AE4H'\<Y$%']?ON2OO8FLY*\;UYJ_>9"
MN;>_#RUP30D'Q[MWR*PNW('E=,C&$9U=K@-W$J0RY8+C5/V%>T3@$"JL2^Y0
MO]#/41OD---$O24T8R )>)W!&W9B@1 \CS+,GMRWL3O5IJY7O8^7U9>XD*A@
M:WWA>IJ_(>U0)F^*+N(0'_S)7Y1DRV%UQ&I<E%07&.8R@OWQU-'$LW9+B8XX
M4?QFDE)!L$_ -@,<YDK!PZ">N+NXIFD?D!"=,9D7P%\I+CI5 !_(,2^V?CQQ
M _[H$F\Q')_;(XU2EE%HMQJCI04E5T,(-9H55J3$Z^F$SI8S+)OH)<JLP]J8
MGJ! :.$.X9N3%3Z"_OXF%SB9M4UI"379ENO4>;Q\%&@RQY511ECZ>OUK!9P#
M_HWT;E& J\!\#,[SR-WMW'L"1A@&LJO5F%9!:S2/8YQMN"J#P^[3J*+/<"=7
MG],90J%?%;*W%%IJFC.'"#?Z)*LJE3/W%<$42&?54GD!I/B>*O2>#-:!25.3
MV_^ZRC)_4@LQ_N=C[+]?"Y'HIQ;B&71BQ*D%0&?Y,%/#H09R/7T+Z P!_L7J
M8'?]*>DMH+7K;"S_"^<MP-7_ZWN-DES)G%\YJ5[F7);? GPQ*R4!.I?8MX!%
MH\MME5\X95/*=_Y_UC^?E0,RRS#@5GU]_.0O4(8K#_&;(PW;L3\J)N,),F36
MXF;W%K L%O<+K)D72.37"SS3NKD@\ WU/_A>'!.( ,GBU_>3_H51KB+Z'V;4
M,@F2!$E0VZ.>563\4.#.OP5X3)#R)C#D7FT?TA]39?VX"?Y9=ALH(!0AC+ZE
MHB**_PW?"W<TCE;I^;>I'U>K);*#C_('D\;\7 D)D-C^F8A*/[.Z*-\)-W%-
MHL<VA>;_A./]]O/\=];\YQ%W?LLZ+DI$'S'+"ECQFOR9(-'Q<\OSZ&>QE#_0
M?M[B_@&2_H&VR_0$V>A'L>,_ZXN,!*3^*-;%\T=]>7G_-,2?C5&;'QC4<_<J
MU63Y22U=?R.2!3+*LM1(0PP@@ZE;P/JV?RLSZ^7-\S/@R5!7,CO!#WGMF/\V
M;]$M8$7??UT7#X+SB9$+OZ"6[V.[+:FV]WUHIR]<7=?9PW!AP4>P VJV\*TC
M@J/ZB!)X+R?$2SJ<>T2Z9XEBW-5 \$4L!3YWM)$V!Q7/HAY)#T19$>,$W %P
MG_IARU/X]63WF2%C1T.CS,'6?2O-OOLA]*N?;8_&+ES.BL\=P+"H\[(9B2E7
M%CH-^5F=]>;)^LMT@@>@,"<P ?;Q+O/'=NYU)>)=**_ ]9I5[;:7MR*K6/E=
M<XS"3I5!DA4+X4MH6!@HAW(WHLA&P:X(4F@DF\Y"^XV^*8H!IR7ND\?.U\FQ
M^\O]GC9"ASV$GS@4[@D-CO>805[$3G-[2BPQM(Z#C"@-M:TTZ_3G2-SJI.8+
M!@=V^#\_X5]_B)G3X\<W?1)C@F$Q[6(G!;64_UB#@@I_1MHMW>-TC'XE*BP6
MB8C*B6QMS[O4:.@:IVX 98*)TOF!EEE(&_79=[\ AT[T?#4<?/@I*Y$IZF 1
MT[@JR:-/2"X7G64F7VD[@.3)=8P."LXPHOT",EICZVA;GYF_C/_X&J/ZZ;G_
MJC!Q/R51DMX,"]T4-XZ4#IE.$7V=<P#Q9?-IY6EM*UPZB')>K"-TRZP S%,L
M4*%,(W0T(+H5?9(K;2?IZ1XJY%FV9*/;F.KL7[1K8_=J!F])Y[W&4^";H\$R
M98_E@:\KVT*Z.P7703Q]T%5RGZBV.X$0*B6'#P'"7I%'.03G7=I-/$>SN[H\
MR2]9\A8&SD8I==*B]S'NB?;L159TW3^1CT.Q/&L\;5R>)\N"S)GBY##J7?99
M $._;\_,$FAC"A*F[TOII*T@'5C%+\POZ!7V/0 _93LSD\:N/*:+7(.N]S>V
M*C;AAN]7L.9&SF5CE4CAJ\5J)/'?:'1;$WN-+(==W7T46-L0ZMGEBLS\1D><
MAX/#SVB&"^DK@5;.+>"#3<GV15''RRHLDU,>>7=[!*,*]0#&YZ,C"WC5NP_N
MK;&%JU'D^QHF>FWA5P/:,]8EPNAJL ">DKR_"I'_?<C8U%Z92-31I[?J2$];
M>?(PT8;AQ8Q+ECF]+Z=*8YOVN3-V8..UD]IYZHU$V]>+D^^-$.4^ H>X.IR+
MN^R5SC5*EEG=68-<G: [4'ZCOR$(]3[-6J.@TLK6YMJ7@^YJ=T'I.="83_JM
MM""4)%VIW:I[,U%XWLW'EVZP:^RX4:4F_JIR4<1H+7&X2[EWI1N%];*RX*M8
M012D!ENSES6\]Q8F468LJPD0TG&@1:+#S54AG<+V<?V7+E'R#OS8QK< @O[7
MN"5KK786A@@62.P7+A;:BZ51YDH@Q#T1B2'%NP:]])2! .-8ESG\W+]JCRQD
MM*G0QEUE<6$G]172ZP2,JYZ#_,C][3]WP^ _#'^L8?]7<&QQQ4[&4RR>TA(]
MG0&P=</A&]0+[*FH4NW&G.O<II3-8?M;0,-=]-2F&?<7FJ_J\^9'/%H_6I67
M[&K"&]S@PT_4MZJ5147.JSE#1ZVNB)VM;5\ERK.8[I-E)^%;#(NYVXF*P,%"
MKL>YN+H3)QW,>A&?)T[(]:;$0WD.R_=%SG>T]C[M@]JPEB/('F8\>C/VG+NA
M=H0.QMT<CQ3?IHWL=K&.W,'Q5VN]OZR&_;20I_X;>_8WLX;Y\4S?!<YI'LRW
MJ/ZE\-K6,VG'BBO7%<IIO]-IM@I[%GH+[:V8?),P;"02/N$8S\["XAWWUM&(
M57\<7:D)RS/V!0/#@7RBP0[EYMVO"WXN2(O+YW$2$]6T#5/<WN1Z$7Z?U11+
MP)-!UL=G;J<E<4)#9()OQ$8"/GDAG50_FL[K;)Z^LH3Q1*"!')X=VK.RDFKD
M)JAAA^->C.3'BQAZ9\PYH,^?MWW01=FY:!^BZ,@K6W@EZ>D6]_:9%@![BZ[Z
M/0'2-J>!WOPPJMJ+\*/.P>18K,:[W2=\J#>$W(ZM6[UI)S8Q(C(.NE!!O@1L
MR\,UU6<BMK)G;O:47;STQU5K7/>E:DNZE0&YZ/]6"O)3]J)A_>_,E&CZ]DG9
M6)F@WQFK\N5@%O\K3WI$@=M#R0\_2*9\5W2>]X%9>XBI\A5)=&:VS EW9?DY
MKPZ"I3'.M')W;-C<_L;NHI=4W*4[*S\6>1WE2#C$+H?8ZNZ]:B?Z34&#QTI,
MFZNIGY<#Y*KXZ<VPO3(UE.YY7$HB1-X_BLF!O6S5OIJ.W:0-E;@YO(BU1,DQ
M"OW.&7W@+?5P/5&&.2NR<GU03V?1?KBR578+.(%XS<!O 6%"L@YEODT&T_N/
M95;9I1TL[.^3?&?5AD@A-;> /2U3*>E*9'XJK'.V2_(/O*TX5SO.% N)J98]
M*#8!["-F.X88"(6X6:XA(<4'$C6I/B9SNOP;^IETV6E;R]^T',IV5:P$],\.
M^[EJ/[1%BK5E7J-[98SNL-G:'8P;X'ND:.B@D8ICK\2",P#KX,"OJ6H([L]D
MO3#9\K1/'-WWSN5B;W*A;N_@7]63^AK)&EO<"VMKZ4MK0(<%S<+1,<LS1]4R
M@R=Y 4)08%@G]>2KUKIQ4)N\'>WF"N1RV&ZR-RFQQ.O^2;5DY'V*.E%95W4,
M>5.6 ?Y^]2B]R2UHT01MLU9'$/O3V@ _27JDI#V(W-C@**<H1, A[.+F[9GF
M#0D">.J7[K(!@^DYT81GMY$W[<B77+%*P36*PHJ6D80[!ENM[-5>+\@N>QQ?
M76CEJ8C&\33 I4H+=HEA^_LGT=6LV7#9.Z"NMQ%@<L#^295SS](#!'IX)]6L
M=HPU1H-@&)N0%/XK9?)DM4ETRNE]"U0\1VFOF QF;W=793K)IV*QO1EHG@?Y
M\'7E6\";A!.<QQ<#@IZ5B7,IA_.C'AI2G%2V*]XJ5+V"X5<4%@5%A0_=+WS'
M6^I;U?G0:U[JJ5Q)C!>.'R^JF+8><F/EU'W -G7T=\I&)X2.T476P9O"#^BF
M'\VX;C1G'RST$'8TFS=%Q74TG'#GN,*_JGZO3ZNWD4@WIFZ7C*O39(CI 7EF
MTICS4@=1) !13:4-7L,E]O"6B5TUATH?5%^]H9'PP5<">1.HT.,5L%=-26+F
MN@&,5;$\--W27T;+]=[Y$-/G:RV'1J BB?SOB<ZO@*,ZN7]#D0CQ@XCPTRY'
M[R^P9[KO&=IXPR.7+B7&CG>X#5T&! LO>2\VZ"F:%P_/#KQF2H=N 91XMX#V
M:=T OBA(Z*G[10K(R=EC!*W8X2&E'#B8:#2:7.A&K&#LBJ9JSFA^N,RC;O<"
M"N5\R#,._ER.;<H6?$15Z>:BC)X*_" /GG1P"4%P2A<J,:;3Z'$_)<F\&LFL
M>8A(,'AAB&>.<(WM>IQ+L5_1.6B"9PR\U%D$3Z+O&4@2((V>^W]8GA48;2KQ
MK8?<3+5P?CEL_*:SGYEY[5$5^6=OL_VIM4;FYV/[WX-1,J!7_"4&-NPV9*S5
MIUA3X;VT([A9!*69ARTD=%-D!9VH29=$IT30*K1*3\<FU=W[19 EMD5RI,O\
M(DZ#9 *D3SN4I)UA>F30EK+'[WT?/L80*O=_S/?VA-HL4<DY8Z?D[[_5/UXH
MRDOGE3R+].=U%\EU-F(2&+":!V0&5CCXJ737&G"1/9)Z:Y[;6*R32.;Q>=*1
M";TLW,H:Z:+/T?VZG7N/8ZL'UM%Q6G!!U)G"TYH9JI=6V' D)].+C6A<#?*]
M)UJ5)#'!<LQ"-O,"M/"R*9JVGE)O*L=9:_OO[4#\+AV/^BD=I_A-*%X'NKLT
MK]B:S=ZR'I$E70K(F/Y]G\"4],2<290Z&L\J'"Z?MG$+"$$I6@"'>6?)C+CH
MP[=&7(?]F)*A.UXI+04^XO63W,>3KHQ?GR[)>Y?K.=:)$7#:HI/.]Z#LG51V
M89^_T+'4[0KEEI=\)W<I_\Y$"1=K-6 ]7GTK1_^^EH_@"@MN+R_$V_SAH0'!
M(50OXD7(@\OR;4;L-1^G=6%I-;C&N0*QWCA]1)YY<TMT?QO'$QB&L&<)ZS'I
M_@V-I9>0UT$5]73%XE?M18H)0M4%?W<^,,4=K]B.]]KG<7*^@BK2WN[F)O<;
M,X,3(*LO4GLS7&#[H77;MP#;VHB\P"9'PD!TNBZT *$BZ,&E$MPHKN'\!*LI
M3J&%T?HK(X?472&TO5D_D+63=_EY3G>KU;1#Y6K;>*^B<68Y\*#NM:^BP,EF
M!^"<6<K&SF2AGRVUO"O=3:CWB-++R[4T#YZ=?*^P<+G@M6_^BZ9+[MKE;H4V
M3XKS7%SV(+T1*L7SL(+G)8;"H#=RT &=*"$=547RDN\KB\8M &_77>7\0?>$
MM"\'A'NQ.2%%E>QYS18#/QWW]MU581I6D"<,S6WZ+0NL#;\*, #8[S>9OWH*
MGV[M1C:4/?64J$EG)6UO]\>,#5!&)[V7V>K>=PL@,GKNY'&D#2-O?OM)\8R:
MHD*P!(*RHR.@C<"^D,JJGL5Y>:)3O'2F9CC LDD>SEC3],*MWVL?$G3\KOH!
M:^>'5;9GA'VODV5%=SJ\OZ^0Y2+SJW&AE:[T;3*LF-)L613EGUY@W+Q_@F+3
MY\9IW4G2"0K583F@#_AF'ZN1@$@8/*O&:T7$@DI[\PU@^OJX7YC54ZXEHGES
MGM'@7*\'X(H4=8;NZ4\W!7)AR8 \UD#&&55^$UA;_*-..] T2KO'#=R"PMZ&
MK5!N06_!O8WZNDC(TT.F0PTD:F1'_HOIG#M*KE;K"J8O[N]J-BH4DVI.W/BS
MO[T%>%<3+BNLX" [8/?FDGL2C:(?T9K'1]P_.@OV.I)*7A%^(-7!VUC^VE[W
M<:2L66:;7''5EQ.N ,201<;\JE((0].;$0[K3T,D-X][NJNESE\ZBQ1==)Q6
MNKZ^F&UF=+)AQFO<FV7: GA?^GF7KK!@"C/U*FB_NN0. <.,*5\.^CLO5UJ)
MK^Z++/=QVL3G@[V%3/CE&@F[=Q+VOK[ T7V2%_B?"?>(G[_1[M\L3VA>MY-N
MA5PFWIA$ -<_4)UEE"O?R8+Z+Z0>$=C7WWSN2OLAF/KG)1"ZT>'.*9=U?LI$
M]OQ-6&3Z4UC$\_)F[\;E%=5!UT^1R>:/B-2/M!]"$M;_ : )'7'Z82@Z>B7G
MLUN ZRU @/H6H"L2FI=[UQGWS.@H__?4'[*3WZ.</])_R$O^!3)@X9/4M.!,
M1JO]3,C[3>;[+S"J/X&NW"UB>L9T,]RJ/Y>,@"?6_HACX"*A8M7OD9CR?B>1
M*%_"]\RO3P^?2CQ\^3'3KZ'[<[L.@D%^HD%8RH!.N:YUJA(3"<DG.)U0KU@?
MV4LS.2[<_L!'X4YTXBQ+0\9K P[T:[CIU#K0?:G=;?>L=QE>."-/-,A]_HK2
MQ!/8$7.UI!/+&=/N1ZUE0,#,VQ?\L/;C.# DJ";<IX_RO>\.TA+,8[E7"Q8Y
MJV?#DZA?;Z>N=0D>HPR#5VQW4EO5G9\:88?%^#1WS7 %;[USI-2F;&8XK*9N
M:(F3;YJ85&RM@>;&?L%PF8\2IUBPU3XS],=74C$ ]<'L$Q#U*BF'2S1;5N6G
M9NS1P^RN \NGL;A<2(ML,>U<L.)3ZSVBHNVNE ?^FCM-PIS[:LOGY6(3!X^;
M.J=9<C,(\&7)F[$),E'B^K0@%[$E&2EAQ;(8$U_&V=[DS)W&\[[#6)#:H0>J
M?(N3.V[S%8%^7VJS2^SW\[/H)I+7C_">X;1(>9X^#A!LL_.7;9L@UPQ6;O*^
M@]JP.C -UL^>)HI;\R4VLM*2GS)N\0@U4&E!F:',/EF+LP!>,5?Z"7KHP_3.
M [,]\JD.!^^/>=T#,NW/J,$':DL7^U?UD"_*=V++/6W?T47;\6GVH/"#'>2,
M7>'GX-X9LNI3,]V.\B7[63K\>WIC7CG68]-59G43]@<FEBDR>19J[!^0T1%4
M<M]N ?*A$V>]7IH)CTL='+R:1+$L739Y53Z2'.KQ7_ECGE$1H7UGD-FT5-UY
M9PM0UTMAEO?1LM;><8T=#U>:*M>$>H^)I7V^GF]46F2H-)@0DL^W@3!9>443
M*Q$O:\_3>Z]/+K5'[-.UCXF0Z>F+T8?*U]3180=A908;:*;;X.2 L8X; VDB
M&D"/3 W*%+\ZY.9:.)?L>;V*A[.^]\:IS6H$;S8;@,<TM1%?0V+R%V+L(1^E
M9\&?MH"*H!$?F<;8K_TB.$$>;VHZ<PG'0Y\_=+0!*HPW?!-YXM%B5A.8+T]3
M^T+<.A'-D3T2<*S3+E[P/+^HDC7?OO$>1WTJN=ZV]=MLKK'80-<*O>4>)SM;
M$=]8#EQCW[O5!)',;^&\;^PWC#-\B.L\(4^EM-?IX9\ZP+H[#=Y8!E(.!,NZ
MR^(ES+-IG^6]'SS$7GQN*,/23RT(N7>^)0_U8>)NBWKGK2[J-Q9#?3TTU,TP
M%:CK91'18& "M8G"D;J[]N:5:N49>O.^(0WS_((/.WRNWM)-QZ!TZK2_[>6C
MQG0"4U<7@:<\,[#3^E*=W1J#.JN1AQ]&!WNQD._Q#Z%^[XK,E=-JA)ZUC9NM
MQ"M5B7PD:;6,=[*(5R%5HW"KC*R.OH\<*GJ97NL3[?4OX)OARZ@3!P<3,IM)
M6XF[2X##4IP>X8^(P:)SD0N9=J>">3!/>B5=GX9]92[[L'W:C1  *#2&7NQA
MVJ=4H5"J8S"08+1SAL:HXD6X6\&YR_R^6A@^4>^CAWA1>PLHU3:5!I^= S]V
M8*8%_0-#92@:;9?H86;M=]M['M;MC_+:D0[X8Z[X/$"P"&FAY9T)>-3:/'G3
M[[-_F82ZE7M<-=/7=?AHV7^FXA9P@53]KB!Q3PQ^D^1M]B;+2-'F,?CL# !4
M!)*)"SMW+]]?'A HW,_?L7F5@H@@4@+ZP65[!L9CD^=TK6&N5W$462?M7ZGN
MU<J05,\0KJ2>:NDR(A12<EIT*3BF'Q8;=/7K45)-KGV?VZF]:E9-L#L5'],9
M3>DKZ1'K\;< 5LZ37%Q-:+NT:3[,H+:YR7N0VBJD]"US(YJ7ZS4SLR(B9K/0
M:O4RK:'YC5=>2BJO* D?!!#=M1IYA,4G!&0+\=$2Z7QYLTR,?\3L=TRU.K],
M=>W5]7)R-6[\%G!,!CB]"ZID74+8;D[9F;;8HRHQA0)#Y$7>6]@\'HXJ,?$-
M.6T+<+NX9M[R)S"<M?:2JO<T+;8Z[=VWX%A8(&YWAPA*P^.L][F%169TS]^M
M:K.M$^/QQ%,DQ-U[;M^9ET99;N%K52*^I;/0[T3DU,F #6379![Q>S@O7GP.
M'N#A*:$%1>[X-*<>5!L&=3 %_EFS_=\#QB="^0<!:+)52#<TN_>M2JL55N?H
MX'MR#_85'(4VQ.8E0I_Z+EQN$2[7WU']) HP2X*U=_JZ0=;0<FM'2F P#UV8
M3]T04P0WNG@W&#Z <66)4C@EI%62@[=H";L7R4WZ)5^Z+5$^$%.ZW5P=_YYV
MK-/D4J,+RRL*;WGY65./V--(;;/+<9DWY8QGJ&3K55?#0,K=0TO=Z>3*D?X&
M3J,>_P>$'X+*Z<WN9R(%"6@LA\1_S"9J;4W43'9P97Z7MF'>DT *)Z>HC[[A
M0IH?_UM%GW_D)NT_]:[V1]XV_L/PAT8;U7</"NZVDJ ?1!:#.G W7DBJ%<\1
M)X]DM7@Z;?*^;?%Q@3R<RELB?"M7,T"/U<"GDNEE,5$(6PH[S+?QHOH8P%25
M8Y8JM6.[#UTY>2OQ'K(>/5E8#\KPV$J!D3Z..Y!!! T?"Y<-0(^!R>1Z8S?J
M2"HN\X0<R75-E%:?TB+\G&>R^4M3,#35F/I)XJLF5D7I_[9X&GD/4RWU4&XM
M^AH- +NP\YY"8UU#/3:+W<L ]F&,?*RDKY&U/YHM]:,"@*8>%E<KKZP5\@)E
M77BW\_E):3KA5'F).1WJ_7BKRQ_5VSF(?U-&I3)OZC/]@C"A2QOH.:1RD',,
MI6%/D\BV(F%KL <761M4;OLS\32]ORI!9@AB-""329B[IUX7I'[II4P=8F:%
MJA+F%&J<_U1X1/XO5:-07SYJFAOIFEL[Q-4^Q2F&[\C?J>RH$-%HOR].=48G
MFG](R/.7,< HI\PQQWXM35B D7A$6V&,?A'MK!CT$0I]@-/1\&S J\ I!!U.
M:/IC &)^- 400Q/)UUZR+A%7U*^,OJ$\OW/J9IX!G5A"LR_B^["U%ZC9^*.Q
M/T8M%UL)U\.7B]V;67YKT7"!ZVBXB?282I2OLNROG4)Z\F\&&#_R_P2 ;!,^
M8<="FR ^L)'\-CH(5T5[9/6:IG)_?UX!]&R>9QNOCYWT1 761(_^!0_N=Z1A
M][,[15QM=UJS/^OT;(VV/?(-9NT,F]*P$^SU8DUP/"/S2[>QX[S>BGV&NP4#
MN?VU7^E7W'D&1L+'%QH%J8J%NIKA^,_7,])=%-C]AAH_+/@FW0@C2*YG+CN3
MW_]U/ICRAG"AMV7L''L_SG:4B'V)VN@UW3#ALGU W2S_!!6*^*8B@V<O<;,M
M'&+X;V;TC^%MXES0FY<DF$%WF: -T+](6JJ8V/\^=51^E"UZ5Y+U+]\2D)R/
M?N4!OD%47/_HVW@ 5:TTV/D[R6H6>6M\H4KR5G7E0B5XYP<.;B&)R%O KP3L
M!")M&*_R8'>HVEBP-A >?*YU$W(M> M FKEB?M]SG(\^$< !8L/9;NW]<!&;
M:N,RAB!->287IU3<)#<1RQ7Z*))>/0:@H4&"B2Z*;NWWMX7_76V_$I#H?R<V
M@&_YL0/Y/<>YJ'FIZ!/15'( .49'WR?_I(2[CW]3X<U=Y;LAB_O>$_Q(?2JY
M9[Y/OL^DW[KV?Y+ ](.",37B%NJ =I=# !I=+1G, 24;4F-.D96G>SG?=OUI
M5'_M,-*(1!:=;P'"2I^?7+I"KDZ \67'RK3@^2K_K=*K$"K[EEM =O$AH6$D
MH/9W5.G?85IY 4]]6[=NO'(&57X':6SG8OU"(?@=IN'U!/G_J>(N%Q6?KCG1
M+&@'.2G_GJSZ;P3$_Q=;1>C&N&$C\?IS+</CNE]*LC)FG3XY2_F0I,MI"@(D
MAAR&LY*CSS<GTI( V:VAZUVA;\ .E7%1?,]#?Z\X$:6OZB[*J-G_+ 0E[*H)
MXT8I'$Y(ZN74+S<'_[32_^O-H:]Z[[@HR?D=-/6["#GI1_P';GY> /V/;)3?
M<4NV<^_^*%?Z.VZ9P!-DI>_EJORH+#;RGX"@X$#';P?F*P.]FBSW(T 2_WO_
MM1(!=QD [D4TEM5 _PAGPX4%7-QSKUN 1D.32:)^W[,WL6V^-GGPF2BNKP]V
ME+QM1^Y&7+6LOMNP-!HO0?&*?)G"S80=B76]D-TE9[JH!V9(.>JK\@_)1/F^
MSD]IWCF+I*U#Q+Y;G;3?9SE6E:L+>M9&D$GUL0P8LU_1+NQ>O@MUG@7?Z0DT
M<<22'4,&?)'-O5<6&;JT2_Y6*E;"9/<AH#M3/8J6WSBV0GUE90LM@$*20R<O
MT%V>2:JSJAMS9 :T9X BVC*]*6+V[+TQ7G1732Z.+C/NA]9]2'A#2%>.DC?U
M.7LYG]U'J>?K>WIO_RL*X$CHX5GY<->]?$+7QLQRQA[TEY^UPGR$$)(W<59E
MMP"K97W]IZWN\RPP3WGC6 Q2D0*M5IN40P,/U<TEPL6G-2_"A655[WC$%L,A
MAFWPY3#J4)Q4Y7R]I2?QV%+:5.!;0*6,F3_NE;1K[I*-5VB;O[L0^YRDT\80
MLPA69@"2L&?5D<QY"/=HM:EIN>6AU5X)LMTC#G2< <?9;2?]FU+XGNH4B.V^
M]$,KPHZ1@ONP0>V76>AB@NK9#^&@J];^X"4/36C/TQDVYT?#@R\"C G(2U#D
MM<Z3/0N&N3]U4F9:*4,^@_IB"2'-XJ/,TKJ(A0SW\,H&/>''-O/ORAU$J*/1
M#<'"Z!V>T-(5(*%U8T9(QV;*C&Y@VF#JQ)*YW%:(Y#9?U04+BII#.,RP#CIO
M1SLI%$%2\[&KZ DRLS^Q=?9C^&GE=QZ+):7>E#?A48O*8]EUP&?3:L/9RAQ4
M\2J][2(<UXALHL.WA#>$)*-?LN;V,@I7KK&4)]IEUZ+:FL7$?;W, YM06CRW
M8&T")G\YD?DEO(2Z_F7/8HEDF1<I_H_.VO[F+.>/787]%HH&HY[:D5O8(!>C
M/R0#F$T $VB:[M*_EY5D"5"RG<%=^792A.CL0*MWJ_M8T[?V).)P;=1/ _W;
M656<#+PQ]?V"T*FLP.!>P[>DMFA?DHSB0BO>E"4!Z FC*3)TDR2% :+: B%
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M:T:$.SR(/=TWFHXP68\:UK=:9YL\2<;&<QLMBW%R@&-=YIC.Z9-]K7[>"YY
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MBPE\QYPFUUB7_!3UH:5E'S!QK7#8F@ (=D]3R73R=6?*V*/CU1E Z/,7;G4
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MO>(:ZQ6?J?7]ZF%8WVSLT7M"!M9G'P_V=$SQ<[)*I+%LK\#/<:71%%[OM)F
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MH\NZ)\9%$7VSHQZOU\Z/.K]I[FG_)H;5[=F!EP\&\/( 7EX9O+RYLZJV8)'
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MS?%I*E,(,8L1>[TWO$P^?J-E:(<AOA/R2^6$8C#\=6O8X%$LTT(?YGC VRZ
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M0+\[[M]F7:K-7[Q5>J/FM3OV\7[-M#.HX&>A@ENU;YM7P5]\@(E1M@;(R)G
M4R_O=Q=:F*<@> H4^,6PJ] H9MO)9F^74:F^VJTA8 E]TDE!P*@:F3O"ZU3,
M+?2]%C<&#?"/#*S'9'G-5[5AJ0MFB,<P--2R_M>(7): P<S;40/14'>LB4I\
MVEM/H9+!B0KUV49^W]Y'Y/?V8=Z+3,7717E?CK-X"7_-RGGR[O\#4$L#!!0
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M:F"T/[^][QKW7%\WJK;77*T[,9I^S92\+YGMQJ0*5N[<..MN#W0*]G<47@7
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M&5AAPM"&2Y.2.(GE,/)DZ.DYEB;*E*G0CLR_5ID'8ZD5DC 4&[8#[,4"8/8
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M:'N VUH6RW83E=O6A&<R700OQC(3AEV(.;M4&<]?-'T)/HW0<O+BR$D;^9=
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MOWU3\*EH>:+$)U;H@,^4C*L5'@S:_8-5Z/!E77?PY[_5X[XF=/)_4$L#!!0
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M)!B0:_>S.W;)9T@,TV^O@F-_&/2._.X+M>EM1=XR69KRL&G)EOYO_&-CK<Z
M?*8JI@54SL52P(J\3;09"7T_?&#[[K3F0T$2612U?G49-(K1HIA301244EF=
MQG]>+;OD0Y&0 S-NX!_ZP[',L6*N[%TP/,222-Y+E9/ =_X@J5165HD:24:@
M8.B5,T@@CT&17M!%0\-@2]Z57:\5UR6T(BD7;7VV'H-DKK @H/6T8&2RQ%I7
M8)5&37)>519)A>5D6*1)!@IDBHIW+6V..J@*HPRL2Q*+OU67E#^(.:,.;:);
M_E1TNV::88FALL1\1;X6<H&FSL"H2G5DHZ]I+)!+*M3[I.-W4&DAF@*[OJ]*
MFC3W.$/AE[6@J0MI#^/=EN6VW'F:;3+>&&<D5#1)8/,!]X'A(N,:'+,"1*B@
MHDBZ4^9#8M7!S4#+/#J^I9A]J5[I(#BT[MDQXKG4F6(D:^B2="[$"E,J+X7!
MZ!JW"OZ><P6FZ:A,P'?0=4 Q>=0.]>B ':ZQ=(O[->8;0 5O>OVAR89;EW@&
M!9X%SQY#=V$H?'$8X@76S+S>#[$J:\JQ4"'5(J %&.4*$58JJ R6NF:88K>*
MTW!I6[.K$F%4U14OY07VO8:. IGMI&SA1*ZYJ*$HL4#;-:L6;$U9=^\ U"-T
M7V>H?43>0ZSF5*U(&-K-(7R4'? ;S5[XX]V>:5XMSD\ZIO?MM'G6"*W3S4FD
M$+2L(&K_V53+X""KVP?3])J(8TBW6VK_-D.:AMI0-OICFZ[MJHVTH#;R[LR4
M;08>H80-S^R ?Z-!WY L45HJY*)U3WOOF,R.8GPZ^NHLT/SO-OWK<1I74LPU
M#-MTV+;O17;[]8-1\_OM.KCV]K';'^S]_73^[O?<HV#O\ =RN-T#]K7F)80"
MO8T;"G94N/N$G;WGGSP)'@#P+[.M>:BM[/]MW7<WCA=LWAZASX;0=ZOH/C!K
MGA6:I\.@7!(LE)R15[[]>UH;O,HCYY3QG'RA"G;?*>QQ]1RX.J<Y_ RRS(;[
MS+#:0^IE06IJ3@+OA:DG5?-20<69.:DU+ZW&&8>43):0S$VC22[2E">@[GA-
M57=MCXV,>S22V?H9*J;)UYF2\X*9-T5216UN;IR';@\T';H!H> %.,U]F\V;
MY[ -9?,8=O> MZ0S<.I>GJ8:5$1O)&=-O <#-^RO:TA-\^UKW_K@V)Y$G_X+
M4$L#!!0    ( )IA5E0+ @$M;P4  #\?   7    =&UB+3(P,C$Q,C,Q>&5X
M,S)D,BYH=&WM66UOVS80_BLW%VL3P'JU$[BR8Z!U$JQ=VP2ILV$?*8FRB%*D
M1M%QO%^_(R4YMK&T19JD'N @L:/C\7@OSQV/XN@7QSD3.1$)3>&WZ<</D,ID
M7E"A(5&4:*0NF,YA*LN2"/A(E6*<PUO%TAD%>.T&@>N[@R/'&8]0U*29(T4$
MH1?BKQ^&X >1/XCZ/;C\" ?7T\FAY3Z]F$S_NCRK5[V\?OOAW00ZCN?]V9MX
MWNGTM![HNWX 4T5$Q323@G#/._O4@4ZN=1EYWF*Q<!<]5ZJ9-[WR<EWPOL>E
MK*B;ZK0S'AD*?E*2CD<%U022G*B*ZI/.]?3<&2"'9IK3\<AKOVO>6*;+\2AE
M-U#I):<GG8*H&1..EF74\TL]Q)D>#F_QW#H+ENH\"GS_UV%)TI2)F<-IIJ,C
M=S"X(RDVRU<T69L6*<J)9C?4R%Z3FG!*5!1+G0^W%_BOF64[+Y-".QDI&%]&
MKZ:LH!5\H@NXD@41K[HU!;\KJECV:FBY*_8/1=%H7FUNU%AJ!C?$UHPX>,,J
M%C/.]#+*69I2@>PO7PQ"OS<<>885W50^EE*:WFJ'<#9#BXT#U[0$\W=<?QN-
MXXT%%]3Z.Y8\Q<&SVQQUUM +W7#DQ4^D88(Y1-4#59Q0I5G&$F+""S*#R?D%
M7,Y5-2<8"2TA&,"U^]F=N/"9)H;IY8O@V!\&O2._NZ,VO:G@32I+4Q[6+=G0
M_[5_;*S5.87/1,5$T,JYN.5T"6\2;49"WW_LF-UKS3L!B12BUJ\N@T8Q(L2<
M<%"TE,KJ-/GCZK8+[T3BPH%A,/@/_>%$%E@RE_8I&!YB381SJ0H(?.=WR*2R
MPDI42:9 18IN.:4)+6*JH!=TT=(PV)!W91=LQ76!5) QWA9HZS*:S!56!#2?
MB!3.;K'8"2S3J$G!JLI"25C.%*LTY%11F:'F74N;HPZJPC#3M N)!>"R"^5W
M@LZH0YKPEC\4WJZ99EAB6EEBL80O0B[0U!DUJA(=V?!K$G/DD@KU/NGX'52:
M\Z;"KIZKDB3-,\Y0^)>VJ*DK:0\#WM;EMMYY.EUGO#'.2 AOLL F!&X$PT7.
M-'7,"C1"!15!TKTR'Q.L#NX&6A;1\1W%;$SU2@?!H77/EA$_2YTI1K*&+F1S
MSI>84T7)#497N%7T[SE3U'0=E0GX%KH."":/VJ(>':2'*RS=X7Z%^090P>M>
M?VBRX<XEGD&!9\&SQ]!]& IW#D-,8,TLZ@T1R[(F# L54BT"6H 1IA!AI:*5
MP5+7#!-L5W$:+FV+=E4BC*JZXF5,8.-KZ"@PM:V4+9S(-><U%"46:+MFU8*M
M*>ON/8!Z@O;K%+6/X)S&:D[4$L+0;@[ADVR!7^GVPN]O]TSW:G%^TC'-;Z?-
MLT9HG6Y.(CDG946C]I]UM0P.\KI_,%VOB3B&=+.G]N\RI.FH#66M0;;IVJ[:
M2 MJ(^_/3-EFX!%*6//,%OC7.O0UR1*E95PN6O>TSX[)["C&X]$79X'F?[/K
M7XV3N))\KNFP38=-^YX9 )WQ>Q?60UT?@IK/KY>\E6./W?Y@[]J'G:0>XN]^
MSST*]@Y_)(?;<K\O*[L0"O0V[AW8/.%&$W;VGG_V)'@$P.]F!_-86]G_V[IO
M;AP[;-X>H3\-H6^7T4-@UAP+FH-@4-X"%DJ6P@O?_CRO#5[EP7NB\(AY02K<
M#XH]LG8 69](07\$6V;+_<G VH-JUT U-3=_#T+5LZHYR1G-X'SUSNHBRUA"
MU3WOH>I>[:FQ\(#V,5^=G&*2?)DI.1>I>14D5=3FX]J-Y^9 TY<;V'$FJ-,\
MMQF\?M/:4-8O6K>O<$LRHT[=P9-,4Q61&\G2)L*#@1OV5W6CIOGVO6Y]-6SO
MFL?_ E!+ P04    " ":8594%&]'A+@0   .1P  %P   '1M8BTR,#(Q,3(S
M,7AE>#1D,38N:'1M[5SI<ALW$GX5K+/9)%4\Y3.4HBJ;EA-79,LER<GF)S@#
MDHAG!F, (XK[]-L', =)279\R55.)9$UQ #=C3Z^/NB#?_7[1\52%HE*Q6_G
M+XY%:I(J5X47B572P].5]DMQ;LI2%N*%LE9GF7AB=;I00OP\&(\'H\&C^_W^
MX0%L-0WOF&(B]H9[\.]H;T^,QI/1H\G>??'JA?CQ]?GT)UK]]&1Z_M>K(S[U
MU>LGQ\^GXDY_./SS[G0X?'K^E#^X-QB-Q;F5A=->FT)FP^'1RSOBSM+[<C(<
MKE:KP>KNP-C%\/QTN/1Y=F^8&>/4(/7IG<,#? +_5S(]/,B5ER)92NN4_^7.
MZ_-G_4>PPFN?J<.#8?S):V<F71\>I/I".+_.U"]W<FD7NNA[4T[NCDJ_#V\.
MX>.--9?]E4[]<C(>C;[?+V6:ZF+1S]3<3T!.#Q\TSZQ>+)N'AIF;6)5)KR\4
M[G[-V:TS8&$9E\U-X?MSF>ML/?GA7.?*B9=J)4Y-+HL?>OP$?CIE]?R'?5KM
M]/_49+P'>V:Z4/VE8K(&XY_W^=!)X!57QW,NM-,SG6F_GBQUFJH"%OSGNT=[
MH[O[!T-<"*(I=X@GR92TDYGQR_U-2>T2P(?S-=K%EU>7OB\SO8#3\&ED%*4@
M1LU_2,*L0\**=YF9+(4/CRZ7( 4/"CI^<#"<,<^?GN8$3%/9?TKTTZ.SZ>GS
M5^?/3UZ*DV?B_+<C,3UY\>KQR[_P L</]\_P]Q?PZ=GYR?3WC\@7ZE@.2AS9
MVAL@N5<RMD/M;A+2.ZKEQ[FB;5:ZA.LNU?CGB?; :0*?GB^52$R>FP)6F>2-
M,',Q_>/TLB>>%\E _(A4[XWV5ZI'?QKOB_#$5+9^9&Q\6KGP[">AG?"PN2FR
MM4@RZ1QN[5126; O8-"JA78@9G#159$J*\Y4@H8GQGNX$M\]:U8?78*W+,#/
M/TX\?CS^^>Z]GI!.2 @0J4H'!T/]Z?5>PU&%G^S=&]POK[-6E.K<9)E9@8-%
M24B1*I=871*'@;T<XI/5,A/P(R?Q@% [MS$0N%/[5=CK;05W-]<@-PV_>R>
M)&V57XO9&J0Z!Y%""!7>T'9!/D(6*7SH/,7$1%D/6R3P"QZKB\38TEB)1[2E
M*G[$+<+='E11LB2+5"7AC0G='TIL?^.3?F(R8R??C>@?$,RT>_#S]L$'P^HP
M:D^/Z+V2_MDZDROWT:E[0MNVZ:!C\:YD68+!R%FF1&D-VK<I7+S(IQ J5M(J
M\:LJE(4+G39<B6.YZHH4W_B(1#_]=7K<)GD@3D JUPFZEBWS*Y#R1@5(O"T]
M M(5QQ<7=>IQ48 .BE,%+\!3V/&9L;D8C_J_#\2G-,)_&&KBM7R6V+C31SS8
M(A@O259^:2SL!Q8I2_3)P0DGH%S@'$G!]D:CWHC_$PX0HZ*G;2_1$Z6TXD)F
ME1+_'B%(+<&=TEJVH_&N'4JZ8G2_S2;_^6[\8+2_<Z>/=K'OB? V9+X=P[;N
M^[,&W_?FY%K2[QS^83R&#(*#[C.0^SXJ>R23I5@"G: 3.X(5QB8,19"[I.0I
M"B4NC,=(:(7"=TF1T%U(R-L@^D'<<\)5LUQ[S^](?B/X5=J6#W0]=%%9A1D+
M?::R !=@;0KA+_'&.O9][=<@AQ2%\6(I+P#H5'G%H!Z/:>2,@?2:/1\GX!OQ
MX&S=$W%?6"*!A[_!?B'R!H+#KL'(D%F*&, 8;4U\AZ7-_K?"KKYJHWFJ+S20
MG-XV@SFK9G_CM</]EW5 15@L/:@.X+4.KD#U+]:H'*" E0>H4Y"V;SGJE@IN
MV2#J7-L(0<D4ZGL:101V-,=S"),$(@!=9!(/F%N3"P\"P5?I)T !/&-FI$T[
M9H$DXH-,+4"KUT)>2)T1'W/ +M^T^L.U^EB_K70:H/&MTNOGP5U>8&TN:&'6
M4-L#+7'.9!7[4BL@"R)-KLKKE7>%];Q95X$Y9@ N!=U:1T==*/"ESBEPW3OT
M#TX$ KS5,Z8 =VF'!#F'P$/[E'*=!QZ":T::4C6#C0DDPR)D39(281X:\P$'
MG+JYK,,%6FY+!"U[%PLKBQ#>\,UV -EE[E<BM&\F]<$F=<KA'B^QY9!OF77]
M=HV%$(PI*)RHO$0DT\-DX0+6D^$!F&J5&6Q08$8YO:B\"$LL;0.Z1=OP8J>+
M-ZB!Z,#;66XW1NVN4<0CVG&.Q0R!!VQ4U<GR3='+-4$3-XAQ,D4>%1KZ? X?
M<Y;JZY-W[-X8$MH97I2J3]TP+0[)*T6GI<KI18&)<_ V\\I7D #=PL3V,3C*
MOI=OE 'I"$62":ZC7:,P-Q0$>IUJ0)%R&DB5#2HNW)ZL^<SD.PLP0&9=U7B?
MT@?8CI>Z:&])JI"8*D/=>Z-8 ^I:GL?V#[M]@$_&(K*:PV%5YB=")A  N'V
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MR+XP.KT)8P_Y;WJAOSKF\/]02P$"% ,4    " ":8594TU512-<0   7K0
M$               @ $     =&UB+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    (
M )IA5E1'3S<VZ0\  /G=   4              "  041  !T;6(M,C R,3$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( )IA5E0+GK0B^2D  !B8 @ 4
M      "  2 A  !T;6(M,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( )IA
M5E2V76";O&D  /'Z!@ 4              "  4M+  !T;6(M,C R,3$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( )IA5E2P,(L9/T4  +HC!0 4
M  "  3FU  !T;6(M,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( )IA5E1?
M"L>56G8# $QD(  4              "  :KZ  !T;6(M,C R,3$R,S%X,3!K
M+FAT;5!+ 0(4 Q0    ( )IA5E2=$9E2I"H  )(O   7              "
M 39Q! !T;6(M,C R,3$R,S%X,3!K,# V+FIP9U!+ 0(4 Q0    ( )IA5E3X
M2;D?VV@  .UR   7              "  0^<! !T;6(M,C R,3$R,S%X,3!K
M,# W+FIP9U!+ 0(4 Q0    ( )IA5E1?3=;)P%,  &)S   7
M  "  1\%!0!T;6(M,C R,3$R,S%X,3!K,# X+FIP9U!+ 0(4 Q0    ( )IA
M5E1B.,C_W3T  -->   7              "  119!0!T;6(M,C R,3$R,S%X
M,3!K,# Y+FIP9U!+ 0(4 Q0    ( )IA5E0FW3YBRH,   *I   7
M      "  2:7!0!T;6(M,C R,3$R,S%X,3!K,#$P+FIP9U!+ 0(4 Q0    (
M )IA5E2#L,BC!C<  /0^   7              "  24;!@!T;6(M,C R,3$R
M,S%X,3!K,#$Q+FIP9U!+ 0(4 Q0    ( )IA5E1*7K@Y#BD  +\O   7
M          "  6!2!@!T;6(M,C R,3$R,S%X,3!K,#$R+FIP9U!+ 0(4 Q0
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M;6(M,C R,3$R,S%X,3!K,#$W+FIP9U!+ 0(4 Q0    ( )IA5E3FH.X5#:D
M !;=   7              "  >7;" !T;6(M,C R,3$R,S%X,3!K,#$X+FIP
M9U!+ 0(4 Q0    ( )IA5E34I%)Z*3   'N3 0 8              "  2>%
M"0!T;6(M,C R,3$R,S%X97@Q,&0Q-"YH=&U02P$"% ,4    " ":85946HU[
MY(4#   ]$0  %P              @ &&M0D =&UB+3(P,C$Q,C,Q>&5X,C%D
M,2YH=&U02P$"% ,4    " ":8594 )"G:%D$   [&@  %P
M@ % N0D =&UB+3(P,C$Q,C,Q>&5X,C-D,2YH=&U02P$"% ,4    " ":8594
MO>50Z<,(  "O-   %P              @ '.O0D =&UB+3(P,C$Q,C,Q>&5X
M,S%D,2YH=&U02P$"% ,4    " ":8594JJ\49KP(  #Z-   %P
M    @ '&Q@D =&UB+3(P,C$Q,C,Q>&5X,S%D,BYH=&U02P$"% ,4    " ":
M8594[25^/'$%  !='P  %P              @ &WSPD =&UB+3(P,C$Q,C,Q
M>&5X,S)D,2YH=&U02P$"% ,4    " ":8594"P(!+6\%   _'P  %P
M        @ %=U0D =&UB+3(P,C$Q,C,Q>&5X,S)D,BYH=&U02P$"% ,4
M" ":8594%&]'A+@0   .1P  %P              @ $!VPD =&UB+3(P,C$Q
D,C,Q>&5X-&0Q-BYH=&U02P4&     !L &P R!P  [NL)

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
